

GenCore version 5.1.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 4, 2004, 16:49:08 ; Search time 245 Seconds
(without alignments)
4.079 Million cell updates/sec

Title: US-10-017-084a-522
Perfect score: 1679
Sequence: 1 gttgtccttcagcaaac.....ataaaagagcaaaaaaa 1679

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 177 seqs, 297588 residues

Total number of hits satisfying chosen parameters: 354

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 177 summaries

Database : rng522.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1679	100.0	1679	1	ADB38667 Novel human secret
2	1679	100.0	1679	1	ADB78344 Novel human secret
3	1679	100.0	1679	1	ADB38115 Novel human secret
4	1679	100.0	1679	1	ADB65687 Novel human secret
5	1679	100.0	1679	1	ADB84992 Human PRO polynucle
6	1679	100.0	1679	1	ADB89667 Human PRO polynucle
7	1679	100.0	1679	1	ADB90399 Human PRO polynucle
8	1679	100.0	1679	1	ADB39500 Novel human secret
9	1679	100.0	1679	1	ADB78098 Novel human secret
10	1679	100.0	1679	1	ADB74028 Human PRO polynucle
11	1679	100.0	1679	1	ADB87164 Human PRO polynucle
12	1679	100.0	1679	1	ADB84746 Novel human secret
13	1679	100.0	1679	1	ADB47123 Novel human secret
14	1679	100.0	1679	1	ADB83861 Human PRO polynucle
15	1679	100.0	1679	1	ADB86730 Novel human secret
16	1679	100.0	1679	1	ADB73016 Human PRO polynucle
17	1679	100.0	1679	1	ADB76744 Human PRO polynucle
18	1679	100.0	1679	1	ADB77335 Novel human secret
19	1679	100.0	1679	1	ADB34492 Novel human secret
20	1679	100.0	1679	1	ADB35596 Human PRO polynucle
21	1679	100.0	1679	1	ADB33940 Human PRO polynucle
22	1679	100.0	1679	1	ADB35044 Human PRO polynucle
23	1679	100.0	1679	1	ADB36148 Human PRO polynucle
24	1679	100.0	1679	1	ADB46543 Novel human secret
25	1679	100.0	1679	1	ADB44170 Human cDNA encodin
26	1679	100.0	1679	1	ADB61530 Human cDNA encodin
27	1679	100.0	1679	1	ADB63894 Human cDNA encodin
28	1679	100.0	1679	1	ADB66994 Human cDNA encodin
29	1679	100.0	1679	1	ADB69118 Human cDNA encodin
30	1679	100.0	1679	1	ADB63178 Human cDNA encodin
31	1679	100.0	1679	1	ADB68243 Human cDNA encodin
32	1679	100.0	1679	1	ADB41563 Human cDNA encodin
33	1679	100.0	1679	1	ADB67618 Human cDNA encodin

34	1679	100.0	1679	1	ADCS2554 Human cDNA encodin
35	1679	100.0	1679	1	ADC36854 Human PRO polynucle
36	1679	100.0	1679	1	ADC42187 Human PRO polynucle
37	1679	100.0	1679	1	ADC21844 Novel human secret
38	1679	100.0	1679	1	ADCS0416 Novel human secret
39	1679	100.0	1679	1	ADC71963 Novel human secret
40	1679	100.0	1679	1	ADCS9942 Novel human secret
41	1679	100.0	1679	1	ADC49875 Novel human secret
42	1679	100.0	1679	1	ADC49074 Novel human secret
43	1679	100.0	1679	1	ADC49591 Novel human secret
44	1679	100.0	1679	1	ADC47452 Novel human secret
45	1679	100.0	1679	1	ADCS2949 Novel human secret
46	1679	100.0	1679	1	ADCS7303 Novel human secret
47	1679	100.0	1679	1	ADCS60494 Novel human secret
48	1679	100.0	1679	1	ADCS0969 Human PRO polynucle
49	1679	100.0	1679	1	ADCS4596 Novel human secret
50	1679	100.0	1679	1	ADCS4594 Novel human secret
51	1679	100.0	1679	1	ADCS3555 Novel human secret
52	1679	100.0	1679	1	ADCS9078 Novel human secret
53	1679	100.0	1679	1	ADCS5956 Novel human secret
54	1679	100.0	1679	1	ADCS8526 Novel human secret
55	1679	100.0	1679	1	ADC47197 Novel human secret
56	1679	100.0	1679	1	ADD03200 Novel human secret
57	1679	100.0	1679	1	ADC90192 Novel human secret
58	1679	100.0	1679	1	ADC69611 cDNA encoding huma
59	1679	100.0	1679	1	ADC48500 Human PRO polynucle
60	1679	100.0	1679	1	ADD10029 Human PRO polynucle
61	1679	100.0	1679	1	ADC78072 Novel human secret
62	1679	100.0	1679	1	ADD04604 Novel human secret
63	1679	100.0	1679	1	ADD06307 Novel human secret
64	1679	100.0	1679	1	ADC80560 Novel human secret
65	1679	100.0	1679	1	ADD11067 Human PRO polynucle
66	1679	100.0	1679	1	ADD10344 Human secreted/tra
67	1679	100.0	1679	1	ADC47948 Human PRO polynucle
68	1679	100.0	1679	1	ADC77826 Novel human secret
69	1679	100.0	1679	1	ADC80008 Novel human secret
70	1679	100.0	1679	1	ADD11304 Human secreted/tra
71	1679	100.0	1679	1	ADD09477 Human PRO polynucle
72	1679	100.0	1679	1	ADD50789 Novel human secret
73	1679	100.0	1679	1	ADD41190 cDNA encoding huma
74	1679	100.0	1679	1	ADCS2329 Novel human secret
75	1679	100.0	1679	1	ADCS1035 cDNA encoding huma
76	1679	100.0	1679	1	ADCS3069 Novel human secret
77	1679	100.0	1679	1	ADCS3621 Human secreted/tra
78	1679	100.0	1679	1	ADCS7097 cDNA encoding huma
79	1679	100.0	1679	1	ADCS1777 Human PRO polynucle
80	1679	100.0	1679	1	ADD02576 Human PRO polynucle
81	1679	100.0	1679	1	ADCS0516 Human PRO polynucle
82	1679	100.0	1679	1	ADD02010 Human PRO polynucle
83	1679	100.0	1679	1	ADCS4192 Novel human secret
84	1679	100.0	1679	1	ADCS0270 Human cDNA encodin
85	1679	100.0	1679	1	ADCS1281 Human PRO polynucle
86	1679	100.0	1679	1	ADCS49556 Human PRO polynucle
87	1679	100.0	1679	1	ADCS2509 Human PRO polynucle
88	1679	100.0	1679	1	ADCS1405 Human PRO polynucle
89	1679	100.0	1679	1	ADCS04019 Human PRO polynucle
90	1679	100.0	1679	1	ADCS2316 Novel human secret
91	1679	100.0	1679	1	ADCS2248 cDNA encoding huma
92	1679	100.0	1679	1	ADD79472 Human cDNA encodin
93	1679	100.0	1679	1	ADCS35610 Human cDNA encodin
94	1679	100.0	1679	1	ADCS16724 Human PRO polynucle
95	1679	100.0	1679	1	ADCS73339 Human PRO polynucle
96	1679	100.0	1679	1	ADCS42008 Human PRO polynucle
97	1679	100.0	1679	1	ADCS17825 Human PRO polynucle
98	1679	100.0	1679	1	ADCS1957 Novel human secret
99	1679	100.0	1679	1	ADCS33420 Novel human secret
100	1679	100.0	1679	1	ADCS3972 cDNA encoding huma
101	1679	100.0	1679	1	ADCS80024 Human PRO polynucle
102	1679	100.0	1679	1	ADCS3061 Human cDNA encodin
103	1679	100.0	1679	1	ADD72697 Human PRO polynucle
104	1679	100.0	1679	1	ADCS19481 Human PRO polynucle
105	1679	100.0	1679	1	ADCS18929 Human PRO polynucle
106	1679	100.0	1679	1	ADCS43135 Human PRO polynucle

107	1679	100.0	1679	1	ADD95914	Human PRO polynucl
108	1679	100.0	1679	1	AD222800	CDNA encoding huma
109	1679	100.0	1679	1	AD778918	CDNA encoding huma
110	1679	100.0	1679	1	AD322868	Novel human secret
111	1679	100.0	1679	1	AD342560	Human PRO polynucl
112	1679	100.0	1679	1	AD317348	Human CDNA encodin
113	1679	100.0	1679	1	AD80576	CDNA encoding huma
114	1679	100.0	1679	1	AD89604	Human PRO polynucl
115	1679	100.0	1679	1	AD340888	Human PRO polynucl
116	1679	100.0	1679	1	AD340887	Human PRO polynucl
117	1679	100.0	1679	1	AD48828	Novel human secret
118	1679	100.0	1679	1	AD381112	Novel human secret
119	1679	100.0	1679	1	AD320999	Novel human secret
120	1679	100.0	1679	1	AD305843	Human PRO polynucl
121	1679	100.0	1679	1	AD76560	Human PRO polynucl
122	1679	100.0	1679	1	AD75072	Human PRO polynucl
123	1679	100.0	1679	1	AD75918	Novel human secret
124	1679	100.0	1679	1	AD985050	Novel human secret
125	1679	100.0	1679	1	AD986876	Novel human secret
126	1679	100.0	1679	1	AD320753	Novel human secret
127	1679	100.0	1679	1	AD339050	Novel human secret
128	1679	100.0	1679	1	AD87924	Human PRO polynucl
129	1679	100.0	1679	1	AD86328	Human PRO polynucl
130	1679	100.0	1679	1	AD305937	Human PRO polynucl
131	1679	100.0	1679	1	AD73592	Human PRO polynucl
132	1679	100.0	1679	1	AD375776	Human CDNA encodin
133	1679	100.0	1679	1	AD348856	Human CDNA encodin
134	1679	100.0	1679	1	AD78422	Novel human secret
135	1679	100.0	1679	1	AD341305	Human secreted/tra
136	1679	100.0	1679	1	AD323352	CDNA encoding huma
137	1679	100.0	1679	1	AD321245	Novel human secret
138	1679	100.0	1679	1	AD77360	Novel human secret
139	1679	100.0	1679	1	AD320507	Novel human secret
140	1679	100.0	1679	1	AD75572	Human PRO polynucl
141	1679	100.0	1679	1	AD74088	Human PRO polynucl
142	1679	100.0	1679	1	AD74334	Human PRO polynucl
143	1679	100.0	1679	1	AD76064	Novel human secret
144	1679	100.0	1679	1	AD85556	Novel human secret
145	1679	100.0	1679	1	AD323904	CDNA encoding huma
146	1679	100.0	1679	1	AD34547	CDNA encoding huma
147	1679	100.0	1679	1	AD87372	Human PRO polynucl
148	1679	100.0	1679	1	AD305105	Human PRO polynucl
149	1679	100.0	1679	1	AD75318	Human PRO polynucl
150	1679	100.0	1679	1	AD76862	Novel human secret
151	1679	100.0	1679	1	AD86630	Novel human secret
152	1679	100.0	1679	1	AD392238	Human PRO polynucl
153	1679	100.0	1679	1	AD341138	Human secreted/tra
154	1679	100.0	1679	1	AD780898	Novel human secret
155	1679	100.0	1679	1	AD318377	Human PRO polynucl
156	1679	100.0	1679	1	AD386866	Human PRO polynucl
157	1679	100.0	1679	1	AD399957	Human CDNA encodin
158	1679	100.0	1679	1	AD77606	Novel human secret
159	1679	100.0	1679	1	AD77852	Novel human secret
160	1679	100.0	1679	1	AD35310	Novel human secret
161	1679	100.0	1679	1	AD73842	Human PRO polynucl
162	1679	100.0	1679	1	AD74580	Human PRO polynucl
163	1679	100.0	1679	1	AD771108	Novel human secret
164	1679	100.0	1679	1	AD35802	Novel human secret
165	1679	100.0	1679	1	AD305351	Human PRO polynucl
166	1679	100.0	1679	1	AD74826	Human PRO polynucl
167	1631.9	99.0	1693	1	AAZ47893	Human protein enco
168	1643.4	97.9	2012	1	AAA8791	Human SECX cDNA Cl
169	1643.4	97.9	2012	1	AD18290	Human molecule (NO
170	1601.4	95.4	1603	1	AAA88790	Human SECX cDNA Cl
171	1601.4	95.4	1603	1	AD18298	Human molecule (NO
172	1571.3	93.6	1873	1	ABK49272	Human Kruppel asso
173	1457	86.8	1678	1	AA157869	Human IG gene rela
174	1442.8	85.9	1839	1	ABT17390	Human polynucleoti
175	1442.8	85.9	1839	1	ABX76448	Lung cancer-associ
176	1316.5	78.4	1690	1	AA159655	Human polynucleoti
177	1032	61.5	1032	1	AAZ47892	Human protein enco

ALIGNMENTS

RESULT 1

AD38667	AD38667 standard; cDNA; 1679 BP.
ID	AD38667
XX	AD38667
AC	AD38667
XX	AD38667
DT	04-DEC-2003 (first entry)
XX	Novel human secreted and transmembrane protein PRO337 cDNA.
DE	Human; secreted and transmembrane protein; PRO; gene; ss;
XX	Tumour necrosis factor alpha release; TNF-alpha release;
KW	Glucose uptake modulator; PFA uptake modulator;
KW	cell proliferation stimulator; cell differentiation stimulator;
KW	cell differentiation inhibitor; cytokine release stimulator;
KW	lung tumore; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX	gene therapy; chromosome identification; chromosome marker.
OS	Homo sapiens.
XX	US2003082766-A1.
PN	01-MAY-2003.
XX	30-MAY-2002; 2002US-00158782.
PD	31-MAR-1997; 97WO-US005230.
XX	12-JUN-1998; 98WO-US012456.
PR	14-JUL-1998; 98WO-US014552.
PR	28-AUG-1998; 98WO-US017888.
PR	10-SEP-1998; 98WO-US018824.
PR	14-SEP-1998; 98WO-US019093.
PR	14-SEP-1998; 98WO-US019094.
PR	14-SEP-1998; 98WO-US019177.
PR	16-SEP-1998; 98WO-US019330.
PR	17-SEP-1998; 98WO-US019437.
PR	07-OCT-1998; 98WO-US021141.
PR	29-OCT-1998; 98WO-US022991.
PR	29-OCT-1998; 98WO-US022992.
PR	20-NOV-1998; 98WO-US024855.
PR	01-DEC-1998; 98WO-US025108.
PR	05-JAN-1999; 99WO-US000106.
PR	08-MAR-1999; 99WO-US005028.
PR	10-MAR-1999; 99WO-US005190.
PR	20-APR-1999; 99WO-US008615.
PR	14-MAY-1999; 99WO-US010733.
PR	02-JUN-1999; 99WO-US012252.
PR	01-SEP-1999; 99WO-US020111.
PR	08-SEP-1999; 99WO-US020594.
PR	13-SEP-1999; 99WO-US020944.
PR	15-SEP-1999; 99WO-US021547.
PR	05-OCT-1999; 99WO-US023089.
PR	29-NOV-1999; 99WO-US028214.
PR	30-NOV-1999; 99WO-US028313.
PR	30-NOV-1999; 99WO-US028409.
PR	01-DEC-1999; 99WO-US028301.
PR	01-DEC-1999; 99WO-US028634.
PR	02-DEC-1999; 99WO-US028551.
PR	02-DEC-1999; 99WO-US028564.
PR	16-DEC-1999; 99WO-US028565.
PR	20-DEC-1999; 99WO-US030095.
PR	20-DEC-1999; 99WO-US030911.
PR	20-DEC-1999; 99WO-US030999.
PR	22-DEC-1999; 99WO-US030720.
PR	30-DEC-1999; 99WO-US031243.
PR	05-JAN-2000; 2000WO-US000219.
PR	06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 10-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 04-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen WB, Goddard A, Godowski P, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
 XX
 DR WPI; 2003-786921/74.
 DR P-PSDB; ADB38668.
 XX
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, detecting the presence of tumor in a mammal, or
 PT modulating the uptake of glucose or free fatty acid by skeletal muscle
 PT cells or adipocyte cells.
 XX
 PS Claim 2; Fig 375; 660pp; English.
 PS
 XX

CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTTGCACAACTTGAGAGCAAC 60
 Db 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTTGCACAACTTGAGAGCAAC 60
 Qy 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 Db 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 Qy 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAATATGCAATTTCTATCTCTTGGCAAT 180
 Db 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAATATGCAATTTCTATCTCTTGGCAAT 180
 Qy 181 CTTACGGGGCTGGCTCTCTGTCTCTTCCAGAGAGTCCCGTGGGAGCGAGATGC 240
 Db 181 CTTACGGGGCTGGCTCTCTGTCTCTTCCAGAGAGTCCCGTGGGAGCGAGATGC 240
 Qy 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
 Db 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
 Qy 301 GTGCATATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGAGACCACTCTCTA 360
 Db 301 GTGCATATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGAGCACTCTCTA 360
 Qy 361 TGTCTGGCAATGACAGTGGTGGCTTGGATCTCTCGGTGGTCTCTTGTAGCAACCAAC 420
 Db 361 TGTCTGGCAATGACAGTGGTGGCTTGGATCTCTCGGTGGTCTCTTGTAGCAACCAAC 420
 Qy 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACAGGGGCCCTTACACCTGCTC 480
 Db 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACAGGGGCCCTTACACCTGCTC 480
 Qy 481 GGTCACAGACAAACCAACCAAGACCTCTAGGTCCACCTCATTTGTGCAAGTATCTCC 540
 Db 481 GGTCACAGACAAACCAACCAAGACCTCTAGGTCCACCTCATTTGTGCAAGTATCTCC 540
 Qy 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCCTCAC 600
 Db 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCCTCAC 600

Db 541 CAAAATTGTAGAGATTCTTTCAGATATCTCCATTATGAAGGGAACAATATTAGCCTCAC 600
Qy 601 CTGATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Qy 661 GGTGGGCTTTGTAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
Db 661 GGTGGGCTTTGTAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
Qy 721 AGGGGACTACAGTGCAGTGCTCCAAATGAGTGGCGCGCGCTGGTAGCGAGAGTAA 780
Db 721 AGGGGACTACAGTGCAGTGCTCCAAATGAGTGGCGCGCGCTGGTAGCGAGAGTAA 780
Qy 781 GGTCAACCGTGAACATATCCACATATCTTCAAGAGCCCAAGGGTACAGGTGTCCCGTGGG 840
Db 781 GGTCAACCGTGAACATATCCACATATCTTCAAGAGCCCAAGGGTACAGGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACACTGCAAGTGTGAAGCCTCAGCAGTCCCTCAGCAGATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGCAAGTGTGAAGCCTCAGCAGTCCCTCAGCAGATTCAGTGGTA 900
Qy 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAGGGGTGAAGTGGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAGGGGTGAAGTGGAAACAGACCTTT 960
Qy 961 CCTCTCAAAATCATCTTCTTCAATGTCTCTGAACATGACTATGGGAATACACTTGGT 1020
Db 961 CCTCTCAAAATCATCTTCTTCAATGTCTCTGAACATGACTATGGGAATACACTTGGT 1020
Qy 1021 GGCCTCAACCAAGCTGGGCGACCAATGCCATCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCCTCAACCAAGCTGGGCGACCAATGCCATCATGCTATTTGGTCCAGGCGCGT 1080
Qy 1081 CAGCGAGGTGAGCAACCGCAGCTCGAGAGGGCAGGCTGGCTGTGGCTGCTCTTCT 1140
Db 1081 CAGCGAGGTGAGCAACCGCAGCTCGAGAGGGCAGGCTGGCTGTGGCTGCTCTTCT 1140
Qy 1141 GGTCTTCACCTGCTCTCAAAATTTTCAATGTGAGTGCACCTTCCCAACCGGGAAGGCT 1200
Db 1141 GGTCTTCACCTGCTCTCAAAATTTTCAATGTGAGTGCACCTTCCCAACCGGGAAGGCT 1200
Qy 1201 GCGCCACCAACCAACCAACAGCAATGGCAACACCGAGCAACCAATTCAGATA 1260
Db 1201 GCGCCACCAACCAACCAACAGCAATGGCAACACCGAGCAACCAATTCAGATA 1260
Qy 1261 TATCAATGAAATAGAGAAACACAGCCTCATGGGACAGAAATTTGGAGGGGGGAAC 1320
Db 1261 TATCAATGAAATAGAGAAACACAGCCTCATGGGACAGAAATTTGGAGGGGGGAAC 1320
Qy 1321 AAAGAATACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGAATACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Qy 1381 TTTAGGTACAAATGAGTTTCTTTCCAAACCGGGAAGAACACAGCACCCCGGCTTGA 1440
Db 1381 TTTAGGTACAAATGAGTTTCTTTCCAAACCGGGAAGAACACAGCACCCCGGCTTGA 1440
Qy 1441 CCCACTGCAAGCTGCATGCTGCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGCATGCTGCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCACAGTGGAAACATTTGGAGTGGCCATCCCAAAATCAATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACAGTGGAAACATTTGGAGTGGCCATCCCAAAATCAATCA 1560
Qy 1561 GTCCATAGAGAGCAAGATGAGACCTTCGGGCCCAAGCGTGGCGCTGGGCGACCTTTG 1620
Db 1561 GTCCATAGAGAGCAAGATGAGACCTTCGGGCCCAAGCGTGGCGCTGGGCGACCTTTG 1620
Qy 1621 GTAGACTGTGCCACAGCGGCTGTGTGTGAACCTGAATTAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACAGCGGCTGTGTGTGAACCTGAATTAAGAGCAAAAAA 1679

RESULT 2

ADB78344
ID ADB78344 standard; cDNA; 1679 BP.
XX
AC ADB78344;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritis; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation; lung tumour;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN US2003092889-A1.
XX
PD 15-MAY-2003.
XX
PF 13-AUG-2002; 2002US-00219478.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021086.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Deenoyers L, Gerritsen ME, Goddard A, Godowski PU;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WJ;
XX
DR WPI; 2003-765495/72.
XX
PT P-PSDB; ADB78345.
XX
PS New isolated PRO polypeptide useful for tissue typing, gene therapy, as
molecular weight markers in protein electrophoresis, and for treating
arthritis and tumors.
XX
PS Claim 2; Fig 125; 308pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
useful for stimulating the proliferation of or gene expression in
pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
for stimulating the proliferation or differentiation of chondrocyte
cells. PRO231, PRO357, PRO725, PRO155, PRO136 or PRO1419 polypeptide
are useful for stimulating the release of tumour necrosis factor (TNF)-
alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
PRO1343, PRO1376, PRO1397, PRO1409, PRO1474, PRO1317, PRO1760, PRO1567,
PRO1887, PRO1328, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
stimulating the proliferation of normal human dermal fibroblasts cells.
PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
PRO5723, PRO5725, PRO1754, or PRO7425 polypeptide are useful for
inhibiting the proliferation of normal human dermal fibroblast cells. PRO
polypeptides such as PRO6004, PRO4981, PRO174, PRO5778, PRO4332, etc.,
are useful for detecting the presence of tumour in a mammal which
involves comparing the level of expression of the above PRO polypeptides
in a test sample of cells taken from the mammal, and a control sample of
normal cells of the same cell type, where a higher level of expression of
the PRO polypeptides in the test sample as compared to the control sample

is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful for screening useful reagents. PRO357, PRO229, PRO272 or PRO405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

```

Best Local Similarity      100.0%; Pred. NO. 6.7e-05;
Matches 1679; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

```

Qy	1	GTGTGTCCTTCAGCGAAACAGTGGATTAAATCTCTCTTGCACAGCTTGAGAGCAAC	60
Db	1	GTGTGTCCTTCAGCGAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC	60
Qy	61	AATCTATCAGGAAGAAAGAAAGAAAAAOCGAACCTGCACAAAGAAAGAAAAAGAG	120
Db	61	AATCTATCAGGAAGAAAGAAAGAAAAAOCGAACCTGCACAAAGAAAGAAAAAGAG	120
Qy	121	AAGAAAAAAATCATGAAGAACCATCCAGCCAAAAATGCAATTTCTATCTTTGGCAAT	180
Db	121	AAGAAAAAAATCATGAAGAACCATCCAGCCAAAAATGCAATTTCTATCTTTGGCAAT	180
Qy	181	CTTCACGGGGCTGGCTGCTCTGTGTCTCTTCCAGAGAGTGCCCGTGGCAGCGGAGATCC	240
Db	181	CTTCACGGGGCTGGCTGCTCTGTGTCTCTTCCAGAGAGTGCCCGTGGCAGCGGAGATCC	240
Qy	241	CACCTTTCCCAAGCTATTGGACAAAGTGACAGCTCCGGCAGGGGAGAGCGCCACCTCAG	300
Db	241	CACCTTTCCCAAGCTATTGGACAAAGTGACAGCTCCGGCAGGGGAGAGCGCCACCTCAG	300
Qy	301	GTGCACTATTGACAAACCGGGTCAACCGGGTGCGCTTGGCTAAACCGCAGCACTTCTCTA	360
Db	301	GTGCACTATTGACAAACCGGGTCAACCGGGTGCGCTTGGCTAAACCGCAGCACTTCTCTA	360
Qy	361	TGCTGGGAATGACAAGTGTGTCTGATCTCTCGGTGTCTCTCTGAGCAACCCCAAC	420
Db	361	TGCTGGGAATGACAAGTGTGTCTGATCTCTCGGTGTCTCTCTGAGCAACCCCAAC	420
Qy	421	GCAGTACAGCATCGAGATCCAGAACCTTGAAGTGTGTATGACGAGGGCCCTTACACCTGCTC	480
Db	421	GCAGTACAGCATCGAGATCCAGAACCTTGAAGTGTGTATGACGAGGGCCCTTACACCTGCTC	480
Qy	481	GGTGCGACAGACACACCCAAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
Db	481	GGTGCGACAGACACACCCAAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
Qy	541	CAAAATTTGTAGAGATTTCTTCAGATATCTCCAAATTAAGAGGGAAACAATATTAGCCTCAC	600
Db	541	CAAAATTTGTAGAGATTTCTTCAGATATCTCCAAATTAAGAGGGAAACAATATTAGCCTCAC	600
Qy	601	CTGCATAGCAACTGTGTAGACAGACCTACGGTTACTTGGAGACACATCTCTCCCAAGC	660
Db	601	CTGCATAGCAACTGTGTAGACAGACCTACGGTTACTTGGAGACACATCTCTCCCAAGC	660
Qy	661	GGTTGGCTTTGTGAGTGAAGAGGAATATTGGAAATTCAGGGCATCACCCGGGAGAGTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGAGGAATATTGGAAATTCAGGGCATCACCCGGGAGAGTC	720
Qy	721	AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCCCGCCCTGGTACGGAGATAA	780
Db	721	AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCCCGCCCTGGTACGGAGATAA	780
Qy	781	GGTCAACCGTGAACTATCCACCAATATTTTCAGAGCCCAAGGGTACAGGTGTCCCGTGG	840
Db	781	GGTCAACCGTGAACTATCCACCAATATTTTCAGAGCCCAAGGGTACAGGTGTCCCGTGG	840

PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S,
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786905/74.
DR P-PSDB; ADB66588.
XX
XX New PRO nucleic acid, useful for preparing a composition for treating
XX e.g. tumor or for tissue typing.
XX
XX Claim 2; Fig 375; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from PMBC cells, for inhibiting the binding of
XX A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping. In generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This sequence encodes
XX a novel human secreted and transmembrane PRO polypeptide.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 1679; DB 1; Length 1679;
XX Best Local Similarity 100.0%; Pred. No. 6.7e-05;
XX Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTCTGCAAGCTTGAGAGCAAC 60
XX
XX 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTCTGCAAGCTTGAGAGCAAC 60
XX
XX 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
XX
XX 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
XX
XX 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAATGCAAAATGCAATCTCTCTGGGCAAT 180

Db 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAATGCAAAATGCAATCTCTCTGGGCAAT 180
Qy 181 CTTACGGGGGTGGCTGTCTGTGTCTCTTCCAAAGGAGTGCCTGTGGCAGCGAGATGC 240
Db 181 CTTACGGGGGTGGCTGTCTGTGTCTCTTCCAAAGGAGTGCCTGTGGCAGCGAGATGC 240
Qy 241 CACCTTCCCCAAAAGCTATGGAACAGCTGACCGTCCGGCAGGGGAGAGCGCCACTCAG 300
Db 241 CACCTTCCCCAAAAGCTATGGAACAGCTGACCGTCCGGCAGGGGAGAGCGCCACTCAG 300
Qy 301 GTGCACACTATTGACAAACCGGGTCAACCGGGTGGCTTGGCTAAACCGCAGCACCCTCTCTA 360
Db 301 GTGCACACTATTGACAAACCGGGTCAACCGGGTGGCTTGGCTAAACCGCAGCACCCTCTCTA 360
Qy 361 TGCTGGGAATGACAAAGTGGTGCCTGATTCCTCGGGTGGTCTTGTGAGCAACACCCAAAC 420
Db 361 TGCTGGGAATGACAAAGTGGTGCCTGATTCCTCGGGTGGTCTTGTGAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAGACGTCGATGTGTATGACGAGGGCCCTTACACTGTCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAGACGTCGATGTGTATGACGAGGGCCCTTACACTGTCTC 480
Qy 481 GGTGAGAGACAGCAACACCCAAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGAGAGACAGCAACACCCAAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Qy 541 CAARATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTTCAC 600
Db 541 CAARATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTTCAC 600
Qy 601 CTGCATAGCAACTGGTAGACAGCCTACCGTTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGCCTACCGTTTACTTTGGAGACACATCTCTCCAAAGC 660
Qy 661 GGTGGCTTTGTGAGTGAAGCGATCTTGGAAATTCAGGGCATCCCGGGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGCGATCTTGGAAATTCAGGGCATCCCGGGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCCCGCCGCTGGTACGGAGAGTAAA 780
Db 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCCCGCCGCTGGTACGGAGAGTAAA 780
Qy 781 GGTCCCGTGAACATCCACCATATTCATTTCAGAGCCAAAGGTCAGGTGTCCTGGG 840
Db 781 GGTCCCGTGAACATCCACCATATTCATTTCAGAGCCAAAGGTCAGGTGTCCTGGG 840
Qy 841 ACAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCCAGCAGAAATTCAGTGTA 900
Db 841 ACAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCCAGCAGAAATTCAGTGTA 900
Qy 901 CAAGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db 901 CAAGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Qy 961 CTTCTCAAAACCTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAATACACTTGGGT 1020
Db 961 CTTCTCAAAACCTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAATACACTTGGGT 1020
Qy 1021 GGCCTCCAAAGCTGGGCGACACAATGCGCAGCATCATGCTATTGTCAGAGCGCGCT 1080
Db 1021 GGCCTCCAAAGCTGGGCGACACAATGCGCAGCATCATGCTATTGTCAGAGCGCGCT 1080
Qy 1081 CAGCGAGGTGACCAACGGCAGCTGCGAGGAGGCGGCTGCTGGCTGCTGCTCTTCT 1140
Db 1081 CAGCGAGGTGACCAACGGCAGCTGCGAGGAGGCGGCTGCTGGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCGAACCGGAAAGGCT 1200
Db 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCGAACCGGAAAGGCT 1200
Qy 1201 GCGCGCACCCACCAACCAACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260

Db 1201 GCGGCCACACACACACACACAGCAATGGCAACACCGACACCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATAGAGAAACACAGCCTCATGGGACAGAAAATTGAGGAGGGGAAC 1320
Db 1261 TATACAAATGAATAGAGAAACACAGCCTCATGGGACAGAAAATTGAGGAGGGGAAC 1320
QY 1321 AAAGATACTTTGGGGGGAAGAGATTTTAAAGAAAGAAATTCGAAATTCGCTTGCAGATA 1380
Db 1321 AAAGATACTTTGGGGGGAAGAGATTTTAAAGAAAGAAATTCGAAATTCGCTTGCAGATA 1380
QY 1381 TTTAGTCAATGGAGTTTCTTTTCCAAAACGGGAAGAACACAGACACCCCGGCTTGGGA 1440
Db 1381 TTTAGTCAATGGAGTTTCTTTTCCAAAACGGGAAGAACACAGACACCCCGGCTTGGGA 1440
QY 1441 CCACATGCAAGCTGCTGCAACTCTTTGGTCCAGTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCACATGCAAGCTGCTGCAACTCTTTGGTCCAGTGGGCAAGGCTCAGCCTC 1500
QY 1501 TCTGCCACACAGAGTGCCTCCACGTCGAAACATTTCTGGAGTGGCCATCCCAAAATTCATCA 1560
Db 1501 TCTGCCACACAGAGTGCCTCCACGTCGAAACATTTCTGGAGTGGCCATCCCAAAATTCATCA 1560
QY 1561 GTCCATAGAGACGACAGATGAGACCTTCCGGCCCAAGCTGGCGCTGCGGGCACTTTG 1620
Db 1561 GTCCATAGAGACGACAGATGAGACCTTCCGGCCCAAGCTGGCGCTGCGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACACGCGGTGTGTGTAACCGTGAATATAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACACACGCGGTGTGTGTAACCGTGAATATAAGAGCAAAAAAAA 1679

RESULT 5
ID ADB84992
ADB84992 standard; cDNA; 1679 BP.

AC ADB84992;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide #63.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritis.
XX
OS Homo sapiens.
XX
PN US2003073817-A1.
XX
PD 17-APR-2003.

XX 26-AUG-2002; 2002US-00227883..
XX 01-AUG-2000; 2000US-0222425P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX WPI; 2003-730024/69.
DR P-PSDB; ADB84993.
DR
XX
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT e.g. in gene therapy, disease diagnosis, chromosome identification and
PT tissue typing.
XX
XX Claim 2; Fig 125; 314pp; English.

XX
CC The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTTAAATCTCTTCACAAAGTTTGAGAGCAAC 60
Db 1 GTTGTGCTCTTCAGCAAAACAGTGGATTTAAATCTCTTCACAAAGTTTGAGAGCAAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAATGCAATTTCTATCTCTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAATGCAATTTCTATCTCTGGGCAAT 180
QY 181 CTTTACCGGGGTGGCTGCTGTCTCTTCCAAAGAGTCCCGTGGCGAGCGAGATGC 240
Db 181 CTTTACCGGGGTGGCTGCTGTCTCTTCCAAAGAGTCCCGTGGCGAGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGACACGTCGCGTCCGCGAGGAGCGCCACCCCTCAG 300
Db 241 CACCTTCCCAAGCTATGGACACGTCGCGTCCGCGAGGAGCGCCACCCCTCAG 300
QY 301 GTGCATTTATGACAAACCGGCTCACCCGGTGGCTGGCTAAACCGCAGCACCATCTCTTA 360
Db 301 GTGCATTTATGACAAACCGGCTCACCCGGTGGCTGGCTAAACCGCAGCACCATCTCTTA 360
QY 361 TGCTGGGAATGACAAAGTGGTGGCTGGATCTCGCGTGGCTCTCTGAGCAGCACCAGAAC 420
Db 361 TGCTGGGAATGACAAAGTGGTGGCTGGATCTCGCGTGGCTCTCTGAGCAGCACCAGAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACCTGAGTGTGTATGACAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACCTGAGTGTGTATGACAGGGCCCTTACACCTGCTC 480
QY 481 GGTGCAGACAGACACCCCAAGACCTCTAGGTGTCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCAGACAGACACCCCAAGACCTCTAGGTGTCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Db 541 CAAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACACAGCCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660

601 CTGATAGCACTGGTAGACAGAGCTTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
661 GGTGGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
661 GGTGGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
721 AGGGGACTACAGTGCAGTGCTCCATGACGTGGCGCGCCGTGTGTACGGAGAGTAAA 780
721 AGGGGACTACAGTGCAGTGCTCCATGACGTGGCGCGCCGTGTGTACGGAGAGTAAA 780
781 GGTCAACCGTGAATATCACCATATCATTTGAGAACCAAGGGTACAGGTTCCCGGTGGG 840
781 GGTCAACCGTGAATATCACCATATCATTTGAGAACCAAGGGTACAGGTTCCCGGTGGG 840
841 ACAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGCGAATTCAGTGGTA 900
841 ACAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGCGAATTCAGTGGTA 900
901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAACAGACCTTT 960
901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAACAGACCTTT 960
961 CCTCTCAAACTCATCTCTTCAATGTCTCTGACATGATGGGAATCTACACTTGGCT 1020
961 CCTCTCAAACTCATCTCTTCAATGTCTCTGACATGATGGGAATCTACACTTGGCT 1020
1021 GGCCTCCAAAGCTGGGCCCAACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCGT 1080
1021 GGCCTCCAAAGCTGGGCCCAACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCGT 1080
1081 CAGGAGGTGAGCAACCGCAGCTGAGGAGGGGAGGCTGGTGTGGTGTGCTCTTCT 1140
1081 CAGGAGGTGAGCAACCGCAGCTGAGGAGGGGAGGCTGGTGTGGTGTGCTCTTCT 1140
1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTAGTGCCACTTCCCAACCGGGAAGGCT 1200
1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTAGTGCCACTTCCCAACCGGGAAGGCT 1200
1201 GCGGCGACACACACCAACACAGCAATGCGCAACAGCGACAGCAACCAATCAGATA 1260
1201 GCGGCGACACACACCAACACAGCAATGCGCAACAGCGACAGCAACCAATCAGATA 1260
1261 TATCAAAATGAAATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320
1261 TATCAAAATGAAATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320
1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1381 TTTAGGTACATGAGTTTCTTTTCCCAACCGGGAAGACACAGCACACCCGGCTTGA 1440
1381 TTTAGGTACATGAGTTTCTTTTCCCAACCGGGAAGACACAGCACACCCGGCTTGA 1440
1441 CCCACTGCAAGCTGCATGGTGCAACTCTTTGGTCCAGTGTGGCAAGGGCTCAGCCTC 1500
1441 CCCACTGCAAGCTGCATGGTGCAACTCTTTGGTCCAGTGTGGCAAGGGCTCAGCCTC 1500
1501 TCTGCCACAGAGTCCCAACGTTGAACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
1501 TCTGCCACAGAGTCCCAACGTTGAACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
1561 GTCCATAGAGACGAATGAGACTTCCGCGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
1561 GTCCATAGAGACGAATGAGACTTCCGCGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
1621 GTAGACTGTGCCACAGCGGTGTGTGTAAGCTGAATTAAGAGAGCAAAAAA 1679
1621 GTAGACTGTGCCACAGCGGTGTGTGTAAGCTGAATTAAGAGAGCAAAAAA 1679

RESULT 6

ADB89667
ID ADB89667 standard; cDNA; 1679 BP.
XX
AC ADB89667;
XX
DT 04-DEC-2003 (first entry)
XX
KW Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082698-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127850.
XX
PR 20-AUG-1998; 98US-0097218P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 98US-00380137.
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-743896/70.
XX
DR P-PSDB; ADB89668.
XX
PT New PRO nucleic acids and encoded polypeptides, useful in the treatment
of cancer.
XX
PS Claim 2; Fig 375; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GTGTGTCCTTCAGCAAAACAGTGATTTAAATCTCCTTGCAACAGCTTGAGCAACAC	60
Db	1	GTGTGTCCTTCAGCAAAACAGTGATTTAAATCTCCTTGCAACAGCTTGAGCAACAC	60
Qy	61	AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
Db	61	AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
Qy	121	AGAGAAAGAAATCATGAAACCATCCAGCCAAATATGCAATTTCTCTCTGGGCAAT	180
Db	121	AGAGAAAGAAATCATGAAACCATCCAGCCAAATATGCAATTTCTCTCTGGGCAAT	180
Qy	181	CTTCAGGGGCTGGCTGTCTGTCTCTTCAAGAGTGGCCGTGCGCAGCGGAGATGC	240
Db	181	CTTCAGGGGCTGGCTGTCTGTCTCTTCAAGAGTGGCCGTGCGCAGCGGAGATGC	240
Qy	241	CACCTTCCCAAGCTATGGAACAGTGACGTCCGGCAGGGGAGAGCGCACCTCAG	300
Db	241	CACCTTCCCAAGCTATGGAACAGTGACGTCCGGCAGGGGAGAGCGCACCTCAG	300
Qy	301	GTGCACTATTGACAAACCGGGTCACCGGGTGGCTTAAACCGCAGCACCATCTCTA	360
Db	301	GTGCACTATTGACAAACCGGGTCACCGGGTGGCTTAAACCGCAGCACCATCTCTA	360
Qy	361	TGCTGGGATGACAGTGTGCTGTGATCTCGGTGTCCTTCTGAGCAACACCAAC	420
Db	361	TGCTGGGATGACAGTGTGCTGTGATCTCGGTGTCCTTCTGAGCAACACCAAC	420
Qy	421	GCAGTACAGCATCGAGATCCAGAACTGTATGATGACGAGGGCCCTTACACCTGCTC	480
Db	421	GCAGTACAGCATCGAGATCCAGAACTGTATGATGACGAGGGCCCTTACACCTGCTC	480
Qy	481	GGTGCAGACAGCAACACCAAGACCTCTAGGGTCCACCTCATTTGTCAGAGTATCTCC	540
Db	481	GGTGCAGACAGCAACACCAAGACCTCTAGGGTCCACCTCATTTGTCAGAGTATCTCC	540
Qy	541	CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCTCAC	600
Db	541	CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCTCAC	600
Qy	601	CTGCATAGCAACTGGTAGACGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC	660
Db	601	CTGCATAGCAACTGGTAGACGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC	660
Qy	661	GGTGTGCTTTGTGAGTGAGAGCAATCTTGGAAATTCAGGGGATCACCCGGGAGCAGTC	720
Db	661	GGTGTGCTTTGTGAGTGAGAGCAATCTTGGAAATTCAGGGGATCACCCGGGAGCAGTC	720
Qy	721	AGGGGACTACAGTGCAGTGCCTCCCAATGACGTGGCCCGCGTGGTACGAGAGTAA	780
Db	721	AGGGGACTACAGTGCAGTGCCTCCCAATGACGTGGCCCGCGTGGTACGAGAGTAA	780
Qy	781	GGTACCGGTAACTATCCACATCATTTTCAAGAGCAAGGGTACAGGTGTCCCGTGGG	840
Db	781	GGTACCGGTAACTATCCACATCATTTTCAAGAGCAAGGGTACAGGTGTCCCGTGGG	840

Qy	841	ACAAAAGGGACACTGCAGTGTGAAGCCTCAGAGTCCCTCAGCAGAAATTCAGTGTGA	900
Db	841	ACAAAAGGGACACTGCAGTGTGAAGCCTCAGAGTCCCTCAGCAGAAATTCAGTGTGA	900
Qy	901	CAAGGATGACAAAGACTGATTTGAAGGAAAGAAAGGGTGAAGTGAAGAAACAGACCTTT	960
Db	901	CAAGGATGACAAAGACTGATTTGAAGGAAAGAAAGGGTGAAGTGAAGAAACAGACCTTT	960
Qy	961	CTCTCAAAACTCATCTTCTCAATCTCTCTGAACATGACTATGGGAACATACACTTGGCT	1020
Db	961	CTCTCAAAACTCATCTTCTCAATCTCTCTGAACATGACTATGGGAACATACACTTGGCT	1020
Qy	1021	GGCTCCCAACAGCTGGGCACACCAATGCCAGCATCATGCTATTGTTGTCAGGCGCCGT	1080
Db	1021	GGCTCCCAACAGCTGGGCACACCAATGCCAGCATCATGCTATTGTTGTCAGGCGCCGT	1080
Qy	1081	CAGCGAGGTGAGCAACCGGCACGTCGAGGAGGGCAGGCTGCGTCTGCTGCTCTTCT	1140
Db	1081	CAGCGAGGTGAGCAACCGGCACGTCGAGGAGGGCAGGCTGCGTCTGCTGCTCTTCT	1140
Qy	1141	GGTCTTGACCTCTCTCAATTTTGTGATGTAGTGCCACTTCCCCACCGGGAAGGCT	1200
Db	1141	GGTCTTGACCTCTCTCAATTTTGTGATGTAGTGCCACTTCCCCACCGGGAAGGCT	1200
Qy	1201	GGCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA	1260
Db	1201	GGCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA	1260
Qy	1261	TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGGGGAAC	1320
Db	1261	TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGGGGAAC	1320
Qy	1321	AAAGAAATCTTTGGGGGGAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTTGACAGATA	1380
Db	1321	AAAGAAATCTTTGGGGGGAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTTGACAGATA	1380
Qy	1381	TTTAGTACAAATGAGAGTTTCTTTCCAAAACGGGAAGAACACAGCACACCCCGCTTGA	1440
Db	1381	TTTAGTACAAATGAGAGTTTCTTTCCAAAACGGGAAGAACACAGCACACCCCGCTTGA	1440
Qy	1441	CCCACTGCAAGTGCATCGTGCACACCTTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGTGCATCGTGCACACCTTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC	1500
Qy	1501	TCTGCCACAGAGTGCCTCCCAACGTCGAAACATTTCTGAGCTGGCCATCCCAATTCATCA	1560
Db	1501	TCTGCCACAGAGTGCCTCCCAACGTCGAAACATTTCTGAGCTGGCCATCCCAATTCATCA	1560
Qy	1561	GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGTGGGGCAGCTTG	1620
Db	1561	GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGTGGGGCAGCTTG	1620
Qy	1621	GTAGACTGTGCCACCGCGGTGTTGTGAACGTGAATAAAGAGCAAAAAA	1679
Db	1621	GTAGACTGTGCCACCGCGGTGTTGTGAACGTGAATAAAGAGCAAAAAA	1679

RESULT 7

ADB90399 standard; cDNA; 1679 BP.

XX AC ADB90399;

XX DT 04-DEC-2003 (first entry)

XX DE Human PRO polynucleotide #188.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; RFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

OS Homo sapiens.

PN US2003082762-A1.

PD 01-MAY-2003.

PP 15-APR-2002; 2002US-00123235.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 01-DEC-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US00106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005130.

PR 14-APR-1999; 99WO-US008615.

PR 20-APR-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028584.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 10-MAR-2000; 2000WO-US005841.

PR 15-MAR-2000; 2000WO-US006319.

PR 20-MAR-2000; 2000WO-US006884.

PR 21-MAR-2000; 2000WO-US007377.

PR 30-MAR-2000; 2000WO-US007532.

PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.

PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001US-00796498.

PR 28-FEB-2001; 2001WO-US006520.

PR 01-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.

PR 14-MAR-2001; 2001US-00808689.

PR 22-MAR-2001; 2001US-00816744.

PR 05-APR-2001; 2001US-00828366.

PR 10-MAY-2001; 2001US-00854208.

PR 18-MAY-2001; 2001US-00854280.

PR 19-MAY-2001; 2001US-00860216.

PR 25-MAY-2001; 2001US-00866028.

PR 25-MAY-2001; 2001US-00866034.

PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001US-00872035.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 14-JUN-2001; 2001US-00882636.

PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.

PR 21-JUN-2001; 2001US-00887879.

PR 22-JUN-2001; 2001WO-US020116.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-JUL-2001; 2001WO-US021735.

PR 18-JUL-2001; 2001US-00908827.

PR 06-AUG-2001; 2001US-00924419.

PR 09-AUG-2001; 2001US-00927796.

PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;

XX WPI; 2003-743899/70.

DR P-PSDE; ADE90400.

PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 in gene therapy, and in the detection and treatment of tumor in a mammal.

XX Claim 2; Fig 375; 649pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTTGCACAACTTGAGCAACAC	60
DB	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTTGCACAACTTGAGCAACAC	60
QY	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
DB	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
QY	121	AAGAAAGAAATCATGAAGAAACCATCAGCCAAATGCAATTCCTCTTGGCAAT	180
DB	121	AAGAAAGAAATCATGAAGAAACCATCAGCCAAATGCAATTCCTCTTGGCAAT	180
QY	181	CTTCAGGGGCTGGCTGCTGTGTCTCTTCAAGGAGTCCCGTCCGAGCGGAGATGC	240
DB	181	CTTCAGGGGCTGGCTGCTGTGTCTCTTCAAGGAGTCCCGTCCGAGCGGAGATGC	240
QY	241	CACCTTCCCAAGCTATGACAACTGACAGCTGCGTCCGCGAGGAGCGCCACCTCAG	300
DB	241	CACCTTCCCAAGCTATGACAACTGACAGCTGCGTCCGCGAGGAGCGCCACCTCAG	300
QY	301	GTGCACCTATTGACAAACCGGCTACCCGGTGGCTGCTTCTTCAAGGAGTCCCGTCCG	360
DB	301	GTGCACCTATTGACAAACCGGCTACCCGGTGGCTGCTTCTTCAAGGAGTCCCGTCCG	360
QY	361	TGCTGGGAATGACAGTGGTGGCTGATCTCTGCGTGGCTCTTCTGAGCAACACCCAC	420
DB	361	TGCTGGGAATGACAGTGGTGGCTGATCTCTGCGTGGCTCTTCTGAGCAACACCCAC	420
QY	421	GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC	480
DB	421	GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC	480
QY	481	GGTGAGAGACAAACCCAAAGACCTTAGGGTCCACCTCATTTGTCAGATATCTCC	540
DB	481	GGTGAGAGACAAACCCAAAGACCTTAGGGTCCACCTCATTTGTCAGATATCTCC	540
QY	541	CAAAATGTAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC	600
DB	541	CAAAATGTAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC	600
QY	601	CTGCATAGCACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCAAAGC	660
DB	601	CTGCATAGCACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCAAAGC	660
QY	661	GGTTGGCTTTGTAGTGAAGCAATCTTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
DB	661	GGTTGGCTTTGTAGTGAAGCAATCTTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
QY	721	AGGGGACTACAGTGCAGTCCCTCCAAATGACGTGGCGCGCCCGTGGTACGGAGATAA	780
DB	721	AGGGGACTACAGTGCAGTCCCTCCAAATGACGTGGCGCGCCCGTGGTACGGAGATAA	780

QY	781	GGTCACCGTGAATCTATCCACCATACATTTTTCAGAAAGCAAGGGTACAGGTGTCTCCCGTGGG	840
DB	781	GGTCACCGTGAATCTATCCACCATACATTTTTCAGAAAGCAAGGGTACAGGTGTCTCCCGTGGG	840
QY	841	ACAAAAGGGGACACTGCAAGTGTGAAGCTCAGAGTCCCTCAGAGAAATTCAGTGGTA	900
DB	841	ACAAAAGGGGACACTGCAAGTGTGAAGCTCAGAGTCCCTCAGAGAAATTCAGTGGTA	900
QY	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAAGTGAAGAACAGACCTTT	960
DB	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAAGTGAAGAACAGACCTTT	960
QY	961	CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGAGGAACTACACTTCGCT	1020
DB	961	CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGAGGAACTACACTTCGCT	1020
QY	1021	GGCTCCCAAGCTGGGCGCACCAATGCCAGCATCATCTATTTCTCCAGCGCGCT	1080
DB	1021	GGCTCCCAAGCTGGGCGCACCAATGCCAGCATCATCTATTTCTCCAGCGCGCT	1080
QY	1081	CAGCGAGTGAAGCAACCGCACCTGAGAGGGGAGGCTGTGGTGTGCTCTCTCT	1140
DB	1081	CAGCGAGTGAAGCAACCGCACCTGAGAGGGGAGGCTGTGGTGTGCTCTCTCTCT	1140
QY	1141	GGTCTTGCACCTGCTCTCAAAATTTTTCATGTAGTGCACCTTCCACCGGAAAGGCT	1200
DB	1141	GGTCTTGCACCTGCTCTCAAAATTTTTCATGTAGTGCACCTTCCACCGGAAAGGCT	1200
QY	1201	GGCTCCCAAGCTGGGCGCACCAATGCCAGCATCATCTATTTCTCCAGCGCGCT	1260
DB	1201	GGCTCCCAAGCTGGGCGCACCAATGCCAGCATCATCTATTTCTCCAGCGCGCT	1260
QY	1261	TATACAAATGAAATTTAGAGAAACACAGCTTCATGGGACAGAAATTTGAGGGAGGGAAC	1320
DB	1261	TATACAAATGAAATTTAGAGAAACACAGCTTCATGGGACAGAAATTTGAGGGAGGGAAC	1320
QY	1321	AAAGAAATCTTTGGGGGAAAGAGTGTAAAAAAGAAATTTGAAAAATTTGCCCTTCAGATA	1380
DB	1321	AAAGAAATCTTTGGGGGAAAGAGTGTAAAAAAGAAATTTGAAAAATTTGCCCTTCAGATA	1380
QY	1381	TTTAGGTACAAATGAGATTTCTTTTCCAAACCGGAAAGACACAGCACCCCGCTTGA	1440
DB	1381	TTTAGGTACAAATGAGATTTCTTTTCCAAACCGGAAAGACACAGCACCCCGCTTGA	1440
QY	1441	CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC	1500
DB	1441	CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC	1500
QY	1501	TCTGCCACAGAGTGCCTCCCAACGCTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA	1560
DB	1501	TCTGCCACAGAGTGCCTCCCAACGCTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA	1560
QY	1561	GTCCATAGAGACGAAACAGATGAGACCTTCCGCGCCCAAGCGTGGCGTCCGCGCACTTTG	1620
DB	1561	GTCCATAGAGACGAAACAGATGAGACCTTCCGCGCCCAAGCGTGGCGTCCGCGCACTTTG	1620
QY	1621	GTAGACTGTGCCACACCGCGCTGTGTGTGAAACGCTGAAATATAAAGAGCAAAAAAAA	1679
DB	1621	GTAGACTGTGCCACACCGCGCTGTGTGTGAAACGCTGAAATATAAAGAGCAAAAAAAA	1679

RESULT 8

ADB39500 standard; cDNA; 1679 BP.

XX AC ADB39500;
XX DT 04-DEC-2003 (first entry)

DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.

OS Homo sapiens.

XX US2003082764-A1.

PN 01-MAY-2003.

XX 03-MAY-2002; 2002US-00137868.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 28-AUG-1998; 98WO-US014552.

PR 10-SEP-1998; 98WO-US017888.

PR 14-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019177.

PR 17-SEP-1998; 98WO-US019330.

PR 07-OCT-1998; 98WO-US019437.

PR 29-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 01-DEC-1998; 98WO-US022992.

PR 01-DEC-1998; 98WO-US024855.

PR 05-JAN-1999; 98WO-US025108.

PR 08-MAR-1999; 98WO-US000106.

PR 10-MAR-1999; 98WO-US005028.

PR 20-APR-1999; 98WO-US005190.

PR 14-MAY-1999; 98WO-US008615.

PR 01-JUN-1999; 98WO-US010733.

PR 01-SEP-1999; 98WO-US012252.

PR 08-SEP-1999; 98WO-US020111.

PR 13-SEP-1999; 98WO-US020594.

PR 15-SEP-1999; 98WO-US020944.

PR 15-SEP-1999; 98WO-US021090.

PR 05-OCT-1999; 98WO-US021547.

PR 29-NOV-1999; 98WO-US023089.

PR 30-NOV-1999; 98WO-US028214.

PR 01-DEC-1999; 98WO-US028313.

PR 01-DEC-1999; 98WO-US028409.

PR 01-DEC-1999; 98WO-US028301.

PR 02-DEC-1999; 98WO-US028634.

PR 02-DEC-1999; 98WO-US028551.

PR 02-DEC-1999; 98WO-US028564.

PR 16-DEC-1999; 98WO-US028565.

PR 20-DEC-1999; 98WO-US030095.

PR 20-DEC-1999; 98WO-US030911.

PR 22-DEC-1999; 98WO-US030939.

PR 30-DEC-1999; 98WO-US030720.

PR 05-JAN-2000; 98WO-US031243.

PR 06-JAN-2000; 2000WO-US000219.

PR 11-FEB-2000; 2000WO-US000277.

PR 18-FEB-2000; 2000WO-US003376.

PR 18-FEB-2000; 2000WO-US003565.

PR 22-FEB-2000; 2000WO-US004341.

PR 24-FEB-2000; 2000WO-US004342.

PR 24-FEB-2000; 2000WO-US004914.

PR 01-MAR-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 10-MAR-2000; 2000WO-US005841.

PR 15-MAR-2000; 2000WO-US006319.

PR 20-MAR-2000; 2000WO-US006884.

PR 21-MAR-2000; 2000WO-US007377.

PR 30-MAR-2000; 2000WO-US007532.

PR 30-MAR-2000; 2000WO-US008439.

PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US020331.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-0082706.
 PR 14-MAR-2001; 2001US-00816744.
 PR 22-MAR-2001; 2001US-00806889.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786919/74.

XX P-PSDB; ADB39501.

DR New secreted and transmembrane PRO polypeptide useful for detecting the
 PT presence of tumor in a mammal, or modulating the uptake of glucose or
 PT free fatty acid by skeletal muscle cells or adipocyte cells.

XX Claim 2; Fig 375; 659pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful

CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTGAGAAAACAGTGGATTAAATCTCTCTGCAAGCTTGAGCAACAC 60
DB 1 GTTGTGCTCTGAGAAAACAGTGGATTAAATCTCTCTGCAAGCTTGAGCAACAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAAACCGAACCTGACAAAAAAGAAAGAAAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAAACCGAACCTGACAAAAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACCAATCAGCCAAAATGCAAAATTCATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAACCAATCAGCCAAAATGCAAAATTCATCTCTTGGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTCTGTGCTCTCTTCAAGAGTGGCCGTCGCGAGGGAGATGC 240
DB 181 CTTTCAGGGGCTGGCTCTGTGCTCTCTTCAAGAGTGGCCGTCGCGAGGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGAGCAACCGTGCAGTCCGGCAGGGGAGCGCCACCTCTCA 300
DB 241 CACCTTCCCAAGCTATGAGCAACCGTGCAGTCCGGCAGGGGAGCGCCACCTCTCA 300
QY 301 GTGCACTATTGACACCGGGTCAACCGGTGGCTGGCTTAAACCGCAGCACCATCTCTA 360
DB 301 GTGCACTATTGACACCGGGTCAACCGGTGGCTGGCTTAAACCGCAGCACCATCTCTA 360
QY 361 TGTGGGAATGACAACTGTGCTGGATCTCTCGGTGGTCTCTGAGCAACACCCAAAC 420
DB 361 TGTGGGAATGACAACTGTGCTGGATCTCTCGGTGGTCTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTGATGTATGACGAGGGCCCTTACCTGTCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTGATGTATGACGAGGGCCCTTACCTGTCTC 480
QY 481 GGTGACAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTGTAGAGATTTCTTCAATATCTCCATTAATGAAGGAAACATATTAGCCTCAC 600
DB 541 CAAAATTGTAGAGATTTCTTCAATATCTCCATTAATGAAGGAAACATATTAGCCTCAC 600
QY 601 CTGATAGCAACTGTGTAGACAGAGCTACGGTTACTTGTGACACATCTCTCCCAAGC 660
DB 601 CTGATAGCAACTGTGTAGACAGAGCTACGGTTACTTGTGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGAGCAATATCTGGAAATTCAGGGCATCACCCGGGAGCATC 720
DB 661 GGTGGCTTTGTGAGTGAAGAGCAATATCTGGAAATTCAGGGCATCACCCGGGAGCATC 720
QY 721 AGGGGACTACGAGTGCAGTCCCAATCACTGCGCGCCCGCGGTGACGAGAGTAA 780
DB 721 AGGGGACTACGAGTGCAGTCCCAATCACTGCGCGCCCGCGGTGACGAGAGTAA 780
QY 781 GGTCCCGGTGAATATCCACCATACATTTTCAAGAGCAAGGTTACAGGTGTCCCGGTGG 840
DB 781 GGTCCCGGTGAATATCCACCATACATTTTCAAGAGCAAGGTTACAGGTGTCCCGGTGG 840

DB 781 GGTCAACGCTGAACATATCCACATACATTTTCAAGAGCAAGGGTACAGGTGTCTCCCGTGGG 840
QY 841 ACAAAAGGGGACACTGCACTGTGAGAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAAGGGGACACTGCACTGTGAGAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTCTTCAATGCTCTGAACATGACTATGGAACATACACTTTCGT 1020
DB 961 CCTCTCAAACTCATCTCTTCAATGCTCTGAACATGACTATGGAACATACACTTTCGT 1020
QY 1021 GGCCTCCAAAGCTGGGCCACACCAATGCAGCATCATCTTTTGGTCCAGGCGCGT 1080
DB 1021 GGCCTCCAAAGCTGGGCCACACCAATGCAGCATCATCTTTTGGTCCAGGCGCGT 1080
QY 1081 CAGCGAGGTGAGCAACGGGCGCTGAGGAGGGCAGGCTGCTGTGGCTGTCTCTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACGGGCGCTGAGGAGGGCAGGCTGCTGTGGCTGTCTCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTCTCAAAATTTTGTGAGTGGCCACTTCCCAACCGGAAAGGCT 1200
DB 1141 GGTCTTGCACTGCTCTCAAAATTTTGTGAGTGGCCACTTCCCAACCGGAAAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAAGCAATGCAACACCGCAGCAACCAATCAGATA 1260
DB 1201 GCGGCCACCAACCAACCAACCAAGCAATGCAACACCGCAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATATGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
DB 1261 TATACAAATGAATATGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
QY 1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
DB 1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
QY 1381 TTTAGGTACAACTGGAGTTTCTTCCCAACCGGAGACACAGCACACCCCGCTTGA 1440
DB 1381 TTTAGGTACAACTGGAGTTTCTTCCCAACCGGAGAGACACAGCACACCCCGCTTGA 1440
QY 1441 CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTCCCGCCACAGTGGAAACATTTGAGAGTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTCCCGCCACAGTGGAAACATTTGAGAGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCGCGCCCAAGCGTGGCGCTGGGCACTTTG 1620
DB 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCGCGCCCAAGCGTGGCGCTGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACAGCGGTGTGTGTGAACGTGAAATTAAGAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACAGCGGTGTGTGTGTGAACGTGAAATTAAGAGAGCAAAAAA 1679

RESULT 9

ADB78098
ID ADB78098 standard; cdna; 1679 BP.

XX ADB78098;

XX 04-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO337 cdna.

XX Human; secreted and transmembrane protein; PRO; gene; es; cytostatic;
KW vulnery; antihypertic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;

KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
XX US2003092886-A1.
XX
PD 15-MAY-2003.
XX
XX 09-AUG-2002; 2002US-00216165.
XX
XX 25-JUL-2000; 2000US-0220607P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021086.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Deenoyers L, Gerritsen ME, Goddard A, Godowski PU;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX WPI; 2003-765494/72.
DR P-PSDB; ADB78099.
XX
XX Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as
PT molecular weight markers in protein electrophoresis, for treating
PT arthritis, tumor.
XX
XX Claim 2; Fig 125; 308pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO155, PRO1366 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO326, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
CC PRO1285, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO328, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO1714, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
SQ

Query Match

Best Local Similarity 100.0%; Score 1679; DB 1; Length 1679;

Pred. No. 6.7e-05;

	Matches 1679;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
QY	1	GTGTGTCTCTCAGCAAAACAGTGGATTAAATCTCTTGTGACAAAGCTTGAGACCAAC	60						
Db	1	GTGTGTCTCTCAGCAAAACAGTGGATTAAATCTCTTGTGACAAAGCTTGAGACCAAC	60						
QY	61	AATCTATCAGGAAACAGAAAGAAAGAAACCGACCTGACAAAGAAAGAAAGAAAG	120						
Db	61	AATCTATCAGGAAACAGAAAGAAAGAAACCGACCTGACAAAGAAAGAAAGAAAG	120						
QY	121	AAGAAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATCTATCTCTTGGGCAAT	180						
Db	121	AAGAAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATCTATCTCTTGGGCAAT	180						
QY	181	CTTCACGGGGCTGGTCTCTGTGTCTCTCCAGAGTGGCCGTCGCGAGGAGATGC	240						
Db	181	CTTCACGGGGCTGGTCTCTGTGTCTCTCCAGAGTGGCCGTCGCGAGGAGATGC	240						
QY	241	CACCTTCCCAAAGCTATGGACAACTGACCGTCCGGCAGGGGAGAGCGCCACCTCAG	300						
Db	241	CACCTTCCCAAAGCTATGGACAACTGACCGTCCGGCAGGGGAGAGCGCCACCTCAG	300						
QY	301	GTGCACTATTGACACCGGTCACCCGGTGGCTGCTTAAACCGCAGCAGCATCTCTTA	360						
Db	301	GTGCACTATTGACACCGGTCACCCGGTGGCTGCTTAAACCGCAGCAGCATCTCTTA	360						
QY	361	TGCTGGGAATGACAAAGTGGTCTCTGCTGCTCTCTCTCTCTCTCTCTCTCTCTCT	420						
Db	361	TGCTGGGAATGACAAAGTGGTCTCTGCTGCTCTCTCTCTCTCTCTCTCTCTCTCT	420						
QY	421	GCAGTACAGCATCGAGATCCAGACGTCGATGTGTATGACGAGGCGCTTACACCTGTC	480						
Db	421	GCAGTACAGCATCGAGATCCAGACGTCGATGTGTATGACGAGGCGCTTACACCTGTC	480						
QY	481	GGTGCAGACAGACAAACCCAAAGACCTCTAGGGTCCACCTCTCTCTCTCTCTCTCT	540						
Db	481	GGTGCAGACAGACAAACCCAAAGACCTCTAGGGTCCACCTCTCTCTCTCTCTCTCT	540						
QY	541	CAAAATTTAGAGATTTCTTCCAGATATCTCCATTAATGAGGAAACAATATTAGCTC	600						
Db	541	CAAAATTTAGAGATTTCTTCCAGATATCTCCATTAATGAGGAAACAATATTAGCTC	600						
QY	601	CTGCATAGCACTCTGACAGACGCTTACGCTTCTCTCTCTCTCTCTCTCTCTCTCT	660						
Db	601	CTGCATAGCACTCTGACAGACGCTTACGCTTCTCTCTCTCTCTCTCTCTCTCTCT	660						
QY	661	GGTTGGCTTTGTGAGTGAAGACGAAATACCTGGAATTCAGGGCATCACCCGGGAGC	720						
Db	661	GGTTGGCTTTGTGAGTGAAGACGAAATACCTGGAATTCAGGGCATCACCCGGGAGC	720						
QY	721	AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCGCTGACGAGAGTAA	780						
Db	721	AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCGCTGACGAGAGTAA	780						
QY	781	GGTACCGGTGAATTCACCATATTCAGAACCCAAAGGGTACAGTGTCCCGTGG	840						
Db	781	GGTACCGGTGAATTCACCATATTCAGAACCCAAAGGGTACAGTGTCCCGTGG	840						
QY	841	ACAAAGGGGACACTGCAGTGTGAGCTCCAGCTCCCTCAGCAGAAATTCAGTGT	900						
Db	841	ACAAAGGGGACACTGCAGTGTGAGCTCCAGCTCCCTCAGCAGAAATTCAGTGT	900						
QY	901	CAAGGATGACAAAGACGATTTGAAAGGAAAGAAAGGGGTGAAAGTGAAGAAAC	960						
Db	901	CAAGGATGACAAAGACGATTTGAAAGGAAAGAAAGGGGTGAAAGTGAAGAAAC	960						
QY	961	CCTCTCAAACTCATCTTCTTCAATGTCTCTGAAATGACTATGGAACTACACTTGG	1020						
Db	961	CCTCTCAAACTCATCTTCTTCAATGTCTCTGAAATGACTATGGAACTACACTTGG	1020						
QY	1021	GGCTCCCAACAGCTGGGCGCACCAATGCCAGCATCATGCTATTGGTCCAGGCGCG	1080						
Db	1021	GGCTCCCAACAGCTGGGCGCACCAATGCCAGCATCATGCTATTGGTCCAGGCGCG	1080						

QY	1081	CAGCAGGTGACACGACGACGCTCGAGGAGGCGAGCTGCGTGGCTGCTCTCTCT	1140	PR	11-MAR-1998;	98US-0077649P.
Db	1081	CAGCAGGTGACACGACGACGCTCGAGGAGGCGAGCTGCGTGGCTGCTCTCTCT	1140	PR	12-MAR-1998;	98US-0077791P.
QY	1141	GTCTTTGACCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	1200	PR	13-MAR-1998;	98US-0078004P.
Db	1141	GTCTTTGACCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	1200	PR	17-MAR-1998;	98US-00040220.
QY	1201	GCGGCACACACACACACACACACACACACACACACACACACACACACACAC	1260	PR	20-MAR-1998;	98US-0078866P.
Db	1201	GCGGCACACACACACACACACACACACACACACACACACACACACACACAC	1260	PR	20-MAR-1998;	98US-0078910P.
QY	1261	TATACAAATGAATATGAAGAAACACAGCAATGGCAATGGCAATGGCAATGGCA	1320	PR	20-MAR-1998;	98US-0078936P.
Db	1261	TATACAAATGAATATGAAGAAACACAGCAATGGCAATGGCAATGGCAATGGCA	1320	PR	25-MAR-1998;	98US-0079294P.
QY	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATGAAATGAAATGAAATGAAAT	1380	PR	26-MAR-1998;	98US-0079656P.
Db	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATGAAATGAAATGAAATGAAAT	1380	PR	27-MAR-1998;	98US-0079663P.
QY	1381	TTTAGTACAAATGAGTGTCTTTTCCCAACCGGAAGAACACAGCAATGGCAATGGCA	1440	PR	27-MAR-1998;	98US-0079664P.
Db	1381	TTTAGTACAAATGAGTGTCTTTTCCCAACCGGAAGAACACAGCAATGGCAATGGCA	1440	PR	27-MAR-1998;	98US-0079689P.
QY	1441	CCCACTGCAAGCTGCATCGTGCAACCTCTTGGTGCCAGTGTGGCAAGGGCTCAGCCTC	1500	PR	27-MAR-1998;	98US-0079728P.
Db	1441	CCCACTGCAAGCTGCATCGTGCAACCTCTTGGTGCCAGTGTGGCAAGGGCTCAGCCTC	1500	PR	30-MAR-1998;	98US-0079920P.
QY	1501	TCGCCCCACAGAGTGTGCCCCACGTGCAATGAGCTTCCCGCCCAAGCGTGGCGCTCGGGCACTTTG	1560	PR	30-MAR-1998;	98US-0079923P.
Db	1501	TCGCCCCACAGAGTGTGCCCCACGTGCAATGAGCTTCCCGCCCAAGCGTGGCGCTCGGGCACTTTG	1560	PR	31-MAR-1998;	98US-0080105P.
QY	1561	GTCCATAGACGCAACAGATGAGCTTCCCGCCCAAGCGTGGCGCTCGGGCACTTTG	1620	PR	31-MAR-1998;	98US-0080107P.
Db	1561	GTCCATAGACGCAACAGATGAGCTTCCCGCCCAAGCGTGGCGCTCGGGCACTTTG	1620	PR	31-MAR-1998;	98US-0080165P.
QY	1621	GTAGACTGTGCCACCGCGGTGTGTGTGAACGCTGTAATGAAAGAGCAAAAAA	1679	PR	01-APR-1998;	98US-0080194P.
Db	1621	GTAGACTGTGCCACCGCGGTGTGTGTGAACGCTGTAATGAAAGAGCAAAAAA	1679	PR	01-APR-1998;	98US-0080327P.
RESULT 10						98US-0080333P.
ADB74028						98US-0080334P.
ID	ADB74028 standard; cdna; 1679 BP.					98US-0081049P.
XX						98US-0081070P.
AC						98US-0081071P.
XX						98US-0081195P.
XX						98US-0081229P.
DT	04-DEC-2003 (first entry)					98US-0081817P.
XX						98US-0081819P.
XX						98US-0081838P.
DE	Human PRO polynucleotide sequence #133.					98US-0081952P.
XX						98US-0082568P.
KW	Human; PRO polypeptide; secreted protein; transmembrane protein;					98US-0082569P.
KW	cell death; neuropathy; neuropathy related disease;					98US-0082700P.
KW	Charcot-Marie-Tooth disorder; Refsum's disease; Krabbe's disease;					98US-0082704P.
KW	chromosome mapping; gene mapping; genetic disorder; septic shock;					98US-0082797P.
KW	antibacterial; immunosuppressive; neuroprotective; gene; ss.					98US-0082804P.
XX	Homo sapiens.					98US-0082804P.
OS						98US-0082804P.
XX						98US-0082804P.
PN	US2003045462-A1.					98US-0082804P.
XX						98US-0082804P.
PD	06-MAR-2003.					98US-0082804P.
XX						98US-0082804P.
PF	16-OCT-2001; 2001US-00978608.					98US-0082804P.
XX						98US-0082804P.
PR	17-OCT-1997; 97US-0062250P.					98US-0082804P.
PR	03-NOV-1997; 97US-0064249P.					98US-0082804P.
PR	13-NOV-1997; 97US-0065311P.					98US-0082804P.
PR	21-NOV-1997; 97US-0066364P.					98US-0082804P.
PR	10-MAR-1998; 98US-0077450P.					98US-0082804P.
PR	11-MAR-1998; 98US-0077632P.					98US-0082804P.
PR	11-MAR-1998; 98US-0077641P.					98US-0082804P.

Query Match	100.0%;	Score 1679;	DB 1;	Length 1679;
Best Local Similarity	100.0%;	Fred. NO. 6.7e-05;	Mismatches 0;	Indels 0; Gaps 0;
Matches 1679;	Conservative 0;			
24-AUG-2000; 2000WO-US023328.				
08-NOV-2000; 2000US-00709238.				
27-NOV-2000; 2000US-00723749.				
01-DEC-2000; 2000WO-US032678.				
20-DEC-2000; 2000US-00747259.				
20-DEC-2000; 2000WO-US034956.				
28-FEB-2001; 2001WO-US006520.				
22-MAR-2001; 2001US-00816744.				
22-MAR-2001; 2001US-00816920.				
22-MAR-2001; 2001WO-US009552.				
10-MAY-2001; 2001US-00854208.				
10-MAY-2001; 2001US-00854280.				
25-MAY-2001; 2001WO-US017092.				
01-JUN-2001; 2001US-00872035.				
01-JUN-2001; 2001WO-US017800.				
05-JUN-2001; 2001US-00874503.				
14-JUN-2001; 2001US-00882636.				
19-JUN-2001; 2001US-00886342.				
20-JUN-2001; 2001WO-US019692.				
29-JUN-2001; 2001WO-US021066.				
09-JUL-2001; 2001WO-US021735.				
30-JUL-2001; 2001US-00918585.				
(GETH) GENENTECH INC.				
Query Match	100.0%;	Score 1679;	DB 1;	Length 1679;
Best Local Similarity	100.0%;	Fred. NO. 6.7e-05;	Mismatches 0;	Indels 0; Gaps 0;
Matches 1679;	Conservative 0;			
1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAGCTTGAGCAACAC 60				
1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAGCTTGAGCAACAC 60				
61 AATCTATCAGGAAGAAAGAAAGAAAGAAACCGACCTGCAGAAAGAAAGAAAGAAAGAAAG 120				
61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAACCGAACCTGCAGAAAGAAAGAAAGAAAG 120				
121 AAGAAAAAATCATGAAACCATCAGCCAAAAATGCACAAATCTATCTCTTGGGCAAT 180				
121 AAGAAAAAATCATGAAACCATCAGCCAAAAATGCACAAATCTATCTCTTGGGCAAT 180				
181 CTTCAAGGGCTGGCTCTCTGTGTCTCTTCCAAAGAGTGCCCGTGCAGCGAGAGATGC 240				
181 CTTCAAGGGCTGGCTCTCTGTGTCTCTTCCAGAGAGTGCCCGTGCAGCGAGAGATGC 240				
241 CACTTCCCCAAGCTATGGACAAAGTGACGGTCCGGCAGGGGGAGAGCGCAACCTCTCAG 300				
241 CACTTCCCCAAGCTATGGACAAAGTGACGGTCCGGCAGGGGGAGAGCGCGCCCTCTCAG 300				
301 GTGCACATATTGACAAACCGGGTCAACCGGGTCCCTGGCTTAAACCGCAGCACCATCTCTTA 360				
301 GTGCACATATTGACAAACCGGGTCAACCGGGTCCCTGGCTTAAACCGCAGCACCATCTCTTA 360				
361 TGTCTGGAAATGACAAGTGGTGCTGTGATCTCTCGGTGGTCTCTTGTAGCAACACCCAAAC 420				
361 TGTCTGGAAATGACAAGTGGTGCTGTGATCTCTCGGTGGTCTCTTGTAGCAACACCCAAAC 420				
421 CGAGTACAGCATCGAGATCAGAAACCTGCATGTGTATGACGAGGGCCCTTACACTGCTC 480				
421 CGAGTACAGCATCGAGATCAGAAACCTGCATGTGTATGACGAGGGCCCTTACACTGCTC 480				
481 GGTGACACAGACAAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540				
481 GGTGACACAGACAAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540				
541 CAAATTTGTAGAGATTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600				
541 CAAATTTGTAGAGATTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600				
601 CTGCATAGCAACTGGTATAGACAGAGCTTACGGTTACTTGGAGACACATCTCTCCCAAGC 660				
601 CTGCATAGCAACTGGTATAGACAGAGCTTACGGTTACTTGGAGACACATCTCTCCCAAGC 660				

PR	15-MAY-1998;	PR	98US-0085697P;
PR	15-MAY-1998;	PR	98US-0085700P;
PR	15-MAY-1998;	PR	98US-0085704P;
PR	18-MAY-1998;	PR	98US-0086023P;
PR	22-MAY-1998;	PR	98US-0086392P;
PR	22-MAY-1998;	PR	98US-0086414P;
PR	22-MAY-1998;	PR	98US-0086430P;
PR	22-MAY-1998;	PR	98US-0086486P;
PR	28-MAY-1998;	PR	98US-0087038P;
PR	28-MAY-1998;	PR	98US-0087106P;
PR	26-JUN-1998;	PR	98US-00105413;
PR	26-JUN-1998;	PR	98US-0090863P;
PR	26-JUN-1998;	PR	98US-0091010P;
PR	01-JUL-1998;	PR	98US-0091355P;
PR	10-JUL-1998;	PR	98US-0094651P;
PR	11-SEP-1998;	PR	98US-0100038P;
PR	07-OCT-1998;	PR	98US-01689978;
PR	07-OCT-1998;	PR	98WO-US021141;
PR	02-NOV-1998;	PR	98US-00184216;
PR	06-NOV-1998;	PR	98US-00187368;
PR	20-NOV-1998;	PR	98WO-0109304P;
PR	20-NOV-1998;	PR	98WO-US024855;
PR	08-MAR-1999;	PR	98US-003254465;
PR	10-MAR-1999;	PR	98WO-US005028;
PR	12-MAR-1999;	PR	98WO-US005190;
PR	22-DEC-1998;	PR	98US-00367213;
PR	22-DEC-1998;	PR	98US-00318517;
PR	23-DEC-1998;	PR	98US-0113296P;
PR	23-DEC-1998;	PR	98US-0113621P;
PR	05-JAN-1999;	PR	98WO-US000106;
PR	08-MAR-1999;	PR	98US-003254465;
PR	10-MAR-1999;	PR	98WO-US005028;
PR	12-MAR-1999;	PR	98WO-US005190;
PR	22-DEC-1998;	PR	98US-00367213;
PR	22-DEC-1998;	PR	98US-0123957P;
PR	29-MAR-1999;	PR	98US-0126773P;
PR	21-APR-1999;	PR	98US-0130232P;
PR	26-APR-1999;	PR	98US-01311022P;
PR	14-MAY-1999;	PR	98US-00311832;
PR	14-MAY-1999;	PR	98US-0134287P;
PR	14-MAY-1999;	PR	98WO-US010733;
PR	02-JUN-1999;	PR	98WO-US012252;
PR	16-JUN-1999;	PR	98US-0139555P;
PR	23-JUN-1999;	PR	98US-0141037P;
PR	07-JUL-1999;	PR	98US-0142680P;
PR	28-JUL-1999;	PR	98US-0146222P;
PR	25-AUG-1999;	PR	98US-00380137;
PR	25-AUG-1999;	PR	98US-00380138;
PR	23-AUG-1999;	PR	98US-00380142;
PR	30-DEC-1999;	PR	98WO-US02508P;
PR	30-NOV-1999;	PR	98US-0162508P;
PR	30-NOV-1999;	PR	98WO-US028313;
PR	02-DEC-1999;	PR	98WO-US028551;
PR	02-DEC-1999;	PR	98WO-US028565;
PR	16-DEC-1999;	PR	98WO-US030095;
PR	16-DEC-1999;	PR	98WO-US031243;
PR	30-DEC-1999;	PR	98WO-US031274;
PR	08-JAN-2000;	PR	200WO-US000219;
PR	08-JAN-2000;	PR	200WO-US000277;
PR	11-FEB-2000;	PR	200WO-US000376;
PR	11-FEB-2000;	PR	200WO-US000365;
PR	18-FEB-2000;	PR	200WO-US004341;
PR	24-FEB-2000;	PR	200WO-US004504;
PR	02-MAR-2000;	PR	200WO-US005841;
PR	10-MAR-2000;	PR	200WO-US006319;
PR	21-MAR-2000;	PR	200WO-US007532;
PR	30-MAR-2000;	PR	200WO-US008439;
PR	17-MAY-2000;	PR	200WO-US013705;
PR	22-MAY-2000;	PR	200WO-US014042;
PR	30-MAY-2000;	PR	200WO-US014941;
PR	02-JUN-2000;	PR	200WO-US015264;
PR	28-JUL-2000;	PR	200WO-US020710;

661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGAAATTCAGGGCATCACCCGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGAAATTCAGGGCATCACCCGGAGCAGTC 720
721 AGGGACTACGAGTGCAGTGCCTTCCAAATGAGTGGCGCGCCCGTGGTACGGAGTAA 780
721 AGGGACTACGAGTGCAGTGCCTTCCAAATGAGTGGCGCGCCCGTGGTACGGAGTAA 780
781 GTTCCCGTGAATATCCACCATATATTTCAAGAGCCCAAGGTGACAGTGTCCCGTGG 840
781 GTTCCCGTGAATATCCACCATATATTTCAAGAGCCCAAGGTGACAGTGTCCCGTGG 840
841 ACAAAGGGGACACTGCTGAGTGTGAAGCTTCAGCATGCTCCCTCAGCAGAAATCCAGTGTA 900
841 ACAAAGGGGACACTGCTGAGTGTGAAGCTTCAGCATGCTCCCTCAGCAGAAATCCAGTGTA 900
901 CAGGATGACAAAGAGTCTGATGAGGAAAGAGGGGTGAAGTGGAAACAGACCTTT 960
901 CAGGATGACAAAGAGTCTGATGAGGAAAGAGGGGTGAAGTGGAAACAGACCTTT 960
961 CTTCTCAAAACTCATCTTCTCAATGCTCTCTGAAATGATGAGTATGGAACTACATTCGGT 1020
961 CTTCTCAAAACTCATCTTCTCAATGCTCTCTGAAATGATGAGTATGGAACTACATTCGGT 1020
1021 GGCCTCAACAGCTGGGCGACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1021 GGCCTCAACAGCTGGGCGACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1081 CAGCAGGTGAGCAACGCGACGTCGAGGAGGCGAGCTGCTGCTGCTGCTGCTGCTTCT 1140
1081 CAGCAGGTGAGCAACGCGACGTCGAGGAGGCGAGCTGCTGCTGCTGCTGCTGCTTCT 1140
1141 GGTCTTGACCTGCTCTCAATTTTGTGATGAGTGCACATCTCCACCCGGGAAGCT 1200
1141 GGTCTTGACCTGCTCTCAATTTTGTGATGAGTGCACATCTCCACCCGGGAAGCT 1200
1201 GCGCGCACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1201 GCGCGCACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1261 TATACAAATGAATATGAGAAACACAGCCTCATGAGGACAGAAATTTGAGGAGGGGAAC 1320
1261 TATACAAATGAATATGAGAAACACAGCCTCATGAGGACAGAAATTTGAGGAGGGGAAC 1320
1321 AAGATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1321 AAGATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1381 TTTAGGTACATGAGTTTCTTTTCCAAACGGGAAGAACACAGCACCACCGGCTTGA 1440
1381 TTTAGGTACATGAGTTTCTTTTCCAAACGGGAAGAACACAGCACCACCGGCTTGA 1440
1441 CCACTGCAAGCTGATCGTGCACCTCTTTGGTGCAGTGTGGCAAGGGCTCAGCCTC 1500
1441 CCACTGCAAGCTGATCGTGCACCTCTTTGGTGCAGTGTGGCAAGGGCTCAGCCTC 1500
1501 TCTGCCACAGAGTGGCCCCACGTAACATTTCTGAGCTGGCCATCTCCAAATTCATCA 1560
1501 TCTGCCACAGAGTGGCCCCACGTAACATTTCTGAGCTGGCCATCTCCAAATTCATCA 1560
1561 GTCCATAGACGAAACGAAATGAGACCTTCGCGCCCAAGCGTGGCCCTCGGGCACTTTC 1620
1561 GTCCATAGACGAAACGAAATGAGACCTTCGCGCCCAAGCGTGGCCCTCGGGCACTTTC 1620
1621 GTAGACTGTGCCACCGGCTGTGTTGTGAACGTTGAATATGAAAGAGCAAAAAA 1679
1621 GTAGACTGTGCCACCGGCTGTGTTGTGAACGTTGAATATGAAAGAGCAAAAAA 1679

RESULT 11
ADB87164
ID ADB87164 standard; cdna; 1679 BP.

XX ADB87164;
XX AC
XX 04-DEC-2003 (first entry)
XX Human PRO polynucleotide #63.
XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
XX tumour; cancer; lung; colon; breast; prostate; rectum; liver;
XX tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
XX pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
XX arthritis; sports injury; cytostatic; antiarthritic.
XX Homo sapiens.
XX OS
XX US2003088067-A1.
XX PN
XX 08-MAY-2003.
XX PD
XX 13-AUG-2002; 2002US-00219479.
XX PF
XX 01-JUN-2001; 2001WO-US017800.
XX PR 29-JUN-2001; 2001WO-US021066.
XX PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-657981/62.
XX P-PSDB; ADB87165.
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
XX useful in gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.
XX Claim 2; Fig 125; 314pp; English.
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers, and in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes. The PRO polypeptides are useful as
XX molecular markers for protein electrophoresis and in tissue typing. This
XX sequence represents a human PRO polynucleotide of the invention.
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 1679; DB 1; Length 1679;
XX Best Local Similarity 100.0%; Pred. No. 6.7e-05;
XX Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAGCAC 60
DB 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAGCAC 60

Db 1561 GTCCATAGAGACGAAACAGANTGAGACCTTCGGGCCCAAGCGTGGCGCTGGCGCACTTTG 1620
Qy 1621 GTACACTGTGCCACCGCGGTGTGTCTGAAACGTCGAATATAAAGAGACCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGCGGTGTGTGTGAAACGTCGAATATAAAGAGACCAAAAAA 1679
RESULT 13
ADB47123
ID ADB47123 standard; cDNA; 1679 BP.
XX ADB47123;
AC ADB47123;
XX 04-DEC-2003 (first entry)
DT 04-DEC-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO337 cDNA.
XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
OS Homo sapiens.
XX US2003082687-A1.
PN US2003082687-A1.
XX 01-MAY-2003.
PD 01-MAY-2003.
XX 19-APR-2002; 2002US-00125930.
PF 19-APR-2002; 2002US-00125930.
XX 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 01-DEC-2000; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786904/74.
DR P-PSDB; ADB47124.
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; Fig 375; 627pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (II) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMBC cells, for inhibiting the binding of
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or

CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTGTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGTTGAGACCAAC 60
Db 1 GTGTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGTTGAGACCAAC 60
Qy 61 AATCTATCAGGAAGAAGAAAGAAACCGACCTGACAAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAGAAAGAAACCGACCTGACAAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAATCATGAAACCAATCCAGCCAAAATGCAAAATCTATCTCTTGGCAAT 180
Db 121 AAGAAAAAATCATGAAACCAATCCAGCCAAAATGCAAAATCTATCTCTTGGCAAT 180
Qy 181 CTTACGGGGTGGCTGCTCTGTGTCTTCCAGGAGTGCCTGCGCAGCGAGATGC 240
Db 181 CTTACGGGGTGGCTGCTCTGTGTCTTCCAAAGGAGTGCCTGCGCAGCGAGATGC 240
Qy 241 CACCTTCCCAAAGCTATGGACAACTGACGGTCCGGCAGGGGAGAGCGCCCTCAG 300
Db 241 CACCTTCCCAAAGCTATGGACAACTGACGGTCCGGCAGGGGAGAGCGCCCTCAG 300
Qy 301 GTGCACTATGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACATCTCTA 360
Db 301 GTGCACTATGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACATCTCTA 360
Qy 361 TCGTGGAGTACCAAGTGGTCTCGCTCGCTCGCTCGCTCGCTCGCTCGCTCGCTCGCT 420
Db 361 TCGTGGAGTACCAAGTGGTCTCGCTCGCTCGCTCGCTCGCTCGCTCGCTCGCTCGCT 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACGTCGATGTCGATGTCGATGTCGATGTCGATGTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACGTCGATGTCGATGTCGATGTCGATGTCGATGTC 480
Qy 481 GGTGACAGCAGACCAACCCCAAGACCTCTAGGTCCTCCTCCTCCTCCTCCTCCTCCTCCT 540
Db 481 GGTGACAGCAGACCAACCCCAAGACCTCTAGGTCCTCCTCCTCCTCCTCCTCCTCCTCCT 540
Qy 541 CAAAATTGTAGAGATTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
Db 541 CAAAATTGTAGAGATTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
Qy 601 CTGCATAGCAACTGGTACAGCAGCGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGGTACAGCAGCGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGGCTTTGTGAGTGAAGCAATATCTTGAATTCAGGTCATCCCGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGCAATATCTTGAATTCAGGTCATCCCGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTCAGTGCCTCCCAAGACCTGCGCGCCCGCTGACGAGAGTAAA 780
Db 721 AGGGGACTACGAGTCAGTGCCTCCCAAGACCTGCGCGCCCGCTGACGAGAGTAAA 780
Qy 781 GGTACCGGTGAATATCCACCATATCTTCAAGCCAAAGGTTACAGGTGTCCCGTGGG 840
Db 781 GGTACCGGTGAATATCCACCATATCTTCAAGCCAAAGGTTACAGGTGTCCCGTGGG 840
Qy 841 AAAAAAGGACACTGTCAGTGTGAAGCTCAGAGTCCCTCAGCAGATTCCTCAGTGTA 900

841 ACARAAAGGGGACACTGACGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCACAGTGGTA 900
QY 901 CAAGGATGACAAAAGACACTGATGAGGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAAGACACTGATGAGGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
QY 961 CCTCTCAAAATCATCTCTTCTCAATGTCTCTGAACATGACTATGGGAATACACTTGGGT 1020
DB 961 CCTCTCAAAATCATCTCTTCTCAATGTCTCTGAACATGACTATGGGAATACACTTGGGT 1020
QY 1021 GGCCTCCAAAGCTGGGCGCACCAATGCGCAGCAGTATGCTATTTGGTCCAGGCGCGT 1080
DB 1021 GGCCTCCAAAGCTGGGCGCACCAATGCGCAGCAGTATGCTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGCCAGGTGAGCAAGCGCAGCTCGAGGAGGCGAGCTGCTGCTGCTGCTCTTCT 1140
DB 1081 CAGCCAGGTGAGCAAGCGCAGCTCGAGGAGGCGAGCTGCTGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTTCTCAATTTTGAATGAGTGGCCACTTCCCGCCCGGGAAGGCT 1200
DB 1141 GGTCTTGCACTGCTTCTCAATTTTGAATGAGTGGCCACTTCCCGCCCGGGAAGGCT 1200
QY 1201 GCGGCGCACCAACACACACACCAATGGCAACACCGACAGCAACCAATCAGATA 1260
DB 1201 GCGGCGCACCAACACACACCAATGGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATAGAGAAACACAGCCTCATCGGACAGAAATTTGAGGAGGGGAAAC 1320
DB 1261 TATACAAATGAATAGAGAAACACAGCCTCATCGGACAGAAATTTGAGGAGGGGAAAC 1320
QY 1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAGAAATTCAGAAATTCAGGAGGGGAAAC 1380
DB 1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAGAAATTCAGAAATTCAGGAGGGGAAAC 1380
QY 1381 TTTAGTACAAATGGAGTTTCTTTTCCCAACCGGGAAGAACACACACACCGGCTTGGG 1440
DB 1381 TTTAGTACAAATGGAGTTTCTTTTCCCAACCGGGAAGAACACACACACCGGCTTGGG 1440
QY 1441 CCCACTGCAAGCTGCATGCTGCAACTCTTTGGTCCAGTGTGGCAGAGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCATGCTGCAACTCTTTGGTCCAGTGTGGCAGAGGCTCAGCCTC 1500
QY 1501 TCTGCCACACAGAGTGCCTCCACAGTGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACACAGAGTGCCTCCACAGTGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATGAGACGAAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
DB 1561 GTCCATGAGACGAAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACCGCGCTGTGTGTAACGCTGAATATAAAGAGCAAAAAAAA 1679
DB 1621 GTAGACTGTGCCACACCGCGCTGTGTGTAACGCTGAATATAAAGAGCAAAAAAAA 1679

RESULT 14

ADB83861
ID ADB83861 standard; cDNA; 1679 BP.
XX AC ADB83861;
XX DT
XX 04-DEC-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO337 cDNA.
XX human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;

gene therapy.
Homo sapiens.
US2003069397-A1.
10-APR-2003.
09-AUG-2002; 2002US-00216159.
25-JUL-2000; 2000US-0220607P.
01-JUN-2001; 2001WO-US017800.
29-JUN-2001; 2001WO-US021066.
09-APR-2002; 2002US-00119480.
(GETH) GENENTECH INC.
Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
Frimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
WPI; 2003-657584/62.
P-PSDB; ADB83862.
New isolated polypeptides designated PRO polypeptides including
polypeptides useful for stimulating the proliferation or differentiation
of specific cell types, and for diagnosing cancer.
Claim 2; Fig 125; 314pp; English.
The invention describes an isolated PRO (secreted and transmembrane)
polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
useful for stimulating the proliferation of or gene expression in
pericyte cells. PRO357, PRO357, PRO1272 or PRO4405 polypeptide are useful
for stimulating the proliferation or differentiation of chondrocyte
cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
are useful for stimulating the release of tumour necrosis factor (TNF)-
alpha from human blood. PRO982, PRO357, PRO1306, PRO1419, PRO214,
PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
PRO1286, PRO1330, PRO1305, PRO1305, PRO1273, PRO1279, PRO1338,
PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
PRO1887, PRO1928, PRO3431, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
PRO9940, PRO6079, PRO3836 or PRO10096 polypeptide are useful for
stimulating the proliferation of normal human dermal fibroblasts cells.
PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
inhibiting the proliferation of normal human dermal fibroblast cells. PRO
polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
are useful for detecting the presence of tumour in a mammal which
involves comparing the level of expression of the above PRO polypeptides
in a test sample of cells taken from the mammal, and a control sample of
normal cells of the same cell type, where a higher level of expression of
the PRO polypeptides in the test sample as compared to the control sample
is indicative of the presence of tumour in the mammal. The tumour is lung
tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
liver tumour. (I) is useful as molecular weight markers, for tissue
typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
useful for chromosome and gene mapping or gene therapy. (II) is useful
for generating transgenic animals or knock-out animals which are useful
for screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
is useful for treating bone and/or cartilage disorders (e.g., arthritis,
sport injuries). This sequence encodes a human secreted and transmembrane
PRO polypeptide.
Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAATCTCTTGCACAGTTTGAGAGCAAC 60
|||||

Db 1 GTTGTGCTCTTCAGCAAAACAGTGGATTTAAATCTCTCTGCAACAGCTTGAGAGCAACAC 60
Qy 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
Db 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
Qy 181 CTTACGGGGCTGCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 240
Db 181 CTTACGGGGCTGCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 240
Qy 241 CACCTTCCCAAGCTATGACAAACGTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 300
Db 241 CACCTTCCCAAGCTATGACAAACGTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 300
Qy 301 GTGCACTATTGACAAACGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 360
Db 301 GTGCACTATTGACAAACGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 360
Qy 361 TGTGGGAATGACAAAGTGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 420
Db 361 TGTGGGAATGACAAAGTGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 420
Qy 421 GCAGTACAGATCGAGATCCAGAACGTCGATGCTGATGAGAGGCGCTTACACCTGCTC 480
Db 421 GCAGTACAGATCGAGATCCAGAACGTCGATGCTGATGAGAGGCGCTTACACCTGCTC 480
Qy 481 GGTGACAGACAAACCAACGCTCTGAGGCTCAGCTCATTGTGCAAGTATCTCC 540
Db 481 GGTGACAGACAAACCAACGCTCTGAGGCTCAGCTCATTGTGCAAGTATCTCC 540
Qy 541 CAAATTTGAGAGATTTCTTCTGAGATATCTCCATTAATGAGAGGAAACAATATTAGCTCTAC 600
Db 541 CAAATTTGAGAGATTTCTTCTGAGATATCTCCATTAATGAGAGGAAACAATATTAGCTCTAC 600
Qy 601 CTGATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGGCTTTGTGAGTGAAGACGATATCTTGGAAATTCAGGGCATCACCGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGACGATATCTTGGAAATTCAGGGCATCACCGGAGCAGTC 720
Qy 721 AGGGGACTACAGTGCAGTGCCTCCATGACGTGGCGCGCGCTGGTGAAGAGATAA 780
Db 721 AGGGGACTACAGTGCAGTGCCTCCATGACGTGGCGCGCGCTGGTGAAGAGATAA 780
Qy 781 GGTCACTGAACTATCAACATATTCAGAACGCAAGGTACAGGTGTCCTCCGTGG 840
Db 781 GGTCACTGAACTATCAACATATTCAGAACGCAAGGTACAGGTGTCCTCCGTGG 840
Qy 841 ACAAAGGGGACACTGCAAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGCAAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Qy 901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Qy 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAAACATGACTATGGGAATTCAGTTCGT 1020
Db 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAAACATGACTATGGGAATTCAGTTCGT 1020
Qy 1021 GGCTTCAAACTGGGCAACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCTTCAAACTGGGCAACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Qy 1081 CAGCGAGTGAACACGCGCTGAGAGGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
Db 1081 CAGCGAGTGAACACGCGCTGAGAGGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140

Qy 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGATGCCACTTCCCAACCCGGGAAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGATGCCACTTCCCAACCCGGGAAAGGCT 1200
Qy 1201 GCCGCCACCCACCCACCAACCAACAGCAATGGCAACCCGACAGCAACCAATTCAGATA 1260
Db 1201 GCCGCCACCCACCCACCAACCAACAGCAATGGCAACCCGACAGCAACCAATTCAGATA 1260
Qy 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAAC 1320
Db 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAAC 1320
Qy 1321 AAGAAATACTTTGGGGGAAAGAGTTTAAABAAGAAATTTGAAATTTGCTTTCAGATA 1380
Db 1321 AAGAAATACTTTGGGGGAAAGAGTTTAAABAAGAAATTTGAAATTTGCTTTCAGATA 1380
Qy 1381 TTTAGGTACATGAGAGTTTCTTTTCCCAACCGGAAAGAAACACAGCACACCCGGCTTGA 1440
Db 1381 TTTAGGTACATGAGAGTTTCTTTTCCCAACCGGAAAGAAACACAGCACACCCGGCTTGA 1440
Qy 1441 CCCACTGCAAGCTGCTGCAACCTCTTTTGGTGGCAGTGTGGGCAAGGCTCAGGCTC 1500
Db 1441 CCCACTGCAAGCTGCTGCAACCTCTTTTGGTGGCAGTGTGGGCAAGGCTCAGGCTC 1500
Qy 1501 TCTGCCACAGAGTGGCCCCCAGCTGGAAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGGCCCCCAGCTGGAAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Qy 1561 GTCCATAGACAGCAAGATGAGACCTTCGGGCCCAAGCGTGGCGTGGGGACATTTG 1620
Db 1561 GTCCATAGACAGCAAGATGAGACCTTCGGGCCCAAGCGTGGCGTGGGGACATTTG 1620
Qy 1621 GTAGACTGTGCCACACCGGCTGTGTGAAACGTGAAATATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACCGGCTGTGTGAAACGTGAAATATAAAGAGCAAAAAA 1679

RESULT 15

ADB86730

ID ADB86730 standard; cDNA; 1679 BP.

XX AC ADB86730;

XX DT 04-DEC-2003 (first entry)

XX DE Human PRO polynucleotide #188.

XX KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003082697-A1.

XX PD 01-MAY-2003.

XX PF 22-APR-2002; 2002US-00127849.

XX PR 20-OCT-1998; 98US-0104987P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 18-FEB-2000; 2000WO-US004342.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S,
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX WPI; 2003-743895/70.
XX P-PSDB; ADB86731.
XX
XX New secreted and transmembrane PRO polypeptides, useful in the diagnosis
XX PT and treatment of cancer.
XX
XX Claim 2; Fig 375; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6,7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCAAGCTTGAGCAACAC 60
DB 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCAAGCTTGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGCACAAAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGCACAAAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAACCAATCCAGCCCAAAATGCACAAATCTCTTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAACCAATCCAGCCCAAAATGCACAAATCTCTTTGGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTGCTGTGTCTCTTCAAGGAGTGCCCGTCGAGCGGAGATGC 240
DB 181 CTTTCAGGGGCTGGCTGCTGTGTCTCTTCAAGGAGTGCCCGTCGAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300

DB 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGACCATCTCTTA 360
DB 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGACCATCTCTTA 360
QY 361 TGTGCGGAATGACAAAGTGGTGGCTGCTGCTCGGTGGTCTTCTGAGCAACACCCAAAC 420
DB 361 TGTGCGGAATGACAAAGTGGTGGCTGCTGCTCGGTGGTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACCGTGGATGTGTATGACGAGGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACCGTGGATGTGTATGACGAGGGGCCCTTACACCTGCTC 480
QY 481 GGTGCGAGACAGCAACCCCAAGACCTCTAGGTCCACCTCATTTGTCGAGTATCTCC 540
DB 481 GGTGCGAGACAGCAACCCCAAGACCTCTAGGTCCACCTCATTTGTCGAGTATCTCC 540
QY 541 CAAAAATTGTAGACATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB 541 CAAAAATTGTAGACATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGAATACCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGACGAATACCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCGCGCTACGGAGAGTAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCGCGCTACGGAGAGTAA 780
QY 781 GGTTCACCGTCAACTATCTCACATACATATTCAGAAAGCCNAGGGTACAGGTGTCTCCCGTGGG 840
DB 781 GGTTCACCGTCAACTATCTCACATACATATTCAGAAAGCCNAGGGTACAGGTGTCTCCCGTGGG 840
QY 841 ACAAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTTCAGCAGAAATTCAGTGGTA 900
QY 901 CAGAGTACCAAAAGACTGATTCAGGAAAGAGAGGGGTGAAAGTGGAAGACAGACCTTT 960
DB 901 CAGAGTACCAAAAGACTGATTCAGGAAAGAGAGGGGTGAAAGTGGAAGACAGACCTTT 960
QY 961 CTTCTCAAAACTCATCTTTCTCAATGTCTCTGAACATGACTATGGGAATACACTTGGCGT 1020
DB 961 CTTCTCAAAACTCATCTTTCTCAATGTCTCTGAACATGACTATGGGAATACACTTGGCGT 1020
QY 1021 GGCCTCCAAACAGCTGGGCCACACCAATGCCAGCATCATCTATTTGGTCCAGCGCGCT 1080
DB 1021 GGCCTCCAAACAGCTGGGCCACACCAATGCCAGCATCATCTATTTGGTCCAGCGCGCT 1080
QY 1081 CAGCGAGGTGAGCAACCGGCACGTCGAGGGGAGGCGTGGCTCTGGTGTGCTCTTTCT 1140
DB 1081 CAGCGAGGTGAGCAACCGGCACGTCGAGGGGAGGCGTGGCTCTGGTGTGCTCTTTCT 1140
QY 1141 GGTCTTGCACCTGCTCTCAAAATTTGATGTAGTGCCACTTCCCAACCGGGAAGGCT 1200
DB 1141 GGTCTTGCACCTGCTCTCAAAATTTGATGTAGTGCCACTTCCCAACCGGGAAGGCT 1200
QY 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
DB 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
QY 1261 TATCAAAATGAATTAAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGAAC 1320
DB 1261 TATCAAAATGAATTAAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGAAC 1320
QY 1321 AAGAAATACCTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAAAATTTGCTTGCAGATA 1380
DB 1321 AAGAAATACCTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAAAATTTGCTTGCAGATA 1380

QY 1381 TTTAGGTACATGAGTTTCTTTTCCAAACGGGAAGAACACAGCACACCCGGCTTGA 1440
 Db 1381 TTTAGGTACATGAGTTTCTTTTCCAAACGGGAAGAACACAGCACACCCGGCTTGA 1440
 QY 1441 CCCACTGACAGCTCATCGTGCAACCTTTGGTCCAGTGGGCAAGGGCTCAGCCTC 1500
 Db 1441 CCCACTGACAGCTCATCGTGCAACCTTTGGTCCAGTGGGCAAGGGCTCAGCCTC 1500
 QY 1501 TCTGCCACAGAGTGCCGCCACGCTGGGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
 Db 1501 TCTGCCACAGAGTGCCGCCACGCTGGGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
 QY 1561 GTCCATAGAGCAGAACAGATGAGACCTTCGCGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
 Db 1561 GTCCATAGAGCAGAACAGATGAGACCTTCGCGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
 QY 1621 GTAGACTGTGCGCACACCGGCTGTGTGTAACGTCGAATATAAAGAGCAAAAAA 1679
 Db 1621 GTAGACTGTGCGCACACCGGCTGTGTGTAACGTCGAATATAAAGAGCAAAAAA 1679

RESULT 16
 ADB73016
 ID ADB73016 standard; cDNA; 1679 BP.
 XX
 AC ADB73016;
 DT
 XX
 DE 04-DEC-2003 (first entry)
 DE Novel human secreted and transmembrane protein PRO337 cDNA.
 KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW chondrocyte cell differentiation; chondrocyte cell proliferation;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 FN US2003092887-A1.
 XX
 PD 15-MAY-2003.
 XX
 PF 12-AUG-2002; 2002US-00218956.
 XX
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 PA (GETH) GENENTECH INC.
 PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JP, Watanabe CX, Wood WI;
 DR WPI; 2003-777258/73.
 DR P-PSDB; ADB73017.
 XX
 PT Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as
 PT molecular weight markers, for treating arthritis, tumor.
 XX
 PS Claim 2; Fig 125; 308pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1150, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-

CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO328, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4332,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCGCAACAC 60
 Db 1 GTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCGCAACAC 60
 QY 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACCTTGACAAAAAAGAGAAAGAAAG 120
 Db 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACCTTGACAAAAAAGAGAAAGAAAG 120
 QY 121 AAAAAAATCATGAAAAACCATCCAGCCAAAATGACAAATCTATCTCTTGGGCAAT 180
 Db 121 AAAAAAATCATGAAAAACCATCCAGCCAAAATGACAAATCTATCTCTTGGGCAAT 180
 QY 181 CTTTCAGGGGCTGGCTGTCTGTCTCTTCCAGAGTGGCCGTGCGCAGCGGAGATGC 240
 Db 181 CTTTCAGGGGCTGGCTGTCTGTCTCTTCCAGAGTGGCCGTGCGCAGCGGAGATGC 240
 QY 241 CACCTTCCCCAAAGCTATGGACAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
 Db 241 CACCTTCCCCAAAGCTATGGACAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
 QY 301 GTGCATATTGACAAACCGGGTCAACCCGGTGGCTGGCTTAAACCCGACGACCATCTCTA 360
 Db 301 GTGCATATTGACAAACCGGGTCAACCCGGTGGCTGGCTTAAACCCGACGACCATCTCTA 360
 QY 361 TGTGGAATGACAAAGTGGTGGCTGGATCTCTCGGTGGTCTTCTTGAGCAACACCCAAAC 420
 Db 361 TGTGGAATGACAAAGTGGTGGCTGGATCTCTCGGTGGTCTTCTTGAGCAACACCCAAAC 420
 QY 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
 Db 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
 QY 481 GGTGCAGACAGCAACACCCAAAGACCTCTAGGTCCACCTCATTTGTCAAGATCTCC 540
 Db 481 GGTGCAGACAGCAACACCCAAAGACCTCTAGGTCCACCTCATTTGTCAAGATCTCC 540
 QY 541 CAAATGTAGAGATTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600

```
Db 541 CAAAATTGTAGATTTCTTCCAGATATCTCCATTATGAAGGGAACAATATTAGCCTCAC 600
Qy 601 CTGCATAGCAACTGGTAGACAGAGCCCTAGCGTTACTTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCCCTAGCGTTACTTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTTCGCTTTGTGAGTGAAGAGCAATATCTTGAATAATCAGGGCATCACCCGGGAGCAGTC 720
Db 661 GGTTCGCTTTGTGAGTGAAGAGCAATATCTTGAATAATCAGGGCATCACCCGGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGCGCGCCGCTGCTACGAGAGTAAA 780
Db 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGCGCGCCGCTGCTACGAGAGTAAA 780
Qy 781 GGTTCACCGTGAATCTCCACCATATATTCAGAACCAAGGTACAGGTGTCCTCCGCTGG 840
Db 781 GGTTCACCGTGAATCTCCACCATATATTCAGAACCAAGGTACAGGTGTCCTCCGCTGG 840
Qy 841 ACAAAAGGGGACACTGCTGCTGAGCTGTCAGCTCCCTCAGCAGATTCCTCAGTGTA 900
Db 841 ACAAAAGGGGACACTGCTGCTGAGCTGTCAGCTCCCTCAGCAGATTCCTCAGTGTA 900
Qy 901 CAAGGATGACAAAGACTGCTGCTGAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGCTGCTGAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
Qy 961 CCTCTCAAACTCATCTTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1020
Db 961 CCTCTCAAACTCATCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1020
Qy 1021 GGCCTCCAAAGCTGGGCGACACCAATATGCGAGCATCATGCTATTTGGTCCAGGCGCGGT 1080
Db 1021 GGCCTCCAAAGCTGGGCGACACCAATATGCGAGCATCATGCTATTTGGTCCAGGCGCGGT 1080
Qy 1081 CAGCGAGGTGAGCAACGGGCGCTGAGGAGGGGAGGCTGCTGCTGCTGCTGCTGCTGCTCTTCT 1140
Db 1081 CAGCGAGGTGAGCAACGGGCGCTGAGGAGGGGAGGCTGCTGCTGCTGCTGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGCACTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1200
Db 1141 GGTCTTGCACTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1200
Qy 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Qy 1261 TATACAAATGAAATAGAGAAACAGAGCTCATGGGACAGAAATTTGAGGAGGAGGAGAC 1320
Db 1261 TATACAAATGAAATAGAGAAACAGAGCTCATGGGACAGAAATTTGAGGAGGAGGAGAC 1320
Qy 1321 AAAGAATACCTTTGGGGGAAAAGAGTTTAAAGAAAGAAATTTGAAATTCCTTGCAGATA 1380
Db 1321 AAAGAATACCTTTGGGGGAAAAGAGTTTAAAGAAAGAAATTTGAAATTCCTTGCAGATA 1380
Qy 1381 TTTAGGTACAAATGAGGTTTCTTTTCCCAACGGGAGAACACAGCACACCCGGCTTGA 1440
Db 1381 TTTAGGTACAAATGAGGTTTCTTTTCCCAACGGGAGAACACAGCACACCCGGCTTGA 1440
Qy 1441 CCCACTGCAAGCTGATCGTGCACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGATCGTGCACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCACCTGCTGAGACATTTCTGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACCTGCTGAGACATTTCTGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACCAACAGATGAGACCTTCCGCGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
Db 1561 GTCCATAGAGACCAACAGATGAGACCTTCCGCGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCAAGCGGTGTGTGTGAATGAAATGAAATGAAATGAAATGAAATGAAAT 1679
Db 1621 GTAGACTGTGCCACCAAGCGGTGTGTGTGAATGAAATGAAATGAAATGAAATGAAATGAAAT 1679
```

RESULT 17
ADB76744
ID ADB76744 standard; cDNA; 1679 BP.
XX
AC ADB76744;
XX
DT 04-DEC-2003 (first entry)
XX
XX Human PRO polynucleotide sequence #133.
XX Human, PRO polypeptide; secreted protein; transmembrane protein;
KW cell death; neuropathy; neuropathy related disease;
KW Charcot-Marie-Tooth disorder; Reifsum's disease; Krabbe's disease;
KW chromosome mapping; gene mapping; genetic disorder; septic shock;
KW antibacterial; immunosuppressive; neuroprotective; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003083248-A1.
XX
PD 01-MAY-2003.
XX
PF 16-OCT-2001; 2001US-00978757.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077731P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 25-MAR-1998; 98US-0078939P.
PR 26-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079684P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 21-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.

PR	23-APR-1998;	98US-0082796P.
PR	27-APR-1998;	98US-0083336P.
PR	28-APR-1998;	98US-0083322P.
PR	29-APR-1998;	98US-0083392P.
PR	29-APR-1998;	98US-0083495P.
PR	29-APR-1998;	98US-0083496P.
PR	29-APR-1998;	98US-0083499P.
PR	29-APR-1998;	98US-0083500P.
PR	29-APR-1998;	98US-0083545P.
PR	29-APR-1998;	98US-0083554P.
PR	29-APR-1998;	98US-0083558P.
PR	29-APR-1998;	98US-0083559P.
PR	30-APR-1998;	98US-0083742P.
PR	05-MAY-1998;	98US-0084366P.
PR	06-MAY-1998;	98US-0084411P.
PR	07-MAY-1998;	98US-0084598P.
PR	07-MAY-1998;	98US-0084600P.
PR	07-MAY-1998;	98US-0084627P.
PR	07-MAY-1998;	98US-0084637P.
PR	07-MAY-1998;	98US-0084639P.
PR	07-MAY-1998;	98US-0084640P.
PR	07-MAY-1998;	98US-0084643P.
PR	13-MAY-1998;	98US-0085323P.
PR	13-MAY-1998;	98US-0085338P.
PR	13-MAY-1998;	98US-0085339P.
PR	15-MAY-1998;	98US-0085573P.
PR	15-MAY-1998;	98US-0085579P.
PR	15-MAY-1998;	98US-0085580P.
PR	15-MAY-1998;	98US-0085582P.
PR	15-MAY-1998;	98US-0085689P.
PR	15-MAY-1998;	98US-0085697P.
PR	15-MAY-1998;	98US-0085700P.
PR	15-MAY-1998;	98US-0085704P.
PR	18-MAY-1998;	98US-0086023P.
PR	22-MAY-1998;	98US-0086392P.
PR	22-MAY-1998;	98US-0086414P.
PR	22-MAY-1998;	98US-0086430P.
PR	22-MAY-1998;	98US-0086486P.
PR	28-MAY-1998;	98US-0087098P.
PR	28-MAY-1998;	98US-0087106P.
PR	28-MAY-1998;	98US-0087208P.
PR	28-JUN-1998;	98US-0090863P.
PR	26-JUN-1998;	98US-0091010P.
PR	01-JUL-1998;	98US-0091359P.
PR	30-JUL-1998;	98US-0094651P.
PR	11-SEP-1998;	98US-0100038P.
PR	07-OCT-1998;	98WO-US02114.
PR	20-NOV-1998;	98US-0109304P.
PR	20-NOV-1998;	98WO-US024855.
PR	22-DEC-1998;	98US-0113296P.
PR	22-DEC-1998;	98US-0113621P.
PR	03-JAN-1999;	98WO-US000106.
PR	08-MAR-1999;	98WO-US005028.
PR	10-MAR-1999;	98WO-US005190.
PR	23-MAR-1999;	98US-0123957P.
PR	29-MAR-1999;	98US-0126773P.
PR	21-APR-1999;	98US-0130232P.
PR	26-APR-1999;	98US-0131022P.
PR	28-APR-1999;	98US-0131445P.
PR	14-MAY-1999;	98US-0134287P.
PR	14-MAY-1999;	98WO-US010733.
PR	02-JUN-1999;	98WO-US012252.
PR	16-JUN-1999;	98US-0139557P.
PR	23-JUN-1999;	98US-0141037P.
PR	07-JUL-1999;	98US-0142680P.
PR	26-JUL-1999;	98US-0145698P.
PR	28-JUL-1999;	98US-0146222P.
PR	23-OCT-1999;	98US-0162506P.
PR	30-NOV-1999;	98WO-US028313.
PR	02-DEC-1999;	98WO-US028551.
PR	16-DEC-1999;	98WO-US028565.
PR	16-DEC-1999;	98WO-US030095.
PR	98US-0082796P.	
PR	98US-0083336P.	
PR	98US-0083322P.	
PR	98US-0083392P.	
PR	98US-0083495P.	
PR	98US-0083496P.	
PR	98US-0083499P.	
PR	98US-0083500P.	
PR	98US-0083545P.	
PR	98US-0083554P.	
PR	98US-0083558P.	
PR	98US-0083559P.	
PR	98US-0083742P.	
PR	98US-0084366P.	
PR	98US-0084411P.	
PR	98US-0084598P.	
PR	98US-0084600P.	
PR	98US-0084627P.	
PR	98US-0084637P.	
PR	98US-0084639P.	
PR	98US-0084640P.	
PR	98US-0084643P.	
PR	98US-0085323P.	
PR	98US-0085338P.	
PR	98US-0085339P.	
PR	98US-0085573P.	
PR	98US-0085579P.	
PR	98US-0085580P.	
PR	98US-0085582P.	
PR	98US-0085689P.	
PR	98US-0085697P.	
PR	98US-0085700P.	
PR	98US-0085704P.	
PR	98US-0086023P.	
PR	98US-0086392P.	
PR	98US-0086414P.	
PR	98US-0086430P.	</

QY	1261	TATACAAATGAAATTAGAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320
Db	1261	TATACAAATGAAATTTAGAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320
QY	1321	AAAGAATACCTTTGGGGGGGAAAAGAGTTTTTAAAAAAGAAATTTGAAAAATTTGCCTTTGCAGATA	1380
Db	1321	AAAGAATACCTTTGGGGGGGAAAAGAGTTTTTAAAAAAGAAATTTGAAAAATTTGCCTTTGCAGATA	1380
QY	1381	TTTAGTACAATGGAGTTCTTTCTTTTCCCAACGGGGAAGAACACAGCACACCCCGGCTTGGGA	1440
Db	1381	TTTAGTACAATGGAGTTCTTTCTTTTCCCAACGGGGAAGAACACAGCACACCCCGGCTTGGGA	1440
QY	1441	CCCACTGCAAGCTGCATCGTGCACACCTCTTTGGTGCACAGTGTGGGCAAGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGCTGCATCGTGCACACCTCTTTGGTGCACAGTGTGGGCAAGGCTCAGCCTC	1500
QY	1501	TCTGCCCAACAGAGTGCCCCACACGCTGGAAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA	1560
Db	1501	TCTGCCCAACAGAGTGCCCCACACGCTGGAAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA	1560
QY	1561	GTCCATAGAGACGAACAGAAATGAGACTTCCGGCCCAAGGCTGCGCTGCGGGCACTTTG	1620
Db	1561	GTCCATAGAGACGAACAGAAATGAGACTTCCGGCCCAAGGCTGCGCTGCGGGCACTTTG	1620
QY	1621	GTAGACTGTGCCACACCGCGCTGTGTGTGTAACGTAATAAAAAAGACAAAAA	1679
Db	1621	GTAGACTGTGCCACACCGCGCTGTGTGTGTAACGTAATAAAAAAGACAAAAA	1679

RESULT 18

ADB77335

ID ADB77335 standard; cDNA; 1679 BP.

XX

AC ADB77335;

XX

DT 04-DEC-2003 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX

KW Human; secreted and transmembrane protein; PRO; Gene: ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW Glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

XX

OS Homo sapiens.

XX

FN US2003082696-A1.

XX

PD 01-MAY-2003.

XX

PF 22-APR-2002; 2002US-00127848.

XX

PR 03-NOV-1998; 98US-0106934P.

PR 26-JUL-1999; 99US-0145698P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 05-JAN-2000; 2000WO-US000219.

PR 18-FEB-2000; 2000WO-US004342.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX

XX (GETH) GENENTECH INC.

XX

XX Baker KP, Bersesini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755109/71.

DR

DR P-PSDB; ADB77336.
XX PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT tumor or for tissue typing.
XX
XX
XX Claim 2; Fig 375; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF- α from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of n-lymphocyte cells, for stimulating
CC the release of a cytokine from BMC cells, for inhibiting the binding of
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGCTGCTTCAGCAAAACAGTGGATTAAATCTCTCTGTCACAACTTCTATCTCTTGGGCAAT 60
DB 1 GTTGCTGCTTCAGCAAAACAGTGGATTAAATCTCTCTGTCACAACTTCTATCTCTTGGGCAAC 60
QY 61 AATCTATCAGGAAGAAGAAAGAAAGAAACCGAATCTGACAAAGAAAGAAAGAAAGAG 120
DB 61 AATCTATCAGGAAGAAGAAAGAAAGAAACCGAATCTGACAAAGAAAGAAAGAAAGAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATCTATCTCTTGGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTCTGTGTCTCTTCCAGAGAGTGCCCGTGGGAGGAGATGC 240
DB 181 CTTTCAGGGGCTGGCTCTGTGTCTCTTCCAGAGAGTGCCCGTGGGAGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGCAACGCTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGCAACGCTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCATCTATTGACAAACCGGCTACCCGGGTGGCTTGGCTAAACCGCAGACCACTCTCTA 360
DB 301 GTGCATCTATTGACAAACCGGCTACCCGGGTGGCTTGGCTAAACCGCAGACCACTCTCTA 360
QY 361 TGCTGGGAATGACAAGTGGTGGCTTGGATCTCGGTGGTCTCTTCTGAGCAACACCCAAAC 420
DB 361 TGCTGGGAATGACAAGTGGTGGCTTGGATCTCGGTGGTCTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAAACGTTGGATGTATGACAGGGGCTTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAAACGTTGGATGTATGACAGGGGCTTTACACCTGCTC 480

QY 481 GGTGCAGACAGACAAACACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCAGACAGACAAACACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCCTTCCAGATATCTCCATTAATGAAGGAAACAAATATTAGCCTC 600
DB 541 CAAATTTGTAGAGATTTCCTTCCAGATATCTCCATTAATGAAGGAAACAAATATTAGCCTC 600
QY 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGAATACTTTGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGACGAATACTTTGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGATACAGTGCAGTGCCTCCATGACGTGGCGCGCCGCTGTCAGCGAGAGTAA 780
DB 721 AGGGGATACAGTGCAGTGCCTCCATGACGTGGCGCGCCGCTGTCAGCGAGAGTAA 780
QY 781 GGTCAACGCTGATATCCACCATATCTTCAAGAGCAAGGGTACAGGTGTCCCGCTGG 840
DB 781 GGTCAACGCTGATATCCACCATATCTTCAAGAGCAAGGGTACAGGTGTCCCGCTGG 840
QY 841 ACAAAGGGGACACTGAGTGTGAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGAGTGTGAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAGGGGTCAAAAGTGGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAGGGGTCAAAAGTGGAAACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTTCAATGTCTGTGAACATGACTNTGGGAACCTACACTTGCCT 1020
DB 961 CCTCTCAAACTCATCTTTCAATGTCTGTGAACATGACTNTGGGAACCTACACTTGCCT 1020
QY 1021 GGCCTCAAAAGCTGGGCGCACACCAATGCGAGCATCATGCTATTTGGTCCAGCGCGCT 1080
DB 1021 GGCCTCAAAAGCTGGGCGCACACCAATGCGAGCATCATGCTATTTGGTCCAGCGCGCT 1080
QY 1081 CAGCGAGTGAAGCAACCGCACGCTGAGGAGGCGCTGCTGGCTGTGCTGCTCTTCT 1140
DB 1081 CAGCGAGTGAAGCAACCGCACGCTGAGGAGGCGCTGCTGGCTGTGCTGCTCTTCT 1140
QY 1141 GGTCTGCACCTGCTCTCAAAATTTGATGTAGTGCCACTTCCCCACCCGGGAAAGGCT 1200
DB 1141 GGTCTGCACCTGCTCTCAAAATTTGATGTAGTGCCACTTCCCCACCCGGGAAAGGCT 1200
QY 1201 GCGCCACCCACCAACCAACAGCAATGCGAAACCGCAGCAGCAACCAATCAGATA 1260
DB 1201 GCGCCACCCACCAACCAACAGCAATGCGAAACCGCAGCAGCAACCAATCAGATA 1260
QY 1261 TATCAATGAATAGAAATAGAAAGAAACAGACCTCTATGCGACAGAAATTTGAGGGGGAAC 1320
DB 1261 TATCAATGAATAGAAATAGAAAGAAACAGACCTCTATGCGACAGAAATTTGAGGGGGAAC 1320
QY 1321 AAAGAATACTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAAGAATACTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGAGTTTCTTTTCCCAACCGGAAAGAACACAGCACACCCGCTTGGGA 1440
DB 1381 TTTAGGTACAAATGAGTTTCTTTTCCCAACCGGAAAGAACACAGCACACCCGCTTGGGA 1440
QY 1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTTGGTGCCAGTGTGGGCAAGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTTGGTGCCAGTGTGGGCAAGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCCGGACGTTGGAGCTGCGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCCGGACGTTGGAGCTGCGCCATCCCAATTCATCA 1560

QY 1561 GTCCATAGACGACAGACAGACCTTCGGGCCAAGCGTGGCGCTGGGGCACTTTG 1620
DB 1561 GTCCATAGACGACAGACAGACCTTCGGGCCAAGCGTGGCGCTGGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCGCGCTGTGTGTGAAAGCTGAAATATAAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCGCGCTGTGTGTGAAAGCTGAAATATAAAGAGCAAAAAA 1679
RESULT 19
ADB34492
ID ADB34492 standard; cDNA; 1679 BP.
AC ADB34492;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 375.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077717-AL.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131818.
XX
PR 07-OCT-1998; 98US-0103328P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen WB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755072/71.
DR P-PSDB; ADB34493.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 375; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6,7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTCTTGCAACAGCTTGAGAGCAACAC 60
DB 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTCTTGCAACAGCTTGAGAGCAACAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAACCGAACCTGACAAAAAGAAAGAAAGAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAACCGAACCTGACAAAAAGAAAGAAAGAG 120
QY 121 AAGAAAAAATCATGAATAACCATCCAGCCAAATGCAATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAATAACCATCCAGCCAAATGCAATCTATCTTGGGCAAT 180
QY 181 CTTTCACGGGGCTGGCTGCTCTGTGTCTTCTTCCAAAGAGTGCCTGTCGACGGAGATGC 240
DB 181 CTTTCACGGGGCTGGCTGCTCTGTGTCTTCTTCCAAAGAGTGCCTGTCGACGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGCAACAGTGCAGGTCCGCGAGGGGAGAGGCCACCTTCAG 300
DB 241 CACCTTCCCAAGCTATGCAACAGTGCAGGTCCGCGAGGGGAGAGGCCACCTTCAG 300
QY 301 GTGCACATATTGACAAACCGGGTCCACCGGGTGGCTTAAACCGCAGCACCATTCTCTA 360
DB 301 GTGCACATATTGACAAACCGGGTCCACCGGGTGGCTTAAACCGCAGCACCATTCTCTA 360
QY 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCGGTGGTCTCTTGTGAGCAACCCCAAC 420
DB 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCGGTGGTCTCTTGTGAGCAACCCCAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTTGATGTATGACGAGGGCCCTTACACCTCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTTGATGTATGACGAGGGCCCTTACACCTCTC 480
QY 481 GGTGACAGACAGCAACCAACCAAGACCTCTAGGTCACCTGATCTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGCAACCAACCAAGACCTCTAGGTCACCTGATCTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACCAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACCAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTAGACACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660

Qy	661	GGTTGGCTTTGTGAGTGAAGACGAATACATTGGAAATTCAGGGGCATCACCCGGGAGCAGTTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGACGAATACATTGGAAATTCAGGGGCATCACCCGGGAGCAGTTC	720
Qy	721	AGGGGACTACGAGTCAGATGCCCTCCAATGACGTGGCGGCCGTCGTAGTACGGAGACTAAA	780
Db	721	AGGGGACTACGAGTCAGATGCCCTCCAATGACGTGGCGGCCGTCGTAGTACGGAGACTAAA	780
Qy	781	GGTCAACGGTGAATATATCCACATACATTTCCAGAAAGCCAAAGGTACAGGTGTCCCTGGG	840
Db	781	GGTCAACGGTGAATATATCCACATACATTTCCAGAAAGCCAAAGGTACAGGTGTCCCTGGG	840
Qy	841	ACAAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGATCCCTCAGCAGAAATTCACAGTGGTA	900
Db	841	ACAAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGATCCCTCAGCAGAAATTCACAGTGGTA	900
Qy	901	CAAGGATGACAAAAGACTGATTTGAAGAAAGAAAGGGGTGAATGTGGAAAAACAGACCTTT	960
Db	901	CAAGGATGACAAAAGACTGATTTGAAGAAAGAAAGGGGTGAATGTGGAAAAACAGACCTTT	960
Qy	961	CTCTCAAAACTCATCTTTCTCAATGTCTCTGAACATGACTATGTGGAACTACACTTTGCGT	1020
Db	961	CTCTCAAAACTCATCTTTCTCAATGTCTCTGAACATGACTATGTGGAACTACACTTTGCGT	1020
Qy	1021	GGCCTCCAAACAAAGCTGGGCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGGT	1080
Db	1021	GGCCTCCAAACAAAGCTGGGCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGGT	1080
Qy	1081	CAGCGAGTGAACAAACGGCAGCTCGAGAGGGCAGGCTGGTCTGGGTGCTGCTCTTCT	1140
Db	1081	CAGCGAGTGAACAAACGGCAGCTCGAGAGGGCAGGCTGGTCTGGGTGCTGCTCTTCT	1140
Qy	1141	GGTCTTGACCTGTCTTCTAAATTTTGAATGTGAGTGCCATTCCTCCACCCCGGAAAGGCT	1200
Db	1141	GGTCTTGACCTGTCTTCTAAATTTTGAATGTGAGTGCCATTCCTCCACCCCGGAAAGGCT	1200
Qy	1201	GCCGCCACCAACCAACACACAAACAGCAATGCAACACGACAGCAACCAATCAGATA	1260
Db	1201	GCCGCCACCAACCAACACACAAACAGCAATGCAACACGACAGCAACCAATCAGATA	1260
Qy	1261	TATACAAATGAAATTAGAAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGGAAC	1320
Db	1261	TATACAAATGAAATTAGAAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGGAAC	1320
Qy	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAATAAGAAATTTGAAATTTGCTTTCAGATA	1380
Db	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAATAAGAAATTTGAAATTTGCTTTCAGATA	1380
Qy	1381	TTTAGGTACAATGAGTTTCTTTTCCAAACGGGAAGAACACAGCACACCCGGCTTGGGA	1440
Db	1381	TTTAGGTACAATGAGTTTCTTTTCCAAACGGGAAGAACACAGCACACCCGGCTTGGGA	1440
Qy	1441	CCCACTGCAAGCTGCATCGTGCACCTCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGGCTC	1500
Db	1441	CCCACTGCAAGCTGCATCGTGCACCTCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGGCTC	1500
Qy	1501	TCTGCCACACAGAGTGCCTCCACAGTGTGGAACATCTTGGAGCTGGCCATCCCAAAATTCATCA	1560
Db	1501	TCTGCCACACAGAGTGCCTCCACAGTGTGGAACATCTTGGAGCTGGCCATCCCAAAATTCATCA	1560
Qy	1561	GTCCATAGACGAAACGAATGAGACCTTCGGGCCCAAGCGTGGCGTGGGGCACTTTG	1620
Db	1561	GTCCATAGACGAAACGAATGAGACCTTCGGGCCCAAGCGTGGCGTGGGGCACTTTG	1620
Qy	1621	GTAGACTGTGCCACACAGGCGTGTGTGTGAAACGTGAAATATAAAGAGCAAAAAAAA	1679
Db	1621	GTAGACTGTGCCACACAGGCGTGTGTGTGAAACGTGAAATATAAAGAGCAAAAAAAA	1679

RESULT 20
ADB35596
ID ADB3
XX

ADBS35596;

04-DEC-2003 (first entry)

Human PRO polynucleotide SEQ ID NO 375.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; PFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

Homo sapiens.

US2003077719-A1.

24-APR-2003.

24-APR-2002; 2002US-00131824.

09-FEB-1999; 99US-0119341P.

01-DEC-1999; 99WO-US028634.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-755074/71.

P-PSDB; ADS35597.

New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.

Claim 2; Fig 375; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting the proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or PFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

XX OS Homo sapiens.
XX PN US2003077716-A1.
XX PD 24-APR-2003.
XX PF 24-APR-2002; 2002US-00131813.
XX PR 07-OCT-1998; 98US-0103315P.
XX PR 01-SEP-1999; 99WO-US020111.
XX PR 18-OCT-1999; 99US-00403297.
XX PR 18-FEB-2000; 2000WO-US004342.
XX PR 10-NOV-2000; 2000WO-US030873.
XX PR 01-DEC-2000; 2000WO-US032878.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W,
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S,
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI; 2003-755071/71.
XX DR P-ESDB; ADB33941.
XX PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
XX PT in tissue typing, and in identifying chromosomes.
XX PS Claim 2; Fig 375; 637pp; English.
XX CC The invention relates to isolated human PRO polypeptides (secreted and
XX CC transmembrane polypeptides) and the polynucleotides encoding them. The
XX CC invention also relates to an antibody which specifically binds to a PRO
XX CC polypeptide, a method for stimulating the release of tumour necrosis
XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX CC proliferation or differentiation of chondrocyte cells and a method for
XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX CC polynucleotides are useful in molecular biology, including uses as
XX CC hybridisation probes, in chromosome and gene mapping, in generating
XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX CC be used in preparing PRO polypeptides by recombinant techniques and in
XX CC generating either transgenic animals or knock-out animals which are
XX CC useful in the development and screening of therapeutically useful
XX CC reagents. The PRO polypeptides or antibodies are used in preparing a
XX CC medicament for treating a condition responsive to the polypeptides or
XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation
XX CC of human microvascular endothelial cells, for modulating the uptake of
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX CC stimulating differentiation of adipocyte cells, for stimulating
XX CC proliferation of or gene expression in pericyte cells, for stimulating
XX CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX CC cells, for inducing endothelial cell tube formation and for treating
XX CC various bone and/or cartilage disorders such as sports injuries and
XX CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX CC from cartilage are useful for treating sports-related joint problems,
XX CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX CC polypeptides are also useful for treating various mammalian haemoglobin-
XX CC associated disorders such as various thalassaemias and conditions which
XX CC may benefit from enhanced local immune system cell infiltration. This
XX CC sequence represents a human PRO polynucleotide of the invention. Note:
XX CC The sequence data for this patent is also available in electronic format
XX CC from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX 1 GTTGTGCTCTTCAGCAACAGTGGAATTAAATCTCTTGCACAGCTTGAGAGCAACAC 60
61 AATCTATCAGGAAGAAGAAAGAAAAAACCAGAACTGACAAAAAGAAAAAGAAAG 120
61 AATCTATCAGGAAGAAGAAAGAAAAAACCAGAACTGACAAAAAGAAAAAGAAAG 120
121 AAGAAAAAATCATGAACCAATCCAGCCCAAAATGCAAAATCTATCTCTTGGGCAAT 180
121 AAGAAAAAATCATGAACCAATCCAGCCCAAAATGCAAAATCTATCTCTTGGGCAAT 180
181 CTTACGGGGGTGCTGCTCTGTCTCTCTTCCAAAGAGTGCCTGCGCAGCGAGATGC 240
181 CTTACGGGGGTGCTGCTCTGTCTCTCTTCCAAAGAGTGCCTGCGCAGCGAGATGC 240
241 CACCTTCCCAAGCTATGACACAGCTGAGCGTCCGCGAGGGGAGAGCGCCACCTCAG 300
241 CACCTTCCCAAGCTATGACACAGCTGAGCGTCCGCGAGGGGAGAGCGCCACCTCAG 300
301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCAACCACTCTTA 360
301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCAACCACTCTTA 360
361 TGCTGGGAATGACAAGTGGTGCCTGGATCTCTCGGTGGTCTTCTGAGCAACCCAAAC 420
361 TGCTGGGAATGACAAGTGGTGCCTGGATCTCTCGGTGGTCTTCTGAGCAACCCAAAC 420
421 CAGGTACAGCATCGAGATCCAGAAACGTGGATGTATGACGAGGGGCCCTTACACCTCTC 480
421 CAGGTACAGCATCGAGATCCAGAAACGTGGATGTATGACGAGGGGCCCTTACACCTCTC 480
481 GGTGAGACAGACAAACCAACCAAGAGCTCTAGGGTCACTCTTGTGCAAGTATCTCC 540
481 GGTGAGACAGACAAACCAACCAAGAGCTCTAGGGTCACTCTTGTGCAAGTATCTCC 540
541 CAAAATTTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAAACAATATTAGCCTCAC 600
541 CAAAATTTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAAACAATATTAGCCTCAC 600
601 CTGCTAGCACTAGTGTAGACAGAGCTTACGGTACTTGTGAGACACATCTCTCCAAAGC 660
601 CTGCTAGCACTAGTGTAGACAGAGCTTACGGTACTTGTGAGACACATCTCTCCAAAGC 660
661 GGTTCGCTTTGTGAGTGAAGAGCAATCTTGGAAATTCAGGGCATCCCGGGAGCAGTC 720
661 GGTTCGCTTTGTGAGTGAAGAGCAATCTTGGAAATTCAGGGCATCCCGGGAGCAGTC 720
721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCCCGTGTACGGAGAGTAAA 780
721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCCCGTGTACGGAGAGTAAA 780
781 GGTACCGGTGAACCTATCCACCATATTTCAAGAGCCAGGGTACAGGTGTCCTCGTGGG 840
781 GGTACCGGTGAACCTATCCACCATATTTCAAGAGCCAGGGTACAGGTGTCCTCGTGGG 840
841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
901 CAAGGATGCAAAAACACTGATTGAAGGAAAGAAAGGGGTGAAGTGGAAAAACAGACCTTT 960
901 CAAGGATGCAAAAACACTGATTGAAGGAAAGAAAGGGGTGAAGTGGAAAAACAGACCTTT 960
961 CTTCTCAAAACTCATCTTCTTCAATGTCTTGAACATGACTATATGGGAACACTACCTTGGT 1020
961 CTTCTCAAAACTCATCTTCTTCAATGTCTTGAACATGACTATATGGGAACACTACCTTGGT 1020
1021 GGCCTCCACAGCTGGGGCCACCAATGCCAGCATCATGCTATTGCTCAGGGCGCGT 1080
1021 GGCCTCCACAGCTGGGGCCACCAATGCCAGCATCATGCTATTGCTCAGGGCGCGT 1080
1081 CAGCGAGTGTAGCAACAGCGCACGTGCGAGGGGCGAGGCTCGCTCTGGCTGCTCTTCT 1140

QY 1021 GGCCTCCACAGCTGGGCGCACCAATGCCAGCATCATGCTATTGCTCAGCGCGGT 1080
DB 1021 GGCCTCCACAGCTGGGCGCACCAATGCCAGCATCATGCTATTGCTCAGCGCGGT 1080
QY 1081 CAGCGAGGTGACCAACGGCAGCTCGAGGAGGCGCGCTGCGTGGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGGTGACCAACGGCAGCTCGAGGAGGCGCGCTGCGTGGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTCTCAAAATTTTGTGAGTGAGTCCCACTCCCAACCGGGAAGGCT 1200
DB 1141 GGTCTTGACCTGCTCTCAAAATTTTGTGAGTGAGTCCCACTCCCAACCGGGAAGGCT 1200
QY 1201 GCGGCACCAACACCAACCAACAGCAATGGCAACACCGACACCAACCAATCAGATA 1260
DB 1201 GCGGCACCAACACCAACCAACAGCAATGGCAACACCGACACCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATATGAAAGAAACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAATATGAAAGAAACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTCAGAAATTCCTTGCAGATA 1380
DB 1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTCAGAAATTCCTTGCAGATA 1380
QY 1381 TTAGTACAATGAGAGTTTCTTTTCCCAACCGGGAAGAAACAGACACACCCGGCTTGA 1440
DB 1381 TTAGTACAATGAGAGTTTCTTTTCCCAACCGGGAAGAAACAGACACACCCGGCTTGA 1440
QY 1441 CCACCTGACGCTGATCTGCACTCTTTGTCAGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCACCTGACGCTGATCTGCACTCTTTGTCAGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCCCCAGCGTGAACATTTGAGTGCGCATTCGCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCCCCAGCGTGAACATTTGAGTGCGCATTCGCAATTCATCA 1560
QY 1561 GTCCATAGACGACAGATGAGCTTCCGCGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
DB 1561 GTCCATAGACGACAGATGAGCTTCCGCGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAACGCGCTGTGTGTGAACGTTGAATATAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAACGCGCTGTGTGTGAACGTTGAATATAAGAGCAAAAAA 1679

RESULT 23
ADB36148
ID ADB36148 standard; cDNA; 1679 BP.

AC ADB36148;

DE 04-DEC-2003 (first entry)

DE Human PRO polynucleotide SEQ ID NO 375.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; PFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

OS Homo sapiens.

PN US2003077720-A1.

XX 24-APR-2003.

XX 24-APR-2002; 2002US-00131930.

XX 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755075/71.
DR P-PSDB; ADB36149.
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
acids, useful for the diagnosis, prevention and/or treatment of tumors,
such as lung, colon, breast, prostate, rectal, cervical and/or liver
tumors.
XX Claim 2; Fig 375; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or PFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems, PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent is also available in electronic format
from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTTCAGCAAAACAGTGGATTTAAATCTCTTGACAAAGCTTGAGACACAC 60
DB 1 GTTGTGCTTTCAGCAAAACAGTGGATTTAAATCTCTTGACAAAGCTTGAGACACAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCCATCCAGCCAAAAATGCAGAAATCTCTCTGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCCATCCAGCCAAAAATGCAGAAATCTCTCTGGCAAT 180

181 CTTTCAAGGGGCTGCTCTCTGCTCTCTTCAAGGAGTCCCGTGGCAGCGGAGATGC 240
181 CTTTCAAGGGGCTGCTCTCTGCTCTCTTCAAGGAGTCCCGTGGCAGCGGAGATGC 240
241 CACCTTCCCAAGCTATGGAACACGTCAGTCCGCGAGGGGAGAGCGCCACCTCTCAG 300
241 CACCTTCCCAAGCTATGGAACACGTCAGTCCGCGAGGGGAGAGCGCCACCTCTCAG 300
301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGCAGCACTCTCTA 360
301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGCAGCACTCTCTA 360
361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCTGGCTGGCTGGCTGGCTGGCTGGCTGGCT 420
361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCTGGCTGGCTGGCTGGCTGGCTGGCTGGCT 420
421 GCAGTACAGCATTCAGATCCAGAACGTCGATGCTATGACAGGGGCTTTACACCTGCTC 480
421 GCAGTACAGCATTCAGATCCAGAACGTCGATGCTATGACAGGGGCTTTACACCTGCTC 480
481 GGTGCAGACAGAACCAACCAAGAGCTCTAGGGTCCACCTCAATTGTGCAAGTATCTCC 540
481 GGTGCAGACAGAACCAACCAAGAGCTCTAGGGTCCACCTCAATTGTGCAAGTATCTCC 540
541 CAATAATTGACAGATTTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
541 CAATAATTGACAGATTTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
601 CTGCATAGCAACTGGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
601 CTGCATAGCAACTGGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
661 GGTGGCTTTGTAGTGAGGACGATATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
661 GGTGGCTTTGTAGTGAGGACGATATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
721 AGGGGACTACGAGTGCAGTCTCCATGACGTGGCGCGCCCGTGGTACGGAGAGTAA 780
721 AGGGGACTACGAGTGCAGTCTCCATGACGTGGCGCGCCCGTGGTACGGAGAGTAA 780
781 GGTCACTGTAACATTCACCATATATTGAGAGCCAGGGTACAGGTGTCCCGTGGG 840
781 GGTCACTGTAACATTCACCATATATTGAGAGCCAGGGTACAGGTGTCCCGTGGG 840
841 ACAAAAGGGGACATGCACTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGAGTGTA 900
841 ACAAAAGGGGACATGCACTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGAGTGTA 900
901 CAGGATGACAAAGACTGATGAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
901 CAGGATGACAAAGACTGATGAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
961 CCTCTCAAAATCATCTTCTCAATGCTCTGAAATGACTATGGAACTACACTTGGT 1020
961 CCTCTCAAAATCATCTTCTCAATGCTCTGAAATGACTATGGAACTACACTTGGT 1020
1021 GGCCTCCAAAGCTGGGCGCACCAATGCGCAGCATCATGCTATTTGGTCCAGCGCGCT 1080
1021 GGCCTCCAAAGCTGGGCGCACCAATGCGCAGCATCATGCTATTTGGTCCAGCGCGCT 1080
1081 CAGCGAGGTGACAAAGCTGGGCGCACCAATGCGCAGCATCATGCTATTTGGTCCAGCGCGCT 1140
1081 CAGCGAGGTGACAAAGCTGGGCGCACCAATGCGCAGCATCATGCTATTTGGTCCAGCGCGCT 1140
1141 GGTCTTGACCTGCTCTCTCAATTTTGTATGAGTGGCCACTTCCCGACCCGGGAAGGCT 1200
1141 GGTCTTGACCTGCTCTCTCAATTTTGTATGAGTGGCCACTTCCCGACCCGGGAAGGCT 1200
1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1261 TATACAAATGAAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320

1261 TATACAAATGAAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320
1321 AAAGAATACTTTGGGGGAAAGAGATTTTAAAGAAAGAAATTTGAAATTTGCCTTCAGATA 1380
1321 AAAGAATACTTTGGGGGAAAGAGATTTTAAAGAAAGAAATTTGAAATTTGCCTTCAGATA 1380
1381 TTATAGTACAATGGAGTTTCTTTTCCCAACCGGGAAGAAACACAGCACACCCGCTTGGG 1440
1381 TTATAGTACAATGGAGTTTCTTTTCCCAACCGGGAAGAAACACAGCACACCCGCTTGGG 1440
1441 CCCACTGCAAGCTGCATCGTCAACCTCTTGGTGGCCAGTGTGGGCAAGGCTCAGCCTC 1500
1441 CCCACTGCAAGCTGCATCGTCAACCTCTTGGTGGCCAGTGTGGGCAAGGCTCAGCCTC 1500
1501 TCTGCCACAGAGTGGCCCGCCACGTCGGAACATTTCTGGAGTGGCCATCCCAATCAATCA 1560
1501 TCTGCCACAGAGTGGCCCGCCACGTCGGAACATTTCTGGAGTGGCCATCCCAATCAATCA 1560
1561 GTCCATAGAGACGACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTGCGGGCACCTTG 1620
1561 GTCCATAGAGACGACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTGCGGGCACCTTG 1620
1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAAACGTGAAATATAAAGAGCAAAAAAAA 1679
1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAAACGTGAAATATAAAGAGCAAAAAAAA 1679

RESULT 24

ADB46543

ID ADB46543 standard; cDNA; 1679 BP.

AC ADB46543;

XX

DT 04-DEC-2003 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX

XX Human; secreted and transmembrane protein; PRO; gene; ss;

XX Tumour necrosis factor alpha release; TNF-alpha release;

XX glucose uptake modulator; PFA uptake modulator;

XX cell proliferation stimulator; cell differentiation stimulator;

XX cell differentiation inhibitor; cytokine release stimulator; tumour;

XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX

XX US2003082692-A1.

XX

XX 01-MAY-2003.

XX

XX 22-APR-2002; 2002US-00127842.

XX

XX 03-MAR-2000; 2000US-0187202P.

XX

XX 01-DEC-2000; 2000WO-05032679.

XX

XX 19-DEC-2001; 2001US-00028072.

XX

XX (GETH) GENENTECH INC.

XX

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

XX

XX WPI; 2003-786906/74.

XX

XX P-PSDB; ADB46544.

XX

XX New PRO nucleic acid, useful for preparing a composition for treating

XX e.g., tumor or for tissue typing.

XX

XX Claim 2; Fig 375; 637pp; English.

XX

CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (III) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.

XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTGCGAAACAGTGGATTTAAATCTCTTGGCAAGCTTGAGAGCAAC 60
 DB 1 GTTGTGCTCTGCGAAACAGTGGATTTAAATCTCTTGGCAAGCTTGAGAGCAAC 60
 QY 61 ATCTATCAGGAAGAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 DB 61 ATCTATCAGGAAGAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 QY 121 AGAAAAAATCATGAAACCATCCAGCAAAATGCAATTTCTCTTTGGGCAAT 180
 DB 121 AGAAAAAATCATGAAACCATCCAGCAAAATGCAATTTCTCTTTGGGCAAT 180
 QY 181 CTTTCAGGGGCTGGCTGCTGCTGCTCTTCCAGAGAGTCCCGTCCGAGCGGAGATGC 240
 DB 181 CTTTCAGGGGCTGGCTGCTGCTGCTCTTCCAGAGAGTCCCGTCCGAGCGGAGATGC 240
 QY 241 CACCTTTCCCAAGCTATGACAAACGTGACGCTCCGAGGGGGAGAGCGCCACCTCAG 300
 DB 241 CACCTTTCCCAAGCTATGACAAACGTGACGCTCCGAGGGGGAGAGCGCCACCTCAG 300
 QY 301 GTGCATATGACAAACGGGTACCCGGGTGGCTGGCTTAAACCGGAGCACCCTCTTA 360
 DB 301 GTGCATATGACAAACGGGTACCCGGGTGGCTGGCTTAAACCGGAGCACCCTCTTA 360
 QY 361 TGTGCGGAATGACAAAGTGTGCTGGATCCTCGCGTGGTCTTCTTGAGCAACCCCAAC 420
 DB 361 TGTGCGGAATGACAAAGTGTGCTGGATCCTCGCGTGGTCTTCTTGAGCAACCCCAAC 420
 QY 421 GCAGTACAGATCAGATCCAGACCTGATGATGATGATGATGATGATGATGATGATGAT 480
 DB 421 GCAGTACAGATCAGATCCAGACCTGATGATGATGATGATGATGATGATGATGATGAT 480
 QY 481 GGTGCGAGACAGCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 DB 481 GGTGCGAGACAGCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 QY 541 CAAAAATTGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
 DB 541 CAAAAATTGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600

DB 541 CAAAAATTGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
 QY 601 CTCATAGCAACTGGTAGACCAAGAGCTACGGTTACTTGGAGACACATCTCTCCAAAGC 660
 DB 601 CTCATAGCAACTGGTAGACCAAGAGCTACGGTTACTTGGAGACACATCTCTCCAAAGC 660
 QY 661 GGTGGCTTTGTGAGTGAGACGAATACTTGGAAATTCAGGGCATCACCGGAGCAGTC 720
 DB 661 GGTGGCTTTGTGAGTGAGACGAATACTTGGAAATTCAGGGCATCACCGGAGCAGTC 720
 QY 721 AGGGGACTACGAGTGCCTTCCCAATGACGTGGCGCGCCCGTGTACGGAGAGTAAA 780
 DB 721 AGGGGACTACGAGTGCCTTCCCAATGACGTGGCGCGCCCGTGTACGGAGAGTAAA 780
 QY 781 GGTACCGGTGAATATCCACCATACATTTTCAGAGCAAGGTTACAGGTGTCCCGTGG 840
 DB 781 GGTACCGGTGAATATCCACCATACATTTTCAGAGCAAGGTTACAGGTGTCCCGTGG 840
 QY 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
 DB 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
 QY 901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGTGAAGTGAAGAAACAGACCTTT 960
 DB 901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGTGAAGTGAAGAAACAGACCTTT 960
 QY 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGAACTTACACTTGGCT 1020
 DB 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGAACTTACACTTGGCT 1020
 QY 1021 GGCTCTCAACAGCTGGGCGCACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGCT 1080
 DB 1021 GGCTCTCAACAGCTGGGCGCACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGCT 1080
 QY 1081 CAGCGAGTGCAGCAACGGCAGCTCGAGGAGGCGAGGCTGCTGCTGCTGCTCTTCT 1140
 DB 1081 CAGCGAGTGCAGCAACGGCAGCTCGAGGAGGCGAGGCTGCTGCTGCTGCTCTTCT 1140
 QY 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGAATGAGTGCCTTCCCAACCGGAAAGGCT 1200
 DB 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGAATGAGTGCCTTCCCAACCGGAAAGGCT 1200
 QY 1201 GCGCCACACCCACCCACCAACAGCAACAGCAATGCGAACCCGACAGCAACCAATCAGATA 1260
 DB 1201 GCGCCACACCCACCCACCAACAGCAACAGCAATGCGAACCCGACAGCAACCAATCAGATA 1260
 QY 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGAGCAAGAAATTTGAGGGAGGGAAC 1320
 DB 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGAGCAAGAAATTTGAGGGAGGGAAC 1320
 QY 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTGCGAGATA 1380
 DB 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTGCGAGATA 1380
 QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGAGAAACACAGCACACCCCGCTTGA 1440
 DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGAGAAACACAGCACACCCCGCTTGA 1440
 QY 1441 CCCACTGCAAGCTGATCGTGCAACCTTTTGTGCCAGTGTGGGAGGGCTCAGGCTC 1500
 DB 1441 CCCACTGCAAGCTGATCGTGCAACCTTTTGTGCCAGTGTGGGAGGGCTCAGGCTC 1500
 QY 1501 TCTGCCACAGAGTGGCCCGCCACCGTGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
 DB 1501 TCTGCCACAGAGTGGCCCGCCACCGTGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
 QY 1561 GTCCATAGAGACGAACAGATGAGACCTTCCGGCCCAAGCGTGGCGTCCGGGACCTTTG 1620
 DB 1561 GTCCATAGAGACGAACAGATGAGACCTTCCGGCCCAAGCGTGGCGTCCGGGACCTTTG 1620
 QY 1621 GTAGACTGTGCCACCGGCTGTGTTGTGAACCTGTAATTAAGGAAAGCAAAAAA 1679
 DB 1621 GTAGACTGTGCCACCGGCTGTGTTGTGAACCTGTAATTAAGGAAAGCAAAAAA 1679

RESULT 25

AD44170

ID AD44170 standard; cDNA; 1679 BP.

XX AC AD44170;

XX DT 18-DEC-2003 (first entry)

XX DE Human cDNA encoding secreted/transmembrane protein, PRO337.

XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
cytosolic; ophthalmological; antiarthritic; osteoplastic; antirheumatic;
vulnerable; auditory; tumour growth; retinal disorder;
sports-related joint problem; articular cartilage defects;
osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

XX OS Homo sapiens.

XX PN US2003054986-A1.

XX PD 20-MAR-2003.

XX PF 16-OCT-2001; 2001US-00981915.

XX PR 17-OCT-1997; 97US-0062250P.

PR PR 13-NOV-1997; 97US-0064249P.

PR PR 13-NOV-1997; 97US-0065311P.

PR PR 10-NOV-1997; 97US-0066364P.

PR PR 10-MAR-1998; 98US-0077450P.

PR PR 11-MAR-1998; 98US-0077632P.

PR PR 11-MAR-1998; 98US-0077641P.

PR PR 11-MAR-1998; 98US-0077649P.

PR PR 12-MAR-1998; 98US-0077791P.

PR PR 13-MAR-1998; 98US-0078004P.

PR PR 17-MAR-1998; 98US-0080402P.

PR PR 20-MAR-1998; 98US-0078866P.

PR PR 20-MAR-1998; 98US-0078910P.

PR PR 20-MAR-1998; 98US-0078936P.

PR PR 20-MAR-1998; 98US-0078939P.

PR PR 25-MAR-1998; 98US-0079294P.

PR PR 26-MAR-1998; 98US-0079656P.

PR PR 27-MAR-1998; 98US-0079663P.

PR PR 27-MAR-1998; 98US-0079664P.

PR PR 27-MAR-1998; 98US-0079689P.

PR PR 27-MAR-1998; 98US-0079728P.

PR PR 27-MAR-1998; 98US-0079786P.

PR PR 30-MAR-1998; 98US-0079920P.

PR PR 30-MAR-1998; 98US-0079923P.

PR PR 31-MAR-1998; 98US-0080105P.

PR PR 31-MAR-1998; 98US-0080107P.

PR PR 31-MAR-1998; 98US-0080125P.

PR PR 31-MAR-1998; 98US-0080194P.

PR PR 01-APR-1998; 98US-0080327P.

PR PR 01-APR-1998; 98US-0080328P.

PR PR 01-APR-1998; 98US-0080333P.

PR PR 01-APR-1998; 98US-0080334P.

PR PR 08-APR-1998; 98US-0081049P.

PR PR 08-APR-1998; 98US-0081070P.

PR PR 08-APR-1998; 98US-0081071P.

PR PR 09-APR-1998; 98US-0081195P.

PR PR 09-APR-1998; 98US-0081203P.

PR PR 09-APR-1998; 98US-0081229P.

PR PR 15-APR-1998; 98US-0081817P.

PR PR 15-APR-1998; 98US-0081819P.

PR PR 15-APR-1998; 98US-0081838P.

PR PR 15-APR-1998; 98US-0081922P.

PR PR 15-APR-1998; 98US-0081955P.

PR PR 21-APR-1998; 98US-0082568P.

PR PR 21-APR-1998; 98US-0082569P.

PR PR 22-APR-1998; 98US-0082700P.

PR PR 22-APR-1998; 98US-0082704P.

PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084415P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98WO-US000106.
PR 05-MAR-1999; 98US-00254465.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98US-00265686.
PR 10-MAR-1999; 98WO-US005190.
PR 12-MAR-1999; 98US-00267213.
PR 12-MAR-1999; 98US-0123957P.
PR 12-MAR-1999; 98US-0126773P.
PR 12-APR-1999; 98US-00284231.
PR 21-APR-1999; 98US-0130232P.
PR 26-APR-1999; 98US-0131022P.
PR 28-APR-1999; 98US-0131445P.
PR 14-MAY-1999; 98US-00311832.

PR	14-MAY-1999;	99US-0134287P.	
PR	14-MAY-1999;	99WO-US010733.	
PR	02-JUN-1999;	99WO-US012252.	
PR	16-JUN-1999;	99US-0139557P.	
PR	23-JUN-1999;	99US-0141037P.	
PR	07-JUL-1999;	99US-0142680P.	
PR	26-JUL-1999;	99US-0145698P.	
PR	28-JUL-1999;	99US-0146222P.	
PR	25-AUG-1999;	99US-00380137.	
PR	25-AUG-1999;	99US-00380138.	
PR	25-AUG-1999;	99US-00380142.	
PR	29-OCT-1999;	99US-0162506P.	
PR	30-NOV-1999;	99WO-US028313.	
PR	02-DEC-1999;	99WO-US028551.	
PR	02-DEC-1999;	99WO-US028565.	
PR	16-DEC-1999;	99WO-US030095.	
PR	30-DEC-1999;	99WO-US031243.	
PR	30-DEC-1999;	99WO-US031274.	
PR	05-JAN-2000;	2000WO-US000219.	
PR	06-JAN-2000;	2000WO-US000277.	
PR	06-JAN-2000;	2000WO-US000376.	
PR	11-FEB-2000;	2000WO-US003565.	
PR	18-FEB-2000;	2000WO-US004341.	
PR	24-FEB-2000;	2000WO-US005004.	
PR	02-MAR-2000;	2000WO-US005841.	
PR	10-MAR-2000;	2000WO-US006319.	
PR	21-MAR-2000;	2000WO-US007532.	
PR	30-MAR-2000;	2000WO-US008439.	
PR	17-MAY-2000;	2000WO-US013705.	
PR	22-MAY-2000;	2000WO-US014042.	
PR	30-MAY-2000;	2000WO-US014941.	
PR	02-JUN-2000;	2000WO-US015264.	
PR	28-JUL-2000;	2000WO-US020710.	
PR	24-AUG-2000;	2000WO-US023328.	
PR	08-NOV-2000;	2000US-00709238.	
PR	27-NOV-2000;	2000US-00723749.	
PR	01-DEC-2000;	2000WO-US032678.	
PR	20-DEC-2000;	2000US-00747259.	
PR	20-DEC-2000;	2000WO-US034956.	
PR	28-FEB-2001;	2001WO-US006520.	
PR	22-MAR-2001;	2001US-00816744.	
PR	22-MAR-2001;	2001US-00816920.	
PR	22-MAR-2001;	2001WO-US009552.	
PR	10-MAY-2001;	2001US-00854208.	
PR	10-MAY-2001;	2001WO-US00854280.	
PR	25-MAY-2001;	2001US-00871092.	
PR	01-JUN-2001;	2001US-00872035.	
PR	01-JUN-2001;	2001WO-US017800.	
PR	05-JUN-2001;	2001US-00874503.	
PR	14-JUN-2001;	2001US-00882636.	
PR	19-JUN-2001;	2001US-00886342.	
PR	20-JUN-2001;	2001WO-US019692.	
PR	29-JUN-2001;	2001WO-US021066.	
PR	09-JUL-2001;	2001WO-US021735.	
PR	30-JUL-2001;	2001US-00918585.	
XX			
PA	(GETH) GENENTECH INC.		
XX			
Query Match 100.0%; Score 1679; DB 1; Length 1679;			
Best Local Similarity 100.0%; Pred. No. 6.7e-05;			
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCCTTCACAAAGCTTGAGAGCAACAC	60
DB	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCCTTCACAAAGCTTGAGAGCAACAC	60
QY	61	AATCTATCAGAAAGAAAGAAAGAAACCGAACCTGACAAAGAAAGAAAGAAAG	120
DB	61	AATCTATCAGAAAGAAAGAAAGAAACCGAACCTGACAAAGAAAGAAAGAAAG	120
QY	121	AAGAAAAAATCATGAATAACCATCCAGCCAAATTCGCAATTCCTCTTGGGCAAT	180

Db	121	AAGAAAAAATCATGAATAACCATCCAGCCAAATTCGCAATTCCTCTTGGGCAAT	180
QY	181	CTTCAAGGGGCTGGCTGCTCTGTCTCTTCCAAAGAGTGCCTGGCGAGCGAGATGC	240
Db	181	CTTCAAGGGGCTGGCTGCTCTGTCTCTTCCAAAGAGTGCCTGGCGAGCGAGATGC	240
QY	241	CACCTTCCCAAAAGCTATGACAAACGCTGACGGTCCGGCAGGGGAGAGCCACCTCAG	300
Db	241	CACCTTCCCAAAAGCTATGACAAACGCTGACGGTCCGGCAGGGGAGAGCCACCTCAG	300
QY	301	GTGCACATATTGACAAACGGGTCAACCGGGTGGCTGGCTAAACCGGAGACCATCTCTA	360
Db	301	GTGCACATATTGACAAACGGGTCAACCGGGTGGCTGGCTAAACCGGAGACCATCTCTA	360
QY	361	TGCTGGCAATGAACAAGTGGTGGCTTGGATCCTCGCTGGTCTCTTCTGAGCAACACCAAC	420
Db	361	TGCTGGCAATGAACAAGTGGTGGCTTGGATCCTCGCTGGTCTCTTCTGAGCAACACCAAC	420
QY	421	GCAGTACAGCATCGAGATCCAGAACGCTGGATCTCGCTGGTCTCTTCTGAGCAACACCAAC	480
Db	421	GCAGTACAGCATCGAGATCCAGAACGCTGGATCTCGCTGGTCTCTTCTGAGCAACACCAAC	480
QY	481	GGTCAGACAGCAACACCAACGCTTCTAGGCTCCTCATTTGTGCAAGTATCTCC	540
Db	481	GGTCAGACAGCAACACCAACGCTTCTAGGCTCCTCATTTGTGCAAGTATCTCC	540
QY	541	CAAAATTTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC	600
Db	541	CAAAATTTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC	600
QY	601	CTGCATAGCAACTGCTAGACAGAGCTACGCTTCTTGGAGACACATCTCTCCAAAGC	660
Db	601	CTGCATAGCAACTGCTAGACAGAGCTACGCTTCTTGGAGACACATCTCTCTCCAAAGC	660
QY	661	GGTTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGAGTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGAGTC	720
QY	721	AGGGGACTACAGTGCAGTCCCTCAATGAGCTGGCGCCCGCTGCTACGGAGAGTAAA	780
Db	721	AGGGGACTACAGTGCAGTCCCTCAATGAGCTGGCGCCCGCTGCTACGGAGAGTAAA	780
QY	781	GGTCACCGTGAACCTATCCACCATATTCAGAACCCAGGGTACAGGTGTCCCCGGTGG	840
Db	781	GGTCACCGTGAACCTATCCACCATATTCAGAACCCAGGGTACAGGTGTCCCCGGTGG	840
QY	841	ACAAAGGGGACACTGCAAGTGTGAAGCTGAGCTGCGCCCGCTCAGCAGAAATTCAGTGT	900
Db	841	ACAAAGGGGACACTGCAAGTGTGAAGCTGAGCTGCGCCCGCTCAGCAGAAATTCAGTGT	900
QY	901	CAAGGATGACAAAGAGCTGATTGAAGGAAAGAAAGGGGTGAAGTGGAAACACAGACCTTT	960
Db	901	CAAGGATGACAAAGAGCTGATTGAAGGAAAGAAAGGGGTGAAGTGGAAACACAGACCTTT	960
QY	961	CCTCTCAAACTCATCTTTTCAATGTCTCTGAACATGATATGGGAACTACACITGGGT	1020
Db	961	CCTCTCAAACTCATCTTTTCAATGTCTCTGAACATGATATGGGAACTACACITGGGT	1020
QY	1021	GGCTTCCAAAGCTGGGCGCACCAATGCCAGCATCATGTATTTGGTCCAGCGCGGT	1080
Db	1021	GGCTTCCAAAGCTGGGCGCACCAATGCCAGCATCATGTATTTGGTCCAGCGCGGT	1080
QY	1081	CAGCGAGTGAAGCAACGGCAGCTCGAGAGGGCAGGTGCGTCTGGCTGTCTCTTCT	1140
Db	1081	CAGCGAGTGAAGCAACGGCAGCTCGAGAGGGCAGGTGCGTCTGGCTGTCTCTTCT	1140
QY	1141	GGCTTGCACCTGCTCTCAATTTTGTATGTAGTGGCCACTTCCCACCCGGGAAAGGCT	1200
Db	1141	GGCTTGCACCTGCTCTCAATTTTGTATGTAGTGGCCACTTCCCACCCGGGAAAGGCT	1200
QY	1201	GGCGCCACCAACCAACCAACAGCAATGGCAATGGCAACCGGAGCAACCAATCAGATA	1260
Db	1201	GGCGCCACCAACCAACCAACAGCAATGGCAATGGCAACCGGAGCAACCAATCAGATA	1260

QY 1261 TATACAAATGAATAGAGAAACACACAGCCTCATGGACAGAAATTTGAGGGGGGAAAC 1320
DB 1261 TATACAAATGAATAGAGAAACACACAGCCTCATGGACAGAAATTTGAGGGGGGAAAC 1320
QY 1321 AAAGAAATACCTTGGGGGAAAGAGTTTTTAAAAAGAAATTTGAAATTCCTTGCAGATA 1380
DB 1321 AAAGAAATACCTTGGGGGAAAGAGTTTTTAAAAAGAAATTTGAAATTCCTTGCAGATA 1380
QY 1381 TTTAGGTACATGAGTTCTTTTCCAAACGGGAGACACAGCACACCCCGCTTGA 1440
DB 1381 TTTAGGTACATGAGTTCTTTTCCAAACGGGAGACACAGCACACCCCGCTTGA 1440
QY 1441 CCCACTGCAAGCTGCATCGTGCACACCTCTTTGGTGCAGTGTGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCATCGTGCACACCTCTTTGGTGCAGTGTGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACAGTGGAAACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCACAGTGGAAACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCGGGCCCAAGCGTGGCGTGGGGCACTTTG 1620
DB 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCGGGCCCAAGCGTGGCGTGGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACAGCGGCTGTGTGTGTAACGTGAATAAAGAGCAAAAAAAA 1679
DB 1621 GTAGACTGTGCCACACAGCGGCTGTGTGTGTAACGTGAATAAAGAGCAAAAAAAA 1679

RESULT 26
ADC61930
ID ADC61930 standard; cDNA; 1679 BP.
XX AC ADC61930;
XX DT 18-DEC-2003 (first entry)
XX DE Human cDNA encoding secreted/transmembrane protein, PRO337.
XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
OS Homo sapiens.
XX US2003049684-A1.
XX PD 13-MAR-2003.
XX PF 24-OCT-2001; 2001US-00017081.
XX PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 21-NOV-1997; 97US-0065311P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077643P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080156P.
PR 01-APR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 15-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 21-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 22-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083332P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 30-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085330P.
PR 15-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085575P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 28-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.

```
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-00211141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0103904P.
PR 20-NOV-1998; 98US-0024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 23-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-0113621P.
PR 05-MAR-1999; 98US-00254465.
PR 08-MAR-1999; 98US-00254465.
PR 10-MAR-1999; 98US-0025686.
PR 12-MAR-1999; 98US-0005190.
PR 12-MAR-1999; 98US-00267213.
PR 29-MAR-1999; 98US-0123957P.
PR 12-APR-1999; 98US-0126773P.
PR 21-APR-1999; 98US-00284291.
PR 26-APR-1999; 98US-0130232P.
PR 28-APR-1999; 98US-0131022P.
PR 14-MAY-1999; 98US-0131445P.
PR 14-MAY-1999; 98US-00311832.
PR 14-MAY-1999; 98US-0134287P.
PR 14-MAY-1999; 98US-010733.
PR 02-JUN-1999; 98US-0126773P.
PR 16-JUN-1999; 98US-0139557P.
PR 23-JUN-1999; 98US-0141037P.
PR 26-JUL-1999; 98US-0142680P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 25-AUG-1999; 98US-00380137.
PR 25-AUG-1999; 98US-00380138.
PR 29-AUG-1999; 98US-00380142.
PR 29-AUG-1999; 98US-0162506P.
PR 30-NOV-1999; 98US-00283113.
PR 02-DEC-1999; 98US-0028551.
PR 02-DEC-1999; 98US-0028565.
PR 16-DEC-1999; 98US-0030095.
PR 30-DEC-1999; 98US-0031243.
PR 30-DEC-1999; 98US-0031274.
PR 05-JAN-2000; 2000US-0000219.
PR 06-JAN-2000; 2000US-0000277.
PR 06-JAN-2000; 2000US-0000376.
PR 11-FEB-2000; 2000US-00003565.
PR 18-FEB-2000; 2000US-0004341.
PR 24-FEB-2000; 2000US-0005004.
PR 02-MAR-2000; 2000US-0005841.
PR 10-MAR-2000; 2000US-0006319.
PR 21-MAR-2000; 2000US-0007532.
PR 30-MAR-2000; 2000US-0008439.
PR 17-MAY-2000; 2000US-0013705.
PR 22-MAY-2000; 2000US-0014042.
PR 30-MAY-2000; 2000US-0014941.
PR 02-JUN-2000; 2000US-0015264.
PR 28-JUL-2000; 2000US-0020710.
PR 24-AUG-2000; 2000US-0023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000US-0032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000US-0034956.
PR 28-FEB-2001; 2001US-0006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001US-00809552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00917092.

PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00872800.
PR 03-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-0019692.
PR 29-JUN-2001; 2001US-0021066.
PR 09-JUL-2001; 2001US-0021735.
PR 30-JUL-2001; 2001US-00918585.
XX (GEITH ) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Deansoyers L, Eaton DL;
PI
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTTGACAAAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTTGACAAAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAACCAACCTGACAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAGAAACCAACCTGACAAAGAAAGAAAG 120
Qy 121 AAGAAAGAAATCATGAAACCATCCAGCAAAATGCAATTCATCTCTTTGGGCAAT 180
Db 121 AAGAAAGAAATCATGAAACCATCCAGCAAAATGCAATTCATCTCTTTGGGCAAT 180
Qy 181 CTTTCAGGGGCTGGCTGCTCTGTGTCTCTTCCAGGAGTGCCTGCGGAGCGGATGC 240
Db 181 CTTTCAGGGGCTGGCTGCTCTGTGTCTCTTCCAGGAGTGCCTGCGGAGCGGATGC 240
Qy 241 CACCTTCCCAAGCTATGGAACACGTGACGGTCCGGAGGGGAGAGGCCACCTTCAG 300
Db 241 CACCTTCCCAAGCTATGGAACACGTGACGGTCCGGAGGGGAGAGGCCACCTTCAG 300
Qy 301 GTGCACCTATTGACAAACCGGCTCACCCTGGCTGCTTAAACCGGAGCAACCTCTCTA 360
Db 301 GTGCACCTATTGACAAACCGGCTCACCCTGGCTGCTTAAACCGGAGCAACCTCTCTA 360
Qy 361 TGTCTGGGAATGACAAAGTGTGCTTGGATCCTCGCTGGTCTCTTGTGAGCAACCCAAAC 420
Db 361 TGTCTGGGAATGACAAAGTGTGCTTGGATCCTCGCTGGTCTCTTGTGAGCAACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACCGTGGATCTCGCTGGTCTCTTGTGAGCAACCCAAAC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACCGTGGATCTCGCTGGTCTCTTGTGAGCAACCCAAAC 480
Qy 481 GGTGCAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Qy 541 CAAAATTGTAGAGATTTCTTCAGATATCTCAATTAATGAAGGGAACAAATATTAGCCTCAC 600
Db 541 CAAAATTGTAGAGATTTCTTCAGATATCTCAATTAATGAAGGGAACAAATATTAGCCTCAC 600
Qy 601 CTGCATAGCAACTGCTAGACCCAGAGCCTACGGTTACTTTGAGAGACACATCTCTCCAAAGC 660
Db 601 CTGCATAGCAACTGCTAGACCCAGAGCCTACGGTTACTTTGAGAGACACATCTCTCCAAAGC 660
Qy 661 GGTTCGGCTTTGTGAGTGAAGACGAATTAATTTGGAAATTCAGGGCATACCCGGGAGAGTC 720
Db 661 GGTTCGGCTTTGTGAGTGAAGACGAATTAATTTGGAAATTCAGGGCATACCCGGGAGAGTC 720
Qy 721 AGGGGACTAGAGTGCAGTGCCTCCAATGAGTGGCGCGCCCTGGTGTAGGAGAGTAA 780
Db 721 AGGGGACTAGAGTGCAGTGCCTCCAATGAGTGGCGCGCCCTGGTGTAGGAGAGTAA 780
Qy 781 GGTTCACCGTGAATTCATCCACATATCATTTTCCAGAGCAAGGATACAGGTGTCCCGTGGG 840
Db 781 GGTTCACCGTGAATTCATCCACATATCATTTTCCAGAGCAAGGATACAGGTGTCCCGTGGG 840
```


PR	06-MAY-1998;	98US-0084441P.	PR	30-DEC-1999;	99WO-US031274.
PR	07-MAY-1998;	98US-0084598P.	PR	05-JAN-2000;	2000WO-US000219.
PR	07-MAY-1998;	98US-0084600P.	PR	06-JAN-2000;	2000WO-US000217.
PR	07-MAY-1998;	98US-0084627P.	PR	06-JAN-2000;	2000WO-US000376.
PR	07-MAY-1998;	98US-0084637P.	PR	11-FEB-2000;	2000WO-US000356.
PR	07-MAY-1998;	98US-0084639P.	PR	18-FEB-2000;	2000WO-US004341.
PR	07-MAY-1998;	98US-0084640P.	PR	24-FEB-2000;	2000WO-US005004.
PR	07-MAY-1998;	98US-0084643P.	PR	02-MAR-2000;	2000WO-US005841.
PR	13-MAY-1998;	98US-0085323P.	PR	10-MAR-2000;	2000WO-US006319.
PR	13-MAY-1998;	98US-0085338P.	PR	21-MAR-2000;	2000WO-US007532.
PR	13-MAY-1998;	98US-0085339P.	PR	10-MAR-2000;	2000WO-US008439.
PR	15-MAY-1998;	98US-0085573P.	PR	17-MAY-2000;	2000WO-US013705.
PR	15-MAY-1998;	98US-0085579P.	PR	22-MAY-2000;	2000WO-US014042.
PR	15-MAY-1998;	98US-0085580P.	PR	30-MAY-2000;	2000WO-US014941.
PR	15-MAY-1998;	98US-0085582P.	PR	02-JUN-2000;	2000WO-US015264.
PR	15-MAY-1998;	98US-0085689P.	PR	28-JUL-2000;	2000WO-US020710.
PR	15-MAY-1998;	98US-0085697P.	PR	24-AUG-2000;	2000WO-US023328.
PR	15-MAY-1998;	98US-0085700P.	PR	08-NOV-2000;	2000US-00709238.
PR	15-MAY-1998;	98US-0085704P.	PR	27-NOV-2000;	2000US-00723749.
PR	18-MAY-1998;	98US-0086023P.	PR	01-DEC-2000;	2000WO-US032678.
PR	22-MAY-1998;	98US-0086392P.	PR	20-DEC-2000;	2000US-00747259.
PR	22-MAY-1998;	98US-0086414P.	PR	20-DEC-2000;	2000WO-US034956.
PR	22-MAY-1998;	98US-0086430P.	PR	28-FEB-2001;	2001WO-US006520.
PR	22-MAY-1998;	98US-0086488P.	PR	22-MAR-2001;	2001US-00816744.
PR	28-MAY-1998;	98US-0087098P.	PR	22-MAR-2001;	2001US-00816920.
PR	28-MAY-1998;	98US-0087106P.	PR	22-MAR-2001;	2001WO-US009552.
PR	28-MAY-1998;	98US-0087208P.	PR	10-MAY-2001;	2001US-00854208.
PR	26-JUN-1998;	98US-00105413.	PR	10-MAY-2001;	2001US-00854280.
PR	26-JUN-1998;	98US-0090863P.	PR	25-MAY-2001;	2001WO-US017092.
PR	26-JUN-1998;	98US-0091010P.	PR	01-JUN-2001;	2001US-00872035.
PR	01-JUL-1998;	98US-0091359P.	PR	05-JUN-2001;	2001WO-US017800.
PR	30-JUL-1998;	98US-0094651P.	PR	14-JUN-2001;	2001US-00874503.
PR	11-SEP-1998;	98US-0100039P.	PR	19-JUN-2001;	2001US-00886342.
PR	07-OCT-1998;	98US-00168978.	PR	20-JUN-2001;	2001WO-US019692.
PR	07-OCT-1998;	98WO-US021141.	PR	29-JUN-2001;	2001WO-US021066.
PR	06-NOV-1998;	98US-00184216.	PR	09-JUL-2001;	2001WO-US021735.
PR	06-NOV-1998;	98US-00187368.	PR	30-JUL-2001;	2001US-00918585.
PR	20-NOV-1998;	98US-0102304P.	XX		
PR	20-NOV-1998;	98WO-US024855.	PA	(GETH) GENENTECH INC.	
PR	27-DEC-1998;	98US-00202054.	XX		
PR	22-DEC-1998;	98US-00218517.		Query Match	100.0%; Score 1679; DB 1; Length 1679;
PR	23-DEC-1998;	98US-0113296P.		Best Local Similarity	100.0%; Pred. No. 6.7e-05;
PR	05-JAN-1999;	98WO-US000106.		Matches 1679; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
PR	05-MAR-1999;	98US-00254465.	Qy	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAACTTCTCTTGGGCAAT 60
PR	08-MAR-1999;	99WO-US005028.	Db	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAACTTCTCTTGGGCAAT 60
PR	10-MAR-1999;	99WO-US005190.	Qy	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
PR	12-MAR-1999;	99US-00267213.	Db	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
PR	29-MAR-1999;	99US-0123957P.	Qy	121	AAGAAAAAATCATGAAACCATCCAGCCAAATTCGCAAAATTCATCTCTTGGGCAAT 180
PR	12-APR-1999;	99US-0126773P.	Db	121	AAGAAAAAATCATGAAACCATCCAGCCAAATTCGCAAAATTCATCTCTTGGGCAAT 180
PR	26-APR-1999;	99US-0130232P.	Qy	181	CTTCACGGGCTGGCTGCTGTGTCTTCTTCCAGGAGTGCCTGCGCAGCGAGATGC 240
PR	28-APR-1999;	99US-0131445P.	Db	181	CTTCACGGGCTGGCTGCTGTGTCTTCTTCCAGGAGTGCCTGCGCAGCGAGATGC 240
PR	14-MAY-1999;	99US-00311832.	Qy	241	CACCTTCCCAAGCTATGGAACACGTCGCGTCCGCGAGGGGAGGCGCCACCTTCAG 300
PR	14-MAY-1999;	99US-0134287P.	Db	241	CACCTTCCCAAGCTATGGAACACGTCGCGTCCGCGAGGGGAGGCGCCACCTTCAG 300
PR	02-JUN-1999;	99WO-US010733.	Qy	301	GTGCACCTATTGACAAACCGGCTCACCCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
PR	16-JUN-1999;	99US-0139557P.	Db	301	GTGCACCTATTGACAAACCGGCTCACCCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
PR	23-JUN-1999;	99US-0141037P.	Qy	361	TGCTGGGAATGACAAAGTGGTGGCTGCTGATCTCTCGGTGGTCTTCTTGAGCAACCCCAAC 420
PR	27-JUL-1999;	99US-0142680P.	Db	361	TGCTGGGAATGACAAAGTGGTGGCTGCTGATCTCTCGGTGGTCTTCTTGAGCAACCCCAAC 420
PR	26-JUL-1999;	99US-0145698P.			
PR	28-JUL-1999;	99US-0146222P.			
PR	25-AUG-1999;	99US-00380137.			
PR	25-AUG-1999;	99US-00380138.			
PR	25-AUG-1999;	99US-00380142.			
PR	29-OCT-1999;	99US-0162506P.			
PR	30-NOV-1999;	99WO-US028313.			
PR	02-DEC-1999;	99WO-US028551.			
PR	16-DEC-1999;	99WO-US030095.			
PR	30-DEC-1999;	99WO-US031243.			

QY 421 GCAGTACAGCATCGAGATCCAGAACGTTGGATGTATGACGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACGTTGGATGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGCGACGACACCAACCAAGACCTCTAGGTCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCGACGACACCAACCAAGACCTCTAGGTCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Db 541 CAAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCACTGGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGCATAGCACTGGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTTGTAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Db 661 GGTGGCTTTTGTAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACAGTGCAGTGCTCCATGAGCTGGCCGCGCCGCTGTAGCGAGGTAAA 780
Db 721 AGGGGACTACAGTGCAGTGCTCCATGAGCTGGCCGCGCCGCTGTAGCGAGGTAAA 780
QY 781 GGTCACTCCGTGAATTCACCATATACATTTAGAAAGCAAGGTACAGGTGTCCCGCTGGG 840
Db 781 GGTCACTCCGTGAATTCACCATATACATTTAGAAAGCAAGGTACAGGTGTCCCGCTGGG 840
QY 841 ACAAAGGGGACATGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGGTGTA 900
Db 841 ACAAAGGGGACATGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGGTGTA 900
QY 901 CAAGGATCAAAAACACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAGCAACAGACCTTT 960
Db 901 CAAGGATCAAAAACACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAGCAACAGACCTTT 960
QY 961 CCTCTCAAAACTCATCTTCTCAATGTCTTGAACATGACATATGGGAACTACACTTCGT 1020
Db 961 CCTCTCAAAACTCATCTTCTCAATGTCTTGAACATGACATATGGGAACTACACTTCGT 1020
QY 1021 GSCCTCCAAAGCTGGGACCAACCAATGCCAGATCATGTATTTGGTCCAGGCGCGCT 1080
Db 1021 GSCCTCCAAAGCTGGGACCAACCAATGCCAGATCATGTATTTGGTCCAGGCGCGCT 1080
QY 1081 CAGCAGGTGAGCAACGGCAGCTGAGAGGGGAGGCTGCTGCTGCTGCTGCTCTCTCT 1140
Db 1081 CAGCAGGTGAGCAACGGCAGCTGAGAGGGGAGGCTGCTGCTGCTGCTGCTCTCTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTAGTGAGTGCCACTTCCCAACCGGGGAAAGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTAGTGAGTGCCACTTCCCAACCGGGGAAAGCT 1200
QY 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
QY 1261 TATACATATGATATGAGGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Db 1261 TATACATATGATATGAGGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAAGAATATCTTTGGGGGAAAGAGTTTTTAAAGAAAGAAATTTGAAATTTGCTTCAGATA 1380
Db 1321 AAAGAATATCTTTGGGGGAAAGAGTTTTTAAAGAAAGAAATTTGAAATTTGCTTCAGATA 1380
QY 1381 TTTAGGTACATGGAGTTTCTTTTCCAAAGGGAAGAACACAGCACACCCGGCTTGA 1440
Db 1381 TTTAGGTACATGGAGTTTCTTTTCCAAAGGGAAGAACACAGCACACCCGGCTTGA 1440
QY 1441 CCCACTGCAAGTGCATCGTCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGTGCATCGTCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500

QY 1501 TCTGCCACAGAGTGGCCCGCCACGTTGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGGCCCGCCACGTTGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAAACAGATGAGACCTTCGCGCCCAAGCGTGCCTGCGGGCCTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGATGAGACCTTCGCGCCCAAGCGTGCCTGCGGGCCTTTG 1620
QY 1621 GTAGACTGTGCCACCAACCGCGCTGTGTTGTGAAACGTGAATATAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACCAACCGCGCTGTGTTGTGAAACGTGAATATAAGAGCAAAAAAAA 1679

RESULT 28
ADC66994
ID ADC66994 standard; cDNA; 1679 BP.
XX
AC ADC66994;
XX
XX
DT 18-DEC-2003 (first entry)
XX
XX Human cDNA encoding secreted/transmembrane protein, PRO337.
XX
XX vulnary; virucide; neuroprotective; cytostatic; gene therapy;
KW tumour cell proliferation inhibitor;
KW secreted and transmembrane protein; PRO; viral infection; wound healing;
KW tissue growth; muscle generation; muscle regeneration;
KW amyotrophic lateral sclerosis; neuropathy; AIDS-associated neuropathy;
KW diabetic peripheral neuropathy; chromosome identification; antagonist;
KW tissue typing; immunohistochemical staining; gene; ss.
XX Homo sapiens.
XX
XX US2003060406-A1.
PN
XX
XX 27-MAR-2003.
XX
XX 30-JUL-2001; 2001US-00918585.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-0004022O.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078938P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 26-JUN-1998; 98US-00105413.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 05-JAN-1999; 99WO-US000106.

PR 05-MAR-1999;	99US-00254465.	CC	CC	The invention describes an isolated secreted and transmembrane PRO
PR 08-MAR-1999;	99WO-US0005028.	CC	CC	polypeptide (I). PRO polypeptide such as PRO13, PRO700, PRO320 or PRO615
PR 09-MAR-1999;	99US-00265686.	CC	CC	is useful in biotechnological and medical research, as well as in various
PR 10-MAR-1999;	99WO-US0005190.	CC	CC	industrial applications. PRO polypeptide such as PRO300, PRO866, PRO703,
PR 12-MAR-1999;	99US-00267213.	CC	CC	PRO708, PRO320, PRO351, PRO381, PRO615, PRO318, PRO772, PRO853,
PR 12-APR-1999;	99US-00284291.	CC	CC	PRO860 or PRO846 is useful for therapeutic purposes. PRO363 is useful
PR 14-MAY-1999;	99US-00311832.	CC	CC	therapeutically in vivo for lessening the effects of viral infection.
PR 14-MAY-1999;	99WO-US010733.	CC	CC	PRO200 is useful for the treatment of wound healing, tissue growth and
PR 02-JUN-1999;	99WO-US012252.	CC	CC	muscle generation and regeneration. PRO337 is useful for treating
PR 25-AUG-1999;	99US-00380137.	CC	CC	amyotrophic lateral sclerosis, neuropathy, AIDS-associated neuropathy or
PR 25-AUG-1999;	99US-00380138.	CC	CC	diabetic peripheral neuropathy. A polynucleotide (II) encoding (I) is
PR 25-AUG-1999;	99US-00380142.	CC	CC	useful for generating transgenic animals or knockout animals which are
PR 30-DEC-1999;	99WO-US028313.	CC	CC	useful in the development and screening of therapeutically useful
PR 03-JAN-2000;	2000WO-US000219.	CC	CC	regents, as probes for generating a pool of sequences for identifying
PR 06-JAN-2000;	2000WO-US000277.	CC	CC	related PRO coding sequences, and to construct hybridisation probes for
PR 06-JAN-2000;	2000WO-US000376.	CC	CC	mapping the gene which encodes the PRO and for the genetic analysis of
PR 11-FEB-2000;	2000WO-US0003565.	CC	CC	individuals with genetic disorders, for recombinantly expressing (I) and
PR 18-FEB-2000;	2000WO-US0004341.	CC	CC	for chromosome identification. (I) is useful as molecular marker for
PR 24-FEB-2000;	2000WO-US0005004.	CC	CC	protein electrophoresis purposes, and as therapeutic agents. (I) is also
PR 02-MAR-2000;	2000WO-US0005841.	CC	CC	useful for screening compounds to identify those that mimic the PRO
PR 10-MAR-2000;	2000WO-US0006319.	CC	CC	polypeptide (agonists) or prevent the effect of the PRO polypeptide
PR 21-MAR-2000;	2000WO-US007532.	CC	CC	(antagonists). (I) and (II) are useful for tissue typing. PRO antibodies
PR 30-MAR-2000;	2000WO-US0008439.	CC	CC	are useful for immunohistochemical staining and/or assay of sample
PR 17-MAY-2000;	2000WO-US013705.	CC	CC	fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g.
PR 22-MAY-2000;	2000WO-US014042.	CC	CC	detecting its expression in specific cells, tissues or serum, and for
PR 30-MAY-2000;	2000WO-US015264.	CC	CC	affinity purification of PRO from recombinant cell culture or natural
PR 02-JUN-2000;	2000WO-US020710.	CC	CC	sources. This sequence encodes a human secreted and transmembrane PRO
PR 28-JUL-2000;	2000WO-US020710.	CC	CC	protein.
PR 24-AUG-2000;	2000WO-US023328.	CC	CC	
PR 08-NOV-2000;	2000US-00709238.	XX	SQ	Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
PR 27-NOV-2000;	2000US-00723749.			Query Match 100.0%; Score 1679; DB 1; Length 1679;
PR 01-DEC-2000;	2000WO-US032678.			Best Local Similarity 100.0%; Pred. No. 6.7e-05;
PR 20-DEC-2000;	2000US-00747259.			Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
PR 20-DEC-2000;	2000WO-US034556.			
PR 28-FEB-2001;	2001WO-US006520.			
PR 22-MAR-2001;	2001US-00816744.			
PR 22-MAR-2001;	2001US-00816920.			
PR 10-MAY-2001;	2001US-00854208.			
PR 25-MAY-2001;	2001WO-US017092.			
PR 01-JUN-2001;	2001US-00872035.			
PR 01-JUN-2001;	2001WO-US017800.			
PR 05-JUN-2001;	2001US-00874503.			
PR 19-JUN-2001;	2001US-00882636.			
PR 27-JUN-2001;	2001US-00886342.			
PR 20-JUN-2001;	2001WO-US019592.			
PR 29-JUN-2001;	2001WO-US021066.			
PR 09-JUL-2001;	2001WO-US021735.			
XX (GETH) GENENTECH INC.				
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;				
XX Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;				
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;				
PI Kijavini IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;				
PI Stewart TA, Tumas D, Williams PM, Wood WI;				
XX WPI; 2003-596568/56.				
XX P-PSDB; ADC66995.				
XX Novel secreted and transmembrane polypeptides and polynucleotides				
XX encoding them, useful for treating wound healing, tissue growth and				
PT muscle generation and regeneration, amyotrophic lateral sclerosis or				
PT neuropathy.				
XX Claim 2; SEQ ID NO 522; 472pp; English.				
XX				
XX				

541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAGGGAACAATATTAGCCTCAC 600
601 CTGATAGCACTGCTAGACAGAGGCTTACGTTACTTTGAGAGACATCTCTCCAAAGC 660
601 CTGATAGCACTGCTAGACAGAGGCTTACGTTACTTTGAGAGACATCTCTCCAAAGC 660
661 GGTGGGCTTTGAGTGAAGACGAAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
661 GGTGGGCTTTGAGTGAAGACGAAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
721 AGGGGACTACGAGTGCAGTCTCAATGAGTGGCGCGCGCTGTGATCGGAGAGTAA 780
721 AGGGGACTACGAGTGCAGTCTCAATGAGTGGCGCGCGCTGTGATCGGAGAGTAA 780
781 GGTCACTGAGTATCAACATATCTTCAAGAGCAAGGTGACAGTGTCCCGGTGGG 840
781 GGTCACTGAGTATCAACATATCTTCAAGAGCAAGGTGACAGTGTCCCGGTGGG 840
841 ACAAAGGGGACATGCGAGTGTGAAGCTCAGAGTGCCTCAGCAGATTCAGTGGTA 900
841 ACAAAGGGGACATGCGAGTGTGAAGCTCAGAGTGCCTCAGCAGATTCAGTGGTA 900
901 CAAGATGACAAAGACATGTTGAAGGAAAGAGGGGTGAAGTGAAGACAGACCTTT 960
901 CAAGATGACAAAGACATGTTGAAGGAAAGAGGGGTGAAGTGAAGACAGACCTTT 960
961 CCTCTCAAACTCATCTTTCTTCAATGCTCTGAACATGATCGGAACTACACTTCGCT 1020
961 CCTCTCAAACTCATCTTTCTTCAATGCTCTGAACATGATCGGAACTACACTTCGCT 1020
1021 GGCCTTCAACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGTCAGGCGCGCT 1080
1021 GGCCTTCAACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGTCAGGCGCGCT 1080
1081 CAGCGAGTGTGAACAGGCAAGTGCAGGAGGCGAGGCTGCTGTGGCTGTGCTCTTCT 1140
1081 CAGCGAGTGTGAACAGGCAAGTGCAGGAGGCGAGGCTGCTGTGGCTGTGCTCTTCT 1140
1141 GGTCTTGCACCTCTCTTCAATTTTGTGATGAGTGCCTTCCCTCCCGGAAAGGCT 1200
1141 GGTCTTGCACCTCTCTTCAATTTTGTGATGAGTGCCTTCCCTCCCGGAAAGGCT 1200
1201 GCGCGCACACACACACCAACAGCAATGCGCAACACGAGCAAGCAACCAATCAGATA 1260
1201 GCGCGCACACACACACCAACAGCAATGCGCAACACGAGCAAGCAACCAATCAGATA 1260
1261 TATACAAATGAATTAGAAGAAACACAGCTTATGGGACAGAAATTTGAGGGAGGGAAC 1320
1261 TATACAAATGAATTAGAAGAAACACAGCTTATGGGACAGAAATTTGAGGGAGGGAAC 1320
1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1381 TTTAGGTACATGGAGTTTCTTTTCCAAACGGGAAAGAACACAGCACACCGGCTTGA 1440
1381 TTTAGGTACATGGAGTTTCTTTTCCAAACGGGAAAGAACACAGCACACCGGCTTGA 1440
1441 CCCACTGCAAGTGCATCGTGCACCTCTTTGGTGCAGTGTGGCAAGGGCTCAGCCTC 1500
1441 CCCACTGCAAGTGCATCGTGCACCTCTTTGGTGCAGTGTGGCAAGGGCTCAGCCTC 1500
1501 TCTGCCCAACAGATGCTCCCACTGAGCAATTTCTGGAGTGCCTCCAAATTCATCA 1560
1501 TCTGCCCAACAGATGCTCCCACTGAGCAATTTCTGGAGTGCCTCCAAATTCATCA 1560
1561 GTCCATAGAGAGCAAGATGAGCTTCCCGGCGCAAGCTGGGCTCGGGGACCTTTG 1620
1561 GTCCATAGAGAGCAAGATGAGCTTCCCGGCGCAAGCTGGGCTCGGGGACCTTTG 1620
1621 GTAGACTGTGCCACCAAGCGGCTGTGTGTGAACCTGTAATTAAGAGCAAAAAA 1679
1621 GTAGACTGTGCCACCAAGCGGCTGTGTGTGAACCTGTAATTAAGAGCAAAAAA 1679

RESULT 29

ADC69118
ID ADC69118 standard; cDNA; 1679 BP.
XX
AC ADC69118;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO337.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003064407-A1.
XX
PD 03-APR-2003.
XX
PF 24-OCT-2001; 2001US-00999834.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064245P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079820P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.

Db 121 AAGAAAAAATCATGAAACCATCCAGCCAAATAATGCACAATCTCTCTTGGCAAT 180
Qy 181 CTTTCAAGGGGTGCTGCTCTGTCTCTCTTCCAGGAGTCCCGTGCAGCGAGGATGC 240
Db 181 CTTTCAAGGGGTGCTGCTCTGTCTCTCTTCCAGGAGTCCCGTGCAGCGAGGATGC 240
Qy 241 CACCTTCCCAAGCTATGAGCAACAGTGACGGTCCGGCAGGGGAGAGGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGAGCAACAGTGACGGTCCGGCAGGGGAGAGGCCACCTCAG 300
Qy 301 GTGCACCTATTGACAAACCGGTTCACCCGGGTGGCTGTAAACCGGAGCACCACCTCTTA 360
Db 301 GTGCACCTATTGACAAACCGGTTCACCCGGGTGGCTGTAAACCGGAGCACCACCTCTTA 360
Qy 361 TGCTGGGAATGACAAGTGGTCCCTGGATCTCTGGGTGCTCTTCTTGAGCAACACCCAAAC 420
Db 361 TGCTGGGAATGACAAGTGGTCCCTGGATCTCTGGGTGCTCTTCTTGAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCATCCAGATCCAGACGAGTGGATGTATGAGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCCAGATCCAGACGAGTGGATGTATGAGAGGGCCCTTACACCTGCTC 480
Qy 481 GGTGCAGACAGCAACACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCAGACAGCAACACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Qy 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAGGGAAACAATATTAGCCTCAC 600
Db 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAGGGAAACAATATTAGCCTCAC 600
Qy 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
Qy 661 GGTGGCTTTGTAGTGAAGACGATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTAGTGAAGACGATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Qy 721 AGGGGACTACAGTGCAGTCCCTCAATGACGTGGCGCCCGCTGTGACGAGAGTAA 780
Db 721 AGGGGACTACAGTGCAGTCCCTCAATGACGTGGCGCCCGCTGTGACGAGAGTAA 780
Qy 781 GGTCAAGTGAACATTCACCAATACATTCGAAAGCCAGGGTACAGGTGTCCCGTGGG 840
Db 781 GGTCAAGTGAACATTCACCAATACATTCGAAAGCCAGGGTACAGGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Qy 901 CAAGATGACAAAAGACTGATTTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db 901 CAAGATGACAAAAGACTGATTTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Qy 961 CCTCTCAAACTCATCTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGCCT 1020
Db 961 CCTCTCAAACTCATCTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGCCT 1020
Qy 1021 GGCTTCAAAAGCTGGGCCACACCAATGCGAGCATCATGTATTTGGTCCAGGGCCGCT 1080
Db 1021 GGCTTCAAAAGCTGGGCCACACCAATGCGAGCATCATGTATTTGGTCCAGGGCCGCT 1080
Qy 1081 CAGCGAGTGAACAGCGCAGTGCAGAGGGAGGCTGGCTGTGGCTGGCTCTTCT 1140
Db 1081 CAGCGAGTGAACAGCGCAGTGCAGAGGGAGGCTGGCTGTGGCTGGCTCTTCT 1140
Qy 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTAGTGCACATTCGCCACCCGGGAAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTAGTGCACATTCGCCACCCGGGAAAGGCT 1200
Qy 1201 GCCGCCACCCACCAACACACAGCAATGCGACACCGCAGCAACCAATCAGATA 1260
Db 1201 GCCGCCACCCACCAACACACAGCAATGCGACACCGCAGCAACCAATCAGATA 1260

RESULT 30
ADC63178

ID ADC63178 standard; cDNA; 1679 BP.

AC ADC63178;

XX 18-DEC-2003 (first entry)

DE Human cDNA encoding secreted/transmembrane protein, PRO337.

KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
vulnery; auditory; tumor growth; retinal disorder;
sports-related joint problem; articular cartilage defects;
osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

XX Homo sapiens.

XX US2003068648-A1.

XX 10-APR-2003.

XX 25-OCT-2001; 2001US-00013921.

XX 17-OCT-1997; 97US-0062250P.

XX 03-NOV-1997; 97US-0064249P.

XX 13-NOV-1997; 97US-0065311P.

XX 21-NOV-1997; 97US-0066364P.

XX 10-MAR-1998; 98US-0077450P.

XX 11-MAR-1998; 98US-0077632P.

XX 11-MAR-1998; 98US-0077641P.

XX 12-MAR-1998; 98US-0077791P.

XX 13-MAR-1998; 98US-0078004P.

XX 20-MAR-1998; 98US-0078886P.

XX 20-MAR-1998; 98US-0078910P.

XX 20-MAR-1998; 98US-0078936P.

XX 25-MAR-1998; 98US-0079294P.

XX 26-MAR-1998; 98US-0079656P.

XX 27-MAR-1998; 98US-0079663P.

XX 27-MAR-1998; 98US-0079664P.

XX 27-MAR-1998; 98US-0079689P.

PR 27-MAR-1998; 98US-0079729P.
PR 27-MAR-1998; 98US-0079782P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080322P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 22-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083393P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084415P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 15-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US0224855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 28-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Garber H, Gerritsen ME;
PI Goddard A, Godowski FJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI, 2003-695924/66.
DR P-PSDB; ADC63179.
XX
PT New isolated secreted and transmembrane PRO polypeptides, useful in the
PT preparation of a medicament for treating a condition responsive to the
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Claim 2; SEQ ID NO 522; 467bp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal

peptide, a PRO extracellular domain with or without its associated signal peptide). Also included are nucleic acids encoding the PRO proteins mentioned above, a vector comprising a PRO nucleic acid, a host cell comprising the vector and producing PRO, a chimeric molecule comprising PRO fused to a heterologous amino acid sequence, and an anti-PRO antibody. PRO337 polypeptide is useful for detecting a PRO4993 polypeptide in a sample suspected of containing PRO4993 polypeptide. Similarly, PRO4993 polypeptide is useful for detecting PRO337 polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive molecule is the toxin, radiolabel, or an antibody. The bioactive molecule

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGACAAAGCTTCAGAGCAACAC 60
DB 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGACAAAGCTTCAGAGCAACAC 60

QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

QY 121 AAGAAAAAATCATGAAACATCCAGCCCAAAATGCAAAATCTCTTCTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAACATCCAGCCCAAAATGCAAAATCTCTTCTGGGCAAT 180

QY 181 CTTTCAAGGGGCTGGTGTCTGTCTCTTCTTCAAGAGAGTCCCGTGGCAGCGAGATGC 240
DB 181 CTTTCAAGGGGCTGGTGTCTGTCTCTTCTTCAAGAGAGTCCCGTGGCAGCGAGATGC 240

QY 241 CACCTTCCCAAGCTATGGAACAGTGCAGGTCCGCGAGGGGAGAGCGCCACCTTCAG 300
DB 241 CACCTTCCCAAGCTATGGAACAGTGCAGGTCCGCGAGGGGAGAGCGCCACCTTCAG 300

QY 301 GTGCATATTGCAACACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTTA 360
DB 301 GTGCATATTGCAACACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTTA 360

QY 361 TGCTGGGAATGCAAGTGGTGGCTGGATCTCTCGGCTGGTCTCTGAGCAACACCGAAC 420
DB 361 TGCTGGGAATGCAAGTGGTGGCTGGATCTCTCGGCTGGTCTCTGAGCAACACCGAAC 420

QY 421 GCAGTACAGCATCGAGATCCAGACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480

QY 481 GGTGACAGACACCAACCAAGACCTCTAGGGTCCACCTATTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACACCAACCAAGACCTCTAGGGTCCACCTATTGTGCAAGTATCTCC 540

QY 541 CAAATTTGTAGAGTTTCTTTCAGATATCTCCATTAAAGAGGAAACAAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGTTTCTTTCAGATATCTCCATTAAAGAGGAAACAAATATTAGCCTCAC 600

QY 601 CTGCATAGCAACTGGTAGACAGAGCTTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTAGACAGAGCTTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660

QY 661 GGTGGCTTTGTAGTGAAGACGATCTCTGGAATTCAGGGCATCACCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGACGATCTCTGGAATTCAGGGCATCACCGGGAGCAGTC 720

QY 721 AGGGACTACGAGTGCAGTCTCCAAATGACGTGGCGCGCCCGTGTGACGAGAGTAAA 780
DB 721 AGGGACTACGAGTGCAGTCTCCAAATGACGTGGCGCGCCCGTGTGACGAGAGTAAA 780

QY 781 GGTACCGGTGACATACCATATCTTACAGAGCCAGAGGTACAGTGTCCCGGTGGG 840
DB 781 GGTACCGGTGACATACCATATCTTACAGAGCCAGAGGTACAGTGTCCCGGTGGG 840

RESULT 31
ADC68243
ID ADC68243 standard; cDNA; 1679 BP.
XX
XX ADC68243;
XX
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO337.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmologic; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

XX OS Homo sapiens.
XX PN US2003069178-A1.
XX PD 10-APR-2003.
XX PF 16-OCT-2001; 2001US-00978423.
XX 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0065364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079669P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 08-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083322P.
PR 28-APR-1998; 98US-0083326P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087088P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 07-JUL-1999; 99US-0141037P.
PR 26-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.

PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUN-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrarini N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier WA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI; 2003-657582/62.
DR P-PSDB; ADC68244.
XX
XX Novel secreted and transmembrane polypeptides, designated PRO
PI polypeptides, and polynucleotides encoding them useful for treating
PI kidney diseases, bone, cartilage and retinal disorders.
XX
XX Claim 2; SEQ ID NO 522; 469pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimaeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTGACAAAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTGACAAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
DB 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
QY 181 CTTTCAGGGGCTGGTCTGTCTGTCTCTTCAAGAGTGCCTGCGCAGCGAGATGC 240
DB 181 CTTTCAGGGGCTGGTCTGTCTGTCTCTTCAAGAGTGCCTGCGCAGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGACAAAGTGAAGTCCGGGAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGGACAAAGTGAAGTCCGGGAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACTATTGACAAACCGGTCAACCGGTGCTGGCTGCTTAAACCGCAGCACCCTCTTA 360
DB 301 GTGCACTATTGACAAACCGGTCAACCGGTGCTGGCTGCTTAAACCGCAGCACCCTCTTA 360
QY 361 TCGTGGGAATGACAAAGTGGTGCCTGGATCTCTGGTGTGCTCTTCTGAGCAACACCCAAAC 420
DB 361 TCGTGGGAATGACAAAGTGGTGCCTGGATCTCTGGTGTGCTCTTCTGAGCAACACCCAAAC 420

QY 421 GCAGTACAGCATCGAGATCCAGAACGTTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGAGACAGCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540
DB 481 GGTGAGACAGCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCTACCAACTGGTAGACAGACCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCTACCAACTGGTAGACAGACCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTTCGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTTCGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCCATGACGTGGCCCGCCCGTGTGTACGGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCCATGACGTGGCCCGCCCGTGTGTACGGAGAGTAAA 780
QY 781 GGTGACCGTGAACATCTCCACCATACATTTCAAGAGCCAAAGGTACAGGTGTCCCGTGGG 840
DB 781 GGTGACCGTGAACATCTCCACCATACATTTCAAGAGCCAAAGGTACAGGTGTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGCACTGAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
DB 841 ACAAAGGGGACACTGCACTGAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
QY 901 CAAGATGACAAAGAACTGATGAAGAAAGAAAGGGGTGAAGTGAAGAAAGAAAGAAAGAAAG 960
DB 901 CAAGATGACAAAGAACTGATGAAGAAAGAAAGGGGTGAAGTGAAGAAAGAAAGAAAGAAAG 960
QY 961 CTTCTCAAAACTCATCTCTTCAATGTCTCTGAAATCATGACTATGAGAACTACACTTGGCT 1020
DB 961 CTTCTCAAAACTCATCTCTTCAATGTCTCTGAAATCATGACTATGAGAACTACACTTGGCT 1020
QY 1021 GGCCTCCAAAGCTGTGGCCACCAATGCCAGCATCATGCTATTGTTGGTCCAGGGCCGCT 1080
DB 1021 GGCCTCCAAAGCTGTGGCCACCAATGCCAGCATCATGCTATTGTTGGTCCAGGGCCGCT 1080
QY 1081 CAGCAGAGGTGAGCAACCGGACCGTCCGAGGAGGCGAGGTGCGTCTGCTGCTCTTCT 1140
DB 1081 CAGCAGAGGTGAGCAACCGGACCGTCCGAGGAGGCGAGGTGCGTCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTGATGAGTGCCACTTCCCCACCCGGGAAAGGCT 1200
DB 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTGATGAGTGCCACTTCCCCACCCGGGAAAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
QY 1261 TATACAAATGAAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAAC 1320
DB 1261 TATACAAATGAAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAAC 1320
QY 1321 AAGAAATACCTTTGGGGGAAAGAGTTTTTAAAGAAATTCAGAAATTCGCTTTGAGATA 1380
DB 1321 AAGAAATACCTTTGGGGGAAAGAGTTTTTAAAGAAATTCAGAAATTCGCTTTGAGATA 1380
QY 1381 TTTAGTACAAATGGAGTTTCTTTTCCAAAACGGGAAAGAAACACAGCACACCCGGCTTGA 1440
DB 1381 TTTAGTACAAATGGAGTTTCTTTTCCAAAACGGGAAAGAAACACAGCACACCCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGCATCGTGCAGAACTCTTTCGTCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCATCGTGCAGAACTCTTTCGTCAGTGTGGGCAAGGGCTCAGCCTC 1500

```
QY 1501 TCTGCCACAGAGTGGCCCAACGTTGGAAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
    |||||
Db 1501 TCTGCCACAGAGTGGCCCAACGTTGGAAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
    |||||
QY 1561 GTCCATAGAGACCAAGACAGATGAGACTTCCGGCCCAAGCGTGGCGCTCGGGGCACTTTG 1620
    |||||
Db 1561 GTCCATAGAGACCAAGACAGATGAGACTTCCGGCCCAAGCGTGGCGCTCGGGGCACTTTG 1620
    |||||
QY 1621 GTAGACTGTGCCACCAACCGCGGTGTGTGAAACGTGAAATAAAGAGCAAAAAA 1679
    |||||
Db 1621 GTAGACTGTGCCACCAACCGCGGTGTGTGAAACGTGAAATAAAGAGCAAAAAA 1679
    |||||

RESULT 32
ADC41563
ID ADC41563 standard; cdna; 1679 BP.
XX
AC ADC41563;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO337.
XX
KW Human; sb; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003072745-A1.
XX
PD 17-APR-2003.
XX
PF 25-OCT-2001; 2001US-00013929.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 12-MAR-1998; 98US-0077649P.
PR 13-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079566P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080155P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082589P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082737P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083332P.
PR 29-APR-1998; 98US-0083352P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083588P.
PR 29-APR-1998; 98US-0083599P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084508P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131032P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
```

PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US028555.
PR 30-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX (GETH) GENENTECH INC.
PI Ashkenazi A, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kijavini IJ, Kho SS, Napier WA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PW, Wood WI;
XX
XX WPI; 2003-743806/70.
XX P-PSDB; ADC41564.
XX
XX Novel isolated secreted and transmembrane PRO polypeptides, useful in the
XX preparation of a medicament for treating a condition responsive to the
XX polypeptide, and as therapeutic agents e.g. vaccines.
XX
XX Claim 2; SEQ ID NO 522; 466pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity
XX to an amino acid sequence chosen from 94 fully defined sequences as given
XX in the specification (including PRO lacking its associated signal
XX peptide, a PRO extracellular domain with or without its associated signal
XX peptide). Also included are nucleic acids encoding the PRO proteins
XX mentioned above, a vector comprising a PRO nucleic acid, a host cell
XX comprising the vector and producing PRO, a chimaeric molecule comprising
XX PRO fused to a heterologous amino acid sequence, and an anti-PRO
XX antibody. PRO337 polypeptide is useful for detecting a PRO4993
XX polypeptide in a sample suspected of containing PRO4993 polypeptide.
XX
XX Query Match 100.0%; Score 1679; DB 1; Length 1679;
XX Best Local Similarity 100.0%; Pred. No. 6,7e-05;
XX Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCCTTCAGCAAAACAGTGGATTAATCTCTTGTGCAAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTCCTTCAGCAAAACAGTGGATTAATCTCTTGTGCAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCGACCAAAATGACAAATCTCTTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCATCGACCAAAATGACAAATCTCTTCTTGGGCAAT 180
QY 181 CTTACGGGCTGGTGTCTCTGTCTCTTCCAAAGAGTGGCCGTCGCGAGAGATGC 240
DB 181 CTTACGGGCTGGTGTCTCTGTCTCTTCCAAAGAGTGGCCGTCGCGAGAGATGC 240
QY 241 CACCTTCCCCAAAGCTATGGACAAAGTACGGTCCGGAGGGGAGAGGCGCCACCTCAG 300
DB 241 CACCTTCCCCAAAGCTATGGACAAAGTACGGTCCGGAGGGGAGAGGCGCCACCTCAG 300
QY 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTTAAACCCGAGCACCATCCTCTA 360
DB 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTTAAACCCGAGCACCATCCTCTA 360
QY 361 TGTGGAATGACAAAGTGGTGTCTGATCTCTGCGTGGTCTCTTGAGCAACACCCAAAC 420
DB 361 TGTGGAATGACAAAGTGGTGTCTGATCTCTGCGTGGTCTCTTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAAAGTGTATGATGACGAGGCGCTTACACCTGTCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAAAGTGTATGATGACGAGGCGCTTACACCTGTCTC 480
QY 481 GGTGAGACAGACAAACCCAAAGCTCTTAGGGTCCACCTCATTTGCAAGTATCTCC 540
DB 481 GGTGAGACAGACAAACCCAAAGCTCTTAGGGTCCACCTCATTTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
QY 601 CTGCATAGCAACTGTGAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCATAGCAACTGTGAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGATATCTTGAAGATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGACGATATCTTGAAGATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCGCGGTGTACGGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCGCGGTGTACGGAGAGTAAA 780
QY 781 GGTACCGGTGAAGTATCCACCATATCTTGAAGGCAAGGATCAGGTGTCCCGGTGGG 840
DB 781 GGTACCGGTGAAGTATCCACCATATCTTGAAGGCAAGGATCAGGTGTCCCGGTGGG 840
QY 841 ACAAAGGGGACACTGCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGATGACAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGAAGTGAAGTGAAGTGA 960
DB 901 CAAGATGACAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGAAGTGAAGTGAAGTGA 960
QY 961 CTTCTCAAAACTCATCTTCTTCAATGTCTCTGAAACATGACTATGGGAATACACTTGGGT 1020
DB 961 CTTCTCAAAACTCATCTTCTTCAATGTCTCTGAAACATGACTATGGGAATACACTTGGGT 1020
QY 1021 GGCCTCCAAAGAGTGGGCGCACCAATGCCAGCATCATGCTATTGGTCCAGGCGCGCT 1080
DB 1021 GGCCTCCAAAGAGTGGGCGCACCAATGCCAGCATCATGCTATTGGTCCAGGCGCGCT 1080

PR	15-MAY-1998;	98US-0085697P.	PI	Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PR	15-MAY-1998;	98US-0085700P.	PI	Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PR	15-MAY-1998;	98US-0085704P.	PI	Goddard A, Godowski PJ, Grimaldi JC, Gurney NF, Hillan KJ;
PR	18-MAY-1998;	98US-0086023P.	PI	Kl javin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PR	22-MAY-1998;	98US-0086392P.	PI	Stewart TA, Tumas D, Williams PW, Wood WI;
PR	22-MAY-1998;	98US-0086414P.	XX	
PR	22-MAY-1998;	98US-0086430P.	DR	WPI: 2003-743810/70.
PR	22-MAY-1998;	98US-0086486P.	DR	P-PSDB; ADC67619.
PR	28-MAY-1998;	98US-0087096P.	XX	
PR	28-MAY-1998;	98US-0087106P.	PT	Novel isolated secreted and transmembrane PRO polypeptides, useful in the
PR	28-MAY-1998;	98US-0087208P.	PT	preparation of a medicament for treating a condition responsive to the
PR	26-JUN-1998;	98US-0090863P.	PT	polypeptide, and as therapeutic agents e.g. vaccines.
PR	26-JUN-1998;	98US-0091010P.	XX	
PR	01-JUL-1998;	98US-0091359P.	PS	Claim 2; SEQ ID NO 522; 464pp; English.
PR	01-JUL-1998;	98US-0094651P.	XX	
PR	11-SEP-1998;	98US-0100038P.	CC	The invention describes an isolated secreted and transmembrane PRO
PR	07-OCT-1998;	98WO-US021141.	CC	polypeptide (1). PRO polypeptide such as PRO213, PRO700, PRO320 or PRO615
PR	20-NOV-1998;	98US-0109304P.	CC	is useful in biotechnological and medical research, as well as in various
PR	20-NOV-1998;	98WO-US024855.	CC	industrial applications. PRO polypeptide such as PRO300, PRO866, PRO703,
PR	22-DEC-1998;	98US-0113296P.	CC	PRO708, PRO320, PRO351, PRO352, PRO381, PRO618, PRO772, PRO853,
PR	23-DEC-1998;	98US-0113621P.	CC	PRO860 or PRO846 is useful for therapeutic purposes. PRO363 is useful
PR	05-JAN-1999;	99WO-US000106.	CC	therapeutically in vivo for lessening the effects of viral infection.
PR	08-MAR-1999;	99WO-US005028.	CC	PRO300 is useful for the treatment of wound healing, tissue growth and
PR	12-MAR-1999;	99WO-US005190.	CC	muscle generation and regeneration. PRO337 is useful for treating
PR	12-MAR-1999;	99US-0123957P.		
PR	29-MAR-1999;	99US-0126773P.	Query Match	100.0%; Score 1679; DB 1; Length 1679;
PR	21-APR-1999;	99US-0130232P.	Best Local Similarity	100.0%; Pred. No. 6.7e-05;
PR	26-APR-1999;	99US-0131022P.	Matches 1679; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
PR	28-APR-1999;	99US-0131445P.		
PR	14-MAY-1999;	99US-0134287P.	QY	1 GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCGACAAAGTTGAGACCAAC 60
PR	02-JUN-1999;	99WO-US010733.	Db	1 GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCGACAAAGTTGAGACCAAC 60
PR	16-JUN-1999;	99US-0139557P.		
PR	23-JUN-1999;	99US-0141037P.	QY	61 AATCTATCAGGAAGAAAGAAAGAAAAAACCAGAACCTGCACAAAAGAAAGAAAG 120
PR	07-JUL-1999;	99US-0142680P.	Db	61 AATCTATCAGGAAGAAAGAAAGAAAAAACCAGAACCTGCACAAAAGAAAGAAAG 120
PR	26-JUL-1999;	99US-0145698P.		
PR	28-JUL-1999;	99US-0146222P.	QY	121 AAGAAAAAATCATGAAACATCCAGCCAAATAATGCACAAATTCATCTCTTGGGCAAT 180
PR	29-OCT-1999;	99US-0182566P.	Db	121 AAGAAAAAATCATGAAACATCCAGCCAAATAATGCACAAATTCATCTCTTGGGCAAT 180
PR	30-NOV-1999;	99WO-US028313.		
PR	02-DEC-1999;	99WO-US028551.	QY	181 CTTTCACGGGGCTGGCTGCTCTGTGTCTCTTCCAAGAGTGGCCGTGCACGGAGATGC 240
PR	16-DEC-1999;	99WO-US028555.	Db	181 CTTTCACGGGGCTGGCTGCTCTGTGTCTCTTCCAAGAGTGGCCGTGCACGGAGATGC 240
PR	30-DEC-1999;	99WO-US030095.		
PR	30-DEC-1999;	99WO-US031243.	QY	241 CACCTTCCCAAGCTATGGACAAAGTCCGGTCCGGAGGGAGAGCGCCACCTCAG 300
PR	05-JAN-2000;	99WO-US031274.	Db	241 CACCTTCCCAAGCTATGGACAAAGTCCGGTCCGGAGGGAGAGCGCCACCTCAG 300
PR	06-JAN-2000;	2000WO-US000217.		
PR	06-JAN-2000;	2000WO-US000376.	QY	301 GTGCACCTATTGACAAACCGGGTCAACCCGGTGGCTGCTTAAACCGCAGCACCATCCTCTA 360
PR	11-FEB-2000;	2000WO-US003565.	Db	301 GTGCACCTATTGACAAACCGGGTCAACCCGGTGGCTGCTTAAACCGCAGCACCATCCTCTA 360
PR	18-FEB-2000;	2000WO-US004341.		
PR	24-FEB-2000;	2000WO-US005004.	QY	361 TGCTGGGAATGACAAAGTGGTGGTCTCGCGTGGTCTCTCTGTAGCAACACCCCAAC 420
PR	02-MAR-2000;	2000WO-US005841.	Db	361 TGCTGGGAATGACAAAGTGGTGGTCTCGCGTGGTCTCTCTGTAGCAACACCCCAAC 420
PR	10-MAR-2000;	2000WO-US006319.		
PR	21-MAR-2000;	2000WO-US007532.	QY	421 GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
PR	30-MAR-2000;	2000WO-US008439.	Db	421 GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
PR	17-MAY-2000;	2000WO-US013705.		
PR	22-MAY-2000;	2000WO-US014042.	QY	481 GGTGACAGACAGCAACCCCAACACCTCTAGGGTCCACCTCATCTGTGCAAGTATCTCC 540
PR	30-MAY-2000;	2000WO-US014941.	Db	481 GGTGACAGACAGCAACCCCAACACCTCTAGGGTCCACCTCATCTGTGCAAGTATCTCC 540
PR	02-JUN-2000;	2000WO-US015264.		
PR	28-JUL-2000;	2000WO-US020710.	QY	541 CAAAATTGTAGAGATTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
PR	24-AUG-2000;	2000WO-US023328.	Db	541 CAAAATTGTAGAGATTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
PR	01-DEC-2000;	2000WO-US032678.		
PR	20-DEC-2000;	2000WO-US034956.	QY	601 CTGCATAGCAACTGGTAGACCAAGCCCTACGGTTACTTGGAGACACATCTCTTCCCAAGC 660
PR	28-FEB-2001;	2001WO-US006520.	Db	601 CTGCATAGCAACTGGTAGACCAAGCCCTACGGTTACTTGGAGACACATCTCTTCCCAAGC 660
PR	22-MAR-2001;	2001WO-US009552.		
PR	25-MAY-2001;	2001WO-US017092.	QY	
PR	01-JUN-2001;	2001WO-US017800.	Db	
PR	20-JUN-2001;	2001WO-US019692.		
PR	29-JUN-2001;	2001WO-US021066.		
PR	09-JUL-2001;	2001WO-US021735.		
PR	30-JUL-2001;	2001US-00918585.		
XX				
PA				
XX				

(GETH) GENENTECH INC.

Qy	661	GGTTGGCTTTGTGAGTGAAGACGAATAC	TTGGAAATTCAGGGCATCACCCGGAGCAGTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGACGAATAC	TTGGAAATTCAGGGCATCACCCGGAGCAGTC	720
Qy	721	AGGGGACTACGAGTGCAGTCCCTCCAAT	GACGTGGCGCGCGCGTGTACGAGAGTAAA	780
Db	721	AGGGGACTACGAGTGCAGTCCCTCCAAT	GACGTGGCGCGCGCGTGTACGAGAGTAAA	780
Qy	781	GGTCAACGTGAACTATCCACCATACATTT	CAGAAGCCAAAGGTACAGGTGTCCCGTGGG	840
Db	781	GGTCAACGTGAACTATCCACCATACATTT	CAGAAGCCAAAGGTACAGGTGTCCCGTGGG	840
Qy	841	ACAAAAGGGGACACTGCAGTGTGAAGCCT	CAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Db	841	ACAAAAGGGGACACTGCAGTGTGAAGCCT	CAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Qy	901	CAAGGATGACAAAAGACTGATTGAAGAA	AGAAAGGGGTGAAGTGGAAAAACAGACCTTT	960
Db	901	CAAGGATGACAAAAGACTGATTGAAGAA	AGAAAGGGGTGAAGTGGAAAAACAGACCTTT	960
Qy	961	CCTCTCAAAACTCATCTTCTTCAATGTCT	CTGAACATGACTATGGGAACTACACTTGGCT	1020
Db	961	CCTCTCAAAACTCATCTTCTTCAATGTCT	CTGAACATGACTATGGGAACTACACTTGGCT	1020
Qy	1021	GGCCTCCAAACAGCTGGGCGACACCAAT	TGCCAGGATCATGTTTGGTCCAGGCGCGT	1080
Db	1021	GGCCTCCAAACAGCTGGGCGACACCAAT	TGCCAGGATCATGTTTGGTCCAGGCGCGT	1080
Qy	1081	CAGCGAGTGAACAAACGGCAGCTCGAG	AGGCGAGGTGGCTCTGGCTGTGCTCTTCT	1140
Db	1081	CAGCGAGTGAACAAACGGCAGCTCGAG	AGGCGAGGTGGCTCTGGCTGTGCTCTTCT	1140
Qy	1141	GGTCTTGCACTGTCTTCTCAAATTTTGA	TGTAGTGCACCTTCCCAACCCGGGAAAGGCT	1200
Db	1141	GGTCTTGCACTGTCTTCTCAAATTTTGA	TGTAGTGCACCTTCCCAACCCGGGAAAGGCT	1200
Qy	1201	GCCGCCACACACACCAACAAACAGCAAT	GGCAACCGCACAGCAACCAATCAGATA	1260
Db	1201	GCCGCCACACACACCAACAAACAGCAAT	GGCAACCGCACAGCAACCAATCAGATA	1260
Qy	1261	TATACAAATGAAATTTAGAAGAAACAC	AGCCTCATGGGACAGAAATTTGAGGGAGGGGAC	1320
Db	1261	TATACAAATGAAATTTAGAAGAAACAC	AGCCTCATGGGACAGAAATTTGAGGGAGGGGAC	1320
Qy	1321	AAAGAAATCTTTGGGGGAAAGAGTTT	TAAAAAAGAAATTTGAAATTTGCTTGCAGATA	1380
Db	1321	AAAGAAATCTTTGGGGGAAAGAGTTT	TAAAAAAGAAATTTGAAATTTGCTTGCAGATA	1380
Qy	1381	TTTATAGGTACAAATGAGTTTCTTTCC	CAACCGGAAAGAACAGCACACCCGGCTTGG	1440
Db	1381	TTTATAGGTACAAATGAGTTTCTTTCC	CAACCGGAAAGAACAGCACACCCGGCTTGG	1440
Qy	1441	CCCACTGCAAGCTGCATCGTGCACCTCT	TGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGCTGCATCGTGCACCTCT	TGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Qy	1501	TCTGCCACAGAGTGCCCGCACGTGGAA	CAATCTGGAGCTGGCCATCCCAAAATCAATCA	1560
Db	1501	TCTGCCACAGAGTGCCCGCACGTGGAA	CAATCTGGAGCTGGCCATCCCAAAATCAATCA	1560
Qy	1561	GTCCTATAGAGACGAACAGATGACACCT	TCCGGCCCAAGCGTGGCGCTGGGGCAGCTTTG	1620
Db	1561	GTCCTATAGAGACGAACAGATGACACCT	TCCGGCCCAAGCGTGGCGCTGGGGCAGCTTTG	1620
Qy	1621	GTAGACTGTGCCACACGGCGTGTGTGT	GAACCGTGAATATAAAGAGCAAAAAAAA	1679
Db	1621	GTAGACTGTGCCACACGGCGTGTGTGT	GAACCGTGAATATAAAGAGCAAAAAAAA	1679

RESULT 34

RESULT 34
ADC62554

ADC62334
ID ADC62554 standard: cDNA: 1679 bp.

28

[illegible]

ADC62554:

18-DEC-2003 (first entry)

Human cDNA encoding secreted/transmembrane protein, PRO337.

Human; ss: gene; secreted protein; transmembrane protein; PRO; cystostatic; opthalmological; antiarthritic; osteopathic; antirheumatic; vulnary; auditory; tumour growth; retinal disorder; sports-related joint problem; articular cartilage defects; osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

Homo sapiens.

US2003073624-A1.

17-APR-2003.

15-OCT-2001: 2001US-00978193.

17-OCT-1997: 97US-0062250P.

03-NOV-1997; 97US-0064249P;
13-NOV-1997; 97US-0065311P;

21-NOV-1997; 97US-0066364P;
10-MAR-1998; 98US-0077450P;

11-MAR-1998; 98US-0077632P.
11-MAR-1998; 98US-0077641P.

11-MAR-1998; 98US-0077649P.
13-MAR-1998; 98US-0077791P.

13-MAR-1998; 98US-0078004P.
17-MAR-1998; 98US-00040220

20-MAR-1998; 98US-0078886P.
20-MAR-1998; 98US-0078910P.

20-MAR-1998; 98US-0078936P.
20-MAR-1998; 98US-0078936P.
20-MAR-1998; 98US-0078936P.

25-MAR-1998; 98US-0079294P.
26-MAR-1998; 98US-0079556P.

27-MAR-1998; 98US-0079663P.
27 MAR 1998; 98US-0079664P.

27-MAR-1998; 98US-0079689P.

27-MAR-1998; 98US-0079786P.

30-MAR-1998; 98US-0079923P.

31-MAR-1998; 98US-0080107P.

01-APR-1998; 98US-0080327P.

01-APR-1998; 98US-0080333P.

08-APR-1998; 98US-0081049P.

08-APR-1998; 98US-0081071P.

09-APR-1998; 98US-0081203P.

15-APR-1998; 98US-0081817P.

15-APR-1998; 98US-0081838P.

15-APR-1998; 98US-0081955P.

21-APR-1998; 98US-0082569P.

22-APR-1998; 98US-0082704P.

22-APR-1998; 98US-0082804P.

27-APR-1998; 98US-0083336P.

29-APR-1998; 98US-0083392P.
29-APR-1998; 98US-0083392P.

156-10000-10000, 156-10000-10000

Query Match	Best Local Similarity	Score 1679; DB 1; Length 1679;	Pred. No. 6.7e-05;	Mismatches 0;	Indels 0;	Gaps 0;
28-JUL-1999;	99US-0146222P.					
25-AUG-1999;	99US-00380137.					
25-AUG-1999;	99US-00380138.					
25-AUG-1999;	99US-00380142.					
29-OCT-1999;	99US-0162506P.					
30-NOV-1999;	99WO-US028313.					
02-DEC-1999;	99WO-US028551.					
02-DEC-1999;	99WO-US028565.					
16-DEC-1999;	99WO-US030095.					
30-DEC-1999;	99WO-US031243.					
30-DEC-1999;	99WO-US031274.					
05-JAN-2000;	2000WO-US000219.					
06-JAN-2000;	2000WO-US000277.					
06-JAN-2000;	2000WO-US000376.					
04-FEB-2000;	2000US-0180165P.					
11-FEB-2000;	2000WO-US003565.					
18-FEB-2000;	2000WO-US004341.					
24-FEB-2000;	2000WO-US005004.					
02-MAR-2000;	2000WO-US005841.					
10-MAR-2000;	2000WO-US006319.					
21-MAR-2000;	2000WO-US007532.					
30-MAR-2000;	2000WO-US008439.					
17-MAY-2000;	2000WO-US013705.					
22-MAY-2000;	2000WO-US014042.					
30-MAY-2000;	2000WO-US014941.					
02-JUN-2000;	2000WO-US015264.					
28-JUL-2000;	2000WO-US020710.					
24-AUG-2000;	2000WO-US023328.					
08-NOV-2000;	2000US-00709238.					
27-NOV-2000;	2000US-00723749.					
01-DEC-2000;	2000WO-US032678.					
20-DEC-2000;	2000US-00747259.					
20-DEC-2000;	2000WO-US034956.					
28-FEB-2001;	2001WO-US006520.					
22-MAR-2001;	2001US-00816744.					
22-MAR-2001;	2001US-00816920.					
22-MAR-2001;	2001WO-US009552.					
10-MAY-2001;	2001US-00854208.					
10-MAY-2001;	2001US-00854280.					
25-MAY-2001;	2001WO-US017092.					
01-JUN-2001;	2001US-00872035.					
01-JUN-2001;	2001WO-US017800.					
05-JUN-2001;	2001US-00874503.					
14-JUN-2001;	2001US-00882636.					
19-JUN-2001;	2001US-00886342.					
20-JUN-2001;	2001WO-US019692.					
29-JUN-2001;	2001WO-US021066.					
09-JUL-2001;	2001WO-US021735.					
30-JUL-2001;	2001US-00918585.					
(GETH) GENENTECH INC.						
Query Match 100.0%; Score 1679; DB 1; Length 1679;						
Best Local Similarity 100.0%; Pred. No. 6.7e-05;						
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;						
QY	1	GTTCGTGCTTCAGCAAAACAGTGGATTAAATCTTCCTTGCAAGCTTGAGACCAAC	60			
DB	1	GTTCGTGCTTCAGCAAAACAGTGGATTAAATCTTCCTTGCAAGCTTGAGACCAAC	60			
QY	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120			
DB	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120			
QY	121	AAGAAAAAAATCATGAAACCATTCAGCCAAAAATGCACAAATTCATCTCTTGGGCAAT	180			

QY 241 CACCTTCCCAAGCTATGGCAACGCTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGGCAACGCTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACTATTGACCAACCGGCTCACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
DB 301 GTGCACTATTGACCAACCGGCTCACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
QY 361 TGCTGGGAATGACAAAGTGGTGGCTGGATCTCGCGTGGTCTCTTGAGCAACACCCAAAC 420
DB 361 TGCTGGGAATGACAAAGTGGTGGCTGGATCTCGCGTGGTCTCTTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAAAGTGGATGTATGACAGGGCCCTTACATCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAAAGTGGATGTATGACAGGGCCCTTACATCTGCTC 480
QY 481 GGTGACAGACAGCAACCAACCAAGCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGCAACCAACCAAGCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
QY 541 CAAAATTGAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTAC 600
DB 541 CAAAATTGAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTAC 600
QY 601 CTGCATAGCAACTGGTACACAGAGCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCATAGCAACTGGTACACAGAGCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGAGCAATATCTTGAATAATCAGGGCATCACCCGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGAGCAATATCTTGAATAATCAGGGCATCACCCGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTCCCAATGACGTGCGCGCCCGTGGTACGGAGAGTAA 780
DB 721 AGGGGACTACGAGTGCAGTCCCAATGACGTGCGCGCCCGTGGTACGGAGAGTAA 780
QY 781 GGTACCGGTGAATTCACCACTATACATTTTCAAGCAAGGATACAGGTGTCCTCGTGG 840
DB 781 GGTACCGGTGAATTCACCACTATACATTTTCAAGCAAGGATACAGGTGTCCTCGTGG 840
QY 841 ACAAAGGGGACCTGACGTGTGAAGCTCACAGTCCCTCAGCAGAAATTCAGTGTGA 900
DB 841 ACAAAGGGGACCTGACGTGTGAAGCTCACAGTCCCTCAGCAGAAATTCAGTGTGA 900
QY 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAGGGGTGAAGTGGAAACACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAGGGGTGAAGTGGAAACACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTCAATGTCTCTGAACATGACTATGGGAACTACACTTGGT 1020
DB 961 CCTCTCAAACTCATCTTCTCAATGTCTCTGAACATGACTATGGGAACTACACTTGGT 1020
QY 1021 GGCTCCCAACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
DB 1021 GGCTCCCAACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGCGAGGTGACCAACGGCAGCTGCGAGGAGGCGAGCTCGTCTGGCTGCTGCTCTCT 1140
DB 1081 CAGCGAGGTGACCAACGGCAGCTGCGAGGAGGCGAGCTCGTCTGGCTGCTGCTCTCT 1140
QY 1141 GGTCTTGCACCTGCTTCTCAATTTTGTGATGTGAGTCCACTTCCACCGGGAAGGCT 1200
DB 1141 GGTCTTGCACCTGCTTCTCAATTTTGTGATGTGAGTCCACTTCCACCGGGAAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACAGCAATGGCAACCGCAGCAACCAATCAGATA 1260
DB 1201 GCGGCCACCAACCAACCAACAGCAATGGCAACCGCAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTAAGAAACACAGCTCATGGGACAGAAATTTGGGAGGGGAGAC 1320
DB 1261 TATACAAATGAATTAAGAAACACAGCTCATGGGACAGAAATTTGGGAGGGGAGAC 1320
QY 1321 AAAGAATACTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAAATTCCTTTGCAGATA 1380

DB 1321 AAAGAATACTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAAATTCCTTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGAAGAACACAGCACACCGGCTTGA 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGAAGAACACAGCACACCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGTCATCTGTCGCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGTCATCTGTCGCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCCCACAGAGTGCCTCCACGTCGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCCCACAGAGTGCCTCCACGTCGGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACAAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
DB 1561 GTCCATAGAGACAAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCGCGGTGTGTGTGAACGTGAATTAATAAAGACGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCGCGGTGTGTGTGAACGTGAATTAATAAAGACGCAAAAAA 1679

RESULT 35

ADC36854

ID ADC36854 standard; cDNA; 1679 BP.

XX ADC36854;

XX 18-DEC-2003 (first entry)

XX Human PRO polynucleotide #63.

XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.

XX Homo sapiens.

XX US2003088065-A1.

XX 08-MAY-2003.

XX 14-AUG-2002; 2002US-00219464.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2003-657979/62.

XX P-PSDB; ADC36855.

XX One hundred and twenty two nucleic acids encoding PRO polypeptides,

XX useful in gene therapy, or for preparing a medicament for treating

XX cancer.

XX Claim 2; Fig 125; 315pp; English.

XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human

blood, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells or for stimulating the proliferation of normal human dermal fibroblasts. The PRO nucleic acids are useful as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant technology, in generating transgenic animals or knock-out animals which may be used in the development and screening of therapeutically useful reagents, in gene therapy, in chromosome identification, as chromosome markers and in generating probes. The PRO polypeptides, or anti-PRO antibodies, are useful for preparing a medicament for treating a condition which is responsive to the PRO polypeptides or anti-PRO antibodies, such as pericyte-associated tumours and bone and/or cartilage disorders (e.g. arthritis, sports injuries), involving inducing the re-differentiation of chondrocytes. The PRO polypeptides are useful as molecular markers for protein electrophoresis, and in tissue typing. This sequence represents a human PRO polynucleotide of the invention.

```

Query Match          100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0

```

Db	721	AGGGGACTACGAGTGAGTGCCTTCCAATGACGTGGCCGCGCGTGTACGAGAGATAAA	780
Qy	781	GGTACCGTGAACTATCCACCACATATTTAGAAGCCAAGGGTACAGGTGTCCCCGTGGG	840
Db	781	GGTACCGTGAACTATCCACCACATATTTAGAAGCCAAGGGTACAGGTGTCCCCGTGGG	840
Qy	841	ACAAAAGGGGACACTGCAGGTGAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTTA	900
Db	841	ACAAAAGGGGACACTGCAGGTGAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTTA	900
Qy	901	CAAGGATGACAAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGGAAAAACAGACCTTT	960
Db	901	CAAGGATGACAAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGGAAAAACAGACCTTT	960
Qy	961	CTCTCAAAACTCATCTTCTCAATGCTCTGAAACATGACTATGCGAACTACACTTTCGT	1020
Db	961	CTCTCAAAACTCATCTTCTCAATGCTCTGAAACATGACTATGCGAACTACACTTTCGT	1020
Qy	1021	GGCTCTCAACAAAGCTGGGCCACCAATGCCAGCATCATGTATTTTGGTCCAGGCCCGCT	1080
Db	1021	GGCTCTCAACAAAGCTGGGCCACCAATGCCAGCATCATGTATTTTGGTCCAGGCCCGCT	1080
Qy	1081	CACGAGGTGAGCAACGGCACGTCGAGGAGGGCAGCGTCTGGCTGTGCTGCTCTTCT	1140
Db	1081	CACGAGGTGAGCAACGGCACGTCGAGGAGGGCAGCGTCTGGCTGTGCTGCTCTTCT	1140
Qy	1141	GGTCTTGCACTGCTTCTCAAAATTTTGTATGTAGTGCCTATTTCCCAACCCGGGAAAGCT	1200
Db	1141	GGTCTTGCACTGCTTCTCAAAATTTTGTATGTAGTGCCTATTTCCCAACCCGGGAAAGCT	1200
Qy	1201	GGCGCACACACACACCAACCAACAGCAATGGCAACACCGACAGCACCAATCAGATA	1260
Db	1201	GGCGCACACACACACCAACCAACAGCAATGGCAACACCGACAGCACCAATCAGATA	1260
Qy	1261	TATACAAATGAAATTAGAGAAAAACAGCGCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320
Db	1261	TATACAAATGAAATTAGAGAAAAACAGCGCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320
Qy	1321	AAAGAAATCTTTGGGGGAAAGAGTTTTTAAAAAGAAATTTGAAATTCGCTTGCAGATA	1380
Db	1321	AAAGAAATCTTTGGGGGAAAGAGTTTTTAAAAAGAAATTTGAAATTCGCTTGCAGATA	1380
Qy	1381	TTTAGGTACAAATGGAGTTTTTCTTTTCCCAACGGGAAGAACACAGCACCCCGCTTGA	1440
Db	1381	TTTAGGTACAAATGGAGTTTTTCTTTTCCCAACGGGAAGAACACAGCACCCCGCTTGA	1440
Qy	1441	CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTGCCAGTGTGGGCAAGGGTCAGCCTC	1500
Db	1441	CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTGCCAGTGTGGGCAAGGGTCAGCCTC	1500
Qy	1501	TTGTGCCACAGAGTGCCCCCAAGTGAAACATTTGTGAGTGTGCCATCCCAAAATTCATCA	1560
Db	1501	TTGTGCCACAGAGTGCCCCCAAGTGAAACATTTGTGAGTGTGCCATCCCAAAATTCATCA	1560
Qy	1561	GTCCATAGAGAGCAACAGAAATGAGACTTCTCGGCCCAACGCTGGCGCTCGGGCACTTTC	1620
Db	1561	GTCCATAGAGAGCAACAGAAATGAGACTTCTCGGCCCAACGCTGGCGCTCGGGCACTTTC	1620
Qy	1621	GTAGACTGTGCCACACCGCGTGTGTGTGTAACCGTGAATTAAGAGAGCAAAAAAAA	1679
Db	1621	GTAGACTGTGCCACACCGCGTGTGTGTGTAACCGTGAATTAAGAGAGCAAAAAAAA	1679

RESULT 36
ADC42187
ID ADC42187 standard; cDNA; 1679 BP.
XX
XX AC ADC42187;
XX
XX 18-DEC-2003 (first entry)
DT
XX
XX Human cDNA encoding secreted/transmembrane protein. PRO3337.

XX Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cystostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumor growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

OS Homo sapiens.

XX US2003104998-A1.

XX 05-JUN-2003.

PD 16-OCT-2001; 2001US-00978643.

XX 17-OCT-1997; 97US-0062250P.

XX 03-NOV-1997; 97US-0064249P.

XX 13-NOV-1997; 97US-0065311P.

XX 21-NOV-1997; 97US-0066364P.

XX 10-MAR-1998; 98US-0077450P.

XX 11-MAR-1998; 98US-0077632P.

XX 11-MAR-1998; 98US-0077641P.

XX 12-MAR-1998; 98US-0077649P.

XX 12-MAR-1998; 98US-0077791P.

XX 13-MAR-1998; 98US-0078004P.

XX 17-MAR-1998; 98US-00040220.

XX 20-MAR-1998; 98US-0078866P.

XX 20-MAR-1998; 98US-0078910P.

XX 20-MAR-1998; 98US-0078936P.

XX 20-MAR-1998; 98US-0078939P.

XX 25-MAR-1998; 98US-0079294P.

XX 26-MAR-1998; 98US-0079656P.

XX 27-MAR-1998; 98US-0079663P.

XX 27-MAR-1998; 98US-0079664P.

XX 27-MAR-1998; 98US-0079689P.

XX 27-MAR-1998; 98US-0079728P.

XX 30-MAR-1998; 98US-0079786P.

XX 30-MAR-1998; 98US-0079920P.

XX 31-MAR-1998; 98US-0079923P.

XX 31-MAR-1998; 98US-0080105P.

XX 31-MAR-1998; 98US-0080107P.

XX 31-MAR-1998; 98US-0080165P.

XX 31-MAR-1998; 98US-0080194P.

XX 01-APR-1998; 98US-0080327P.

XX 01-APR-1998; 98US-0080328P.

XX 01-APR-1998; 98US-0080333P.

XX 01-APR-1998; 98US-0080334P.

XX 08-APR-1998; 98US-0081049P.

XX 08-APR-1998; 98US-0081070P.

XX 08-APR-1998; 98US-0081071P.

PR 29-APR-1998; 98US-0083554P.

PR 29-APR-1998; 98US-0083558P.

PR 29-APR-1998; 98US-0083559P.

PR 30-APR-1998; 98US-0083742P.

PR 05-MAY-1998; 98US-0084366P.

PR 06-MAY-1998; 98US-0084414P.

PR 06-MAY-1998; 98US-0084441P.

PR 07-MAY-1998; 98US-0084598P.

PR 07-MAY-1998; 98US-0084600P.

PR 07-MAY-1998; 98US-0084627P.

PR 07-MAY-1998; 98US-0084837P.

PR 07-MAY-1998; 98US-0084839P.

PR 07-MAY-1998; 98US-0084640P.

PR 07-MAY-1998; 98US-0084643P.

PR 13-MAY-1998; 98US-0085323P.

PR 13-MAY-1998; 98US-0085338P.

PR 15-MAY-1998; 98US-0085339P.

PR 15-MAY-1998; 98US-0085573P.

PR 15-MAY-1998; 98US-0085579P.

PR 15-MAY-1998; 98US-0085580P.

PR 15-MAY-1998; 98US-0085582P.

PR 15-MAY-1998; 98US-0085689P.

PR 15-MAY-1998; 98US-0085697P.

PR 15-MAY-1998; 98US-0085700P.

PR 15-MAY-1998; 98US-0085704P.

PR 18-MAY-1998; 98US-0086023P.

PR 22-MAY-1998; 98US-0086392P.

PR 22-MAY-1998; 98US-0086414P.

PR 22-MAY-1998; 98US-0086430P.

PR 22-MAY-1998; 98US-0086486P.

PR 28-MAY-1998; 98US-0087098P.

PR 28-MAY-1998; 98US-0087106P.

PR 28-MAY-1998; 98US-0087208P.

PR 26-JUN-1998; 98US-00105413.

PR 26-JUN-1998; 98US-0090863P.

PR 26-JUN-1998; 98US-0091010P.

PR 01-JUL-1998; 98US-0091359P.

PR 30-JUL-1998; 98US-0094651P.

PR 11-SEP-1998; 98US-0100038P.

PR 07-OCT-1998; 98US-0106897P.

PR 07-OCT-1998; 98WO-US021141.

PR 07-OCT-1998; 98US-00184216.

PR 06-NOV-1998; 98US-00187368.

PR 20-NOV-1998; 98US-0109304P.

PR 20-NOV-1998; 98WO-US024855.

PR 07-DEC-1998; 98US-00202054.

PR 22-DEC-1998; 98US-00218517.

PR 22-DEC-1998; 98US-0113296P.

PR 23-DEC-1998; 98US-0113621P.

PR 05-JAN-1999; 99WO-US000106.

PR 05-MAR-1999; 99US-00254465.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99US-00265686.

PR 10-MAR-1999; 99WO-US0005190.

PR 12-MAR-1999; 99US-00267213.

PR 12-MAR-1999; 99US-0123957P.

PR 29-MAR-1999; 99US-0126773P.

PR 12-APR-1999; 99US-00284291.

PR 21-APR-1999; 99US-0130232P.

PR 26-APR-1999; 99US-0131022P.

PR 28-APR-1999; 99US-0131445P.

PR 14-MAY-1999; 99US-00311832.

PR 14-MAY-1999; 99US-0134287P.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 16-JUN-1999; 99US-0139557P.

PR 23-JUN-1999; 99US-0141037P.

PR 07-JUL-1999; 99US-0142680P.

PR 26-JUL-1999; 99US-0145698P.

PR 28-JUL-1999; 99US-0146222P.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 25-AUG-1999; 99US-00380142.

```

PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003365.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019892.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX (GETH ) GENENTECH INC.
XX

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCCTTCACAAAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCCTTCACAAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAACCGAACCTGACAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAACCGAACCTGACAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAARACCATCCAGCCAAATATGCAATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAARACCATCCAGCCAAATATGCAATCTATCTCTTGGGCAAT 180
QY 181 CTTTCACGGGGTGGCTGCTGTGTCTCTTCCAGGAGTGCCTGCGCAGCGAGATGC 240
DB 181 CTTTCACGGGGTGGCTGCTGTGTCTCTTCCAGGAGTGCCTGCGCAGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGACACAGTGCAGGTCCGCGAGGGGAGAGCCACCTCTAG 300
DB 241 CACCTTCCCAAGCTATGACACAGTGCAGGTCCGCGAGGGGAGAGCCACCTCTAG 300
QY 301 GTGCACCTATTGACAAACCGGGTGCCTGGCTGCTAAACCGGAGCAACCTCTCTA 360

```

```

DB 301 GTGCACCTATTGACAAACCGGGTGCCTGGCTGCTAAACCGGAGCAACCTCTCTA 360
QY 361 TGTCTGGGAATGACAAAGTGGTGGATCTCGGTGGTCTCTTGAGCAACACCCAAAC 420
DB 361 TGTCTGGGAATGACAAAGTGGTGGATCTCGGTGGTCTCTTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAGCTGGATGTGATGACGAGGGCCCTTACACTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAGCTGGATGTGATGACGAGGGCCCTTACACTGCTC 480
QY 481 GGTGAGACAGACAAACCCAAAGACCTTAGGGTCCACTATTTGCAAGTATCTCC 540
DB 481 GGTGAGACAGACAAACCCAAAGACCTTAGGGTCCACTATTTGCAAGTATCTCC 540
QY 541 CAARATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB 541 CAARATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCATAGCAACTGGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTTCGCTTTGTGAGTGAAGACGATACCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTTCGCTTTGTGAGTGAAGACGATACCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGTGACGAGAGTAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGTGACGAGAGTAA 780
QY 781 GGTCAACCGTGAACCTTCCACCATACATTTAGAGCCCAAGGGTACAGGTGTCCTCCGCTGG 840
DB 781 GGTCAACCGTGAACCTTCCACCATACATTTAGAGCCCAAGGGTACAGGTGTCCTCCGCTGG 840
QY 841 ACAAAGGGGACACTGTCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTTCCAGTGGTA 900
DB 841 ACAAAGGGGACACTGTCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTTCCAGTGGTA 900
QY 901 CAGGATGACAAAGACATGATTGAAGGAAAGAGGGTGAAAGTGGAAACACACACCTTT 960
DB 901 CAGGATGACAAAGACATGATTGAAGGAAAGAGGGTGAAAGTGGAAACACACACCTTT 960
QY 961 CCTCTCAAAACCTCATCTTTCTCAATGTCTCTGAACATGACTATGGGAACATACACTTGGCT 1020
DB 961 CCTCTCAAAACCTCATCTTTCTCAATGTCTCTGAACATGACTATGGGAACATACACTTGGCT 1020
QY 1021 GGCCTCCAAAGCTGGGCGCACCAATGCGCAGCATATGCTATTTGGTCCAGGCGCGCT 1080
DB 1021 GGCCTCCAAAGCTGGGCGCACCAATGCGCAGCATATGCTATTTGGTCCAGGCGCGCT 1080
QY 1081 CAGCGAGTGAAGCAACGGCAGCTCGAGGAGGCGAGGCTGCGTCTGGTCTGCTCTTCT 1140
DB 1081 CAGCGAGTGAAGCAACGGCAGCTCGAGGAGGCGAGGCTGCGTCTGGTCTGCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTCTCAAAATTTTGATGTGAGTGCCACTTCCCAACCGGGGAAAGCT 1200
DB 1141 GGTCTTGCACTGCTCTCAAAATTTTGATGTGAGTGCCACTTCCCAACCGGGGAAAGCT 1200
QY 1201 GCGGCCACCCACCCACCAACACACAGCATGCAACACCGAGCAACCAATCAGATA 1260
DB 1201 GCGGCCACCCACCCACCAACACACAGCATGCAACACCGAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTTAGAAGAAACACAGCTCTATGGGACAGAAATTTAGGGAGGGGAAAC 1320
DB 1261 TATACAAATGAAATTTAGAAGAAACACAGCTCTATGGGACAGAAATTTAGGGAGGGGAAAC 1320
QY 1321 AAGGAATCTTTGGGGGAAAGAGATTTTAAAGAAATTTGAAATTTGCCCTTCAGATA 1380
DB 1321 AAGGAATCTTTGGGGGAAAGAGATTTTAAAGAAATTTGAAATTTGCCCTTCAGATA 1380
QY 1381 TTTAGGTACAATGAGATTTTCTTTTCCAAACGGGAGAAACACAGCAACACCGGCTTGA 1440

```


Db 1381 TTATGGTACATGGAGTTTCTTTTCCCAACGGGAAGAACACAGCACACCCGGCTTGA 1440
QY 1441 CCACATGCAAGTGCATGCTGCAACTCTTTGGTCCAGTGTGGCAGGGCTCAGCTC 1500
Db 1441 CCACATGCAAGTGCATGCTGCAACTCTTTGGTCCAGTGTGGCAGGGCTCAGCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACGTCGGAACATCTCGAGCTGGCCATCCCAAAATCAATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACGTCGGAACATCTCGAGCTGGCCATCCCAAAATCAATCA 1560
QY 1561 GTCCATAGAGACGACAGATGAGACCTTCGGCCCAAGCGTGGCGTGGCGCACTTTG 1620
Db 1561 GTCCATAGAGACGACAGATGAGACCTTCGGCCCAAGCGTGGCGTGGCGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACAGCGCTGTGTGTGGAACCTGTAATTAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACAGCGCTGTGTGTGGAACCTGTAATTAAGAGCAAAAAA 1679

RESULT 37
ADC21844
ID ADC21844 standard; cDNA; 1679 BP.
XX AC ADC21844;
XX DT
XX 18-DEC-2003 (first entry)
XX Human PRO polynucleotide #63.
XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX
XX Homo sapiens.
XX US2003096969-A1.
XX 22-MAY-2003.
XX 29-AUG-2002; 2002US-00232225.
XX 02-JUN-2000; 2000WO-US015264.
XX 05-JUN-2000; 2000US-0209832P.
XX 20-JUN-2000; 2000US-0212901P.
XX 22-JUN-2000; 2000US-0213807P.
XX 25-JUL-2000; 2000US-0219556P.
XX 25-JUL-2000; 2000US-0220585P.
XX 25-JUL-2000; 2000US-0220605P.
XX 25-JUL-2000; 2000US-0220624P.
XX 25-JUL-2000; 2000US-0220638P.
XX 25-JUL-2000; 2000US-0220664P.
XX 25-JUL-2000; 2000US-0220666P.
XX 26-JUL-2000; 2000US-0220893P.
XX 01-AUG-2000; 2000US-0222425P.
XX 28-AUG-2000; 2000US-0227133P.
XX 23-AUG-2000; 2000WO-US023352.
XX 24-AUG-2000; 2000WO-US023328.
XX 10-NOV-2000; 2000WO-US030873.
XX 28-NOV-2000; 2000US-0253646P.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 20-DEC-2000; 2000WO-US034956.
XX 28-FEB-2001; 2001WO-US006520.
XX 25-MAY-2001; 2001WO-US017092.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
(GETH) GENENTECH INC.

PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
DR WPI: 2003-765526/72.
XX P-PSDB; ADC21845.
PT Novel isolated PRO polypeptide useful for tissue typing, as molecular
XX weight markers in protein electrophoresis, for treating arthritis, tumor.
PS Claim 2; Fig 125; 308pp; English.
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTCGACAAAGTTGAGAGCAAC 60
Db 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTCGACAAAGTTGAGAGCAAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAATGCAAAATCTATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAATGCAAAATCTATCTCTTGGGCAAT 180
QY 181 CTTTACGGGGCTGGCTGCTGTGTCTCTTCCAGGAGTCCCGTGGCGAGCGAGATGC 240
Db 181 CTTTACGGGGCTGGCTGCTGTGTCTCTTCCAGGAGTCCCGTGGCGAGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGACAAACGTGACGGTCCGCGAGGGGAGAGCGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGGACAAACGTGACGGTCCGCGAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACATTATGACAAACCGGGTCAACCGGGTGGCTTAAACCGGAGCACCATTCTTA 360
Db 301 GTGCACATTATGACAAACCGGGTCAACCGGGTGGCTTAAACCGGAGCACCATTCTTA 360
QY 361 TGCTGGGAATGACAAGTGGTGGCTTGGATCTCTCGGTGGTCTCTCTGAGCAACACCCAAAC 420
Db 361 TGCTGGGAATGACAAGTGGTGGCTTGGATCTCTCGGTGGTCTCTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACCTGCTC 480

QY 481 GGTGCAGACAGCAACACCCCAAGACCTCTAGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB |||||
QY 481 GGTGCAGACAGCAACACCCCAAGACCTCTAGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB |||||
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
DB |||||
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
DB |||||
QY 601 CTGCATAGCAACTGTGTAGACAGAGCTAGCGTTACTTGGAGACACATCTCTCCCAAGC 660
DB |||||
QY 601 CTGCATAGCAACTGTGTAGACAGAGCTAGCGTTACTTGGAGACACATCTCTCCCAAGC 660
DB |||||
QY 661 GGTGGCTTTGTGAGTGAAGACCAATTAATTTGGAATTCAGGGCATCACCCGGGAGCAGTC 720
DB |||||
QY 661 GGTGGCTTTGTGAGTGAAGACCAATTAATTTGGAATTCAGGGCATCACCCGGGAGCAGTC 720
DB |||||
QY 721 AGGGGACTAGGTGAGTGGCTTCCATGACGTGGCGCGCGCTGGTACGAGAGTAA 780
DB |||||
QY 721 AGGGGACTAGGTGAGTGGCTTCCATGACGTGGCGCGCGCTGGTACGAGAGTAA 780
DB |||||
QY 781 GGTCCACGTGAATATCCACATACATTTTCCAGAGCAAGGGTACAGGTGTCCCGTGG 840
DB |||||
QY 781 GGTCCACGTGAATATCCACATACATTTTCCAGAGCAAGGGTACAGGTGTCCCGTGG 840
DB |||||
QY 841 ACAAGGGGACACTGAGTGTGAGCTTCCAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGTA 900
DB |||||
QY 841 ACAAGGGGACACTGAGTGTGAGCTTCCAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGTA 900
DB |||||
QY 901 CAAGGATGACAAAGACTGATTTGAAGGAAAGAGGGGTGAAAGTGGAAACAGACCTTT 960
DB |||||
QY 901 CAAGGATGACAAAGACTGATTTGAAGGAAAGAGGGGTGAAAGTGGAAACAGACCTTT 960
DB |||||
QY 961 CCTCTCAAACTCATCTTCTTCAATGTCTGACATGACTATGGCACTACACTTGGCT 1020
DB |||||
QY 961 CCTCTCAAACTCATCTTCTTCAATGTCTGACATGACTATGGCACTACACTTGGCT 1020
DB |||||
QY 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCCCGT 1080
DB |||||
QY 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCCCGT 1080
DB |||||
QY 1081 CAGCGAGTGAAGCAACGGCAGCTGAGAGGGGAGGCTGGCTGTGGCTGTGCTCTTCT 1140
DB |||||
QY 1081 CAGCGAGTGAAGCAACGGCAGCTGAGAGGGGAGGCTGGCTGTGGCTGTGCTCTTCT 1140
DB |||||
QY 1141 GGTCTTGACCTGCTTCTCAATTTTGAATGTGAGTGCCACTTCCCAACCGGGAAGGCT 1200
DB |||||
QY 1141 GGTCTTGACCTGCTTCTCAATTTTGAATGTGAGTGCCACTTCCCAACCGGGAAGGCT 1200
DB |||||
QY 1201 GCCGCCACCCACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
DB |||||
QY 1201 GCCGCCACCCACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
DB |||||
QY 1261 TATCAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB |||||
QY 1261 TATCAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB |||||
QY 1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTTCAGATA 1380
DB |||||
QY 1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTTCAGATA 1380
DB |||||
QY 1381 TTTAGGTACATGGAGTTTCTTTTCCAAACGGGAAGACACAGCACACCCGCTTGG 1440
DB |||||
QY 1381 TTTAGGTACATGGAGTTTCTTTTCCAAACGGGAAGACACAGCACACCCGCTTGG 1440
DB |||||
QY 1441 CCCACTGAAGTGCATCGTCAACCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCTC 1500
DB |||||
QY 1441 CCCACTGAAGTGCATCGTCAACCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCTC 1500
DB |||||
QY 1501 TCTGCCACAGAGTGCCTCCCGCGTGGACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB |||||
QY 1501 TCTGCCACAGAGTGCCTCCCGCGTGGAGCAATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB |||||

QY 1561 GTCCATAGACGAAACAGATGAGACTTCCGGCCCAAGCGTGGCGCTGCGGCACCTTG 1620
DB |||||
QY 1561 GTCCATAGACGAAACAGATGAGACTTCCGGCCCAAGCGTGGCGCTGCGGCACCTTG 1620
DB |||||
QY 1621 GTAGACTGTCCACCGCGGTGTGTGTGAACGTGAAATTAAGAGACCAAAAAA 1679
DB |||||
QY 1621 GTAGACTGTCCACCGCGGTGTGTGTGAACGTGAAATTAAGAGACCAAAAAA 1679
DB |||||

RESULT 38

ADC50416

ID ADC50416 standard; cDNA; 1679 BP.

XX

AC ADC50416;

XX

DT 18-DEC-2003 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX

Human; secreted and transmembrane protein; PRO; secreted polypeptide;
transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
rectum; kidney; cervix; liver; microvascular endothelial cell;
glucose uptake modulator; FFA uptake modulator; cell proliferation;
cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
immune system cell infiltration; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker; gene; ss.

OS Homo sapiens.

XX

XX US2003092106-A1.

PN

PD 15-MAY-2003.

XX

XX 24-APR-2002; 2002US-00131822.

PF

XX

XX 19-AUG-1998; 98US-0097141P.

PR

PR 02-JUN-1999; 99WO-US012252.

PR

PR 25-AUG-1999; 99US-00380137.

PR

PR 30-MAR-2000; 2000WO-US008439.

PR

PR 01-DEC-2000; 2000WO-US032678.

PR

PR 19-DEC-2001; 2001US-00028072.

XX

XX (GETH) GENENTECH INC.

XX

PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

XX

XX WPI; 2003-801171/75.

DR

DR P-PSDB; ADC50417.

XX

XX New secreted and transmembrane nucleic acid useful for treating

XX inflammation, organ failure, atherosclerosis, cardiac injury,

XX infertility, birth defects, premature aging, acquired immunodeficiency

XX syndrome or cancer.

XX

XX Claim 2; Fig 375; 637pp; English.

XX

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating

antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells, for T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05; Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GTGTGTCTTCAGCAAAACAGTGGATTTAAATCTCTTTGCACAAGCTTTGAGAGCAACAC	60
Db	1	GTGTGTCTTCAGCAAAACAGTGGATTTAAATCTCTTTGCACAAGCTTTGAGAGCAACAC	60
Qy	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
Db	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
Qy	121	AAGAAAAAATCATGAAACCATCAGCCAAAAATTCGCAATTCCTCTTTGGGCAAT	180
Db	121	AAGAAAAAATCATGAAACCATCAGCCAAAAATTCGCAATTCCTCTTTGGGCAAT	180
Qy	181	CTTACCGGGCTGGTCTGTCTCTTCCAGGAGTCCCGTGGCAGGGAGATGC	240
Db	181	CTTACCGGGCTGGTCTGTCTCTTCCAGGAGTCCCGTGGCAGGGAGATGC	240
Qy	241	CACCTCCCAAGCTATGACAACTGACGCTCCGCGAGGGGAGCGCCACCCCTCAG	300
Db	241	CACCTCCCAAGCTATGACAACTGACGCTCCGCGAGGGGAGCGCCACCCCTCAG	300
Qy	301	GTGCACATTTGACAAACCGGTACCCGGGTGGCTGGCTAAACCGCAGCAACATCTCTTA	360
Db	301	GTGCACATTTGACAAACCGGTACCCGGGTGGCTGGCTAAACCGCAGCAACATCTCTTA	360
Qy	361	TGCTGGGAATGACAGTGGTGGCTGGATCTCTCGGTGGTCTTCTCAGCAACACCCAAAC	420
Db	361	TGCTGGGAATGACAGTGGTGGCTGGATCTCTCGGTGGTCTTCTCAGCAACACCCAAAC	420
Qy	421	GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGCGCCCTTACACCTGCTC	480
Db	421	GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGCGCCCTTACACCTGCTC	480
Qy	481	GTTGTCAGACAGCAACACCCAAAGACCTCTAGGTCACCTCATTTGTCAGATCTCTCC	540
Db	481	GTTGTCAGACAGCAACACCCAAAGACCTCTAGGTCACCTCATTTGTCAGATCTCTCC	540
Qy	541	CAAAATTTGATAGATTTCTTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC	600
Db	541	CAAAATTTGATAGATTTCTTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC	600
Qy	601	CTGCATAGCAACTGGTAGACAGAGCTAGGTTACTTTGGAGACATCTCTCCCAAGC	660
Db	601	CTGCATAGCAACTGGTAGACAGAGCTAGGTTACTTTGGAGACATCTCTCTCCCAAGC	660

RESULT 39
ADC71963
ID ADC71963 standard; cDNA; 1679 BP.

Qy	661	GGTTGGCTTTGTGAGTGAAGACGAATACCTTTGGAATTCAGGGCATCACCCGGAGCAGTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGACGAATACCTTTGGAATTCAGGGCATCACCCGGAGCAGTC	720
Qy	721	AGGGGACTACGAGTGCAGTCCCTCCCAATGACGTGGCGCCCGCTGTACGGAGAGTAAA	780
Db	721	AGGGGACTACGAGTGCAGTCCCTCCCAATGACGTGGCGCCCGCTGTGTGAGAGAGTAAA	780
Qy	781	GGTCAACCGTGAACATATCCACATACATTTCAGAAGCCAAAGGTACAGGTGTCCCGTGGG	840
Db	781	GGTCAACCGTGAACATATCCACATACATTTCAGAAGCCAAAGGTACAGGTGTCCCGTGGG	840
Qy	841	ACAAAAGGGGACACTGACGTGTGAAGCTCAGAGTCCCTCAGCAGCAATTCAGTGTGTA	900
Db	841	ACAAAAGGGGACACTGACGTGTGAAGCTCAGAGTCCCTCAGCAGCAATTCAGTGTGTA	900
Qy	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT	960
Db	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT	960
Qy	961	CCTCTCAAACTCATCTTCTTCAATGTCTGTACATGACTATGGGAACCTACACTTCGCT	1020
Db	961	CCTCTCAAACTCATCTTCTTCAATGTCTGTACATGACTATGGGAACCTACACTTCGCT	1020
Qy	1021	GGCTCTCAAAAGCTGGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGCGCCGT	1080
Db	1021	GGCTCTCAAAAGCTGGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGCGCCGT	1080
Qy	1081	CAGCGAGTGAAGAAACGGCAGCTCGAGAGGGGAGGCTGGCTGTGGCTGTGCTCTTCT	1140
Db	1081	CAGCGAGTGAAGAAACGGCAGCTCGAGAGGGGAGGCTGGCTGTGGCTGTGCTCTTCT	1140
Qy	1141	GGTCTTGACCTGCTTCTCAAAATTTTGATGTGAGTGCACCTTCCCAACCCGGGAAAGGCT	1200
Db	1141	GGTCTTGACCTGCTTCTCAAAATTTTGATGTGAGTGCACCTTCCCAACCCGGGAAAGGCT	1200
Qy	1201	GGCGCCACACCAACCAACAGCAAGCAACAGCAACAGCAACAGCAACCAATCAGATA	1260
Db	1201	GGCGCCACACCAACCAACAGCAAGCAACAGCAACAGCAACCAATCAGATA	1260
Qy	1261	TATACAAATGAAATTTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC	1320
Db	1261	TATACAAATGAAATTTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC	1320
Qy	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAAAATTTGCTTTCAGATA	1380
Db	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAAAATTTGCTTTCAGATA	1380
Qy	1381	TTTAGGTACAAATGAGTTTCTTTCCCAACCGGAGAGAACACAGCACACCCGGCTTGGGA	1440
Db	1381	TTTAGGTACAAATGAGTTTCTTTCCCAACCGGAGAGAACACAGCACACCCGGCTTGGGA	1440
Qy	1441	CCCCTGCAAGCTGCATGTGCACACCTTTTGGTCCAGTGTGGGCAAGGCTCAGGCTC	1500
Db	1441	CCCCTGCAAGCTGCATGTGCACACCTTTTGGTCCAGTGTGGGCAAGGCTCAGGCTC	1500
Qy	1501	TCTGCCACAGAGTGCACCCACGCTGGACATCTCTGGAGCTGGCCATCCCAATTCATCA	1560
Db	1501	TCTGCCACAGAGTGCACCCACGCTGGACATCTCTGGAGCTGGCCATCCCAATTCATCA	1560
Qy	1561	GTCCATAGAGACGAACAGAAATGAGACCTTCCGGGCCCAAGCGTGGCGCTGCGGGCATTG	1620
Db	1561	GTCCATAGAGACGAACAGAAATGAGACCTTCCGGGCCCAAGCGTGGCGCTGCGGGCATTG	1620
Qy	1621	GTAGACTGTGCCACACCGCGTGTGTGTGAAACGTGAAATTAAGAGCAAAAAA	1679
Db	1621	GTAGACTGTGCCACACCGCGTGTGTGTGAAACGTGAAATTAAGAGCAAAAAA	1679

XX AC AD71963;
XX
XX 18-DEC-2003 (first entry)
XX
XX DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
XX OS Homo sapiens.
XX
XX FN US2003092107-A1.
XX
XX PD 15-MAY-2003.
XX
XX PF 24-APR-2002; 2002US-0031828.
XX
XX PR 07-OCT-1998; 98US-0103315P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX PA (GETH) GENENTECH INC.
XX
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX DR WPI; 2003-801172/75.
DR P-PSDB; ADC71964.
XX
XX PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX PS Claim 2; Fig 375; 637pp; English.
XX
XX CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for

CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassemias
CC and conditions which benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 1679; DB 1; Length 1679;
XX Best Local Similarity 100.0%; Pred. No. 6.7e-05;
XX Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGTCCTTCAGCAAAACAGTGATTTAAATCTCTTCCTTGCAAGCTTGAGAGCAACAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGATTTAAATCTCTTCCTTGCAAGCTTGAGAGCAACAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAAAAGAAACCGAACCTGACAAAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAAAAAGAAACCGAACCTGACAAAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACCCAGCCAAATGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAACCCAGCCAAATGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
QY 181 CTTACCGGGTGGTGTCTGTGTCTTCCAAAGAGTGCCTGCGGACGCGGAGATGC 240
DB 181 CTTACCGGGTGGTGTCTGTGTCTTCCAAAGAGTGCCTGCGGACGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGACACGTCGCGGACGCGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGACACGTCGCGGACGCGGAGAGCGCCACCTCAG 300
QY 301 GTGCACTATTGACAAACCGGGTCCACCCGGTGGCTGTGTTAAACCGACGACCATCTCTA 360
DB 301 GTGCACTATTGACAAACCGGGTCCACCCGGTGGCTGTGTTAAACCGACGACCATCTCTA 360
QY 361 TGCTGGGATGACAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 420
DB 361 TGCTGGGATGACAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTTGATGATGATGATGATGATGATGATGATGATGATG 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTTGATGATGATGATGATGATGATGATGATGATGATG 480
QY 481 GGTGACAGACACACACACACACACACACACACACACACACACACACACACACACACACAC 540
DB 481 GGTGACAGACACACACACACACACACACACACACACACACACACACACACACACACACAC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCACTGTAGACAGACGCTACCGTTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCACTGTAGACAGACGCTACCGTTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGTGCTTTGTGAGTGAAGACGAATATCTGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGTGCTTTGTGAGTGAAGACGAATATCTGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGAGACTACAGTGCAGTGCCTCAATGACGTGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 780
DB 721 AGGGAGACTACAGTGCAGTGCCTCAATGACGTGCGCGCGCGCGCGCGCGCGCGCGCGCG 780
QY 781 GGTACCGTGAATCTCCACCATATCATTTGAGAACCAAGGTCACAGGTGTCCCGGTGGG 840
DB 781 GGTACCGTGAATCTCCACCATATCATTTGAGAACCAAGGTCACAGGTGTCCCGGTGGG 840

Db 781 GGTCACTGAACTATCCACCATACATTTTCAAGAACCAAGGTACAGGTGTCCCGTGGG 840
QY 841 ACAAAAGGGGACACTGAGTGTGAGCTCAGCAGTCCCTCAGCAGAAATCCAGTGGTA 900
Db 841 ACAAAAGGGGACACTGAGTGTGAGCTCAGCAGTCCCTCAGCAGAAATCCAGTGGTA 900
QY 901 CAAGGATGACAAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
QY 961 CTTCTCAAACTCATCTCTTCTCAATGTCTCTGAATGACTATGGGAACACTACCTTCGCT 1020
Db 961 CTTCTCAAACTCATCTCTTCTCAATGTCTCTGAATGACTATGGGAACACTACCTTCGCT 1020
QY 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGATCATGCTATTTGGTCCAGCGCGCT 1080
Db 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGATCATGCTATTTGGTCCAGCGCGCT 1080
QY 1081 CAGCAGGTGAGCAACGGCAGCTGAGGAGGAGGCTGTGCTGTGCTCTCTCTCT 1140
Db 1081 CAGCAGGTGAGCAACGGCAGCTGAGGAGGAGGCTGTGCTGTGCTCTCTCTCTCT 1140
QY 1141 GGTCTTGCACCTGCTCTCTCAATTTTGAATGTGAGTGGCCACTTCCCGCGGAAAGCT 1200
Db 1141 GGTCTTGCACCTGCTCTCTCAATTTTGAATGTGAGTGGCCACTTCCCGCGGAAAGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
QY 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAG 1320
Db 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAG 1320
QY 1321 AAAGAAATCTTTGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGAAATCTTTGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGTCAATTTGAGTGTCTTTTCCCAACGGGAAAGAACACAGCAGCAGCGGCTTGA 1440
Db 1381 TTTAGTCAATTTGAGTGTCTTTTCCCAACGGGAAAGAACACAGCAGCAGCGGCTTGA 1440
QY 1441 CCCTGCAAGTGCATCTGTCAACCTCTTTTGGTCCAGTGTGGCAGAGGGCTCAGCGCT 1500
Db 1441 CCCTGCAAGTGCATCTGTCAACCTCTTTTGGTCCAGTGTGGCAGAGGGCTCAGCGCT 1500
QY 1501 TGTGCCACAGAGTGCCTCCACAGTGCAGATCTTGTGAGTGGCCATCCCAATTCATCA 1560
Db 1501 TGTGCCACAGAGTGCCTCCACAGTGCAGATCTTGTGAGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGAGCAACAGAAATCAGACCTTCCGGCCCAAGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGAGCAACAGAAATCAGACCTTCCGGCCCAAGCGTGGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAACCGCGTGTGTGTAACCTGTAATTAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCAACCGCGTGTGTGTAACCTGTAATTAAGAGCAAAAAA 1679

RESULT 40

ADC59942

ID ADC59942 standard; cDNA; 1679 BP.

XX AC ADC59942;

XX AC ADC59942;

DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
rectum; kidney; cervix; liver; microvascular endothelial cell;

KW Glucose uptake modulator; FFA uptake modulator; cell proliferation;
cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
immune system cell infiltration; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker; gene; es.
XX Homo sapiens.

OS US2003092105-A1.

XX 15-MAY-2003.

PD 24-APR-2002; 2002US-00131821.

XX 09-DEC-1999; 99US-0170262P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801170/75.

DR P-PSDB; ADC59943.

XX New secreted and transmembrane nucleic acids and polypeptides, designated

as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.

XX Claim 2; Fig 375; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
cells, for stimulating differentiation of adipocyte cells, for
stimulating proliferation of or gene expression in pericyte cells, or
stimulating the proliferation of inner ear utricular supporting cells or
T-lymphocyte cells, for inducing endothelial cell tube formation and for
treating various bone and/or cartilage disorders such as sports injuries
and arthritis. PRO polypeptides which stimulate the release of
proteoglycans from cartilage are useful for treating sports-related joint
problems, articular cartilage defects, osteoarthritis and rheumatoid
arthritis. PRO polypeptides are also useful for treating various
mammalian haemoglobin-associated disorders such as various thalassemias
and conditions which may benefit from enhanced local immune system cell
infiltration. This sequence represents a human PRO polynucleotide of the
invention. Note: The sequence data for this patent is also available in
electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match				100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity				100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative				0; Mismatches 0; Indels 0; Gaps 0;
QY	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCAAGCTTGAGAGCAAC	60	
DB	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCAAGCTTGAGAGCAAC	60	
QY	61	AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGCACAAAAGAAAGAAAGAAAG	120	
DB	61	AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGCACAAAAGAAAGAAAGAAAG	120	
QY	121	AAGAAAAAATCATGAAAAACATCCAGCCAAAATGCAAAATCTATCTCTTGGGCAAT	180	
DB	121	AAGAAAAAATCATGAAAAACATCCAGCCAAAATGCAAAATCTATCTCTTGGGCAAT	180	
QY	181	CTTACGGGGTGGCTGCTCTGTCTCTTCCAGAGAGTGCCCTGGCGCAGCGAGATGC	240	
DB	181	CTTACGGGGTGGCTGCTCTGTCTCTTCCAGAGAGTGCCCTGGCGCAGCGAGATGC	240	
QY	241	CACCTTCCCAAAAGCTATGGAACAGTGCAGCGTCCGGCAGGGGAGAGCGCCACCTCAG	300	
DB	241	CACCTTCCCAAAAGCTATGGAACAGTGCAGCGTCCGGCAGGGGAGAGCGCCACCTCAG	300	
QY	301	GTGCACTATTGCAACCGGGTCAACCGGGTGGCTTCTGAGCAACACCCCAAAAC	360	
DB	301	GTGCACTATTGCAACCGGGTCAACCGGGTGGCTTCTGAGCAACACCCCAAAAC	360	
QY	361	TGCTGGGAATGCAAGTGGTGGTCTGAGTCTGCTGAGCAACACCCCAAAAC	420	
DB	361	TGCTGGGAATGCAAGTGGTGGTCTGAGTCTGCTGAGCAACACCCCAAAAC	420	
QY	421	GCAGTACAGATCGAGATCCAGAGCGTGGATGTGTATGAACGGGCGCTTACCTGCTC	480	
DB	421	GCAGTACAGATCGAGATCCAGAGCGTGGATGTGTATGAACGGGCGCTTACCTGCTC	480	
QY	481	GCTGACAGACAAACACCAAGACCTCTAGGGTCCACCTATTGTGCAAGTATCTCC	540	
DB	481	GCTGACAGACAAACACCAAGACCTCTAGGGTCCACCTATTGTGCAAGTATCTCC	540	
QY	541	CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAAATATTAGCCTCAC	600	
DB	541	CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAAATATTAGCCTCAC	600	
QY	601	CTGCATAGCAACTGGTAGACAGAGCTTACGGTTACTTTGGAGACACATCTCTCCCAAGC	660	
DB	601	CTGCATAGCAACTGGTAGACAGAGCTTACGGTTACTTTGGAGACACATCTCTCCCAAGC	660	
QY	661	GTTGGCTTTGTGAGTGAAGACGAATACCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720	
DB	661	GTTGGCTTTGTGAGTGAAGACGAATACCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720	
QY	721	AGGGGACTACGAGTGCAGTCCATGACGTGGCGCGCCGTGGTAGCGAGAGTAAA	780	
DB	721	AGGGGACTACGAGTGCAGTCCATGACGTGGCGCGCCGTGGTAGCGAGAGTAAA	780	
QY	781	GGTCAACCGTGAATATCACCATACTTTCAGAACCAAGGGTACAGGTGTCCCGTGGG	840	
DB	781	GGTCAACCGTGAATATCACCATACTTTCAGAACCAAGGGTACAGGTGTCCCGTGGG	840	
QY	841	ACAAAAGGGGACCTGAGTGTGAGCTCAGAGTCCCTCAGCAAGATTCAGTGGTA	900	
DB	841	ACAAAAGGGGACCTGAGTGTGAGCTCAGAGTCCCTCAGCAAGATTCAGTGGTA	900	
QY	901	CAAGGATCAAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT	960	
DB	901	CAAGGATCAAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT	960	
QY	961	CCTCTCAAACTCATCTTCTTCAATGTCTGACATGATCTATGGAACTACACTTGGT	1020	
DB	961	CCTCTCAAACTCATCTTCTTCAATGTCTGACATGATCTATGGAACTACACTTGGT	1020	
QY	1021	GGCCTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTGGTCCAGCGCGCT	1080	

DB	1021	GGCCTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTGGTCCAGCGCGCT	1080	
QY	1081	CAGCAGGTGAGCAACGGCAAGTGCAGAGGGCAGGCTGCGTCTGCTGCTCTTCT	1140	
DB	1081	CAGCAGGTGAGCAACGGCAAGTGCAGAGGGCAGGCTGCGTCTGCTGCTCTTCT	1140	
QY	1141	GCTCTTGACACCTGCTCTCAAAATTTGATGTGAGTGCCACTTCCCCACCGGGAAGGCT	1200	
DB	1141	GCTCTTGACACCTGCTCTCAAAATTTGATGTGAGTGCCACTTCCCCACCGGGAAGGCT	1200	
QY	1201	GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA	1260	
DB	1201	GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA	1260	
QY	1261	TATACAAATGAATAGAGAAACACACACCTCATGCGGACAGAAATTTGAGGAGGGGAAC	1320	
DB	1261	TATACAAATGAATAGAGAAACACACACCTCATGCGGACAGAAATTTGAGGAGGGGAAC	1320	
QY	1321	AAAGAATATCTTTGGGGGGAAGAGTTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA	1380	
DB	1321	AAAGAATATCTTTGGGGGGAAGAGTTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA	1380	
QY	1381	TTTAGGTACATGGAGTTTTCTTTTCCAAAGGGGAAGAACACAGCACACCGGCTTGGGA	1440	
DB	1381	TTTAGGTACATGGAGTTTTCTTTTCCAAAGGGGAAGAACACAGCACACCGGCTTGGGA	1440	
QY	1441	CCCACTGCAAGTGCATCGTCAACCTCTTTGGTGCAGTGTGGCAAGGCTCAGCCTC	1500	
DB	1441	CCCACTGCAAGTGCATCGTCAACCTCTTTGGTGCAGTGTGGCAAGGCTCAGCCTC	1500	
QY	1501	TCGCGCACAGAGTGCCTCCAGCGAGAACATCTGGAGCTGGCCATCCCAATCAATCA	1560	
DB	1501	TCGCGCACAGAGTGCCTCCAGCGAGAACATCTGGAGCTGGCCATCCCAATCAATCA	1560	
QY	1561	GTCCATAGAGACAAAGATGAGACCTTCGCGCCCAAGCGTGGCGCTGCGGCACTTG	1620	
DB	1561	GTCCATAGAGACAAAGATGAGACCTTCGCGCCCAAGCGTGGCGCTGCGGCACTTG	1620	
QY	1621	GTAGACTGTGCCACCAACCGGCTGTGTGAAACGTGAAATATAAAGAGCAAAAAA	1679	
DB	1621	GTAGACTGTGCCACCAACCGGCTGTGTGAAACGTGAAATATAAAGAGCAAAAAA	1679	

RESULT 41

AD49875
ID ADC49875 standard; cDNA; 1679 BP.

XX ADC49875;
AC AC
XX DT

18-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO337 cDNA.

DE human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumor necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumor; lung tumor;
KW colon tumor; breast tumor; prostate tumor; rectal tumor;
KW liver tumor; tissue typing; chromosome mapping; gene mapping;
gene therapy.

XX Homo sapiens.
OS
XX US2003088064-A1.

XX 08-MAY-2003.

XX 14-AUG-2002; 2002US-00219075.

XX 25-JUL-2000; 2000US-0220605P.

PR

PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WL;
XX WPI; 2003-801154/75.
DR P-PADB; ADC49876.
XX
PT New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.
XX
PS Claim 2; SEQ ID NO 125; 314pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (i). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblast cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGTGCAAGCTTGAGAGCAAC 60
DB 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGTGCAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAGAAACCATCGCCCAAAATGCNATTTCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAGAAACCATCGCCCAAAATGCNATTTCTCTTGGGCAAT 180
QY 181 CTTACGGGGGCTGTGCTCTGTCTCTTCTCAAGAGAGTGCCTGTGCGAGCGGAGATGC 240

DB 181 CTTACGGGGGCTGTGCTCTGTCTCTTCTCAAGAGAGTGCCTGTGCGAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGAACAACGTGACGCTCCGGAGGGGAGAGCGCCACCTCTAG 300
DB 241 CACCTTCCCAAGCTATGGAACAACGTGACGCTCCGGAGGGGAGAGCGCCACCTCTAG 300
QY 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGACCATCTCTTA 360
DB 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGACCATCTCTTA 360
QY 361 TGTGGGAATGACAAAGTGGTCTCGCTCGCTGCTTCTTCTGAGCAACACCCAAAC 420
DB 361 TGTGGGAATGACAAAGTGGTCTCGCTCGCTGCTTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGATCGAGATCCAGAACGCTGGATGATGACGAGCGGCTTACACCTGCTC 480
DB 421 GCAGTACAGATCGAGATCCAGAACGCTGGATGATGACGAGCGGCTTACACCTGCTC 480
QY 481 GGTGACAGACAGAACCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGAACCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB 541 CAAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACCAATCTTGGAAATTCAGGGGATCACCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGACCAATCTTGGAAATTCAGGGGATCACCGGGAGCAGTC 720
QY 721 AGGGGACTAGCAGTGCAGTCCCTCAATGACGTGGCGGCGCGCTGGTACGGAGAGTAAA 780
DB 721 AGGGGACTAGCAGTGCAGTCCCTCAATGACGTGGCGGCGCGCTGGTACGGAGAGTAAA 780
QY 781 GGTACCGTGAACATTCACCATACATTTTCCAGAACCAAGGGTACAGGTGTCCTCCGTTGG 840
DB 781 GGTACCGTGAACATTCACCATACATTTTCCAGAACCAAGGGTACAGGTGTCCTCCGTTGG 840
QY 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAGACTGATTGAAGAAAGAGGGGTGAAGTGGAAGAAAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTGAAGAAAGAGGGGTGAAGTGGAAGAAAGACCTTT 960
QY 961 CTTCTCAAAACTCATCTTCTCAATGCTGCTGAACATGACTATGGAACTACACTTGGCT 1020
DB 961 CTTCTCAAAACTCATCTTCTCAATGCTGCTGAACATGACTATGGAACTACACTTGGCT 1020
QY 1021 GGCTTCAACCAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGCT 1080
DB 1021 GGCTTCAACCAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGCT 1080
QY 1081 CAGCGAGTTCAGCAACGGGACGCTCGAGGGGAGGGTGGCTGGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGTTCAGCAACGGGACGCTCGAGGGGAGGGTGGCTGGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACCTCTCTTCAAAATTTTGTGATGTGAGTGCCACTTCCCAACCGGGAAGGCT 1200
DB 1141 GGTCTTGCACCTCTCTTCAAAATTTTGTGATGTGAGTGCCACTTCCCAACCGGGAAGGCT 1200
QY 1201 GCGGCCACACACACACACACAAAGCAATGGCAACCGGAGCAACCAATCATGATA 1260
DB 1201 GCGGCCACACACACACACAAAGCAATGGCAACCGGAGCAACCAATCATGATA 1260
QY 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATTGGGACAGAAATTTGAGGGAGGGGAAAC 1320

1261	Db	TATACAAATGAAATTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC	1320
1321	Qy	AAAGAAATACTTTGGGGGGAAGAGTTTTAAAAAGAAAAATGGAAATTTGCTTTGCAGATA	1380
1321	Db	AAAGAAATACTTTGGGGGGAAGAGTTTTAAAAAGAAAAATGGAAATTTGCTTTGCAGATA	1380
1381	Qy	TTTAGGTACAAATGGAGTTTTCTTTTCCAAACGGGAAGAACACAGCACACCCCGGCTTGGGA	1440
1381	Db	TTTAGGTACAAATGGAGTTTTCTTTTCCAAACGGGAAGAACACAGCACACCCCGGCTTGGGA	1440
1441	Qy	CCCACTGCAAGCTGCATCGTGCAACCTCTTTGTGCCAGTGTGGGCAAGGGCTCAGGCTC	1500
1441	Db	CCCACTGCAAGCTGCATCGTGCAACCTCTTTGTGCCAGTGTGGGCAAGGGCTCAGGCTC	1500
1501	Qy	TCCTGCCACAGAGTCCGCCCAACGCTGGAAACATTTGGAGCTTGGCCATCCCAAAATTCAAATCA	1560
1501	Db	TCCTGCCACAGAGTCCGCCCAACGCTGGAAACATTTGGAGCTTGGCCATCCCAAAATTCAAATCA	1560
1561	Qy	GTCCATAGACACGAACGAATGAGACCTTCGGCCCAAGCGTGGCGCTGGCGGCACCTTTG	1620
1561	Db	GTCCATAGACACGAACGAATGAGACCTTCGGCCCAAGCGTGGCGCTGGCGGCACCTTTG	1620
1621	Qy	GTAGACTGTCCCAACCACCGGCGTGTGTTGTGAAACGTGAAATAAAAAAGACAAAAAATA	1679
1621	Db	GTAGACTGTCCCAACCACCGGCGTGTGTTGTGAAACGTGAAATAAAAAAGACAAAAAATA	1679

RESULT 42

AD49074	
ID	AD49074 standard; cDNA, 1679 BP.
XX	
AC	AD49074;
XX	
DT	19-DEC-2003 (first entry)
XX	
DE	Novel human secreted and transmembrane protein PRO337 cDNA.
XX	
KW	human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW	vulnerable; antiarthritic; pericyte cell proliferation;
KW	pericyte cell differentiation; chondrocyte cell proliferation;
KW	chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW	(TNF)-alpha release; dermal fibroblast cell proliferation;
KW	dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW	colon tumour; breast tumour; prostate tumour; rectal tumour;
KW	liver tumour; tissue typing; chromosome mapping; gene mapping;
KW	gene therapy.
XX	
OS	Homo sapiens.
XX	
PN	US2003088070-A1.
XX	
PD	08-MAY-2003.
XX	
PF	28-AUG-2002; 2002US-00230260.
XX	
PR	01-JUN-2001; 2001WO-US017800.
PR	29-JUN-2001; 2001WO-US021066.
PR	09-APR-2002; 2002US-00119480.
XX	
PA	(GETH) GENENTECH INC.
XX	
XX	Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WT;
PI	P-PSDB; ADC49075.
XX	
DR	WPI; 2003-801155/75.
XX	
DR	P-PSDB; ADC49075.
XX	
PT	New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT	in gene therapy, chromosome identification, tissue typing, or as
PT	hybridization probes in chromosome and gene mapping.
XX	
PS	Claim 2; SEQ ID NO 125; 315pp; English.

481 GGTGAGACAGACCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db GGTGAGACAGACCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
481 GGTGAGACAGACCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Qy CAAATTTAGAGATTTCTTTCAGATATCTTCATTAATGAAGGGAACAATATTAGCCTCAC 600
Db CAAATTTAGAGATTTCTTTCAGATATCTTCATTAATGAAGGGAACAATATTAGCCTCAC 600
Qy CTGCATACCACTGCTGACAGACGCTTACGTTACTTTGGAGACACATCTCTCCCAAGC 660
Db CTGCATACCACTGCTGACAGACGCTTACGTTACTTTGGAGACACATCTCTCCCAAGC 660
Qy GGTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Db GGTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Qy AGGGGACTACGAGTGCAGTCTCCATGAGTGGCGCGCGCTGTGAGAGAGTAA 780
Db AGGGGACTACGAGTGCAGTCTCCATGAGTGGCGCGCGCTGTGAGAGAGTAA 780
Qy GGTCACTGAACTATCCACCATATATTTCAGAAAGCCAAAGGTACAGGTGTCCCGTGGG 840
Db GGTCACTGAACTATCCACCATATATTTCAGAAAGCCAAAGGTACAGGTGTCCCGTGGG 840
Qy ACAAAGGGGACACTGCAAGTGAAGCTCAGAGTCCCTCAGCAGATTCCTCAGAGTGGTA 900
Db ACAAAGGGGACACTGCAAGTGAAGCTCAGAGTCCCTCAGCAGATTCCTCAGAGTGGTA 900
Qy CAAAGATGACAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAAGTGGAAACACAGACCTTT 960
Db CAAAGATGACAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAAGTGGAAACACAGACCTTT 960
Qy CCTCTCAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACATACCTTGGT 1020
Db CCTCTCAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACATACCTTGGT 1020
Qy GSCCTCCAAAGCTGGGCGCACCAATGCGAGCATCATGCTATTGTCTCAGCGCGCT 1080
Db GSCCTCCAAAGCTGGGCGCACCAATGCGAGCATCATGCTATTGTCTCAGCGCGCT 1080
Qy CAGCAGGTGACCAACGCGCTCGAGGAGGCGAGCTGCGCTGCTGCTGCTCTTCT 1140
Db CAGCAGGTGACCAACGCGCTCGAGGAGGCGAGCTGCGCTGCTGCTGCTCTTCT 1140
Qy GGTCTGCACTGCTCTCTCAATTTTGTGAGTGGCCACTTCCACCGCGGGAAGGCT 1200
Db GGTCTGCACTGCTCTCTCAATTTTGTGAGTGGCCACTTCCACCGCGGGAAGGCT 1200
Qy GCGGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db GCGGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Qy TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
Db TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
Qy AAAAGATATCTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db AAAAGATATCTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Qy TTTAGTCAATTTGAGTGTCTTTTCCAAACCGGGAAGAACACAGCACACCGGCTTGG 1440
Db TTTAGTCAATTTGAGTGTCTTTTCCAAACCGGGAAGAACACAGCACACCGGCTTGG 1440
Qy CCCACTGCAAGTGTGATCTGTCGAACTCTTTGGTGGCAGTGTGGCAAGGGCTCAGCCTC 1500
Db CCCACTGCAAGTGTGATCTGTCGAACTCTTTGGTGGCAGTGTGGCAAGGGCTCAGCCTC 1500
Qy TCTGCCCAAGAGTGTGCTGCAAGTGTGCAAGTGTGCAAGTGTGCAAGTGTGCAAGT 1560
Db TCTGCCCAAGAGTGTGCTGCAAGTGTGCAAGTGTGCAAGTGTGCAAGTGTGCAAGT 1560

Qy 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCGCGCCCAACGCTGGCGCTTCGCGCACTTTG 1620
Db 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCGCGCCCAACGCTGGCGCTTCGCGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCAACGCGCTGTGTTGTGAACACCTGAAATTAATAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCAACGCGCTGTGTTGTGAACACCTGAAATTAATAAGAGCAAAAAA 1679

RESULT 43

ADC49591

ID ADC49591 standard; cDNA; 1679 BP.

XX ADC49591;

XX AC

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX KW human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
XX KW vulnary; antiarthritic; pericyte cell proliferation;
XX KW pericyte cell differentiation; chondrocyte cell proliferation;
XX KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
XX KW (TNF)-alpha release; dermal fibroblast cell proliferation;
XX KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
XX KW colon tumour; breast tumour; prostate tumour; rectal tumour;
XX KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX KW gene therapy.

XX OS Homo sapiens.

XX XX US2003088071-A1.

XX PN

XX PD 08-MAY-2003.

XX XX 29-AUG-2002; 2002US-00232231.

XX XX 01-JUN-2001; 2001WO-US017800.

XX XX 29-JUN-2001; 2001WO-US021066.

XX XX 09-APR-2002; 2002US-00119480.

XX XX (GETH) GENENTECH INC.

XX XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX XX WPI; 2003-801156/75.

XX XX P-PSDB; ADC49592.

XX XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
XX XX in gene therapy, chromosome identification, tissue typing, or as
XX XX hybridization probes in chromosome and gene mapping.

XX XX Claim 2; SEQ ID NO 125; 315pp; English.

XX XX The invention describes an isolated PRO (secreted and transmembrane)
XX XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX XX useful for stimulating the proliferation of or gene expression in
XX XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX XX for stimulating the proliferation or differentiation of chondrocyte
XX XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX XX are useful for stimulating the release of tumour necrosis factor (TNF)-
XX XX alpha from human blood. PRO982, PRO357, PRO1083, PRO840, PRO1080,
XX XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
XX XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
XX XX PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
XX XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1367,
XX XX PRO1897, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
XX XX PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX XX stimulating the proliferation of normal human dermal fibroblasts cells.
XX XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX XX PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for

CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO1714, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (i) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (ii) encoding (i) is
 CC useful for chromosome and gene mapping or gene therapy. (ii) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.

XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCCTTGCACAAGCTTGAGAGCAAC 60
 Db 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCCTTGCACAAGCTTGAGAGCAAC 60
 Qy 61 AATCTATCAGAAAGAAAGAAAGAAACCGAATCCAGCAATATGCAATATCTCTTTGGGCAAT 120
 Db 61 AATCTATCAGAAAGAAAGAAAGAAACCGAATCCAGCAATATGCAATATCTCTTTGGGCAAT 120
 Qy 121 AAGAAAAAATCATGAAACCATCCAGCCAAATAATGCAATATCTCTTTGGGCAAT 180
 Db 121 AAGAAAAAATCATGAAACCATCCAGCCAAATAATGCAATATCTCTTTGGGCAAT 180
 Qy 181 CTTACGGGGTGGCTGCTGTCTCTCTCCAGAGATGCGGTGCGGAGCGGATGC 240
 Db 181 CTTACGGGGTGGCTGCTGTCTCTCTCCAGAGATGCGGTGCGGAGCGGATGC 240
 Qy 241 CACCTTCCCAAAAGCTATGGAACACGTGACGGTCCGGCAGGGGAGAGCCACCTCAG 300
 Db 241 CACCTTCCCAAAAGCTATGGAACACGTGACGGTCCGGCAGGGGAGAGCCACCTCAG 300
 Qy 301 GTGCATATTGACAAACGGGTGACCCGGTGGCTGCTTAACCGGAGCACCATCTCTTA 360
 Db 301 GTGCATATTGACAAACGGGTGACCCGGTGGCTGCTTAACCGGAGCACCATCTCTTA 360
 Qy 361 TGCTGGGAATGACAAAGTGGTGGTCTCTGCGGTGCTCTCTGAGCAACACCCAAAC 420
 Db 361 TGCTGGGAATGACAAAGTGGTGGTCTCTGCGGTGCTCTCTGAGCAACACCCAAAC 420
 Qy 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACAGGGCCCTTACACCTGCTC 480
 Db 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACAGGGCCCTTACACCTGCTC 480
 Qy 481 GGTGACAGACAAACACCCAAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 Db 481 GGTGACAGACAAACACCCAAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 Qy 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAAACAATATTAGCTTCAC 600
 Db 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAAACAATATTAGCTTCAC 600
 Qy 601 CTGCATAGCAATCGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCCAAAGC 660
 Db 601 CTGCATAGCAATCGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCCAAAGC 660
 Qy 661 GGTGGCTTTGTAGTGAAGACGAATATTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
 Db 661 GGTGGCTTTGTAGTGAAGACGAATATTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
 Qy 721 AGGGGACTACAGTGCAGTGCTCTCAATGACGTGGCGGCCCGCTGTGTACGGAGAGTAAA 780

Db 721 AGGGGACTACAGTGCAGTGCTCTCAATGACGTGGCGGCCCGCTGTGTACGGAGTAAA 780
 Qy 781 GGTCAACCGTGAACATATCCACCATATTTTCAAGAGCAAGGGTACAGGTCTCCCGTGG 840
 Db 781 GGTCAACCGTGAACATATCCACCATATTTTCAAGAGCAAGGGTACAGGTCTCCCGTGG 840
 Qy 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGAGTGA 900
 Db 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGAGTGA 900
 Qy 901 CAAGGATGACAAAAAGACTGATTGAAGGAAAAAGGGGTGAAAGTGAAGAACAGACCTTT 960
 Db 901 CAAGGATGACAAAAAGACTGATTGAAGGAAAAAGGGGTGAAAGTGAAGAACAGACCTTT 960
 Qy 961 CTTCTCAAACTCATCTCTTCAATGTCTCTGAACATGACTATGGGAACATACACTTGGT 1020
 Db 961 CTTCTCAAACTCATCTCTTCAATGTCTCTGAACATGACTATGGGAACATACACTTGGT 1020
 Qy 1021 GGCCTCCAAAGCTGGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
 Db 1021 GGCCTCCAAAGCTGGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
 Qy 1081 CAGCGAGTGAAGCAACCGCAGCTCGAGAGGGCAGGTGCGTCTGGCTGCTGCTCTTCT 1140
 Db 1081 CAGCGAGTGAAGCAACCGCAGCTCGAGAGGGCAGGTGCGTCTGGCTGCTGCTCTTCT 1140
 Qy 1141 GGTCTTGACCTGCTCTCAAAATTTTGAATGTGAGTGCACCTTCCCCACCCGGGAAAGCT 1200
 Db 1141 GGTCTTGACCTGCTCTCAAAATTTTGAATGTGAGTGCACCTTCCCCACCCGGGAAAGCT 1200
 Qy 1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
 Db 1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
 Qy 1261 TATACAAATGAAATTTAGAAAGAAACACACGCTCTATGGGACAGAAATTTGAGGGAGGGAAC 1320
 Db 1261 TATACAAATGAAATTTAGAAAGAAACACACGCTCTATGGGACAGAAATTTGAGGGAGGGAAC 1320
 Qy 1321 AAAGAATATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTTCAGATA 1380
 Db 1321 AAAGAATATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTTCAGATA 1380
 Qy 1381 TTTAGTACAATGAGTCTTCTTCCCAACCGGAGAAACACAGCACACCCGCTTGGGA 1440
 Db 1381 TTTAGTACAATGAGTCTTCTTCCCAACCGGAGAAACACAGCACACCCGCTTGGGA 1440
 Qy 1441 CCCACTGCAAGCTGCATCGTCAACCTTTTGGTCCAGTGTGGGCAAGGGCTCAGGCTC 1500
 Db 1441 CCCACTGCAAGCTGCATCGTCAACCTTTTGGTCCAGTGTGGGCAAGGGCTCAGGCTC 1500
 Qy 1501 TCTGCCACAGAGTGCCTCCCGCAGTGGACATTTCTGGAGCTGCCATCCCAATTCATCA 1560
 Db 1501 TCTGCCACAGAGTGCCTCCCGCAGTGGACATTTCTGGAGCTGCCATCCCAATTCATCA 1560
 Qy 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGGGCCAAGCGTGGCTGGCGGACATTG 1620
 Db 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGGGCCAAGCGTGGCTGGCGGACATTG 1620
 Qy 1621 GTAGACTGTGCCACACCGCGTGTGTGTAACGTGTAATTAAGAGCAAGCAAAAAA 1679
 Db 1621 GTAGACTGTGCCACACCGCGTGTGTGTAACGTGTAATTAAGAGCAAGCAAAAAA 1679

RESULT 44

ID ADC47452
 XX ADC47452 standard; cDNA; 1679 BP.

XX AC ADC47452;

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO337 cDNA.

Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic; vulvuary; antiarthritic; pericyte cell proliferation; pericyte cell differentiation; chondrocyte cell proliferation; chondrocyte cell differentiation; tumour necrosis factor alpha release; (TNF)-alpha release; dermal fibroblast cell proliferation; lung tumour; dermal fibroblast cell differentiation inhibitor; tumour; lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour; liver tumour; tissue typing; chromosome mapping; gene mapping; gene therapy.

Homo sapiens.

US2003088072-A1.

08-MAY-2003.

29-AUG-2002; 2002US-00232233.

25-JUL-2000; 2000US-0220605P.

01-JUN-2001; 2001WO-US017800.

29-JUN-2001; 2001WO-US021086.

09-APR-2002; 2002US-00119480.

(GETH) GENENTECH. INC.

Baker KP, Deenoyers L, Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI, WPI; 2003-801157/75.

P-PSDB; ADC47453.

New PRO polypeptide for use as molecular weight markers for protein electrophoresis purposes and for detecting the presence of tumor in a mammal.

Claim 2; Fig 125; 314pp; English.

The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO229, PRO1372 or PRO405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214, PRO247, PRO337, PRO536, PRO363, PRO531, PRO1083, PRO840, PRO1080, PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412, PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567, PRO1887, PRO1328, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322, PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells. PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

Db	961	CTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGGAATACACTTGGCT	1020	PR	14-JUL-1998;	98WO-US014552.
Qy	1021	GGCTCCAAAGCTGGGCGCACCAATGCCAGCATCATCTATTTGGTCCAGGCGCGCT	1080	PR	28-AUG-1998;	98WO-US017888.
Db	1021	GGCTCCAAAGCTGGGCGCACCAATGCCAGCATCATCTATTTGGTCCAGGCGCGCT	1080	PR	10-SEP-1998;	98WO-US018824.
Qy	1081	CAGCGAGTGAGCAACGGCGAGTGGAGAGGGGAGGCTGGCTGGCTGGCTGGCTTTCT	1140	PR	14-SEP-1998;	98WO-US019093.
Db	1081	CAGCGAGTGAGCAACGGCGAGTGGAGAGGGGAGGCTGGCTGGCTGGCTTTCT	1140	PR	14-SEP-1998;	98WO-US019094.
Qy	1141	GGTCTTGCACTGCTTCTCAAAATTTTGGTGGCTGGCTGGCTGGCTGGCTGGCT	1200	PR	14-SEP-1998;	98WO-US019177.
Db	1141	GGTCTTGCACTGCTTCTCAAAATTTTGGTGGCTGGCTGGCTGGCTGGCTGGCT	1200	PR	16-SEP-1998;	98WO-US019330.
Qy	1201	GGCGCCACACACACACACACACACACACACACACACACACACACACACACAC	1260	PR	17-SEP-1998;	98WO-US019437.
Db	1201	GGCGCCACACACACACACACACACACACACACACACACACACACACACACAC	1260	PR	07-OCT-1998;	98WO-US021141.
Qy	1261	TATCAATGAAATTTAGAGAAACACACAGCTTCATGGGACAGAAATTTGAGGGAGGGG	1320	PR	29-OCT-1998;	98WO-US022991.
Db	1261	TATCAATGAAATTTAGAGAAACACACAGCTTCATGGGACAGAAATTTGAGGGAGGGG	1320	PR	29-OCT-1998;	98WO-US022992.
Qy	1321	AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAGGGAGGGG	1380	PR	01-DEC-1998;	98WO-US024855.
Db	1321	AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAGGGAGGGG	1380	PR	01-DEC-1998;	98WO-US025108.
Qy	1381	TTTAGGTACATGAGTTTCTTTTCCCAACGGGAGAGACACAGCACACCCGGCTTGA	1440	PR	05-JAN-1999;	98WO-US000106.
Db	1381	TTTAGGTACATGAGTTTCTTTTCCCAACGGGAGAGACACAGCACACCCGGCTTGA	1440	PR	08-MAR-1999;	98WO-US005028.
Qy	1441	CCCACTGCAAGCTGCATCGTCAACCTTTTGGTGGCAGTGGGCAAGGGCTCAGCCTC	1500	PR	10-MAR-1999;	98WO-US005190.
Db	1441	CCCACTGCAAGCTGCATCGTCAACCTTTTGGTGGCAGTGGGCAAGGGCTCAGCCTC	1500	PR	10-MAR-1999;	2000WO-US006319.
Qy	1501	TCTGCCACAGAGTGGCCCGGACATCTTGGAGCTGGCCATCCCAATTCATCA	1560	PR	20-APR-1999;	98WO-US008615.
Db	1501	TCTGCCACAGAGTGGCCCGGACATCTTGGAGCTGGCCATCCCAATTCATCA	1560	PR	14-MAY-1999;	98WO-US010733.
Qy	1561	GTCCATAGAGACGACAGATGAGACCTTCGCGCCCAAGCGTGGCGTGGCGGACCTTG	1620	PR	01-SEP-1999;	98WO-US012252.
Db	1561	GTCCATAGAGACGACAGATGAGACCTTCGCGCCCAAGCGTGGCGTGGCGGACCTTG	1620	PR	01-SEP-1999;	98WO-US020111.
Qy	1621	GTAGCTGTGCACACCGCGCTGTTGTGAACGCTGAATATAAAGAGCAAAAAA	1679	PR	08-SEP-1999;	98WO-US020594.
Db	1621	GTAGCTGTGCACACCGCGCTGTTGTGAACGCTGAATATAAAGAGCAAAAAA	1679	PR	13-SEP-1999;	98WO-US020944.
RESULT 45					15-SEP-1999;	98WO-US021090.
ADC52949					15-SEP-1999;	98WO-US021547.
ID	ADC52949 standard; cDNA; 1679 BP.				05-OCT-1999;	98WO-US023089.
AC	ADC52949;				29-NOV-1999;	98WO-US028214.
XX	18-DEC-2003 (first entry)				30-NOV-1999;	98WO-US028409.
DT	Novel human secreted and transmembrane protein cDNA Seq ID375.				01-DEC-1999;	98WO-US028301.
DE	human; PRO; membrane bound protein; membrane bound receptor;				01-DEC-1999;	98WO-US028634.
XX	cell proliferation; cell migration; cell differentiation;				02-DEC-1999;	98WO-US028551.
KW	mitogenic factor; survival factor; cytotoxic factor;				02-DEC-1999;	98WO-US028564.
KW	differentiation factor; neuroepithelial; hormone; cell receptor;				16-DEC-1999;	98WO-US030095.
KW	receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.				20-DEC-1999;	98WO-US030911.
XX	Homo sapiens.				20-DEC-1999;	98WO-US030999.
OS	US2003087365-A1.				22-DEC-1999;	98WO-US030720.
XX	08-MAY-2003.				30-DEC-1999;	98WO-US031243.
XX	23-APR-2002; 2002US-00128689.				05-JAN-2000;	2000WO-US000219.
PN	31-MAR-1997; 97WO-US005230.				06-JAN-2000;	2000WO-US000277.
PR	12-JUN-1999; 98WO-US012456.				11-FEB-2000;	2000WO-US000376.
PR					11-FEB-2000;	2000WO-US003565.
PR					18-FEB-2000;	2000WO-US004341.
PR					18-FEB-2000;	2000WO-US004342.
PR					22-FEB-2000;	2000WO-US004342.
PR					24-FEB-2000;	2000WO-US004914.
PR					24-FEB-2000;	2000WO-US005004.
PR					01-MAR-2000;	2000WO-US005601.
PR					02-MAR-2000;	2000WO-US005746.
PR					02-MAR-2000;	2000WO-US005841.
PR					15-MAR-2000;	2000WO-US006884.
PR					20-MAR-2000;	2000WO-US007377.
PR					21-MAR-2000;	2000WO-US007532.
PR					30-MAR-2000;	2000WO-US008439.
PR					30-MAR-2000;	2000WO-US013705.
PR					22-MAY-2000;	2000WO-US014042.
PR					30-MAY-2000;	2000WO-US014941.
PR					02-JUN-2000;	2000WO-US015264.
PR					28-JUL-2000;	2000WO-US020710.
PR					11-AUG-2000;	2000WO-US022031.
PR					23-AUG-2000;	2000WO-US023522.
PR					24-AUG-2000;	2000WO-US023328.
PR					08-NOV-2000;	2000WO-US030952.
PR					10-NOV-2000;	2000WO-US030873.
PR					01-DEC-2000;	2000WO-US032678.
PR					20-DEC-2000;	2000US-00747259.
PR					20-DEC-2000;	2000WO-US034956.
PR					28-FEB-2001;	2001US-00796498.
PR					28-FEB-2001;	2001WO-US006520.
PR					01-MAR-2001;	2001WO-US006666.
PR					09-MAR-2001;	2001US-00802706.

PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001US-00872035.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001US-00891962.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001US-00892011.
 PR 29-JUN-2001; 2001US-00892011.
 PR 09-JUL-2001; 2001US-00901735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 PR XX
 PA (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-801150/75.
 DR P-PSDB; ADC52950.
 XX
 PT New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor.
 XX
 PS Claim 2; SEQ ID NO 375; 637pp; English.
 XX
 CC This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neuropeptides and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytosolic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTTGTCTCTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAACAC 60
 DB 1 GTTGTCTCTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAACAC 60
 QY 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGCACAAAAAGAAAGAAAG 120
 |||||

Db 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGCACAAAAAGAAAGAAAG 120
 QY 121 AAGAAAAAATCATGAACACATCCAGCCAAAAATGCAAAATCTATCTCTGGSCAAT 180
 Db 121 AAGAAAAAATCATGAACACATCCAGCCAAAAATGCAAAATCTATCTCTGGSCAAT 180
 QY 181 CTTCAAGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGCCTGCGGAGGAGATGC 240
 Db 181 CTTCAAGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGCCTGCGGAGGAGATGC 240
 QY 241 CACCTTCCCAAGCTATGGACAACTGAGCGTCCGCGAGGGGAGAGCGCCACCTCAG 300
 Db 241 CACCTTCCCAAGCTATGGACAACTGAGCGTCCGCGAGGGGAGAGCGCCACCTCAG 300
 QY 301 GTGCACCTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGACCACTCTTA 360
 Db 301 GTGCACCTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGACCACTCTTA 360
 QY 361 TGCTGGGAATGACAAAGTGGTGGCTGGATCTCGCTGGTGGCTCTTGAGCAACACCCAAAC 420
 Db 361 TGCTGGGAATGACAAAGTGGTGGCTGGATCTCGCTGGTGGCTCTTGAGCAACACCCAAAC 420
 QY 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGGGCCCTTACACCTGCTC 480
 Db 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGGGCCCTTACACCTGCTC 480
 QY 481 GGTGCAGACAGACACCAACCAAGACCTTAGGTCCACCTCATTTGTGCAAGTATCTCC 540
 Db 481 GGTGCAGACAGACACCAACCAAGACCTTAGGTCCACCTCATTTGTGCAAGTATCTCC 540
 QY 541 CMAAATGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
 Db 541 CMAAATGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
 QY 601 CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
 Db 601 CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
 QY 661 GTTGGCTTTGTGAGTGACGACGAATTAATTTGGAATTCAGGGCATCACCGGAGCAGTC 720
 Db 661 GTTGGCTTTGTGAGTGACGACGAATTAATTTGGAATTCAGGGCATCACCGGAGCAGTC 720
 QY 721 AGGGCACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGGTACGAGAGTAAA 780
 Db 721 AGGGCACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGGTACGAGAGTAAA 780
 QY 781 GGTCCACGTGAATTCACCATACATTTTCCAGAACCAAGGTTACAGGTCTCCCGTGGG 840
 Db 781 GGTCCACGTGAATTCACCATACATTTTCCAGAACCAAGGTTACAGGTCTCCCGTGGG 840
 QY 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATCCAGTGGTA 900
 Db 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATCCAGTGGTA 900
 QY 901 CAAGGATGACAAAGACTGATTGAAGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
 Db 901 CAAGGATGACAAAGACTGATTGAAGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
 QY 961 CCTCTCAAAACTCATCTTCTTCAATGTCTGAACATGACTATGGGAACTACACTTGGCT 1020
 Db 961 CCTCTCAAAACTCATCTTCTTCAATGTCTGAACATGACTATGGGAACTACACTTGGCT 1020
 QY 1021 GGCCTCCAAACAGCTGGGCCACACCAATGCCAGCATCATCTATTTGGTCCAGCGCCGT 1080
 Db 1021 GGCCTCCAAACAGCTGGGCCACACCAATGCCAGCATCATCTATTTGGTCCAGCGCCGT 1080
 QY 1081 CAGCGGCTGAGCAACCGGCACGTGAGGAGGGCAGGCTGGCTCTGGCTGTCTTCTTCT 1140
 Db 1081 CAGCGGCTGAGCAACCGGCACGTGAGGAGGGCAGGCTGGCTGTCTTCTTCTTCTTCT 1140
 QY 1141 GGTCTTCCACTGCTTCTTCAAAATTTTGAATGAGTGCACCTTCCCAACCGGAAAGGCT 1200
 Db 1141 GGTCTTCCACTGCTTCTTCAAAATTTTGAATGAGTGCACCTTCCCAACCGGAAAGGCT 1200

Db 601 CTGCTAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGGCTTTGTAGTGAAGACGAATCTTGAATTCAGGGCATCACCCGGAGCAGTC 720
Db 661 GGTGGCTTTGTAGTGAAGACGAATCTTGAATTCAGGGCATCACCCGGAGCAGTC 720
Qy 721 AGGGGACTAGAGTGCAGTGCCTCCCAATGACGTGGCGCGCGTGGTACGAGAGTAA 780
Db 721 AGGGGACTAGAGTGCAGTGCCTCCCAATGACGTGGCGCGCGTGGTACGAGAGTAA 780
Qy 781 GGTCAAGGTGAATATCCACATATTTCAAGCAAGGGTACAGTGTCCCGTGG 840
Db 781 GGTCAAGGTGAATATCCACATATTTCAAGCAAGGGTACAGTGTCCCGTGG 840
Qy 841 ACAAAGGGGACACTCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGATTCAGTGGTA 900
Qy 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAAAGGGTGAAGTGGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAAAGGGTGAAGTGGAAACAGACCTTT 960
Qy 961 CCTCTCAAACTCATCTTCTCAATCTCTGACATGACTATGGGAATCAGTTCGGT 1020
Db 961 CCTCTCAAACTCATCTTCTCAATCTCTGACATGACTATGGGAATCAGTTCGGT 1020
Qy 1021 GGCTCTCAACAGCTGGGCGACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCTCTCAACAGCTGGGCGACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Qy 1081 CAGCGAGGTGAGCAAGCGACGTCGAGGAGGCGAGCTCGTCTGCTCTCTCTCTCT 1140
Db 1081 CAGCGAGGTGAGCAAGCGACGTCGAGGAGGCGAGCTCGTCTGCTCTCTCTCTCT 1140
Qy 1141 GGTCTTGACCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1200
Db 1141 GGTCTTGACCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1200
Qy 1201 GCGGCCACACACACCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCA 1260
Db 1201 GCGGCCACACACACCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCA 1260
Qy 1261 TATACAAATGAATTTAGAGAAACACAGCTCTATGGGACAGAAATTTGAGGAGGGGAA 1320
Db 1261 TATACAAATGAATTTAGAGAAACACAGCTCTATGGGACAGAAATTTGAGGAGGGGAA 1320
Qy 1321 AAGAAATACCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTCCTCTTGAGATA 1380
Db 1321 AAGAAATACCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTCCTCTTGAGATA 1380
Qy 1381 TTTAGGTACATGAGTGTCTTTTCCAAACCGGAGAACACAGCTCTATGGGACAGAAAT 1440
Db 1381 TTTAGGTACATGAGTGTCTTTTCCAAACCGGAGAACACAGCTCTATGGGACAGAAAT 1440
Qy 1441 CCCACTGCAAGTGCATCGTGTCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGTGCATCGTGTCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACACAGTGTGGGCAAGTGTGGGCAAGTGTGGGCAAGTGTGGGCAAGTGTGG 1560
Db 1501 TCTGCCACACAGTGTGGGCAAGTGTGGGCAAGTGTGGGCAAGTGTGGGCAAGTGTGG 1560
Qy 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCCGGCCCAAGCGTGGCGCTCGCGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCCGGCCCAAGCGTGGCGCTCGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCGCGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1679
Db 1621 GTAGACTGTGCCACCGCGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1679

RESULT 47

ADCC60494
ID ADC60494 standard; cDNA; 1679 BP.
XX
AC ADC60494;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003087367-A1.
XX
PD 08-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131825.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028501.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.

```
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000365.
PR 18-FEB-2000; 2000WO-US000341.
PR 18-FEB-2000; 2000WO-US000432.
PR 22-FEB-2000; 2000WO-US000444.
PR 24-FEB-2000; 2000WO-US000494.
PR 24-FEB-2000; 2000WO-US000504.
PR 01-MAR-2000; 2000WO-US000501.
PR 02-MAR-2000; 2000WO-US000574.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US000843.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030352.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00871092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-801152/75.
DR P-PSDB; ADC60495.
XX
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
XX Claim 2; Fig 375; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
```

```
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
```

```
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCAACAGCTTGAGAGCAAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCAACAGCTTGAGAGCAAC 60

QY 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACCTTGACAAAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACCTTGACAAAAAGAAAGAAAG 120

QY 121 AAGAAAAAAATCATGAAACCATCCAGCAAAAAATGCACAAATCTATCTTTGGGCAAT 180
DB 121 AAGAAAAAAATCATGAAACCATCCAGCAAAAAATGCACAAATCTATCTTTGGGCAAT 180

QY 181 CTTACGGGGCTGGCTGCTCTGTGTCTTTCAGAGAGTGCCCGTCGCGAGGAGATGC 240
DB 181 CTTACGGGGCTGGCTGCTCTGTGTCTTTCAGAGAGTGCCCGTCGCGAGGAGATGC 240

QY 241 CACCTTCCCAAAGCTATGGCAACGTCACGTCGCGAGGGGAGAGGCCACCCCTCAG 300
DB 241 CACCTTCCCAAAGCTATGGCAACGTCACGTCGCGAGGGGAGAGGCCACCCCTCAG 300

QY 301 GTGCATATTGCAACCGGGTCAACCGGGTGGCTGCTGCTTAAACCGCAGCAACCATCTCTTA 360
DB 301 GTGCATATTGCAACCGGGTCAACCGGGTGGCTGCTGCTTAAACCGCAGCAACCATCTCTTA 360

QY 361 TCGTGGGAATGCAAGTGTGCTCGATCCCTCGCTGTGTCTTCTTGAGCAACACCCCAAC 420
DB 361 TCGTGGGAATGCAAGTGTGCTCGATCCCTCGCTGTGTCTTCTTGAGCAACACCCCAAC 420

QY 421 CGAGTACAGCATCGAGATCCAGAACGTGGATGTGTATACGAGGGCCCTTACACCTGCTC 480
DB 421 CGAGTACAGCATCGAGATCCAGAACGTGGATGTGTATACGAGGGCCCTTACACCTGCTC 480

QY 481 GGTGACAGACAGAACACCCCAACACCTTAGGGTCCACCTCATTTGCGAGTATCTCC 540
DB 481 GGTGACAGACAGAACACCCCAACACCTTAGGGTCCACCTCATTTGCGAGTATCTCC 540
```

541 CAAAATTGTAGAGATTCTTCCAGATATCTCCATTATGAAGGACAAATATTAGCTCAC 600
Db CAAAATTGTAGAGATTCTTCCAGATATCTCCATTATGAAGGACAAATATTAGCTCAC 600
601 CTGCATAGCAACTGGTGTAGACAGAGCTACGGTTACTTGGAGACACATCTTCCAAAGC 660
Db CTGCATAGCAACTGGTGTAGACAGAGCTACGGTTACTTGGAGACACATCTTCCAAAGC 660
661 GGTTCGCTTTGTAGTGAAGAGCAATACCTTGAATTTAGGGCCTACCCGGGAGCAGTC 720
Db GGTTCGCTTTGTAGTGAAGAGCAATACCTTGAATTTAGGGCCTACCCGGGAGCAGTC 720
721 AGGGGACTACGAGTGTGAGTGTGCTTCCATGACGTGCGCGCTGCTGACGAGAGTAAA 780
Db AGGGGACTACGAGTGTGAGTGTGCTTCCATGACGTGCGCGCTGCTGACGAGAGTAAA 780
781 GGTTCACGCTGACTATCCACCTATCATTTTCAAGAGCAGAGGTACAGGTGTCCCGTGG 840
Db GGTTCACGCTGACTATCCACCTATCATTTTCAAGAGCAGAGGTACAGGTGTCCCGTGG 840
841 ACAAAGGGGACACTCAGTGTGAGGCTTCCAGAGTCCCTCAGCAGATTCAGAGTGTGA 900
Db ACAAAGGGGACACTCAGTGTGAGGCTTCCAGAGTCCCTCAGCAGATTCAGAGTGTGA 900
901 CAAGGATGACAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGGAAAAACAGACCTTT 960
Db CAAGGATGACAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGGAAAAACAGACCTTT 960
961 CCTCTCAAACTCATCTTCTCAATCTCTCTGAAATGATGATGAGTCACTACATCTTGCT 1020
Db CCTCTCAAACTCATCTTCTCAATCTCTCTGAAATGATGATGAGTCACTACATCTTGCT 1020
1021 GGCTCCCAAGCTGGGCGACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGCT 1080
Db GGCTCCCAAGCTGGGCGACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGCT 1080
1081 CAGGAGGTGAGCAACGGCAGCTGCGAGGAGGAGGCTGCTGCTGCTGCTGCTCTTCT 1140
Db CAGGAGGTGAGCAACGGCAGCTGCGAGGAGGAGGCTGCTGCTGCTGCTGCTCTTCT 1140
1141 GGTCTTGCACCTGCTCTCAAAATTTTGTGAGTGCCTATTTCCCAACCGCGGAAAGGCT 1200
Db GGTCTTGCACCTGCTCTCAAAATTTTGTGAGTGCCTATTTCCCAACCGCGGAAAGGCT 1200
1201 GCGGCCACACACACACACACACACACACACACACACACACACACACACACACAT 1260
Db GCGGCCACACACACACACACACACACACACACACACACACACACACACACACAT 1260
1261 TATACAAATGAAATTTAGAGAAACACAGCTCTATGCGACAGAAATTTGAGGAGGAGGAC 1320
Db TATACAAATGAAATTTAGAGAAACACAGCTCTATGCGACAGAAATTTGAGGAGGAGGAC 1320
1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTCGCTTGCAGATA 1380
Db AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTCGCTTGCAGATA 1380
1381 TTTAGGTACAAATGAGTTTCTTTTCCAAACCGGAAAGAACACAGACACACCGGCTTGA 1440
Db TTTAGGTACAAATGAGTTTCTTTTCCAAACCGGAAAGAACACAGACACACCGGCTTGA 1440
1441 CCACCTGCAAGTGCATCGTGCACCTCTTTGGTGCAGTGTGGGCAAGGCTCAGCCTC 1500
Db CCACCTGCAAGTGCATCGTGCACCTCTTTGGTGCAGTGTGGGCAAGGCTCAGCCTC 1500
1501 TCTGCCACACAGAGTGGCCCGACCTGGAACATCTTGGAGCTGGGCATCTCCAAATTCATCA 1560
Db TCTGCCACACAGAGTGGCCCGACCTGGAACATCTTGGAGCTGGGCATCTCCAAATTCATCA 1560
1561 GTCCATAGACGACGAAATGAGACTTCCCGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
Db GTCCATAGACGACGAAATGAGACTTCCCGCCCAAGCGTGGCGCTGCGGCACTTTG 1620

Qy 1621 GTAGACTGTGCCACACCGCGTGTGTGTGAACGTGAATAAAAAAGACAAAAAAA 1679
Db 1621 GTAGACTGTGCCACACCGCGTGTGTGTGAACGTGAATAAAAAAGACAAAAAAA 1679
RESULT 48
ADC50969
ID ADC50969 standard; cDNA; 1679 BP.
XX AC ADC50969;
XX DT 18-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX KW Human: secreted and transmembrane protein; PRO; secreted polypeptide;
transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
rectum; kidney; cervix; liver; microvascular endothelial cell;
glucose uptake modulator; FFA uptake modulator; cell proliferation;
cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage defect; osteoarthritis;
sports injury; proteoglycan; articular cartilage disorder; thalassaemia;
rheumatoid arthritis; haemoglobin-associated disorder; gene mapping;
immune system cell infiltration; chromosome mapping; gene mapping; ss.
gene therapy; chromosome identification; chromosome marker; gene; ss.
OS Homo sapiens.
XX US2003087361-A1.
XX PN 08-MAY-2003.
XX PD 22-APR-2002; 2002US-00127841.
XX PF 09-SEP-1998; 98US-0099536P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032878.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX PA Baker KP, Beresini M, Deforge L, Desnovers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801146/75.
XX P-PSDB; ADC50970.
XX PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
and for manufacturing a medicament for diagnosing or treating tumor.
XX PS Claim 2; Fig 375; 637pp; English.
XX CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or

antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query March	100.0%;	Score 1679;	DB 1;	Length 1679;
Best Local Similarity	100.0%;	Pred. No. 6.7e-05;		
Matches 1679;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0

Qy	1	GTGTGTCCTTCAGCAAAACAGTGATTTAAATCTCTCTTGCA	CAAGCTTGAGAGCAACAC	60
Db	1	GTGTGTCCTTCAGCAAAACAGTGATTTAAATCTCTCTTGCA	CAAGCTTGAGAGCAACAC	60
Qy	61	AATCTATCAGGAAGAAAGAAAGAAACCGAAGCTGACAA	AAAAAGAAAGAAAGAAAG	120
Db	61	AATCTATCAGGAAGAAAGAAAGAAACCGAAGCTGACAA	AAAAAGAAAGAAAGAAAG	120
Qy	121	AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCA	AAATTCATCTCTTTGGGCAAT	180
Db	121	AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCA	AAATTCATCTCTTTGGGCAAT	180
Qy	181	CTTCAGGGGCTGGCTGCTCTGTCTCTTCCAGGAGTGCC	CGCTGCGCAGCGGAGATGC	240
Db	181	CTTCAGGGGCTGGCTGCTCTGTCTCTTCCAGGAGTGCC	CGCTGCGCAGCGGAGATGC	240
Qy	241	CACCTTCCCAAGCTATGGAACAACGTGACCGTCCGG	CCGGGAGAGCGCCACCTCAG	300
Db	241	CACCTTCCCAAGCTATGGAACAACGTGACCGTCCGG	CCGGGAGAGCGCCACCTCAG	300
Qy	301	GTGCATTTGTGAACACCGGCTCACCGGGTGGCTTAA	CCGCGAGCAGCATCTCTTA	360
Db	301	GTGCATTTGTGAACACCGGCTCACCGGGTGGCTTAA	CCGCGAGCAGCATCTCTTA	360
Qy	361	TGCTGGGAATGACAAGTGTGCTCGATCTCTGGGTGCT	TCCTTCTGAGCAACACCCAAAC	420
Db	361	TGCTGGGAATGACAAGTGTGCTCGATCTCTGGGTGCT	TCCTTCTGAGCAACACCCAAAC	420
Qy	421	GCAGTACAGCTGAGATCCGAAACGTGGATGCTGTA	GACGAGGGCCCTTACACCTGCTC	480
Db	421	GCAGTACAGCTGAGATCCGAAACGTGGATGCTGTA	GACGAGGGCCCTTACACCTGCTC	480
Qy	481	GGTGACAGACAACACCCCAAGACCTTAGGGTCCACCT	CAATTTGCAAGTATCTCC	540
Db	481	GGTGACAGACAACACCCCAAGACCTTAGGGTCCACCT	CAATTTGCAAGTATCTCC	540
Qy	541	CAAAATGTAGAGATTTCTTCAGATATCTCCATTAAT	GAAAGGGAACCAATATTAGCTC	600
Db	541	CAAAATGTAGAGATTTCTTCAGATATCTCCATTAAT	GAAAGGGAACCAATATTAGCTC	600
Qy	601	CTGCATAGCAACTGGTGTAGACGAGACCTACGGTTAC	TTTGGAGACACATCTCTCCCAAGC	660
Db	601	CTGCATAGCAACTGGTGTAGACGAGACCTACGGTTAC	TTTGGAGACACATCTCTCCCAAGC	660
Qy	661	GGTTGGCTTTGTGAGTGAAGCAATATTGGAAATTC	AGGGATTCAGGGGACGATC	720
Db	661	GGTTGGCTTTGTGAGTGAAGCAATATTGGAAATTC	AGGGATTCAGGGGACGATC	720
Qy	721	AGGGGACTACGAGTGCAGTGGCTCTCAATGACGTGG	CCGCCGCCCTGGTACGGAGATAA	780

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.

XX Homo sapiens.

XX US2003087362-A1.

XX 08-MAY-2003.

XX 22-APR-2002; 2002US-00127844.

XX 05-JUN-2000; 2000US-0209832P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;

XX WPI; 2003-801147/75.

XX P-PSDB; ADC55497.

XX New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor.

XX Claim 2; Fig 375; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match	100.0%	Score 1679;	DB 1;	Length 1679;
Best Local Similarity	100.0%	Pred. No. 6.7e-05;		
Matches 1679;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy 1	GTGTGTCCTTACGCAAAACAGTGGATTTAAATCTCTCTGTCACAAAGCTTGAGAGCAAC	60		
Db 1	GTGTGTCCTTACGCAAAACAGTGGATTTAAATCTCTCTGTCACAAAGCTTGAGAGCAAC	60		
Qy 61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120		
Db 61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120		
Qy 121	AAGAAAAAATCATGAAAAACCATCCAGCCAAATATGCAAAATATCTATCTCTTTGGGCAAT	180		
Db 121	AAGAAAAAATCATGAAAAACCATCCAGCCAAATATGCAAAATATCTATCTCTTTGGGCAAT	180		
Qy 181	CTTCACGGGCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	240		
Db 181	CTTCACGGGCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	240		
Qy 241	CACCTTCCCAAGCTATGGAACAAAGTACGGTCCGCGAGGGGAGAGCCACCTTCAG	300		
Db 241	CACCTTCCCAAGCTATGGAACAAAGTACGGTCCGCGAGGGGAGAGCCACCTTCAG	300		
Qy 301	GTGCACATTTGACAAACCGGCTCACCCGGTGGCTTAAACCGGAGCAACCTCTCTA	360		
Db 301	GTGCACATTTGACAAACCGGCTCACCCGGTGGCTTAAACCGGAGCAACCTCTCTA	360		
Qy 361	TGCTGGGAATGACAAAGTGGTGGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	420		
Db 361	TGCTGGGAATGACAAAGTGGTGGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	420		
Qy 421	GCAGTACAGCTGAGATCCAGAACGTTGATGATGATGATGATGATGATGATGATGATGATGAT	480		
Db 421	GCAGTACAGCTGAGATCCAGAACGTTGATGATGATGATGATGATGATGATGATGATGATGAT	480		
Qy 481	GGTGCACAGACAAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC	540		
Db 481	GGTGCACAGACAAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC	540		
Qy 541	CAAAATTTGAGAGATTTCTTCAGATATCTCCATTAATTAAGGGGAAACAATATTAGCCTCAC	600		
Db 541	CAAAATTTGAGAGATTTCTTCAGATATCTCCATTAATTAAGGGGAAACAATATTAGCCTCAC	600		
Qy 601	CTGCATAGCAACTGTGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC	660		
Db 601	CTGCATAGCAACTGTGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC	660		
Qy 661	GGTTGGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720		
Db 661	GGTTGGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720		
Qy 721	AGGGGACTACGAGTGCAGTGCCTCCATGACGTGGCGCGCGCGCGCGCGCGCGCGCGCGCG	780		
Db 721	AGGGGACTACGAGTGCAGTGCCTCCATGACGTGGCGCGCGCGCGCGCGCGCGCGCGCGCG	780		
Qy 781	GGTCACCGTGAACATPACCATACATATTCAGAAAGCAAGGGTACAGGTGTCCCGGTGGG	840		
Db 781	GGTCACCGTGAACATPACCATACATATTCAGAAAGCAAGGGTACAGGTGTCCCGGTGGG	840		
Qy 841	ACAAAAGGGGACACTGCAAGTGTGAGGCTCAGCAGTCCCTCAGCAGCAATTCAGAGTGGTA	900		
Db 841	ACAAAAGGGGACACTGCAAGTGTGAGGCTCAGCAGTCCCTCAGCAGCAATTCAGAGTGGTA	900		
Qy 901	CAAGGATGACAAAGACTGTGTTGAAGGAAAGAGGGGTGAAAGTGGAAGCAAGACCTTT	960		
Db 901	CAAGGATGACAAAGACTGTGTTGAAGGAAAGAGGGGTGAAAGTGGAAGCAAGACCTTT	960		
Qy 961	CCTCTCAAAACTCATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	1020		
Db 961	CCTCTCAAAACTCATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	1020		

QY 421 GCAGTACAGATCGAGATCCAGAACGTGGATGTATGATGAGGCGCTTACACCTGCTC 480
Db 421 GCAGTACAGATCGAGATCCAGAACGTGGATGTATGATGAGGCGCTTACACCTGCTC 480
QY 481 GGTGACAGACAAACCCAAAGACCTCTAGGGTCCACCTCATTTGTCAGATATCTCC 540
Db 481 GGTGACAGACAAACCCAAAGACCTCTAGGGTCCACCTCATTTGTCAGATATCTCC 540
QY 541 CAAATTTGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Db 541 CAAATTTGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGCATAGCAACTGGTACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGAGTGAAGAGCAATCTTGAATTCAGGCGATCACC CGGGAGCAGTC 720
Db 661 GGTGGCTTTGAGTGAAGAGCAATCTTGAATTCAGGCGATCACC CGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTCCCTCCCAATGACGTGGCGCGCCCGTGTACGGAGAGTAA 780
Db 721 AGGGGACTACGAGTGCAGTCCCTCCCAATGACGTGGCGCGCCCGTGTACGGAGAGTAA 780
QY 781 GGTACGGTGAATCTCCACATACATTTTCAGAGCCAAAGGTACAGGTGTCCTCCGTGG 840
Db 781 GGTACGGTGAATCTCCACATACATTTTCAGAGCCAAAGGTACAGGTGTCCTCCGTGG 840
QY 841 ACAAAGGGGACACTGAGTGTCAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGAGTGTCAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAGACTGATTAAGAGAAAGGGGTGAAAGTGGAAAAAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGATTAAGAGAAAGGGGTGAAAGTGGAAAAAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTCAATGCTCTGACATGATGAGAACTACACTTGGT 1020
Db 961 CCTCTCAAACTCATCTTCTCAATGCTCTGACATGATGAGAACTACACTTGGT 1020
QY 1021 GGCTTCAAACTGAGTGGGACCAACCAATGCGAGCATCATGCTATTGTTCCAGGGCGCT 1080
Db 1021 GGCTTCAAACTGAGTGGGACCAACCAATGCGAGCATCATGCTATTGTTCCAGGGCGCT 1080
QY 1081 CAGGAGTGAACAAAGGACGTCGAGGAGGAGGCGCTGCTGCTGCTGCTGCTTCT 1140
Db 1081 CAGGAGTGAACAAAGGACGTCGAGGAGGAGGCGCTGCTGCTGCTGCTGCTTCT 1140
QY 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGTGATGAGTGCACCTTCCCGCCCGGAAAGCT 1200
Db 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGTGATGAGTGCACCTTCCCGCCCGGAAAGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
Db 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
QY 1261 TATACAAATGAATTAAGAAACACAGCCTCATGAGGACAGAAATTTAGGAGGGGAAAC 1320
Db 1261 TATACAAATGAATTAAGAAACACAGCCTCATGAGGACAGAAATTTAGGAGGGGAAAC 1320
QY 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACATGAGTGTCTTTTCCAAACGGGAAAGAACACAGACACACCGGCTTGA 1440
Db 1381 TTTAGGTACATGAGTGTCTTTTCCAAACGGGAAAGAACACAGACACACCGGCTTGA 1440
QY 1441 CCACCTGCAAGTGCATGCTGCAACCTTTTGGTGGCAAGTGTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCACCTGCAAGTGCATGCTGCAACCTTTTGGTGGCAAGTGTGGGCAAGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGGCCCCACGTCGGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560

Db 1501 TCTGCCACAGAGTGGCCCCACGTCGGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACAAACAGAAATGAGACCTTCGCGCCCAAGCGTGGCGTGGGCACTTTG 1620
Db 1561 GTCCATAGAGACAAACAGAAATGAGACCTTCGCGCCCAAGCGTGGCGTGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCGCGTGTGTGTAACAGTGAATAAAAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGCGTGTGTGTAACAGTGAATAAAAAAGAGCAAAAAA 1679
RESULT 51
ADCS3555
ID ADCS3555 standard; cDNA; 1679 BP.
XX
AC ADCS3555;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein cDNA Seq ID375.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophin; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
PN US2003087364-A1.
XX
PD 08-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128688.
XX
PR 09-FEB-1999; 99US-0119341P.
PR 01-DEC-1999; 99WO-US028634.
PR 01-DEC-2000; 2000WO-US032878.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerlesen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801149/75.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.
XX
PS Claim 2; SEQ ID NO 375; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
and transmembrane proteins. Extracellular proteins play important roles
in the formation, differentiation and maintenance of multicellular
organisms. The fate of many individual cells (for example proliferation,
migration or differentiation) is typically governed by information
received from other cells and the immediate environment. The information
is often transmitted by secreted polypeptides (for example mitogenic
factors, survival factors, cytotoxic factors, differentiation factors,
neuropeptides or hormones) which are received and interpreted by diverse
cell receptors or membrane bound proteins. These membrane bound proteins
as in the blocking of receptor-ligand interactions. The current invention
provides the amino acid sequences of novel human membrane bound receptors
and proteins, along with the cDNA sequences encoding them. The novel
proteins of the invention may have cytostatic activities through the
stimulation of chondrocytes. The nucleic acids of the invention may be
useful for the manufacture of a medicament for diagnosing or treating a
tumour in a mammal. In addition, they may be useful for measuring or

CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.

XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60
DB 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAATCCAGCCAAATGCAAAATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAATCCAGCCAAATGCAAAATCTATCTCTTGGGCAAT 180
QY 181 CTTACGGGGTGGTGTCTGTCTCTTTCAGAGAGTGCCGTGCGAGCGGAGATGC 240
DB 181 CTTACGGGGTGGTGTCTGTCTCTTTCAGAGAGTGCCGTGCGAGCGGAGATGC 240
QY 241 CACCTTCCCAAAGCTATGGCAACAGTGCAGCGTCCGCGAGGGGAGAGCCACCTCAG 300
DB 241 CACCTTCCCAAAGCTATGGCAACAGTGCAGCGTCCGCGAGGGGAGAGCCACCTCAG 300
QY 301 GTGCACTATTGCAACACCGGGTCAACCGGGTGGCTGGCTAAACCGAGACCAATCTCTTA 360
DB 301 GTGCACTATTGCAACACCGGGTCAACCGGGTGGCTGGCTAAACCGAGCACCATCTCTTA 360
QY 361 TGCTGGGAATGACAAGTGGTCCCTGGATCCCTGGTGGTCTCTGAGCAACACCCAAAC 420
DB 361 TGCTGGGAATGACAAGTGGTCCCTGGATCCCTGGTGGTCTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTTGGATGTGTATGACAGGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTTGGATGTGTATGACAGGGGCCCTTACACCTGCTC 480
QY 481 GGTGACAGACAGACACACCAAGACCTCTAGAGTCCACCTCATTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGACACCAAGACCTCTAGAGTCCACCTCATTGTGCAAGTATCTCC 540
QY 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAAATATTAGCCTCAC 600
DB 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAAATATTAGCCTCAC 600
QY 601 CTGCATAGCACTGGTAGACAGAGCTTACGTTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCACTGGTAGACAGAGCTTACGTTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
QY 721 AGGGGACTACAGTGCAGTCTCCATGACGTGGCGCGCCGCTGTGAGAGATGAAA 780
DB 721 AGGGGACTACAGTGCAGTCTCCATGACGTGGCGCGCCGCTGTGAGAGATGAAA 780
QY 781 GGTCAACCGTGAACATATCACCATATCTTCAGAGACCAAGGTTACAGGTGTCCCGTGGG 840
DB 781 GGTCAACCGTGAACATATCACCATATCTTCAGAGACCAAGGTTACAGGTGTCCCGTGGG 840
QY 841 ACAGAGGGGACATGAGGTGTGAGCTCAGAGTCCCTCAGCAGAAATCCAGTGTGA 900
DB 841 ACAGAGGGGACATGAGGTGTGAGCTCAGAGTCCCTCAGCAGAAATCCAGTGTGA 900
QY 901 CAAGGATGACAAAAGACTGATTGAGGAAAGAAAAGGGGTGAAAGTGGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAAGACTGATTGAGGAAAGAAAAGGGGTGAAAGTGGAAACAGACCTTT 960
```

RESULT 52

ADC59078

ID ADC59078 standard; cDNA; 1679 BP.

XX

AC

AC

XX

DT

18-DEC-2003 (first entry)

XX

DE

Novel human secreted and transmembrane protein cDNA Seq ID375.

XX

KW

human; PRO; membrane bound protein; membrane bound receptor;

KW

cell proliferation; cell migration; cell differentiation;

KW

mitogenic factor; survival factor; cytotoxic factor;

KW

differentiation factor; neurotrophin; hormone; cell receptor;

KW

receptor-ligand interaction; cytoskeletal; tumour; ss; gene.

XX

OS

Homo sapiens.

XX

XX

US2003087359-A1.

XX

08-MAY-2003.

XX

22-APR-2002; 2002US-00127834.

XX 17-SEP-1998; 98US-0100710P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1998; 98US-00403297.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
 PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S,
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-801144/75.
 DR P-PSDB; ADC59079.
 XX
 PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
 PT and for manufacturing a medicament for diagnosing or treating tumor.
 XX
 PS Claim 2; SEQ ID NO 375; 637pp; English.
 XX
 CC This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neuropeptides or hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTTGTCTCTTTCAGCAAAACAGTGGATTAAATCTCTTGTGCAAGCTTGAGAGCAAC 60
 DB 1 GTTGTCTCTTTCAGCAAAACAGTGGATTAAATCTCTTGTGCAAGCTTGAGAGCAAC 60
 QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 QY 121 AAGAAAAAAATCATGAAAAACCATCAGCCAAAAATGCACAAATCTATCTCTTGGGCAAT 180
 DB 121 AAGAAAAAAATCATGAAAAACCATCAGCCAAAAATGCACAAATCTATCTCTTGGGCAAT 180
 QY 181 CTTTCAGGGGCTGGTGTCTGTCTGTCTTCTTCAAGAGTGCCCGTGCAGCGAGATGC 240
 DB 181 CTTTCAGGGGCTGGTGTCTGTCTGTCTTCTTCAAGAGTGCCCGTGCAGCGAGATGC 240
 QY 241 CACCTTCCCAAGCTATGACAAAGTACGGTCCGGCAGGGGGAGAGCGCCCTCAG 300
 DB 241 CACCTTCCCAAGCTATGACAAAGTACGGTCCGGCAGGGGGAGAGCGCCCTCAG 300
 QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTGGCTAAACCGCAGCAACATCTCTTA 360
 DB 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTGGCTAAACCGCAGCAACATCTCTTA 360

QY 361 TGCTGGGAATGACAAGTGGTGCTTGGATCCTCGCTGGTCTCTTCTGAGCAACACCCAAAC 420
 DB 361 TGCTGGGAATGACAAGTGGTGCTTGGATCCTCGCTGGTCTCTTCTGAGCAACACCCAAAC 420
 QY 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
 DB 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
 QY 481 GGTGCGACAGACAACCCCAAGACCTCTAGGTTCCACCTCATTTGTGCAAGTATCTCC 540
 DB 481 GGTGCGACAGACAACCCCAAGACCTCTAGGTTCCACCTCATTTGTGCAAGTATCTCC 540
 QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
 DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
 QY 601 CTGCATAGCAACTGCTAGACAGAGCTTACGTTACTTTGGAGACACATCTCTCCAAAGC 660
 DB 601 CTGCATAGCAACTGCTAGACAGAGCTTACGTTACTTTGGAGACACATCTCTCCAAAGC 660
 QY 661 GGTGTGGCTTTGTGAGTGAAGACCAATACCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
 DB 661 GGTGTGGCTTTGTGAGTGAAGACCAATACCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
 QY 721 AGGGGACTACGAGTGCAGTCCCTCCAAATGACGTGGCGCGCCCTGGTACGAGAGTAAA 780
 DB 721 AGGGGACTACGAGTGCAGTCCCTCCAAATGACGTGGCGCGCCCTGGTACGAGAGTAAA 780
 QY 781 GGTTCACCGTGAATCTCCACCATACATATTCAGAAAGCAAGGGTACAGGTGTCCCGTGGG 840
 DB 781 GGTTCACCGTGAATCTCCACCATACATATTCAGAAAGCAAGGGTACAGGTGTCCCGTGGG 840
 QY 841 ACAAAAGGGAACACTGCAAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
 DB 841 ACAAAAGGGAACACTGCAAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
 QY 901 CAAGGATGACAAAGACTGATTCAAGGAAAGAAAGGSGTGAAAGTGGAAGACAGACTTT 960
 DB 901 CAAGGATGACAAAGACTGATTCAAGGAAAGAAAGGSGTGAAAGTGGAAGACAGACTTT 960
 QY 961 CTTCTCAAAACTCATCTTCTTCAATCTCTGTAACATGACTATGGAACATACACTTTCGCT 1020
 DB 961 CTTCTCAAAACTCATCTTCTTCAATCTCTGTAACATGACTATGGAACATACACTTTCGCT 1020
 QY 1021 GGCTCCCAACAGCTGGGCCACACCAATCCAGCATCATGCTATTTGGTCCAGGCCCGT 1080
 DB 1021 GGCTCCCAACAGCTGGGCCACACCAATCCAGCATCATGCTATTTGGTCCAGGCCCGT 1080
 QY 1081 CAGCGAGGTGAGCAACGGCAACGGTCCGAGGAGGGCAGGCTGCGTCTGCTGCTCTTCT 1140
 DB 1081 CAGCGAGGTGAGCAACGGCAACGGTCCGAGGAGGGCAGGCTGCGTCTGCTGCTCTTCT 1140
 QY 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGTGTGAGTGCACCTCCCAACCCGGGAAAGCT 1200
 DB 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGTGTGAGTGCACCTCCCAACCCGGGAAAGCT 1200
 QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
 DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
 QY 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGCGGACAGAAATTTGAGGAGGGGAAC 1320
 DB 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGCGGACAGAAATTTGAGGAGGGGAAC 1320
 QY 1321 AAGAAATATCTTTGGGGGAAAGAGTTTTTAAAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
 DB 1321 AAGAAATATCTTTGGGGGAAAGAGTTTTTAAAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
 QY 1381 TTTAGGTACAAATGGAGTTTTTCTTTTCCAAAACGGGAGAAACACAGCACACCCGGCTTGA 1440
 DB 1381 TTTAGGTACAAATGGAGTTTTTCTTTTCCAAAACGGGAGAAACACAGCACACCCGGCTTGA 1440

Qy 1441 CCCACTGACAGCTGATCGTGCAACCTCTTTGGTGGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTGGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCGCCACAGCTGGGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCGCCACAGCTGGGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Qy 1561 GTCCATAGACGACGACAGATGACACCTTCGGGCCAAGCGTGGCGTGGGGCACTTTTG 1620
Db 1561 GTCCATAGACGACGACAGATGACACCTTCGGGCCAAGCGTGGCGTGGGGCACTTTTG 1620
Qy 1621 GTAGACTGTGCCACACAGCGGTGTGTGTGAACCTGCAAAATATAAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACACAGCGGTGTGTGTGAACCTGCAAAATATAAAGAGCAAAAAAAA 1679

RESULT 53
ID ADCS5956 standard; cDNA; 1679 BP.
AC ADCS5956;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein cDNA Seq ID375.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuroepithelial; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
PN US2003087360-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127836.
XX
PR 17-NOV-1998; 98US-0108802P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI: 2003-801145/75.
DR P-PSDB; ADCS5957.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; SEQ ID NO 375; 637pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted
XX and transmembrane proteins. Extracellular proteins play important roles
XX in the formation, differentiation and maintenance of multicellular
XX organisms. The rate of many individual cells (for example proliferation,
XX migration or differentiation) is typically governed by information
XX received from other cells and the immediate environment. The information
XX is often transmitted by secreted polypeptides (for example mitogenic
XX factors, survival factors, cytotoxic factors, differentiation factors,
XX neurotrophins and hormones) which are received and interpreted by diverse

CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGTCCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60
Db 1 GTTGTGTCCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAACCCGAAACCTGCACAAAAAGAGAAAAAGAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAACCCGAAACCTGCACAAAAAGAGAAAAAGAG 120
Qy 121 AAGAAAAAATCATGAAACCATCCAGCCAAATATGCAATATCTCTCTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAACCATCCAGCCAAATATGCAATATCTCTCTGGGCAAT 180
Qy 181 CTTACGGGGTGGTGTCTGTCTCTTCCAAAGAGTGGCCCTGCGGAGGAGATGC 240
Db 181 CTTACGGGGTGGTGTCTGTCTCTTCCAAAGAGTGGCCCTGCGGAGGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGACAGCTGACGCTCCGCGAGGGGAGAGCGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGACAGCTGACGCTCCGCGAGGGGAGAGCGCCACCTCAG 300
Qy 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGCAATCTCTTA 360
Db 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGCAATCTCTTA 360
Qy 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCTGCGTGGTCTCTGTGAGCAACCCAAAC 420
Db 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCTGCGTGGTCTCTGTGAGCAACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACGTTGATGTATGACGAGGGCCCTTACACTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACGTTGATGTATGACGAGGGCCCTTACACTGCTC 480
Qy 481 GGTGAGACAGACACACACCCAGAGCTCTAGGCTCCACCTCATTTGTCAGATATCTCC 540
Db 481 GGTGAGACAGACACACACCCAGAGCTCTAGGCTCCACCTCATTTGTCAGATATCTCC 540
Qy 541 CAAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Db 541 CAAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Qy 601 CTGCAATGCACTGCTAGACAGGACCTACCGTTACTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCAATGCACTGCTAGACAGGACCTACCGTTACTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGCGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Db 661 GGTGCGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTCACTGCTCCATGAGCTGGCCGCGCGCTGGTACGGAGAGTAA 780
Db 721 AGGGGACTACGAGTCACTGCTCCATGAGCTGGCCGCGCGCTGGTACGGAGAGTAA 780
Qy 781 GGTGCGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 840

241 QY CACCTTCCCAAGCTATGACAACTGACGGTCCGGCAGGGGAGAGCGCCACCTCTAG 300
241 Db CACCTTCCCAAGCTATGACAACTGACGGTCCGGCAGGGGAGAGCGCCACCTCTAG 300
301 QY GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
301 Db GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
361 QY TGCTGGGAATGACAAAGTGGTCCCTGATCTCTCGCTGGTCTCTCTGAGCAACACCCAAAC 420
361 Db TGCTGGGAATGACAAAGTGGTCCCTGATCTCTCGCTGGTCTCTCTGAGCAACACCCAAAC 420
421 QY GCAGTACAGCATCGAGATCCAGAACTGGGATGTGTATGACAGGGGCCCTTACACCTGTCTC 480
421 Db GCAGTACAGCATCGAGATCCAGAACTGGGATGTGTATGACAGGGGCCCTTACACCTGTCTC 480
481 QY GGTGACAGACAGAAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
481 Db GGTGACAGACAGAAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
541 QY CAAAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
541 Db CAAAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
601 QY CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
601 Db CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
661 QY GGTGCGCTTTGTGAGTGAAGACGAACTACTTGGAAATTCAGGGCATCACCGGAGCAGTC 720
661 Db GGTGCGCTTTGTGAGTGAAGACGAACTACTTGGAAATTCAGGGCATCACCGGAGCAGTC 720
721 QY AGGGGACTACGAGTGCAGTCCCTCAATGACGTGGCGCGCCCGTGTAGCGGAGATAA 780
721 Db AGGGGACTACGAGTGCAGTCCCTCAATGACGTGGCGCGCCCGTGTAGCGGAGATAA 780
781 QY GGTCAACGCTGACATCCACATACATTTTCAAGCCCAAGGGTACAGGTGTCCTCCCTGGG 840
781 Db GGTCAACGCTGACATCCACATACATTTTCAAGCCCAAGGGTACAGGTGTCCTCCCTGGG 840
841 QY ACAAAGGGGACACTGACAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
841 Db ACAAAGGGGACACTGACAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
901 QY CAAGGATGACAAAGACTGTATGAGGAAAGAGGGTGAAGTGAAGGAAACAGACCTTT 960
901 Db CAAGGATGACAAAGACTGTATGAGGAAAGAGGGTGAAGTGAAGGAAACAGACCTTT 960
961 QY CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGGCT 1020
961 Db CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGGCT 1020
1021 QY GGCCTCCAAAGCTGGGCCACCAATGCGCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1021 Db GGCCTCCAAAGCTGGGCCACCAATGCGCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1081 QY CAGCGAGTGAACAAACGGCAGCTCGAGGAGGAGGCTGGCTGTGGCTGCTCTTCT 1140
1081 Db CAGCGAGTGAACAAACGGCAGCTCGAGGAGGAGGCTGGCTGTGGCTGCTCTTCT 1140
1141 QY GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCCTTCCCAACCGGAAAGGCT 1200
1141 Db GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCCTTCCCAACCGGAAAGGCT 1200
1201 QY GCCGCCACCAACCAACCAACAGCAATGCGCAACCGCAGCAACCAATCATAGATA 1260
1201 Db GCCGCCACCAACCAACCAACAGCAATGCGCAACCGCAGCAACCAATCATAGATA 1260
1261 QY TATACAAATGAATTAAGAGAAACACAGCTCTATGGGACAGAAATTTGAGGAGGGGAAC 1320
1261 Db TATACAAATGAATTAAGAGAAACACAGCTCTATGGGACAGAAATTTGAGGAGGGGAAC 1320
1321 QY AAGAAATCTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTTCAGATA 1380

RESULT 55

ADC47197

ID ADC47197 standard; cDNA; 1679 BP.

XX AC ADC47197;

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
vulnary; antiarthritic; pericyte cell proliferation;
XX KW pericyte cell differentiation; chondrocyte cell proliferation;
XX KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
(TNF)-alpha release; dermal fibroblast cell proliferation; lung tumour;
XX KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
XX KW colon tumour; breast tumour; prostate tumour; rectal tumour;
XX KW liver tumour; tissue typing; chromosome mapping; gene mapping;
gene therapy.

XX OS Homo sapiens.

XX PN US2003105288-A1.

XX PD 05-JUN-2003.

XX PF 13-AUG-2002; 2002US-00219070.

XX PR 25-JUL-2000; 2000US-0220666P.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Deanyers L, Gerritsen WE, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WT;

XX DR WPI; 2003-801246/75.

XX DR P-PSDB; ADC47198.

XX PT New isolated nucleic acid encoding a secreted and transmembrane

XX PT polypeptide (PRO), for use in recombinantly producing a PRO polypeptide,
as a hybridization probe, and in gene therapy.

XX XX Claim 2; Fig 125; 308pp; English.

XX CC The invention describes an isolated PRO (secreted and transmembrane)

XX CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are

useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO329, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood. PRO382, PRO357, PRO725, PRO1306, PRO1419, PRO214, PRO247, PRO337, PRO526, PRO363, PRO533, PRO1083, PRO840, PRO1080, PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412, PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1340, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567, PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322, PRO9840, PRO6079, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells. PRO181, PRO329, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, PRO5723, PRO5715, or PRO7425 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 GTTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCCTGCGCAAGCTTGAGGCAACAC 60
DB |||||||
QY 1 GTTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCCTGCGCAAGCTTGAGGCAACAC 60
DB |||||||
QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB |||||||
QY 121 AAGAAAGAAATCATGAAACATCCAGCCAAATGCAATTTCTCTCTTGGGCAT 180
DB |||||||
QY 121 AAGAAAGAAATCATGAAACATCCAGCCAAATGCAATTTCTCTCTTGGGCAT 180
DB |||||||
QY 181 CTTTCAGGGGCTGGCTGCTGTGTCTCTTCCAAAGAGTGCCCGTGGCAGGGAGATGC 240
DB |||||||
QY 181 CTTTCAGGGGCTGGCTGCTGTGTCTCTTCCAAAGAGTGCCCGTGGCAGGGAGATGC 240
DB |||||||
QY 241 CACCTTCCCAAGCTATGAGCAACGTGACGGTCCGGCGAGGGGAGCGCCACCTCTGAG 300
DB |||||||
QY 241 CACCTTCCCAAGCTATGAGCAACGTGACGGTCCGGCGAGGGGAGCGCCACCTCTGAG 300
DB |||||||
QY 301 GTGCACATTTGACAAACCGGTACCCTGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
DB |||||||
QY 301 GTGCACATTTGACAAACCGGTACCCTGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
DB |||||||
QY 361 TGTGGGAATGACAAAGTGGTGGATCTCTGGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 420
DB |||||||
QY 361 TGTGGGAATGACAAAGTGGTGGATCTCTGGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 420
DB |||||||
QY 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGACGGGGCCCTTACACCTGTCTC 480
DB |||||||
QY 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGACGGGGCCCTTACACCTGTCTC 480
DB |||||||
QY 481 GGTGCAGACACACACCAACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB |||||||
```


XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 375; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human macrovascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTCTTGTGACAAAGCTTGAGAGCAAC 60
DB 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTCTTGTGACAAAGCTTGAGAGCAAC 60

QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

QY 121 AAGAAAAAAATCATGAAACCAATCAGGCCAAATATGCAATCTCTCTTGGGCAAT 180
DB 121 AAGAAAAAAATCATGAAACCAATCAGGCCAAATATGCAATCTCTCTTGGGCAAT 180

QY 181 CTTTACGGGGCTGGTGTCTGTGTCTCTTCAAGAGAGTGCCGTGCGAGCGGAGATGC 240
DB 181 CTTTACGGGGCTGGTGTCTGTGTCTCTTCAAGAGAGTGCCGTGCGAGCGGAGATGC 240

QY 241 CACCTTCCCAAGCTATGAGCAAAAGTACGAGTTCGGGAGGGGAGCGCCACCTTCAG 300
DB 241 CACCTTCCCAAGCTATGAGCAAAAGTACGAGTTCGGGAGGGGAGCGCCACCTTCAG 300

QY 301 GTGCACTATTGACAAACCGGCTCACCGGGTGGCTGGCTTAACCCGAGCAACCTCTCTA 360
DB 301 GTGCACTATTGACAAACCGGCTCACCGGGTGGCTGGCTTAACCCGAGCAACCTCTCTA 360

QY 361 TCGTGGGATGCAAGTGTGCTGTGATCTCTCGCTGGTCTCTTCTGAGCAACCCCAAC 420

DB 361 TCGTGGGATGCAAGTGTGCTGTGATCTCTCGCTGGTCTCTTCTGAGCAACCCCAAC 420

QY 421 GCAGTACAGCATCGAGATCCAGAACTGATGTATGATGACAGGGCCCTTACACCTGTCTC 480

DB 421 GCAGTACAGCATCGAGATCCAGAACTGATGTATGATGACAGGGCCCTTACACCTGTCTC 480

QY 481 GGTGCAGACAGCAACACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

DB 481 GGTGCAGACAGCAACACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

QY 541 CAAAAATTTAGAGATTTCTTTCAGATATCTCCATTTAATGAAGGAAACAATATTAGCCTCAC 600

DB 541 CAAAAATTTAGAGATTTCTTTCAGATATCTCCATTTAATGAAGGAAACAATATTAGCCTCAC 600

QY 601 CTCATAGCACTGTGTAGACAGAGCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660

DB 601 CTCATAGCACTGTGTAGACAGAGCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660

QY 661 GGTGTGGCTTTGTGAGTGAAGACGAATPACTTGGAAATTCAGGGCATCACCGGAGCAGTC 720

DB 661 GGTGTGGCTTTGTGAGTGAAGACGAATPACTTGGAAATTCAGGGCATCACCGGAGCAGTC 720

QY 721 AGGGGACTAGTGTGAGTGTCTTCAATGACGTGGCGCGCGCGCTGTGTAGGAGATAA 780

DB 721 AGGGGACTAGTGTGAGTGTCTTCAATGACGTGGCGCGCGCGCTGTGTAGGAGATAA 780

QY 781 GGTTCACCGTGAATCTCCACCATACATTTTCAAGGCAAGGGTACAGGTGTCCCGGTGG 840

DB 781 GGTTCACCGTGAATCTCCACCATACATTTTCAAGGCAAGGGTACAGGTGTCCCGGTGG 840

QY 841 AAAAAAGGACACTGAGTGTGAGCTTCAAGCTTCAAGCTTCCCTCAGCAGAAATTCAGTGTGA 900

DB 841 AAAAAAGGACACTGAGTGTGAGCTTCAAGCTTCAAGCTTCCCTCAGCAGAAATTCAGTGTGA 900

QY 901 CAAGGATGACAAAGACTGATTTCAAGGAAAGAGGGTGAAGAGTGGAAAAACAGACCTTT 960

DB 901 CAAGGATGACAAAGACTGATTTCAAGGAAAGAGGGTGAAGAGTGGAAAAACAGACCTTT 960

QY 961 CTTCTCAAACTCATTTCTTCAATCTCTCTGAAATGACTATGGGAACTACACTTGGCT 1020

DB 961 CTTCTCAAACTCATTTCTTCAATCTCTCTGAAATGACTATGGGAACTACACTTGGCT 1020

QY 1021 GGCTTCCCAAGCTGGGCAACCAATGCCAGCATCATGCTATTTGGTCCAGGGCCCGT 1080

DB 1021 GGCTTCCCAAGCTGGGCAACCAATGCCAGCATCATGCTATTTGGTCCAGGGCCCGT 1080

QY 1081 CAGCGAGGTGAGCAACCGGACAGTGCAGAGGGGAGGCTGCTGTGCTGTCTCTTCT 1140

DB 1081 CAGCGAGGTGAGCAACCGGACAGTGCAGAGGGGAGGCTGCTGTGCTGTCTCTTCT 1140

QY 1141 GGTCTTGCACCTGCTTCAAAATTTTGTGATGTGAGTGCACCTTCCCAACCGGGAAGGCT 1200

DB 1141 GGTCTTGCACCTGCTTCAAAATTTTGTGATGTGAGTGCACCTTCCCAACCGGGAAGGCT 1200

QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260

DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260

QY 1261 TATACAAATGAATATGAGAGAAACACAGCTTCAATGGGACAGAAATTTGAGGGAGGGGAAC 1320

DB 1261 TATACAAATGAATATGAGAGAAACACAGCTTCAATGGGACAGAAATTTGAGGGAGGGGAAC 1320

QY 1321 AAGAAATACTTTTGGGGGAAAGAGTGTAAAAAAGAAATTTGAAATTTGCTTTGCAGATA 1380

DB 1321 AAGAAATACTTTTGGGGGAAAGAGTGTAAAAAAGAAATTTGAAATTTGCTTTGCAGATA 1380

QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAAACCGGGAAGAAACACAGCACACCCGGCTTGA 1440

DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAAACCGGGAAGAAACACAGCACACCCGGCTTGA 1440

QY 1441 CCCACTGCAAGCTGCAATCGTGTGCAACCTCTTTGTGTGCAAGTGTGGGCAAGGGCTCACGCTC 1500

DB 1441 CCCACTGCAAGCTGCAATCGTGTGCAACCTCTTTGTGTGCAAGTGTGGGCAAGGGCTCACGCTC 1500


```
QY 781 GGTCAACCGTGAACATATCCACCATACATTTTCAGAACGCAAGGTTACAGGTGTCCTCCGTTGGG 840
Db 781 GGTCAACCGTGAACATATCCACCATACATTTTCAGAACGCAAGGTTACAGGTGTCCTCCGTTGGG 840
QY 841 ACAAAGGGGACACTGTCAGTGTGAAGCTTCAGCATGCCCTCCAGCAGAAATTCAGTGTGTA 900
Db 841 ACAAAGGGGACACTGTCAGTGTGAAGCTTCAGCATGCCCTCCAGCAGAAATTCAGTGTGTA 900
QY 901 CAAGGATGACAAAGACATGATTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTTT 960
Db 901 CAAGGATGACAAAGACATGATTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTTT 960
QY 961 CTTCTCAAAATCATCTCTTCTTCAATGTCTCTGAAATCATGATATGCGAACTACCTTGGT 1020
Db 961 CTTCTCAAAATCATCTCTTCTTCAATGTCTCTGAAATCATGATATGCGAACTACCTTGGT 1020
QY 1021 GGCCTCCACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGTCAGGCGCGCT 1080
Db 1021 GGCCTCCACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGTCAGGCGCGCT 1080
QY 1081 CAGCGAGTGTGACCAAGCGCACCTGCGAGGAGGCGCTGCTGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGTGACCAAGCGCACCTGCGAGGAGGCGCTGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAATTTTGTGATGTCAGTGCACCTTCCCGACCGGAAAGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAATTTTGTGATGTCAGTGCACCTTCCCGACCGGAAAGCT 1200
QY 1201 GCGCGCACCAACACCAACCAACCAAGCAATGCGCAACACCGACCAACCAATCAGATA 1260
Db 1201 GCGCGCACCAACACCAACCAACCAAGCAATGCGCAACACCGACCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGGAC 1320
Db 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGGAC 1320
QY 1321 AAAGATATCTTTGGGGGAAAGAGTTTTTAAAGAAAGAAATTTGAAATTCGCTTGCAGATA 1380
Db 1321 AAAGATATCTTTGGGGGAAAGAGTTTTTAAAGAAAGAAATTTGAAATTCGCTTGCAGATA 1380
QY 1381 TTATGATCAATGGAGTTTCTTTTCCCAAGCGGAAAGCAACAGACACCGCGGTTGGA 1440
Db 1381 TTATGATCAATGGAGTTTCTTTTCCCAAGCGGAAAGCAACAGACACCGCGGTTGGA 1440
QY 1441 CCACCTGCAAGTGCATGTCGCAACTCTTTGTCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCACCTGCAAGTGCATGTCGCAACTCTTTGTCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACAGTGGAAATTTCTGGAGTGGCCATGCCAAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACAGTGGAAATTTCTGGAGTGGCCATGCCAAATTCATCA 1560
QY 1561 GTCCATAGACGACAGATGAGCTTCCGGCCCGAGCGTGGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGACGACAGATGAGCTTCCGGCCCGAGCGTGGCGTGGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCGCGGTGTGTGTGAACGTGAATATAAAGACCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGCGGTGTGTGTGAACGTGAATATAAAGACCAAAAAA 1679

RESULT 58
ID ADC69611
XX standard; cDNA; 1679 BP.
AC ADC69611;
XX
XX
DT 01-JAN-2004 (first entry)
XX cDNA encoding human PRO polypeptide #188.
DE Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
```

```
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone formation; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
XX
EN US2003194770-A1.
XX
PD 16-OCT-2003.
XX
XX 21-MAY-2002; 2002US-00152375.
XX
XX 03-MAR-2000; 2000US-0187202P.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Deanoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-844453/78.
XX P-PSDB; ADC69612.
XX
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for the diagnosis, prevention and/or treatment of tumors,
XX such as lung, colon, breast, prostate, rectal, cervical and/or liver
XX tumors.
XX
XX Claim 2; Fig 375; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or PFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems, PRO
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence encodes a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format from
XX the USPTO website at seqdata.uspto.gov.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
```

Query Match				100.0%;	Score 1679;	DB 1;	Length 1679;
Best Local Similarity				100.0%;	Pred. No. 6.7e-05;		
Matches 1679;				Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	GTTCGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAGCTTGAGAGCAACAC	60				
Db	1	GTTCGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAGCTTGAGAGCAACAC	60				
Qy	61	AATCTATCAGAAAGAAAGAAAGAAACCGACCTGACAAAGAAAGAAAGAAAG	120				
Db	61	AATCTATCAGAAAGAAAGAAAGAAACCGACCTGACAAAGAAAGAAAGAAAG	120				
Qy	121	AAGAAAAAATCATGAAAAATCATCCAGCCAAATAATGCAAAATCTATCTCTTGGGCAAT	180				
Db	121	AAGAAAAAATCATGAAAAATCATCCAGCCAAATAATGCAAAATCTATCTCTTGGGCAAT	180				
Qy	181	CTTCACGGGGTGGCTGCTGCTGCTCTCTCTCCAGAGAGTGCCGTCGCGAGCGAGATGC	240				
Db	181	CTTCACGGGGTGGCTGCTGCTGCTCTCTCTCCAGAGAGTGCCGTCGCGAGCGAGATGC	240				
Qy	241	CACCTTCCCAAGCTATGGACAACAGTGAACGCTCCGGCAGGGGAGAGCGCCACCTCAG	300				
Db	241	CACCTTCCCAAGCTATGGACAACAGTGAACGCTCCGGCAGGGGAGAGCGCCACCTCAG	300				
Qy	301	GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATTCTCTA	360				
Db	301	GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATTCTCTA	360				
Qy	361	TGCTGGGAATGACAAAGTGGTGGCTGGATCTCGGTGGTCTCTCTGAGCAACACCCAAAC	420				
Db	361	TGCTGGGAATGACAAAGTGGTGGCTGGATCTCGGTGGTCTCTCTGAGCAACACCCAAAC	420				
Qy	421	GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGAAGAGGGCCCTTACACCTGCTC	480				
Db	421	GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGAAGAGGGCCCTTACACCTGCTC	480				
Qy	481	GGTGACAGACACACACACACCTAGAGCTCCAGCTCCTCCTCCTGAGCAACACCTCTCC	540				
Db	481	GGTGACAGACACACACACACCTAGAGCTCCAGCTCCTCCTCCTGAGCAACACCTCTCC	540				
Qy	541	CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAAACAAATATTAGCTTCAC	600				
Db	541	CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAAACAAATATTAGCTTCAC	600				
Qy	601	CTGCATAGCACTGGTAGACAGAGCTTACGTTTACTTGGAGACACATCTCTCCAAAGC	660				
Db	601	CTGCATAGCACTGGTAGACAGAGCTTACGTTTACTTGGAGACACATCTCTCCAAAGC	660				
Qy	661	GTTTGGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720				
Db	661	GTTTGGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720				
Qy	721	AGGGGACTACGAGTGCAGTCTCCATGACGTGGCGCCGCGCTGGTAGGAGATGATAA	780				
Db	721	AGGGGACTACGAGTGCAGTCTCCATGACGTGGCGCCGCGCTGGTAGGAGATGATAA	780				
Qy	781	GTCACCGTGAACATATCCACCATACATTTTCAAGAACCAAGGGTACAGGTGTCCCGTGGG	840				
Db	781	GTCACCGTGAACATATCCACCATACATTTTCAAGAACCAAGGGTACAGGTGTCCCGTGGG	840				
Qy	841	ACAAAAGGGGACATGCGAGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA	900				
Db	841	ACAAAAGGGGACATGCGAGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA	900				
Qy	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT	960				
Db	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT	960				
Qy	961	CCTCTCAAAAATCTATCTTCTTCAATGTCTCTGAAACATGACATATGGGAATCTACCTTCGT	1020				
Db	961	CCTCTCAAAAATCTATCTTCTTCAATGTCTCTGAAACATGACATATGGGAATCTACCTTCGT	1020				

Qy	1021	GGCCTCCAAACAGCTGGGCCACACAATGCCAGCATCATGCTATTGCTCAGGCGCGT	1080
Db	1021	GGCCTCCAAACAGCTGGGCCACACAATGCCAGCATCATGCTATTGCTCAGGCGCGT	1080
Qy	1081	CAGCAGGTGAGCAACCGCACGTCGAGAGGCGAGGTGCGTCTGGCTGCTCTTCT	1140
Db	1081	CAGCAGGTGAGCAACCGCACGTCGAGAGGCGAGGTGCGTCTGGCTGCTCTTCT	1140
Qy	1141	GTCCTTGCACCTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCAACCGGGGAAAGCT	1200
Db	1141	GTCCTTGCACCTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCAACCGGGGAAAGCT	1200
Qy	1201	GGCGCCACCAACCAACCAACCAACAGCAATGCAACACCGACAGCAACCAATCAGATA	1260
Db	1201	GGCGCCACCAACCAACCAACCAACAGCAATGCAACACCGACAGCAACCAATCAGATA	1260
Qy	1261	TATACAAATGAATTTAGAGAAACACACGCTCATGGGACAGAAATTTGAGGAGGGGAAAC	1320
Db	1261	TATACAAATGAATTTAGAGAAACACACGCTCATGGGACAGAAATTTGAGGAGGGGAAAC	1320
Qy	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCCTTGCAGATA	1380
Db	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCCTTGCAGATA	1380
Qy	1381	TTTAGGTACAAATGGAGTTTCTTTTCCCAACGGGAGAAACACAGCACACCCGCTTGGGA	1440
Db	1381	TTTAGGTACAAATGGAGTTTCTTTTCCCAACGGGAGAAACACAGCACACCCGCTTGGGA	1440
Qy	1441	CCCACTGCAAGCTGTCATCGTCAACCTCTTTTGGTGCAGAGTGTGGGCAAGGCTCAGGCTC	1500
Db	1441	CCCACTGCAAGCTGTCATCGTCAACCTCTTTTGGTGCAGAGTGTGGGCAAGGCTCAGGCTC	1500
Qy	1501	TCGTCGCCACAGAGTCCCCCAGCTGGGAACATTCGAGCTGGCCATCCCAATTCATCA	1560
Db	1501	TCGTCGCCACAGAGTCCCCCAGCTGGGAACATTCGAGCTGGCCATCCCAATTCATCA	1560
Qy	1561	GTCCATAGAGACGAAACAGAAATGAGACCTTCGCGGCCAAGCGTGGCGTGGCGGACATTG	1620
Db	1561	GTCCATAGAGACGAAACAGAAATGAGACCTTCGCGGCCAAGCGTGGCGTGGCGGACATTG	1620
Qy	1621	GTAGACTGTGCCACACCGCGTGTGTGAAACGTGAAATAAAAAGAGCAAAAAA	1679
Db	1621	GTAGACTGTGCCACACCGCGTGTGTGAAACGTGAAATAAAAAGAGCAAAAAA	1679

RESULT 59

ADC48500

ID ADC48500 standard; cDNA; 1679 BP.

XX

AC ADC48500;

XX

DT 01-JAN-2004 (first entry)

XX

DE Human PRO polynucleotide #188.

XX

Human; gens; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

OS Homo sapiens.

XX

XX

XX

XX

XX

XX

PF 21-MAY-2002; 2002US-00152391.

Db 1261 TATACAAATGAAATAGAGAAACACAGCTCATGGACAGAAATTTGAGGAGGGGAC 1320
Qy 1321 AAAGAATATTTGGGGGAAAGAGTTTAAATAAGAAATGAAATTCCTTGCAGATA 1380
Db 1321 AAAGAATATTTGGGGGAAAGAGTTTAAATAAGAAATGAAATTCCTTGCAGATA 1380
Qy 1381 TTTAGGTACATGAGTTTCTTTTCCCAACCGGGAAGACACAGCACACCCGGCTTGGG 1440
Db 1381 TTTAGGTACATGAGTTTCTTTTCCCAACCGGGAAGACACAGCACACCCGGCTTGGG 1440
Qy 1441 CCCACTGCAAGCTCATGTCGTCACACTTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTCATGTCGTCACACTTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTCCCGCCAGCTGGACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTCCCGCCAGCTGGACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGTGGCGCACTTTG 1620
Db 1561 GTCCATAGAGACGACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGTGGCGCACTTTG 1620
Qy 1621 GTAGACTGTGCACACGCGCTGTGTGTAACGTGAATTAATAAGACGCAAAAAA 1679
Db 1621 GTAGACTGTGCACACGCGCTGTGTGTAACGTGAATTAATAAGACGCAAAAAA 1679
RESULT 60
ADD10029
ID ADD10029 standard; cDNA; 1679 BP.
AC ADD10029;
DT 01-JAN-2004 (first entry)
DE Human PRO polynucleotide #188.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalasassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003194776-A1.
PN 16-OCT-2003.
PD 29-MAY-2002; 2002US-00157785.
PF 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-852596/79.
DR P-PSDB; ADD10030.
XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of proteoglycans from
PT cartilage and inhibiting the differentiation of adipocyte cells.

XX Claim 2; Fig 375; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells and for treating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalasassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGTCCTTCAGCAAAACAGTGAGTAAATCTCTTCGACAAAGCTTGAGAGCAACAC 60
Db 1 GTTGTGTCCTTCAGCAAAACAGTGAGTAAATCTCTTCGACAAAGCTTGAGAGCAACAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAAAAACCAGAACCTTGACAAAAAGAGAAAAAGAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAAAACCAGAACCTTGACAAAAAGAGAAAAAGAG 120
Qy 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
Qy 181 CTTACGGGGCTGGTGTCTGTGTCTCTTCCAGAGTGTCCCGTGGCGAGAGATGC 240
Db 181 CTTACGGGGCTGGTGTCTGTGTCTCTTCCAGAGTGTCCCGTGGCGAGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGGAACAAGTACAGTCCGCGAGGGGGAGAGCCACCCCTCAG 300
Db 241 CACCTTCCCAAGCTATGGAACAAGTACAGTCCGCGAGGGGGAGAGCCACCCCTCAG 300
Qy 301 GTGCACTATGTGAACCCGGGTCAACCCGGGTGGCTGTGCTAAACCCGAGCAACCATCTCTA 360
Db 301 GTGCACTATGTGAACCCGGGTCAACCCGGGTGGCTGTGCTAAACCCGAGCAACCATCTCTA 360
Qy 361 TCGTGGGAATGAAAGTGTGTCTGTCTCTCTGATCTCTCTCTCTCTCTCTCTCTCTCT 420
Db 361 TCGTGGGAATGAAAGTGTGTCTGTCTCTCTGATCTCTCTCTCTCTCTCTCTCTCTCT 420
Qy 421 GCAGTACAGCATCGAGATCCAGACGTGGATGTGTATGACGAGGCCCTTACACCTGTCTC 480

Db 421 GCAGTACAGCATCGAGATCCAGAACGTTGGATGTATGACGAGGGCCCTTACACCTGCTC 480
Qy 481 GGTGACAGACAAACCCAAAGACCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGACAGACAAACCCAAAGACCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540
Qy 541 CAAATTTGAGAGATTTCTTTCAATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
Db 541 CAAATTTGAGAGATTTCTTTCAATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
Qy 601 CTGCATAGCAACTGGTACAGAGACCTACGTTACTTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGGTACAGAGACCTACGTTACTTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGGCTTTGTGAGTGAAGACGATCTTGAATTCAGGACATCACCCGGGACGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGACGATCTTGAATTCAGGACATCACCCGGGACGTC 720
Qy 721 AGGGGACTACGAGTGCAGTCCCTCCAAATGACGTGCGCGCCGCTGGTACGAGAGTAAA 780
Db 721 AGGGGACTACGAGTGCAGTCCCTCCAAATGACGTGCGCGCCGCTGGTACGAGAGTAAA 780
Qy 781 GGTCAACCTGTAATCTCCACATACATTTCAAGAGCCAGGTACAGGTGTCCTCCGCTGG 840
Db 781 GGTCAACCTGTAATCTCCACATACATTTCAAGAGCCAGGTACAGGTGTCCTCCGCTGG 840
Qy 841 ACAAAGGGGACACTGCTGAGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGCTGAGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Qy 901 CAAGGATGACAAAGACTGATTAAGGAAAGAAAGGGGTGAAGTGGAAACACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGATTAAGGAAAGAAAGGGGTGAAGTGGAAACACAGACCTTT 960
Qy 961 CTTCTCAAACTCATCTTCTCAATGCTCTGAAATGATGACTATGGAACTACACTTGGT 1020
Db 961 CTTCTCAAACTCATCTTCTCAATGCTCTGAAATGATGACTATGGAACTACACTTGGT 1020
Qy 1021 GGCCTCCAAAGCTGGGACACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCCTCCAAAGCTGGGACACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Qy 1081 CAGCAGGTGAGCAAGCAGCTGCGAGGAGGCGGCTGCTGCTGCTGCTCTCTCT 1140
Db 1081 CAGCAGGTGAGCAAGCAGCTGCGAGGAGGCGGCTGCTGCTGCTGCTCTCTCTCT 1140
Qy 1141 GGTCTTGACCTGCTCTCTCAATTTTGTATGATGCTGCTGCTGCTGCTGCTGCTGCT 1200
Db 1141 GGTCTTGACCTGCTCTCTCAATTTTGTATGATGCTGCTGCTGCTGCTGCTGCTGCT 1200
Qy 1201 GCGCCACCAACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Qy 1261 TATACAAATGAATTAAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC 1320
Db 1261 TATACAAATGAATTAAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC 1320
Qy 1321 AAGAAATCTTTGGGGGAAGAGATTTTAAAGAAATTTGAATTCCTTTCAGATA 1380
Db 1321 AAGAAATCTTTGGGGGAAGAGATTTTAAAGAAATTTGAATTCCTTTCAGATA 1380
Qy 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAAGGGAAGAACACAGACACCCCGGCTTGA 1440
Db 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAAGGGAAGAACACAGACACCCCGGCTTGA 1440
Qy 1441 CCACCTGCAAGCTGCACTGTCACCTCTTTGTCAGTGTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCACCTGCAAGCTGCACTGTCACCTCTTTGTCAGTGTGGGCAAGGCTCAGCCTC 1500
Qy 1501 TCTGCCCAACAGAGTGGCCCGCAGCTGGAACATTTCTGAGCTGGCCATCTCCCAATTCATCA 1560
Db 1501 TCTGCCCAACAGAGTGGCCCGCAGCTGGAACATTTCTGAGCTGGCCATCTCCCAATTCATCA 1560

RESULT 61

ADC78072

ID ADC78072 standard; cDNA; 1679 BP.

XX ADC78072;

AC ADC78072;

XX 01-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO337 cDNA.

Human; secreted and transmembrane protein; PRO; Gene; ss; cytostatic;
vulnerable; antiarthritic; pericyte cell proliferation;
pericyte cell differentiation; chondrocyte cell proliferation;
chondrocyte cell differentiation; tumour necrosis factor alpha release;
(TNF)-alpha release; dermal fibroblast cell proliferation;
dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
colon tumour; breast tumour; prostate tumour; rectal tumour;
liver tumour; tissue typing; chromosome mapping; gene mapping;

XX Homo sapiens.

OS Homo sapiens.

XX US2003096972-A1.

XX 22-MAY-2003.

XX 29-AUG-2002; 2002US-00232234.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2003-765523/72.

XX P-PSDB; ADC78073.

Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as
molecular weight markers, for treating arthritis and tumor.

PS Claim 2; Fig 125; 308pp; English.

The invention describes an isolated PRO (secreted and transmembrane)
polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
useful for stimulating the proliferation of or gene expression in
pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
for stimulating the proliferation or differentiation of chondrocyte
cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO419 polypeptide
are useful for stimulating the release of tumour necrosis factor (TNF)-
alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
PRO1343, PRO1376, PRO1387, PRO1409, PRO1473, PRO1760, PRO1567,
PRO1887, PRO1928, PRO3441, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
PRO3940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
stimulating the proliferation of normal human dermal fibroblasts cells.

PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for

inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Query Macchi
Best Local Similarity
100.0%; score 1075; DB 1
100.0%; Pred. No. 6.7e-05;

Best local similarity 100.0%, Freq. NO. 8.7e-03;
Matches 1679; Conservative 0; Mismatches 0;
Indels 0; Gaps 0;

Qy	1	GTTGTGTCCTTCAGCAAAACAGTGAATTAATCTCTCTTGCACAGCTTGTAGAGCAAC	60
Db	1	GTTGTGTCCTTCAGCAAAACAGTGAATTAATCTCTCTTGCACAGCTTGTAGAGCAAC	60
Qy	61	AATCTATCAGGAAGAAAGAAAGAAAAACCGCAACCTGCAAAAGAAAGAAAAAGAG	120
Db	61	AATCTATCAGGAAGAAAGAAAGAAAAACCGCAACCTGCAAAAGAAAGAAAAAGAG	120
Qy	121	AAGAAAAAAATCATGAAAAACATCCAGCCAAAAAATGCACAATTCATCTCTTGGGCAAT	180
Db	121	AAGAAAAAAATCATGAAAAACATCCAGCCAAAAAATGCACAATTCATCTCTTGGGCAAT	180
Qy	181	CTTCACGGCGCTGCTGTGTCTCTTCCAAAGAGTGCCTGGTGCAGCGGAGATGC	240
Db	181	CTTCACGGCGCTGCTGTGTCTCTTCCAAAGAGTGCCTGGTGCAGCGGAGATGC	240
Qy	241	CACCTTCCCAAAGCTATGGAACAACGTGACGGTCCGGAGGGGAGAGGCCACCCCTCAG	300
Db	241	CACCTTCCCAAAGCTATGGAACAACGTGACGGTCCGGAGGGGAGAGGCCACCCCTCAG	300
Qy	301	GTGCACATATTGACAACCGGGTCACCCGGTGGCTTAAACCGCAGCACCATCTCTTA	360
Db	301	GTGCACATATTGACAACCGGGTCACCCGGTGGCTTAAACCGCAGCACCATCTCTTA	360
Qy	361	TGCTGGGAATGACAAAGTGGTGCTTGGATCTCTGGTGGTCTTCTGTAGCAACACCAAC	420
Db	361	TGCTGGGAATGACAAAGTGGTGCTTGGATCTCTGGTGGTCTTCTGTAGCAACACCAAC	420
Qy	421	GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGTC	480
Db	421	GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGTC	480
Qy	481	GGTGACAGACAGCAACACCCAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
Db	481	GGTGACAGACAGCAACACCCAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
Qy	541	CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAAGGAAACAATATTAGCCTC	600
Db	541	CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAAGGAAACAATATTAGCCTC	600
Qy	601	CTGCATAGCAACTGGGTAGACAGACCTACGGTTACTTTGGAGACACATCTCTCCCCAAGC	660
Db	601	CTGCATAGCAACTGGGTAGACAGACCTACGGTTACTTTGGAGACACATCTCTCCCCAAGC	660
Qy	661	GGTTGGCTTTGTGTGAGAGCAATATCTCGMAATTCAGGCATCCACGGGAGCAGTC	720
Db	661	GGTTGGCTTTGTGTGAGAGCAATATCTCGMAATTCAGGCATCCACGGGAGCAGTC	720
Qy	721	AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCGCTGGTACCGAGAGTAA	780

RESULT 62

RESUL 62
ADD04604

ADD04604
ID ADD04604 standard; cDNA; 1679 BP.

XX
DT
409507WY

AC ADD04604:

AC
XX
ADJ04604;

DT 01-JAN-2004 (first entry)

XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
 KW cell differentiation; skeletal muscle cell; adipocyte cell;
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
 KW immune system cell infiltration; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker; gene; ss.

OS Homo sapiens.

XX US2003087354-A1.

PN 08-MAY-2003.

XX 22-APR-2002; 2002US-00127827.

XX 17-AUG-1998; 98US-0096991P.

PR 02-JUN-1999; 99WO-US012252.

PR 25-AUG-1999; 99US-00380137.

PR 30-MAR-2000; 2000WO-US008439.

PR 30-MAY-2000; 2000WO-US014941.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801139/75.

DR P-PSDB; ADD04605.

XX New PRO nucleic acid, useful for manufacturing a medicament for

PT diagnosing or treating tumor.

XX Claim 2; Fig 375; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC and conditions which may benefit from enhanced local immune system cell

CC infiltration. This sequence represents a human PRO polynucleotide of the

CC invention. Note: The sequence data for this patent is also available in

XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGTTTGGAGCAAC 60

Db 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGTTTGGAGCAAC 60

Qy 61 AATCTATCAGGAAGAAAGAAAGAAACCCGAGACCTGACAAAGAAAGAAAGAAAG 120

Db 61 AATCTATCAGGAAGAAAGAAAGAAACCCGAGACCTGACAAAGAAAGAAAGAAAG 120

Qy 121 AAGAAAAAATATGAAAAACCATCCAGGCCAAATAATGCAAAATCTATCTCTTGGGCAAT 180

Db 121 AAGAAAAAATATGAAAAACCATCCAGGCCAAATAATGCAAAATCTATCTCTTGGGCAAT 180

Qy 181 CTTTCAAGGGGCTGCTGCTGCTCTTCCAGGAGTCCCTGCGCAGCGGAGATGC 240

Db 181 CTTTCAAGGGGCTGCTGCTGCTCTTCCAGGAGTCCCTGCGCAGCGGAGATGC 240

Qy 241 CACCTTCCCCAAAGCTATGGACAAACGTGACGGTCCGGCAGGGGAGAGCGCACCTCAG 300

Db 241 CACCTTCCCCAAAGCTATGGACAAACGTGACGGTCCGGCAGGGGAGAGCGCACCTCAG 300

Qy 301 GTGCACTATTGACAAACCGGGTCAACCGGTGGCTGCTAAACCGCAGCACCCTCTTA 360

Db 301 GTGCACTATTGACAAACCGGGTCAACCGGTGGCTGCTAAACCGCAGCACCCTCTTA 360

Qy 361 TGCTGGGAATGACAAAGTGGTGCCTGGATCCTCGCGTGTCTCTTCTGAGCAACACCCAAAC 420

Db 361 TGCTGGGAATGACAAAGTGGTGCCTGGATCCTCGCGTGTCTCTTCTGAGCAACACCCAAAC 420

Qy 421 GCAGTACAGCATCGAGATCCAGAACCTGAGATGTGTATGACAGGGCCCTTACCTGCTC 480

Db 421 GCAGTACAGCATCGAGATCCAGAACCTGAGATGTGTATGACAGGGCCCTTACCTGCTC 480

Qy 481 GGTGACAGACAGCAACACCCAAAGACCTCTAGGGTCCACCTCATTGTGCAAGTATCTCC 540

Db 481 GGTGACAGACAGCAACACCCAAAGACCTCTAGGGTCCACCTCATTGTGCAAGTATCTCC 540

Qy 541 CAAAATTGTAGAGATTTTTCAGATATCTCCATTAAATGAAGGGAACAATATTAGCCTCAC 600

Db 541 CAAAATTGTAGAGATTTTTCAGATATCTCCATTAAATGAAGGGAACAATATTAGCCTCAC 600

Qy 601 CTGCATAGCACTGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660

Db 601 CTGCATAGCACTGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660

Qy 661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720

Db 661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720

Qy 721 AGGGGACTACAGTGCAGTGCCTCCATGAGTGGCGCGCCCGTGGTACGAGAGTAAA 780

Db 721 AGGGGACTACAGTGCAGTGCCTCCATGAGTGGCGCGCCCGTGGTACGAGAGTAAA 780

Qy 781 GGTCAACCGTGAACCTATCCACCATACATTTTCAAGAACCAAGGGTACAGGTGTCCCGTGGG 840

Db 781 GGTCAACCGTGAACCTATCCACCATACATTTTCAAGAACCAAGGGTACAGGTGTCCCGTGGG 840

Qy 841 ACAAAGGGGACATGCAAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900

Db 841 ACAAAGGGGACATGCAAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900

Qy 901 CAAGGATCACAAAAGACATGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACACACCTTT 960

Db 901 CAAGGATCACAAAAGACATGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACACACCTTT 960

Db 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGGAACATACACTTGGCT 1020
Db 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGGAACATACACTTGGCT 1020
QY 1021 GGCCTCAAAAGCTGGGCGACCAATGCGAGCATCATCTATTGTTGGTCCAGGCGCGT 1080
Db 1021 GGCCTCAAAAGCTGGGCGACCAATGCGAGCATCATCTATTGTTGGTCCAGGCGCGT 1080
QY 1081 CAGGAGGTGAGCAACGCGCTGCGAGGAGGCGCTGCTGCTGCTGCTGCTTCT 1140
Db 1081 CAGGAGGTGAGCAACGCGCTGCGAGGAGGCGCTGCTGCTGCTGCTGCTTCT 1140
QY 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCCTTCCCAACCCGGGAAAGGCT 1200
Db 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCCTTCCCAACCCGGGAAAGGCT 1200
QY 1201 GCCGCCACACACACACACACACACACACACACACACACACACACACACACACACAC 1260
Db 1201 GCCGCCACACACACACACACACACACACACACACACACACACACACACACACACAC 1260
QY 1261 TATCAAAATGAATTAGAAGAAACACACACACACACACACACACACACACACACACAC 1320
Db 1261 TATCAAAATGAATTAGAAGAAACACACACACACACACACACACACACACACACACAC 1320
QY 1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACATGAGTGTCTTTTCCAAACCGGGAAGACACACACACACACACACACAC 1440
Db 1381 TTTAGGTACATGAGTGTCTTTTCCAAACCGGGAAGACACACACACACACACACACAC 1440
QY 1441 CCCACTGCAAGCTGATGCTGCAACCTTTTGGTGCAGTGTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGATGCTGCAACCTTTTGGTGCAGTGTGGGCAAGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACGCTGGAACTTCTGGAGCTGGCCATCCCAAAATCAATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACGCTGGAACTTCTGGAGCTGGCCATCCCAAAATCAATCA 1560
QY 1561 GTCCATAGAGACGACAGATGAGACCTTCCGGCCCAAGCTGCGCTGGGGCAGCTTTG 1620
Db 1561 GTCCATAGAGACGACAGATGAGACCTTCCGGCCCAAGCTGCGCTGGGGCAGCTTTG 1620
QY 1621 GTAGACTGTGCCACCGCGCTGTTGTGAAAGTGAATATAAGAGCAAAAGAAA 1679
Db 1621 GTAGACTGTGCCACCGCGCTGTTGTGAAAGTGAATATAAGAGCAAAAGAAA 1679

RESULT 63

ID ADD06307
AC ADD06307;
XX ADD06307;
DT 01-JAN-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO337 cDNA.
DE human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX gene therapy.
OS Homo sapiens.
XX

PN US2003073816-A1.
XX 17-APR-2003.
PF 26-AUG-2002; 2002US-00227873.
XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WJ;
XX WPI; 2003-644807/61.
DR P-PSDB; ADD06308.
XX
PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX
PS Claim 2; SEQ ID NO 125; 314pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF).
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO326, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1336,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1760, PRO1567,
CC PRO1887, PRO1328, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO409,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of expression of the above PRO polypeptides
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (II) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
XX
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred.No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTTCAGCAAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTTCAGCAAGCTTGAGAGCAAC 60
QY 61 ATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 ATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

QY	121	AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAATTCATCTCTTTGGGCAAT	180
Db	121	AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAATTCATCTCTTTGGGCAAT	180
QY	181	CTTCACGGGGCTGGCTGCTCTGTGTCTTCCTCAAGGAGTGCCTGTGGCGCAGCGAGATGC	240
Db	181	CTTCACGGGGCTGGCTGCTCTGTGTCTTCCTCAAGGAGTGCCTGTGGCGCAGCGAGATGC	240
QY	241	CACCTTCCCAAGCTATGGAACACGCTCCGCGAGGGGAGAGCGCACCCCTCAG	300
Db	241	CACCTTCCCAAGCTATGGAACACGCTCCGCGAGGGGAGAGCGCACCCCTCAG	300
QY	301	GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGTAAACCGCAGCACCATCTCTTA	360
Db	301	GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGTAAACCGCAGCACCATCTCTTA	360
QY	361	TGCTGGGAATGACAAAGTGGTGCCTTGGATCCCTCGCTGGTCTTCTGAGCAACACCCAAAC	420
Db	361	TGCTGGGAATGACAAAGTGGTGCCTTGGATCCCTCGCTGGTCTTCTGAGCAACACCCAAAC	420
QY	421	GCAGTACAGCATCGAGATCCAGACGCTGGATGTCTATGACGAGGGCCCTTACACCTGCTC	480
Db	421	GCAGTACAGCATCGAGATCCAGACGCTGGATGTCTATGACGAGGGCCCTTACACCTGCTC	480
QY	481	GGTGCAGACAGAACCAACCAACAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
Db	481	GGTGCAGACAGAACCAACCAACAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
QY	541	CAAAATTTGTAGAGATTTCTTCAGATATCTCCATTAAATGAGGGGAACATATTAGCCCTC	600
Db	541	CAAAATTTGTAGAGATTTCTTCAGATATCTCCATTAAATGAGGGGAACATATTAGCCCTC	600
QY	601	CTGCATAGCAACTGGTGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC	660
Db	601	CTGCATAGCAACTGGTGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC	660
QY	661	GGTTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCGGAGAGATC	720
Db	661	GGTTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCGGAGAGATC	720
QY	721	AGGGGACTACAGTGTGAGTGCCTCCAAATGACGTGGCGCGCCCGTGTGACGAGAGTAAA	780
Db	721	AGGGGACTACAGTGTGAGTGCCTCCAAATGACGTGGCGCGCCCGTGTGACGAGAGTAAA	780
QY	781	GGTCACCGTGAACCTATCCACATACATTTGAGAGCCCAAGGTACAGGTGTCCCGTGGG	840
Db	781	GGTCACCGTGAACCTATCCACATACATTTGAGAGCCCAAGGTACAGGTGTCCCGTGGG	840
QY	841	ACAAAAGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTTCAGCAGAAATTCAGTGGTA	900
Db	841	ACAAAAGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTTCAGCAGAAATTCAGTGGTA	900
QY	901	CAAGGATGACAAAAGACTGATTGAAGGAAGAAAGGGGTGAAGTGGAAACACAGACCTTT	960
Db	901	CAAGGATGACAAAAGACTGATTGAAGGAAGAAAGGGGTGAAGTGGAAACACAGACCTTT	960
QY	961	CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACCTACACTTCGT	1020
Db	961	CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACCTACACTTCGT	1020
QY	1021	GGCTCCAAACAGCTGGGCCACACCAATGCCAGCATATGCTATTTGGTCCAGCGCGCGT	1080
Db	1021	GGCTCCAAACAGCTGGGCCACACCAATGCCAGCATATGCTATTTGGTCCAGCGCGCGT	1080
QY	1081	CAGCGAGGTGAGCAACGGCAGCTCGAGAGGGGCGAGGCTGCTCTGGCTGTCTCTTCT	1140
Db	1081	CAGCGAGGTGAGCAACGGCAGCTCGAGAGGGGCGAGGCTGCTCTGGCTGTCTCTTCT	1140
QY	1141	GGTCTTGCACCTGCTTCTCAAAATTTTGATGTGATGCCACTTCCCAACCCGGGAAAGGCT	1200
Db	1141	GGTCTTGCACCTGCTTCTCAAAATTTTGATGTGATGCCACTTCCCAACCCGGGAAAGGCT	1200

QY	1201	GC	CGCCACCA	CCACCA	CAACAC	CAACAG	CAGCAT	TGGCCAC	CACCGAC	AGCAACCA	ATTCAGATA	1260
Db	1201	GC	CGCCACCA	CCACCA	CCACCA	CAACAC	CAGCAT	TGGCCAC	CACCGAC	AGCAACCA	ATTCAGATA	1260
QY	1261	TATA	CAAAATGA	AATTAGA	AGAAAC	CACAG	CGCTCAT	TGGGAC	CAGAAATTT	TGAGG	AGGGGAAC	1320
Db	1261	TATA	CAAAATGA	AATTAGA	AGAAAC	CACAG	CGCTCAT	TGGGAC	CAGAAATTT	TGAGG	AGGGGAAC	1320
QY	1321	AA	AGATATCT	TTTGGG	GGGAAA	GAGATTT	TAA	AAAAAGAA	ATTTGAA	AAATTCGCTT	GCAGATA	1380
Db	1321	AA	AGATATCT	TTTGGG	GGGAAA	GAGATTT	TAA	AAAAAGAA	ATTTGAA	AAATTCGCTT	GCAGATA	1380
QY	1381	TTT	AGGTACA	ATGGAG	TTTTCT	TTTCC	CAACCGG	GAAGAAC	CACAG	CACACCCCGGCTT	TGGA	1440
Db	1381	TTT	AGGTACA	ATGGAG	TTTTCT	TTTCC	CAACCGG	GAAGAAC	CACAG	CACACCCCGGCTT	TGGA	1440
QY	1441	CCC	ACTGCA	AGCTGC	ATCGT	GCAACCTCT	TTT	TGTCG	CCAGTGTG	GGCAAGGCTC	AGCCTC	1500
Db	1441	CCC	ACTGCA	AGCTGC	ATCGT	GCAACCTCT	TTT	TGTCG	CCAGTGTG	GGCAAGGCTC	AGCCTC	1500
QY	1501	TC	TGCCCA	CAGAGT	GGCCCC	CACGTG	GAACAT	CTCG	AGCTGGCC	ATCCCCAAAT	TCATCA	1560
Db	1501	TC	TGCCCA	CAGAGT	GGCCCC	CACGTG	GAACAT	CTCG	AGCTGGCC	ATCCCCAAAT	TCATCA	1560
QY	1561	GT	CCATAG	AGACAA	CAGAT	AGAGCTT	CCG	CCCAAG	CGTGG	CGCTCGGG	GCACCTTTG	1620
Db	1561	GT	CCATAG	AGACAA	CAGAT	AGAGCTT	CCG	CCCAAG	CGTGG	CGCTCGGG	GCACCTTTG	1620
QY	1621	GT	AGACTGT	GCCAC	CACGG	CGCTGT	TGT	TGTG	AAACGTG	AAATATA	AAAAAGACAA	1679
Db	1621	GT	AGACTGT	GCCAC	CACGG	CGCTGT	TGT	TGTG	AAACGTG	AAATATA	AAAAAGACAA	1679

RESULT 64
ADC80560
ID ADC80560 standard; cDNA; 1679 BP.
XX
XX ADC80560;
XX
XX
XX 01-JAN-2004 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO337 cDNA.
XX
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
XX transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
XX rectum; kidney; cervix; liver; microvascular endothelial cell;
XX glucose uptake modulator; FFA uptake modulator; cell proliferation;
XX cell differentiation; skeletal muscle cell; adipocyte cell;
XX pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
XX immune system cell infiltration; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
XX Homo sapiens.
XX
XX
XX US2003092103-A1.
XX
XX 15-MAY-2003.
XX
XX 24-APR-2002; 2002US-00131815.
XX
XX 22-DEC-1998; 98US-0113511P.
XX PR 01-DEC-1999; 99WO-US028634.
XX PR 22-FEB-2000; 2000WO-US004414.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnovers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
FI Smith V, Stewart RA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX P-PSDB; ADC80561.
DR WPI; 2003-801168/75.
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; Fig 375; 637pp; English.
PS The invention relates to isolated human PRO polypeptides (secreted and
PS transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting the proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTCTGACACAGCTTGAGAGCAACAC 60
DB 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTCTGACACAGCTTGAGAGCAACAC 60
QY 61 AATCTATCAGGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 120
DB 61 AATCTATCAGGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 120
QY 121 AAGAAAAAATATGAAAAACATCCAGCCAAATGCAAAATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATATGAAAAACATCCAGCCAAATGCAAAATCTATCTCTTGGGCAAT 180
QY 181 CTTACGGGGGTGGGTGCTGTGTCTCTTCAAGGAGTGCCTGCGCAGCGAGATGC 240
DB 181 CTTACGGGGGTGGGTGCTGTGTCTCTTCAAGGAGTGCCTGCGCAGCGAGATGC 240
QY 241 CACCTTCCCAAGATATGAGACAGTGCAGCGTCCGGCAGGGGAGAGCGCACCTTCAG 300
DB 241 CACCTTCCCAAGATATGAGACAGTGCAGCGTCCGGCAGGGGAGAGCGCACCTTCAG 300
QY 301 GTGCACATTATGACAAACCGGGTCAACCGGGTGGCTAAACCGCAGCACCATCTCTCTA 360

DB 301 GTGCACATTATGACAAACCGGGTCAACCGGGTGGCTAAACCGCAGCACCATCTCTCTA 360
QY 361 TGTCTGGGAATGACAAAGTGGTCTCGGTGATCTCTCGGTGCTCTCTGAGCAACACCCAAAC 420
DB 361 TGTCTGGGAATGACAAAGTGGTCTCGGTGATCTCTCGGTGCTCTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGTCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGTCTC 480
QY 481 GGTGACAGACAGAACACCAACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTTCC 540
DB 481 GGTGACAGACAGAACACCAACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCCAGATATCTTCCATTAATGAAGGAGCAATATAGCTTAC 600
DB 541 CAAATTTGTAGAGATTTCTTCCAGATATCTTCCATTAATGAAGGAGCAATATATAGCTTAC 600
QY 601 CTGCAATAGCAATCTGTAGACAGACCTTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCAATAGCAATCTGTAGACAGACCTTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGACGATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGACGATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGCACTACGAGTGCAGTGCCTCCAATGACGTGGCCGCCCGGTGTCACGAGAGTAAA 780
DB 721 AGGGCACTACGAGTGCAGTGCCTCCAATGACGTGGCCGCCCGGTGTCACGAGAGTAAA 780
QY 781 GGTACCGTGAACATATCCACCATATCTTTAGAACCCAAAGGGTACAGTGTCCCGTGGG 840
DB 781 GGTACCGTGAACATATCCACCATATCTTTAGAACCCAAAGGGTACAGTGTCCCGTGGG 840
QY 841 ACAGAGGGGACACTGTCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCACAGTGTA 900
DB 841 ACAGAGGGGACACTGTCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCACAGTGTA 900
QY 901 CAAGATGACAAAAGACTGATTGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 960
DB 901 CAAGATGACAAAAGACTGATTGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 960
QY 961 CTTCTCAAAACCTCATCTTCTTCAATGTCTCTGACATGACTATGGAACTACACTTGGT 1020
DB 961 CTTCTCAAAACCTCATCTTCTTCAATGTCTCTGACATGACTATGGAACTACACTTGGT 1020
QY 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGT 1080
DB 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGCGAGGTGACAAACGGCAGCTGAGGAGGCGGCTGCTGCTGCTGCTGCTTCTTCT 1140
DB 1081 CAGCGAGGTGACAAACGGCAGCTGAGGAGGCGGCTGCTGCTGCTGCTGCTTCTTCT 1140
QY 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGTATGTGAGTGCCACTTTCCCCACCCCGGAAAGCT 1200
DB 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGTATGTGAGTGCCACTTTCCCCACCCCGGAAAGCT 1200
QY 1201 GCGGCCACCAACCAACCAACAGCAATGGCAACACCGCAGCAGCAACCAATCAGATA 1260
DB 1201 GCGGCCACCAACCAACCAACAGCAATGGCAACACCGCAGCAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTTGGGGAGGGGAAAC 1320
DB 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTTGGGGAGGGGAAAC 1320
QY 1321 AAGAAATATCTTTGGGGGAGAGAGTTTAAAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
DB 1321 AAGAAATATCTTTGGGGGAGAGAGTTTAAAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
QY 1381 TTTAGTACAAATGGAGTTTCTTTTCCCAAAACCGGAGAGAACACAGCACACCCGGCTTGG 1440

Db 1381 TTTAGGTAAATGGAGTTTCTTTTCCCAACGGGAAGAACACACAGCACACCCTGGTGG 1440

Qy 1441 CCCACTGCAAGCTGATGTCACAACTCTTTGGTGCCAGTGTGGCAAGGCTCAGCCTC 1500

Db 1441 CCCACTGCAAGCTGATGTCACAACTCTTTGGTGCCAGTGTGGCAAGGCTCAGCCTC 1500

Qy 1501 TTTGCCCCAGAGTCCCTCCCAAGTGGAAATCTTGGAGCTGGCCATCCCAAAATCAATCA 1560

Db 1501 TTTGCCCCAGAGTCCCTCCCAAGTGGAAATCTTGGAGCTGGCCATCCCAAAATCAATCA 1560

Qy 1561 GTCCATAGAGAGACAGATGAGACCTTCCGGCCCAAGCTGGCGTGGCGGCACTTTG 1620

Db 1561 GTCCATAGAGAGACAGATGAGACCTTCCGGCCCAAGCTGGCGTGGCGGCACTTTG 1620

Qy 1621 GTAGACTGTGCCACCAAGCGCTGTGTGTGAAACGTGAAATGAAAGAGCAAAAAA 1679

Db 1621 GTAGACTGTGCCACCAAGCGCTGTGTGTGAAACGTGAAATGAAAGAGCAAAAAA 1679

RESULT 65

ADD11067

AC ADD11067 standard; cDNA; 1679 BP.

XX AC ADD11067;

XX AC ADD11067;

DT 01-JAN-2004 (first entry)

XX Human PRO polynucleotide #188.

DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX Homo sapiens.

OS Homo sapiens.

XX US2003194774-A1.

PN 16-OCT-2003.

XX 21-MAY-2002; 2002US-00152399.

PF 03-MAR-2000; 2000US-0187202P.

XX 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

PA Baker KP, Bersini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-852594/79.

DR P-PSDB; ADD11068.

XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful

PT for detecting a tumor, stimulating the proliferation or differentiation

PT of chondrocyte cells and stimulating the release of tumor necrosis factor

PT alpha.

XX Claim 2; SEQ ID NO 375; 637pp; English.

PS The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems, PRO

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This

CC sequence represents a human PRO polynucleotide of the invention. Note:

CC The sequence data for this patent is also available in electronic format

CC from USPIO at seqdata.uspto.gov/sequence.html.

XX

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTTCGACAACTTGAGAGCAAC 60

Db 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTTCGACAACTTGAGAGCAAC 60

Qy 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

Db 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

Qy 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCACAAATTCATCTCTTGGGCAAT 180

Db 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCACAAATTCATCTCTTGGGCAAT 180

Qy 181 CTTTCAGCGGGCTGCTGCTCTGTGTCTTCTTCCAAAGAGTGCCTGCGAGCGGAGATGC 240

Db 181 CTTTCAGCGGGCTGCTGCTCTGTGTCTTCTTCCAAAGAGTGCCTGCGAGCGGAGATGC 240

Qy 241 CACCTTCCCAAGCTATGACAAACGTGACGCTCCGCGAGGGGGAGAGCCCACTCTCAG 300

Db 241 CACCTTCCCAAGCTATGACAAACGTGACGCTCCGCGAGGGGGAGAGCCCACTCTCAG 300

Qy 301 GTGCACATTTGACAAACCGGGTCCACCGGGTGGCTGCTAAACCGCAGCACCCTCTCTA 360

Db 301 GTGCACATTTGACAAACCGGGTCCACCGGGTGGCTGCTAAACCGCAGCACCCTCTCTA 360

Qy 361 TGCTGGGAATGACAAGTGGTGCCTTGGATCTCTCGCTGGTCTCTTGTAGCAACCCCAAC 420

Db 361 TGCTGGGAATGACAAGTGGTGCCTTGGATCTCTCGCTGGTCTCTTGTAGCAACCCCAAC 420

Qy 421 GCAGTACAGATCGAGATCCAGACGTTGATGATGAGAGGGCCCTTACACCTGCTC 480

Db 421 GCAGTACAGATCGAGATCCAGACGTTGATGATGAGAGGGCCCTTACACCTGCTC 480

Qy 481 GGTGCAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

Db 481 GGTGCAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

Qy 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAGACAAATATTAGCTCAC 600

Db 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACATATTAGCTCAC 600
Qy 601 CTGCATAGCAACTGGTAGACAGAGCCCTACGGTTACTTTGGAGACATCTCTCCAAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCCCTACGGTTACTTTGGAGACATCTCTCCAAAGC 660
Qy 661 GGTGGCTTTGTGAGTGAAGACCAATCTTGGAAATTCAGGGCATCACCGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGACCAATCTTGGAAATTCAGGGCATCACCGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTGCAGTGCCTCCATGACGTGGCGCCCGTGTACGGAGATAA 780
Db 721 AGGGGACTACGAGTGCAGTGCCTCCATGACGTGGCGCCCGTGTACGGAGATAA 780
Qy 781 GGTCAACGCTGAATATTCACATACATTTTCAAGACCAAGGTACAGGTGTCCTGGG 840
Db 781 GGTCAACGCTGAATATTCACATACATTTTCAAGACCAAGGTACAGGTGTCCTGGG 840
Qy 841 ACAAAGGGGACACTGACGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
Db 841 ACAAAGGGGACACTGACGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
Qy 901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
Qy 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGAACTACACTTGCCT 1020
Db 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGAACTACACTTGCCT 1020
Qy 1021 GGCCTCAACAGCTGGGCGCACCAATGCGAGATCATGCTATTTGGTCCAGGCCCT 1080
Db 1021 GGCCTCAACAGCTGGGCGCACCAATGCGAGATCATGCTATTTGGTCCAGGCCCT 1080
Qy 1081 CAGGAGGTGAGCAACGGCAGCTCGAGAGGGGAGGCTGCTGCTGCTGCTCTTCT 1140
Db 1081 CAGGAGGTGAGCAACGGCAGCTCGAGAGGGGAGGCTGCTGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGCACTGCTTCTCAAAATTTTGAATGTGAGTGCATCTCCCAACCGGAAAGGCT 1200
Db 1141 GGTCTTGCACTGCTTCTCAAAATTTTGAATGTGAGTGCATCTCCCAACCGGAAAGGCT 1200
Qy 1201 GCGCCACCAACCAACCAACAGCAATGCGAACACCGACAGCAACCAATCAGATA 1260
Db 1201 GCGCCACCAACCAACCAACAGCAATGCGAACACCGACAGCAACCAATCAGATA 1260
Qy 1261 TATCAAAATGAATTAAGAGAAACACAGCTCTATGGAGCAAGAAATTTGAGGGAGGGAAC 1320
Db 1261 TATCAAAATGAATTAAGAGAAACACAGCTCTATGGAGCAAGAAATTTGAGGGAGGGAAC 1320
Qy 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Qy 1381 TTTAGGTACAAATGAGTTTCTTTCCAAACCGGAGAAACACAGCACACCCGGCTTGA 1440
Db 1381 TTTAGGTACAAATGAGTTTCTTTCCAAACCGGAGAAACACAGCACACCCGGCTTGA 1440
Qy 1441 CCCACTGCAAGCTCATCGTGCACCTCTTTGGTCCAGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTCATCGTGCACCTCTTTGGTCCAGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCCAACGCTGGAACATTTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCCAACGCTGGAACATTTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGACGACAGATGAGACCTTCGCGCCCAAGCGTGGCGCTGGGCACTTTG 1620
Db 1561 GTCCATAGACGACAGATGAGACCTTCGCGCCCAAGCGTGGCGCTGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCGCGGTGTGTGTGTGAAGCTGAAATATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGCGGTGTGTGTGTGAAGCTGAAATATAAAGAGCAAAAAA 1679

RESULT 66

ADD10344

ID ADD10344 standard; cDNA; 1679 BP.

XX AC ADD10344;

XX DT 01-JAN-2004 (first entry)

XX DE Human secreted/transmembrane PRO polypeptide cDNA #28.

XX ss; gene; human; secreted protein; transmembrane protein;
KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; angiogenesis;
KW endothelial cell apoptosis; smooth muscle cell growth;
KW endothelial cell tube formation.

XX OS Homo sapiens.

XX PN US2003105011-A1.

XX PD 05-JUN-2003.

XX PF 16-AUG-2002; 2002US-00223084.

XX PR 15-SEP-2000; 2000US-0232887P.

PR 20-JUN-2001; 2001WO-US019692.

PR 09-JUL-2001; 2001WO-US021735.

PR 20-FEB-2002; 2002US-00081056.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Ferriaza N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
PI Watanabe CK, Williams PM, Wood WI, Ye W;

XX DR WPI; 2003-810831/76.

DR P-PSDB; ADD10345.

XX PT New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide for treating a cardiovascular, endothelial, or angiogenic
PT disorder in a mammal, such as cancer or age-related macular degeneration.

XX PS Claim 2; SEQ ID NO 55; 493pp; English.

XX CC The invention relates to an isolated nucleic acid encoding a secreted and
CC transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
CC by the nucleic acid, or an agonist or antagonist, is used to treat a
CC cardiovascular, endothelial, or angiogenic disorder in a mammal,
CC preferably a human. The human may have suffered a myocardial infarction
CC or has cardiac hypertrophy, trauma, a cancer, or age-related macular
CC degeneration. The cardiac hypertrophy is characterized by the presence of
CC an elevated level of pR-2 alpha. A PRO polypeptide, given in the
CC specification, or an agonist is used to inhibit or stimulate endothelial
CC cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
CC hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
CC PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
CC polypeptide, given in the specification, or an agonist is used to
CC stimulate or inhibit smooth muscle cell growth, or to induce endothelial
CC cell tube formation. The present sequence represents a cDNA encoding a
CC PRO polypeptide of the invention.

XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAACAC 60

Db 1 GTTGTGCTCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAACAC 60

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Gurney SL, Smith V;
PI Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-844454/78.
DR P-PSDB; ADCA7949.

XX PT New secreted and transmembrane PRO polypeptides and nucleic acids useful
PT for detecting a tumor, stimulating the release of proteoglycans from
PT cartilage and stimulating the proliferation of endothelial cells.

XX PS Claim 2; Fig 375; 637pp; English.

XX CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6,7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTCTCTTCAGCAACAGTGGATTAAATCTCCTTGACAGCTTGAGAGCACAC 60
DB 1 GTTGTCTCTTCAGCAACAGTGGATTAAATCTCCTTGACAGCTTGAGAGCACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGACAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGACAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAGAAATCATGAAGCAATCCAGCCAAATGCAATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAGAAATCATGAAGCAATCCAGCCAAATGCAATCTATCTCTTGGGCAAT 180
QY 181 CTTACCGGGGTGGTGTCTGTGTCTCTTCCAGAGAGTGCCCGTGCGAGCGAGATGC 240
DB 181 CTTACCGGGGTGGTGTCTGTGTCTCTTCCAGAGAGTGCCCGTGCGAGCGAGATGC 240
QY 241 CACCTTCCCAAGATATGGACACGTCACGGTCCGCGAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGATATGGACACGTCACGGTCCGCGAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360

Db 1381 TTTAGGTAAATGAGATTTCTTTTCCCAACGGGAAGAACACACAGCACACCCGGCTTGGGA 1440
 Qy 1441 CCCACTGCAAGCTGCATCGTGCACACTCTTTTGGTCCAGTGTGGCGAAGGGCTCAGCGCTC 1500
 Db 1441 CCCACTGCAAGCTGCATCGTGCACACTCTTTTGGTCCAGTGTGGCGAAGGGCTCAGCGCTC 1500
 Qy 1501 TCTGCCACAGAGTGGCCCCCAGCTGGAACATCTCTGGAGCTGGCCATCCCAATTCATCA 1560
 Db 1501 TCTGCCACAGAGTGGCCCCCAGCTGGAACATCTCTGGAGCTGGCCATCCCAATTCATCA 1560
 Qy 1561 GTCCATAGAGCAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCACCTTTG 1620
 Db 1561 GTCCATAGAGCAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCACCTTTG 1620
 Qy 1621 GTAGACTGTGCCACCAAGCGGTGTGTGTGAAACGTGAAATAAAGAGCAAAAAA 1679
 Db 1621 GTAGACTGTGCCACCAAGCGGTGTGTGTGAAACGTGAAATAAAGAGCAAAAAA 1679

RESULT 68
 ADC77826
 ID ADC77826 standard; cDNA; 1679 BP.
 XX
 AC ADC77826;
 DT
 DT 01-JAN-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO337 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 XX US2003088066-A1.
 XX
 PD 08-MAY-2003.
 XX
 XX 13-AUG-2002; 2002US-00219466.
 XX
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-657980/62.
 DR P-PSDB; ADC77827.
 DR
 XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful in gene therapy, or for preparing a medicament for treating a
 PT condition that is responsive to the PRO polypeptide or anti-PRO antibody,
 PT e.g. cancer.
 XX
 XX Claim 2; Fig 125; 314pp; English.
 PS
 XX The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF) -

CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO1083, PRO840, PRO1080.
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO5004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 GTTGTGCTTCTCAGCAACAGTGGATTTAAATCTCTTGCACAACTTGAGAGCAACAC 60
 Db 1 GTTGTGCTTCTCAGCAACAGTGGATTTAAATCTCTTGCACAACTTGAGAGCAACAC 60
 Qy 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACTGTACAAAAAGAAAGAAAAAGAG 120
 Db 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACTGTACAAAAAGAAAGAAAAAGAG 120
 Qy 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAATGCAAAATCTATCTCTTGGGCAAT 180
 Db 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAATGCAAAATCTATCTCTTGGGCAAT 180
 Qy 181 CTTTCAAGGGCTGGCTCTGTGTCTTCTTCCAGGAGTCCCGTGCAGCGAGAGATGC 240
 Db 181 CTTTCAAGGGCTGGCTCTGTGTCTTCTTCCAGGAGTCCCGTGCAGCGAGAGATGC 240
 Qy 241 CACTTCCCAAGCTATGGAACAGTGAAGTCCCGCAGGGGAGAGCCGACCCCTCAG 300
 Db 241 CACTTCCCAAGCTATGGAACAGTGAAGTCCCGCAGGGGAGAGCCGACCCCTCAG 300
 Qy 301 GTGCACATTATGACAAACCGGGTCAACCGGGTGGCTAAACCGCAGACCAATCTCTTA 360
 Db 301 GTGCACATTATGACAAACCGGGTCAACCGGGTGGCTAAACCGCAGACCAATCTCTTA 360
 Qy 361 TCGTGGGAATGACAAAGTGGTCCCTGGATCTCTGGGTGGTCTTCTGAGCAACACCCAAAC 420
 Db 361 TCGTGGGAATGACAAAGTGGTCCCTGGATCTCTGGGTGGTCTTCTGAGCAACACCCAAAC 420
 Qy 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGAGAGGGCCCTTACACCTGCTC 480
 Db 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGAGAGGGCCCTTACACCTGCTC 480
 Qy 481 GGTGCAGACAGAACCAACCCAAAGACCTTAGGGTCCACTATTGTGCAAGTATCTCC 540
 Db 481 GGTGCAGACAGAACCAACCCAAAGACCTTAGGGTCCACTATTGTGCAAGTATCTCC 540
 Qy 541 CAAATTTGAGAGATTTCTCAGATATCTCCATTAATGAAGGGGAACAATATTACCTTCAC 600

Db 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAGGGAACAATATTAGCCTCAC 600
Qy 601 CTGATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Qy 661 GGTGGGCTTTGTAGTGAAGACGAATACTTTGGAATTCAGGGATCACCGGAGAGATC 720
Db 661 GGTGGGCTTTGTAGTGAAGACGAATACTTTGGAATTCAGGGATCACCGGAGAGATC 720
Qy 721 AGGGGACTACAGTGCAGTCTCCATAGAGTGGCGCGCGCGTGTGTGAGAGATGATA 780
Db 721 AGGGGACTACAGTGCAGTCTCCATAGAGTGGCGCGCGCGTGTGTGAGAGATGATA 780
Qy 781 GGTCAACGTTGAACATTCACCATATCTTCAGAGCAAGGTCACAGTCTCCCGTGGG 840
Db 781 GGTCAACGTTGAACATTCACCATATCTTCAGAGCAAGGTCACAGTCTCCCGTGGG 840
Qy 841 ACAAAGGGGACATGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
Db 841 ACAAAGGGGACATGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
Qy 901 CAAGGATGACAAAGATCTGATTGAAGGAAGAAGGGGTGAAGTGGAAACAGACTTT 960
Db 901 CAAGGATGACAAAGATCTGATTGAAGGAAGAAGGGGTGAAGTGGAAACAGACTTT 960
Qy 961 CCTCTCAAACTCATCTTTCAATGTCTCTGAACATGACTATGGGAATTCACCTTCGGT 1020
Db 961 CCTCTCAAACTCATCTTTCAATGTCTCTGAACATGACTATGGGAATTCACCTTCGGT 1020
Qy 1021 GGCCTCCAGAGTGGGACCAACCAATGCTCCAGCATCATCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCCTCCAGAGTGGGACCAACCAATGCTCCAGCATCATCTATTTGGTCCAGGCGCGT 1080
Qy 1081 CAGCGAGTGAACCAACGCGCTCGAGAGGCGAGGCTGCGTCTGGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGAACCAACGCGCTCGAGAGGCGAGGCTGCGTCTGGCTGCTCTTCT 1140
Qy 1141 GGTCTTGACCTGCTTCTCAATTTTGAATGAGTGCACCTTCCACCGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAATTTTGAATGAGTGCACCTTCCACCGGGAAGGCT 1200
Qy 1201 CGCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
Db 1201 CGCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
Qy 1261 TATACAAATGAATTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320
Db 1261 TATACAAATGAATTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320
Qy 1321 AAGAATACTTTGGGGGAAAGATTTTAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
Db 1321 AAGAATACTTTGGGGGAAAGATTTTAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
Qy 1381 TTTAGGTACAAATGAGATTTCTTTTCCAAACCGGGAAGAACACAGCACACCCCGCTTGA 1440
Db 1381 TTTAGGTACAAATGAGATTTCTTTTCCAAACCGGGAAGAACACAGCACACCCCGCTTGA 1440
Qy 1441 CCCACTGCAAGCTCATGTCGCAACCTTTTGGTCCAGTGTGGCAAGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTCATGTCGCAACCTTTTGGTCCAGTGTGGCAAGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGGCCCAACGATGACACCTTCGCGCCCAAGCGTGGCGTGGGCACTTTG 1560
Db 1501 TCTGCCACAGAGTGGCCCAACGATGACACCTTCGCGCCCAAGCGTGGCGTGGGCACTTTG 1560
Qy 1561 GTCCATAGACGACAAACAGATGACACCTTCGCGCCCAAGCGTGGCGTGGGCACTTTG 1620
Db 1561 GTCCATAGACGACAAACAGATGACACCTTCGCGCCCAAGCGTGGCGTGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCGCGGTGTGTGTGAAGCTGAATTAATAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGCGGTGTGTGTGAAGCTGAATTAATAAGAGCAAAAAA 1679

RESULT 69

ADC80008
ID ADC80008 standard; cDNA; 1679 BP.
XX
AC ADC80008;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
rectum; kidney; cervix; liver; microvascular endothelial cell;
glucose uptake modulator; PFA uptake modulator; cell proliferation;
cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
immune system cell infiltration; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003087358-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127833.
XX
PR 01-SEP-1998; 98US-0098750P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801143/75.
DR P-PSDB; ADC80009.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.
XX
PS Claim 2; Fig 375; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of

KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; angiogenesis;
KW endothelial cell apoptosis; smooth muscle cell growth;
KW endothelial cell tube formation.

XX Homo sapiens.

XX US2003105013-A1.

XX 05-JUN-2003.

XX 16-AUG-2002; 2002US-00223090.

XX 20-JUN-2001; 2001WO-US019692.

XX 09-JUL-2001; 2001WO-US021735.

XX 20-FEB-2002; 2002US-00081056.

XX (GETH) GENENTECH INC.

XX Baker KP, Ferrara N, Gerber H, Gerecht H, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
PI Watanabe CK, Williams FM, Wood WI, Ye W;

XX WPI; 2003-801242/75.

XX P-PSDB; ADD11305.

XX New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide, useful for treating a cardiovascular, endothelial, or
PT angiogenic disorder in a mammal, such as cancer or age-related macular
PT degeneration.

XX Claim 2; SEQ ID NO 55; 493pp; English.

XX The invention relates to an isolated nucleic acid encoding a secreted and
XX transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
XX by the nucleic acid, or an agonist or antagonist, is used to treat a
XX cardiovascular, endothelial, or angiogenic disorder in a mammal,
XX preferably a human. The human may have suffered a myocardial infarction
XX or has cardiac hypertrophy, trauma, a cancer, or age-related macular
XX degeneration. The cardiac hypertrophy is characterized by the presence of
XX an elevated level of pGF-2 alpha. A PRO polypeptide, given in the
XX specification, or an agonist is used to inhibit or stimulate endothelial
XX cell growth in a mammal. PRO1 or an agonist is used to induce cardiac
XX hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
XX PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
XX polypeptide, given in the specification, or an agonist is used to
XX stimulate or inhibit smooth muscle cell growth, or to induce endothelial
XX cell tube formation. The present sequence represents a cDNA encoding a
XX PRO polypeptide of the invention.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

XX Query Match 100.0%; Score 1679; DB 1; Length 1679;

XX Best Local Similarity 100.0%; Pred. No. 6.7e-05;

XX Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60

DB 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60

QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

QY 121 AAGAAAAAATCATGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180

DB 121 AAGAAAAAATCATGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180

QY 181 CTTACGGGGTGGTGTCTGTCTCTTCTTCAAGAGAGTCCCGTGCAGCGAGATGC 240

DB 181 CTTACGGGGTGGTGTCTGTCTCTTCTTCAAGAGAGTCCCGTGCAGCGAGATGC 240

QY 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGCGAGGGGGAGAGCGCCACCTCAG 300

DB 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGCGAGGGGGAGAGCGCCACCTCAG 300

QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGGAGCAACCTCTTA 360

DB 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGGAGCAACCTCTTA 360

QY 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCCGCTGGTCTCTTCTGAGCAACCCAAAC 420

DB 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCCGCTGGTCTCTTCTGAGCAACCCAAAC 420

QY 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480

DB 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480

QY 481 GGTGAGACGACAAACCCAGAGACCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540

DB 481 GGTGAGACGACAAACCCAGAGACCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540

QY 541 CAAAATTGTAGAGATTTCTTCAGATATCTCATTAAATGAAGGGAAACAATATTAGCCTCAC 600

DB 541 CAAAATTGTAGAGATTTCTTCAGATATCTCATTAAATGAAGGGAAACAATATTAGCCTCAC 600

QY 601 CTGCATAGCACTGGTAGACGAGACCTAGCGTTACTTGGAGACACATCTCTCCCAAGC 660

DB 601 CTGCATAGCACTGGTAGACGAGACCTAGCGTTACTTGGAGACACATCTCTCCCAAGC 660

QY 661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720

DB 661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720

QY 721 AGGGGACTACAGTGGAGTGCCTCCAATGAGCTGGCGCGCGCGCGTGTAGCGAGAGTAAA 780

DB 721 AGGGGACTACAGTGGAGTGCCTCCAATGAGCTGGCGCGCGCGCGTGTAGCGAGAGTAAA 780

QY 781 GGTCACTGTAACATATCCACCATACATTTCAAGAGCCAAAGGGTACAGGTGTCTCCCGTGG 840

DB 781 GGTCACTGTAACATATCCACCATACATTTCAAGAGCCAAAGGGTACAGGTGTCTCCCGTGG 840

QY 841 ACAAAGGGGACACTGCACTGCAAGTGTGAAGCTTCAAGAGCCAAAGGGTACAGGTGTCTCCCGTGG 900

DB 841 ACAAAGGGGACACTGCACTGCAAGTGTGAAGCTTCAAGAGCCAAAGGGTACAGGTGTCTCCCGTGG 900

QY 901 CAAGGATGACAAAGACTGATTGAGGAAAGAAAGGGGTGAAGTGGAAACACACCTTT 960

DB 901 CAAGGATGACAAAGACTGATTGAGGAAAGAAAGGGGTGAAGTGGAAACACACCTTT 960

QY 961 CCTCTCAAAACCTCATCTTTCTTCAATGTCTCTGAAACATGACTATGCGGAACATACCTTGGCT 1020

DB 961 CCTCTCAAAACCTCATCTTTCTTCAATGTCTCTGAAACATGACTATGCGGAACATACCTTGGCT 1020

QY 1021 GGCTTCCCAAGCTGGGCGCACCAATGCCAGATCATGTCTTTTGGTCCAGGCGCGCT 1080

DB 1021 GGCTTCCCAAGCTGGGCGCACCAATGCCAGATCATGTCTTTTGGTCCAGGCGCGCT 1080

QY 1081 CAGCGAGGTGAGCAACCGGCACTCGAGAGGGGAGGTGGCTGTGGCTGTGCTTCTTCT 1140

DB 1081 CAGCGAGGTGAGCAACCGGCACTCGAGAGGGGAGGTGGCTGTGGCTGTGCTTCTTCT 1140

QY 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGTATGTGAGTGCCTTCCCGCGGAAAGGCT 1200

DB 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGTATGTGAGTGCCTTCCCGCGGAAAGGCT 1200

QY 1201 GCGCGCACCCACCCACCAACCAACAGCAATGGCAACCCGACAGCAACCAATCAGATA 1260

DB 1201 GCGCGCACCCACCCACCAACCAACAGCAATGGCAACCCGACAGCAACCAATCAGATA 1260

QY 1261 TATACAAATGAATTAGAGAGAACACGCTCATCGGACAGAAATTTGAGGGAGGGGAGC 1320

DB 1261 TATACAAATGAATTAGAGAGAACACGCTCATCGGACAGAAATTTGAGGGAGGGGAGC 1320

QY 1321 AAGAAATACCTTTGGGGGGGAAAGAGTGTAAAAAAGAAATTTGAAATTTGCTTTCAGATA 1380

Db 1321 AAGAAATACCTTGGGGGAAAAGATTTTAAAAAGAAATGAAATTCCTTGCAGATA 1380
Qy 1381 TTTAGGTACAAATGAGTTTCTTTTCCCAACGGGAAGAACACAGACACACCGGCTTGA 1440
Db 1381 TTTAGGTACAAATGAGTTTCTTTTCCCAACGGGAAGAACACAGACACACCGGCTTGA 1440
Qy 1441 CCACCTGACAGCTGCATCGTGAACCTCTTGTGTCAGTGTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCACCTGACAGCTGCATCGTGAACCTCTTGTGTCAGTGTGGGCAAGGCTCAGCCTC 1500
Qy 1501 TCTGCCACACAGAGTGGCCCCACAGTGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Db 1501 TCTGCCACACAGAGTGGCCCCACAGTGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Qy 1561 GTCCATAGACAGAACAGATGAGACTTCCGGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
Db 1561 GTCCATAGACAGAACAGATGAGACTTCCGGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCGCGTGTGTGTAACAGTGAATAAAAAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGCGTGTGTGTAACAGTGAATAAAAAAGAGCAAAAAAAA 1679
RESULT 71
ADD09477
ID ADD09477 standard; cDNA; 1679 BP.
XX
AC ADD09477;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003194775-A1.
XX
XX 16-OCT-2003.
XX
XX 28-MAY-2002; 2002US-00156848.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2003-852595/79.
XX
XX P-PSDB; ADD09478.
XX
XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
XX for detecting a tumor, stimulating the release of tumor necrosis factor
XX alpha from blood and stimulating the release of proteoglycans from
XX cartilage.
XX
XX Claim 2; Fig 375; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTGTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGACAAAGCTTGAGAGCAAC 60
Db 1 GTGTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGACAAAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAAATCATGAAAAACCATCCAGCCAAAAATGCACAAATTTCTTCTTGGGCAAT 180
Db 121 AAGAAAAAAATCATGAAAAACCATCCAGCCAAAAATGCACAAATTTCTTCTTGGGCAAT 180
Qy 181 CTTTCAGGGGCTGGCTGCTGTCTTCTTCAGAGAGTCCCGTGGCAGCGAGATGC 240
Db 181 CTTTCAGGGGCTGGCTGCTGTCTTCTTCAGAGAGTCCCGTGGCAGCGAGATGC 240
Qy 241 CACCTTCCCAAAGCTATGGACAACGTCACGTCCTCGGAGGGGAGAGCGCCCTCAG 300
Db 241 CACCTTCCCAAAGCTATGGACAACGTCACGTCCTCGGAGGGGAGAGCGCCCTCAG 300
Qy 301 GTGCATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGACACATCTCTA 360
Db 301 GTGCATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGACACATCTCTA 360
Qy 361 TGCTGGGAATGACAGTGGTGGCTGGATCTCGCTGGCTCTCTTGAGCAACACCCCAAC 420
Db 361 TGCTGGGAATGACAGTGGTGGCTGGATCTCGCTGGCTCTCTTGAGCAACACCCCAAC 420
Qy 421 GCAGTACAGATCGAGATCCAGAACGTCGATGTGTATGACGAGGGCCCTTACCTGTCTC 480
Db 421 GCAGTACAGATCGAGATCCAGAACGTCGATGTGTATGACGAGGGCCCTTACCTGTCTC 480
Qy 481 GGTGCAGACAGACACACACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1372 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.

XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GTGTGTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAAAAC	60
Db	1	GTGTGTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAAAAC	60
Qy	61	AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
Db	61	AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
Qy	121	AAGAAAGAAATCATGAAGAACCATCAGCCCAAAATGCAATTCATCTCTTGGCAAT	180
Db	121	AAGAAAGAAATCATGAAGAACCATCAGCCCAAAATGCAATTCATCTCTTGGCAAT	180
Qy	181	CTTCACGGGCTGGCTCTGTCTCTTCCAAAGAGTCCCGTCCGAGCGGAGATGC	240
Db	181	CTTCACGGGCTGGCTCTGTCTCTTCCAAAGAGTCCCGTCCGAGCGGAGATGC	240
Qy	241	CACCTTCCCAAGCTATGACAACTGACGCTGCGGTCGGGAGAGCGCCACCTCAG	300
Db	241	CACCTTCCCAAGCTATGACAACTGACGCTGCGGTCGGGAGAGCGCCACCTCAG	300
Qy	301	GTGCACATATTGACAAACCGGCTACCCGGTGGCTTAAACCGCAGCACCATCTCTA	360
Db	301	GTGCACATATTGACAAACCGGCTACCCGGTGGCTTAAACCGCAGCACCATCTCTA	360
Qy	361	TGCTGGGAATGACAAAGTGTGCTGATCTCCGCTGGTCTTCTGAGCAACCCAAAC	420
Db	361	TGCTGGGAATGACAAAGTGTGCTGATCTCCGCTGGTCTTCTGAGCAACCCAAAC	420
Qy	421	GCAGTACAGATCGAGATCCAGAACGTTGATGTATGACGAGGCGCTTACACCTGCTC	480
Db	421	GCAGTACAGATCGAGATCCAGAACGTTGATGTATGACGAGGCGCTTACACCTGCTC	480
Qy	481	GGTGACAGACAAACCAACCAAGACCTTAGGGTCCACTCATTTGTGCAAGTATCTCC	540
Db	481	GGTGACAGACAAACCAACCAAGACCTTAGGGTCCACTCATTTGTGCAAGTATCTCC	540
Qy	541	CAAAATGTAGATTTCTTCAGATCTCCATTAATGAAGGAAACAATATTAGGCTCAC	600
Db	541	CAAAATGTAGATTTCTTCAGATCTCCATTAATGAAGGAAACAATATTAGGCTCAC	600
Qy	601	CTGCATAGCACTGGTAGACAGAGCTACGGTTACTTTGAGACACATCTCTCCCAAGC	660
Db	601	CTGCATAGCACTGGTAGACAGAGCTACGGTTACTTTGAGACACATCTCTCCCAAGC	660
Qy	661	GGTTGGCTTTGTGAGTGAAGCAAGTACTTGGAAATTCAGGGCATCACCGGGAGCAGTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGCAAGTACTTGGAAATTCAGGGCATCACCGGGAGCAGTC	720
Qy	721	AGGGGACTACAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGTACGGAGGTAA	780
Db	721	AGGGGACTACAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGTACGGAGGTAA	780

Qy	781	GGTCACCGTGAACTATCCACCATACATTTTCAGAAAGCAAGGTTACAGGTGTCCCGTGGG	840
Db	781	GGTCACCGTGAACTATCCACCATACATTTTCAGAAAGCAAGGTTACAGGTGTCCCGTGGG	840
Qy	841	ACAAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Db	841	ACAAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Qy	901	CAAGATGACAAAGACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAACAGACCTTT	960
Db	901	CAAGATGACAAAGACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAACAGACCTTT	960
Qy	961	CCTCTCAAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGAACATACACTTCGCT	1020
Db	961	CCTCTCAAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGAACATACACTTCGCT	1020
Qy	1021	GGCTCCCAAGCTGGGCGCACCAATGCGAGCATCATCTATTTTGGTCCAGGCGCGT	1080
Db	1021	GGCTCCCAAGCTGGGCGCACCAATGCGAGCATCATCTATTTTGGTCCAGGCGCGT	1080
Qy	1081	CAGCGAGTGTGAGCAACCGCACGCTCGAGAGGGGAGGCTGCGTCTGGCTGTGCTCTTCT	1140
Db	1081	CAGCGAGTGTGAGCAACCGCACGCTCGAGAGGGGAGGCTGCGTCTGGCTGTGCTCTTCT	1140
Qy	1141	GGTCTTGACCTGCTCTTCAAAATTTTGGTGTGAGTGCCTTCCCGGAGGAGGCT	1200
Db	1141	GGTCTTGACCTGCTCTTCAAAATTTTGGTGTGAGTGCCTTCCCGGAGGAGGCT	1200
Qy	1201	GCCTCCACACACCAACCAACAGCAATGTCACACCGCAGCAACCAATCAGATA	1260
Db	1201	GCCTCCACACACCAACCAACAGCAATGTCACACCGCAGCAACCAATCAGATA	1260
Qy	1261	TATCAAAATGAATGTAGAAAGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCCTTCAGATA	1320
Db	1261	TATCAAAATGAATGTAGAAAGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCCTTCAGATA	1320
Qy	1321	AAAGAAATTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCCTTCAGATA	1380
Db	1321	AAAGAAATTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCCTTCAGATA	1380
Qy	1381	TTTAGGTACAAATGGAGTTTCTTTTCCAAACCGGAAAGAACACAGCACACCCGGCTTGGGA	1440
Db	1381	TTTAGGTACAAATGGAGTTTCTTTTCCAAACCGGAAAGAACACAGCACACCCGGCTTGGGA	1440
Qy	1441	CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGGCTC	1500
Db	1441	CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGGCTC	1500
Qy	1501	TCTGCCCAAGAGTCCCGCCACGTTGGGAACATTTGGAGCTGGCCATCCCAAAATTCATCA	1560
Db	1501	TCTGCCCAAGAGTCCCGCCACGTTGGGAACATTTGGAGCTGGCCATCCCAAAATTCATCA	1560
Qy	1561	GTCCATAGAGACGACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTCGCGGCACTTTG	1620
Db	1561	GTCCATAGAGACGACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTCGCGGCACTTTG	1620
Qy	1621	GTAGACTGTGCCACCAACCGGCTGTGTGTGAAACGTGAATTAAGAGCAAAAAAAA	1679
Db	1621	GTAGACTGTGCCACCAACCGGCTGTGTGTGAAACGTGAATTAAGAGCAAAAAAAA	1679

RESULT 73

ADD41190
ID ADD41190 standard; cDNA; 1679 BP.

XX
AC ADD41190;
XX
DT 15-JAN-2004 (first entry)
XX

DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
XX US2003203438-A1.
XX
XX 30-OCT-2003.
XX
XX 15-MAY-2002; 2002US-00146786.
XX
XX 24-NOV-1997; 97US-0066511P.
XX PR 16-SEP-1998; 98WO-US019330.
XX PR 25-AUG-1999; 99US-00380139.
XX PR 22-FEB-2000; 2000WO-US004414.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-875645/81.
XX DR P-P8DB; ADD41191.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
XX PRO4978, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; SEQ ID NO 375; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from PMBC cells, for inhibiting the binding of
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver: tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This sequence encodes
XX a novel human secreted and transmembrane PRO polypeptide.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 1679; DB 1; Length 1679;
XX Best Local Similarity 100.0%; Pred. No. 6.7e-05;
XX Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 GTTGTGCTCCTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
61 AATCTATCAGGAAGAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
61 AATCTATCAGGAAGAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
121 AAGAAAAAATCATGAAACCATCCAGCAAAATGACAAATTCATCTCTTGGGCAAT 180
121 AAGAAAAAATCATGAAACCATCCAGCAAAATGACAAATTCATCTCTTGGGCAAT 180
181 CTTTCAGGGGCTGGCTGCTCTCTCTTCCAGAGAGTGCCTGCGCAGCGGAGATGC 240
181 CTTTCAGGGGCTGGCTGCTCTCTCTTCCAGAGAGTGCCTGCGCAGCGGAGATGC 240
241 CACCTTCCCAAGATATGACAAAGTGCCTGCGCAGCGGAGAGAGCGCCACCTCAG 300
241 CACCTTCCCAAGATATGACAAAGTGCCTGCGCAGCGGAGAGAGCGCCACCTCAG 300
301 GTGCACATATTGACAAAGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 360
301 GTGCACATATTGACAAAGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 360
361 TGTGCGAATGACAAAGTGCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
361 TGTGCGAATGACAAAGTGCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
421 GCAGTACACATCGAGATCCAGAAAGTGCCTGCTGCTGCTGCTGCTGCTGCTGCT 480
421 GCAGTACACATCGAGATCCAGAAAGTGCCTGCTGCTGCTGCTGCTGCTGCTGCT 480
481 GGTGCGAGACAGCAACCCCAAGACCTCTAGGTCACCTCTCTGTCAGAGTATCTCC 540
481 GGTGCGAGACAGCAACCCCAAGACCTCTAGGTCACCTCTCTGTCAGAGTATCTCC 540
541 CAAATTTAGAGATTTCTTCAGATATCTTCAGATATCTTCAGATATCTTCAGAT 600
541 CAAATTTAGAGATTTCTTCAGATATCTTCAGATATCTTCAGATATCTTCAGAT 600
601 CTGCATAGCAACTGGTAGACACAGAGCTACGGTTACTTTGGAGACACATCTCTCC 660
601 CTGCATAGCAACTGGTAGACACAGAGCTACGGTTACTTTGGAGACACATCTCTCC 660
661 GGTGCTTTGTGAGTGAAGACGATATCTGGAATTCAGGTCACCTCCCGGAGAGT 720
661 GGTGCTTTGTGAGTGAAGACGATATCTGGAATTCAGGTCACCTCCCGGAGAGT 720
721 AGGGGACTACGAGTGCCTCTCAATGACCTGGCGCGCGCGCGCGCGCGCGCGTAA 780
721 AGGGGACTACGAGTGCCTCTCAATGACCTGGCGCGCGCGCGCGCGCGCGTAA 780
781 GGTACCGTGAATCTCCACATATCTTCAGAGCAAGGTCACAGGTGTCCTCCCGTGG 840
781 GGTACCGTGAATCTCCACATATCTTCAGAGCAAGGTCACAGGTGTCCTCCCGTGG 840
841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGG 900
841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGG 900
901 CAAGGATGACAAAGACTGATTTGAAGAAAGAGGGGTGAAGTGAAGAAACAGACTTT 960
901 CAAGGATGACAAAGACTGATTTGAAGAAAGAGGGGTGAAGTGAAGAAACAGACTTT 960
961 CTTCTCAAAACTCATCTTCTTCAATGCTCTGAAACATGACTATGGGAACTACACTTGC 1020
961 CTTCTCAAAACTCATCTTCTTCAATGCTCTGAAACATGACTATGGGAACTACACTTGC 1020
1021 GGCTCTCAACAGCTGGGCGACACCAATGCGAGCATCTGCTATTTGGTCCAGGCGCGT 1080
1021 GGCTCTCAACAGCTGGGCGACACCAATGCGAGCATCTGCTATTTGGTCCAGGCGCGT 1080
1081 CAGCGAGTGCAGCAACGGGACGTCGAGGAGGGGAGCTGCTGCTGCTGCTGCTGCTCT 1140

QY 1 GTTGTGCTCCTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60

Db 1081 CAGCGAGGTGAGCAACGCGACGTCGAGGAGGCGAGCTGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGCACCTGCTTCTCAATTTTGTGAGTGCCACTTCCACACCGCGGAAGGCT 1200
Db 1141 GGTCTTGCACCTGCTTCTCAATTTTGTGAGTGCCACTTCCACACCGCGGAAGGCT 1200
Qy 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
Db 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
Qy 1261 TATACAAATGAATTAAGAAACACAGAGCTCATGGGACAGAAATTTGAGGAGGAGGAGAC 1320
Db 1261 TATACAAATGAATTAAGAAACACAGAGCTCATGGGACAGAAATTTGAGGAGGAGGAGAC 1320
Qy 1321 AAAGAATACCTTTGGGGGGAAGAGAGTTTAAAGAAAGAAATTTGAAATTCCTTGCAGATA 1380
Db 1321 AAAGAATACCTTTGGGGGGAAGAGAGTTTAAAGAAAGAAATTTGAAATTCCTTGCAGATA 1380
Qy 1381 TTTAGGTACATGAGTTTCTTTTCCCAACGGGAGACACAGACACACCGGCTTGA 1440
Db 1381 TTTAGGTACATGAGTTTCTTTTCCCAACGGGAGACACAGACACACCGGCTTGA 1440
Qy 1441 CCACCTGCAAGCTGCTGTCGCACTCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCACCTGCAAGCTGCTGTCGCACTCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGGCCCACTGCGAATTTCTGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGGCCCACTGCGAATTTCTGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGACGACGACGATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
Db 1561 GTCCATAGACGACGACGATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCGGCTGTGTGTGAACGTTGAATTAATAAAGACGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGGCTGTGTGTGAACGTTGAATTAATAAAGACGCAAAAAA 1679

RESULT 74

ADD52329

ID ADD52329 standard; cDNA; 1679 BP.

XX AC ADD52329;

XX 15-JAN-2004 (first entry)

XX cDNA encoding human PRO polypeptide #188.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; PFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.

XX Homo sapiens.

XX US2003194769-A1.

XX 16-OCT-2003.

XX 21-MAY-2002; 2002US-00152374.

XX 09-DEC-1999; 99US-0170262P.

XX 01-DEC-2000; 2000WO-00032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX MPI: 2003-852593/79.
XX P-FSDB; ADD52330.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for detection of tumors, modulating the uptake of glucose
XX or free fatty acids and stimulating the release of proteoglycans from
XX cartilage.

XX Claim 2; Fig 375; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or PFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence encodes a human PRO polypeptide of the invention. Note: the
XX sequence data for this patent is also available in electronic format from
XX the USPTO website at seqdata.uspto.gov.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

XX Query Match 100.0%; Score 1679; DB 1; Length 1679;
XX Best Local Similarity 100.0%; Pred. No. 6.7e-05;
XX Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGACAAAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGACAAAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAAAAACCAGACCTGCACAAAAAGAAAAAGAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAAAACCAGACCTGCACAAAAAGAAAAAGAG 120
Qy 121 AAGAAAAAATCATGAAAAACATCCAGCAAAATGCATTTCTTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACATCCAGCAAAATGCATTTCTTCTTGGGCAAT 180
Qy 181 CTTACGGGGCTGGCTGCTCTGTGTCTTTTCAAGAGTGCCCGTGGCAGCGGAGATGC 240
Db 181 CTTACGGGGCTGGCTGCTCTGTGTCTTTTCAAGAGTGCCCGTGGCAGCGGAGATGC 240
Qy 241 GACCTTCCCCAAGCTATGGACAGCTCCGTCGAGGGGAGAGCGCCACCTCAG 300

CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1134, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1025, PRO1181, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.

XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATAGAGGAAACAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATAGAGGAAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACCTGGTGTAGACAGAGCCTACGGTTACTTGTGAGACACATCTCTCCCAAAGC 660
DB 601 CTGCATAGCAACCTGGTGTAGACAGAGCCTACGGTTACTTGTGAGACACATCTCTCCCAAAGC 660
QY 661 GTTTGGCTTTGTGTAGTGAAGACGAATACTTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GTTTGGCTTTGTGTAGTGAAGACGAATACTTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCCAAATACGTGGCGCGCCCGTGTACGGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCCAAATACGTGGCGCGCCCGTGTACGGAGAGTAAA 780
QY 781 GGTCAACGTGACACTATCCACATACATTTTCAAGACCAAGGTTACAGGTCTCCCGTGGG 840
DB 781 GGTCAACGTGACACTATCCACATACATTTTCAAGACCAAGGTTACAGGTCTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGATGACAAAAGACTGATTGAAGAAAGAGGGTGAAGTGAAGAAACAGACCTTT 960
DB 901 CAAGATGACAAAAGACTGATTGAAGAAAGAGGGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CCTCTCAAAACTCATCTTTTCAATGTCTCTGAACATGACTATGGGAACATACACTTCGCT 1020
DB 961 CCTCTCAAAACTCATCTTTTCAATGTCTCTGAACATGACTATGGGAACATACACTTCGCT 1020
QY 1021 GGCCTTCAAAAGCTGGGCGCACCAATGCCAGCATCATGTTATTTGGTTCAGGCGCGCT 1080
DB 1021 GGCCTTCAAAAGCTGGGCGCACCAATGCCAGCATCATGTTATTTGGTTCAGGCGCGCT 1080
QY 1081 CAGCGAGTGTAGCAACGCGCTGAGAGGCGAGGCTGGTGTGGCTGTGGCTCTTCT 1140
DB 1081 CAGCGAGTGTAGCAACGCGCTGAGAGGCGAGGCTGGTGTGGCTGTGGCTCTTCT 1140
QY 1141 GGTCTTGCACTGTCTTCTCAAAATTTTGTATGTAGTGCATTTCCCAACCCGGGAAAGCT 1200
DB 1141 GGTCTTGCACTGTCTTCTCAAAATTTTGTATGTAGTGCATTTCCCAACCCGGGAAAGCT 1200
QY 1201 GCCGCCACCAACCAACCAACAGCAATGCAACAGCAACAGCAACCAACCAACAGCA 1260
DB 1201 GCCGCCACCAACCAACCAACAGCAATGCAACAGCAACAGCAACCAACCAACAGCA 1260
QY 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTAAAGAAATTTGAAATTTGAAATTTG 1380
DB 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTAAAGAAATTTGAAATTTGAAATTTG 1380
QY 1381 TTTAGGTACAATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCACACCCGGCTTGA 1440
DB 1381 TTTAGGTACAATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCACACCCGGCTTGA 1440
QY 1441 CCCACTGCAAGTGCATGTGCAACCTTTTGGTGCAGTGTGGCAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGTGCATGTGCAACCTTTTGGTGCAGTGTGGCAGGGCTCAGCCTC 1500
QY 1501 TCTGCCCAACAGAGTGCCTCCACAGTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCCAACAGAGTGCCTCCACAGTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGAGCAACAGATGAGACCTTCGGCCCAAGCGTGGCGCTCGCGGACCTTTG 1620
DB 1561 GTCCATAGAGAGCAACAGATGAGACCTTCGGCCCAAGCGTGGCGCTCGCGGACCTTTG 1620
QY 1621 GTAGACTGTGCCACACCGCGGTGTGTGTGAAACGTGTAATATAAAGAGCAAAAAA 1679

Claim 2; Fig 375; 638pp; English.

PS The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCCACAGCTTGAGAGCAAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCCACAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 120
DB 61 AATCTATCAGGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATCTCTTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATCTCTTTGGGCAAT 180
QY 181 CTTTCAAGGGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240
DB 181 CTTTCAAGGGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240
QY 241 CACCTTCCCAAGCTATGACAACTGACGCTGCGGCGGGGAGAGCGCCACCTCTAG 300
DB 241 CACCTTCCCAAGCTATGACAACTGACGCTGCGGCGGGGAGAGCGCCACCTCTAG 300
QY 301 GTGCACATATTGACAAACCGGGTACCCGGGTGGCTGCTGCTGCTGCTGCTGCTGCTG 360
DB 301 GTGCACATATTGACAAACCGGGTACCCGGGTGGCTGCTGCTGCTGCTGCTGCTG 360
QY 361 TGCTGGGAATGACAAAGTGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 420
DB 361 TGCTGGGAATGACAAAGTGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 420
QY 421 GCAGTACAGCATCGAGATCAGAAACGTTGATGTATGACAGGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCAGAAACGTTGATGTATGACAGGGGCCCTTACACCTGCTC 480

QY 481 GGTGCAGACAGCAACACACCCAAAGACCTCTAGGGTCCACCTCATTGTGCAAGTATCTCC 540
DB 481 GGTGCAGACAGCAACACACCCAAAGACCTCTAGGGTCCACCTCATTGTGCAAGTATCTCC 540
QY 541 CAAAATTGTAGAGATTTCTTCCAGATATCTCCATTAAATGAGGGAACAATATTAGCCTCAC 600
DB 541 CAAAATTGTAGAGATTTCTTCCAGATATCTCCATTAAATGAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACAGAGCCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTAGACAGAGCCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGACGAATATTCTGGAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGACGAATATTCTGGAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCCATGACGTGGCGCCGCGCTGGTACGAGAGATAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCCATGACGTGGCGCCGCGCTGGTACGAGAGATAA 780
QY 781 GGTCAACCGTGAACATATCCACCATACATTTAGAAAGCCAAAGGGTACAGGTGTCCCGTGG 840
DB 781 GGTCAACCGTGAACATATCCACCATACATTTAGAAAGCCAAAGGGTACAGGTGTCCCGTGG 840
QY 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGTA 900
DB 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGTA 900
QY 901 CAAGGATCACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT 960
DB 901 CAAGGATCACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT 960
QY 961 CTTCTCAAACTCATCTTCTTCAATGTCTGAAACATGACTATGGGAACATCAGCTTGGT 1020
DB 961 CTTCTCAAACTCATCTTCTTCAATGTCTGAAACATGACTATGGGAACATCAGCTTGGT 1020
QY 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGTATTGTGTCAGGCGCCGT 1080
DB 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGTATTGTGTCAGGCGCCGT 1080
QY 1081 CAGCAGGTGAGCAACCGCACGTCGAGAGGGGAGGTGCGCTCTGGGTGCTGCTCTTCT 1140
DB 1081 CAGCAGGTGAGCAACCGCACGTCGAGAGGGGAGGTGCGCTCTGGGTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACCTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCCACCCGGGAAAGGCT 1200
DB 1141 GGTCTTGCACCTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCCACCCGGGAAAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
QY 1261 TATCAAAATGAATTAGAGAGAAACAGCCTCATGGGACGAAATTTGAGGAGGGGAA 1320
DB 1261 TATCAAAATGAATTAGAGAGAAACAGCCTCATGGGACGAAATTTGAGGAGGGGAA 1320
QY 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380
DB 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380
QY 1381 TTTAGGTACAATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCACACCCGGCTTGA 1440
DB 1381 TTTAGGTACAATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCACACCCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGATCGTGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGATCGTGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGGCCCGCCAGCTGGGAACATCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGGCCCGCCAGCTGGGAACATCTGGAGCTGGCCATCCCAATTCATCA 1560

QY 1561 GTCCATAGAGACGACAGATGAGACCTTCGCGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
 Db 1561 GTCCATAGAGACGACAGATGAGACCTTCGCGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
 QY 1621 GTAGACTGTGCCACCAACGCGCGTGTGTGTAACCTGTAATATAAAGAGCAAAAAA 1679
 Db 1621 GTAGACTGTGCCACCAACGCGCGTGTGTGTAACCTGTAATATAAAGAGCAAAAAA 1679

RESULT 77

ADD53621
 ID ADD53621 standard; cDNA; 1679 BP.

XX AC ADD53621;

XX DT 15-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX OS US2003203437-A1.

XX PN 30-OCT-2003.

XX PF 15-MAY-2002; 2002US-00146728.

XX PR 01-JUL-1998; 98US-0091360P.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 01-DEC-2000; 2000US-00380137.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

XX DR WPI; 2003-875644/81.

XX DR P-PSDB; ADP53622.

XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.

XX PS Claim 2; SEQ ID NO 375; 659pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful

CC in assays to identify other proteins or molecules involved in chromosome
 CC interaction. A polynucleotide (III) encoding (I) is useful in chromsome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (III) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTTAAATCTCTTTCGCAAAAGTGGAGCAACAC 60

Db 1 GTTGTGTCCTTCAGCAAAACAGTGGATTTAAATCTCTTTCGCAAAAGTGGAGCAACAC 60

QY 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGACAAAAGAAAGAAAGAAAG 120

Db 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGACAAAAGAAAGAAAGAAAG 120

QY 121 AAAAAAATCATGAAAAATCCAGCCAAATGCAAAATGCAAAATCTCTTGGGCAAT 180

Db 121 AAAAAAATCATGAAAAATCCAGCCAAATGCAAAATGCAAAATCTCTTGGGCAAT 180

QY 181 CTTACGGGCTGGCTGCTCTGCTCTCTTCCAAAGAGTCCGCGCAGCGGAGATGC 240

Db 181 CTTACGGGCTGGCTGCTCTGCTCTCTTCCAAAGAGTCCGCGCAGCGGAGATGC 240

QY 241 CACCTTCCCAAGCTATGCAACACGCTGCGGTCGGGAGGAGAGAGCCACCCCTCAG 300

Db 241 CACCTTCCCAAGCTATGCAACACGCTGCGGTCGGGAGGAGAGAGCCACCCCTCAG 300

QY 301 GTGCACATTTGCAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCCTCTTA 360

Db 301 GTGCACATTTGCAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCCTCTTA 360

QY 361 TGTGGAATGACAAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420

Db 361 TGTGGAATGACAAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420

QY 421 GCAGTACAGCATCGAGATCCAGAACCTGATGATGATGATGATGATGATGATGATGATGAT 480

Db 421 GCAGTACAGCATCGAGATCCAGAACCTGATGATGATGATGATGATGATGATGATGATGAT 480

QY 481 GGTGCAAGACAGCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540

Db 481 GGTGCAAGACAGCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540

QY 541 CAAAAATGATGATTTCTTCAGATATCTCCATTAATGAAGGAGCAATATTAGCTCTAC 600

Db 541 CAAAAATGATGATTTCTTCAGATATCTCCATTAATGAAGGAGCAATATTAGCTCTAC 600

QY 601 CTGCATAGCAACTGCTAGACACGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660

Db 601 CTGCATAGCAACTGCTAGACACGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660

QY 661 GTTGTGCTTTGTGAGTGAAGCAAGAAATCTTGGAAATTCAGGGGATCACCCGGGAGAGTC 720

Db 661 GTTGTGCTTTGTGAGTGAAGCAAGAAATCTTGGAAATTCAGGGGATCACCCGGGAGAGTC 720

QY 721 AGGGGACTACGAGTGCAGTSCCTTCAATGACGTGGCGCGCGCGCGCGCGCGCGCGCGCGCG 780

Db 721 AGGGGACTACGAGTGCAGTSCCTTCAATGACGTGGCGCGCGCGCGCGCGCGCGCGCGCG 780

QY 781 GGTACCGGTGAATATCCACCATATCTTTCAGAAAGCAAGGGTACAGGTGTCCTCCCTGGG 840

endothelial cell apoptosis; smooth muscle cell growth;
endothelial cell tube formation.

Homo sapiens.

US2003105012-A1.

PD 05-JUN-2003.

XX 16-AUG-2002; 2002US-00223088.

XX 15-SEP-2000; 2000US-0232887P.

XX 20-JUN-2001; 2001WO-US019692.

XX 09-JUL-2001; 2001WO-US021735.

XX 20-FEB-2002; 2002US-00081056.

XX (GETH) GENENTECH INC.

XX Baker KP, Ferrara N, Gerber H, Gerecht ME, Goddard A;
XX Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
XX Watanabe CK, Williams PM, Wood WI, Ye W;

DR WPI; 2003-829354/77.

DR P-PSDB; ADD37098.

XX New isolated nucleic acids encoding a secreted and transmembrane
XX polypeptide for treating a cardiovascular, endothelial, or angiogenic
XX disorder in a mammal, such as cancer or age-related macular degeneration.

XX Claim 2; SEQ ID NO 55; 492pp; English.

XX The invention relates to an isolated nucleic acid encoding a secreted and
XX transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
XX by the nucleic acid, or an agonist or antagonist, is used to treat a
XX cardiovascular, endothelial, or angiogenic disorder in a mammal,
XX preferably a human. The human may have suffered a myocardial infarction
XX or has cardiac hypertrophy, trauma, a cancer, or age-related macular
XX degeneration. The cardiac hypertrophy is characterised by the presence of
XX an elevated level of PGR-2 alpha. A PRO polypeptide, given in the
XX specification, or an agonist is used to inhibit or stimulate endothelial
XX cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
XX hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
XX PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
XX polypeptide, given in the specification, or an agonist is used to
XX stimulate or inhibit smooth muscle cell growth, or to induce endothelial
XX cell tube formation. The present sequence represents a cDNA encoding a
XX PRO polypeptide of the invention.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTTAAATCTCTTTCGACAAAGTTGAGAGCAAC 60
Db 1 GTTGTGTCCTTCAGCAAAACAGTGGATTTAAATCTCTTTCGACAAAGTTGAGAGCAAC 60

QY 61 AATCTATCAGGAAGAAAGAAAGAAAACCGAACCTGCACAAAAGAGAAAGAGAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAACCGAACCTGCACAAAAGAGAAAGAGAG 120

QY 121 AAGAAAAAATCATGAAACCATCCAGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAACCATCCAGCAAAATGCAAAATCTATCTCTTGGGCAAT 180

QY 181 CTTTACGGGGCTGGCTGCTGTGTCTTTCGAGAGTGCCTGCGGAGCGGAGATGC 240
Db 181 CTTTACGGGGCTGGCTGCTGTGTCTTTCGAGAGTGCCTGCGGAGCGGAGATGC 240

QY 241 CACCTTCCCAAGCTATGGACAACTGACGGTCCGGCAGGGGAGAGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGGACAACTGACGGTCCGGCAGGGGAGAGCCACCTCAG 300

factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTCCACAAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTCCACAAGCTTGAGAGCAAC 60

Qy 61 AATCTATCAGAAAGAGAAAGAAACCAACCTGACAAAGAGAAAGAAAGAG 120
Db 61 AATCTATCAGAAAGAGAAAGAAACCAACCTGACAAAGAGAAAGAAAGAG 120

Qy 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATTCATCTTTGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATTCATCTTTGGCAAT 180

Qy 181 CTTTACGGGGCTGGCTCTGTGTCTCTTCCAGAGATGCCGTCGCGAGCGGATGC 240
Db 181 CTTTACGGGGCTGGCTCTGTGTCTCTTCCAGAGATGCCGTCGCGAGCGGATGC 240

Qy 241 CACCTTCCCAAGCTATGACAACTGACGGTCCGGCAGGGGAGAGCGCCCTCAG 300
Db 241 CACCTTCCCAAGCTATGACAACTGACGGTCCGGCAGGGGAGAGCGCCCTCAG 300

Qy 301 GTGCACATATGACAAACCGGGTACCCGGGTGGCTTAAACCGCGAGCACTCTCTA 360
Db 301 GTGCACATATGACAAACCGGGTACCCGGGTGGCTTAAACCGCGAGCACTCTCTA 360

Qy 361 TGCTGGGAATGACAAGTGGTGGCTGGATCTCGGTGGTCTCTGAGCAACCCAAAC 420
Db 361 TGCTGGGAATGACAAGTGGTGGCTGGATCTCGGTGGTCTCTGAGCAACCCAAAC 420

Qy 421 GCAGTACAGCATCAGATCCAGAACTGGATGTGTATGACAGGGGCCCTTACCTGCTC 480
Db 421 GCAGTACAGCATCAGATCCAGAACTGGATGTGTATGACAGGGGCCCTTACCTGCTC 480

Qy 481 GGTGCAGACAGAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCAGACAGAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540

Qy 541 CAAAAATTGATAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600

541 CAAAAATTGATAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Qy 601 CTGCATACCAACTGTAGACAGAGCCTTACCGTTTACTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGCATACCAACTGTAGACAGAGCCTTACCGTTTACTTGGAGACACATCTCTCCAAAGC 660
Qy 661 GTTGGCTTTTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
Db 661 GTTGGCTTTTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTGCACTGCTCCATGACGTGGCGCGCCCGTGGTACGAGAGTAAA 780
Db 721 AGGGGACTACGAGTGCACTGCTCCATGACGTGGCGCGCCCGTGGTACGAGAGTAAA 780
Qy 781 GGTCACTGAACTATCCACCATACATTTTCAAGAACCAAGGTTACAGTGTCCCGTGG 840
Db 781 GGTCACTGAACTATCCACCATACATTTTCAAGAACCAAGGTTACAGTGTCCCGTGG 840
Qy 841 ACAAAGGGGACCTGCACTGAGCTGAGCTCAGCTCCCTCAGCAGAAATTCAGTGTGA 900
Db 841 ACAAAGGGGACCTGCACTGAGCTGAGCTCAGCTCAGCTCCCTCAGCAGAAATTCAGTGTGA 900
Qy 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT 960
Db 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT 960
Qy 961 CCTCTCAAACTCATCTTCTTCAATGTCTTGAACATGACTATGGAACTACACTTGGT 1020
Db 961 CCTCTCAAACTCATCTTCTTCAATGTCTTGAACATGACTATGGAACTACACTTGGT 1020
Qy 1021 GSCCTCCCAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTTGGTCCAGGCGCGT 1080
Db 1021 GSCCTCCCAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTTGGTCCAGGCGCGT 1080
Qy 1081 CAGCAGGTGAGCAACCGCACGTCGAGGAGGCGAGCTGCTCTGGCTGCTCTCTTCT 1140
Db 1081 CAGCAGGTGAGCAACCGCACGTCGAGGAGGCGAGCTGCTCTGGCTGCTCTCTTCT 1140
Qy 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTAGTGCCACTTCCCACCCGGGAAAGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTAGTGCCACTTCCCACCCGGGAAAGCT 1200
Qy 1201 GCGGCGACACACCAACAGCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
Db 1201 GCGGCGACACACCAACAGCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
Qy 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAA 1320
Db 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAA 1320
Qy 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAAAATTTGCCTTGCAGATA 1380
Db 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAAAATTTGCCTTGCAGATA 1380
Qy 1381 TTTAGGTACATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCACCCTGCTTGA 1440
Db 1381 TTTAGGTACATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCACCCTGCTTGA 1440
Qy 1441 CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGGCCCGCCAGTGGAACTCTTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGGCCCGCCAGTGGAACTCTTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGGGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGGGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACCGCGCTGTGTGTGAAAAGTGAATAAAGAGCAAAAAAAA 1679

Db 1621 GTAGACTGTCACCCAGCGCGTGTGTGTGAACCTGAATAAAGAGCAAAAAA 1679

RESULT 80
ADD02576
ID ADD02576 standard; cDNA; 1679 BP.
XX
AC ADD02576;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003203431-A1.
XX
PD 30-OCT-2003.
XX
PF 24-APR-2002; 2002US-00131820.
XX
PR 28-OCT-1998; 98US-0106030P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen MB, Goodard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875638/81.
DR P-PSDB; ADD02577.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 375; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of

CC Glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1 GTTGTGCTCTTACGCAAAACAGTGGATTTAAATCTCTTCGACAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTCTTACGCAAAACAGTGGATTTAAATCTCTTCGACAGCTTGAGAGCAAC 60
Oy 61 AATCTATCAGGAAAGAAAGAAAGAAAAAACCAGACCTGACAAAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAAGAAAGAAAGAAAAAACCAGACCTGACAAAAAGAAAGAAAG 120
Oy 121 AAGAAAAAATCATGAAACCAATCCAGCCAAAAATGCAATTTCTATCTCTTGGCAAT 180
Db 121 AAGAAAAAATCATGAAACCAATCCAGCCAAAAATGCAATTTCTATCTCTTGGCAAT 180
Oy 181 CTTACGGGGCTGGCTGCTGCTGCTCTCTTCCAGGAGTGGCGTGGCAGCGGAGATGC 240
Db 181 CTTACGGGGCTGGCTGCTGCTGCTCTCTTCCAGGAGTGGCGTGGCAGCGGAGATGC 240
Oy 241 CACCTTCCCAAGCTATGACAAACCTGACGCTCCGGAGGGGGAGAGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGACAAACCTGACGCTCCGGAGGGGGAGAGCCACCTCAG 300
Oy 301 GTCACATTTAGCAACCGGCTACCGGGTGGCTGGCTAAACCCGAGCACCATCTCTA 360
Db 301 GTCACATTTAGCAACCGGCTACCGGGTGGCTGGCTAAACCCGAGCACCATCTCTA 360
Oy 361 TGTGGGAATGACAAGTGGTGGCTGGATCTCGCTGGTCTTCTGAGCAACCCCAAC 420
Db 361 TGTGGGAATGACAAGTGGTGGCTGGATCTCGCTGGTCTTCTGAGCAACCCCAAC 420
Oy 421 GCAGTACAGCATCGAGATCCAGAACGTTGATGATGACGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACGTTGATGATGACGAGGGCCCTTACACCTGCTC 480
Oy 481 GGTGCAGACAGCAACCCCAAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
Db 481 GGTGCAGACAGCAACCCCAAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
Oy 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTTATGAGGGAACAATATTAGCTTAC 600
Db 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTTATGAGGGAACAATATTAGCTTAC 600
Oy 601 CTGCATAGCAACTGGTAGACAGAGCTTACGGTTACTTTGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCTTACGGTTACTTTGAGACACATCTCTCCCAAGC 660
Oy 661 GGTGGCTTTTGTAGTGAAGCAACCAATCTTGGAAATCAGGGCATCACCGGGAGGATC 720
Db 661 GGTGGCTTTTGTAGTGAAGCAACCAATCTTGGAAATCAGGGCATCACCGGGAGGATC 720
Oy 721 AGGGGACTACGAGTGCAGTGCCTCCATGACGTGGCGCGCCCGCTGGTACGGAGAGTAA 780
Db 721 AGGGGACTACGAGTGCAGTGCCTCCATGACGTGGCGCGCCCGCTGGTACGGAGAGTAA 780

QY 781 GGTCAACGCTGATATCCACATACATATTTGAGAAGCAAGGTACAGGTGTCCCGTGGG 840
Db 781 GGTCAACGCTGATATCCACATACATATTTGAGAAGCAAGGTACAGGTGTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGCAGAATTTCCAGTGGTA 900
Db 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGCAGAATTTCCAGTGGTA 900
QY 901 CAAGGATGACAAAGACTGATTGAGGAAAGAGGGGTGAAGTGGAAAAAGACCTTTT 960
Db 901 CAAGGATGACAAAGACTGATTGAGGAAAGAGGGGTGAAGTGGAAAAAGACCTTTT 960
QY 961 CCTCTCAAACTCATCTTCTCAATTTCTGAACATGACTATGGAACTACACTTGGCT 1020
Db 961 CCTCTCAAACTCATCTTCTCAATTTCTGAACATGACTATGGAACTACACTTGGCT 1020
QY 1021 GGCTCCAAAGCTGGGCGACACCAATGCGAGCATCATCTATTGGTCCAGGCGCGCT 1080
Db 1021 GGCTCCAAAGCTGGGCGACACCAATGCGAGCATCATCTATTGGTCCAGGCGCGCT 1080
QY 1081 CAGGAGGTGAGCAACGGGCGCTGAGGAGGGCAGGCTGGCTGGCTGGCTGGCTTCTT 1140
Db 1081 CAGGAGGTGAGCAACGGGCGCTGAGGAGGGCAGGCTGGCTGGCTGGCTGGCTTCTT 1140
QY 1141 GGTCTTCACCTGCTTCTCAATTTCTGAATGAGTGCCACTTCCCGACCGGAAAGGCT 1200
Db 1141 GGTCTTCACCTGCTTCTCAATTTCTGAATGAGTGCCACTTCCCGACCGGAAAGGCT 1200
QY 1201 GCGCCACCCACCCACCAACACAGCAATGCGACACCGCAGCAGCAACCAATCAGATA 1260
Db 1201 GCGCCACCCACCCACCAACACAGCAATGCGACACCGCAGCAGCAACCAATCAGATA 1260
QY 1261 TATCAAAATGAATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAC 1320
Db 1261 TATCAAAATGAATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAC 1320
QY 1321 AAAGATACCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGATACCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACATGAGTATTTCTTTCCAAACGGGAAAGACACAGCACACCGGCTTGA 1440
Db 1381 TTTAGGTACATGAGTATTTCTTTTCCAAACGGGAAAGACACAGCACACCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGATCGTCAACCTTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGATCGTCAACCTTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGGCCCAACGTTGGAACATTTGAGAGTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGGCCCAACGTTGGAACATTTGAGAGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAAACAGATGAGACCTTCCGGGCCCAAGCGTGGCGTGGCGGACCTTG 1620
Db 1561 GTCCATAGAGACGAAACAGATGAGACCTTCCGGGCCCAAGCGTGGCGTGGCGGACCTTG 1620
QY 1621 GTAGACTGTGCCACACGGCTGTGTTGTGAACCTGTAATTAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACGGCTGTGTTGTGAACCTGTAATTAAGAGCAAAAAA 1679

RESULT 81
ADD50516
ID ADD50516 standard; cDNA; 1679 BP.
XX AC
XX AC
XX AC
XX AC
DT 15-JAN-2004 (first entry)
XX Human PRO polynucleotide #63.
DE Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;

KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX Homo sapiens.
XX US2003096971-A1.
XX 22-MAY-2003.
XX 29-AUG-2002; 2002US-00232229.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Deenoyers L, Gerritsen MB, Goddard A, Godowski PJ,
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WL;
XX WPI; 2003-765528/72.
XX P-PSDB; ADD50517.
XX Novel isolated PRO polypeptide useful for tissue typing, as molecular
XX weight markers in protein electrophoresis, for treating arthritis, tumor.
XX Claim 2; Fig 125; 308pp; English.
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers and in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes. The PRO polypeptides are useful as
XX molecular markers for protein electrophoresis, and in tissue typing. This
XX sequence represents a human PRO polynucleotide of the invention.
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCGACAAAGCTTGAGCAACAC 60
Db 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCGACAAAGCTTGAGCAACAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAAATCATGAAACCATCCAGCAAAATTCGCAAAATTTCTCTTTGGGCAAT 180
Db 121 AAGAAAAAAATCATGAAACCATCCAGCAAAATTCGCAAAATTTCTCTTTGGGCAAT 180

181 CTTACGGGGTGGCTGCTCTGTCTCTTCAAGAGTGGCCCTGGCGACGGAGATGC 240
181 CTTACGGGGTGGCTGCTCTGTCTCTTCAAGAGTGGCCCTGGCGACGGAGATGC 240
241 CACCTTCCCAAGAGTATGGACAAGCTGACGGTCCGGCAGGGGAGCGGCACCTCAG 300
241 CACCTTCCCAAGAGTATGGACAAGCTGACGGTCCGGCAGGGGAGCGGCACCTCAG 300
301 GTGCACTATTGACAACCGGGTCAACCGGGTGGCCCTGAAACCGCAGCACCATCTCTA 360
301 GTGCACTATTGACAACCGGGTCAACCGGGTGGCCCTGAAACCGCAGCACCATCTCTA 360
361 TGTGGGAATGACAAGTGGTGGCTGGATCTCTGGCTGGTCTCTTCTGAGCAACACCCAAAC 420
361 TGTGGGAATGACAAGTGGTGGCTGGATCTCTGGCTGGTCTCTTCTGAGCAACACCCAAAC 420
421 GCAGTACAGATCGAGATCCAGAACGTTGATGACAGGGCCCTTACACCTGCTC 480
421 GCAGTACAGATCGAGATCCAGAACGTTGATGACAGGGCCCTTACACCTGCTC 480
481 GTGCAAGACAGAACCCCAAGACCTCTAGGTCACCTCATTTGTGCAAGTATCTCC 540
481 GTGCAAGACAGAACCCCAAGACCTCTAGGTCACCTCATTTGTGCAAGTATCTCC 540
541 CAAATTTGAGAGATTTCTTCAAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
541 CAAATTTGAGAGATTTCTTCAAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
601 CTGCATAGCAACTGTGAGACGAGCCTACGTTACTTTGGAGACACATCTCTCCAAAGC 660
601 CTGCATAGCAACTGTGAGACGAGCCTACGTTACTTTGGAGACACATCTCTCCAAAGC 660
661 GGTGGCTTTGTGAGTGAAGAGAACTATCTGGAATTCAGGGCATCACCGGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGAGAACTATCTGGAATTCAGGGCATCACCGGGAGCAGTC 720
721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCGCTGGTACGAGAGTAAA 780
721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCGCTGGTACGAGAGTAAA 780
781 GGTCAACGTGAATATCCACCATACATTTCAAGCCAGAGGTACAGGTGCCCCGCTGG 840
781 GGTCAACGTGAATATCCACCATACATTTCAAGCCAGAGGTACAGGTGCCCCGCTGG 840
841 ACAAAGGGGACACTGCACTGTGAAGCCTTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
841 ACAAAGGGGACACTGCACTGTGAAGCCTTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
901 CAGGATGACAAAAGTGAATGAAGGAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
901 CAGGATGACAAAAGTGAATGAAGGAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
961 CCTCTCAAAACTCATCTTCTCAATGCTCTCAACATGACTATGGAACTACACTTGGCT 1020
961 CCTCTCAAAACTCATCTTCTCAATGCTCTCAACATGACTATGGAACTACACTTGGCT 1020
1021 GGCCTTCAACAGCTGGGCGACACCAATGCGAGCATCATGCTATTGTCAGGGCGCGT 1080
1021 GGCCTTCAACAGCTGGGCGACACCAATGCGAGCATCATGCTATTGTCAGGGCGCGT 1080
1081 CAGCGAGGTGAGCAACGGCAGCTCGAGGAGGCGAGGCTCGCTGCTGCTGCTCTTCT 1140
1081 CAGCGAGGTGAGCAACGGCAGCTCGAGGAGGCGAGGCTCGCTGCTGCTGCTCTTCT 1140
1141 GGTCTTGCACCTGCTTCTCAATTTTGTATGTGAGTGCCACTTCCCAACCGGGGAAGGCT 1200
1141 GGTCTTGCACCTGCTTCTCAATTTTGTATGTGAGTGCCACTTCCCAACCGGGGAAGGCT 1200
1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320

1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320
1321 AAGAGATACCTTTGGGGGAAAGAGATTTTAAABAAAGAAATTTGAAATTTGCCTTGAGATA 1380
1321 AAGAGATACCTTTGGGGGAAAGAGATTTTAAABAAAGAAATTTGAAATTTGCCTTGAGATA 1380
1381 TTTAGTACAAATGGAGTTTCTTTTCCCAACCGGGAAGAACACACACACCCCGGCTTGA 1440
1381 TTTAGTACAAATGGAGTTTCTTTTCCCAACCGGGAAGAACACACACACCCCGGCTTGA 1440
1441 CCACTGCAAGTGCATCGTCAACCTCTTCTGTCAGTGGCGAGTGGCAAGGGCTCAGCCTC 1500
1441 CCACTGCAAGTGCATCGTCAACCTCTTCTGTCAGTGGCGAGTGGCAAGGGCTCAGCCTC 1500
1501 TCTGCCACACAGAGTGGCCCGCCACGTCGAACTTCTGAGCTGCCCATCCAAATTCATCA 1560
1501 TCTGCCACACAGAGTGGCCCGCCACGTCGAACTTCTGAGCTGCCCATCCAAATTCATCA 1560
1561 GTCCATAGAGACGAACAGATGAGACCTTCCGCCCCCAGCGTGGCGCTCGGGCACTTTG 1620
1561 GTCCATAGAGACGAACAGATGAGACCTTCCGCCCCCAGCGTGGCGCTCGGGCACTTTG 1620
1621 GTAGACTGTGCCACACCGCGCTGTGTGTGAACCTGTAATTAAGAGACAAAAA 1679
1621 GTAGACTGTGCCACACCGCGCTGTGTGTGAACCTGTAATTAAGAGACAAAAA 1679

RESULT 82
ADD02010
ID ADD02010 standard; cDNA; 1679 BP.
XX
AC ADD02010;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
FN US2003203430-A1.
XX
PD 30-OCT-2003.
XX
PP 23-APR-2002; 2002US-00128685.
XX
PR 11-AUG-1998; 98US-0096143P.
PR 02-JUN-1999; 99WO-US012252.
PR 30-MAR-2000; 2000US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-875637/81.
DR P-FSDB; ADD02011.
XX

PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.

Claim 2: Fig 375: 637pp: English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other; 0 X

Query Match	100.0%;	Score 1679;	DB 1;	Length 1679;
Best Local Similarity	100.0%;	Pred. No. 6.7e-05;		
Matches 1679;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	GTCTGTGCTTCACGAAACAGTGGATTAAATCTCTTGTCACAAAGCTTGAGAGCAACAC	60	
Db	1	GTCTGTGCTTCACGAAACAGTGGATTAAATCTCTTGTCACAAAGCTTGAGAGCAACAC	60	
Qy	61	AATCTATCAGGAAGAAGAAAGAAAAAACCAGAACTTGACAAAAAGAGAAAAAGAG	120	
Db	61	AATCTATCAGGAAGAAGAAAGAAAAAACCAGAACTTGACAAAAAGAGAAAAAGAG	120	
Qy	121	AAGAAAAAANAATCATGAAAAACCATCCAGCCAAAAAATGCACAAATTTCTATCTCTGGGCAAT	180	
Db	121	AAGAAAAAANAATCATGAAAAACCATCCAGCCAAAAAATGCACAAATTTCTATCTCTGGGCAAT	180	
Qy	181	CTTTCACGGGGCTGGCTGCTCTGTGTCTCTCTTCCAAAGGAGTGCCCTGGCGACGCGAGATGC	240	
Db	181	CTTTCACGGGGCTGGCTGCTCTGTGTCTCTCTTCCAAAGGAGTGCCCTGGCGACGCGAGATGC	240	
Qy	241	CACCTTCCCBAAGCTATGGACAAGTGCACGGTCCGGCAGGGGGAGAGCGGCACCCCTCAG	300	
Db	241	CACCTTCCCBAAGCTATGGACAAGTGCACGGTCCGGCAGGGGGAGAGCGGCACCCCTCAG	300	
Qy	301	GTGCACATATTGACAAACCGGGTTCACCCGGGTGGCTTGGCTAAACCGCAGCACCATCTCTCTA	360	
Db	301	GTGCACATATTGACAAACCGGGTTCACCCGGGTGGCTTGGCTTAAACCGCAGCACCATCTCTCTA	360	
Qy	361	TGCTGGGAATGACAAGTGGTGGCTGGATCTCTCGCGTGTCTCTTGTAGCAACAACCCAAAC	420	
Db	361	TGCTGGGAATGACAAGTGGTGGCTGGATCTCTCGCGTGTCTCTTGTAGCAACAACCCAAAC	420	

QY 1501 TCTGCCACAGAGTCCCGCCAGCTGGAGACATCTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTCCCGCCAGCTGGAGACATCTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGAGCAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGTCCGGGCACCTTTG 1620
DB 1561 GTCCATAGAGAGCAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGTCCGGGCACCTTTG 1620
QY 1621 GTAGACTGTGCCACACAGCGCGTGTCTGTGAAACGTGAATATAAAGAGCAAAAAAAA 1679
DB 1621 GTAGACTGTGCCACACAGCGCGTGTCTGTGAAACGTGAATATAAAGAGCAAAAAAAA 1679

RESULT 83

ADD54192
ID ADD54192 standard; cDNA; 1679 BP.

XX AC ADD54192;
XX DT 15-JAN-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
XX KW Tumour necrosis factor alpha release; TNF-alpha release;
XX KW Glucose uptake modulator; FFA uptake modulator;
XX KW Cell proliferation stimulator; cell differentiation stimulator;
XX KW Cell differentiation inhibitor; cytokine release stimulator; tumour;
XX KW Lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX KW Cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX KW Gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX US US2003203432-A1.
XX PD 30-OCT-2003.
XX PF 10-MAY-2002; 2002US-00142886.
XX PR 05-JUN-2000; 2000US-0209832P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI: 2003-875639/81.
XX DR P-PSDB; ADD54193.

XX PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
XX PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
XX PT generating antisense RNA and DNA, and in gene therapy.

XX PS Claim 2; SEQ ID NO 375; 637pp; English.

XX CC The invention describes 305 nucleic acids encoding PRO (secreted and
XX CC transmembrane) polypeptides (1). (1) is useful for stimulating the
XX CC release of TNF-alpha from human blood, for modulating the uptake of
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX CC stimulating the proliferation or differentiation of chondrocyte cells,
XX CC for stimulating the proliferation of or gene expression in pericyte
XX CC cells, for stimulating the release of proteoglycans from cartilage, for
XX CC stimulating the proliferation of inner ear utricular supporting cells,
XX CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX CC the release of a cytokine from PBM cells, for inhibiting the binding of
XX CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX CC cells, for stimulating proliferation of endothelial cells, for detecting
XX CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (1) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (1) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(1)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTGACAAAGCTTGAGAGCAACAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTGACAAAGCTTGAGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAAAACCAGAACTTGACAAAAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAAAACCAGAACTTGACAAAAAAGAAAGAAAG 120
QY 121 AGAAAAAATAATCATGAAACCATCCAGCCAAATATGACAAATCTCTCTTGGGCAAT 180
DB 121 AGAAAAAATAATCATGAAACCATCCAGCCAAATATGACAAATCTCTCTTGGGCAAT 180
QY 181 CTTTACGGGGTGGTGTCTCTGTGTCTTCCAAGAGTGCCTGCGCAGCGGAGATGC 240
DB 181 CTTTACGGGGTGGTGTCTCTGTGTCTTCCAAGAGTGCCTGCGCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGAACAGTGCAGTCCGCGAGGGGAGAGCCCACTCTCAG 300
DB 241 CACCTTCCCAAGCTATGGAACAGTGCAGTCCGCGAGGGGAGAGCCCACTCTCAG 300
QY 301 GTGCACATATTGCAACCGGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCATCTCTA 360
DB 301 GTGCACATATTGCAACCGGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCATCTCTA 360
QY 361 TGTCTGGAAATGACAGTGTGTGTGTCTCTGATCCTCGCGTGGTCTTCTGAGCAACACCCAAAC 420
DB 361 TGTCTGGAAATGACAGTGTGTGTGTCTCTGATCCTCGCGTGGTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGCTGATGTATGACAGGGGCCCTTACACCTGTCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGCTGATGTATGACAGGGGCCCTTACACCTGTCTC 480
QY 481 GGTGCGAGACAGCAACCCCAAGAAAGCTTCTAGGTCTCACTTCTGCGAAGATATCTCC 540
DB 481 GGTGCGAGACAGCAACCCCAAGAAAGCTTCTAGGTCTCACTTCTGCGAAGATATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCTCTAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCTCTAC 600
QY 601 CTGCTATAGCAACTGTGTAGACAGAGCTTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
DB 601 CTGCTATAGCAACTGTGTAGACAGAGCTTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
QY 661 GGTGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGGCATCACCCGGGAGCAGTCT 720
DB 661 GGTGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGGCATCACCCGGGAGCAGTCT 720
QY 721 AGGGGACTACAGTGTGAGTGTCTTCAATGAGTGGCGCGCCCGTGGTACGGAGAGTAAA 780
DB 721 AGGGGACTACAGTGTGAGTGTCTTCAATGAGTGGCGCGCCCGTGGTACGGAGAGTAAA 780

QY	781	GGTCAACCGTGAATATCCACCATACATTTTCAAGAGCCAAAGGTACAGGTGTCCTCCGTTGGG	840
Db	781	GGTCAACCGTGAATATCCACCATACATTTTCAAGAGCCAAAGGTACAGGTGTCCTCCGTTGGG	840
QY	841	ACAAAGGGGACACTGACGTGTGAGCCCTCAGCAGTCCCTCAGCAGAAATCCAGTGTA	900
Db	841	ACAAAGGGGACACTGACGTGTGAGCCCTCAGCAGTCCCTCAGCAGAAATCCAGTGTA	900
QY	901	CAAGGATGACAAAGACTGATTGAAGAGAAAGGGGTGAAGTGGAAAAACAGACCTTT	960
Db	901	CAAGGATGACAAAGACTGATTGAAGAGAAAGGGGTGAAGTGGAAAAACAGACCTTT	960
QY	961	CTCTCAAACTCATCTTCTCAATGCTCTGAACATGACTATGGAACTACACATGGGT	1020
Db	961	CTCTCAAACTCATCTTCTCAATGCTCTGAACATGACTATGGAACTACACATGGGT	1020
QY	1021	GGCTCCCAACAGCTGGGACACACCAATGCCAGCATCATGCTATTGGTCCAGGGCCGT	1080
Db	1021	GGCTCCCAACAGCTGGGACACACCAATGCCAGCATCATGCTATTGGTCCAGGGCCGT	1080
QY	1081	CAGGAGGTGAGCAACGGCACGTCGAGAGGGGAGGCTGGTCTGGCTCTCTTCT	1140
Db	1081	CAGGAGGTGAGCAACGGCACGTCGAGAGGGGAGGCTGGTCTGGCTCTCTTCT	1140
QY	1141	GGTCTTGACCTCTCTCAAAATTTTGAATGTGAGTGCCACTTCCCAACCCGGGAAAGGT	1200
Db	1141	GGTCTTGACCTCTCTCAAAATTTTGAATGTGAGTGCCACTTCCCAACCCGGGAAAGGT	1200
QY	1201	GGCGCACACACACCAACACACAGCAATGGCAACCGAGCAACCAATCAGATA	1260
Db	1201	GGCGCACACACACCAACACACAGCAATGGCAACCGAGCAACCAATCAGATA	1260
QY	1261	TATACAAATGAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAAC	1320
Db	1261	TATACAAATGAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAAC	1320
QY	1321	AAAGAAATCTTTGGGGGAAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA	1380
Db	1321	AAAGAAATCTTTGGGGGAAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA	1380
QY	1381	TTTAGGTACATGAGTTTCTTTTCCCAACGGGAGAACACAGACACCCGGCTTGA	1440
Db	1381	TTTAGGTACATGAGTTTCTTTTCCCAACGGGAGAACACAGACACCCGGCTTGA	1440
QY	1441	CCCACTGCAAGCTGCACTGCACTTTTGTGTCAGGTGGGCAAGGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGCTGCACTGCACTTTTGTGTCAGGTGGGCAAGGGCTCAGCCTC	1500
QY	1501	TCTGCCACAGAGTGGCCCACTGCGAATCTTGGAGTGGCCATCCCAATTCATCA	1560
Db	1501	TCTGCCACAGAGTGGCCCACTGCGAATCTTGGAGTGGCCATCCCAATTCATCA	1560
QY	1561	GTCCATAGACAGCAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTGGGCACTTTG	1620
Db	1561	GTCCATAGACAGCAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTGGGCACTTTG	1620
QY	1621	GTAGACTGTCCACCAACCGGCTGTGTGTAACGTTGAAATTAAGAGCAAAAAA	1679
Db	1621	GTAGACTGTCCACCAACCGGCTGTGTGTAACGTTGAAATTAAGAGCAAAAAA	1679

RESULT 84
ADD50270
ID ADD50270 standard; cDNA; 1679 BP.
XX
AC ADD50270;
XX
AC
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #63.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW

KW	tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW	pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
XX	arthritis; sports injury; cytostatic; antiarthritic.
OS	Homo sapiens.
PN	US2003096970-A1.
XX	
PD	22-MAY-2003.
XX	
PF	29-AUG-2002; 2002US-00232227.
XX	
PR	26-JUL-2000; 2000US-0220893P.
PR	01-JUN-2001; 2001WO-US017800.
PR	29-JUN-2001; 2001WO-US021066.
PR	09-APR-2002; 2002US-00119480.
XX	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Deenoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX	
DR	WPI; 2003-765527/72.
DR	P-PSDB; ADD50271.
XX	
PT	Novel isolated PRO polypeptides useful as molecular weight markers in
PT	protein electrophoresis, and useful for tissue typing, for treating
PT	arthritis, tumor.
XX	
PS	Claim 2; Fig 125; 308pp; English.
XX	
CC	The invention relates to human PRO polypeptides (secreted and
CC	transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC	The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC	diagnostics, biosensors or bioreactors. They are particularly useful for
CC	detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC	prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC	stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC	blood, for stimulating the proliferation or differentiation of
CC	chondrocyte cells, for stimulating the proliferation of or gene
CC	expression in pericyte cells or for stimulating the proliferation of
CC	normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC	hybridisation probes, in chromosome and gene mapping, in generating
CC	antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC	technology, in generating transgenic animals or knock-out animals which
CC	may be used in the development and screening of therapeutically useful
CC	reagents, in gene therapy, in chromosome identification, as anti-PRO
CC	markers and in generating probes. The PRO polypeptides, or anti-PRO
CC	antibodies, are useful for preparing a medicament for treating a
CC	condition which is responsive to the PRO polypeptides or anti-PRO
CC	antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC	disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC	differentiation of chondrocytes. The PRO polypeptides are useful as
CC	molecular markers for protein electrophoresis, and in tissue typing. This
CC	sequence represents a human PRO polynucleotide of the invention.
XX	
SQ	Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAGCTTGAGAGCAACAC 60
Db 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAGCTTGAGAGCAACAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAAAACCCAGACCTGACAAAAAGAGAAAAAGAG 120
Db 61 AATCTATCAGAAAGAAAGAAAGAAAAACCCAGACCTGACAAAAAGAGAAAAAGAG 120
QY 121 AAGAAAAAATCATGAAATCCATCCAGCCAAAAATGCACAAATCTATCTCTTGGCAAT 180
Db 121 AAGAAAAAATCATGAAATCCATCCAGCCAAAAATGCACAAATCTATCTCTTGGCAAT 180

QY 181 CTTTACCGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGGCCGTGGCGAGCGGAGATGC 240
DB 181 CTTTACCGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGGCCGTGGCGAGCGGAGATGC 240
QY 241 CACCTTCCCCAAAGATATGAGCAACGCTGAGCGGTCCGCGAGGGGAGAGCGCCACCTTCAG 300
DB 241 CACCTTCCCCAAAGATATGAGCAACGCTGAGCGGTCCGCGAGGGGAGAGCGCCACCTTCAG 300
QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTCTA 360
DB 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTCTA 360
QY 361 TGCTGGGAATGACAAAGTGGTGGCTGGATCTCGCGTGGTCTCTTCTGAGCAACACCCAAAC 420
DB 361 TGCTGGGAATGACAAAGTGGTGGCTGGATCTCGCGTGGTCTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAAGTACAGATCGAGATTCAGAACTGGATGTGATCAGCAGGGCCCTTACACCTGCTC 480
DB 421 GCAAGTACAGATCGAGATTCAGAACTGGATGTGATCAGCAGGGCCCTTACACCTGCTC 480
QY 481 GGTGAGAGACAAACCCAAAGACCTCTAGGCTCACTTCTGAGCAAGTATCTCC 540
DB 481 GGTGAGAGACAAACCCAAAGACCTCTAGGCTCACTTCTGAGCAAGTATCTCC 540
QY 541 CAAAATTGTGAGATTTCTTCTGAGATATCTCCATTATGAAGGACACATATTAGCCTCAC 600
DB 541 CAAAATTGTGAGATTTCTTCTGAGATATCTCCATTATGAAGGACACATATTAGCCTCAC 600
QY 601 CTGCTATGACAACTGTGAGACCAAGCCCTACGGTTACTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCTATGACAACTGTGAGACCAAGCCCTACGGTTACTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGGAAATTCAGGGCATCACCGGGAGCATC 720
DB 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGGAAATTCAGGGCATCACCGGGAGCATC 720
QY 721 AGGGGACTACGATGAGTGCCTCCAAATGAGTGGCCGCGCCGCTGGTACGGAGATGAA 780
DB 721 AGGGGACTACGATGAGTGCCTCCAAATGAGTGGCCGCGCCGCTGGTACGGAGATGAA 780
QY 781 GGTCCCGTGAATCTACCACTATATTCAGAGCCAGGGTACAGGTGCCCCGGGG 840
DB 781 GGTCCCGTGAATCTACCACTATATTCAGAGCCAGGGTACAGGTGCCCCGGGG 840
QY 841 ACAAAGGGGACACTGCACTGTGAAGCTTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGCACTGTGAAGCTTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAAGTGAACAAAGACTGATTAAGGAAGAAAGGGGTGAAGTGAAGACACACTTT 960
DB 901 CAAAGTGAACAAAGACTGATTAAGGAAGAAAGGGGTGAAGTGAAGACACACTTT 960
QY 961 CTTCTCAAACTCATCTTCTCAATGTCTCTGAAATGATGGAAGTACACTTTCGT 1020
DB 961 CTTCTCAAACTCATCTTCTCAATGTCTCTGAAATGATGGAAGTACACTTTCGT 1020
QY 1021 GGCCTTCAACAGTGGGCGCACCAATGCGAGCATCATGCTATTTGTCAGGCGCGGT 1080
DB 1021 GGCCTTCAACAGTGGGCGCACCAATGCGAGCATCATGCTATTTGTCAGGCGCGGT 1080
QY 1081 CAGCGAGTGAACACCGGCACTGAGAGGGGAGCGCTGCGTCTGGCTGGCTCTTCT 1140
DB 1081 CAGCGAGTGAACACCGGCACTGAGAGGGGAGCGCTGCGTCTGGCTGGCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTTCTCAAAATTTGTGATGTGAGTGGCACTTCCCGACCGGGAAAGGCT 1200
DB 1141 GGTCTTGCACTGCTTCTCAAAATTTGTGATGTGAGTGGCACTTCCCGACCGGGAAAGGCT 1200
QY 1201 GCGCCACCAACACCAACCAACAGCAATGGAACACCGCAGCAGCAACCAATCAGATA 1260
DB 1201 GCGCCACCAACACCAACCAACAGCAATGGAACACCGCAGCAGCAACCAATCAGATA 1260

QY 1261 TATACAAATGAAATTAGAAGAAACACAGCTCTATGGGACAGAAATTTGAGGGAGGGGAAC 1320
DB 1261 TATACAAATGAAATTAGAAGAAACACAGCTCTATGGGACAGAAATTTGAGGGAGGGGAAC 1320
QY 1321 AAAGAATACCTTTGGGGGAAAAGAGCTTTTAAAAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380
DB 1321 AAAGAATACCTTTGGGGGAAAAGAGCTTTTAAAAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380
QY 1381 TTTAGTACAATGAGAGTTTCTTTTCCAAAACGGGAAGAAACACAGCACACCCGGCTTGG 1440
DB 1381 TTTAGTACAATGAGAGTTTCTTTTCCAAAACGGGAAGAAACACAGCACACCCGGCTTGG 1440
QY 1441 CCACATGCAAGCTGCATCGTCAACCTCTTTGGTCCAGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCACATGCAAGCTGCATCGTCAACCTCTTTGGTCCAGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACCTGGAACATTTCTGGAGTGGCCATCCAAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCACCTGGAACATTTCTGGAGTGGCCATCCAAATTCATCA 1560
QY 1561 GTCCATAGAGAGCAAGCAATGAGACCTTCGCGCCCAAGCGTGGCGCTCGGCACTTTG 1620
DB 1561 GTCCATAGAGAGCAAGCAATGAGACCTTCGCGCCCAAGCGTGGCGCTCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGTGAAACGTGAAATAAAAAGAGCAAAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGTGAAACGTGAAATAAAAAGAGCAAAAAAAA 1679

RESULT 85

ADDS1281

ID ADDS1281 standard; cDNA; 1679 BP.

XX AC ADDS1281;

XX DT 15-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;

XX KW vulnary; antileukemic; pericyte cell proliferation;

XX KW pericyte cell differentiation; chondrocyte cell proliferation;

XX KW chondrocyte cell differentiation; tumour necrosis factor alpha release;

XX KW (TNF)-alpha release; dermal fibroblast cell proliferation;

XX KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;

XX KW colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW liver tumour; tissue typing; chromosome mapping; gene mapping;

XX KW gene therapy.

XX OS Homo sapiens.

XX PN US2003105289-A1.

XX PD 05-JUN-2003.

XX PF 13-AUG-2002; 2002US-00219472.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX XX (GETH) GENENTECH INC.

XX XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX XX WPI; 2003-829359/77.

XX XX P-PSDE; ADDS1282.

XX XX New isolated nucleic acids and their encoded secreted and transmembrane

XX XX polypeptides (PRO), useful e.g. for stimulating cell proliferation or

XX XX differentiation and for diagnosis of cancer.

XX XX

Claim 2; Fig 125; 308pp; English.

The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO982, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF) - alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO2114, PRO337, PRO326, PRO363, PRO531, PRO1083, PRO840, PRO1080, PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412, PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567, PRO1887, PRO1328, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322, PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells. PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, PRO5723, PRO5725, PRO7154 or PRO7425 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO1714, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTCTTGACAAAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTCTTGACAAAGCTTGAGAGCAAC 60

Qy 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

Qy 121 AAGAAAAAAATCATGAAACCAATCCAGCAAAATATGCAATTTCTCTCTGGGCAAT 180
Db 121 AAGAAAAAAATCATGAAACCAATCCAGCAAAATATGCAATTTCTCTCTGGGCAAT 180

Qy 181 CTTTCAGGGGCTGGCTGTCTGTGTCTCTTCCAGAGTGGCCGTGGCAGCGAGATGC 240
Db 181 CTTTCAGGGGCTGGCTGTCTGTGTCTCTTCCAGAGTGGCCGTGGCAGCGAGATGC 240

Qy 241 CACCTTCCCAAGCTATGGAACAACGTGACGCTCCGGCAGGGGAGAGCGCCACCTTCAG 300
Db 241 CACCTTCCCAAGCTATGGAACAACGTGACGCTCCGGCAGGGGAGAGCGCCACCTTCAG 300

Qy 301 GTGCACTATTGACAAACGGGTGACCCGGTGGCTGGCTTAACCGCAGCACCCTCTCTA 360
Db 301 GTGCACTATTGACAAACGGGTGACCCGGTGGCTGGCTTAACCGCAGCACCCTCTCTA 360

Qy 361 TGTGGGAATGACAGTGGTGGCTGGATCCTCGCTGGTCTTCTGAGCAACCCCAAC 420
Db 361 TGTGGGAATGACAGTGGTGGCTGGATCCTCGCTGGTCTTCTGAGCAACCCCAAC 420

Qy 421 GCAGTACAGCATCCAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACCTGCTC 480

Db	1501	TTGTGCCACAGAGTGCCGCCACGCTGGGAACATCTTGGAGCTGGCCATCCCAATTCATCA	1560
Qy	1561	GTCCATAGAGACGAACAGAATGAGACCTTCGGGCCCAAGCGTGGCGCTGGCGGCACCTTTG	1620
Db	1561	GTCCATAGAGACGAACAGAATGAGACCTTCGGGCCCAAGCGTGGCGCTGGCGGCACCTTTG	1620
Qy	1621	GTGACTGTGCCACCAACGGCGTGTGTTGTGAACACGTCAAAATAAAGAGCAAAAAAAA	1679
Db	1621	GTGACTGTGCCACCAACGGCGTGTGTTGTGAACACGTGAAATAAAGAGCAAAAAAAA	1679

QY 301 GTGCACTATTGCAACCGGGTCAACCGGGTGGCTTAACCGCAGCAGCACCCTCTCTA 360
DB |||||
QY 301 GTGCACTATTGCAACCGGGTCAACCGGGTGGCTTAACCGCAGCAGCACCCTCTCTA 360
DB |||||
QY 361 TGCTGGGAATGACAAAGTGTGCTCGATCCTCGCGTGTCTTCTGAGCAACACCCAAAC 420
DB |||||
QY 361 TGCTGGGAATGACAAAGTGTGCTCGATCCTCGCGTGTCTTCTGAGCAACACCCAAAC 420
DB |||||
QY 421 GCAGTACAGCATCGAGATCCAGACGTGTGATGTATGACGAGGGCCCTTACACCTGCTC 480
DB |||||
QY 421 GCAGTACAGCATCGAGATCCAGACGTGTGATGTATGACGAGGGCCCTTACACCTGCTC 480
DB |||||
QY 481 GGTGACAGACAGCAACACCCAAAGACCTCTAGGGTCCACCTCACTGTGCAAGTATCTCC 540
DB |||||
QY 481 GGTGACAGACAGCAACACCCAAAGACCTCTAGGGTCCACCTCACTGTGCAAGTATCTCC 540
DB |||||
QY 541 CAAATTTGAGATTTCTTCAGATATCTCCATTTGAAGGGAACAATATTAGCCTCAC 600
DB |||||
QY 541 CAAATTTGAGATTTCTTCAGATATCTCCATTTGAAGGGAACAATATTAGCCTCAC 600
DB |||||
QY 601 CTGCATAGCACTGTGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
DB |||||
QY 601 CTGCATAGCACTGTGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
DB |||||
QY 661 GGTGCTGTTGTGAGTGAAGACGAATACCTTGGAATTCAGGGGATCACCCGGAGCAGTC 720
DB |||||
QY 661 GGTGCTGTTGTGAGTGAAGACGAATACCTTGGAATTCAGGGGATCACCCGGAGCAGTC 720
DB |||||
QY 721 AGGGGACTAGCTGAGTGCCTCCAAATGACGTGGCGCGCGGTGATACGAGAGTAAA 780
DB |||||
QY 721 AGGGGACTAGCTGAGTGCCTCCAAATGACGTGGCGCGCGGTGATACGAGAGTAAA 780
DB |||||
QY 781 GGTCCCGTGAATATCCACATACATTTCAAGAGCCAAAGGGTACAGGTGTCCTCCGTGGG 840
DB |||||
QY 781 GGTCCCGTGAATATCCACATACATTTCAAGAGCCAAAGGGTACAGGTGTCCTCCGTGGG 840
DB |||||
QY 841 ACAAGAGGACACTGCTGATGACGCTCAAGCTCAGCAGTCCCTCAGCAGAGATTCAGGTGTA 900
DB |||||
QY 841 ACAAGAGGACACTGCTGATGACGCTCAAGCTCAGCAGTCCCTCAGCAGAGATTCAGGTGTA 900
DB |||||
QY 901 CAAGGATGACAAAGACTGATTGAAGGAAGAAAGGGTGAAGTGGAAAAAGACCTTT 960
DB |||||
QY 901 CAAGGATGACAAAGACTGATTGAAGGAAGAAAGGGTGAAGTGGAAAAAGACCTTT 960
DB |||||
QY 961 CCTCTCAAACTCATCTTCTCAATCTCTGACATGATATGGGAATCACTATGCTGCT 1020
DB |||||
QY 961 CCTCTCAAACTCATCTTCTCAATCTCTGACATGATATGGGAATCACTATGCTGCT 1020
DB |||||
QY 1021 GGCTTCCAAAGTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
DB |||||
QY 1021 GGCTTCCAAAGTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
DB |||||
QY 1081 CAGGAGGTGAGCAACGGCAGCTGAGAGGAGGAGGCTGGTCTGCTGCTCTTCT 1140
DB |||||
QY 1081 CAGGAGGTGAGCAACGGCAGCTGAGAGGAGGAGGCTGGTCTGCTGCTCTTCT 1140
DB |||||
QY 1141 GGTCTTCACTGCTCTCAAAATTTGATGTAGTGCACCTTCCCAACCGGGAAGAGGT 1200
DB |||||
QY 1141 GGTCTTCACTGCTCTCAAAATTTGATGTAGTGCACCTTCCCAACCGGGAAGAGGT 1200
DB |||||
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB |||||
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB |||||
QY 1261 TATCAAAATGAATTTAGAGAAACACAGCCTCTAGGAGAGAAATTTAGGGAGGGGAAAC 1320
DB |||||
QY 1261 TATCAAAATGAATTTAGAGAAACACAGCCTCTAGGAGAGAAATTTAGGGAGGGGAAAC 1320
DB |||||
QY 1321 AAAGAACTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB |||||
QY 1321 AAAGAACTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB |||||

QY 1381 TTTAGGTACAAATGGAGTTTTTTTCCCAAAACGGGAAGAACACAGCACACCGGGTTGA 1440
DB |||||
QY 1381 TTTAGGTACAAATGGAGTTTTTTTCCCAAAACGGGAAGAACACAGCACACCGGGTTGA 1440
DB |||||
QY 1441 CCCTACTGCAAGCTGCATCTGTGCAACCTTTTGTGCAAGTGTGGCAAGGGCTCAGCCTC 1500
DB |||||
QY 1441 CCCTACTGCAAGCTGCATCTGTGCAACCTTTTGTGCAAGTGTGGCAAGGGCTCAGCCTC 1500
DB |||||
QY 1501 TCTGCCACAGAGTGTGCCCCCAGCGTGGAAATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
DB |||||
QY 1501 TCTGCCACAGAGTGTGCCCCCAGCGTGGAAATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
DB |||||
QY 1561 GTCCATAGACAGCAACAGATGAGACTTCCGCCCAAGCGTGGCGTGGCGGACCTTTG 1620
DB |||||
QY 1561 GTCCATAGACAGCAACAGATGAGACTTCCGCCCAAGCGTGGCGTGGCGGACCTTTG 1620
DB |||||
QY 1621 GTAGCTGTGCCACCGCGGTGTGTGAAACGTGAAATATAAAGAGCAAAAAA 1679
DB |||||
QY 1621 GTAGCTGTGCCACCGCGGTGTGTGAAACGTGAAATATAAAGAGCAAAAAA 1679
DB |||||
RESULT 88
ADD91405
ID ADD91405 standard; cDNA; 1679 BP.
XX
AC ADD91405;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199055-A1.
XX
PD 23-OCT-2003.
XX
PF 12-APR-2002; 2002US-00121063.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018924.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 2000WO-US006319.
PR 14-MAY-1999; 99WO-US008615.
PR 02-JUN-1999; 99WO-US010733.
PR 01-SEP-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.

09-AUG-2001; 2001US-009277796.
 16-AUG-2001; 2001US-00031836.
 19-DEC-2001; 2001US-00028072.
 (GETH) GENENTECH INC.
 Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI; 2003-900165/82.
 P-PSDB; ADD91406.
 Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 useful for treating pericyte-associated tumors, diabetes and various bone
 and/or cartilage disorders, e.g. arthritis.
 Claim 2; SEQ ID NO 375; 636pp; English.
 The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating differentiation of adipocyte cells, for stimulating
 proliferation of or gene expression in pericyte cells, for stimulating
 the proliferation of inner ear utricular supporting cells or T-lymphocyte
 cells, for inducing endothelial cell tube formation and for treating
 various bone and/or cartilage disorders such as sports injuries and
 arthritis. PRO polypeptides which stimulate the release of proteoglycans
 from cartilage are useful for treating sports-related joint problems, PRO
 articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 polypeptides are also useful for treating various mammalian haemoglobin-
 associated disorders such as various thalassemias and conditions which
 may benefit from enhanced local immune system cell infiltration. This
 sequence represents a human PRO polynucleotide of the invention. Note:
 The sequence data for this patent is also available in electronic format
 from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6,7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0

QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCCTTGACCAAGCTTGAGCAAC 60
 Db 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCCTTGACCAAGCTTGAGCAAC 60
 QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 Db 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 QY 121 AAGAAAAAAAATCATGAAAAACCATCCAGCCAAAATGCACAAATCTTCTCTTGGGCAAT 180
 Db 121 AAGAAAAAAAATCATGAAAAACCATCCAGCCAAAATGCACAAATCTTCTCTTGGGCAAT 180
 QY 181 CTTACGGGGCTGGCTGCTCTCTCTTCTTCAAGAGATGCCCGTCCAGCGGAGATGC 240
 Db 181 CTTACGGGGCTGGCTGCTCTCTCTTCTTCAAGAGATGCCCGTCCAGCGGAGATGC 240

181 CTTTCAAGGAGTGTCCCGTGCAGCGGAGATGC 240
241 CACCTTCCCAAGCTATGACAACTGACGGTCCGCGAGGGGAGAGCGCCACCTCAG 300
241 CACCTTCCCAAGCTATGACAACTGACGGTCCGCGAGGGGAGAGCGCCACCTCAG 300
301 GTGCACATATTGACAAACCGGTGACCGGGTGGCTGGCTTAACCGCAGACCAATCTCTTA 360
301 GTGCACATATTGACAAACCGGTGACCGGGTGGCTGGCTTAACCGCAGACCAATCTCTTA 360
361 TGCTGGCAATGACAAAGTGGTGGTGGATCTCGGGTGGTCTTCTGAGCAACACCCAAAC 420
361 TGCTGGCAATGACAAAGTGGTGGTGGATCTCGGGTGGTCTTCTGAGCAACACCCAAAC 420
421 GCAGTACAGCATCGAGATCCAGAACTGGATGTATGACGAGGGCCCTTACACCTGCTC 480
421 GCAGTACAGCATCGAGATCCAGAACTGGATGTATGACGAGGGCCCTTACACCTGCTC 480
481 GGTGAGCAACGACCAACCAAGACCTCTAGGTCACCTCATTTGTCGACGATCTCC 540
481 GGTGAGCAACGACCAACCAAGACCTCTAGGTCACCTCATTTGTCGACGATCTCC 540
541 CAAAATTGTAGATTTCTTTCAGATATCTCATTATGAAGGGAACAATATTAGCCTCAC 600
541 CAAAATTGTAGATTTCTTTCAGATATCTCATTATGAAGGGAACAATATTAGCCTCAC 600
601 CTGCATAGCACTGGTAGACAGAGCTCTAGGTCACCTTACTTGGAGACACATCTCTCCAAAGC 660
601 CTGCATAGCACTGGTAGACAGAGCTCTAGGTCACCTTACTTGGAGACACATCTCTCCAAAGC 660
661 GGTGGCTTTGTGAGTGAAGCAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGCAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
721 AGGGGATCTAGAGTGGCTCCATGAGTGGCGCGCGCGCTGTGTAGAGAGTAA 780
721 AGGGGATCTAGAGTGGCTCCATGAGTGGCGCGCGCGCTGTGTAGAGAGTAA 780
781 GGTCAAGCTGATATCACCACATATTCAGAAAGCAAGGTACAGGTCTCCCGCTGGG 840
781 GGTCAAGCTGATATCACCACATATTCAGAAAGCAAGGTACAGGTCTCCCGCTGGG 840
841 ACAAAGGGGACATGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
841 ACAAAGGGGACATGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
901 CAAGGATGACAAAGCTGATTTGAAGGAAAGAGGGGTGAAGTGAAGCAAGACCTTT 960
901 CAAGGATGACAAAGCTGATTTGAAGGAAAGAGGGGTGAAGTGAAGCAAGACCTTT 960
961 CCTCTCAAACCTCATCTTCTTCAATGTCTCTGAAATGACATGATGGGAATACACTTGCCT 1020
961 CCTCTCAAACCTCATCTTCTTCAATGTCTCTGAAATGACATGATGGGAATACACTTGCCT 1020
1021 GGCTTCCAAAGCTGGGCAACCAATGCGAGCATCATGCTATTTGGTCCAGCGCGCT 1080
1021 GGCTTCCAAAGCTGGGCAACCAATGCGAGCATCATGCTATTTGGTCCAGCGCGCT 1080
1081 CAGCGAGGTGAGCAACGSCAGTCCAGAGGGGAGGCTGGCTCTGGCTGGCTCTTCT 1140
1081 CAGCGAGGTGAGCAACGSCAGTCCAGAGGGGAGGCTGGCTCTGGCTGGCTCTTCT 1140
1141 GGTCTTGACCTGCTTCTCAATTTTGAATGAGTGGTCCACTTCCCAACCGGGAAGGCT 1200
1141 GGTCTTGACCTGCTTCTCAATTTTGAATGAGTGGTCCACTTCCCAACCGGGAAGGCT 1200
1201 GCCGCCACCAACCAACCAACCAAGCAATGGCAACCGCAGCAGCAACCAATTCAGATA 1260
1201 GCCGCCACCAACCAACCAACCAAGCAATGGCAACCGCAGCAGCAACCAATTCAGATA 1260
1261 TATCAAAATGAATTAGAAGAAACACAGCTCTATGGGACAGAAATTTGAGGGAGGGAAC 1320
1261 TATCAAAATGAATTAGAAGAAACACAGCTCTATGGGACAGAAATTTGAGGGAGGGAAC 1320

RESULT 89

AD04019
ID ADE04019 standard; cDNA; 1679 BP.
XX
AC ADE04019;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; paricycle cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199057-A1.
XX
PD 23-OCT-2003.
XX
PF 15-APR-2002; 2002US-00123213.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-NOV-1998; 98WO-US022992.
PR 01-DEC-1998; 98WO-US024855.
PR 05-JAN-1999; 98WO-US025108.
PR 08-MAR-1999; 98WO-US000106.
PR 10-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.

```
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 03-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.

PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900167/82.
XX P-PSDB; ADE04020.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX Claim 2; Fig 375; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTGCACAACTTGAGAGCAACAC 60
Db 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTGCACAACTTGAGAGCAACAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAAAAACCAGAACTGCACAAAAAGAAAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAAAACCAGAACTGCACAAAAAGAAAAAGAAAG 120
Qy 121 AAGAAAAAATCATGAAACCATCCAGCAAAATGACAAATTCATCTCTTGGCAAT 180
```

Db 121 |||||ATGAAAAAATCATGAAAAACCATCAGCCAAAAATGCAAAATCTATCTCTTGGGCAAT 180
Qy 181 CTTTCAGGGGCTGGCTGCTCTGTGTCTCTTCAAGGAGTGCCGTGCGCAGCGGAGATGC 240
Db 181 CTTTCAGGGGCTGGCTGCTCTGTGTCTCTTCAAGGAGTGCCGTGCGCAGCGGAGATGC 240
Qy 241 CACCTTCCCAAGAGCTATGGAACAACTGACGGTTCGGGCAAGGGGAGAGCGCCACCTCAG 300
Db 241 CACCTTCCCAAGAGCTATGGAACAACTGACGGTTCGGGCAAGGGGAGAGCGCCACCTCAG 300
Qy 301 GTGCACTATTGACAAACCGGCTCACCGGCTGGCTTAAACCGCAGCACCACCTCTCTA 360
Db 301 GTGCACTATTGACAAACCGGCTCACCGGCTGGCTTAAACCGCAGCACCACCTCTCTA 360
Qy 361 TGTGGAATGACAACTGCTGCTGATCCTGCGGTGCTTCTTGTAGCAACACCCAAAC 420
Db 361 TGTGGAATGACAACTGCTGCTGATCCTGCGGTGCTTCTTGTAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCTGAGATCCAGAACCTGATGTATGACGAGGCGCTTACACCTGCTC 480
Db 421 GCAGTACAGCTGAGATCCAGAACCTGATGTATGACGAGGCGCTTACACCTGCTC 480
Qy 481 GGTGCGAGACAGAACCCCAAGACCTCTAGGGTCCAACCTCATTTGTCAAGTATCTCC 540
Db 481 GGTGCGAGACAGAACCCCAAGACCTCTAGGGTCCAACCTCATTTGTCAAGTATCTCC 540
Qy 541 CAAAATTGTAGATTTCTTCAATATCTCCATTAATGAAGGAAACAATATTAGCTCTAC 600
Db 541 CAAAATTGTAGATTTCTTCAATATCTCCATTAATGAAGGAAACAATATTAGCTCTAC 600
Qy 601 CTGCATAGCAACTGTGAGACAGAGCCTAGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGCATAGCAACTGTGAGACAGAGCCTAGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Qy 661 GGTGGCTTTGTAGTGAAGACAAATCTTGGAATTCAGGCAATCACCGGAGCAGTC 720
Db 661 GGTGGCTTTGTAGTGAAGACAAATCTTGGAATTCAGGCAATCACCGGAGCAGTC 720
Qy 721 AGGGACTACAGTGCAGTCCCTCCATGACGTGGCGCGCCGCTGCTACGAGAGATAA 780
Db 721 AGGGACTACAGTGCAGTCCCTCCATGACGTGGCGCGCCGCTGCTACGAGAGATAA 780
Qy 781 GGTCAACGCTGAATCTCCACATACATTTCAAGGCAAGGGTACAGGTGTCCCGTGG 840
Db 781 GGTCAACGCTGAATCTCCACATACATTTCAAGGCAAGGGTACAGGTGTCCCGTGG 840
Qy 841 ACAAAGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTA 900
Db 841 ACAAAGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTA 900
Qy 901 CAAGGATGACAAAGACTGATTGAAGAAAGAGGGTGAAAGTGGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGATTGAAGAAAGAGGGTGAAAGTGGAAACAGACCTTT 960
Qy 961 CCTCTCAAACTCATCTTCTCAATGTCTCTGAACATGATATGGGAACTACACTTGGCT 1020
Db 961 CCTCTCAAACTCATCTTCTCAATGTCTCTGAACATGATATGGGAACTACACTTGGCT 1020
Qy 1021 GGCCTCAACAGGTGGGCGACCACTATGCGATCATGCTATTTGGTCCAGGCGCT 1080
Db 1021 GGCCTCAACAGGTGGGCGACCACTATGCGATCATGCTATTTGGTCCAGGCGCT 1080
Qy 1081 CAGGAGGTGACAAACGGCAGCTGAGGAGGCGGCTGGCTGGCTGGCTGGCTGGCTGGCT 1140
Db 1081 CAGGAGGTGACAAACGGCAGCTGAGGAGGCGGCTGGCTGGCTGGCTGGCTGGCTGGCT 1140
Qy 1141 GGTCTTCACTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCAACCGGGAAGGCT 1200
Db 1141 GGTCTTCACTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCAACCGGGAAGGCT 1200
Qy 1201 GCGCCACCCACCAACCAACAGCAATGCGCAACCGGACAGCAACCAATCAGATA 1260

Db 1201 GCGCCACCCACCCACCAACCAACAGCAATGGCAACCCGACAGCAACCAATCAGATA 1260
Qy 1261 TATACAAATGAAATTAAGAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGAAC 1320
Db 1261 TATACAAATGAAATTAAGAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGAAC 1320
Qy 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
Db 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
Qy 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGCTTGA 1440
Db 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGCTTGA 1440
Qy 1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTGTCAGCTGTCGAGGCTGAGGCTCAGGCTC 1500
Db 1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTGTCAGCTGTCGAGGCTGAGGCTCAGGCTC 1500
Qy 1501 TCTGCCCAACAGAGTCCCGCCACCTGGAACATTTCTGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCCAACAGAGTCCCGCCACCTGGAACATTTCTGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGAAACAGATGACCTTCGGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGATGACCTTCGGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACCGCGTGTGTGAAACGTGAAATATAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACCGCGTGTGTGAAACGTGAAATATAAGAGCAAAAAA 1679

RESULT 90
ADE32316
ID ADE32316 standard; cDNA; 1679 BP.
XX
AC ADE32316;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumor necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003194765-A1.
XX
PD 16-OCT-2003.
XX
PF 09-MAY-2002; 2002US-00142889.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-899784/82.
DR P-PSDB; ADE32317.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
useful for treating pericyte-associated tumors, diabetes and various bone

PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; SEQ ID NO 375; 636pp; English.
 PS The invention describes 305 nucleic acids encoding PRO (secreted and
 XX transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of
 CC A-peptide to factor V1RA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCCCTTGCAAGCTTGAGAGCAACAC 60
 DB 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCCCTTGCAAGCTTGAGAGCAACAC 60
 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
 DB 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCAAGAGAGTCCCGTGGCGAGGAGATGC 240
 DB 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCAAGAGAGTCCCGTGGCGAGGAGATGC 240
 241 CACCTTCCCAAGCTATGGCAAGTCAAGTCCGCGAGGAGGAGCGCCACCCCTCAG 300
 DB 241 CACCTTCCCAAGCTATGGCAAGTCAAGTCCGCGAGGAGGAGCGCCACCCCTCAG 300
 301 GTGCACTATTGCAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
 DB 301 GTGCACTATTGCAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
 361 TCGTGGGAATGCAAGTGGTGGCTGGATCTCGGTGGCTGGCTGGCTGGCTGGCTGG 420
 DB 361 TCGTGGGAATGCAAGTGGTGGCTGGATCTCGGTGGCTGGCTGGCTGGCTGGCTGG 420
 421 GCAGTACAGCATCGAGATCCAGAAAGTGGATGTGTATGACGAGGGCCCTTACCTGCTC 480
 DB 421 GCAGTACAGCATCGAGATCCAGAAAGTGGATGTGTATGACGAGGGCCCTTACCTGCTC 480
 481 GGTGACAGACAGACCAACCAAGACCTTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540

DB 481 GGTGACAGACAGACCAACCCCAAGACCTTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540
 QY 541 CAAAATTTGTAGAGATTTCTTCAGATATCTTCATTAATGAAGGAAACAATATTAGCCTCAC 600
 DB 541 CAAAATTTGTAGAGATTTCTTCAGATATCTTCATTAATGAAGGAAACAATATTAGCCTCAC 600
 QY 601 CTGCATAGCAACTGTGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
 DB 601 CTGCATAGCAACTGTGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
 QY 661 GGTGGCTTTGTGAGTGAAGAGCATCTTGGAAATTCAGGAGCATCCCGGGAGCAGTC 720
 DB 661 GGTGGCTTTGTGAGTGAAGAGCATCTTGGAAATTCAGGAGCATCCCGGGAGCAGTC 720
 QY 721 AGGGAGTACAGAGTGCAGTGCCTCAATGAGCGTGGCCCGCCGGTGGTACGGAGAGTAAA 780
 DB 721 AGGGAGTACAGAGTGCAGTGCCTCAATGAGCGTGGCCCGCCGGTGGTACGGAGAGTAAA 780
 QY 781 GGTACCGTGAATCTCCACCATCATTTTCAGAGCCAGAGGTACAGTGTCCCGGTGG 840
 DB 781 GGTACCGTGAATCTCCACCATCATTTTCAGAGCCAGAGGTACAGTGTCCCGGTGG 840
 QY 841 ACAAAGGGGACACTGCACTGAGTGAAGCTCCAGCTCCCTCAGCAGAAATTCAGTGGTA 900
 DB 841 ACAAAGGGGACACTGCACTGAGTGAAGCTCCAGCTCCCTCAGCAGAAATTCAGTGGTA 900
 QY 901 CAAGGATGACAAAGACATCTGATTTGAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
 DB 901 CAAGGATGACAAAGACATCTGATTTGAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
 QY 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGAAATGATGACTATGGAACTACACTTGGT 1020
 DB 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGAAATGATGACTATGGAACTACACTTGGT 1020
 QY 1021 GGCCTCCACAGCTGGGCAACCAATGCCAGCATCATGCTATTTGCTCCAGGCGCGT 1080
 DB 1021 GGCCTCCACAGCTGGGCAACCAATGCCAGCATCATGCTATTTGCTCCAGGCGCGT 1080
 QY 1081 CAGCGAGTGTAGCAACCGCACGTCGAGGAGGCGAGGCTGGCTGCTGCTCTTCT 1140
 DB 1081 CAGCGAGTGTAGCAACCGCACGTCGAGGAGGCGAGGCTGGCTGCTGCTCTTCT 1140
 QY 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTGAGTGCCTTCCCAACCGGGAAGGCT 1200
 DB 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTGAGTGCCTTCCCAACCGGGAAGGCT 1200
 QY 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
 DB 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
 QY 1261 TATACAAATGAAATTTAGAGAAACACAGCTCATGGACAGAAATTTGAGGAGGAGGAC 1320
 DB 1261 TATACAAATGAAATTTAGAGAAACACAGCTCATGGACAGAAATTTGAGGAGGAGGAC 1320
 QY 1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
 DB 1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
 QY 1381 TTTAGTACAAATGGAGTTTCTTTTCCAAAGCGGGAAGAAACAGACACACCCGGCTTGA 1440
 DB 1381 TTTAGTACAAATGGAGTTTCTTTTCCAAAGCGGGAAGAAACAGACACACCCGGCTTGA 1440
 QY 1441 CCCACTGCAAGTGCATCGTGCACCTCTTTCGTCGAGTGGCGAGGAGGCTCAGCCTC 1500
 DB 1441 CCCACTGCAAGTGCATCGTGCACCTCTTTCGTCGAGTGGCGAGGAGGCTCAGCCTC 1500
 QY 1501 TCTGCCCAAGAGTGCAGTGCAGTGCAGTGCAGTGCAGTGCAGTGCAGTGCAGTGC 1560
 DB 1501 TCTGCCCAAGAGTGCAGTGCAGTGCAGTGCAGTGCAGTGCAGTGCAGTGCAGTGC 1560
 QY 1561 GTCCATAGAGAGCAGACAGAAATGAGACCTTCCGCGCCCAACCGTGGCGCTGCGGCACTTTG 1620
 DB 1561 GTCCATAGAGAGCAGACAGAAATGAGACCTTCCGCGCCCAACCGTGGCGCTGCGGCACTTTG 1620

PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; Fig 375; 639pp; English.
 PS The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTGTGTCTCTCAGCAAAACAGTGAATTAATCTCCTTGTCACACGCTTGAGAGCAAC 60
 DB |||||
 QY 1 GTGTGTCTCTCAGCAAAACAGTGAATTAATCTCCTTGTCACACGCTTGAGAGCAAC 60
 DB |||||
 QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 DB |||||
 QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 DB |||||
 QY 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
 DB |||||
 QY 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
 DB |||||
 QY 181 CTTTCAGGGGCTGGCTGTCTGTCTCTCTTCAAGAGAGTGCCTGCGCAGCGAGATGC 240
 DB |||||
 QY 181 CTTTCAGGGGCTGGCTGTCTGTCTCTCTTCAAGAGAGTGCCTGCGCAGCGAGATGC 240
 DB |||||
 QY 241 CACTTTCCTCCCAAGCTATGGAACAAGTACGCGTCCGGCAGGGGAGAGCGGCACCTCAG 300
 DB |||||
 QY 241 CACTTTCCTCCCAAGCTATGGAACAAGTACGCGTCCGGCAGGGGAGAGCGGCACCTCAG 300
 DB |||||
 QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAACCGCAGCACCATCTCTTA 360
 DB |||||
 QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAACCGCAGCACCATCTCTTA 360
 DB |||||
 QY 361 TGCTGGGAATGACAAAGTGTGCTGGATCTCGGTGCTGCTCTTCTTGTAGCAACACCCAAAC 420
 DB |||||
 QY 361 TGCTGGGAATGACAAAGTGTGCTGGATCTCGGTGCTGCTCTTCTTGTAGCAACACCCAAAC 420
 DB |||||
 QY 421 GCAGTACAGATCGAGATCCAGACGCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
 DB |||||

DB 421 GCAGTACAGATCGAGATCCAGACGCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
 QY |||||
 DB 481 GGTGCAGACAGACACACACCCCAAGACCTCTAGGCTCCACCTCATTTGCAAGTATCTCC 540
 QY |||||
 DB 481 GGTGCAGACAGACACACACCCCAAGACCTCTAGGCTCCACCTCATTTGCAAGTATCTCC 540
 QY |||||
 DB 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTTAATGAGGGAACAATATTAGCCTCAC 600
 QY |||||
 DB 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTTAATGAGGGAACAATATTAGCCTCAC 600
 QY |||||
 DB 601 CTGCATAGCAACTGGGTAGACACGAGCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
 QY |||||
 DB 601 CTGCATAGCAACTGGGTAGACACGAGCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
 QY |||||
 DB 661 GGTTCGCTTTGAGTGAAGAGCAATACCTTGAATTCAGGCAATACCCGGGAGCAGTC 720
 QY |||||
 DB 661 GGTTCGCTTTGAGTGAAGAGCAATACCTTGAATTCAGGCAATACCCGGGAGCAGTC 720
 QY |||||
 DB 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCGCGCGCGCGCGCGCG 780
 QY |||||
 DB 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCGCGCGCGCGCGCGCG 780
 QY |||||
 DB 781 GGTACCGTGAATATCCACCATACATTTCAAGAGCAAGGTACAGGTGTCCCGTGGG 840
 QY |||||
 DB 781 GGTACCGTGAATATCCACCATACATTTCAAGAGCAAGGTACAGGTGTCCCGTGGG 840
 QY |||||
 DB 841 ACAAAGGGGACACTGCACTGAGTGAAGCTCCAGCTCCCTCAGCAGAAATTCAGTGGTA 900
 QY |||||
 DB 841 ACAAAGGGGACACTGCACTGAGTGAAGCTCCAGCTCCCTCAGCAGAAATTCAGTGGTA 900
 QY |||||
 DB 901 CAAGATGACAAAGACTGATTTGAAGAAAGAAAGGGGTGAAGTGGAAACACAGACCTTT 960
 QY |||||
 DB 901 CAAGATGACAAAGACTGATTTGAAGAAAGAAAGGGGTGAAGTGGAAACACAGACCTTT 960
 QY |||||
 DB 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTCAATGCTCTGAAATGCTGAACTACACTTGGT 1020
 QY |||||
 DB 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGAAATGCTGAACTACACTTGGT 1020
 QY |||||
 DB 1021 GGCTTCAAAAGCTGGGCGCACCAATGCCAGCATCATCTATTTGTCFCAAGGGCGCT 1080
 QY |||||
 DB 1021 GGCTTCAAAAGCTGGGCGCACCAATGCCAGCATCATCTATTTGTCFCAAGGGCGCT 1080
 QY |||||
 DB 1081 CAGCAGGTGAGCAACGCGCACCTCGAGGAGGCGAGCTGCTGCTGCTGCTGCTCTTCT 1140
 QY |||||
 DB 1081 CAGCAGGTGAGCAACGCGCACCTCGAGGAGGCGAGCTGCTGCTGCTGCTCTTCT 1140
 QY |||||
 DB 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGAATGTCAGTGCCACTTTCCCAACCCGGGAAAGGT 1200
 QY |||||
 DB 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGAATGTCAGTGCCACTTTCCCAACCCGGGAAAGGT 1200
 QY |||||
 DB 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
 QY |||||
 DB 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
 QY |||||
 DB 1261 TATACAAATGAAATTAAGAAAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
 QY |||||
 DB 1261 TATACAAATGAAATTAAGAAAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
 QY |||||
 DB 1321 AAGAAATATTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTCGCTTGCAGATA 1380
 QY |||||
 DB 1321 AAGAAATATTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTCGCTTGCAGATA 1380
 QY |||||
 DB 1381 TTTAGGTACAATGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA 1440
 QY |||||
 DB 1381 TTTAGGTACAATGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA 1440
 QY |||||
 DB 1441 CCCACTGCAAGCTGATCGTGCACCTCTTTTGGTGCAGTGTGGGAGGGCTCAGCCTC 1500
 QY |||||
 DB 1441 CCCACTGCAAGCTGATCGTGCACCTCTTTTGGTGCAGTGTGGGAGGGCTCAGCCTC 1500
 QY |||||
 DB 1501 TCTGCCCAACAGAGTGGCCCAACGCTGGAACATTTCTGAGCTGGCCATCCCAAAATTCATCA 1560
 QY |||||

Db 1501 TCTGCCACAGAGTGCCCCACGTCGGAACATTTCTGGAGCTGGCCATCCCCAAATTCATCA 1560
Qy 1561 GTCCATAGACGACGACGATGAGACTTCCGSCCAAGCGTGGCGCTGGGCGACTTTG 1620
Db 1561 GTCCATAGACGACGACGATGAGACTTCCGSCCAAGCGTGGCGCTGGGCGACTTTG 1620
Qy 1621 GTAGACTGCCACCGCGCTGTGTGTAACGTAATGAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGCCACCGCGCTGTGTGTAACGTAATGAAAGAGCAAAAAA 1679
RESULT 92
ADD79472
ID ADD79472 standard; cDNA; 1679 BP.
XX AC ADD79472;
XX AC ADD79472;
DT 29-JAN-2004 (first entry)
XX cDNA encoding human PRO polypeptide #188.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003203428-A1.
XX 30-OCT-2003.
XX 22-APR-2002; 2002US-00127852.
XX 09-DEC-1999; 99US-0170262P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX P-PSDB; ADD79473.
XX WPI; 2003-875635/81.
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX Claim 2; Fig 375; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides), and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCAAGCTTGAGACAAC 60
Db 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCAAGCTTGAGACAAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGCACAAAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGCACAAAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAAATCATGAAAAACCATCCAGCCAAAAATGCACAAATCTATCTTGGGCAAT 180
Db 121 AAGAAAAAAATCATGAAAAACCATCCAGCCAAAAATGCACAAATCTATCTTGGGCAAT 180
Qy 181 CTTACGGGGCTGGCTGCTCTCTCTCCAGAGGAGTGCCCGCGGCGGAGAGATGC 240
Db 181 CTTACGGGGCTGGCTGCTCTCTCTCCAGAGGAGTGCCCGCGGCGGAGAGATGC 240
Qy 241 CACCTTCCCCAAAGCTATGGACAACGTGACGGTCCGGCAGGGGGAGAGCGCCCTCAG 300
Db 241 CACCTTCCCCAAAGCTATGGACAACGTGACGGTCCGGCAGGGGGAGAGCGCCCTCAG 300
Qy 301 GTGCATATTGACACACCGGGTCAACCGGGTCCCTGCTTCCAGAGGAGTGCCCGCGGAGAGATGC 360
Db 301 GTGCATATTGACACACCGGGTCAACCGGGTCCCTGCTTCCAGAGGAGTGCCCGCGGAGAGATGC 360
Qy 361 TGCTGGGAATGACAAAGTGGTGGCTGCTCTCTCGGGTGGTCTCTTGAGCAACACCCCAAC 420
Db 361 TGCTGGGAATGACAAAGTGGTGGCTGCTCTCTCGGGTGGTCTCTTGAGCAACACCCCAAC 420
Qy 421 GCAGTACAGATCGAGATCCAGAACGTTGATGACAGGGCCCTTACACTGCTC 480
Db 421 GCAGTACAGATCGAGATCCAGAACGTTGATGACAGGGCCCTTACACTGCTC 480
Qy 481 GGTGCAGACAGACACACCAACCCAGAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCAGACAGACACACCAACCCAGAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Qy 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGGCTCAC 600
Db 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGGCTCAC 600
Qy 601 CTGCATAGCAACTGGTAGACAGAGCCCTACGGTACTTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCCCTACGGTACTTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTTCGGCTTTGTAGTGAAGACGAATATCTTGGAAATTCAGGCGATCACCGGGAGACGTC 720
Db 661 GGTTCGGCTTTGTAGTGAAGACGAATATCTTGGAAATTCAGGCGATCACCGGGAGACGTC 720

661	DB	GGTTGGCTTTGTGAGTGAAGACGAATACTTCTGGAAAATTCAGGGGATCACCCGGGAGCAGTC	720
721	QY	AGGGAGCTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCCCGTGGTACGAGAGTAAA	780
721	DB	AGGGAGCTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCCCGTGGTACGAGAGTAAA	780
781	QY	GGTCAACCGTGAACTATCCACCATACATTTTCAGAAAGCCAAAGGTTACAGAGTGTCCCGTGGG	840
781	DB	GGTCAACCGTGAACTATCCACCATACATTTTCAGAAAGCCAAAGGTTACAGAGTGTCCCGTGGG	840
841	QY	ACAAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
841	DB	ACAAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
901	QY	CAAGGATGACAAAAGACACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAACAGACCTTT	960
901	DB	CAAGGATGACAAAAGACACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAACAGACCTTT	960
961	QY	CCTCTCAAAACTCATCTTTCTTCAATGTCTCTGAACTATGAGTCTTGGAACTACACTTGGT	1020
961	DB	CCTCTCAAAACTCATCTTTCTTCAATGTCTCTGAACTATGAGTCTTGGAACTACACTTGGT	1020
1021	QY	GGCTTCCACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTTCAGGCGCCGT	1080
1021	DB	GGCTTCCACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTTCAGGCGCCGT	1080
1081	QY	CAGCAGGTGAGCAACGGCACGTCAGAGAGGCGAGGCTGGTCTGGCTGCTGCCTCTTCT	1140
1081	DB	CAGCAGGTGAGCAACGGCACGTCAGAGAGGCGAGGCTGGTCTGGCTGCTGCCTCTTCT	1140
1141	QY	GGTCTGACCTGCTTCTCAAAATTTTGNATGTAGTGCCACTTCCCACCGGGGAAAGGCT	1200
1141	DB	GGTCTGACCTGCTTCTCAAAATTTTGNATGTAGTGCCACTTCCCACCGGGGAAAGGCT	1200
1201	QY	GGCGCCACCAACCAACCAACAGCAATGGCAACCGCACGCAACCAATCAGATA	1260
1201	DB	GGCGCCACCAACCAACCAACAGCAATGGCAACCGCACGCAACCAATCAGATA	1260
1261	QY	TATACAAATGAAATTTAGAAAGAAAACAGGCTCATGGGACAGAAATTTGAGGAGGGGAAAC	1320
1261	DB	TATACAAATGAAATTTAGAAAGAAAACAGGCTCATGGGACAGAAATTTGAGGAGGGGAAAC	1320
1321	QY	AAAGAATACTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAATTCGCTTTCAGATA	1380
1321	DB	AAAGAATACTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAATTCGCTTTCAGATA	1380
1381	QY	TTTAGGTAACAATGGAGTTTCTTTTCCAAACGGGAGAAACACAGACACCCGGCTTGGAA	1440
1381	DB	TTTAGGTAACAATGGAGTTTCTTTTCCAAACGGGAGAAACACAGACACCCGGCTTGGAA	1440
1441	QY	CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
1441	DB	CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
1501	QY	TTTGCCCAACAGATGCCCCACAGTGGAAACATTTCTGGAGCTGGGCCATCCCAAAATCAATCA	1560
1501	DB	TTTGCCCAACAGATGCCCCACAGTGGAAACATTTCTGGAGCTGGGCCATCCCAAAATCAATCA	1560
1561	QY	GTCCATAGAGACGAACAGATGAGACCTTCCGGGCCCAAGCGTGGCGCTGGGGCACTTTG	1620
1561	DB	GTCCATAGAGACGAACAGATGAGACCTTCCGGGCCCAAGCGTGGCGCTGGGGCACTTTG	1620
1621	QY	GTAGACTGTCACCAACCGCGCTGTGTGTGAAACGTGAAATTAATAAGACAAAAAAA	1679
1621	DB	GTAGACTGTCACCAACCGCGCTGTGTGTGAAACGTGAAATTAATAAGAGAAAAAAA	1679

RESULT 93

ADE35610

ID ADE35610 standard; cDNA; 1679 BP.

XX

AC ADE35610;

DT	29-JAN-2004	(first entry)	
XX			
DE	Human cDNA encoding secreted/transmembrane protein, PRO3337.		
XX			
XX	Human; ss; gene; secreted protein; transmembrane protein; PRO;		
KW	cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;		
KW	vulnery; auditory; tumour growth; retinal disorder;		
KW	sports-related joint problem; articular cartilage defects;		
XX	osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.		
XX			
OS	Homo sapiens.		
XX			
PN	US2003203434-A1.		
XX			
PD	30-OCT-2003.		
XX			
PF	18-OCT-2001; 2001US-00145088.		
XX			
XX	15-MAY-1998; 98US-0085689P.		
PR	08-MAR-1999; 99WO-US005028.		
PR	28-APR-1999; 99US-0131445P.		
PR	25-AUG-1999; 99US-00380138.		
PR	18-FEB-2000; 2000WO-US004341.		
PR	30-JUL-2001; 2001US-00918585.		
XX			
PA	(GETH) GENENTECH INC.		
XX			
PI	Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;		
PI	Perrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;		
PI	Goddard A, Godowski PJ, Grimaldi JC, Gurney AU, Hillan KJ;		
PI	Klijavain IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;		
PI	Stewart TA, Tumas D, Williams PM, Wood WI;		
XX			
XX	WPI; 2003-875641/81.		
DR	P-PSDB; ADE35611.		
XX			
PT	New genes, and its encoded secreted and transmembrane polypeptides,		
PT	useful for treating e.g. lung or breast tumors, osteoarthritis,		
PT	rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,		
PT	hypoinsulinemia or wounds.		
PT			

Claim 2: SEO ID NO 522: 462pp: English.

The invention relates to an isolated PRO polypeptide (secreted or transmembrane protein) having at least 80 amino acid sequence identity to an amino acid sequence chosen from 94 fully defined sequences as given in the specification (including PRO lacking its associated signal peptide, a PRO extracellular domain with or without its associated signal peptide). Also included are nucleic acids encoding the PRO proteins. mentioned above, a vector comprising a PRO nucleic acid, a host cell comprising the vector and producing PRO, a chimeric molecule comprising PRO fused to a heterologous amino acid sequence, and an anti-PRO antibody. PRO337 polypeptide is useful for detecting a PRO4993 polypeptide in a sample suspected of containing PRO4993 polypeptide. Similarly, PRO4993 polypeptide is useful for detecting PRO337 polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive molecule is the toxin, radiolabel, or an antibody. The bioactive molecule causes death of the cell. PRO337 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO725, PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337 polypeptide is useful for modulating at least one biological activity of the cell expressing PRO337 polypeptide, where the cell is killed. PRO337 polypeptide or anti-PRO4993 polypeptide is useful for modulating the biological activity of the cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for modulating the biological activity of the cell expressing PRO1559 polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-

CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence encodes a PRO protein.
XX
SQ

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GTGTGTCCTTCAGCAAAACAGTGGATTTAAATCTCTCTGCGCAAGCTTGAGAGCAACAC	60
Db	1	GTGTGTCCTTCAGCAAAACAGTGGATTTAAATCTCTCTGCGCAAGCTTGAGAGCAACAC	60
Qy	61	AATCTATCAGGAAGAAAGAAAGAAACCGAAGCTGACAAAAGAAAGAAAGAAAG	120
Db	61	AATCTATCAGGAAGAAAGAAAGAAACCGAAGCTGACAAAAGAAAGAAAGAAAG	120
Qy	121	ARGAAAAAATCATGAAACCATCCAGCCGCAAAAATGCAATTCCTCTTTGGCAAT	180
Db	121	ARGAAAAAATCATGAAACCATCCAGCCGCAAAAATGCAATTCCTCTTTGGCAAT	180
Qy	181	CTTCACGGGCTGGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	240
Db	181	CTTCACGGGCTGGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	240
Qy	241	CACCTTCCCAAGCTATGACAAACGTCGAGCTCCGCGAGGGGAGAGCGCCACCTCTAG	300
Db	241	CACCTTCCCAAGCTATGACAAACGTCGAGCTCCGCGAGGGGAGAGCGCCACCTCTAG	300
Qy	301	GTGCACTATTGACAAACCGGCTCACCGGGTGGCTGCTTAACCGCAGACCAATCTCTA	360
Db	301	GTGCACTATTGACAAACCGGCTCACCGGGTGGCTGCTTAACCGCAGACCAATCTCTA	360
Qy	361	TGCTGGGAATGACAAAGTGGTGGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	420
Db	361	TGCTGGGAATGACAAAGTGGTGGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	420
Qy	421	GCAGTACAGCATCAGATCCAGAAAGTGGATGATGATGATGATGATGATGATGATGAT	480
Db	421	GCAGTACAGCATCAGATCCAGAAAGTGGATGATGATGATGATGATGATGATGATGAT	480
Qy	481	GGTCAGACAGCAACCAACCAAGACCTCTAGGGTCCACTCAATGTGCAAGTATCTCC	540
Db	481	GGTCAGACAGCAACCAACCAAGACCTCTAGGGTCCACTCAATGTGCAAGTATCTCC	540
Qy	541	CAAAATGTAGAGATTCTTCAGATATCTCCATTAATGAAGGAAACAAATTTAGCCTCAG	600
Db	541	CAAAATGTAGAGATTCTTCAGATATCTCCATTAATGAAGGAAACAAATTTAGCCTCAG	600
Qy	601	CTGCATAGCACTGGTAGACAGAGCTCTAGGTTTCTCTCTCTCTCTCTCTCTCTCTCT	660
Db	601	CTGCATAGCACTGGTAGACAGAGCTCTAGGTTTCTCTCTCTCTCTCTCTCTCTCTCT	660
Qy	661	GGTTGGCTTTGTAGTGAAGACGAATCTTGGAATTCAGGGCATCACCGGGAGCAGTC	720
Db	661	GGTTGGCTTTGTAGTGAAGACGAATCTTGGAATTCAGGGCATCACCGGGAGCAGTC	720
Qy	721	AGGGGATCTAGTGCAGTGCCTCCATGAGTGGCGCGCGCTGTAGCGAGAGTAA	780
Db	721	AGGGGATCTAGTGCAGTGCCTCCATGAGTGGCGCGCGCTGTAGCGAGAGTAA	780
Qy	781	GGTCACCGTGAATCTATCCACCATACATTTAGAGGCAAGGGTACAGGTCTCCCGTGG	840
Db	781	GGTCACCGTGAATCTATCCACCATACATTTAGAGGCAAGGGTACAGGTCTCCCGTGG	840
Qy	841	ACAAAGGGGACCTGAGTGTGAGCTCAGCATCCCTCAGCAGAAATTCAGTGGTA	900
Db	841	ACAAAGGGGACCTGAGTGTGAGCTCAGCATCCCTCAGCAGAAATTCAGTGGTA	900

Qy	901	CAAGATGACAAAAGACTGATTGAGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT	960
Db	901	CAAGATGACAAAAGACTGATTGAGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT	960
Qy	961	CCTCTCAAACTCATCTCTTCTCAATGCTCTGAACATGACTATGAGGAACTACACTTCGT	1020
Db	961	CCTCTCAAACTCATCTCTTCTCAATGCTCTGAACATGACTATGAGGAACTACACTTCGT	1020
Qy	1021	GGCTTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT	1080
Db	1021	GGCTTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT	1080
Qy	1081	CAGCGAGTGGAGCAACCGCAGCTCGAGGAGGAGGCTGCTGCTGGCTGCTGCTCTTCT	1140
Db	1081	CAGCGAGTGGAGCAACCGCAGCTCGAGGAGGAGGCTGCTGCTGGCTGCTGCTCTTCT	1140
Qy	1141	GGTCTTGCACTGCTCTCTCAAAATTTTATGATGAGTGCACCTTCCCAACCGGGGAAAGCT	1200
Db	1141	GGTCTTGCACTGCTCTCTCAAAATTTTATGATGAGTGCACCTTCCCAACCGGGGAAAGCT	1200
Qy	1201	GGCGCCACCAACCAACCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCA	1260
Db	1201	GGCGCCACCAACCAACCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCA	1260
Qy	1261	TATACAAATGAAATTTAGAAAGAAACACAGCTCTCATGGGACAGAAATTTGAGGGAGGGAAC	1320
Db	1261	TATACAAATGAAATTTAGAAAGAAACACAGCTCTCATGGGACAGAAATTTGAGGGAGGGAAC	1320
Qy	1321	AAAGAAATTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTCAGATA	1380
Db	1321	AAAGAAATTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTCAGATA	1380
Qy	1381	TTTAGTCAATGAGATTTTCTTTTCCAAACGGGAAAGAACACAGCACACCCGGCTTGGGA	1440
Db	1381	TTTAGTCAATGAGATTTTCTTTTCCAAACGGGAAAGAACACAGCACACCCGGCTTGGGA	1440
Qy	1441	CCCACTGCAAGTGCATGTCGCAACCTTTTGGTGCAGTGTGGCAAGGCTCAGCTC	1500
Db	1441	CCCACTGCAAGTGCATGTCGCAACCTTTTGGTGCAGTGTGGCAAGGCTCAGCTC	1500
Qy	1501	TCGTGCCACAGAGTGCCTCCACGCTGGAACTTCTGGAGCTGCCATCCCAATTCATCA	1560
Db	1501	TCGTGCCACAGAGTGCCTCCACGCTGGAACTTCTGGAGCTGCCATCCCAATTCATCA	1560
Qy	1561	GTCCATAGAGACGAACAGAAATGAGACTTCCGGCCCAAGCGTGGCGCTGGCGGCACTTTG	1620
Db	1561	GTCCATAGAGACGAACAGAAATGAGACTTCCGGCCCAAGCGTGGCGCTGGCGGCACTTTG	1620
Qy	1621	GTAGACTGTGCCACCGCGCTGTGTTGTAACCTGTAACCTGTAACCTGTAACCTGTAAC	1679
Db	1621	GTAGACTGTGCCACCGCGCTGTGTTGTAACCTGTAACCTGTAACCTGTAACCTGTAAC	1679

RESULT 94
ADE16724
ID ADE16724 standard; cDNA; 1679 BP.
XX ADE16724;
AC ADE16724;
XX
DT 29-JAN-2004 (first entry)
XX
XX Human cDNA encoding secreted/transmembrane protein, PRO337.
DE Human; ss; gene; secreted protein; transmembrane protein; PRO;
XX cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulvar; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
XX
XX
XX US2003203435-A1.
XX

Db 1081 CAGCAGAGTGAGCAACGCGACGTCGAGAGGGGAGGCTGCTGCTGCTGCTCTCTCT 1140
QY 1141 GGTCTTGCACCTGCTCTCTCAAAATTTTGTAGTGCCATCTTCCACCCGCGGAAAGGCT 1200
Db 1141 GGTCTTGCACCTGCTCTCTCAAAATTTTGTAGTGCCATCTTCCACCCGCGGAAAGGCT 1200
QY 1201 GCGGCCACACACACACACACACACACACACACACACACACACACACACACACACAC 1260
Db 1201 GCGGCCACACACACACACACACACACACACACACACACACACACACACACACACAC 1260
QY 1261 TATACAAATGAATTAAGAAAGAAACACACACACACACACACACACACACACACACAC 1320
Db 1261 TATACAAATGAATTAAGAAAGAAACACACACACACACACACACACACACACACACAC 1320
QY 1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGCTTCCCTTGCAGATA 1380
Db 1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGCTTCCCTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGAGTTTCTTTTCCCAACCGGGAAGAACACACACACACACACAC 1440
Db 1381 TTTAGGTACAAATGAGTTTCTTTTCCCAACCGGGAAGAACACACACACACACACAC 1440
QY 1441 CCACATGCAAGTGCATGCGTGCACCTCTTTTGTGTCAGTGTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCACATGCAAGTGCATGCGTGCACCTCTTTTGTGTCAGTGTGGGCAAGGCTCAGCCTC 1500
QY 1501 TCTGCCACACAGTGCCTCCACGTCGGAACATTTCTGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACACAGTGCCTCCACGTCGGAACATTTCTGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGACGACGACGACGACGACGACGACGACGACGACGACGACGACGACGACGAC 1620
Db 1561 GTCCATAGACGACGACGACGACGACGACGACGACGACGACGACGACGACGACGACGAC 1620
QY 1621 GTAGACTGTCGCCACCGCGGTGTGTGTAACGTCGAATTAAGAAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTCGCCACCGCGGTGTGTGTAACGTCGAATTAAGAAAGAGCAAAAAAAA 1679

RESULT 95
ADD73339
ID ADD73339 standard; cDNA; 1679 BP.
AC ADD73339;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO337.
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritis; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
FN US2003203436-A1.
XX
PD 30-OCT-2003.
XX
PF 18-OCT-2001; 2001US-00145129.
XX
PR 22-MAY-1998; 98US-0086414P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US0005028.
PR 12-APR-1999; 99US-00284291.
PR 25-AUG-1999; 99US-00380138.
PR 18-FEB-2000; 2000WO-US004341.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.

XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen WE;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Klijavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart VA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-875643/81.
DR P-FSDB; ADD73340.
XX
PT New PRO genes and encoded secreted and transmembrane polypeptides, useful
PT for treating e.g. lung or breast tumors, osteoarthritis, rheumatoid
PT arthritis, obesity, diabetes, hyperinsulinemia, hypoinsulinemia or
PT wounds.
XX
PS Claim 2; SEQ ID NO 522; 453pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence encodes a PRO protein.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTGTGTCTTCAGCAAAACAGTGGATTTAAATCTCTTGACACAGCTTGAGACCAAC 60
Db 1 GTGTGTCTTCAGCAAAACAGTGGATTTAAATCTCTTGACACAGCTTGAGACCAAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATATGAAAAACCATCCAGCCAAAAATGCAAAATTTCTCTTGGGCAAT 180
Db 121 AAGAAAAAATATGAAAAACCATCCAGCCAAAAATGCAAAATTTCTCTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTGCTCTGTGTCTCTTCCACGAGTGCCCGTGCAGCGGAGATGC 240

Db 181 CTTTCAGGGGGTGGCTGCTCTGTGTCTCTTCCAAAGGAGTCCCGTGGCAGCGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGAGCAACGCTGACGGTCCGGCAGGGGAGAGCGCACCTCTCAG 300
Db 241 CACCTTCCCAAGCTATGAGCAACGCTGACGGTCCGGCAGGGGAGAGCGCACCTCTCAG 300
Qy 301 GTGCACTATTGACAAACCGGGTCAACCCGGTGGCTGTGATGACAGCGGCGCTTCTCTTA 360
Db 301 GTGCACTATTGACAAACCGGGTCAACCCGGTGGCTGTGATGACAGCGGCGCTTCTCTTA 360
Qy 361 TGCTGGGAATGCAAGTGTGCTGGATCTCTGGGTGGTCTCTGAGCAACACCCAAAC 420
Db 361 TGCTGGGAATGCAAGTGTGCTGGATCTCTGGGTGGTCTCTGAGCAACACCCAAAC 420
Qy 421 GCAGTACAGATCGAGATCCAGAACGCTGGATGTGATGACAGGGCGCTTACACCTGCTC 480
Db 421 GCAGTACAGATCGAGATCCAGAACGCTGGATGTGATGACAGGGCGCTTACACCTGCTC 480
Qy 481 GGTGACAGACAGAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540
Db 481 GGTGACAGACAGAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540
Qy 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTAC 600
Db 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTAC 600
Qy 601 CTGCTAGCAACTGTGACAGACGCTACGTTACTTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCTAGCAACTGTGACAGACGCTACGTTACTTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGGCTTTGTGAGTGAAGAGCAATATCTTGAAATTCAGGGCATCACCCGGGAGCATC 720
Db 661 GGTGGCTTTGTGAGTGAAGAGCAATATCTTGAAATTCAGGGCATCACCCGGGAGCATC 720
Qy 721 AGGGGACTACAGTGCAGTGCCTCCAAAGACGTGCGCGCCCGTGGTACGAGAGTAA 780
Db 721 AGGGGACTACAGTGCAGTGCCTCCAAAGACGTGCGCGCCCGTGGTACGAGAGTAA 780
Qy 781 GGTCAACCGTGAATTCACCAATATATTTCAAGCCCAAGGATACAGTGTCCCGTGGG 840
Db 781 GGTCAACCGTGAATTCACCAATATATTTCAAGCCCAAGGATACAGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACACTGCAGTGTGAAGCTTCAGACGTCAGCTCCCTCAGCAGATTCAGTGT 900
Db 841 ACAAAGGGGACACTGCAGTGTGAAGCTTCAGACGTCAGCTCCCTCAGCAGATTCAGTGT 900
Qy 901 CAAGGATCAAAAGACTGATTGAAGGAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db 901 CAAGGATCAAAAGACTGATTGAAGGAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Qy 961 CCTCTCAAAACTCATCTTCTCAATGTCTCTGAAACATGATGAGGAACTACATTTGGT 1020
Db 961 CCTCTCAAAACTCATCTTCTCAATGTCTCTGAAACATGATGAGGAACTACATTTGGT 1020
Qy 1021 GGCTCCAAAGCTGGGCGACACCAATCCAGCATCATGCTATTTGTCAGGGCGCGT 1080
Db 1021 GGCTCCAAAGCTGGGCGACACCAATCCAGCATCATGCTATTTGTCAGGGCGCGT 1080
Qy 1081 CAGCAGGTGAGCAACCGGACGCTCGAGGAGGCGAGCTGCTGCTGGCTGCTCTCTCT 1140
Db 1081 CAGCAGGTGAGCAACCGGACGCTCGAGGAGGCGAGCTGCTGCTGGCTGCTCTCTCT 1140
Qy 1141 GGTCTTGCACCTGCTCTCAATTTTGTGATGCTGAGTGCACCTTCCCAACCCGGGAAGCT 1200
Db 1141 GGTCTTGCACCTGCTCTCAATTTTGTGATGCTGAGTGCACCTTCCCAACCCGGGAAGCT 1200
Qy 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Qy 1261 TATACAAATGAATTAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAC 1320

Db 1261 TATACAAATGAATTAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
Qy 1321 AAGAATACTTTGGGGGAAAAGAGTTTTTAAAAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
Db 1321 AAGAATACTTTGGGGGAAAAGAGTTTTTAAAAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
Qy 1381 TTTAGTACAATGGAGTTTTCTTTTCCCAACGGGAAGAACACAGACACACCGGCTTGA 1440
Db 1381 TTTAGTACAATGGAGTTTTCTTTTCCCAACGGGAAGAACACAGACACACCGGCTTGA 1440
Qy 1441 CCACCTGCAAGCTGCATCGTGCAACCTCTTTGGTCCCAAGTGTGGCAAGGGCTCAGCCTC 1500
Db 1441 CCACCTGCAAGCTGCATCGTGCAACCTCTTTGGTCCCAAGTGTGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCCAAGAGTGGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1560
Db 1501 TCTGCCCAAGAGTGGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1560
Qy 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTTCCGGGCGGCGGCGGCGGCGGCGGCGG 1620
Db 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTTCCGGGCGGCGGCGGCGGCGGCGGCGG 1620
Qy 1621 GTAGACTGTGCCACGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1679
Db 1621 GTAGACTGTGCCACGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1679

RESULT 96

ADE42008

ID ADE42008 standard; cDNA; 1679 BP.

XX ADE42008;

XX AC

XX XX

XX DT 29-JAN-2004 (first entry)

XX XX

XX DE Human PRO polynucleotide #188.

XX XX

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX KW liver; microvascular endothelial cell; glioma; FFA;

XX KW skeletal muscle cell; adipocyte cell; pericyte cell;

XX KW inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;

XX KW immune system cell infiltration.

XX OS Homo sapiens.

XX XX

XX EN US2003194772-A1.

XX XX

XX PD 16-OCT-2003.

XX XX

XX PF 21-MAY-2002; 2002US-00152386.

XX XX

XX PR 03-MAR-2000; 2000US-0187202P.

XX PR 01-DEC-2000; 2000MO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX XX

XX PA (GETH) GENENTECH INC.

XX XX

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX XX

XX DR WPI; 2003-899788/82.

XX DR P-PSDE; ADE42009.

XX XX

XX PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,

XX PT useful for treating pericyte-associated tumors, diabetes and various bone

XX PT and/or cartilage disorders, e.g. arthritis.

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

Claim 2; Fig 3/5; 637bp; English.

PS The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTCGACAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTCGACAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAGAAGAAAGAAACCCGACCTGCAAAAAGAGAAAGAAAGAG 120
Db 61 AATCTATCAGGAAGAAGAAAGAAACCCGACCTGCAAAAAGAGAAAGAAAGAG 120
Qy 121 AAGAAAAAATATGAAAAACCATCCAGCCGCAAAATGCAATCTATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATATGAAAAACCATCCAGCCGCAAAATGCAATCTATCTCTTGGGCAAT 180
Qy 181 CTTACGGGGTGGCTGCTGCTGCTCTTCCAGGAGTGCCTGGCGAGCGGAGATGC 240
Db 181 CTTACGGGGTGGCTGCTGCTGCTCTTCCAGGAGTGCCTGGCGAGCGGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGGAACAACGTCAGCGTCCGCGAGGGAGAGCCCAACCTCAG 300
Db 241 CACCTTCCCAAGCTATGGAACAACGTCAGCGTCCGCGAGGGAGAGCCCAACCTCAG 300
Qy 301 GTGCACATTTGCAACCGGTCACCGGGTGGCTGCTTAAACCGAGACCATCTCTTA 360
Db 301 GTGCACATTTGCAACCGGTCACCGGGTGGCTGCTTAAACCGAGACCATCTCTTA 360
Qy 361 TGCTGGGAATGACAAGTGGTGGATCTCTCGGCTGGTCTCTTGAGCAACACCCAAAC 420
Db 361 TGCTGGGAATGACAAGTGGTGGATCTCTCGGCTGGTCTCTTGAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGACGTTGGATGCTGATGACGAGGCGCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGACGTTGGATGCTGATGACGAGGCGCTTACACCTGCTC 480

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX Claim 2; SEQ ID NO 375; 637bp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems.
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAGAAGAAAGAAACCGAACCTGCACAAAAGAAAGAAAGAG 120
Db 61 AATCTATCAGGAAGAAGAAAGAAACCGAACCTGCACAAAAGAAAGAAAGAG 120
Qy 121 AAGAAAAAATCATGAAACCATCCAGCCAAAATGCAAAATCTATCTCTTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAACCATCCAGCCAAAATGCAAAATCTATCTCTTTGGGCAAT 180
Qy 181 CTTACGGGGTGGCTCTCTGTCTCTTCCAGAGAGTCCCGTGCAGCGGAGATGC 240
Db 181 CTTACGGGGTGGCTCTCTGTCTCTTCCAGAGAGTCCCGTGCAGCGGAGATGC 240
Qy 241 CACCTTCCCCAAGCTATGGAACACGTGACGGTCCGCGAGGGGAGAGCGCCACCTTCAG 300
Db 241 CACCTTCCCCAAGCTATGGAACACGTGACGGTCCGCGAGGGGAGAGCGCCACCTTCAG 300
Qy 301 GTGCACATTTGCAACCGGGTCAACCGGGTGGCTGGCTTAACCGGAGACCATCTCTTA 360
Db 301 GTGCACATTTGCAACCGGGTCAACCGGGTGGCTGGCTTAACCGGAGACCATCTCTTA 360
Qy 361 TGCTGGGAATGACAAGTGGTGGCTGGATCTCTCGGTGGTCTCTCTGAGCAACACCAAC 420

Db 361 TGCTGGGAATGACAAGTGGTGGCTGGATCTCGGTGGTCTCTCTGAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGACGCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACGCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
Qy 481 GGTGACAGACAGCAACCAACCCCAAGAGACCTCTAGGGTCCACCTATTGTGCAAGTATCTCC 540
Db 481 GGTGACAGACAGCAACCAACCCCAAGAGACCTCTAGGGTCCACCTATTGTGCAAGTATCTCC 540
Qy 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAAATGAAGGGAACATATATAGCCTCAC 600
Db 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAAATGAAGGGAACATATATAGCCTCAC 600
Qy 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATCCCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATCCCGGGAGCAGTC 720
Qy 721 AGGGGACTACAGTGCAGTGCCTCCAAATGAGTGGCCCGCGCTGCTACGGAGAGTAAA 780
Db 721 AGGGGACTACAGTGCAGTGCCTCCAAATGAGTGGCCCGCGCTGCTACGGAGAGTAAA 780
Qy 781 GGTCAACGTGAATCATCCATACATTTCAAGACCAAGGGTACAGGTGTCCTCCGCTGG 840
Db 781 GGTCAACGTGAATCATCCATACATTTCAAGACCAAGGGTACAGGTGTCCTCCGCTGG 840
Qy 841 ACAGAGGGGACACGTGAGTGCCTCAGAGTCCCTCAGCAGTAATTCAGTGTGTA 900
Db 841 ACAGAGGGGACACGTGAGTGCCTCAGAGTCCCTCAGCAGTAATTCAGTGTGTA 900
Qy 901 CAAGATGACAAAACATGATTGAAGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT 960
Db 901 CAAGATGACAAAACATGATTGAAGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT 960
Qy 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGACATGATATGGGAATCAGCTTGGT 1020
Db 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGACATGATATGGGAATCAGCTTGGT 1020
Qy 1021 GGCCTCCAACTAGCTGGGCCACCAATGCCAGCATCATGTATTGTTCAGGCGCGCT 1080
Db 1021 GGCCTCCAACTAGCTGGGCCACCAATGCCAGCATCATGTATTGTTCAGGCGCGCT 1080
Qy 1081 CAGCAGGTGACACGCAAGTCCAGAGGGGAGGCTGCTGCTGCTGCTGCTCTTCT 1140
Db 1081 CAGCAGGTGACACGCAAGTCCAGAGGGGAGGCTGCTGCTGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGTATGTGAGTGCACCTTCCCCACCCGGGAAAGCT 1200
Db 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGTATGTGAGTGCACCTTCCCCACCCGGGAAAGCT 1200
Qy 1201 GCGGCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db 1201 GCGGCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Qy 1261 TATACAAATGAAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320
Db 1261 TATACAAATGAAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320
Qy 1321 AAGAAATTTCTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCCCTTGAGATA 1380
Db 1321 AAGAAATTTCTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCCCTTGAGATA 1380
Qy 1381 TTTAGGTACAATGGAGTTTCTTTTCCAAACCGGAAGAACACAGCACACCCGGGCTTGA 1440
Db 1381 TTTAGGTACAATGGAGTTTCTTTTCCAAACCGGAAGAACACAGCACACCCGGGCTTGA 1440
Qy 1441 CCCATGCAAGCTGATCGTGCAACCTTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCATGCAAGCTGATCGTGCAACCTTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500

QY 1501 TCTGCCACAGAGTCCCGCCACGCTGGACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 20-DEC-1999; 99WO-US030720.
PR 20-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 15-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-0082366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 29-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
FA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX
PI

QY 1501 TCTGCCACAGAGTCCCGCCACGCTGGACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTCCCGCCACGCTGGACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGAGCAACAGAAATAGACCTTCCGGCCCAAGCGTGGCGCTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGAGCAACAGAAATAGACCTTCCGGCCCAAGCGTGGCGCTGGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACGCGCTGTCTTGTGAACGTGAATATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACGCGCTGTCTTGTGAACGTGAATATAAAGAGCAAAAAA 1679

RESULT 98
ADD91957
ID ADD91957 standard; cDNA; 1679 BP.
XX
AC ADD91957;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear intricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199053-A1.
XX
PD 23-OCT-2003.
XX
PF 12-APR-2002; 2002US-00121053.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98WO-US019437.
PR 29-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.

Db 1381 TTAGGTACATGAGTTTCTTTTCCCAAGGGAAGAACACACAGCACACCCGGCTTGA 1440
Qy 1441 CCACATGAAGTGCATCGTGAACCTTTTGGTCCAGTGTGGCAGAGGCTCAGCCTC 1500
Db 1441 CCACATGAAGTGCATCGTGAACCTTTTGGTCCAGTGTGGCAGAGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTCCGCCACGTCGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTCCGCCACGTCGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGAGCAACAGAACTTCCGGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGAGCAACAGAACTTCCGGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
Qy 1621 GTAGACTGGCCACACGCGTGTCTGTGAACCTGAAATATAAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGGCCACACGCGTGTGTGTGAACCTGAAATATAAAGAGCAAAAAAAA 1679
RESULT 99
ADE33420
ID ADE33420 standard; cDNA; 1679 BP.
XX ADE33420;
AC ADE33420;
XX
XX 29-JAN-2004 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO337 cDNA.
XX
XX Human; secreted and transmembrane protein; PRO; Gene: ss;
XX Tumour necrosis factor alpha release; TNF-alpha release;
XX Glucose uptake modulator; PFA uptake modulator;
XX cell proliferation stimulator; cell differentiation stimulator;
XX cell differentiation inhibitor; cytokine release stimulator; tumour;
XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX cervical tumour; liver tumour; chromosome mapping; Gene mapping;
XX gene therapy; chromosome identification; chromosome marker.
XX
XX Homo sapiens.
CS
XX
XX US2003194767-A1.
XX
XX 16-OCT-2003.
XX
XX 16-MAY-2002; 2002US-00147497.
XX
XX 26-AUG-1998; 98US-0097951P.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380137.
XX 30-MAR-2000; 2000WO-US008439.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-999796/82.
XX P-PSDB; ADE33421.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; SEQ ID NO 375; 636pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or PFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,

CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMBC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Qy
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTGTGTCTCTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGACGACAC 60
Db 1 GTGTGTCTCTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGACGACAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAACCAACCTGACAAAAAAGAAAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAACCAACCTGACAAAAAAGAAAAAGAAAG 120
Qy 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAATGACAAATCTATCTCTTGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAATGACAAATCTATCTCTTGGCAAT 180
Qy 181 CTTTCAGGGGCTGGCTGTCTGTGTCTCTTCCAAAGAGTGCCTGCGCAGCGGATGC 240
Db 181 CTTTCAGGGGCTGGCTGTCTGTGTCTCTTCCAAAGAGTGCCTGCGCAGCGGATGC 240
Qy 241 CACCTTCCCAAGCTATGACACAGTGCAGTCCGGAGGGGAGAGCGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGACACAGTGCAGTCCGGAGGGGAGAGCGCCACCTCAG 300
Qy 301 GTGCATCTATTGACAAACCGGCTCACCCGGTGGCTTAAACCCGAGCACCATCCTCTA 360
Db 301 GTGCATCTATTGACAAACCGGCTCACCCGGTGGCTTAAACCCGAGCACCATCCTCTA 360
Qy 361 TGTGGGAATGACAAAGTGTGGTCTGGATCTCGCTGGTCTCTTGTGAGCAACACCAAC 420
Db 361 TGTGGGAATGACAAAGTGTGGTCTGGATCTCGCTGGTCTCTTGTGAGCAACACCAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACAGGGGCCCTTACACCTGTCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACAGGGGCCCTTACACCTGTCTC 480
Qy 481 GGTGCGACAGACAAACCCAAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCGACAGACAAACCCAAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Qy 541 CAAAAATTGTAGAGATTCTTTCAGATATCTCATTATTAAGGGGAACAATATTAGCCTCAC 600
Db 541 CAAAAATTGTAGAGATTCTTTCAGATATCTCATTATTAAGGGGAACAATATTAGCCTCAC 600
Qy 601 CTGCATAGCAACTGGTAGACAGAGCTAGGTTACTTGGAGACACATCTCTCCCAAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCTAGGTTACTTGGAGACACATCTCTCCCAAAGC 660

Qy	661	GGTTGGCTTTGTGAGTGAACGAATACCTTGGAATTCAGGGCATCACCCGGGAGCAGTC	720
Ds	661	GGTTGGCTTTGTGAGTGAACGAATACCTTGGAATTCAGGGCATCACCCGGGAGCAGTC	720
Qy	721	AGGGGACTACGAGTGCAGTCCCAATGACGTGGCGCCCGTGTGACGAGAGTAA	780
Ds	721	AGGGGACTACGAGTGCAGTCCCAATGACGTGGCGCCCGTGTGACGAGAGTAA	780
Qy	781	GGTACCGTGAATATCCACATACATTTGAGAGCCAGGGTACAGGTGTCCCGTGGG	840
Ds	781	GGTACCGTGAATATCCACATACATTTGAGAGCCAGGGTACAGGTGTCCCGTGGG	840
Qy	841	ACAAAAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Ds	841	ACAAAAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Qy	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGGAAAACAGACCTTT	960
Ds	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGGAAAACAGACCTTT	960
Qy	961	CCTCTCAAACTCATCTTCTCAATGCTCTGAACATGATATGGGAATTCACATTTGCT	1020
Ds	961	CCTCTCAAACTCATCTTCTCAATGCTCTGAACATGATATGGGAATTCACATTTGCT	1020
Qy	1021	GGCTCCCAAGCTGGGCGCACCAATGCCAGCATCATCTATTGGTCCAGGCGCGT	1080
Ds	1021	GGCTCCCAAGCTGGGCGCACCAATGCCAGCATCATCTATTGGTCCAGGCGCGT	1080
Qy	1081	CAGCGAGTGAACAGCGCAGCTGAGAGGAGGAGGCTGCTGCTGCTGCTTCT	1140
Ds	1081	CAGCGAGTGAACAGCGCAGCTGAGAGGAGGAGGCTGCTGCTGCTGCTTCT	1140
Qy	1141	GGTCTTGACCTGCTTCTCAATTTTGAATGTGAGTGCCACTTCCCAACCGGGAAGGCT	1200
Ds	1141	GGTCTTGACCTGCTTCTCAATTTTGAATGTGAGTGCCACTTCCCAACCGGGAAGGCT	1200
Qy	1201	GGCGCCACACACACACACACAGCAATGGCAACAGCGACAGCAACCAATCAGATA	1260
Ds	1201	GGCGCCACACACACACACACAGCAATGGCAACAGCGACAGCAACCAATCAGATA	1260
Qy	1261	TATCAATGAAATAGAGAAACACAGCTCTATGGGACAGAAATTTAGGAGGAGGGAAC	1320
Ds	1261	TATCAATGAAATAGAGAAACACAGCTCTATGGGACAGAAATTTAGGAGGAGGGAAC	1320
Qy	1321	AAAGAACTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTTCAGATA	1380
Ds	1321	AAAGAACTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTTCAGATA	1380
Qy	1381	TTTAGGTACATGAGTTCCTTTTCCAAACGGGAGAGAACAGCACACCCGGCTTGA	1440
Ds	1381	TTTAGGTACATGAGTTCCTTTTCCAAACGGGAGAGAACAGCACACCCGGCTTGA	1440
Qy	1441	CCCACTGCAAGCTGCATCGTGCACACCTTTTGGTGGCAGTGTGGGCAAGGCTCAGCCTC	1500
Ds	1441	CCCACTGCAAGCTGCATCGTGCACACCTTTTGGTGGCAGTGTGGGCAAGGCTCAGCCTC	1500
Qy	1501	TCTGCCACAGAGTGGCCCAACGAGTGAACATTCCTGGAGCTGGCCATCCCAATTTCAATCA	1560
Ds	1501	TCTGCCACAGAGTGGCCCAACGAGTGAACATTCCTGGAGCTGGCCATCCCAATTTCAATCA	1560
Qy	1561	GTCCATGAGACGACAGAAATGAGACCTTCGGGCCCAAGCGTGGCGTGGCGCACTTTG	1620
Ds	1561	GTCCATGAGACGACAGAAATGAGACCTTCGGGCCCAAGCGTGGCGTGGCGCACTTTG	1620
Qy	1621	GTAGACTGTGCCACACGCGGTGTGTTGTAAGCTGAATATAAAGAGCAAAAAA	1679
Ds	1621	GTAGACTGTGCCACACGCGGTGTGTTGTAAGCTGAATATAAAGAGCAAAAAA	1679

RESULT 100
ADE33972
ID ADE33972 standard; cDNA; 1679 BP.

XX	AC	ADE33972;	
XX	DT	29-JAN-2004 (first entry)	
XX	DE	Novel human secreted and transmembrane protein PRO337 cDNA.	
XX	KW	Human; secreted and transmembrane protein; PRO; gene; ss;	
XX	KW	Tumour necrosis factor alpha release; TNF-alpha release;	
XX	KW	Glucose uptake modulator; FFA uptake modulator;	
XX	KW	cell proliferation stimulator; cell differentiation stimulator;	
XX	KW	cell differentiation inhibitor; cytokine release stimulator; tumour;	
XX	KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;	
XX	KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;	
XX	KW	gene therapy; chromosome identification; chromosome marker.	
OS		Homo sapiens.	
XX	PN	US2003194791-A1.	
XX	XX	16-OCT-2003.	
XX	XX	11-APR-2002; 2002US-00121046.	
XX	PF	31-MAR-1997; 97WO-US005230.	
XX	PR	12-JUN-1998; 98WO-US012456.	
XX	PR	14-JUL-1998; 98WO-US014552.	
XX	PR	28-AUG-1998; 98WO-US017888.	
XX	PR	10-SEP-1998; 98WO-US018824.	
XX	PR	14-SEP-1998; 98WO-US019093.	
XX	PR	14-SEP-1998; 98WO-US019094.	
XX	PR	16-SEP-1998; 98WO-US019177.	
XX	PR	17-SEP-1998; 98WO-US019330.	
XX	PR	07-OCT-1998; 98WO-US019437.	
XX	PR	29-OCT-1998; 98WO-US021141.	
XX	PR	29-OCT-1998; 98WO-US022992.	
XX	PR	20-NOV-1998; 98WO-US024855.	
XX	PR	01-DEC-1998; 98WO-US025108.	
XX	PR	05-JAN-1999; 99WO-US000106.	
XX	PR	08-MAR-1999; 99WO-US005028.	
XX	PR	10-MAR-1999; 99WO-US005190.	
XX	PR	20-APR-1999; 99WO-US006319.	
XX	PR	14-MAY-1999; 99WO-US008615.	
XX	PR	02-JUN-1999; 99WO-US010733.	
XX	PR	01-SEP-1999; 99WO-US012252.	
XX	PR	08-SEP-1999; 99WO-US020111.	
XX	PR	13-SEP-1999; 99WO-US020594.	
XX	PR	15-SEP-1999; 99WO-US020944.	
XX	PR	15-SEP-1999; 99WO-US021090.	
XX	PR	05-OCT-1999; 99WO-US021547.	
XX	PR	29-NOV-1999; 99WO-US023089.	
XX	PR	30-NOV-1999; 99WO-US028214.	
XX	PR	30-NOV-1999; 99WO-US028313.	
XX	PR	30-NOV-1999; 99WO-US028409.	
XX	PR	01-DEC-1999; 99WO-US028301.	
XX	PR	02-DEC-1999; 99WO-US028634.	
XX	PR	02-DEC-1999; 99WO-US028551.	
XX	PR	02-DEC-1999; 99WO-US028554.	
XX	PR	16-DEC-1999; 99WO-US030095.	
XX	PR	20-DEC-1999; 99WO-US030911.	
XX	PR	22-DEC-1999; 99WO-US030999.	
XX	PR	30-DEC-1999; 99WO-US030720.	
XX	PR	30-DEC-1999; 99WO-US031243.	
XX	PR	05-JAN-2000; 99WO-US031274.	
XX	PR	06-JAN-2000; 2000WO-US000219.	
XX	PR	06-JAN-2000; 2000WO-US000277.	
XX	PR	11-FEB-2000; 2000WO-US000376.	
XX	PR	18-FEB-2000; 2000WO-US003565.	
XX	PR	18-FEB-2000; 2000WO-US004341.	
XX	PR	18-FEB-2000; 2000WO-US004342.	
XX	PR	22-FEB-2000; 2000WO-US004414.	

24-FEB-2000; 2000WO-US004914.
24-FEB-2000; 2000WO-US005004.
01-MAR-2000; 2000WO-US005060.
02-MAR-2000; 2000WO-US005746.
02-MAR-2000; 2000WO-US005841.
15-MAR-2000; 2000WO-US005884.
20-MAR-2000; 2000WO-US007777.
21-MAR-2000; 2000WO-US007532.
30-MAR-2000; 2000WO-US008439.
17-MAY-2000; 2000WO-US013705.
22-MAY-2000; 2000WO-US014042.
30-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
11-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US008520.
01-MAR-2001; 2001WO-US008666.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-899790/82.
P-PSDB; ADE33973.
Two hundred and seventy five nucleic acids encoding PRO polypeptides,
useful for treating pericyte-associated tumors, diabetes and various bone
and/or cartilage disorders, e.g. arthritis.
Claim 2; SEQ ID NO 375; 636pp; English.
The invention describes 305 nucleic acids encoding PRO (secreted and
transmembrane) polypeptides (I). (I) is useful for stimulating the
release of TNF-alpha from human blood, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating the proliferation or differentiation of chondrocyte cells,
for stimulating the proliferation of or gene expression in pericyte
cells, for stimulating the release of proteoglycans from cartilage, for

stimulating the proliferation of inner ear utricular supporting cells,
for stimulating the proliferation of T-lymphocyte cells, for stimulating
the release of a cytokine from PBMC cells, for inhibiting the binding of
A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
cells, for stimulating proliferation of endothelial cells, for detecting
the presence of tumour in a mammal. The tumour is lung, colon, breast,
prostate, rectal, cervical or liver tumour. The oligonucleotide probes
are useful for isolating genomic and cDNA nucleotide sequences or
antisense probes. (I) is also useful as therapeutic agent. PRO is useful
in assays to identify other proteins or molecules involved in binding
interaction. A polynucleotide (II) encoding (I) is useful in chromosome
and gene mapping, in generation of antisense RNA and DNA, in the
preparation of PRO polypeptide, for generating transgenic animals or
knockout animals which in turn are useful in the development and
screening of therapeutically useful reagents, in gene therapy, for
chromosome identification, as chromosome marker, and for generating
probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
detecting its expression in specific cells, tissues or serum, and for
affinity purification of PRO from recombinant cell culture or natural
sources. (I) and (II) are useful for tissue typing. This sequence encodes
a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTCTTGCACAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTCTTGCACAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAACCCGAACTTGACAAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAACCCGAACTTGACAAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAATCATGAAACCATCCAGCCAAAATGCAAAATTCATCTCTTGGCAAT 180
Db 121 AAGAAAAAATCATGAAACCATCCAGCCAAAATGCAAAATTCATCTCTTGGCAAT 180
Qy 181 CTTACGCGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGCCCGTCCGAGCGGAGATGC 240
Db 181 CTTACGCGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGCCCGTCCGAGCGGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGGACAACGTGACGCTCCGAGAGGGGAGAGCGCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGGACAACGTGACGCTCCGAGAGGGGAGAGCGCACCTCAG 300
Qy 301 GTGCACCTATTGACAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
Db 301 GTGCACCTATTGACAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
Qy 361 TGTGGGAATGACAAGTGGTGGATCCTCGGTGGTCTCTTGTGAGCAACACCCAAAC 420
Db 361 TGTGGGAATGACAAGTGGTGGATCCTCGGTGGTCTCTTGTGAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACAGGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACAGGGGCCCTTACACCTGCTC 480
Qy 481 GGTGACAGACAGAACCCACCCAAAGACCTCTAGGGTCCACCTCATTTGTGGAAGTATCTCC 540
Db 481 GGTGACAGACAGAACCCACCCAAAGACCTCTAGGGTCCACCTCATTTGTGGAAGTATCTCC 540
Qy 541 CAAAATTTGTAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTTCAC 600
Db 541 CAAAATTTGTAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTTCAC 600
Qy 601 CTGCATAGCAACTGGTAGACCAAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
Db 601 CTGCATAGCAACTGGTAGACCAAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
Qy 661 GGTGGGCTTTGTGAGTGAAGACGAAATACITGGAAATTCAGGGCATCACCGGGAGCAGTC 720

Db 661 GGTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGCATCACCCGGGAGCAGTC 720
Qy 721 AGGGGACTAGAGTGCAGTGCCTCCAAATGAGTGGCGCGCGTGGTACGAGAGTAA 780
Db 721 AGGGGACTAGAGTGCAGTGCCTCCAAATGAGTGGCGCGCGTGGTACGAGAGTAA 780
Qy 781 GGTACCGGTGAATCTCCACATACATTTTCAGAAAGCAAGGGTACAGGTGTCCTCGTGG 840
Db 781 GGTACCGGTGAATCTCCACATACATTTTCAGAAAGCAAGGGTACAGGTGTCCTCGTGG 840
Qy 841 ACAAAGGGGACACTGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGATTCAGAGTGA 900
Db 841 ACAAAGGGGACACTGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGATTCAGAGTGA 900
Qy 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAAAACAGACCTTT 960
Qy 961 CCTCTCAAACTCATCTTCTCAATGCTCTGAGCATGATGGAATGCACTACCTGGT 1020
Db 961 CCTCTCAAACTCATCTTCTCAATGCTCTGAGCATGATGGAATGCACTACCTGGT 1020
Qy 1021 GGCTCCAAAGTGGGCGACACCAATGCCAGCATCATGCTATTGTTGGTCCAGGCGCGT 1080
Db 1021 GGCTCCAAAGTGGGCGACACCAATGCCAGCATCATGCTATTGTTGGTCCAGGCGCGT 1080
Qy 1081 CAGGAGGTGAGCAAGGACGTCGAGAGGCGAGGCTGCTGCTGCTGCTGCTTCT 1140
Db 1081 CAGGAGGTGAGCAAGGACGTCGAGAGGCGAGGCTGCTGCTGCTGCTGCTTCT 1140
Qy 1141 GGTCTGACCTGCTTCTCAAAATTTTGTAGTGGTCCCTTCCCAAGGAAAGGCT 1200
Db 1141 GGTCTGACCTGCTTCTCAAAATTTTGTAGTGGTCCCTTCCCAAGGAAAGGCT 1200
Qy 1201 GCGGCCACACCGACCAACACAGCAATGGGACACCGGACCAACCAATCAGATA 1260
Db 1201 GCGGCCACACCGACCAACACAGCAATGGGACACCGGACCAACCAATCAGATA 1260
Qy 1261 TATCAAAATGAATTTAGAGAAACACAGCAATGGGACAGAAATTTGAGGAGGGGAC 1320
Db 1261 TATCAAAATGAATTTAGAGAAACACAGCAATGGGACAGAAATTTGAGGAGGGGAC 1320
Qy 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTTCAGATA 1380
Db 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTTCAGATA 1380
Qy 1381 TTTAGGTACAAATGAGTTTCTTTTCCAAACCGGAGAACACAGCACACCCGGCTTGA 1440
Db 1381 TTTAGGTACAAATGAGTTTCTTTTCCAAACCGGAGAACACAGCACACCCGGCTTGA 1440
Qy 1441 CCCACTGCAAGTGCATCGTGCACCTTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGTGCATCGTGCACCTTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCAGTGGAACTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCAGTGGAACTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCGGGGTGTGTGAAAGCTGAAATTAAGAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGGGGTGTGTGAAAGCTGAAATTAAGAGAGCAAAAAA 1679

RESULT 101
ADD80024
ID ADD80024 standard; cDNA; 1679 BP.
XX
AC ADD80024;

XX DT 29-JAN-2004 (first entry)
XX XX cDNA encoding human PRO polypeptide #188.
XX KW Human; gene; ss: PRO; secreted polypeptide; transmembrane polypeptide;
KW tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX OS Homo sapiens.
XX XX US2003207417-A1.
XX PN 06-NOV-2003.
XX PD
XX XX 07-MAY-2002; 2002US-00140805.
XX PF 31-MAR-1997; 97WO-US005230.
XX PR 12-JUN-1998; 98WO-US012456.
XX PR 14-JUL-1998; 98WO-US014552.
XX PR 28-AUG-1998; 98WO-US017888.
XX PR 10-SEP-1998; 98WO-US018824.
XX PR 14-SEP-1998; 98WO-US019093.
XX PR 14-SEP-1998; 98WO-US019094.
XX PR 14-SEP-1998; 98WO-US019177.
XX PR 16-SEP-1998; 98WO-US019330.
XX PR 17-SEP-1998; 98WO-US019437.
XX PR 07-OCT-1998; 98WO-US021141.
XX PR 29-OCT-1998; 98WO-US022591.
XX PR 29-OCT-1998; 98WO-US022592.
XX PR 20-NOV-1998; 98WO-US024855.
XX PR 01-DEC-1998; 98WO-US025108.
XX PR 05-JAN-1999; 99WO-US000106.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 10-MAR-1999; 99WO-US005190.
XX PR 20-APR-1999; 99WO-US008615.
XX PR 14-MAY-1999; 99WO-US010733.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 01-SEP-1999; 99WO-US020111.
XX PR 08-SEP-1999; 99WO-US020594.
XX PR 13-SEP-1999; 99WO-US020944.
XX PR 15-SEP-1999; 99WO-US021090.
XX PR 15-SEP-1999; 99WO-US021547.
XX PR 05-OCT-1999; 99WO-US023089.
XX PR 29-NOV-1999; 99WO-US028214.
XX PR 30-NOV-1999; 99WO-US028313.
XX PR 30-NOV-1999; 99WO-US028409.
XX PR 01-DEC-1999; 99WO-US028301.
XX PR 01-DEC-1999; 99WO-US028634.
XX PR 02-DEC-1999; 99WO-US028551.
XX PR 02-DEC-1999; 99WO-US028564.
XX PR 12-DEC-1999; 99WO-US028565.
XX PR 20-DEC-1999; 99WO-US030911.
XX PR 20-DEC-1999; 99WO-US030999.
XX PR 22-DEC-1999; 99WO-US030720.
XX PR 30-DEC-1999; 99WO-US031243.
XX PR 05-JAN-2000; 2000WO-US000219.
XX PR 06-JAN-2000; 2000WO-US000277.
XX PR 11-FEB-2000; 2000WO-US000376.
XX PR 18-FEB-2000; 2000WO-US000355.
XX PR 18-FEB-2000; 2000WO-US004341.
XX PR 22-FEB-2000; 2000WO-US004342.
XX PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-875867/81.
 DR P-PSDB; ADD80025.

XX New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor, for chromosome mapping or for tissue
 PT typing.

XX Claim 2; Fig 375; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumor necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAACTTGCAGAGCAACAC 60
 Db 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAACTTGCAGAGCAACAC 60
 Qy 61 AATCTATCAGGAAGAAAGAAAGAAACCGAAGCTGACAAAGAAAGAAAGAAAGAG 120
 Db 61 AATCTATCAGGAAGAAAGAAAGAAACCGAAGCTGACAAAGAAAGAAAGAAAGAG 120
 Qy 121 AAGAAAAAATCATGAAACCATCCAGCCAAATGCAATTTCTATCTCTTGGGCAAT 180
 Db 121 AAGAAAAAATCATGAAACCATCCAGCCAAATGCAATTTCTATCTCTTGGGCAAT 180
 Qy 181 CTTCAAGGGGCTGGCTCTGTGTCTTTCAGAGAGTGCCGTCGCGAGCGAGATGC 240
 Db 181 CTTCAAGGGGCTGGCTCTGTGTCTTTCAGAGAGTGCCGTCGCGAGCGAGATGC 240
 Qy 241 CACCTTCCCAAGCTATGACAAAGTACGCGTCCGCGAGGGGAGAGCCACCTCAG 300
 Db 241 CACCTTCCCAAGCTATGACAAAGTACGCGTCCGCGAGGGGAGAGCCACCTCAG 300
 Qy 301 GTGCACATTATGACAAACCGGTTCACCGGGTGGCTGGCTAAACCGCAGCAACCTCTTA 360
 Db 301 GTGCACATTATGACAAACCGGTTCACCGGGTGGCTGGCTAAACCGCAGCAACCTCTTA 360
 Qy 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCCTCGCTGGTCTCTTCTGAGCAACCCAAAC 420
 Db 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCCTCGCTGGTCTCTTCTGAGCAACCCAAAC 420
 Qy 421 GCAGTACAGATCGAGATCCAGAACGTTGATGTATGACAGGGGCGCTTACACCTGCTC 480
 Db 421 GCAGTACAGATCGAGATCCAGAACGTTGATGTATGACAGGGGCGCTTACACCTGCTC 480
 Qy 481 GGTGACAGACAAACCCCAAGACCTTAGGTCCACCTCATTTGTGCAAGTATCTCC 540
 Db 481 GGTGACAGACAAACCCCAAGACCTTAGGTCCACCTCATTTGTGCAAGTATCTCC 540
 Qy 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
 Db 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600

Qy	601	CTGCAATGACAACTGGTGTAGACAGAGCCTCAGGTTACTTTGGAGACATCTCTCTCCCAAAGC	560
Db	601	CTGCAATGACAACTGGTGTAGACAGAGCCTCAGGTTACTTTGGAGACATCTCTCTCCCAAAGC	660
Qy	661	GGTTGGCTTTGTGAGTGAAGACCAATACTTTGGAAATTCAGGGCATCACCGGAGCAGTCTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGACCAATACTTTGGAAATTCAGGGCATCACCGGAGCAGTCTC	720
Qy	721	AGGGGACTACGAGTGCAGTGCCTCCATGACGTGTGGCGCGCCCGTGGTACGGAGGTAA	780
Db	721	AGGGGACTACGAGTGCAGTGCCTCCATGACGTGTGGCGCGCCCGTGGTACGGAGGTAA	780
Qy	781	GGTCACCGTGAACTTATCCACATACATTTTCAGAAAGCCAAAGGGTACAGGTGTCCCGGTGGG	840
Db	781	GGTCACCGTGAACTTATCCACATACATTTTCAGAAAGCCAAAGGGTACAGGTGTCCCGGTGGG	840
Qy	841	ACAAAAGGGACACTGCAGTGTGAGCGCTCAGCAGTCCCTCAGCAGAAATTCAGGTGGTA	900
Db	841	ACAAAAGGGACACTGCAGTGTGAGCGCTCAGCAGTCCCTCAGCAGAAATTCAGGTGGTA	900
Qy	901	CAAGGATGACAAAGAGCTGATTTGAAGAAAGAAAGGGGTGAAATGGAAACAGACCTTT	960
Db	901	CAAGGATGACAAAGAGCTGATTTGAAGAAAGAAAGGGGTGAAATGGAAACAGACCTTT	960
Qy	961	CCTCTCAAAACTCATCTTTTCATGTCTGTGACATGACTNTGGGAATCTACACTTGCCT	1020
Db	961	CCTCTCAAAACTCATCTTTTCATGTCTGTGACATGACTNTGGGAATCTACACTTGCCT	1020
Qy	1021	GGCTCTCAAACAAGCTGGCGCCACCAATGCCAGCATCATGCTATTGGTCCAGGCGCCGT	1080
Db	1021	GGCTCTCAAACAAGCTGGCGCCACCAATGCCAGCATCATGCTATTGGTCCAGGCGCCGT	1080
Qy	1081	CAGCGAGTGCACAAACGGCAGTGTGAGGAGGGCAGGCTGGCTGTGGCTGTGCTCTTCT	1140
Db	1081	CAGCGAGTGCACAAACGGCAGTGTGAGGAGGGCAGGCTGGCTGTGGCTGTGCTCTTCT	1140
Qy	1141	GGTCTTGCACTGTCTCTCAAAATTTTGATGTAGTGCACATTTCCCAACC CGGGAAGGCT	1200
Db	1141	GGTCTTGCACTGTCTCTCAAAATTTTGATGTAGTGCACATTTCCCAACC CGGGAAGGCT	1200
Qy	1201	GGCGCCACCCACCCACCAACACACAGCAATGCAACACCGACAGCAACCAATCAGATA	1260
Db	1201	GGCGCCACCCACCCACCAACACACAGCAATGCAACACCGACAGCAACCAATCAGATA	1260
Qy	1261	TATACAAATGAAATTTAGAAGAAACACAGCCTCATTTGGACAGAAATTTGAGGGAGGGGAAC	1320
Db	1261	TATACAAATGAAATTTAGAAGAAACACAGCCTCATTTGGACAGAAATTTGAGGGAGGGGAAC	1320
Qy	1321	AAGAAATACTTTGGGGGGAAGAGTTTAAAAAAGAAATTTGAAATTTGCTCTGCAGATA	1380
Db	1321	AAGAAATACTTTGGGGGGAAGAGTTTAAAAAAGAAATTTGAAATTTGCTCTGCAGATA	1380
Qy	1381	TTTAGGTACAAATGAGTTTCTTTTCCAAACGGGAAGAACACAGCACACCCGGCTTGGGA	1440
Db	1381	TTTAGGTACAAATGAGTTTCTTTTCCAAACGGGAAGAACACAGCACACCCGGCTTGGGA	1440
Qy	1441	CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTGCCAGTGTGGCAGAGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTGCCAGTGTGGCAGAGGCTCAGCCTC	1500
Qy	1501	TCTGCCACACAGAGTGCCCCACAGTGTGGAACATTTCTGTGAGTGTGGCCATCCCAAAATCAATCA	1560
Db	1501	TCTGCCACACAGAGTGCCCCACAGTGTGGAACATTTCTGTGAGTGTGGCCATCCCAAAATCAATCA	1560
Qy	1561	GTCCATAGAGACGAATGAGACCTTCCGGGCCCAAGCGTGGCGTGTGGGCACTTTTG	1620
Db	1561	GTCCATAGAGACGAATGAGACCTTCCGGGCCCAAGCGTGGCGTGTGGGCACTTTTG	1620
Qy	1621	GTAGACTGTGCCACCAACCGGCTGTGTGTGAAACGTGTGAAATATAAAGAGCAAAAAA	1679
Db	1621	GTAGACTGTGCCACCAACCGGCTGTGTGTGAAACGTGTGAAATATAAAGAGCAAAAAA	1679

RESULT 102
ADD93061
ID ADD93061 standard; cDNA; 1679 BP.
XX AC
XX ADD93061;
XX
XX 29-JAN-2004 (first entry)
XX
XX Human PRO polynucleotide #188.
XX
XX Human; gene; 88; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX US2003194769-A1.
XX
XX 16-OCT-2003.
XX
XX 21-MAY-2002; 2002US-C0152371.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Bersini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen MB, Goodard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-899787/82.
XX PR P-PSDB; ADD93062.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides, bone
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; SEQ ID NO 375; 636pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumors). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting the proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems, CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO CC polypeptides are also useful for treating various mammalian haemoglobin- CC associated disorders such as various thalassemias and conditions which CC may benefit from enhanced local immune system cell infiltration. This CC sequence represents a human PRO polynucleotide of the invention. Note: CC the sequence data for this patent is also available in electronic format CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGCAAC 60
DB 1 GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAATATGCAATTTCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAATATGCAATTTCTATCTCTTGGGCAAT 180
QY 181 CTTTCAGGGGCTGGTCTCTGTCTCTTCCAAAGAGTCCCGTCCGCGAGATGC 240
DB 181 CTTTCAGGGGCTGGTCTCTGTCTCTTCCAAAGAGTCCCGTCCGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGACAAAGTGCAGCTCCGGCAGGGGAGAGCGCCCTCAG 300
DB 241 CACCTTCCCAAGCTATGGACAAAGTGCAGCTCCGGCAGGGGAGAGCGCCCTCAG 300
QY 301 GTGCATATGCAACCGGTCAACCGGTGGCTTAAACCGAGACCATCTCTTA 360
DB 301 GTGCATATGCAACCGGTCAACCGGTGGCTTAAACCGAGACCATCTCTTA 360
QY 361 TGTGTGGAAATGCAAGTGTGCTGGATCTCTGCGTGGTCTTCTGAGCAACACCAAC 420
DB 361 TGTGTGGAAATGCAAGTGTGCTGGATCTCTGCGTGGTCTTCTGAGCAACACCAAC 420
QY 421 GCATGACATGAGATCGAGATCCAGAAAGTGTATGACGAGGCGCTTACCTGCTC 480
DB 421 GCATGACATGAGATCGAGATCCAGAAAGTGTATGACGAGGCGCTTACCTGCTC 480
QY 481 GGTGACAGACAGCAACCAACCTCTAGGCTCCACCTCATTTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGCAACCAACCTCTAGGCTCCACCTCATTTGCAAGTATCTCC 540
QY 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAAGGGAACAATATTAGCCTCAC 600
DB 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGATAGCAACTGGTAGACAGAGCTACGGTTACTTGGACACATCTCTCCCAAGC 660
DB 601 CTGATAGCAACTGGTAGACAGAGCTACGGTTACTTGGACACATCTCTCCCAAGC 660
QY 661 GGTGCTTTGTGAGTGAAGAGCAATATCTTGAATTCAGGGCATCACCGGGAGCAGTC 720
DB 661 GGTGCTTTGTGAGTGAAGAGCAATATCTTGAATTCAGGGCATCACCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTCTCCAAATGACGTGGCGCGCGCTGTTACGGAGAGTAA 780
DB 721 AGGGGACTACGAGTGCAGTCTCCAAATGACGTGGCGCGCGCTGTTACGGAGAGTAA 780
QY 781 GGTACCGTGAATATCCACCAATATTCAGAGCAAGGTAAGGTGTCCTCCGCTGG 840
DB 781 GGTACCGTGAATATCCACCAATATTCAGAGCAAGGTAAGGTGTCCTCCGCTGG 840
QY 841 ACAAAGGGGACATGTCAGTGTGAGCTCAGAGTCCCTCAGCAGAAATCCAGTGTA 900

DB 841 ACAAAGGGGACACTGCAGTGTGAAGCCCTCAGAGTCCCTCAGCAGAAATCCAGTGTA 900
QY 901 CAAAGGTGACAAAGACTGATTAAGAGAAAGAGAGGGGTGAAGTGGAAAAACAGACCTTT 960
DB 901 CAAAGGTGACAAAGACTGATTAAGAGAAAGAGAGGGGTGAAGTGGAAAAACAGACCTTT 960
QY 961 CTTCTAAAACACTCATCTTCTTCAATGCTCTGAAACATGATGGAACATACACTTGGT 1020
DB 961 CTTCTAAAACACTCATCTTCTTCAATGCTCTGAAACATGATGGAACATACACTTGGT 1020
QY 1021 GGCTTCCAAACAGCTGGGACACACCAATGCCAGCATCATGCTATTGGTCCAGGGCGCT 1080
DB 1021 GGCTTCCAAACAGCTGGGACACACCAATGCCAGCATCATGCTATTGGTCCAGGGCGCT 1080
QY 1081 CAGCGAGTGAAGCAACCGGACAGTGCAGAGAGGGAGGCTGCTGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGTGAAGCAACCGGACAGTGCAGAGAGGGAGGCTGCTGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACTCTCTTCAAAATTTTGAATGAGTGCCTTCCCTCCCGGAAAGGCT 1200
DB 1141 GGTCTTGCACTCTCTTCAAAATTTTGAATGAGTGCCTTCCCTCCCGGAAAGGCT 1200
QY 1201 GCGCCACACCAACCAACCAACAGCAATGGCAACACCGAGCAACCAATCAGATA 1260
DB 1201 GCGCCACACCAACCAACCAACAGCAATGGCAACACCGAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
DB 1261 TATACAAATGAAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
QY 1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTCTTTCCCAACCGGAGAAACACAGCACACCGGCTTGA 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTTCCCAACCGGAGAAACACAGCACACCGGCTTGA 1440
QY 1441 CCACCTGCAAGTGCATCTGCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCACCTGCAAGTGCATCTGCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACAGTGAACATTTCTGGAGCTGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCACAGTGAACATTTCTGGAGCTGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGACAGCAACAGAAATGAGACCTTCCGCGCCCAAGCTGCGGCTCGGGCCTTTG 1620
DB 1561 GTCCATAGACAGCAACAGAAATGAGACCTTCCGCGCCCAAGCTGCGGCTCGGGCCTTTG 1620
QY 1621 GTAGACTGTGCCACCGGCTGTGTGTGAACGTGAATTAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCGGCTGTGTGTGAACGTGAATTAAGAGCAAAAAA 1679

RESULT 103

ADD72697

ID ADD72697 standard; cDNA; 1679 BP.

XX AC ADD72697;

XX DT 29-JAN-2004 (first entry)

XX DE Human cDNA encoding secreted/transmembrane protein, PRO337.

XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
XX cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
XX vulnerable; auditory; tumour growth; retinal disorder;
XX sports-related joint problem; articular cartilage defects;
XX osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX OS Homo sapiens.

PN US2003194781-A1.
XX 16-OCT-2003.
XX 19-OCT-2001; 2001US-00164929.
XX 30-MAR-1998; 98US-0079920P.
XX 07-OCT-1998; 98WO-US021141.
XX 20-NOV-1998; 98WO-US0204855.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US0005028.
XX 10-MAR-1999; 99WO-US0005190.
XX 15-APR-1999; 99WO-US0008313.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99WO-US0380138.
XX 30-NOV-1999; 99WO-US028313.
XX 02-DEC-1999; 99WO-US028551.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.
XX 30-DEC-1999; 99WO-US031243.
XX 30-DEC-1999; 99WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 06-JAN-2000; 2000WO-US000376.
XX 11-FEB-2000; 2000WO-US003365.
XX 18-FEB-2000; 2000WO-US004341.
XX 24-FEB-2000; 2000WO-US005004.
XX 02-MAR-2000; 2000WO-US005941.
XX 10-MAR-2000; 2000WO-US006319.
XX 21-MAR-2000; 2000WO-US007532.
XX 30-MAR-2000; 2000WO-US008439.
XX 17-MAY-2000; 2000WO-US013705.
XX 22-MAY-2000; 2000WO-US014042.
XX 30-MAY-2000; 2000WO-US014941.
XX 02-JUN-2000; 2000WO-US015264.
XX 28-JUN-2000; 2000WO-US020710.
XX 24-AUG-2000; 2000WO-US023328.
XX 01-DEC-2000; 2000WO-US032878.
XX 20-DEC-2000; 2000WO-US034956.
XX 28-FEB-2001; 2001WO-US006520.
XX 22-MAR-2001; 2001WO-US009552.
XX 25-MAY-2001; 2001WO-US017092.
XX 01-JUN-2001; 2001WO-US017800.
XX 20-JUN-2001; 2001WO-US019692.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-JUL-2001; 2001WO-US021735.
XX 30-JUL-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen WE;
XX Goddard A, Godowski P, Grimaldi JC, Gurney AL, Hillan KJ;
XX Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
XX Stewart TA, Tunas D, Williams PM, Wood WI;
XX WPI; 2003-852598/79.
XX P-PSDB; ADD72698.
XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
XX for stimulating the release of tumor necrosis factor alpha from human
XX blood and stimulating the proliferation of differentiation of chondrocyte
XX cells.
XX Claim 2; SEQ ID NO 522; 462pp; English.
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity
XX to an amino acid sequence chosen from 94 fully defined sequences as given
XX in the specification (including PRO lacking its associated signal
XX peptide, a PRO extracellular domain with or without its associated signal
XX peptide). Also included are nucleic acids encoding the PRO proteins

CC mentioned above, a vector comprising a PRO nucleic acid), a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence encodes a PRO protein.
XX
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6,7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTTCAGCAACACAGTGGATTAAATCTCTTCGACAGCTTGAGCAACAC 60
DB 1 GTTGTGCTCTTCAGCAACACAGTGGATTAAATCTCTTCGACAGCTTGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACATCCAGCAACAAATGCAAAATCTCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAACATCCAGCAACAAATGCAAAATCTCTCTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTGCTGCTGCTCTTCCAGGAGTGCCCGTCGCGAGGAGATGC 240
DB 181 CTTACGGGGCTGGCTGCTGCTGCTCTTCCAGGAGTGCCCGTCGCGAGGAGATGC 240
QY 241 CACCTTCCCAAGTATGGACACGTACCGTCCGGCAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGTATGGACACGTACCGTCCGGCAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACTATTGCAACACCGGGTCAACCGGGTGGCTGCTGCTGCTGCTGCTGCTGCT 360
DB 301 GTGCACTATTGCAACACCGGGTCAACCGGGTGGCTGCTGCTGCTGCTGCTGCTGCT 360
QY 361 TCGTGGGAATGCAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 420
DB 361 TCGTGGGAATGCAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATCAGCGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATCAGCGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGAGCAGACAAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGAGCAGACAAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

QY	541	CAAAAATTGTAGAGATTCTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC	600
Db	541	CAAAAATTGTAGAGATTCTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC	600
QY	601	CTGCATAGCAACTGGTAGACACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAAGC	660
Db	601	CTGCATAGCAACTGGTAGACACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAAGC	660
QY	661	GGTTGGCTTTGTGAGTGAAGACGAACTATTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGACGAACTATTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
QY	721	AGGGGACTACAGTGCAGTGCTCCCAATGACGTGGCGCGCCCGTGTGACGGAGAGTAAA	780
Db	721	AGGGGACTACAGTGCAGTGCTCCCAATGACGTGGCGCGCCCGTGTGACGGAGAGTAAA	780
QY	781	GGTCACCGTGAACTATCCACCATACATTTCAGAAGCCAAAGGTACAGGTCTCCCCGGGG	840
Db	781	GGTCACCGTGAACTATCCACCATACATTTCAGAAGCCAAAGGTACAGGTCTCCCCGGGG	840
QY	841	ACAAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Db	841	ACAAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
QY	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGGAACAACAGACCTTT	960
Db	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGGAACAACAGACCTTT	960
QY	961	CCTCTCAAAACTCATCTCTTCTCAATGTCTCTGAACATGACTATGCGGAACCTACCTTCGT	1020
Db	961	CCTCTCAAAACTCATCTCTTCTCAATGTCTCTGAACATGACTATGCGGAACCTACCTTCGT	1020
QY	1021	GGCTCTCAACAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCT	1080
Db	1021	GGCTCTCAACAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCT	1080
QY	1081	CAGCGAGTGAAGCAACCGCACGTCGAGAGGGCAGGTGCGTCTGGCTGCTCTTCT	1140
Db	1081	CAGCGAGTGAAGCAACCGCACGTCGAGAGGGCAGGTGCGTCTGGCTGCTCTTCT	1140
QY	1141	GGTCTTGCACTGCTCTCAAAATTTGATGTAGTGCCACTTCCCAACCCGGGAAAGSCT	1200
Db	1141	GGTCTTGCACTGCTCTCAAAATTTGATGTAGTGCCACTTCCCAACCCGGGAAAGSCT	1200
QY	1201	GCCGCCACCAACCAACCAACAGCAATGCGAACACCGACAGCAACCAATCAGATA	1260
Db	1201	GCCGCCACCAACCAACCAACAGCAATGCGAACACCGACAGCAACCAATCAGATA	1260
QY	1261	TATACAAATGAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC	1320
Db	1261	TATACAAATGAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC	1320
QY	1321	AAAGAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCCTTCAGATA	1380
Db	1321	AAAGAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCCTTCAGATA	1380
QY	1381	TTTAGGTACAATGAGTTTTCTTTTCCAAACGGGAGAACACAGCACACCCGGCTTTGGA	1440
Db	1381	TTTAGGTACAATGAGTTTTCTTTTCCAAACGGGAGAACACAGCACACCCGGCTTTGGA	1440
QY	1441	CCCACTGCAAGCTGATCGTGCAACCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGCTGATCGTGCAACCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
QY	1501	TCTGCCACAGAGTGCCGCCACGTGGAACTATTGGAGCTGGCCATCCCAAAATTCATCA	1560
Db	1501	TCTGCCACAGAGTGCCGCCACGTGGAACTATTGGAGCTGGCCATCCCAAAATTCATCA	1560
QY	1561	GTCATATGAGACGAACAGAAATGAGACCTTCGGGCCCAAGCGTGGCGCTCGGGCAGCTTG	1620
Db	1561	GTCATATGAGACGAACAGAAATGAGACCTTCGGGCCCAAGCGTGGCGCTCGGGCAGCTTG	1620
QY	1621	GTAGACTGTGCCACCAACGCGCGTGTGTGTGAAACGTGAAATTAATAAGACAAAAA	1679

Db 1621 GTGACTGTGCCACCGCGTGTGTGTGAACGCTGTAATAAAGAGCAAAAAA 1679

RESULT 104

AD E19481

ID ADE19481 standard; cDNA; 1679 BP.

XX

AC ADE19481;

XX

DT 29-JAN-2004 (first entry)

XX

DE Human PRO polynucleotide #188.

XX

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX immune system cell infiltration.

XX

OS Homo sapiens.

XX

PN US2003199025-A1.

XX

PD 23-OCT-2003.

XX

PF 21-MAY-2002; 2002US-00152385.

XX

PR 03-MAR-2000; 2000US-0187202P.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX

XX (GETH) GENENTECH INC.

XX

PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-900156/82.

DR P-PSDB; ADE19482.

XX

PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,

PT useful for treating pericyte-associated tumors, diabetes and various bone

PT and/or cartilage disorders, e.g. arthritis.

XX

PS Claim 2; SEQ ID NO 375; 648pp; English.

XX

CC The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells for

CC stimulating differentiation of adipocyte cells, for stimulating

CC

CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTCCAGAAAAGAGTGGATTAAATCTCTTCGCAAGCTTGAGAGCAACAC 60
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1 GTTGTGCTTCCAGAAAAGAGTGGATTAAATCTCTTCGCAAGCTTGAGAGCAACAC 60
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 61 AATCTATCAGGAAAGAAAGAAAACCGAACCCTGACAAAAGAGAAAAGAAAG 120
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 61 AATCTATCAGGAAAGAAAGAAAACCGAACCCTGACAAAAGAGAAAAGAAAG 120
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 121 AAGAAAATAATCATGAACCATCCAGCCAAAATGCAATCTCTTTGGGCAAT 180
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 121 AAGAAAATAATCATGAACCATCCAGCCAAAATGCAATCTCTTTGGGCAAT 180
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 181 CTTACGGGGCTGGCTGCTGTCTCTTCCAGAGAGTCCCGTGGCGAGCGAGATGC 240
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 181 CTTACGGGGCTGGCTGCTGTCTCTTCCAGAGAGTCCCGTGGCGAGCGAGATGC 240
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 241 CACCTTCCCAAGCTATGACAACGTGACGGTCCGCGAGGGGAGAGCGCCCTCAG 300
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 241 CACCTTCCCAAGCTATGACAACGTGACGGTCCGCGAGGGGAGAGCGCCCTCAG 300
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 301 GTGCACATATTGACAACCGGGTACCCGGTGGCTTAAACCGCAGACCATCTCTA 360
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 301 GTGCACATATTGACAACCGGGTACCCGGTGGCTTAAACCGCAGACCATCTCTA 360
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 361 TGCTGGGAATGCAAGTGGTCCCTGATTCCTCGGCTGGTCTTCTGAGCAACCCAAAC 420
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 361 TGCTGGGAATGCAAGTGGTCCCTGATTCCTCGGCTGGTCTTCTGAGCAACCCAAAC 420
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 421 GCAGTACAGCATCCAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 421 GCAGTACAGCATCCAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 481 GGTGAGACAGACCAACCAAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 481 GGTGAGACAGACCAACCAAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 541 CAAAATTGTAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 541 CAAAATTGTAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 601 CTGCATAGCAACTGGTAGACAGACGCTTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 601 CTGCATAGCAACTGGTAGACAGACGCTTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 661 GGTGGCTTTGTGAGTGAAGCGAATATTGGAATTCAGGGCATACCCGGGAGCAGTC 720
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 661 GGTGGCTTTGTGAGTGAAGCGAATATTGGAATTCAGGGCATACCCGGGAGCAGTC 720
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGGTACGGAGGTAAA 780
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGGTACGGAGGTAAA 780
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 781 GGTACCGGTGAATATATCCACCATACATTTGAGAAGCGAGGTACAGGTGCCCGGTGGG 840

DB 781 GGTACCGGTGAATATATCCACCATACATTTTCAGAACCCAGGGTACAGGTGTCCCGGTGGG 840
QY 841 ACAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGAGTGTA 900
DB 841 ACAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGAGTGTA 900
QY 901 CAGGATCACAAAAGACATGATTAAGGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
DB 901 CAGGATCACAAAAGACATGATTAAGGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
QY 961 CTTCTCAAAACATCTATCTTTCAATGTCTCTGAACATGACTATGGGAACTACCTTGGT 1020
DB 961 CTTCTCAAAACATCTATCTTTCAATGTCTCTGAACATGACTATGGGAACTACCTTGGT 1020
QY 1021 GGCCTCCAAAGCTGGGGCCACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGT 1080
DB 1021 GGCCTCCAAAGCTGGGGCCACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGCGAGGTGAGCAACCGGACGCTCGAGGAGGCGAGGCTGCGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACCGGACGCTCGAGGAGGCGAGGCTGCGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTATGTAGTGCACCTTCCACCCGGGAAAGCT 1200
DB 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTATGTAGTGCACCTTCCACCCGGGAAAGCT 1200
QY 1201 GCGCCACACCCACCAACCAACAGCAATGGCAACACAGCAGCAACCAATCAGATA 1260
DB 1201 GCGCCACACCAACCAACCAACAGCAATGGCAACACAGCAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATATGAGAAACACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAATATGAGAAACACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAGAAATCTTTGGGGGAAAGAGCTTTTAAAGAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380
DB 1321 AAGAAATCTTTGGGGGAAAGAGCTTTTAAAGAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACGGGAAAGAACACAGCACACCCGGCTTGG 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACGGGAAAGAACACACAGCACACCCGGCTTGG 1440
QY 1441 CCCACTGCAAGCTGATGTCGCACTCTTTGGTCCAGTGTGGCAAGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGATGTCGCACTCTTTGGTCCAGTGTGGCAAGGCTCAGCCTC 1500
QY 1501 TCTGCCCAAGAGTGCCTCCACGCTGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCCAAGAGTGCCTCCACGCTGGAACATTTCTGGAGCTGGCCATTCATCA 1560
QY 1561 GTCCATAGAGAGCAACAGATGAGACCTTCGCGCCCAAGCGTGGCGCTGGCGGCACTTTG 1620
DB 1561 GTCCATAGAGAGCAACAGATGAGACCTTCGCGCCCAAGCGTGGCGCTGGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAAGCGCTGTGTGTGAAACGCTGAAATATAAGAGCAAAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAAGCGCTGTGTGTGAAACGCTGAAATATAAGAGCAAAAAAAA 1679

RESULT 105

ADE18929
ID ADE18929 standard; cDNA; 1679 BP.

XX ADE18929;

AC AC

XX 29-JAN-2004 (first entry)

DT Human PRO polynucleotide #198.

DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003199026-A1.

XX 23-OCT-2003.

XX 20-MAY-2002; 2002US-00152393.

XX 03-MAR-2000; 2000US-0187202P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-000157/82.

XX P-PSDB; ADE18930.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.

XX Claim 2; SEQ ID NO 375; 636pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTCTTACGAAAAACAGTGGATTTAAATCTCTTTGCAACAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTCTTACGAAAAACAGTGGATTTAAATCTCTTTGCAACAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAAATCATGAAAAACCATCCAGCAAAAAATGCAAAATCTTATCTCTTGGGCAAT 180
Db 121 AAGAAAAAAATCATGAAAAACCATCCAGCAAAAAATGCAAAATCTTATCTCTTGGGCAAT 180
Qy 181 CTTTACGGGGCTGGCTGCTCTGTGTCTTCTTCAAGAGAGTGCCTGCGCAGGGAGATGC 240
Db 181 CTTTACGGGGCTGGCTGCTCTGTGTCTTCTTCAAGAGAGTGCCTGCGCAGGGAGATGC 240
Qy 241 CACCTTCCCCARAGCTATGCAACACGTGACGGTCCGGCAGGGGGAGAGCGCACCTCTAG 300
Db 241 CACCTTCCCCARAGCTATGCAACACGTGACGGTCCGGCAGGGGGAGAGCGCACCTCTAG 300
Qy 301 GTGCACCTATTGACACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCATCTCTTA 360
Db 301 GTGCACCTATTGACACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCATCTCTTA 360
Qy 361 TGTCTGGGAATGACAGTGGTGGCTGGATCCTCGCGTGGTCTCTTGTAGCAACACCCAAAC 420
Db 361 TGTCTGGGAATGACAGTGGTGGCTGGATCCTCGCGTGGTCTCTTGTAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACCGTGGATGTGTATGACGAGGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACCGTGGATGTGTATGACGAGGGGCCCTTACACCTGCTC 480
Qy 481 GGTGCGACAGACAAACCCCAAGACCTCTAGGTGTCACCTCATTTGTCGAAGTATCTCC 540
Db 481 GGTGCGACAGACAAACCCCAAGACCTCTAGGTGTCACCTCATTTGTCGAAGTATCTCC 540
Qy 541 CAAAAATTGTAGAGATTTCTTACAGATATCTCCATTAAATGAAGGAAACAATATTAGCCTCAC 600
Db 541 CAAAAATTGTAGAGATTTCTTACAGATATCTCCATTAAATGAAGGAAACAATATTAGCCTCAC 600
Qy 601 CTGCATAGCAACTGGTAGACAGAGCTACGTTACTTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCTACGTTACTTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGTGGCTTTGTGAGTGAAGACCAATACCTTGAAGAAATTCAGGGCATCACCGGGAGCAGTC 720
Db 661 GGTGTGGCTTTGTGAGTGAAGACCAATACCTTGAAGAAATTCAGGGCATCACCGGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTGCAGTGCCTTCAATGACGTGGCGCGCCCGTGGTAGAGAGTAAA 780
Db 721 AGGGGACTACGAGTGCAGTGCCTTCAATGACGTGGCGCGCCCGTGGTAGAGAGTAAA 780
Qy 781 GGTCCACCGTCAACTATCCACATACATTTTCAAGAGCAAGGGGTACAGGTGTCCCCGTGGG 840
Db 781 GGTCCACCGTCAACTATCCACATACATTTTCAAGAGCAAGGGGTACAGGTGTCCCCGTGGG 840
Qy 841 ACAGAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCTAGCAGAAATTCAGTGGTAA 900
Db 841 ACAGAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCTAGCAGAAATTCAGTGGTAA 900
Qy 901 CAAGGATGACAAAGACTGATTGAAAGAAAGAGGGGTGAAAGTGGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGATTGAAAGAAAGAGGGGTGAAAGTGGAAACAGACCTTT 960
Qy 961 CTTCTCAAAACTCATCTTCTTCAATGCTCTGAAACATGATATGGGAACTATCACTTGGCGT 1020
Db 961 CTTCTCAAAACTCATCTTCTTCAATGCTCTGAAACATGATATGGGAACTATCACTTGGCGT 1020
Qy 1021 GGCTCCCAACAGCTGGGCCACACCAATGCCACATCATGCTATTTGGTCCAGGCCCGCT 1080
Db 1021 GGCTCCCAACAGCTGGGCCACACCAATGCCACATCATGCTATTTGGTCCAGGCCCGCT 1080

QY 1081 CAGCGAGGTGAGCAACGGACGCTCGAGGAGGCGAGGCTGCGTCTGCTGCTGCTCTCTCT 1140
Db 1081 CAGCGAGGTGAGCAACGGACGCTCGAGGAGGCGAGGCTGCGTCTGCTGCTGCTCTCTCT 1140
QY 1141 GGTCTTGCACCTGCTCTCTCAAAATTTTGTATGTAGTGCCTCTTCCCAACCCGCGGAAGGCT 1200
Db 1141 GGTCTTGCACCTGCTCTCTCAAAATTTTGTATGTAGTGCCTCTTCCCAACCCGCGGAAGGCT 1200
QY 1201 GCGGCCACACACACACACACACACACACACACACACACACACACACACACACACACACAT 1260
Db 1201 GCGGCCACACACACACACACACACACACACACACACACACACACACACACACACACAT 1260
QY 1261 TATACAAATGAATTAAGAAAGAACACAGCCTCATGGGACAGAAATTTGAGGAGGAGGAGAAC 1320
Db 1261 TATACAAATGAATTAAGAAAGAACACAGCCTCATGGGACAGAAATTTGAGGAGGAGGAGAAC 1320
QY 1321 AAAGATATCTTGGGGGGAAGAGATTTTAAAGAAATTTGAAATTTGCTTGCCTGAGATA 1380
Db 1321 AAAGATATCTTGGGGGGAAGAGATTTTAAAGAAATTTGAAATTTGCTTGCCTGAGATA 1380
QY 1381 TTTAGGTACATAGGATTTTCTTTTCCCAACCGGGAAGAACACAGACACACCCGGCTTGA 1440
Db 1381 TTTAGGTACATAGGATTTTCTTTTCCCAACCGGGAAGAACACAGACACACCCGGCTTGA 1440
QY 1441 CCACCTGCAAGTGCATGCGCAACCTCTTTGTGTCAGTGTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCACCTGCAAGTGCATGCGCAACCTCTTTGTGTCAGTGTGGGCAAGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCCAACGCTGGAACATCTCTGAGCTGGCCATCCCAATTTCAATCA 1560
Db 1501 TCTGCCACAGAGTGCCCAACGCTGGAACATCTCTGAGCTGGCCATCCCAATTTCAATCA 1560
QY 1561 GTCCATGAGACGACAAAGATAGACCTTCCGCGCCCAAGGCTGCGCTGCGGCACTTTG 1620
Db 1561 GTCCATGAGACGACAAAGATAGACCTTCCGCGCCCAAGGCTGCGCTGCGGCACTTTG 1620
QY 1621 GTAGCTGTCCACCGCGCTGTGTGTAACGTAATTAAGAAAGAGCAAAAAA 1679
Db 1621 GTAGCTGTCCACCGCGCTGTGTGTAACGTAATTAAGAAAGAGCAAAAAA 1679

RESULT 106
ID ADE43125
XX ADE43125 standard; cDNA; 1679 BP.
AC ADE43125;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003199033-A1.
PN
XX
PD 23-OCT-2003.
XX
XX 28-MAY-2002; 2002US-00156845.
PF
XX 05-JUN-2000; 2000US-0209832P.
PR
XX 01-DEC-2000; 2000WO-US032578.
PR

PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900162/82.
DR P-PSDB; ADE43126.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; Fig 375; 636pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
SQ
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTGTGTCTCTTTCAGCAAAACAGTGGATTTAAATCTCTTGCACAGCTTGAGACACAC 60
Db 1 GTGTGTCTCTTTCAGCAAAACAGTGGATTTAAATCTCTTGCACAGCTTGAGACACAC 60
QY 61 ATCTATCAGGAAGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 ATCTATCAGGAAGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAAATCATGAAAAACCATCCAGCCAAAAATGCACAAATTCATCTCTTGGGCAAT 180
Db 121 AAGAAAAAAATCATGAAAAACCATCCAGCCAAAAATGCACAAATTCATCTCTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTGCTCTGTGTCTCTTCCAGGAGTCCCGGCGGAGATGC 240
Db 181 CTTACGGGGCTGGCTGCTCTGTGTCTCTTCCAGGAGTCCCGGCGGAGATGC 240

QY 241 CACCTTCCCAAGCTATGGCAACGTCACGGTCGGGAGGGGAGAGCGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGGCAACGTCACGGTCGGGAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
Db 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
QY 361 TGCTGGGAATGACAAAGTGTGCTGGATCTCGGTGTCTCTTCTGAGCAACACCGAAAC 420
Db 361 TGCTGGGAATGACAAAGTGTGCTGGATCTCGGTGTCTCTTCTGAGCAACACCGAAAC 420
QY 421 GCAGTACAGATCGAGATCCAGAAAGTGTATGATGACAGAGGCGCTTACACTGCTC 480
Db 421 GCAGTACAGATCGAGATCCAGAAAGTGTATGATGACAGAGGCGCTTACACTGCTC 480
QY 481 GGTGACAGACAGAACACCGCCAAAGACCTCTAGGTTCACCTCATTTGTGGAAGTATCTCC 540
Db 481 GGTGACAGACAGAACACCGCCAAAGACCTCTAGGTTCACCTCATTTGTGGAAGTATCTCC 540
QY 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
Db 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
QY 601 CTGATAGCAACTGTGTAGACAGAGCTACGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGATAGCAACTGTGTAGACAGAGCTACGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGAAATTCAGGSCATCACCGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGAAATTCAGGSCATCACCGGAGCAGTC 720
QY 721 AGGGGACTACGATGAGTCTCCAAATGAGTGGCCGCGCGGTGTCAGGAGGTAAA 780
Db 721 AGGGGACTACGATGAGTCTCCAAATGAGTGGCCGCGCGGTGTCAGGAGGTAAA 780
QY 781 GGTCCCGTGAATCTACCAATATATTCAGAGCCAGGATACAGGTGTCGCGGTGG 840
Db 781 GGTCCCGTGAATCTACCAATATATTCAGAGCCAGGATACAGGTGTCGCGGTGG 840
QY 841 ACAAAGGGGACACTGCACTGTGAAGCTTCAGAGTCCCTCAGCAGAAATTCAGTGTGA 900
Db 841 ACAAAGGGGACACTGCACTGTGAAGCTTCAGAGTCCCTCAGCAGAAATTCAGTGTGA 900
QY 901 CAAGGATGACAAAGCTATTTGAAGGAGAAAGGGGTGAAGTGAAGGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGCTATTTGAAGGAGAAAGGGGTGAAGTGAAGGAAACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTCAATGCTCTGAAACATGACTATGGGAATCTACCTTGGT 1020
Db 961 CCTCTCAAACTCATCTTCTCAATGCTCTGAAACATGACTATGGGAATCTACCTTGGT 1020
QY 1021 GGGCTCAACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGGCTCAACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGCGAGGTGAGCAACCGGACGTCGAGGAGGCGAGGCTGCGTCTGGCTGCTCTTCT 1140
Db 1081 CAGCGAGGTGAGCAACCGGACGTCGAGGAGGCGAGGCTGCGTCTGGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTGTAGTGGCTGCGCTTCCCGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAAAATTTGTAGTGGCTGCGCTTCCCGGGAAGGCT 1200
QY 1201 GCGCGCACCAACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
Db 1201 GCGCGCACCAACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320
Db 1261 TATACAAATGAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320
QY 1321 AAAGAATACTTTGGGGGGAAGAGCTTTTAAAAAAGAAATTCAGAAATTCGCTTGCAGATA 1380

Db 1321 AAAGAATACTTTGGGGGGAAGAGCTTTTAAAAAAGAAATTCAGAAATTCGCTTGCAGATA 1380
QY 1381 TTTAGTACAATGGAGTTTCTTTTCCCAAAACGGGAAGAACACAGCACACCGGCTTGA 1440
Db 1381 TTTAGTACAATGGAGTTTCTTTTCCCAAAACGGGAAGAACACAGCACACCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGATCGTGCACCTCTTTGGTGGCAGTGTGGGAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGATCGTGCACCTCTTTGGTGGCAGTGTGGGAGGGCTCAGCCTC 1500
QY 1501 TCTGCCCCACAGAGTGGCCCAACATCTCTGAGTGTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCCCACAGAGTGGCCCAACATCTCTGAGTGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGACAGAAATGAGACCTTCCGCCCCAAGCTGGCGCTGCGGCACTTTG 1620
Db 1561 GTCCATAGAGACGACAGAAATGAGACCTTCCGCCCCAAGCTGGCGCTGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCACCGGCTGTGTGTGAACGTTGAAATAAAAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACCACCGGCTGTGTGTGAACGTTGAAATAAAAAGAGCAAAAAAAA 1679

RESULT 107
ADD95914
ID ADD95914 standard; cDNA; 1679 Bp.
XX
AC ADD95914;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear uricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
FN US2003199059-A1.
XX
PD 23-OCT-2003.
XX
PF 15-APR-2002; 2002US-00123322.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.

```
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US011252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020940.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US009439.
PR 17-MAY-2000; 2000WO-US013705.
PR 23-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023528.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 21-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 22-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900168/82.
DR P-FSDB; ADD959315.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; Fig 375; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
```

```
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60
QY 61 AATCTATCAGAAAGAAAGAAAAAACCAGAACTCGACAAAAAGAGAAAAAGAG 120
DB 61 AATCTATCAGAAAGAAAGAAAAAACCAGAACTCGACAAAAAGAGAAAAAGAG 120
QY 121 AAGAAAAAATCATGAAATCCACGACCAAAATGCACAAATCTCTCTTGGCAAT 180
DB 121 AAGAAAAAATCATGAAATCCACGACCAAAATGCACAAATCTCTCTTGGCAAT 180
```

QY 181 CTTTCAAGGGGTGGCTGCTGTCTGTCTTCTTCAAGGAGTGCCCTGCGCAGCGGAGATGC 240
Db 181 CTTTCAAGGGGTGGCTGCTGTCTGTCTTCTTCAAGGAGTGCCCTGCGCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGACAAGCTACGCTCGCGGAGGGGAGAGCGCACCTCTCAG 300
Db 241 CACCTTCCCAAGCTATGGACAAGCTACGCTCGCGGAGGGGAGAGCGCACCTCTCAG 300
QY 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
Db 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
QY 361 TGCTGGGAATGACAGTGGTGGCTGGATCTCGGTGTGTCTTCTGAGCAACACCCAAAC 420
Db 361 TGCTGGGAATGACAGTGGTGGCTGGATCTCGGTGTGTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCTACGAGATCCAGAAAGTGTGTATGACAGGGGCGCTTTACCTCTCTC 480
Db 421 GCAGTACAGCTACGAGATCCAGAAAGTGTGTATGACAGGGGCGCTTTACCTCTCTC 480
QY 481 GGTGACAGACACACACACACACCTTCTAGGGTCCACCTCATTTGCGAAGTATCTCC 540
Db 481 GGTGACAGACACACACACACACCTTCTAGGGTCCACCTCATTTGCGAAGTATCTCC 540
QY 541 CAAAAATTGAGAGATTTCTTTCAGATATCTCCATTAAATGAAGGGAACAAATATTAGCCTCAC 600
Db 541 CAAAAATTGAGAGATTTCTTTCAGATATCTCCATTAAATGAAGGGAACAAATATTAGCCTCAC 600
QY 601 CTGCTAGCACTGTGACACAGACCTACGTTTACTTTGGAGACACATCTTCCCAAGC 660
Db 601 CTGCTAGCACTGTGACACAGACCTACGTTTACTTTGGAGACACATCTTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGAATACTTTGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGACGAATACTTTGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGACTACAGTGCAGTGCCTCCAAATGAGCTGGCCGCGCCGCTGTGTACGGAGTAA 780
Db 721 AGGGACTACAGTGCAGTGCCTCCAAATGAGCTGGCCGCGCCGCTGTGTACGGAGTAA 780
QY 781 GGTTCACCGTGAATATCCACCATATATTTCAGAACCAAGGTTACAGTGTCCCGTGGG 840
Db 781 GGTTCACCGTGAATATCCACCATATATTTCAGAACCAAGGTTACAGTGTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGCGAGTGAAGCTTCAGCAGTCCCTCAGCAGAAATTCAGTGTGTA 900
Db 841 ACAAAGGGGACACTGCGAGTGAAGCTTCAGCAGTCCCTCAGCAGAAATTCAGTGTGTA 900
QY 901 CAGGATGACAAAGACTGATTGAAGGAAGAAAGGGTGAAGTGAAGAAACAGACCTTT 960
Db 901 CAGGATGACAAAGACTGATTGAAGGAAGAAAGGGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAAACATGATATGGGAACTACATTCGGT 1020
Db 961 CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAAACATGATATGGGAACTACATTCGGT 1020
QY 1021 GGCCTCCACAGCTGGGCGCACCAATCCAGCATCATGCTATTGTGTCAGGGCGCGGT 1080
Db 1021 GGCCTCCACAGCTGGGCGCACCAATCCAGCATCATGCTATTGTGTCAGGGCGCGGT 1080
QY 1081 CAGCGAGGTGAGCAACGCGACGTCGAGGAGGCGAGCTGCGTCTGGCTGCTCTCTTCT 1140
Db 1081 CAGCGAGGTGAGCAACGCGACGTCGAGGAGGCGAGCTGCGTCTGGCTGCTCTCTTCT 1140
QY 1141 GGTCTTGCACCTGCTTCTCAAAATTTGATGTGAGTGCACATCTCCACCGGGAAGGCT 1200
Db 1141 GGTCTTGCACCTGCTTCTCAAAATTTGATGTGAGTGCACATCTCCACCGGGAAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
Db 1201 GCGGCCACCAACCAACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260

QY 1261 TATACAAATGAATTTAGAAAGAACACACGCTCATGGGACAGAAATTTTGGGGGGGAAAC 1320
Db 1261 TATACAAATGAATTTAGAAAGAACACACGCTCATGGGACAGAAATTTTGGGGGGGAAAC 1320
QY 1321 AAAGAATACTTTTGGGGGAAAAGAGTTTTTAAAAAGAAAATTTGAAAATTTGCCTTTGCAGATA 1380
Db 1321 AAAGAATACTTTTGGGGGAAAAGAGTTTTTAAAAAGAAAATTTGAAAATTTGCCTTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTTTCTTTCCAAACGGGAAGAACACACGACACCCGGCTTTGGA 1440
Db 1381 TTTAGGTACAAATGGAGTTTTTCTTTCCAAACGGGAAGAACACACGACACCCGGCTTTGGA 1440
QY 1441 CCACCTGCAAGCTGCATCGTGCAACCTCTTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCACCTGCAAGCTGCATCGTGCAACCTCTTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACAGCTGGAACATTTCTGAGAGTGGCCATCCAAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACAGCTGGAACATTTCTGAGAGTGGCCATCCAAATTCATCA 1560
QY 1561 GTCCATAGAGAGCAACAGAAATGAGACCTTCCGGGCCCCAAGCGTGGCGCTGCGGGCACTTTG 1620
Db 1561 GTCCATAGAGAGCAACAGAAATGAGACCTTCCGGGCCCCAAGCGTGGCGCTGCGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACCGCGCTGTGTGTGAAACCTGTGTAACCTGAAATTAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACCGCGCTGTGTGTGAAACCTGTGTAACCTGAAATTAAGAGCAAAAAA 1679

RESULT 108

ADE22800

ID ADE22800 standard; cDNA; 1679 BP.

XX AC ADE22800;

XX AC ADE22800;

DT 29-JAN-2004 (first entry)

XX cDNA encoding human PRO polypeptide #188.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

XX Homo sapiens.

XX US2003199064-A1.

XX 23-OCT-2003.

XX 19-APR-2002; 2002US-00125932.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

05-JAN-1999; 99WO-US000106.
08-MAR-1999; 99WO-US0005028.
10-MAR-1999; 99WO-US0005190.
20-MAR-1999; 2000WO-US0006319.
20-APR-1999; 99WO-US0008615.
14-MAY-1999; 99WO-US010733.
02-JUN-1999; 99WO-US012252.
01-SEP-1999; 99WO-US020111.
08-SEP-1999; 99WO-US020594.
13-SEP-1999; 99WO-US020944.
15-SEP-1999; 99WO-US021090.
15-SEP-1999; 99WO-US021547.
05-OCT-1999; 99WO-US021089.
29-NOV-1999; 99WO-US028214.
30-NOV-1999; 99WO-US028313.
30-NOV-1999; 99WO-US028409.
01-DEC-1999; 99WO-US028301.
01-DEC-1999; 99WO-US028634.
02-DEC-1999; 99WO-US028551.
02-DEC-1999; 99WO-US028564.
02-DEC-1999; 99WO-US028565.
16-DEC-1999; 99WO-US030095.
20-DEC-1999; 99WO-US030911.
20-DEC-1999; 99WO-US030999.
22-DEC-1999; 99WO-US030720.
30-DEC-1999; 99WO-US031243.
30-DEC-1999; 99WO-US031274.
05-JAN-2000; 2000WO-US000219.
06-JAN-2000; 2000WO-US000277.
06-JAN-2000; 2000WO-US000376.
11-FEB-2000; 2000WO-US000356.
18-FEB-2000; 2000WO-US004341.
18-FEB-2000; 2000WO-US004342.
22-FEB-2000; 2000WO-US004414.
24-FEB-2000; 2000WO-US004914.
24-FEB-2000; 2000WO-US005004.
01-MAR-2000; 2000WO-US005601.
02-MAR-2000; 2000WO-US005746.
12-MAR-2000; 2000WO-US005841.
15-MAR-2000; 2000WO-US006884.
20-MAR-2000; 2000WO-US007377.
21-MAR-2000; 2000WO-US007332.
30-MAR-2000; 2000WO-US008439.
17-MAY-2000; 2000WO-US013705.
22-MAY-2000; 2000WO-US014042.
30-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015364.
28-JUL-2000; 2000WO-US020710.
11-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006666.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.

19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.
Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-900169/82.
P-PSDB; ADE22801.

Two hundred and seventy five nucleic acids encoding PRO polypeptides,
useful for treating pericyte-associated tumors, diabetes and various bone
and/or cartilage disorders, e.g. arthritis.

Claim 2; Fig 375; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence encodes a human PRO polypeptide of the invention. Note: The
sequence data for this patent is also available in electronic format from
the USPTO website at seqdata.uspto.gov.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTTCCTTGACACAGCTTGAGACAC 60
Db 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTTCCTTGACACAGCTTGAGACAC 60
Qy 61 AATCTATCAGAAAGACAAAGAAAAACCGACCTTGACAAAAAGACAAAGAG 120

D _b	61	AATCTATCAGGAAGAAGAAAGAAAAACCGAACCTTGACAAAAAAGAAAGAAAAGG	120
Q _y	121	AAGAAAAAAATCATGAAAAACCATTCCAGGCCAAAAATGCACAATTCATTCTTTGGCAAT	180
D _b	121	AAGAAAAAAATCATGAAAAACCATTCCAGGCCAAAAATGCACAATTCATTCTTTGGCAAT	180
Q _y	181	CTTTCACGGGCTGGCTGCTCTGTGTCTCTTCCAGAGGTGCCGTCGCGAGCGGAGATGC	240
D _b	181	CTTTCACGGGCTGGCTGCTCTGTGTCTCTTCCAGAGGTGCCGTCGCGAGCGGAGATGC	240
Q _y	241	CACCTTCCCCAAAGCTATGGAACAACGTGACGGTCCGGCAGGGGAGAGGCCACCTCTAG	300
D _b	241	CACCTTCCCCAAAGCTATGGAACAACGTGACGGTCCGGCAGGGGAGAGGCCACCTCTAG	300
Q _y	301	GTCGACTATTGACAACCGGGTCAACCGGGTGCGCTGGCTAAACCGGACGACCATCTCTTA	360
D _b	301	GTCGACTATTGACAACCGGGTCAACCGGGTGCGCTGGCTAAACCGGACGACCATCTCTTA	360
Q _y	361	TGCTGGAAATGACAAGTGGTGCTCGGATCTCGCGTGCTCTCTTGAGCAACACCCAAAC	420
D _b	361	TGCTGGAAATGACAAGTGGTGCTCGGATCTCGCGTGCTCTCTTGAGCAACACCCAAAC	420
Q _y	421	GCAGTACAGCATCAGATCCAGAACGTGGATGTGTAGCAGGGGCCCTTTACACCTGCTC	480
D _b	421	GCAGTACAGCATCAGATCCAGAACGTGGATGTGTAGCAGGGGCCCTTTACACCTGCTC	480
Q _y	481	GGTGAGACAGACAACCAACCAAGACCTCTAGGTCACCTCATTTGTGCAAGTATCTCC	540
D _b	481	GGTGAGACAGACAACCAACCAAGACCTCTAGGTCACCTCATTTGTGCAAGTATCTCC	540
Q _y	541	CAAAATTTAGAGATTTCTTCAGATACTCCATTAAATGAAGGGAACAATATTAGCCTCAC	600
D _b	541	CAAAATTTAGAGATTTCTTCAGATACTCCATTAAATGAAGGGAACAATATTAGCCTCAC	600
Q _y	601	CTGCATAGCAAATCGGTAGACACAGAGCCTTAGGTTACTTTGGAGACACATCTCTCCAAAGC	660
D _b	601	CTGCATAGCAAATCGGTAGACACAGAGCCTTAGGTTACTTTGGAGACACATCTCTCCAAAGC	660
Q _y	661	GTTTGGCTTTCTGAGTGAAGACGAATACTTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
D _b	661	GTTTGGCTTTCTGAGTGAAGACGAATACTTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
Q _y	721	AGGGGACTACAGGTGCAGTGCCTCCAATGACGTGGCCGCGCGGTGTGTCGGAGAGTAA	780
D _b	721	AGGGGACTACAGGTGCAGTGCCTCCAATGACGTGGCCGCGCGGTGTGTCGGAGAGTAA	780
Q _y	781	GGTCACCGTGAACTATCCACCATACATTTTCAGAAAGCAAGGGTACAGGTGTCCCCTGGG	840
D _b	781	GGTCACCGTGAACTATCCACCATACATTTTCAGAAAGCAAGGGTACAGGTGTCCCCTGGG	840
Q _y	841	ACAAAAGGGHACATGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
D _b	841	ACAAAAGGGHACATGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Q _y	901	CAAGGATCACAAAAGACTGATTGAAGGAAAGAAAGGGGTCAAGTGTGAAACACAGACTTT	960
D _b	901	CAAGGATCACAAAAGACTGATTGAAGGAAAGAAAGGGGTCAAGTGTGAAACACAGACTTT	960
Q _y	961	CCTCTCAAACTCATCTCTTTCAATGTCTCTGAACATGACTATGGGAACATCACTTGCCT	1020
D _b	961	CCTCTCAAACTCATCTCTTTCAATGTCTCTGAACATGACTATGGGAACATCACTTGCCT	1020
Q _y	1021	GGCTTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT	1080
D _b	1021	GGCTTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT	1080
Q _y	1081	CAGCGAGGTGACCAACGSCAGTCGAGGAGGCGAGGTGGCTCTGGCTGTGCTCTTCT	1140
D _b	1081	CAGCGAGGTGACCAACGSCAGTCGAGGAGGCGAGGTGGCTCTGGCTGTGCTCTTCT	1140
Q _y	1141	GGTCTTGCACTGTCTCTCAATTTTGTGTAGTGCACATTCCTCCACCCCGGAAAGGCT	1200
D _b	1141	GGTCTTGCACTGTCTCTCAATTTTGTGTAGTGCACATTCCTCCACCCCGGAAAGGCT	1200

QY	1201	GCGCCACCACCCACCCAAACAAACAGCAATGGCAACACCGCAGCAACCAATCAGATA	1260
Db	1201	GCGCCACCACCCACCCAAACAAACAGCAATGGCAACACCGCAGCAACCAATCAGATA	1260
QY	1261	TATACAATGAAATATAGAAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC	1320
Db	1261	TATACAATGAAATATAGAAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC	1320
QY	1321	AAAGATACATTTGGGGGGAAGAGTTTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA	1380
Db	1321	AAAGATACATTTGGGGGGAAGAGTTTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA	1380
QY	1381	TTTAGGTACAAATGGAGTTTTCTTTCCCAACCGGGAAGAACACAGCACACCCCGCTTGGGA	1440
Db	1381	TTTAGGTACAAATGGAGTTTTCTTTCCCAACCGGGAAGAACACAGCACACCCCGCTTGGGA	1440
QY	1441	CCCACTGCAAGCTGCATCGTGCAACCTCTTTTGTGTCAGCTGTGGCGAAGGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGCTGCATCGTGCAACCTCTTTTGTGTCAGCTGTGGCGAAGGGCTCAGCCTC	1500
QY	1501	TCTGCCACAGAGTGCCTCCACGCTGGGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA	1560
Db	1501	TCTGCCACAGAGTGCCTCCACGCTGGGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA	1560
QY	1561	GTCCATAGACAGCAACAGAAATGAGACCTTCGGGCCCAAGCGTGCGCTCGGGCAGCTTTG	1620
Db	1561	GTCCATAGACAGCAACAGAAATGAGACCTTCGGGCCCAAGCGTGCGCTCGGGCAGCTTTG	1620
QY	1621	GTAGACTGTGCCACCGCGGTGTGTGTGAACCTGAAACGTGAATATAAAGAGCAAAAAAAA	1679
Db	1621	GTAGACTGTGCCACCGCGGTGTGTGTGAACCTGAAACGTGAATATAAAGAGCAAAAAAAA	1679
RESULT 109			
ADD78918			
ID	ADD78918 standard; cDNA; 1679 BP.		
XX	AC ADD78918;		
XX	29-JAN-2004 (first entry)		
XX	cDNA encoding human PRO polypeptide #188.		
XX	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
XX	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
XX	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
XX	liver; microvascular endothelial cell; glucose; RFA;		
XX	skeletal muscle cell; adipocyte cell; pericyte cell;		
XX	inner ear utricular supporting cell; T-lymphocyte cell;		
XX	endothelial cell tube formation; bone disorder; cartilage disorder;		
XX	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
XX	rheumatoid arthritis; haemoglobin-associated disorder thalassemia;		
XX	immune system cell infiltration.		
OS	Homo sapiens.		
XX	US2003203429-A1.		
XX	30-OCT-2003.		
XX	22-APR-2002; 2002US-00127900.		
XX	05-JUN-2000; 2000US-0209832P.		
XX	01-DEC-2000; 2000WO-0032678.		
XX	19-DEC-2001; 2001US-00028072.		
XX	(GETH) GENENTECH INC.		
XX	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;		
XX	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;		
XX	PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;		

DR WPI: 2003-875636/81.
 XX P-PSDB; ADD78919.
 PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
 XX tumors.
 PS Claim 2; Fig 375; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear intricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTTGTGTCCTTCAGCAAAAACAGTGGATTAAATCTCCTTGCAACAAGCTTGAGAGCAACAC 60
 DB 1 GTTGTGTCCTTCAGCAAAAACAGTGGATTAAATCTCCTTGCAACAAGCTTGAGAGCAACAC 60
 QY 61 AATCTATCAGAAAGAAAGAAAGAAACCGAACCTGACAAAAGAGAAAGAAAGAG 120
 DB 61 AATCTATCAGAAAGAAAGAAAGAAACCGAACCTGACAAAAGAGAAAGAAAGAG 120
 QY 121 AAGAAAAAATCATGAAACCACTCCAGCCCAAAATTCACAAATCTCTCTTGGGCAAT 180
 DB 121 AAGAAAAAATCATGAAACCACTCCAGCCCAAAATTCACAAATCTCTCTTGGGCAAT 180
 QY 181 CTTACGGGGTGCGCTGCTCTGTGTCTCTTCCAGGAGTCCCGTCGACGGAGATGC 240
 DB 181 CTTACGGGGTGCGCTGCTGCTGTCTCTTCCAGGAGTCCCGTCGACGGAGATGC 240
 QY 241 CACCTTCCCAAGCTATGACACAGTGCAGGTCGCGAGGGAGAGCGCCACCTTCAG 300
 DB 241 CACCTTCCCAAGCTATGACACAGTGCAGGTCGCGAGGGAGAGCGCCACCTTCAG 300
 QY 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGACCAATCTCTTA 360
 DB 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGACCAATCTCTTA 360

QY 361 TGCTGGGAATGACAAGTGGTGCTCGGATCCTCGGTGGTCTCTTCTGAGCAACACCCAAAC 420
 DB 361 TGCTGGGAATGACAAGTGGTGCTCGGATCCTCGGTGGTCTCTTCTGAGCAACACCCAAAC 420
 QY 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGCGCTTACACCTGCTC 480
 DB 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGCGCTTACACCTGCTC 480
 QY 481 GGTCCAGACAGAACCAACCAACGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 DB 481 GGTCCAGACAGAACCAACCAACGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 QY 541 CAAAATTGTAGAGATTTCTTTCAGATATCTCAATTAATGAAGGGAAACAATATTAGCCTCAC 600
 DB 541 CAAAATTGTAGAGATTTCTTTCAGATATCTCAATTAATGAAGGGAAACAATATTAGCCTCAC 600
 QY 601 CTGCATAGCACTCGGTAGACAGAGCGCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
 DB 601 CTGCATAGCACTCGGTAGACAGAGCGCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
 QY 661 GGTGGGCTTTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
 DB 661 GGTGGGCTTTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
 QY 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCCCTGGTACGAGAGTAAA 780
 DB 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCCCTGGTACGAGAGTAAA 780
 QY 781 GGTCAACCGTGAACATATCACCATATCATTTTCAGAAAGCCAAAGGTACAGGTGTCCCCTGGG 840
 DB 781 GGTCAACCGTGAACATATCACCATATCATTTTCAGAAAGCCAAAGGTACAGGTGTCCCCTGGG 840
 QY 841 ACAAAAGGGACATCGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGAGTGA 900
 DB 841 ACAAAAGGGACATCGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGAGTGA 900
 QY 901 CAAGGATGACAAAAAGACTGATTGAAGGAAGAAAGGGGTGAAAGTGGAAGAACACACCTTT 960
 DB 901 CAAGGATGACAAAAAGACTGATTGAAGGAAGAAAGGGGTGAAAGTGGAAGAACACACCTTT 960
 QY 961 CCTCTCAAAACTCATCTTCTTCAATGTCTGAACATGATCTATGGGAACATACACTTGGT 1020
 DB 961 CCTCTCAAAACTCATCTTCTTCAATGTCTGAACATGATCTATGGGAACATACACTTGGT 1020
 QY 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
 DB 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
 QY 1081 CAGCGAGTGTAGCAACCGGACGTCGAGAGGGCAGGTGGCTCTGGCTGTGCTCTTCT 1140
 DB 1081 CAGCGAGTGTAGCAACCGGACGTCGAGAGGGCAGGTGGCTCTGGCTGTGCTCTTCT 1140
 QY 1141 GGTCTTGCACTGCTTCTCAAAATTTTGATGTAGTGGCCTTCCCAACCGGGGAAAGCT 1200
 DB 1141 GGTCTTGCACTGCTTCTCAAAATTTTGATGTAGTGGCCTTCCCAACCGGGGAAAGCT 1200
 QY 1201 GCCGCCACCAACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
 DB 1201 GCCGCCACCAACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
 QY 1261 TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320
 DB 1261 TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320
 QY 1321 AAAGAATATCTTTGGGGGAAAGAGTGTATAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
 DB 1321 AAAGAATATCTTTGGGGGAAAGAGTGTATAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
 QY 1381 TTTAGGTACATGAGTGTCTTTTCCCAACCGGGAAGAACACACACCGGCTTGA 1440
 DB 1381 TTTAGGTACATGAGTGTCTTTTCCCAACCGGGAAGAACACACACCGGCTTGA 1440

QY 1441 CCCACTGCAAGTGCATCGTGCACACCTTTTGGTCCAGTGTGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGTGCATCGTGCACACCTTTTGGTCCAGTGTGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTSCCCGCCAGTGGACATCTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTSCCCGCCAGTGGACATCTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCGGGCCAAGCGTGGCGGCACCTTTG 1620
DB 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCGGGCCAAGCGTGGCGGCACCTTTG 1620
QY 1621 GTAGACTGTGCCACACAGCGCTGTGTGTAAGCTGAAATATAAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACACAGCGCTGTGTGTAAGCTGAAATATAAAGAGCAAAAAA 1679

RESULT 110
ADE32868
ID ADE32868 standard; cDNA; 1679 BP.
XX ADE32868;
AC ADE32868;
XX ADE32868;
DT 29-JAN-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO337 cDNA.
DE Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW Cell proliferation stimulator; cell differentiation stimulator;
KW Cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
OS Homo sapiens.
XX
XX
XX US2003194766-A1.
XX 16-OCT-2003.
XX
XX 14-MAY-2002; 2002US-00145874.
XX
XX 05-JUN-2000; 2000US-0209832P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CX, Wood WI, Zhang Z;
XX
XX WPI; 2003-899785/82.
XX P-PSDB; ADE32869.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX
XX
XX Claim 2; SEQ ID NO 375; 636pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from PBMC cells, for inhibiting the binding of

CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAAC 60
QY 61 ATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 ATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAATGCACAAATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAATGCACAAATCTATCTCTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTGTCTGTGTCTTCCAGAGTGGCCCTGCGCAGCGAGATGC 240
DB 181 CTTACGGGGCTGGCTGTCTGTGTCTTCCAGAGTGGCCCTGCGCAGCGAGATGC 240
QY 241 CACCTTCCCAAAAGCTATGCAAAAGTACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAAAGCTATGCAAAAGTACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCATATTGACACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGGACCATCTCTTA 360
DB 301 GTGCATATTGACACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGGACCATCTCTTA 360
QY 361 TGTGGAATGACAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 420
DB 361 TGTGGAATGACAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 420
QY 421 GCAGTACAGATCGAGATCCAGAACGTTGGATGTGTATGACAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGATCGAGATCCAGAACGTTGGATGTGTATGACAGGGCCCTTACACCTGCTC 480
QY 481 GGTCAGACAGACACCCCAAGACCTTAGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTCAGACAGACACCCCAAGACCTTAGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
DB 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
QY 601 CTCGATAGCACTGGTAGCAGCGCTAGCTTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTCGATAGCACTGGTAGCAGCGCTAGCTTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGTGCTTTGTGAGTGAAGCAATATCTTGGAAATTCAGGGCATCCCGGAGCAGTTC 720
DB 661 GGTGTGCTTTGTGAGTGAAGCAATATCTTGGAAATTCAGGGCATCCCGGAGCAGTTC 720

721 AGGGAGTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCCGTTGGTACGAGAGTAAA 780
721 AGGGAGTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCCGTTGGTACGAGAGTAAA 780
781 GGTACCGGTGAATATCCACATACATATTCAGAGCCAGAGGTACAGGTGTCCTCCGTTGG 840
781 GGTACCGGTGAATATCCACATACATATTCAGAGCCAGAGGTACAGGTGTCCTCCGTTGG 840
841 ACAAAGGGGACACTGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAGATTCAGAGTGA 900
841 ACAAAGGGGACACTGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAGATTCAGAGTGA 900
901 CAAGGATGACAAAGACTGATTCAGAGGAAGAGGGGTGAAGTGGAAAAAGACCTTT 960
901 CAAGGATGACAAAGACTGATTCAGAGGAAGAGGGGTGAAGTGGAAAAAGACCTTT 960
961 CCTCTCAAACTCATCTTCTCAATGCTCTGAACATGATATGGGAATCACTACCTTGGCT 1020
961 CCTCTCAAACTCATCTTCTCAATGCTCTGAACATGATATGGGAATCACTACCTTGGCT 1020
1021 GGCTTCCAAACAGTGGGCGACACCAATGTCAGCATCATCTATTTGGTCCAGGCGCGT 1080
1021 GGCTTCCAAACAGTGGGCGACACCAATGTCAGCATCATCTATTTGGTCCAGGCGCGT 1080
1081 CAGGAGGTGAGCAACCGGACGCTGAGAGGGGAGGCTGCTGCTGCTGCTGCTGCTTCT 1140
1081 CAGGAGGTGAGCAACCGGACGCTGAGAGGGGAGGCTGCTGCTGCTGCTGCTGCTTCT 1140
1141 GGTCTTCCAGTCTTCTCAAAATTTGATGTAGTGCATCTCCCAACCGGGAAGAGCT 1200
1141 GGTCTTCCAGTCTTCTCAAAATTTGATGTAGTGCATCTCCCAACCGGGAAGAGCT 1200
1201 GCGCCACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1201 GCGCCACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1261 TATACAAATGAATTTAGAGAAACACAGCCTCTATGGGACAGAAATTTAGGGAGGGGAA 1320
1261 TATACAAATGAATTTAGAGAAACACAGCCTCTATGGGACAGAAATTTAGGGAGGGGAA 1320
1321 AAGAAATACCTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1321 AAGAAATACCTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1381 TTTAGTACATGAGTGTCTTTTCCAAACCGGGAAGAACACAGACACACCGGCTTGA 1440
1381 TTTAGTACATGAGTGTCTTTTCCAAACCGGGAAGAACACAGACACACCGGCTTGA 1440
1441 CCCACTGACGCTGCATGCTGCACCTCTTTGGTCCAGTGTGGGAGGGGCTCAGCCTC 1500
1441 CCCACTGACGCTGCATGCTGCACCTCTTTGGTCCAGTGTGGGAGGGGCTCAGCCTC 1500
1501 TCTGCCACAGAGTGCCTCCACGCTGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
1501 TCTGCCACAGAGTGCCTCCACGCTGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
1561 GTCCATGAGACGACAGATGACACCTTCGCGCCAGGCTGCGCTGGGCACTTTG 1620
1561 GTCCATGAGACGACAGATGACACCTTCGCGCCAGGCTGCGCTGGGCACTTTG 1620
1621 GTAGACTGTCCACACGCGCTGTGTGTGAACCTGAAATTAAGAGCAAGCAAAAAA 1679
1621 GTAGACTGTCCACACGCGCTGTGTGTGAACCTGAAATTAAGAGCAAGCAAAAAA 1679

RESULT 111
ADE42560
ID ADE42560 standard; cDNA; 1679 BP.
XX
AC ADE42560;
XX
DT 29-JAN-2004 (first entry)
XX

DE Human PRO polynucleotide #188.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
XX US2003199032-A1.
PN
XX 23-OCT-2003.
PD
XX 28-MAY-2002; 2002US-00156844.
PF
XX 03-MAR-2000; 2000US-0187202P.
PR
XX 01-DEC-2000; 2000WO-US032678.
PR
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX WPI; 2003-900161/82.
DR P-PSDB; ADE42561.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; Fig 375; 636pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems, PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.

```
Query Match      100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0;
```

961	DB	CTCTCAAAACTCATCTTCTCAATGTCTCTGAACATGACTATATGGGAACATACACTTTGGCGT	1021
1021	QY	GGCTCCAAACAGCTGGGCCACCAAAATGCCAGCATCATGTATTTTGGTCCAGCGCGCGT	1080
1021	DB	GGCTCCAAACAGCTGGGCCACCAAAATGCCAGCATCATGTATTTGGTCCAGCGCGCGT	1080
1081	QY	CAGCGAGGTGAGCAACGGCACGCTCGAGGAGGCGAGGCTGTGGCTGTGGCTCTTTCT	1140
1081	DB	CAGCGAGGTGAGCAACGGCACGCTCGAGGAGGCGAGGCTGTGGCTGTGGCTCTTTCT	1140
1141	QY	GGTCTTGACCTGCTTCTCAAAATTTTGTATGTAGTGGCCACTTCCCAACCCGGGAAAGGCT	1200
1141	DB	GGTCTTGACCTGCTTCTCAAAATTTTGTATGTAGTGGCCACTTCCCAACCCGGGAAAGGCT	1200
1201	QY	GCCGCCACCAACCAACCAACAGCAATGGCAACACCGAGCAGCAACCAATTCAGATA	1260
1201	DB	GCCGCCACCAACCAACCAACAGCAATGGCAACACCGAGCAGCAACCAATTCAGATA	1260
1261	QY	TATCAAAATGAATTAGAAGAAACACAGCGCTCATGGGACAGAAATTTGAGGAGGGGAAC	1320
1261	DB	TATCAAAATGAATTAGAAGAAACACAGCGCTCATGGGACAGAAATTTGAGGAGGGGAAC	1320
1321	QY	AAAGAAATCTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCCTTCAGATA	1380
1321	DB	AAAGAAATCTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCCTTCAGATA	1380
1381	QY	TTTAGGTACAAATGAGGTTTTCTTTTCCCAAAACGGGAGAAACACAGCACACCCGGCTTGGGA	1440
1381	DB	TTTAGGTACAAATGAGGTTTTCTTTTCCCAAAACGGGAGAAACACAGCACACCCGGCTTGGGA	1440
1441	QY	CCCACCTCAAGCTGCATCGTGCACACTCTTTTGGTGCAGTGTGGGCAAGGGCTCAGCGTC	1500
1441	DB	CCCACCTCAAGCTGCATCGTGCACACTCTTTTGGTGCAGTGTGGGCAAGGGCTCAGCGTC	1500
1501	QY	TCTGCCACAGAGTGCCCCACAGTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA	1560
1501	DB	TCTGCCACAGAGTGCCCCACAGTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA	1560
1561	QY	GTCCATAGAGACGAACAGAAATGAGACCTTCCGGCCCCAAGCGTGGCGCTCGCGGCACTTTG	1620
1561	DB	GTCCATAGAGACGAACAGAAATGAGACCTTCCGGCCCCAAGCGTGGCGCTCGCGGCACTTTG	1620
1621	QY	GTAGACTGTGCCACCAACGGCGTGTGTGTGAAACGTGAAATAAAAAGAGCAAAAAAAA	1679
1621	DB	GTAGACTGTGCCACCAACGGCGTGTGTGTGAAACGTGAAATAAAAAGAGCAAAAAAAA	1679

RESULT 112

ADL17348

ADL17348 standard: cDNA: 1679 BP.

RES001 112
ADE17348
IP ADE17348 standard: cDNA: 1679 BP.

XX
DT 29-JAN-2004 (first entry)

XX DE Human cDNA encoding secreted/transmembrane protein, PRO337.

xx Human; ss; gene; secreted protein; transmembrane protein; PRO;
 xx cytosolic; ophthalmological; antirheumatic; osteopathic; antirheumatic;
 kw vulvar; auditory; tumour growth; retinal disorder;
 kw sports-related joint problem; articular cartilage defects;
 kw osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

XX Homo sapiens.

XX PN US2003203433-A1.

30-OCT-2003.

18-OCT-2001; 2001US-00145016.

PR 06-MAY-1998; 98US-0084414P.

4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
8

05-JAN-1999; 99WO-US000106.
 08-MAR-1999; 99WO-US0005028.
 12-APR-1999; 99US-00284291.
 25-AUG-1999; 99US-00380138.
 18-FEB-2000; 2000WO-US004341.
 30-JUL-2001; 2001US-00918585.
 (GETH) GENENTECH INC.
 Ashkenazi AJ, Baker KP, Botstein D, Deenoyers L, Eaton DL;
 Ferrara N, Filvaroff E, Fong S, Gao W, Garber H, Gerritsen ME;
 Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Shelton DL;
 Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Williams PM, Wood WI;
 Stewart TA, Tumas D, Williams PM, Wood WI;
 WPI; 2003-875640/81.
 P-PSDB; ADE17349.
 New genes, and its encoded secreted and transmembrane polypeptides,
 useful for treating e.g. lung or breast tumors, osteoarthritis,
 rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,
 hypoinsulinemia or wounds.
 Claim 2; SEQ ID NO 522; 459pp; English.
 The invention relates to an isolated PRO polypeptide (secreted or
 transmembrane protein) having at least 80% amino acid sequence identity
 to an amino acid sequence chosen from 94 fully defined sequences as given
 in the specification (including PRO lacking its associated signal
 peptide), a PRO extracellular domain with or without its associated signal
 peptide). Also included are nucleic acids encoding the PRO proteins
 mentioned above, a vector comprising a PRO nucleic acid), a host cell
 comprising the vector and producing PRO, a chimeric molecule comprising
 PRO fused to a heterologous amino acid sequence, and an anti-PRO
 antibody. PRO337 polypeptide is useful for detecting a PRO4993
 polypeptide in a sample suspected of containing PRO4993 polypeptide.
 Similarly, PRO4993 polypeptide is useful for detecting PRO337
 polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
 PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
 PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
 bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
 molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
 causes death of the cell. PRO337 polypeptide is useful for linking a
 bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
 PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
 to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
 useful for linking a bioactive molecule to a cell expressing PRO725,
 PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
 polypeptide is useful for modulating at least one biological activity of
 the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
 polypeptide or anti-PRO4993 polypeptide is useful for modulating the
 biological activity of the cell expressing PRO4993 polypeptide; PRO725,
 PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
 modulating the biological activity of the cell expressing PRO1559
 polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
 PRO739 polypeptide is useful for modulating the biological activity of
 the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
 polypeptides are useful for inhibiting tumour growth, retinal disorders,
 sports-related joint problems, inhibiting tumour growth, retinal disorders,
 osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
 mammals. The present sequence encodes a PRO protein.
 Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTTGTGCTTCAGCAACAGTGGATTAAATCTCTCCGACAAAGCTTGAGGCAACAC 60
 Db 1 GTTGTGCTTCAGCAACAGTGGATTAAATCTCTCCGACAAAGCTTGAGGCAACAC 60
 QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

Db 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 QY 121 AAGGAAAGAAATCATGAAACCATCCAGCCAAAGAAATGCAAAATCTCTTGGGCAAT 180
 Db 121 AAGGAAAGAAATCATGAAACCATCCAGCCAAAGAAATGCAAAATCTCTTGGGCAAT 180
 QY 181 CTTTCAAGGGGCTGGCTCTCTGTGTCTCTTCCAGGAGTCCCGTGGCAGCGAGATGC 240
 Db 181 CTTTCAAGGGGCTGGCTCTCTGTGTCTCTTCCAGGAGTCCCGTGGCAGCGAGATGC 240
 QY 241 CACCTTCCGCAAGCTATGACACACGAGTGGGTCCGCGAGGGGAGAGCCACCTCAG 300
 Db 241 CACCTTCCGCAAGCTATGACACACGAGTGGGTCCGCGAGGGGAGAGCCACCTCAG 300
 QY 301 GTGCACATATTGACAAACCGGGTCAACCCGGGTGGCTGTGCTAAACCGCAGCACCATCTCTA 360
 Db 301 GTGCACATATTGACAAACCGGGTCAACCCGGGTGGCTGTGCTAAACCGCAGCACCATCTCTA 360
 QY 361 TGTCTGGGAGTGAACAAGTGGTGGCTCTGGATCTCTGGGTGGTCTTCTGAGCAACACCCAAAC 420
 Db 361 TGTCTGGGAGTGAACAAGTGGTGGCTCTGGATCTCTGGGTGGTCTTCTGAGCAACACCCAAAC 420
 QY 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGAGAGGGGCCCTTACACCTGCTC 480
 Db 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGAGAGGGGCCCTTACACCTGCTC 480
 QY 481 GGTGAGAGAGACAAACCAACCAAGAGCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 Db 481 GGTGAGAGAGACAAACCAACCAAGAGCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
 Db 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
 QY 601 CTGCATAGCAACTGGTGTAGACAGAGCTTACGGTTTACTTTGGAGACACATCTCTCCAAAGC 660
 Db 601 CTGCATAGCAACTGGTGTAGACAGAGCTTACGGTTTACTTTGGAGACACATCTCTCCAAAGC 660
 QY 661 GGTGGCTTGTGAGTGAAGACGAAATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
 Db 661 GGTGGCTTGTGAGTGAAGACGAAATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
 QY 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGGCGCCCTGCGTACGAGAGTAAA 780
 Db 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGGCGCCCTGCGTACGAGAGTAAA 780
 QY 781 GGTACCGTGAACATATCCACCATATTCAGAGCCAGGGTACAGGTGTCCTCCGCTGGG 840
 Db 781 GGTACCGTGAACATATCCACCATATTCAGAGCCAGGGTACAGGTGTCCTCCGCTGGG 840
 QY 841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
 Db 841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
 QY 901 CAGGATGACAAAGACTGATTGAAGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
 Db 901 CAGGATGACAAAGACTGATTGAAGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
 QY 961 CCTCTCAAAACTCATCTTCTTCAATGTCTGAAACATGACTATGGGAACTACACTTGGT 1020
 Db 961 CCTCTCAAAACTCATCTTCTTCAATGTCTGAAACATGACTATGGGAACTACACTTGGT 1020
 QY 1021 GGCCTCAAGCTGGGCGCACCAATGCCAGCATATGCTATTTGGTCCAGGCGCGGT 1080
 Db 1021 GGCCTCAAGCTGGGCGCGCACCAATGCCAGCATATGCTATTTGGTCCAGGCGCGGT 1080
 QY 1081 CAGCGAGTGAAGCAACGCGACGTGAGGAGGCGAGGTGCGCTCTGGCTGCTCTTCT 1140
 Db 1081 CAGCGAGTGAAGCAACGCGACGTGAGGAGGCGAGGTGCGCTCTGGCTGCTCTTCT 1140
 QY 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCCGCACCCGGGAAAGCT 1200

Db 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGGCCACTTCCCAACCCGGGAAAGGCT 1200
Qy 1201 GCCGCCACCCACCCACCAACACACACACGCAATGCAACACCGACAGCAACCAATCATGATA 1260
Db 1201 GCCGCCACCCACCCACCAACACACACACGCAATGCAACACCGACAGCAACCAATCATGATA 1260
Qy 1261 TATACAAATGAAATTTAGAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Db 1261 TATACAAATGAAATTTAGAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Qy 1321 AAAGATATCTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGATATCTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Qy 1381 TTTAGGTACATGAGTTTCTTTTCCCAACGGGAAAGAAACACAGCAGCAACCCGGCTTGGGA 1440
Db 1381 TTTAGGTACATGAGTTTCTTTTCCCAACGGGAAAGAAACACAGCAGCAACCCGGCTTGGGA 1440
Qy 1441 CCCACTGCAAGTGCATGCTGCAACCTTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGTGCATGCTGCAACCTTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACACAGTGTGCCCGCCACGTCGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACACAGTGTGCCCGCCACGTCGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGACAGATGAGACCTTCCGGCCACGCTGGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGACGACAGATGAGACCTTCCGGCCACGCTGGCGTGGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACGCGCTGTGTGTGAAACCTGAAATTAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACACGCGCTGTGTGTGAAACCTGAAATTAAGAGCAAAAAAAA 1679

RESULT 113
ADD80576
ID ADD80576 standard; cDNA; 1679 BP.
XX
AC ADD80576;
XX
DT 29-JAN-2004 (first entry)
DE cDNA encoding human PRO polypeptide #188.
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003207418-A1.
XX
PD 06-NOV-2003.
XX
PF 07-MAY-2002; 2002US-00140809.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US005520.
PR 09-MAR-2001; 2001WO-US005666.
PR 14-MAR-2001; 2001US-00802706.
PR 22-MAR-2001; 2001US-00808689.
PR 05-APR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-008666028.

PR	25-MAY-2001; 2001US-00866034.	QY	1	GTGTGTCCTTTCAGCAAAAACAGTGGATTTAAATCTCTCTTGCAACAGCTTGAGAGCAACAC	60
PR	25-MAY-2001; 2001US-00866034.	DB	1	GTGTGTCCTTTCAGCAAAAACAGTGGATTTAAATCTCTCTTGCAACAGCTTGAGAGCAACAC	60
PR	01-JUN-2001; 2001US-00872035.	QY	61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
PR	01-JUN-2001; 2001US-00872035.	DB	61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
PR	05-JUN-2001; 2001US-00874503.	QY	121	AAGAAAAAATCATGAAAAACCATCCAGCCAAATATGCAAAATCTATCTCTTGGGGAAT	180
PR	05-JUN-2001; 2001US-00874503.	DB	121	AAGAAAAAATCATGAAAAACCATCCAGCCAAATATGCAAAATCTATCTCTTGGGGAAT	180
PR	14-JUN-2001; 2001US-00882636.	QY	181	CTTCAAGGGGCTGGCTCTCTGTGTCTCTTCCAGGAGTCCCGTGGCGAGCGAGATGC	240
PR	14-JUN-2001; 2001US-00882636.	DB	181	CTTCAAGGGGCTGGCTCTCTGTGTCTCTTCCAGGAGTCCCGTGGCGAGCGAGATGC	240
PR	20-JUN-2001; 2001US-00887879.	QY	241	CACCTTCCCAAAGCTATGGAACAACTGACGGTCCGCGAGGGGAGAGCGCCCTCAG	300
PR	20-JUN-2001; 2001US-00887879.	DB	241	CACCTTCCCAAAGCTATGGAACAACTGACGGTCCGCGAGGGGAGAGCGCCCTCAG	300
PR	22-JUN-2001; 2001US-00920116.	QY	301	GTGCACATTTGACAAACCGGTCCACCGGTGGCTGGCTAAACCGCAGCACCCTCTCTA	360
PR	22-JUN-2001; 2001US-00920116.	DB	301	GTGCACATTTGACAAACCGGTCCACCGGTGGCTGGCTAAACCGCAGCACCCTCTCTA	360
PR	23-JUN-2001; 2001US-00921066.	QY	361	TGCTGGGAATGACAAAGTGGTGGTCTCTCGGTGGTCTCTCTGAGCAACACCCAAAC	420
PR	23-JUN-2001; 2001US-00921066.	DB	361	TGCTGGGAATGACAAAGTGGTGGTCTCTCGGTGGTCTCTCTGAGCAACACCCAAAC	420
PR	03-JUL-2001; 2001US-00908827.	QY	421	GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACAGGGCCCTTACACCTGTC	480
PR	03-JUL-2001; 2001US-00908827.	DB	421	GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACAGGGCCCTTACACCTGTC	480
PR	06-AUG-2001; 2001US-00924419.	QY	481	GGTGACAGACACAAACCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
PR	06-AUG-2001; 2001US-00924419.	DB	481	GGTGACAGACACAAACCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
PR	09-AUG-2001; 2001US-00927796.	QY	541	CAAAATTTAGAGATTTCTTCCAGTATCTCCATTAATGAAGGGAAACAATATTAGCCTCAC	600
PR	09-AUG-2001; 2001US-00927796.	DB	541	CAAAATTTAGAGATTTCTTCCAGTATCTCCATTAATGAAGGGAAACAATATTAGCCTCAC	600
PR	16-AUG-2001; 2001US-00931836.	QY	601	CTGCATACCAACTGGTAGACAGAGCTTACGGTTACTTGGAGACACATCTCTCCCAAGC	660
PR	16-AUG-2001; 2001US-00931836.	DB	601	CTGCATACCAACTGGTAGACAGAGCTTACGGTTACTTGGAGACACATCTCTCCCAAGC	660
PR	19-DEC-2001; 2001US-00028072.	QY	661	GGTTGGCTTTGTAGTGAAGACGAATTTTGGAAATTTAGGGCATCACCCGGGAGCAGTC	720
PR	19-DEC-2001; 2001US-00028072.	DB	661	GGTTGGCTTTGTAGTGAAGACGAATTTTGGAAATTTAGGGCATCACCCGGGAGCAGTC	720
PR	(GETH) GENENTECH INC.	QY	721	AGGGGACTACGAGTGCAGTGCCTCCATGACGTGCGCGCCCGTGGTACGAGAGTAAA	780
PR	(GETH) GENENTECH INC.	DB	721	AGGGGACTACGAGTGCAGTGCCTCCATGACGTGCGCGCCCGTGGTACGAGAGTAAA	780
PR	Baker KP, Bersesini M, Deforge L, Deenoysers L, Filvaroff E, Gao W;	QY	781	GGTCAACCGTGAACCTATCCACCATATTTTCAAGAGCCCAAGGGTACAGTGTCCCGTGGG	840
PR	Baker KP, Bersesini M, Deforge L, Deenoysers L, Filvaroff E, Gao W;	DB	781	GGTCAACCGTGAACCTATCCACCATATTTTCAAGAGCCCAAGGGTACAGTGTCCCGTGGG	840
PR	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	QY	841	ACAAAAGGGGACACTGAGTGTGAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
PR	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	DB	841	ACAAAAGGGGACACTGAGTGTGAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
PR	PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	QY	901	CAAGGATCAAAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT	960
PR	PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	DB	901	CAAGGATCAAAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT	960
PR	WPI: 2003-875868/81.	QY	961	CTCTCAAAATCTATCTTCTTCAATGTCTGAAACATGACTATGGGAATCAGCTGGGT	1020
PR	WPI: 2003-875868/81.	DB	961	CTCTCAAAATCTATCTTCTTCAATGTCTGAAACATGACTATGGGAATCAGCTGGGT	1020
PR	P-PSDB; ADD80577.	QY	1021	GGCTTCCAAAGCTGGGCCACACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGT	1080
PR	P-PSDB; ADD80577.	DB	1021	GGCTTCCAAAGCTGGGCCACACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGT	1080
PR	New PRO nucleic acid, useful for manufacturing a medicament for	QY	1081	CAGCGAGGTGAGCAACCGGACGCTGAGAGGGGAGGCTGGCTGGCTGGCTCTCTCT	1140
PR	New PRO nucleic acid, useful for manufacturing a medicament for	DB	1081	CAGCGAGGTGAGCAACCGGACGCTGAGAGGGGAGGCTGGCTGGCTGGCTCTCTCT	1140
PR	diagnosing or treating tumor, for chromosome mapping or for tissue				
PR	typing.				
PR	Claim 2; Fig 375; 638pp; English.				
PR	The invention relates to isolated human PRO polypeptides (secreted and				
PR	transmembrane polypeptides) and the polynucleotides encoding them. The				
PR	invention also relates to an antibody which specifically binds to a PRO				
PR	polypeptide, a method for stimulating the release of tumour necrosis				
PR	factor-alpha (TNF-alpha) from human blood, a method for stimulating the				
PR	proliferation or differentiation of chondrocyte cells and a method for				
PR	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,				
PR	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The				
PR	polynucleotides are useful in molecular biology, including uses as				
PR	hybridisation probes, in chromosome and gene mapping, in generating				
PR	antisense RNA and DNA and in gene therapy. The polynucleotides may also				
PR	be used in preparing PRO polypeptides by recombinant techniques and in				
PR	generating either transgenic animals or knock-out animals which are				
PR	useful in the development and screening of therapeutically useful				
PR	reagents. The PRO polypeptides or antibodies are used in preparing a				
PR	medicament for treating a condition responsive to the polypeptides or				
PR	antibodies, such as tumours, for stimulating and inhibiting proliferation				
PR	of human microvascular endothelial cells, for modulating the uptake of				
PR	glucose or FFA by skeletal muscle cells or adipocyte cells, for				
PR	stimulating differentiation of adipocyte cells, for stimulating				
PR	proliferation of or gene expression in pericyte cells, for stimulating				
PR	cells, for inducing endothelial cell tube formation and for treating				
PR	various bone and/or cartilage disorders such as sports injuries and				
PR	arthritis. PRO polypeptides which stimulate the release of proteoglycans				
PR	from cartilage are useful for treating sports-related joint problems,				
PR	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO				
PR	polypeptides are also useful for treating various mammalian haemoglobin-				
PR	associated disorders such as various thalassemias and conditions which				
PR	may benefit from enhanced local immune system cell infiltration. This				
PR	sequence encodes a human PRO polypeptide of the invention. Note: The				
PR	sequence data for this patent is also available in electronic format from				
PR	the USPTO website at seqdata.uspto.gov.				
PR	Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;				
PR	Query Match 100.0%; Score 1679; DB 1; Length 1679;				
PR	Best Local Similarity 100.0%; Pred. NO. 6.7e-05;				
PR	Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;				

Db 241 CACCTTCCCAAGACTATGGAACAAGTACGGTCCGGACGGGGAGAGGGCCACCTCAG 300
Qy 301 GTGCACTATTGACAACCGGGTCAACCGGGTGGCTGGCTAAACCGGACCAATCCTCTA 360
Db 301 GTGCACTATTGACAACCGGGTCAACCGGGTGGCTGGCTAAACCGGACCAATCCTCTA 360
Qy 361 TGTGGGATGACAAGTGTGCTGATCCTCGCGTGGTCTTCTGAGCAACACCAAC 420
Db 361 TGTGGGATGACAAGTGTGCTGATCCTCGCGTGGTCTTCTGAGCAACACCAAC 420
Qy 421 GCAGTACAGCATGAGATCCAGAACCTGGATGTGATGACGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATGAGATCCAGAACCTGGATGTGATGACGAGGGCCCTTACACCTGCTC 480
Qy 481 GGTGACAGACCAACCAAGACCTCTAGGCTCAGCTCATTTGTCAGTATCTCC 540
Db 481 GGTGACAGACCAACCAAGACCTCTAGGCTCAGCTCATTTGTCAGTATCTCC 540
Qy 541 CAAAAATTGTAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCTCAC 600
Db 541 CAAAAATTGTAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCTCAC 600
Qy 601 CTGCTAGCACTGTGACAGAGCTAGGTTACTTGGACACATCTCTCCCAAGC 660
Db 601 CTGCTAGCACTGTGACAGAGCTAGGTTACTTGGACACATCTCTCCCAAGC 660
Qy 661 GGTGGCTTTGTGAGTGAAGCAATACCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGCAATACCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
Qy 721 AGGGGACTACAGTGCAGTGCCTCCAAATGACGTGGCGCGCGCTGGTACGAGAGTAA 780
Db 721 AGGGGACTACAGTGCAGTGCCTCCAAATGACGTGGCGCGCGCTGGTACGAGAGTAA 780
Qy 781 GGTACCGTGAATCCACCATACATTTAGAGGCAAGGGTACAGGTGTCCCGTGG 840
Db 781 GGTACCGTGAATCCACCATACATTTAGAGGCAAGGGTACAGGTGTCCCGTGG 840
Qy 841 AAAAAAGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 AAAAAAGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Qy 901 CAAGGATGACAAAGACTGATTCAGGAAGAGGGGTGAAGTGGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGATTCAGGAAGAGGGGTGAAGTGGAAACAGACCTTT 960
Qy 961 CCTCTCAAAACTCATCTTCTCAATGTCTCTGAACATGACTATGGGAACCTACACTTGGCT 1020
Db 961 CCTCTCAAAACTCATCTTCTCAATGTCTCTGAACATGACTATGGGAACCTACACTTGGCT 1020
Qy 1021 GGCTTCAACAGTGGGACACCAATGCGATCATGCTATTTGGTCCAGCGCGCT 1080
Db 1021 GGCTTCAACAGTGGGACACCAATGCGATCATGCTATTTGGTCCAGCGCGCT 1080
Qy 1081 CAGCGAGTGAACCGGACGTCGAGGAGGCGGCTGCTGCTGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGAACCGGACGTCGAGGAGGCGGCTGCTGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTGACCTGCTTCTCAAAATTTGATGTGATGCTTCCCAACCGGGAAGGCT 1200
Db 1141 GGTCTGACCTGCTTCTCAAAATTTGATGTGATGCTTCCCAACCGGGAAGGCT 1200
Qy 1201 GCGGCCACCAACCAACCAACAGCAATGGCAACCGGACCAACCAATCAGATA 1260
Db 1201 GCGGCCACCAACCAACCAACAGCAATGGCAACCGGACCAACCAATCAGATA 1260
Qy 1261 TATCAAAATGAATAGAGAAACACAGCTCTATGGGACAGAAATTTAGGGAGGGGAC 1320
Db 1261 TATCAAAATGAATAGAGAAACACAGCTCTATGGGACAGAAATTTAGGGAGGGGAC 1320
Qy 1321 AAGAATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAGAATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380

Qy 1381 TTTAGGTACATGAGTCTTTTCTTTCCRAACGGGAAGACACAGCACACCCGGCTTGA 1440
Db 1381 TTTAGGTACATGAGTCTTTTCTTTCCRAACGGGAAGACACAGCACACCCGGCTTGA 1440
Qy 1441 CCCACTCAAGCTGCTATCGTGAACCTCTTTGGTGGCAGTGTGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTCAAGCTGCTATCGTGAACCTCTTTGGTGGCAGTGTGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGGCCCCACAGTGGACATTTGAGCTGGGCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGGCCCCACAGTGGACATTTGAGCTGGGCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACCAACAGAAATGAGACCTTCCGGCCCCAAGCGTGGCGTGGGCACTTTG 1620
Db 1561 GTCCATAGAGACCAACAGAAATGAGACCTTCCGGCCCCAAGCGTGGCGTGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACCGCGTGTGTGTGAACCTGAATATAAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACACCGCGTGTGTGTGAACCTGAATATAAAGAGCAAAAAAAA 1679

RESULT 115

ADE40888 standard; cDNA; 1679 BP.

AC ADE40888;

DT 29-JAN-2004 (first entry)

DE Human PRO polynucleotide #188.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; PFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

Homo sapiens.

OS US2003199031-A1.

XX 23-OCT-2003.

XX 28-MAY-2002; 2002US-00156842.

XX 05-JUN-2000; 2000US-0209832P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-900160/82.

P-PsDB; ADE40889.

Two hundred and seventy five nucleic acids encoding PRO polypeptides,
useful for treating pericyte-associated tumors, diabetes and various bone
and/or cartilage disorders, e.g. arthritis.

Claim 2; Fig 375; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO

polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, PRO articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	GTGTGTCCTCAGGAAAACAGTGATTTAAATCTCTCTGACAGCTTTGAGCAACAC	60
DB	1	GTGTGTCCTCAGGAAAACAGTGATTTAAATCTCTCTGACAGCTTTGAGCAACAC	60
QY	61	AATCTATCAGGAAAGAAAGAAAACCGAACTCGACAAAAGAAAAGAAAG	120
DB	61	AATCTATCAGGAAAGAAAGAAAACCGAACTCGACAAAAGAAAAGAAAG	120
QY	121	AAGAAAAAATCATGAAAACCATCCAGCCAAAATGCAAAATCTCTCTGCGCAAT	180
DB	121	AAGAAAAAATCATGAAAACCATCCAGCCAAAATGCAAAATCTCTCTGCGCAAT	180
QY	181	CTTCAGGGGCTGGCTGCTCTGTCTCTTCAAGAGTGCCCGCGCAGCGAGATGC	240
DB	181	CTTCAGGGGCTGGCTGCTCTGTCTCTTCAAGAGTGCCCGCGCAGCGAGATGC	240
QY	241	CACCTTCCCAAGCTATGGAACAAGTACGTCGCGCAGGGGAGAGCGCCCTCAG	300
DB	241	CACCTTCCCAAGCTATGGAACAAGTACGTCGCGCAGGGGAGAGCGCCCTCAG	300
QY	301	GTGCATATTGACACCGGGTCAACCGGGTGCCCTGAGTAAACCGCAGCATCTCTA	360
DB	301	GTGCATATTGACACCGGGTCAACCGGGTGCCCTGAGTAAACCGCAGCATCTCTA	360
QY	361	TGCTGGGAATGACAAGTGTGCTGATCTCTCGCGTGTCTTCTGAGCAACCCAAAC	420
DB	361	TGCTGGGAATGACAAGTGTGCTGATCTCTCGCGTGTCTTCTGAGCAACCCAAAC	420
QY	421	GCAGTACAGTCAGATCAGAACTGATGATGACAGGGGCTTACACCTGCTC	480
DB	421	GCAGTACAGTCAGATCAGAACTGATGATGACAGGGGCTTACACCTGCTC	480
QY	481	GGTGACAGACAAACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
DB	481	GGTGACAGACAAACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540

QY	541	CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGACATATTTAGCCTCAC	600
DB	541	CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGACATATTTAGCCTCAC	600
QY	601	CTGCATAGCAACTGTGTAGACCAAGCCCTACGGTTACTTTGGAGACATCTCTCCAAAGC	660
DB	601	CTGCATAGCAACTGTGTAGACCAAGCCCTACGGTTACTTTGGAGACATCTCTCCAAAGC	660
QY	661	GGTTGGCTTTGTAGTGAAGACGATATCTTGAATTCAGGGCATCAGGGGAGCAGTC	720
DB	661	GGTTGGCTTTGTAGTGAAGACGATATCTTGAATTCAGGGCATCAGGGGAGCAGTC	720
QY	721	AGGGGACTACAGTGCAGTGCCTCCAAATGACGTGCGCGCGCGCTGGTACGAGAGTAAA	780
DB	721	AGGGGACTACAGTGCAGTGCCTCCAAATGACGTGCGCGCGCGCTGGTACGAGAGTAAA	780
QY	781	GGTACCGTGAATATTCACCATATCATTTTCAAGACCAAGGTACAGTGTCTCCGTTGG	840
DB	781	GGTACCGTGAATATTCACCATATCATTTTCAAGACCAAGGTACAGTGTCTCCGTTGG	840
QY	841	ACAAAAGGGGACACTGTCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATCCAGTGTGA	900
DB	841	ACAAAAGGGGACACTGTCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATCCAGTGTGA	900
QY	901	CAAGGATGACAAAGACTGATTTGAAGGAAAAGAGGGTGAAGTGGAAAACAGACCTTT	960
DB	901	CAAGGATGACAAAGACTGATTTGAAGGAAAAGAGGGTGAAGTGGAAAACAGACCTTT	960
QY	961	CTCTCAAAACTCATCTCTTCAATGTCTCTCAACATGACTATGGAACTACACTTGGT	1020
DB	961	CTCTCAAAACTCATCTCTTCAATGTCTCTCAACATGACTATGGAACTACACTTGGT	1020
QY	1021	GGCTTCAAAAGCTGGGCAACCAATGCCAGCATCATGCTATTTGGTTCAGGGCGCT	1080
DB	1021	GGCTTCAAAAGCTGGGCAACCAATGCCAGCATCATGCTATTTGGTTCAGGGCGCT	1080
QY	1081	CAGGAGGTGAGCAACGGCAGCTCGAGGAGGCGAGCTGCTGCTGCTGCTGCTCTTCT	1140
DB	1081	CAGGAGGTGAGCAACGGCAGCTCGAGGAGGCGAGCTGCTGCTGCTGCTGCTCTTCT	1140
QY	1141	GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCGCAGGAAAGGT	1200
DB	1141	GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCGCAGGAAAGGT	1200
QY	1201	GGCGCCACCAACCAACCAAGCAAGTGGCAACCCGACAGCAACCAATCAGATA	1260
DB	1201	GGCGCCACCAACCAACCAAGCAAGTGGCAACCCGACAGCAACCAATCAGATA	1260
QY	1261	TATACAAATGAAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGAAC	1320
DB	1261	TATACAAATGAAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGAAC	1320
QY	1321	AAAGAAATCTTTGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCTTGCAGATA	1380
DB	1321	AAAGAAATCTTTGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCTTGCAGATA	1380
QY	1381	TTTAGGTACAAATGGAGTTTTTTTCCCAACCGGGAAGAACACAGCACCCCGGTTGA	1440
DB	1381	TTTAGGTACAAATGGAGTTTTTTTCCCAACCGGGAAGAACACAGCACCCCGGTTGA	1440
QY	1441	CCCACTGCAGCTGCATCTGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC	1500
DB	1441	CCCACTGCAGCTGCATCTGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC	1500
QY	1501	TCTGCCCAACAGAGTGGCCCCCAGCTGGAAATTTCTGGAGCTGGCCATCCCAAAATCAATCA	1560
DB	1501	TCTGCCCAACAGAGTGGCCCCCAGCTGGAAATTTCTGGAGCTGGCCATCCCAAAATCAATCA	1560
QY	1561	GTCCATAGACCAACAGAAATGAGCTTCCGGCCCAAGGCTGGCGCTGGGGCACTTTG	1620
DB	1561	GTCCATAGACCAACAGAAATGAGCTTCCGGCCCAAGGCTGGCGCTGGGGCACTTTG	1620
QY	1621	GTAGACTGTGCCACCAACCGGCGTGTGTGTGAAACGTGAAATATAAAGAGCAAAAAA	1679

DB 1621 GTAGACTGTGCCACCGCGGTGTGTGTGAACGTGAATAAAGAGCAAAAAA 1679

RESULT 116
ADE04687
ID ADE04687 standard; cDNA; 1679 BP.
XX ADE04687;
AC
XX
XX
XX 29-JAN-2004 (first entry)
XX
XX Human PRO polynucleotide #188.
XX
XX Human; gene; se; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.
XX Homo sapiens.
XX OS
XX US2003199034-A1.
XX
XX 23-OCT-2003.
XX
XX 28-MAY-2001; 2001US-00156846.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Bresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX P-PSDB; ADE04688.
XX
XX WPI; 2003-900163/82.
XX
XX P-PSDB; ADE04688.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; Fig 375; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
SQ

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCACCAAGCTTGAGAGCAACAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCACCAAGCTTGAGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
QY 181 CTTACGGGGTGGTGTCTGTGTCTTCTCAAGAGTGGCCGTGCGCAGCGGAGATGC 240
DB 181 CTTACGGGGTGGTGTCTGTGTCTTCTCAAGAGTGGCCGTGCGCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGCAAGCTGCGTCCGGGAGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGGCAAGCTGCGTCCGGGAGGAGAGCGCCACCTCAG 300
QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCCTCTTA 360
DB 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCCTCTTA 360
QY 361 TCGTGGGAATGACAAAGTGTGCTGGATCTCGCTGGTCTCTTCTGAGCAACACCCCAAC 420
DB 361 TCGTGGGAATGACAAAGTGTGCTGGATCTCGCTGGTCTCTTCTGAGCAACACCCCAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGCGAGACAGAACACCCCAAGCCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCGAGACAGAACACCCCAAGCCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAAATGAAGGGAAACAAATATTAGCCTCAC 600
DB 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAAATGAAGGGAAACAAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTGGAGACCGCTACGGTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTGGAGACCGCTACGGTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGAGAAATPACTTGAATAATTCAGGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGAGAAATPACTTGAATAATTCAGGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTCCCTTCCAAATGAGTGGCCGCCCGTGGTACGGAGAGTAA 780
DB 721 AGGGGACTACGAGTGCAGTCCCTTCCAAATGAGTGGCCGCCCGTGGTACGGAGAGTAA 780
QY 781 GGTCAACGTGAATCTCCACCATACATTTTCAGAGCCAAAGGTACAGGTGTCCCGTGGG 840

781 GGTCCACGCTGAACTATCCACCATACATTTTCAAGAGCCAAAGGTACAGGTGTCCTCCGCTGGG 840
841 ACAAAGGGGACACTGCAAGTGAAGCTCAGCAGTCCCTCAGCAGATTCAGTGGTA 900
841 ACAAAGGGGACACTGCAAGTGAAGCTCAGCAGTCCCTCAGCAGATTCAGTGGTA 900
901 CAAGGATGACAAAACACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
901 CAAGGATGACAAAACACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
961 CTTCTCAAACTCATCTCTTCTCAATGCTCTGAAACATGACTATGGGAACATCACTTGGT 1020
961 CTTCTCAAACTCATCTCTTCTCAATGCTCTGAAACATGACTATGGGAACATCACTTGGT 1020
1021 GGCCTCCAAAGCTGGGCGCACCAATGCGCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1021 GGCCTCCAAAGCTGGGCGCACCAATGCGCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1081 CAGCGAGTGAAGCAACCGCACTGAGAGGGCGGCTGCGTGGCTGCTGCTCTTCT 1140
1081 CAGCGAGTGAAGCAACCGCACTGAGAGGGCGGCTGCGTGGCTGCTGCTCTTCT 1140
1141 GGTCTTGCACCTGCTTCTCAATTTTGTGAGTGGCACTTCCACCCCGGGAAGGCT 1200
1141 GGTCTTGCACCTGCTTCTCAATTTTGTGAGTGGCACTTCCACCCCGGGAAGGCT 1200
1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1261 TATACAAATGAATAGAAAGCAACAGCTCTCATGGGAGCAAAATTCAGGAGGGGAAC 1320
1261 TATACAAATGAATAGAAAGCAACAGCTCTCATGGGAGCAAAATTCAGGAGGGGAAC 1320
1321 AAAGATACTTTGGGGGAAAAGAGTTTAAAGAAAGAAATGAAATTCAGTTCAGATA 1380
1321 AAAGATACTTTGGGGGAAAAGAGTTTAAAGAAAGAAATGAAATTCAGTTCAGATA 1380
1381 TTTAGTCAATGAGGCTTTCTTTTCCCAACGGGAAAGCAACAGCAGCAGCAGCAGCAGC 1440
1381 TTTAGTCAATGAGGCTTTCTTTTCCCAACGGGAAAGCAACAGCAGCAGCAGCAGCAGC 1440
1441 CCACCTGCAAGCTGCACTGCAACCTTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
1441 CCACCTGCAAGCTGCACTGCAACCTTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
1501 TCTGCCCCAGAGTGCCCCCGTGGCAATCTTGGAGTGGCCATCCCAATTCATCA 1560
1501 TCTGCCCCAGAGTGCCCCCGTGGCAATCTTGGAGTGGCCATCCCAATTCATCA 1560
1561 GTCCATAGAGACGAACAGAAATGAGACTTCCGCGCCCAAGCGTGGCGCTCGCGGCACTTTG 1620
1561 GTCCATAGAGACGAACAGAAATGAGACTTCCGCGCCCAAGCGTGGCGCTCGCGGCACTTTG 1620
1621 GTAGACTGTGCCACCGCGGTGTGTGCAACGTGAATTAAGAGCAAAAAA 1679
1621 GTAGACTGTGCCACCGCGGTGTGTGCAACGTGAATTAAGAGCAAAAAA 1679

RESULT 117

ADC48828

ID ADC48828 standard; cDNA; 1679 BP.

XX

AC ADC48828;

XX

DT 15-JAN-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;

KW vulnary; antarthritic; pericyte cell proliferation;

KW pericyte cell differentiation; chondrocyte cell proliferation;

KW chondrocyte cell differentiation; tumour necrosis factor alpha release;

KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX gene therapy.
XX Homo sapiens.
XX OS
XX US2003092888-A1.
XX
XX 15-MAY-2003.
XX
XX 13-AUG-2002; 2002US-00219468.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENEVECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX P-PSDB; ADC48829.
XX WPI; 2004-031186/03.
XX
XX Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as
XX molecular weight markers in protein electrophoresis, for treating
XX arthritis, tumor.
XX
XX Claim 2; SEQ ID NO 125; 308pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF)-
XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
XX PRO247, PRO337, PRO525, PRO363, PRO531, PRO1083, PRO840, PRO1080,
XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
XX PRO1230, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1947, PRO1567,
XX PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3443, PRO3444, PRO4322,
XX PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX stimulating the proliferation of normal human dermal fibroblasts cells.
XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX PRO5723, PRO5725, PRO154, or PRO7425 polypeptide are useful for
XX inhibiting the proliferation of normal human dermal fibroblast cells. PRO
XX polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
XX are useful for detecting the presence of tumour in a mammal which
XX involves comparing the level of expression of the above PRO polypeptides
XX in a test sample of cells taken from the mammal, and a control sample of
XX normal cells of the same cell type, where a higher level of expression of
XX the PRO polypeptides in the test sample as compared to the control sample
XX is indicative of the presence of tumour in the mammal. The tumour is lung
XX tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
XX liver tumour. (I) is useful as molecular weight markers, for tissue
XX typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
XX useful for chromosome and gene mapping or gene therapy. (II) is useful
XX for generating transgenic animals or knock-out animals which are useful
XX screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
XX is useful for treating bone and/or cartilage disorders (e.g., arthritis,
XX sport injuries). This sequence encodes a human secreted and transmembrane
XX PRO polypeptide.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query March

100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGAATTTAAATCTCTTTGCAAAAGCTTGAGAGCAAC 60
Db |||||
QY 1 GTTGTGTCCTTCAGCAAAACAGTGAATTTAAATCTCTTTGCAAAAGCTTGAGAGCAAC 60
Db |||||
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db |||||
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db |||||
QY 121 AAGAAAAAAATCATGAAAAACCATCAGCCAAAAATGCAAAATCTATCTCTTTGGGCAAT 180
Db |||||
QY 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCAAGAGAGTCCCGTCCGAGCGGAGATGC 240
Db |||||
QY 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCAAGAGAGTCCCGTCCGAGCGGAGATGC 240
Db |||||
QY 241 CACCTTTCCCAAGCTATGGAACAACGTGACGGTCCGGCAGGGGGAGAGCGCCCTCAG 300
Db |||||
QY 241 CACCTTTCCCAAGCTATGGAACAACGTGACGGTCCGGCAGGGGGAGAGCGCCCTCAG 300
Db |||||
QY 301 GTGCACATTTGACAAACGGGTACCCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
Db |||||
QY 301 GTGCACATTTGACAAACGGGTACCCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
Db |||||
QY 361 TGTCTGGGAATGACAAGTGTGCTCGATCTCTCGGTGGTCTCTCTGAGCAACACCAAC 420
Db |||||
QY 361 TGTCTGGGAATGACAAGTGTGCTCGATCTCTCGGTGGTCTCTCTGAGCAACACCAAC 420
Db |||||
QY 421 GCAGTACAGCATCAGATCAGAAACGTGGATGTGATGAGAGGGCCCTTACACCTGCTC 480
Db |||||
QY 421 GCAGTACAGCATCAGATCAGAAACGTGGATGTGATGAGAGGGCCCTTACACCTGCTC 480
Db |||||
QY 481 GGTGCGAGACAGCAACACCAAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
Db |||||
QY 481 GGTGCGAGACAGCAACACCAAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
Db |||||
QY 541 CAAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTAC 600
Db |||||
QY 541 CAAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTAC 600
Db |||||
QY 601 CTGCATAGCACTGGTAGACAGAGCTACGGTACTTTGGAGACATCTCTCCCAAGC 660
Db |||||
QY 601 CTGCATAGCACTGGTAGACAGAGCTACGGTACTTTGGAGACATCTCTCCCAAGC 660
Db |||||
QY 661 GGTGGCTTTGTGAGTGAAGACGAATACITTTGAAATTCAGGGCATCACCCGGAGCAGTC 720
Db |||||
QY 661 GGTGGCTTTGTGAGTGAAGACGAATACITTTGAAATTCAGGGCATCACCCGGAGCAGTC 720
Db |||||
QY 721 AGGGGACTACGAGTGCAGTCTCCAAATGACGTGGCGCGCCGCTGGTACGGAGGTAA 780
Db |||||
QY 721 AGGGGACTACGAGTGCAGTCTCCAAATGACGTGGCGCGCCGCTGGTACGGAGGTAA 780
Db |||||
QY 781 GGTCAACGTGAATCATCCACATACATTTGAGAGCCCAAGGGTACAGGTGTCCCGTGGG 840
Db |||||
QY 781 GGTCAACGTGAATCATCCACATACATTTGAGAGCCCAAGGGTACAGGTGTCCCGTGGG 840
Db |||||
QY 841 ACAAAGGGGACATGAGCTGTGAGCTCAGCAGTCCCTCAGCAGCAATTCAGTGGTA 900
Db |||||
QY 841 ACAAAGGGGACATGAGCTGTGAGCTCAGCAGTCCCTCAGCAGCAATTCAGTGGTA 900
Db |||||
QY 901 CAAGGATGACAAAAGACTGATTGAAGAAAGAAAGGGGTGAAAGTGAAGAAACAGACCTTT 960
Db |||||
QY 901 CAAGGATGACAAAAGACTGATTGAAGAAAGAAAGGGGTGAAAGTGAAGAAACAGACCTTT 960
Db |||||
QY 961 CCTCTCAAAATCATCTTTCAATGTCTTGAACTATGGAATGGAAGTCACTTGCCT 1020
Db |||||
QY 961 CCTCTCAAAATCATCTTTCAATGTCTTGAACTATGGAAGTCACTTGCCTTGCCT 1020
Db |||||
QY 1021 GGCCTCCACAGCTGGGCGACCAATGCCAGCATCATGTATTTGCTCCAGCGCGCT 1080
Db |||||
QY 1021 GGCCTCCACAGCTGGGCGACCAATGCCAGCATCATGTATTTGCTCCAGCGCGCT 1080
Db |||||

QY 1081 CAGCGAGGTGAGCAACGGCACGTCGAGGAGGGCAGGCTGGCTGCTGCTGCTCTTCT 1140
Db |||||
QY 1081 CAGCGAGGTGAGCAACGGCACGTCGAGGAGGGCAGGCTGGCTGCTGCTGCTCTTCT 1140
Db |||||
QY 1141 GGTCTTGACACTGCTTCTCAAATTTTGAATTTGATGTAGTGCACCTTCCCAACCCGGGAAAGGCT 1200
Db |||||
QY 1141 GGTCTTGACACTGCTTCTCAAATTTTGAATTTGATGTAGTGCACCTTCCCAACCCGGGAAAGGCT 1200
Db |||||
QY 1201 GCGGCCACACACACACCAACAGCAACAGCAACAGCAACAGCAACAGCAACCAATCAGATA 1260
Db |||||
QY 1201 GCGGCCACACACACACCAACAGCAACAGCAACAGCAACAGCAACCAATCAGATA 1260
Db |||||
QY 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC 1320
Db |||||
QY 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC 1320
Db |||||
QY 1321 AAGAATATCTTTGGGGGAAAGAGTTTTTAAAGAGAAATTTGAAATTTGCTTGCAGATA 1380
Db |||||
QY 1321 AAGAATATCTTTGGGGGAAAGAGTTTTTAAAGAGAAATTTGAAATTTGCTTGCAGATA 1380
Db |||||
QY 1381 TTTAGGTACAAATGGAGTTTTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGGGA 1440
Db |||||
QY 1381 TTTAGGTACAAATGGAGTTTTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGGGA 1440
Db |||||
QY 1441 CCCACTGCAAGCTGCATCGTGCAACCTTTTGGTCCAGTGTGGGCAAGGCTCAGCCTC 1500
Db |||||
QY 1441 CCCACTGCAAGCTGCATCGTGCAACCTTTTGGTCCAGTGTGGGCAAGGCTCAGCCTC 1500
Db |||||
QY 1501 TCTGCCACAGAGTGCCGCCACGTCGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Db |||||
QY 1501 TCTGCCACAGAGTGCCGCCACGTCGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Db |||||
QY 1561 GTCCATAGAGACGAACAGATGAGACCTTCCGGCCCAAGCGTGGCGTGGGCACTTTG 1620
Db |||||
QY 1561 GTCCATAGAGACGAACAGATGAGACCTTCCGGCCCAAGCGTGGCGTGGGCACTTTG 1620
Db |||||
QY 1621 GTAGACTGTGCCACACCGCGTGTGTGAAACGTGAAATATAAAGAGCAAAAAAAA 1679
Db |||||
QY 1621 GTAGACTGTGCCACACCGCGTGTGTGAAACGTGAAATATAAAGAGCAAAAAAAA 1679
Db |||||

RESULT 118
ADC81112
ID ADC81112 standard; cDNA; 1679 BP.
XX
AC ADC81112;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
OS Homo sapiens.
XX
XX US2003092115-A1.
PN
XX
XX 15-MAY-2003.
PD
XX
XX 30-MAY-2002; 2002US-00158785.
PF
XX
XX 05-JUN-2000; 2000US-0209832P.
PR

PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-020238/02.
DR P-PSDB; ADC81113.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX Claim 2; Fig 375; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTCTCTCAGCAAAACAGTGGATTAAATCTCTTTCGCAACAGCTTGAGCAACAC 60
DB 1 GTTGTCTCTCAGCAAAACAGTGGATTAAATCTCTTTCGCAACAGCTTGAGCAACAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAAATCATCAAAACCATCAGGCAAAATTCACAAATTCCTCTTGGGCAAT 180
DB 121 AAGAAAAAAATCATCAAAACCATCAGGCAAAATTCACAAATTCCTCTTGGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTGCTCTGTGCTCTTTCAGAGAGTGCCCTGTCGCGCAGCGGAGTGC 240

DB 181 CTTTCAGGGGCTGGCTGCTCTGTGCTCTTTCAGAGAGTGCCCTGTCGCGCAGCGGAGTGC 240
QY 241 CACCTTCCCAAGCTATGGCAACAGTCCGGTCGGCAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGGCAACAGTCCGGTCGGCAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACTATTTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCCGACGACCATCTCTA 360
DB 301 GTGCACTATTTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCCGACGACCATCTCTA 360
QY 361 TGTCTGGATGACAAAGTGTGCTGCTGATCTCTCGCTGGTCTCTTCTGAGCAACACCCAAAC 420
DB 361 TGTCTGGATGACAAAGTGTGCTGCTGATCTCTCGCTGGTCTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTCGATGTATGACGAGGGCCCTTACACCTGTCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTCGATGTATGACGAGGGCCCTTACACCTGTCTC 480
QY 481 GTGTCAGACAGCAACACCCCAAGACCTCTAGGTCACACCTCATTTGTGCAAGTATCTCC 540
DB 481 GTGTCAGACAGCAACACCCCAAGACCTCTAGGTCACACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAGGGAACAATATTAGCTCTAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAGGGAACAATATTAGCTCTAC 600
QY 601 CTGCATAGCAACTGTGTAGACGACGCTACGCTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGTGTAGACGACGCTACGCTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGTGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGTGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTAGAGTGCAGTGCCTCCAAATGACGTGGCGCGCCCGCTGGTACGGAGAGTAA 780
DB 721 AGGGGACTAGAGTGCAGTGCCTCCAAATGACGTGGCGCGCCCGCTGGTACGGAGAGTAA 780
QY 781 GGTCAACGCTGAATATCCACCATCATATTTGAGAAGCAAGGTCACAGTGTCTCCCGTGG 840
DB 781 GGTCAACGCTGAATATCCACCATCATATTTGAGAAGCAAGGTCACAGTGTCTCCCGTGG 840
QY 841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGAGTCCCTCAGCAGANTTCAGTGTGA 900
DB 841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGAGTCCCTCAGCAGANTTCAGTGTGA 900
QY 901 CAAGGATGACAAAGACTCATTTGAAGGAAAGAGGGTGAAGGTCGAAAGCAAGACCTTT 960
DB 901 CAAGGATGACAAAGACTCATTTGAAGGAAAGAGGGTGAAGGTCGAAAGCAAGACCTTT 960
QY 961 CTTCTCAAACTCATCTCTTCAATGTCTCTGAACATGACTATGGGAATACACTTTGCGT 1020
DB 961 CTTCTCAAACTCATCTCTTCAATGTCTCTGAACATGACTATGGGAATACACTTTGCGT 1020
QY 1021 GGCTCTCAACAGCTGGGCCACACCAATGCGAGCATCATGTCTATTTGGTCCAGGGCCGT 1080
DB 1021 GGCTCTCAACAGCTGGGCCACACCAATGCGAGCATCATGTCTATTTGGTCCAGGGCCGT 1080
QY 1081 CAGCGAGGTGAGCAACGCGCAGTGTGAAGGGGAGGGGAGGGTCTGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACGCGCAGTGTGAAGGGGAGGGGAGGGTCTGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACTCTCTTCAATTTTGTGAGTGCCTCTTCCCAACCCGGGAAAGGCT 1200
DB 1141 GGTCTTGCACTCTCTTCAATTTTGTGAGTGCCTCTTCCCAACCCGGGAAAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATTCAGATA 1260
DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATTCAGATA 1260
QY 1261 TATACAAATGAATTAAGAAAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGAAAC 1320
DB 1261 TATACAAATGAATTAAGAAAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGAAAC 1320

QY 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTCCTTGCCTTCAGATA 1380
 DB 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTCCTTGCCTTCAGATA 1380
 QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGGGA 1440
 DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGGGA 1440
 QY 1441 CCACATGCAAGTGCATCGTGCACCTTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
 DB 1441 CCACATGCAAGTGCATCGTGCACCTTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
 QY 1501 TCTGCCACACAGTGTGCCACGTGGAACATCTTGGAGTGGCCATCCCAAAATTCATCA 1560
 DB 1501 TCTGCCACACAGTGTGCCACGTGGAACATCTTGGAGTGGCCATCCCAAAATTCATCA 1560
 QY 1561 GTCCATAGACGCAACAGATGAGACTTCCGGCCCAAGCGTGGCGCTCGGCGCACTTTG 1620
 DB 1561 GTCCATAGACGCAACAGATGAGACTTCCGGCCCAAGCGTGGCGCTCGGCGCACTTTG 1620
 QY 1621 GTAGACTGTGCCACCGCGGTGTGTGTGTAACGTTGTAATTAAGAGCAAAAAA 1679
 DB 1621 GTAGACTGTGCCACCGCGGTGTGTGTGTAACGTTGTAATTAAGAGCAAAAAA 1679

RESULT 119
 ADE20999
 ID ADE20999 standard; CDNA; 1679 BP.
 AC ADE20999;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO337 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 XX US2003100735-A1.
 PD 29-MAY-2003.
 XX
 XX 28-AUG-2002; 2002US-00230433.
 XX
 XX 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 PI WPI; 2004-008985/01.
 DR P-FSD8; ADE21000.
 XX
 XX New polypeptides and nucleic acids encoding the polypeptides, useful
 PT in gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.
 XX
 XX Claim 2; Fig 125; 308pp; English.
 PS
 XX The invention describes an isolated PRO (secreted and transmembrane)
 CC

CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO155, PRO1306 or PRO419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1035, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO3431, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO5079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4308,
 CC PRO5723, PRO5725, PRO7154 or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g. arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 SQ

Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAAC 60
 DB 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAAC 60
 QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 QY 121 AAGAAAAAATCATGAAAAACATCCAGCCAAAAATGCACAAATTTCTATCTTTGGCAAT 180
 DB 121 AAGAAAAAATCATGAAAAACATCCAGCCAAAAATGCACAAATTTCTATCTTTGGCAAT 180
 QY 181 CTTACGGGGTGGCTGCTCTTCTTCCAGAGTGGCGTCCGCGAGGAGATGC 240
 DB 181 CTTACGGGGTGGCTGCTCTTCTTCCAGAGTGGCGTCCGCGAGGAGATGC 240
 QY 241 CACCTTCCCAAGCTATGGAACAACGTACCGTCCGGCAGGGGAGAGCGCCACCTCAG 300
 DB 241 CACCTTCCCAAGCTATGGAACAACGTACCGTCCGGCAGGGGAGAGCGCCACCTCAG 300
 QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCAACATCTCTA 360
 DB 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCAACATCTCTA 360
 QY 361 TCGTGGGAATGACAAAGTGGTGGTCTCGGTGGTCTCTTCTGAGCAACACCCCAAC 420
 DB 361 TCGTGGGAATGACAAAGTGGTGGTCTCGGTGGTCTCTTCTGAGCAACACCCCAAC 420
 QY 421 GCAGTACAGATCGAGATCCAGAACGTGATGTATGACGAGGGCCCTTACCTGCTC 480
 DB 421 GCAGTACAGATCGAGATCCAGAACGTGATGTATGACGAGGGCCCTTACCTGCTC 480

QY 481 GGTGAGACAGACACACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGAGACAGACACACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCACTGTGTAGACGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCACTGTGTAGACGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTTCGGCTTTGTGAGTGAAGACCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTTCGGCTTTGTGAGTGAAGACCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGAAGTGCCTCCAAATGACGTGCGCGCGCCGTGTGACGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGAAGTGCCTCCAAATGACGTGCGCGCGCCGTGTGACGAGAGTAAA 780
QY 781 GGTCAACCGTGAATCTATCCACCATATATTTCAGAACCAAGGATACAGGTGTCCCGGTGGG 840
DB 781 GGTCAACCGTGAATCTATCCACCATATATTTCAGAACCAAGGATACAGGTGTCCCGGTGGG 840
QY 841 ACAAAGGGGACACTGCACTGTGAAGCCTTCAGACGTCCCTCAGCAGAAATTCAGGTGTA 900
DB 841 ACAAAGGGGACACTGCACTGTGAAGCCTTCAGACGTCCCTCAGCAGAAATTCAGGTGTA 900
QY 901 CAGGATGACAAAGACTGATTTGAAGGAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
DB 901 CAGGATGACAAAGACTGATTTGAAGGAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CCTCTCAAAACTCATCTTCTCAATGTCTCTGAAATGATGATGGAACATCACTTTGGT 1020
DB 961 CCTCTCAAAACTCATCTTCTCAATGTCTCTGAAATGATGATGGAACATCACTTTGGT 1020
QY 1021 GGCCTTCACAGCTGGGACACCAATGCCAGCATCATGCTATTGTGCCAGGCGCGT 1080
DB 1021 GGCCTTCACAGCTGGGACACCAATGCCAGCATCATGCTATTGTGCCAGGCGCGT 1080
QY 1081 CAGCAGGTGAGCAACCGGACGCTCGAGGAGGCGAGCTGCGTCTGCTGCTCTCTCT 1140
DB 1081 CAGCAGGTGAGCAACCGGACGCTCGAGGAGGCGAGCTGCGTCTGCTGCTCTCTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAATTTTGTGATGAGTGCCATCTCCACCCGCGGGAAGCT 1200
DB 1141 GGTCTTGACCTGCTTCTCAATTTTGTGATGAGTGCCATCTCCACCCGCGGGAAGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260
DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260
QY 1261 TATACAAATGAATTAAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAATTAAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAAGATACTTTGGGGGGAAGAGATTTTAAAGAAATTTGAAATTTGCTTTCAGATA 1380
DB 1321 AAAGATACTTTGGGGGGAAGAGATTTTAAAGAAATTTGAAATTTGCTTTCAGATA 1380
QY 1381 TTTAGTACAAATGAGATTTCTTTTCCAAACGGGAAGAACACAGCACACCCGGGTTGA 1440
DB 1381 TTTAGTACAAATGAGATTTCTTTTCCAAACGGGAAGAACACAGCACACCCGGGTTGA 1440
QY 1441 CCCACTGCAAGCTGCTGCACTCTTTTGTGCGAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCTGCACTCTTTTGTGCGAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCCCCAGCTGGAACATTTCTGAGCTGGCCATCCCAATTAATCA 1560
DB 1501 TCTGCCACAGAGTGCCCCCAGCTGGAACATTTCTGAGCTGGCCATCCCAATTAATCA 1560
QY 1561 GTCCATAGAGACGACAGATGAGACCTTCGCGCCCAAGCGTGGCGCTCGCGGCACTTTG 1620

DB 1561 GTCCATAGAGACGACAGATGAGACCTTCGCGCCCAAGCGTGGCGCTCGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGTAACCTGAAATTAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGTAACCTGAAATTAAGAGCAAAAAA 1679
RESULT 120
ADE05843
ID ADE05843 standard; cDNA; 1679 BP.
XX AC ADE05843;
XX XX
DT 29-JAN-2004 (first entry)
XX XX
DE Human PRO polynucleotide #63.
XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX Homo sapiens.
OS
XX US2003100728-A1.
FN
XX
PD 29-MAY-2003.
XX
PF 28-AUG-2002; 2002US-00230024.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
(GETH) GENENTECH INC.
Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
P1 Grimaldi JC, Gurney AL, Smith V, Stephen JF, Watanabe CK, Wood WI;
XX WPI; 2004-008978/01.
DR P-PSDB; ADE05844.
XX
New secreted and transmembrane PRO polypeptides and nucleic acids, useful
in gene therapy, or for preparing a medicament for treating a condition
that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
cancer.
Claim 2; Fig 125; 308pp; English.
The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioreactors. They are particularly useful for
detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
prostate tumour, rectal tumour or liver tumour) in a mammal, for
stimulating the release of tumour necrosis factor (TNF)-alpha from human
blood, for stimulating the proliferation or differentiation of
chondrocyte cells, for stimulating the proliferation of or gene
expression in pericyte cells or for stimulating the proliferation of
normal human dermal fibroblasts. The PRO nucleic acids are useful as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA, in preparing PRO polypeptides by recombinant
technology, in generating transgenic animals or knock-out animals which
may be used in the development and screening of therapeutically useful
reagents, in gene therapy, in chromosome identification, as chromosome
markers, in generating probes. The PRO polypeptides, or anti-PRO
antibodies, are useful for preparing a medicament for treating a
condition which is responsive to the PRO polypeptides or anti-PRO
antibodies, such as pericyte-associated tumours and bone and/or cartilage
disorders (e.g. arthritis, sports injuries), involving inducing the re-
differentiation of chondrocytes. The PRO polypeptides are useful as

CC molecular markers for protein electrophoresis, and in tissue typing. This
XX sequence represents a human PRO polynucleotide of the invention.

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6,7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTGCAAGCTTGAGAGCAACAC	60
DB	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTGCAAGCTTGAGAGCAACAC	60
QY	61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
DB	61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
QY	121	AAGAAAAAATCATGAATACCATCCAGCCCAAAATGCAATCTCTCTTGGCAAT	180
DB	121	AAGAAAAAATCATGAATACCATCCAGCCCAAAATGCAATCTCTCTTGGCAAT	180
QY	181	CTTCACGGGGCTGCTGCTCTGTCTCTTCCAAAGAGTGCCTGCGCAGCGGAGATGC	240
DB	181	CTTCACGGGGCTGCTGCTCTGTCTCTTCCAAAGAGTGCCTGCGCAGCGGAGATGC	240
QY	241	CACCTTCCCAAGCTATGACAACTGACGTCGGGAGGGGAGCGCCACCTCTAG	300
DB	241	CACCTTCCCAAGCTATGACAACTGACGTCGGGAGGGGAGCGCCACCTCTAG	300
QY	301	GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCCTCTTA	360
DB	301	GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCCTCTTA	360
QY	361	TGCTGGGAATGACAAAGTGGTGGATCTCTCGGTGGTCTCTGAGCAACCCCAAC	420
DB	361	TGCTGGGAATGACAAAGTGGTGGATCTCTCGGTGGTCTCTGAGCAACCCCAAC	420
QY	421	GCAGTACAGCATCAGATCCAGAACGTGGATGTATGACGAGGGCCCTTACACCTGCTC	480
DB	421	GCAGTACAGCATCAGATCCAGAACGTGGATGTATGACGAGGGCCCTTACACCTGCTC	480
QY	481	GGTCAGACAGCAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC	540
DB	481	GGTCAGACAGCAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC	540
QY	541	CAAAATTGTAGAGATTCTTCAGATATCTCATTATTAAGGGAAACAATATTAGCCTCAC	600
DB	541	CAAAATTGTAGAGATTCTTCAGATATCTCATTATTAAGGGAAACAATATTAGCCTCAC	600
QY	601	CTGCATAGCAACTCGTAGACAGAGCCTACGGTTACTTTGAGAGACATCTCTCCAAAGC	660
DB	601	CTGCATAGCAACTCGTAGACAGAGCCTACGGTTACTTTGAGAGACATCTCTCCAAAGC	660
QY	661	GGTTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCGGAGCAGTC	720
DB	661	GGTTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCGGAGCAGTC	720
QY	721	AGGGGACTACGAGTGCAGTGCCTTCAATGACGTGGCGCGCCCGTGTGTACGGAGTAAA	780
DB	721	AGGGGACTACGAGTGCAGTGCCTTCAATGACGTGGCGCGCCCGTGTGTACGGAGTAAA	780
QY	781	GCTCACGCTGACATATCCACATACATTCAGAGCCCAAGGTACAGGTCTCCCGTGG	840
DB	781	GCTCACGCTGACATATCCACATACATTCAGAGCCCAAGGTACAGGTCTCCCGTGG	840
QY	841	ACAAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCTCAGCAGAATTCAGTGGTA	900
DB	841	ACAAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCTCAGCAGAATTCAGTGGTA	900
QY	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT	960
DB	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT	960

RESULT 121
ADD76560

ID ADD76560 standard; cDNA; 1679 BP.

XX AC ADD76560;

XX XX 29-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #188.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage defect; osteoarthritis;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX OS Homo sapiens.

XX XX US2003100087-A1.

XX PN

[illegible]

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTCTTGGCAAGCTTGAGAGCAAC 60
DB 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTCTTGGCAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACCAATCAGCCAAATTCGCAAAATTCATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAACCAATCAGCCAAATTCGCAAAATTCATCTCTTGGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTGCTGTCTCTTCCAGGAGTCCCGTGCAGCGGAGATGC 240
DB 181 CTTTCAGGGGCTGGCTGCTGTCTCTTCCAGGAGTCCCGTGCAGCGGAGATGC 240
QY 241 CACCTTCCCCAAAGCTATGACAACTGACGGTTCGGGCGAGGGGAGCGCCACCTCTAG 300
DB 241 CACCTTCCCCAAAGCTATGACAACTGACGGTTCGGGCGAGGGGAGCGCCACCTCTAG 300
QY 301 GTGCATATTGACAAACCGGTACCCGGTGGCTGGCTTAACCCGAGCAACCATCTCTTA 360
DB 301 GTGCATATTGACAAACCGGTACCCGGTGGCTGGCTTAACCCGAGCAACCATCTCTTA 360
QY 361 TGTGGAATGACAAAGTGTGCTGGATCTCTCGCTGGCTCTTCTGAGCAACACCCAAAC 420
DB 361 TGTGGAATGACAAAGTGTGCTGGATCTCTCGCTGGCTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCAGAACTGAGATGATGATGATGATGATGATGATGATGATG 480
DB 421 GCAGTACAGCATCGAGATCAGAACTGAGATGATGATGATGATGATGATGATGATGATG 480
QY 481 GGTGCAGACAGAACCAACCAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCAGACAGAACCAACCAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTAC 600
QY 601 CTGCATAGCACTGGTAGACAGAGCTACGGTTACTTTGAGAGACATCTCTCCAAAGC 660
DB 601 CTGCATAGCACTGGTAGACAGAGCTACGGTTACTTTGAGAGACATCTCTCCAAAGC 660
QY 661 GTTGGCTTTGTGAGTGAAGACGAATACCTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
DB 661 GTTGGCTTTGTGAGTGAAGACGAATACCTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
QY 721 AGGGACTACGAGTGCAGTCCCTCAATGACGTGGCCCGCCGCTGTACGGAGAGTAA 780
DB 721 AGGGACTACGAGTGCAGTCCCTCAATGACGTGGCCCGCCGCTGTACGGAGAGTAA 780
QY 781 GGTCAACCGTGAACCTATCCACCATACTTCCAGAGCCAGGGTACAGGTCTCCCGTGG 840
DB 781 GGTCAACCGTGAACCTATCCACCATACTTCCAGAGCCAGGGTACAGGTCTCCCGTGG 840
QY 841 ACAAAGGGGACACTGAGTGTGAGCTCAGGATCCCTCAGCAGAAATTCAGGTGTA 900
DB 841 ACAAAGGGGACACTGAGTGTGAGCTCAGGATCCCTCAGCAGAAATTCAGGTGTA 900

QY 901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGTGAAGTGGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGTGAAGTGGAAACAGACCTTT 960
QY 961 CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGAACCTACACTTGGCGT 1020
DB 961 CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGAACCTACACTTGGCGT 1020
QY 1021 GGCTTCCAAAGCTGGGCCACACCAATGCCACATCATGCTATTTGGTCCAGGCGCGT 1080
DB 1021 GGCTTCCAAAGCTGGGCCACACCAATGCCACATCATGCTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGCGAGTCCAGCAACCGGACGCTCGAGGAGGGGAGGCTGCTGCTGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGTCCAGCAACCGGACGCTCGAGGAGGGGAGGCTGCTGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTCCACTGCTTCTCAAAATTTGATGTAGTGCCACTTCCGCCACCCGGGAAAGGCT 1200
DB 1141 GGTCTTCCACTGCTTCTCAAAATTTGATGTAGTGCCACTTCCGCCACCCGGGAAAGGCT 1200
QY 1201 GCCGCCACCCACCAACCAACAGCAATGGCAACCGGACGAGCAACCAATCAGATA 1260
DB 1201 GCCGCCACCCACCAACCAACAGCAATGGCAACCGGACGAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGGAAC 1320
DB 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGGAAC 1320
QY 1321 AAGAATACCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAGAATACCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACATGGAGTTTCTTTTCCAAACCGGAAAGAACACAGCACACCCGGCTTGA 1440
DB 1381 TTTAGGTACATGGAGTTTCTTTTCCAAACCGGAAAGAACACAGCACACCCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGATGTCACCTTTTGGTCCAGTGGGAGGAGGCTCAGGCTC 1500
DB 1441 CCCACTGCAAGCTGATGTCACCTTTTGGTCCAGTGGGAGGAGGCTCAGGCTC 1500
QY 1501 TCTGCCACAGAGTGGCCCAACGTCGAAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGGCCCAACGTCGAAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGCCCAAGCGTGGGCTGCGGCACTTG 1620
DB 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGCCCAAGCGTGGGCTGCGGCACTTG 1620
QY 1621 GTAGACTGTGCCACACCGCGCTGTGTGTGAAACGTGAAATATAAGAGCAAAAAAAA 1679
DB 1621 GTAGACTGTGCCACACCGCGCTGTGTGTGAAACGTGAAATATAAGAGCAAAAAAAA 1679

RESULT 122
ADD75072
ID ADD75072 standard; cDNA; 1679 BP.
XX AC ADD75072;
XX XX 29-JAN-2004 (first entry)
XX XX Human PRO polynucleotide #63.
XX DE Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
XX KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
XX KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
XX KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
XX KW arthritis; sports injury; cytostatic; antiarthritic.
XX OS Homo sapiens.
XX XX
XX PN US2003100712-A1.

Db 1321 AAGAATACTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAATTCCTTCAGATA 1380
Qy 1381 TTAGTACATGGAGTTTCTTTTCCAAACGGGAAGAACACAGACACCCGGTTGGA 1440
Db 1381 TTAGTACATGGAGTTTCTTTTCCAAACGGGAAGAACACAGACACCCGGTTGGA 1440
Qy 1441 CCACCTGCAAGCTGCACTGCACTCTTTTGGTCCAGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCACCTGCAAGCTGCACTGCACTCTTTTGGTCCAGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCACAGTGGAAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACAGTGGAAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGCAAGATGAGACCTTCCGGCCCAAGCTGGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGCAAGATGAGACCTTCCGGCCCAAGCTGGCGTGGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACCGCGTGTGTGTGAACCTGTAATATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACCGCGTGTGTGTGAACCTGTAATATAAAGAGCAAAAAA 1679

RESULT 123
ADD75818
ID ADD75818 standard; cDNA; 1679 BP.
AC ADD75818;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
KW vulnary; antihypertensive; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
US2003100717-A1.
XX
XX 29-MAY-2003.
XX
XX 13-AUG-2002; 2002US-00219465.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX
XX 29-JUN-2001; 2001WO-US021066.
XX
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX P-PSDB; ADD75819.
XX
XX WPI; 2004-008967/01.
XX
XX P-PSDB; ADD75819.
XX
XX New secreted and transmembrane PRO polypeptide useful for preparing a
XX medicament for treating a condition that is responsive to the PRO
XX polypeptide or anti-PRO antibody, e.g. cancer.
XX
XX Claim 2; SEQ ID NO 125; 308pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful

for stimulating the proliferation or differentiation of chondrocyte
cells. PRO221, PRO357, PRO725, PRO155, PRO1306 or PRO1419 polypeptide
are useful for stimulating the release of tumour necrosis factor (TNF)-
alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,
PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
stimulating the proliferation of normal human dermal fibroblast cells.
PRO181, PRO329, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
inhibiting the proliferation of normal human dermal fibroblast cells. PRO
polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
are useful for detecting the presence of tumour in a mammal which
involves comparing the level of expression of the above PRO polypeptides
in a test sample of cells taken from the mammal, and a control sample of
normal cells of the same cell type, where a higher level of expression of
the PRO polypeptides in the test sample as compared to the control sample
is indicative of the presence of tumour in the mammal. The tumour is lung
tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
liver tumour. (I) is useful as molecular weight markers, for tissue
typing, or as therapeutic agents. A polynucleotide (ii) encoding (I) is
useful for chromosome and gene mapping or gene therapy. (ii) is useful
for generating transgenic animals or knock-out animals which are useful
screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
is useful for treating bone and/or cartilage disorders (e.g., arthritis,
sport injuries). This sequence encodes a human secreted and transmembrane
PRO polypeptide.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGCTTCACAAACAGTGGATTAAATCTCTTCACAAAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTTCACAAACAGTGGATTAAATCTCTTCACAAAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
Db 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
Qy 181 CTTACAGGGGCTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240
Db 181 CTTACAGGGGCTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240
Qy 241 CACCTTCCCAAGCTATGGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
Qy 301 GTGCACATTTGACAAACCGGGTCAACCGGGTGGCTGCTGCTGCTGCTGCTGCTGCT 360
Db 301 GTGCACATTTGACAAACCGGGTCAACCGGGTGGCTGCTGCTGCTGCTGCTGCTGCT 360
Qy 361 TGCTGGGAATGACAAAGTGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
Db 361 TGCTGGGAATGACAAAGTGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
Qy 421 GCAGTACAGATTCGAGATCCAGACGTGGATGATGATGATGATGATGATGATGATGAT 480
Db 421 GCAGTACAGATTCGAGATCCAGACGTGGATGATGATGATGATGATGATGATGATGAT 480
Qy 481 GGTGACAGACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 540
Db 481 GGTGACAGACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 540

QY 541 CAAATTTGAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Db 541 CAAATTTGAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGTGATAGCAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGTGATAGCAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGAATACTTTGAAATTCAGGCGCATCCCGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGACGAATACTTTGAAATTCAGGCGCATCCCGGAGCAGTC 720
QY 721 AGGGACTACGATGAGTGCCTCCAAATGATGTCGCGCGCGCGCGCTGATGACGAGATGAA 780
Db 721 AGGGACTACGATGAGTGCCTCCAAATGATGTCGCGCGCGCGCGCTGATGACGAGATGAA 780
QY 781 GGTCCCGTGAATTCACCAATACATTTCAAGCAAGGATACAGTGTCCCGTGGG 840
Db 781 GGTCCCGTGAATTCACCAATACATTTCAAGCAAGGATACAGTGTCCCGTGGG 840
QY 841 ACAAAAGGGGACATGCACTGTGAAGCCTCAGCAGTCCCGCTCAGCAGAAATTCAGTGTA 900
Db 841 ACAAAAGGGGACATGCACTGTGAAGCCTCAGCAGTCCCGCTCAGCAGAAATTCAGTGTA 900
QY 901 CAGGATGCAAAAGACTCATTTGAAGGAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db 901 CAGGATGCAAAAGACTCATTTGAAGGAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CTTCTCAAACTCATCTTCTCAATGTCTCTGAACATGATATGGGAATCACTTTGGT 1020
Db 961 CTTCTCAAACTCATCTTCTCAATGTCTCTGAACATGATATGGGAATCACTTTGGT 1020
QY 1021 GGCTCCACAGCTGGGCGCACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCTCCACAGCTGGGCGCACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGCAGGTGAGCAAGCGCAGCTCGAGGAGGCGAGCTCGCTGCTGCTCTCTTCT 1140
Db 1081 CAGCAGGTGAGCAAGCGCAGCTCGAGGAGGCGAGCTCGCTGCTGCTCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTCTCAATTTTGTGATGAGTCCCATCTCCCGCGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGCTCTCAATTTTGTGATGAGTCCCATCTCCCGCGGGAAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAAGCAATGGCAACCGACGCAACCAATCAGATA 1260
Db 1201 GCGGCCACCAACCAACCAACCAAGCAATGGCAACCGACGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
Db 1261 TATACAAATGAATTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
QY 1321 AAAGATACCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGATACCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTAGGTACAAATGGAGTTTCTTTTCCAAACGGGAAGAACACAGACACCGGCTTGA 1440
Db 1381 TTAGGTACAAATGGAGTTTCTTTTCCAAACGGGAAGAACACAGACACCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGATCGTGCAACTCTTTTGTGCGAGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGATCGTGCAACTCTTTTGTGCGAGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGATGCGCCCACTGAGAAATTCAGTGGGCAATTCCTCAATTCATCA 1560
Db 1501 TCTGCCACAGATGCGCCCACTGAGAAATTCAGTGGGCAATTCCTCAATTCATCA 1560
QY 1561 GTCCATGACAGCAAGATGAGCTTCCGSCCAAGCTGGCGCTCGGCGCACTTGG 1620
Db 1561 GTCCATGACAGCAAGATGAGCTTCCGSCCAAGCTGGCGCTCGGCGCACTTGG 1620

QY 1621 GTAGACTGTGCCACCAACGCGGTGTGTGTGAACCTGAAATTAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCAACGCGGTGTGTGTGAACCTGAAATTAAGAGCAAAAAA 1679
RESULT 124
ADD85050
ID ADD85050 standard; cDNA; 1679 BP.
XX AC ADD85050;
XX XX
DT 29-JAN-2004 (first entry)
XX XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX XX
OS Homo sapiens.
XX XX
PN US2003100722-A1.
XX XX
PD 29-MAY-2003.
XX XX
PF 13-AUG-2002; 2002US-00219476.
XX XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX XX
(GETH) GENENTECH INC.

Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Gurney AL, Smith V, Stephen JF, Watanabe CK, Wood WI;
WPI: 2004-008972/01.
P-PSDB; ADD85053.

New secreted and transmembrane PRO polypeptide useful for preparing a
medicament for treating a condition that is responsive to the PRO
polypeptide or anti-PRO antibody, e.g. cancer.

Claim 2; SEQ ID NO 125; 308pp; English.

The invention describes an isolated PRO (secreted and transmembrane)
polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
useful for stimulating the proliferation of or gene expression in
pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
for stimulating the proliferation or differentiation of chondrocyte
cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
are useful for stimulating the release of tumour necrosis factor (TNF)-
alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
PRO1887, PRO1928, PRO3431, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
PRO9940, PRO8079, PRO9836 or PRO10096 polypeptide are useful for
stimulating the proliferation of normal human dermal fibroblasts cells.
PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
inhibiting the proliferation of normal human dermal fibroblast cells. PRO
polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
are useful for detecting the presence of tumour in a mammal which
involves comparing the level of expression of the above PRO polypeptides

CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (III) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.

XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCGCAAAAGTTGAGAGCAACAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCGCAAAAGTTGAGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAGAAAGAAACCGAACTGACAAAAGAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAGAAAGAAACCGAACTGACAAAAGAGAAAGAAAG 120
QY 121 AAGAAABAAATCATGAAACCATCCAGCCAAATATCTATCTCTTGGCAAT 180
DB 121 AAGAAABAAATCATGAAACCATCCAGCCAAATATCTATCTCTTGGCAAT 180
QY 181 CTTCAAGGGGCTGGCTCTGTGTCTCTTCCAGGAGTCCCGTGGCAGCGGAGATGC 240
DB 181 CTTCAAGGGGCTGGCTCTGTGTCTCTTCCAGGAGTCCCGTGGCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGACACGTGACGTGCGGCGGGGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGACACGTGACGTGCGGCGGGGAGCGCCACCTCAG 300
QY 301 GTGCACTATTGCAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
DB 301 GTGCACTATTGCAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
QY 361 TGCTGGGAATGCAAGTGGTGGCTGGATCTCTCGGTGGTCTTCTGAGCAACCCAAAC 420
DB 361 TGCTGGGAATGCAAGTGGTGGCTGGATCTCTCGGTGGTCTTCTGAGCAACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTATGACGAGGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTATGACGAGGGGCCCTTACACCTGCTC 480
QY 481 GGTGACAGACAGAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTCGTAGACAGAGCCTACGGTTACTTTGAGAGACATCTCTCCAAAGC 660
DB 601 CTGCATAGCAACTCGTAGACAGAGCCTACGGTTACTTTGAGAGACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGCAATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGCAATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTTCAATGACGTGGCGCCCGCTGTGTA CGGAGATPAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTTCAATGACGTGGCGCCCGCTGTGTA CGGAGATPAA 780
QY 781 GGTCAACGCTGACATATCCACCATATTCAGAGCCAGGGTACAGTGTCCCGCTGGG 840

DB 781 GGTCAACGCTGACATATCCACATATATTCAGAGCCAGGGTACAGGTGTCCCGTGGG 840
QY 841 ACAAAGGGGAGCACTGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGAGCACTGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAAGACTGATTGAAGCAAGAAAGGGGTGAAAGTGGAAAACAGACCTTT 960
DB 901 CAAGGATGACAAAAGACTGATTGAAGCAAGAAAGGGGTGAAAGTGGAAAACAGACCTTT 960
QY 961 CTTCTAAAACATCATCTCTTCAATGTCTTGAACATGATCTATGGGAACATACCTTGGT 1020
DB 961 CTTCTAAAACATCATCTCTTCAATGTCTTGAACATGATCTATGGGAACATACCTTGGT 1020
QY 1021 GGCCTCCAAACAGCTGGGCCACACCAATGCCAGCATCATGTATTTGGTCCAGCGCGGT 1080
DB 1021 GGCCTCCAAACAGCTGGGCCACACCAATGCCAGCATCATGTATTTGGTCCAGCGCGGT 1080
QY 1081 CAGCGAGTGTAGCAACCGCACGTGAGGAGGGCAGGTGCGTCTGGTGTGCTCTTCT 1140
DB 1081 CAGCGAGTGTAGCAACCGCACGTGAGGAGGGCAGGTGCGTCTGGTGTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTCTCAAAATTTTGAATGTGAGTGGCCACTTCCCGCCCGGAAAGGCT 1200
DB 1141 GGTCTTGACCTGCTCTCAAAATTTTGAATGTGAGTGGCCACTTCCCGCCCGGAAAGGCT 1200
QY 1201 GCCGCCACACACACCAACCAACAGCAATGCAACACCGACAGCAACCAATCAGATA 1260
DB 1201 GCCGCCACACACACCAACCAACAGCAATGCAACACCGACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGGAC 1320
DB 1261 TATACAAATGAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGGAC 1320
QY 1321 AAAGAAATATCTTGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCCCTTCAGATA 1380
DB 1321 AAAGAAATATCTTGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCCCTTCAGATA 1380
QY 1381 TTTAGGTCAATGAGTTTTCTTTCCAAACGGGAGAACACAGCACACCGCGCTTGA 1440
DB 1381 TTTAGGTCAATGAGTTTTCTTTCCAAACGGGAGAAACACAGCACACCGCGCTTGA 1440
QY 1441 CCCACTGCAAGCTGATCGTCAACCTCTTTGGTGCCAGTGTGGCAGAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGATCGTCAACCTCTTTGGTGCCAGTGTGGCAGAGGGCTCAGCCTC 1500
QY 1501 TCTGCCCAAGAGTCCCCCAAGTGTGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCCAAGAGTCCCCCAAGTGTGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGCGACAGATGAGACCTTCCGGCCCAAGCTGGCGCTCGGGCACTTTG 1620
DB 1561 GTCCATAGAGCGACAGATGAGACCTTCCGGCCCAAGCTGGCGCTCGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAAGCGCTGTGTGTGAACGTGAAATTAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAAGCGCTGTGTGTGAACGTGAAATTAAGAGCAAAAAA 1679

RESULT 125

ADD86876
ID ADD86876 standard; cDNA; 1679 BP.

XX

AC ADD86876;

XX 29-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO337 cDNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;

XX vulnery; antiarthritic; pericyte cell proliferation;

XX pericyte cell differentiation; chondrocyte cell proliferation;

KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
XX
XX Homo sapiens.
OS
XX
XX US2003100738-A1.
FN
XX
XX 29-MAY-2003.
PD
XX
XX 29-AUG-2002; 2002US-00232222.
PF
XX
XX 15-SEP-2000; 2000US-0232887P.
PR
XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
PR
XX
XX (GETH) GENENTECH INC.
PA

XX Baker KP, Desnoyers L, Gerritsen WE, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX P-PSDB; ADD86877.
XX WPI; 2004-008988/01.
XX
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
XX in gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.
XX
XX Claim 2; SEQ ID NO 125; 308pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (i). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO229, PRO1272 or PRO405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF)-
XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
XX PRO247, PRO337, PRO536, PRO363, PRO531, PRO1083, PRO840, PRO1080,
XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
XX PRO1286, PRO1330, PRO1347, PRO1308, PRO1273, PRO1279, PRO1340, PRO1338,
XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1517, PRO1760, PRO1567,
XX PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
XX PRO3940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX stimulating the proliferation of normal human dermal fibroblasts cells.
XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX PRO5723, PRO5725, PRO7134, or PRO7425 polypeptide are useful for
XX inhibiting the proliferation of normal human dermal fibroblast cells. PRO
XX polypeptides such as PRO6004, PRO4981, PRO1174, PRO5778, PRO4332, etc.,
XX are useful for detecting the presence of tumour in a mammal which
XX involves comparing the level of expression of the above PRO polypeptides
XX in a test sample of cells taken from the mammal, and a control sample of
XX normal cells of the same cell type, where a higher level of expression of
XX the PRO polypeptides in the test sample as compared to the control sample
XX is indicative of the presence of tumour in the mammal. The tumour is lung
XX tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
XX liver tumour. (ii) is useful as molecular weight markers, for tissue
XX typing, or as therapeutic agents. A polynucleotide (ii) encoding (i) is
XX useful for chromosome and gene mapping or gene therapy. (iii) is useful
XX for generating transgenic animals or knock-out animals which are useful
XX screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
XX is useful for treating bone and/or cartilage disorders (e.g., arthritis,
XX sport injuries). This sequence encodes a human secreted and transmembrane
XX PRO polypeptide.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
XX

Query Match 100.0%; Score 1679; DB 1; Length 1679;
XX

Best Local Similarity 100.0%; Pred. No. 6.7e-05;				Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1	GTGTGTCTCTCAGCAAAACAGTGGATTAAATCTCTCTGACAAAGCTTGAGCAACAC	60				
Db	1	GTGTGTCTCTCAGCAAAACAGTGGATTAAATCTCTCTGACAAAGCTTGAGCAACAC	60				
QY	61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120				
Db	61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120				
QY	121	AAGAAAAAATCATGAAAAACATCCAGCCAAAAAATGCAAAATTCATCTCTTGGGCAAT	180				
Db	121	AAGAAAAAATCATGAAAAACATCCAGCCAAAAAATGCAAAATTCATCTCTTGGGCAAT	180				
QY	181	CTTTCAGGGGTGGCTGCTCTGTGTCTCTTCCAGGAGTGCCTGCGCAGCGAGATGC	240				
Db	181	CTTTCAGGGGTGGCTGCTGTGTCTCTTCCAGGAGTGCCTGCGCAGCGAGATGC	240				
QY	241	CACCTTCCCAAGCTATGGACAAAGTGCAGCGTCCGCGAGGGAGAGCGCCCTCAG	300				
Db	241	CACCTTCCCAAGCTATGGACAAAGTGCAGCGTCCGCGAGGGAGAGCGCCCTCAG	300				
QY	301	GTGCACTATTGACAAACCGGGTCCACCGGGTGGCTTAAACCGCAGCACCCTCTCTA	360				
Db	301	GTGCACTATTGACAAACCGGGTCCACCGGGTGGCTTAAACCGCAGCACCCTCTCTA	360				
QY	361	TGCTGGGAATGACAAAGTGGTCTCTGCTGCTCTCTGCTGCTCTCTGACAAAC	420				
Db	361	TGCTGGGAATGACAAAGTGGTCTCTGCTGCTCTCTGCTGCTCTCTGACAAAC	420				
QY	421	GCAGTACAGATCGAGATCCAGACGTGGATGTGTATGACGAGGGCCCTTACCTGCTC	480				
Db	421	GCAGTACAGATCGAGATCCAGACGTGGATGTGTATGACGAGGGCCCTTACCTGCTC	480				
QY	481	GGTGCAGACAGCAAAACCCCAAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC	540				
Db	481	GGTGCAGACAGCAAAACCCCAAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC	540				
QY	541	CAAAATTGAGAGATTTCTTCAGATATCTCCATTAATGAGGGAACAATATTAGCCTCAC	600				
Db	541	CAAAATTGAGAGATTTCTTCAGATATCTCCATTAATGAGGGAACAATATTAGCCTCAC	600				
QY	601	CTGCATAGCAATCTGTAGACACAGAGCTACGGTTACTTTGGAGACACATCTCTCCAAAGC	660				
Db	601	CTGCATAGCAATCTGTAGACACAGAGCTACGGTTACTTTGGAGACACATCTCTCCAAAGC	660				
QY	661	GGTTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGCAATCCCGGAGCAGTC	720				
Db	661	GGTTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGCAATCCCGGAGCAGTC	720				
QY	721	AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGGTACGGAGAGTAAA	780				
Db	721	AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGGTACGGAGAGTAAA	780				
QY	781	GGTCAACCGTGAATATCCACCATATATTTGAGAACCAAGGTTACAGTGTCCCGTGGG	840				
Db	781	GGTCAACCGTGAATATCCACCATATATTTGAGAACCAAGGTTACAGTGTCCCGTGGG	840				
QY	841	ACAAAAGGGGACACTCGAGTGTGAAGCCTCAGAGTCCCTCAGCAGAAATTCAGTGTGA	900				
Db	841	ACAAAAGGGGACACTCGAGTGTGAAGCCTCAGAGTCCCTCAGCAGAAATTCAGTGTGA	900				
QY	901	CAAGGATGACAAAGACTGATTGAGAAAGAAAGAGGGTGAAGTGGAAAAACAGACCTTT	960				
Db	901	CAAGGATGACAAAGACTGATTGAGAAAGAAAGAGGGTGAAGTGGAAAAACAGACCTTT	960				
QY	961	CCCTCTCAAACTCATCTTCTCAATGCTCTGAAATGACTATGGAACTACACTTGCCT	1020				
Db	961	CCCTCTCAAACTCATCTTCTCAATGCTCTGAAATGACTATGGAACTACACTTGCCT	1020				
QY	1021	GGCCTTCAACAGCTGGGCCACCAATCCAGCATCATGCTATTGTTGGTCCAGGGCCCT	1080				

QY 241 CACCTTCCCAAGCTATGACCAACGTCGCGTCCGACGGGGAGAGCGCCACCTCTCAG 300
DB 241 CACCTTCCCAAGCTATGACCAACGTCGCGTCCGACGGGGAGAGCGCCACCTCTCAG 300
QY 301 GTGCACTATTGACAAACCGGCTCACCCGGGTGGCTGGCTTAAACCGCAGCACCACCTCTCTA 360
DB 301 GTGCACTATTGACAAACCGGCTCACCCGGGTGGCTGGCTTAAACCGCAGCACCACCTCTCTA 360
QY 361 TGCTGGGAATGACAAGTGGTGGTCCCTGGATCCTCGGTGGTCTCTCTGAGCAACACCCAAAC 420
DB 361 TGCTGGGAATGACAAGTGGTGGTCCCTGGATCCTCGGTGGTCTCTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACGAGATCGAGATCCAGACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACGAGATCGAGATCCAGACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGACAGACAAACACCAAGAGCCTTAGGGTCCACCTATTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAAACACCAAGAGCCTTAGGGTCCACCTATTGTGCAAGTATCTCC 540
QY 541 CAAATTTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAAACAATATTAGCCTCAC 600
DB 541 CAAATTTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGTGACAGAGCCTTAGGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCATAGCAACTGTGACAGAGCCTTAGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGACGAATCTTGAATTCAGGGCATACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGACGAATCTTGAATTCAGGGCATACCCGGGAGCAGTC 720
QY 721 AGGGACTACGAGTGCAGTCTCCATGACGTGGCGCGCGCTGTGACGAGAGTAAA 780
DB 721 AGGGACTACGAGTGCAGTCTCCATGACGTGGCGCGCGCTGTGACGAGAGTAAA 780
QY 781 GGTCAACCGTGAACATACCATACATTTAGAGACCAAGGTTACAGGTGTCCTCGTGG 840
DB 781 GGTCAACCGTGAACATACCATACATTTAGAGACCAAGGTTACAGGTGTCCTCGTGG 840
QY 841 ACAAAGGGGACATCGAGTGTGAGCCTCAGCAGTCCCTCAGCAGATTCACAGTGGTA 900
DB 841 ACAAAGGGGACATCGAGTGTGAGCCTCAGCAGTCCCTCAGCAGATTCACAGTGGTA 900
QY 901 CAAGGATGACAAAGACTGATTGAGGAAAGAGGGGTGAAAGTGGAAACACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTGAGGAAAGAGGGGTGAAAGTGGAAACACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGACATGACTATGGGACTACATTCGCT 1020
DB 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGACATGACTATGGGAACTACATTCGCT 1020
QY 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATGCTATTGTCAGGCGCGCT 1080
DB 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATGCTATTGTCAGGCGCGCT 1080
QY 1081 CAGCAGGTGAGCAACGGCAGCTCGAGAGGGCAGGCTGCGTCTGGCTGCTCTCTCT 1140
DB 1081 CAGCAGGTGAGCAACGGCAGCTCGAGAGGGCAGGCTGCGTCTGGCTGCTCTCTCTCT 1140
QY 1141 GGTCTTGCACTGCTTCTCAATTTTGTGAGTGGCCACTTCCCAACCCGGGAAAGGCT 1200
DB 1141 GGTCTTGCACTGCTTCTCAATTTTGTGAGTGGCCACTTCCCAACCCGGGAAAGGCT 1200
QY 1201 GCGGCGACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB 1201 GCGGCGACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
QY 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
DB 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320

QY 1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACAATGGAGTTTCTTTTCCCAACCGGGAAGAAACACAGCACACCCGCTTGG 1440
DB 1381 TTTAGGTACAATGGAGTTTCTTTTCCCAACCGGGAAGAAACACAGCACACCCGCTTGG 1440
QY 1441 CCCTCTGCAAGCTGATCGTCAACCTTTTGGTGCCAGTGTGGCAAGGCTCAGCCTC 1500
DB 1441 CCCTCTGCAAGCTGATCGTCAACCTTTTGGTGCCAGTGTGGCAAGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGGCCCGCCACGTCGGAACATCTCTGGAGCTGCCATCCCAATCAATCA 1560
DB 1501 TCTGCCACAGAGTGGCCCGCCACGTCGGAACATCTCTGGAGCTGCCATCCCAATCAATCA 1560
QY 1561 GTCATAGAGACGAACAGAAATGAGACCTTCCGCGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
DB 1561 GTCATAGAGACGAACAGAAATGAGACCTTCCGCGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACCGCGTGTGTTGTAACCTGTAACCTGTAACCTGTAACCTGTAAC 1679
DB 1621 GTAGACTGTGCCACACCGCGTGTGTTGTAACCTGTAACCTGTAACCTGTAACCTGTAAC 1679

RESULT 127

ADE39050

ID ADE39050 standard; cDNA; 1679 BP.

AC ADE39050;

XX 29-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO337 cDNA.

Human; secreted and transmembrane protein; PRO; Gene; ss; cytostatic;
vulnerary; antiarthritic; pericyte cell proliferation;
pericyte cell differentiation; chondrocyte cell proliferation;
chondrocyte cell differentiation; tumour necrosis factor alpha release;
(TNF)-alpha release; dermal fibroblast cell proliferation;
dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
colon tumour; breast tumour; prostate tumour; rectal tumour;
liver tumour; tissue typing; chromosome mapping; gene mapping;
gene therapy.

XX Homo sapiens.

XX US2003096362-A1.

XX 22-MAY-2003.

XX 29-AUG-2002; 2002US-00233205.

XX 25-JUL-2000; 2000US-0220585P.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

(GETH) GENENTECH INC.

Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

Grimaldi JC, Gurney AL, Smith V, Stephen JF, Watanabe CK, Wood WI;

P-PSDB; ADE39051.

WPI; 2004-008944/01.

DR P-PSDB; ADE39051.

XX New isolated, secreted and transmembrane PRO polypeptide for diagnosing,

preventing and/or treating tumors, such as lung, colon, breast, prostate,

rectal, and/or liver tumors.

XX Claim 2; Fig 125; 308pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane)

CC

CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO329, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO533, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO5940, PRO6079, PRO9836 or PRO1096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4581, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTCAGCAAAACAGTGGATTTAAATCTCTTGCACAACTTGAGAGCAAC 60
DB 1 GTTGTGCTCTCAGCAAAACAGTGGATTTAAATCTCTTGCACAACTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAACCGAAGCTGACAAAGAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAACCGAAGCTGACAAAGAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAACCATCCAGCAAAATGCAATCTCTCTTGGCAAT 180
DB 121 AAGAAAAAATCATGAAAACCATCCAGCAAAATGCAATCTCTCTTGGCAAT 180
QY 181 CTTCCAGGGGTGGCTCTCTGTCTCTTCCAGAGAGTGGCGTGGCAGCGGAGATGC 240
DB 181 CTTCCAGGGGTGGCTCTGTGTCTCTTCCAGAGAGTGGCGTGGCAGCGGAGATGC 240
QY 241 CACTTCCCCAAAGCTATGACAAACGTGAGGTTCGGCAGGGGGAGAGCGCCACCTCAG 300
DB 241 CACTTCCCCAAAGCTATGACAAACGTGAGGTTCGGCAGGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGAGACCATCTCTTA 360
DB 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGAGACCATCTCTTA 360
QY 361 TGCTGGGAATGACAAAGTGGTGGCTTGGATCTCTGGGTGGTCTCTTGAGCAACCCAAAC 420
DB 361 TGCTGGGAATGACAAAGTGGTGGCTTGGATCTCTGGGTGGTCTCTTGAGCAACCCAAAC 420
QY 421 GCATTCAGCATCCAGATCCAGATCGATGATGATGAGAGGGCCCTTACACCTGCTC 480
DB 421 GCATTCAGCATCCAGATCCAGATCGATGATGATGAGAGGGCCCTTACACCTGCTC 480

481 GGTGCGACGACGACCAACCCACAGAGCCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540
DB GGTGCGACGACGACCAACCCACAGAGCCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCCAGATATCTCCATTAATTAAGAGGAAACAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCCAGATATCTCCATTAATTAAGAGGAAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCACTGCTAGACGAGCCTAGGTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCACTGCTAGACGAGCCTAGGTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGGCTTTCTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGGCTTTCTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCAATGAGCTGCGCGCCCTGATACGGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCAATGAGCTGCGCGCCCTGATACGGAGAGTAAA 780
QY 781 GGTCAACGCTGAACATATCACCATATCTTCAAGAGCCAGAGGTGTCCTCCCGTGGG 840
DB 781 GGTCAACGCTGAACATATCACCATATCTTCAAGAGCCAGAGGTGTCCTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGATGACAAAGACTGATTTGAGGAAGAGAGAGGAGTGAAGTGAAGAAACAGACCTTT 960
DB 901 CAAGATGACAAAGACTGATTTGAGGAAGAGAGAGGAGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CTTCTCAAAACTCATCTTTCTTCAATGTCTGAAACATGATATGGAACATACCTTCGT 1020
DB 961 CTTCTCAAAACTCATCTTTCTTCAATGTCTGAAACATGATATGGAACATACCTTCGT 1020
QY 1021 GGCCTTCAAAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCT 1080
DB 1021 GGCCTTCAAAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCT 1080
QY 1081 CAGCGAGGTGAGCAACCGGACGCTCGAGAGGCGAGGCTGCGTCTGGCTGCTCTCTCTCT 1140
DB 1081 CAGCGAGGTGAGCAACCGGACGCTCGAGAGGCGAGGCTGCGTCTGGCTGCTCTCTCTCT 1140
QY 1141 GGTCTTGACCTGCTCTTCAAAATTTGATGTAGTGCACCTTCCGCCACCCGGGAAAGGCT 1200
DB 1141 GGTCTTGACCTGCTCTTCAAAATTTGATGTAGTGCACCTTCCGCCACCCGGGAAAGGCT 1200
QY 1201 GCGGCGCACCCACCCACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
DB 1201 GCGGCGCACCCACCCACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTTAGAAAGAAACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320
DB 1261 TATACAAATGAAATTTAGAAAGAAACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320
QY 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCTTGAGATA 1380
DB 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCTTGAGATA 1380
QY 1381 TTTAGGTA CAATGGAGTTTCTTTTCCAAACCGGAAAGAAACAGCAACCCCGGCTTGA 1440
DB 1381 TTTAGGTA CAATGGAGTTTCTTTTCCAAACCGGAAAGAAAGCAACCCCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTCCAGTGTGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTCCAGTGTGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCCA CAGAGTCCCCCAGCTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCCA CAGAGTCCCCCAGCTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGAGCAACAGATGAGACCTTCCGGCCCCAGCGTGGCGCTCGCGGCACTTTG 1620

Db 1561 GTCCATAGAGACGAATGAGACCTTCGGGCCCAAGCGTGCGCTGGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACCGCGTGTGTGTAACGTGAATATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACCGCGTGTGTGTAACGTGAATATAAAGAGCAAAAAA 1679
RESULT 128
ADD87924
ID ADD87924 standard; cDNA, 1679 BP.
AC ADD87924;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003092113-A1.
XX
PD 15-MAY-2003.
XX
XX 16-MAY-2002; 2002US-00147523.
XX
PR 09-DEC-1999; 99US-0170262P.
XX
PR 01-DEC-2000; 2000WO-US032678.
XX
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
DR WPI: 2004-02037/02.
DR P-PSDB; ADD87925.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 2; Fig 375; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
SQ
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAACAC 60
Db 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAACAC 60
Qy 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAATCATGAAACCATCCAGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAACCATCCAGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
Qy 181 CTTACGGGGCTGGTGTCTGTCTTCTTCAAGAGTGCCTGCGGAGCGGAGATGC 240
Db 181 CTTACGGGGCTGGTGTCTGTCTTCTTCAAGAGTGCCTGCGGAGCGGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGGACAACTGACGGTCCGGCAGGGGAGAGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGGACAACTGACGGTCCGGCAGGGGAGAGCCACCTCAG 300
Qy 301 GTGCACTATTGACACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCCTCTA 360
Db 301 GTGCACTATTGACACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCCTCTA 360
Qy 361 TGTGGGAATGACAGTGGTGTCTGTGATCTCTCGCTGGTCTTCTTGAGCAACCCAAAC 420
Db 361 TGTGGGAATGACAGTGGTGTCTGTGATCTCTCGCTGGTCTTCTTGAGCAACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGCCCTTACACCTGTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGCCCTTACACCTGTC 480
Qy 481 GGTGACAGACACACCCCAAGACCTTAGGGTCCACCTCATTTGCAAGTATCTCC 540
Db 481 GGTGACAGACACACCCCAAGACCTTAGGGTCCACCTCATTTGCAAGTATCTCC 540
Qy 541 CAAATTTGAGAGATTCTTCAGATATCTCCATTAAATGAAGGAAACAATATTAGCCTAC 600
Db 541 CAAATTTGAGAGATTCTTCAGATATCTCCATTAAATGAAGGAAACAATATTAGCCTAC 600
Qy 601 CTCATAGCACTGGTAGACAGGCTACGTTACTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTCATAGCACTGGTAGACAGGCTACGTTACTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGGCTTTGTGAGTGAAGCAATACCTTGGAAATTCAGGGCATCACCCTGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGCAATACCTTGGAAATTCAGGGCATCACCCTGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCGCGTGGTACGAGATGAAA 780

Db 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCCGTGGTACGAGAGTAA 780
Qy 781 GGTCCCGTGAATTCACCAATACATTTTCAAGCCCAAGGTTACAGTGTCCCGTGGG 840
Db 781 GGTCCCGTGAATTCACCAATACATTTTCAAGCCCAAGGTTACAGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACATGTCAGTGTGAAGCTTCAGAGTCCCTCAGCAGATTCAGTGTGA 900
Db 841 ACAAAGGGGACATGTCAGTGTGAAGCTTCAGAGTCCCTCAGCAGATTCAGTGTGA 900
Qy 901 CAAAGGATGACAAAGAGTCTGATTAAGGAAGAAAGGGTGAAGTGGAAACAGACCTTT 960
Db 901 CAAAGGATGACAAAGAGTCTGATTAAGGAAGAAAGGGTGAAGTGGAAACAGACCTTT 960
Qy 961 CTTCTCAAAACTCATCTTCTCAATGTCTCTGAACATGACTATGGGAACTACACTTGGT 1020
Db 961 CTTCTCAAAACTCATCTTCTCAATGTCTCTGAACATGACTATGGGAACTACACTTGGT 1020
Qy 1021 GGCTTCAACAGCTGGGACACCAATGCGAGCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCTTCAACAGCTGGGACACCAATGCGAGCATGCTATTTGGTCCAGGCGCGT 1080
Qy 1081 CAGCAGGTGAGCAAGCGACGTCGAGGAGGCGAGGCTGCTGCTGCTCTCTTCT 1140
Db 1081 CAGCAGGTGAGCAAGCGACGTCGAGGAGGCGAGGCTGCTGCTGCTCTCTTCT 1140
Qy 1141 GGTCTTGACCTGCTCTCAATTTTGTATGTCGCTTCCCACTCCCGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGCTCTCAATTTTGTATGTCGCTTCCCACTCCCGGGAAGGCT 1200
Qy 1201 GCGCCACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260
Db 1201 GCGCCACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260
Qy 1261 TATACAAATGAATTAAGAAAGAAACAGAGCTCTATGGGACAGAAATTTGGGGAGG 1320
Db 1261 TATACAAATGAATTAAGAAAGAAACAGAGCTCTATGGGACAGAAATTTGGGGAGG 1320
Qy 1321 AAGGATACCTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAGGATACCTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Qy 1381 TTTAGTACATGAGTGTCTTTTCCCAACCGGGAAGAAACAGACACACCGGCTTGA 1440
Db 1381 TTTAGTACATGAGTGTCTTTTCCCAACCGGGAAGAAACAGACACACCGGCTTGA 1440
Qy 1441 CCACTCAAGCTGATCGTGCACCTTTTGGTCCAGTGTGGCAAGGCTCAGCCTC 1500
Db 1441 CCACTCAAGCTGATCGTGCACCTTTTGGTCCAGTGTGGCAAGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCACGTCGAACTTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACGTCGAACTTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATGACGACGAATGAGACCTTCCGCGCCAGGCTGCGCTGCGGACCTTTG 1620
Db 1561 GTCCATGACGACGAATGAGACCTTCCGCGCCAGGCTGCGCTGCGGACCTTTG 1620
Qy 1621 GTAGCTGTGCCACACCGGCTGTGTGTGAACCTGAAATATAAGAGCAAAAAA 1679
Db 1621 GTAGCTGTGCCACACCGGCTGTGTGTGAACCTGAAATATAAGAGCAAAAAA 1679

RESULT 129
ADD86328
ID ADD86328 standard; cDNA; 1679 BP.
XX
AC ADD86328;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003203440-A1.
XX 30-OCT-2003.
XX 29-MAY-2002; 2002US-00157798.
XX 05-JUN-2000; 2000US-0209832P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-021363/02.
XX P-PSDB; ADD86329.
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO114 or
XX PRO4978, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; Fig 375; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon,
XX breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems, PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.

XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2004-008977/01.
XX P-PSDB; ADE05598.
XX
XX New secreted and transmembrane PRO polypeptide useful for preparing a
XX medicament for treating a condition that is responsive to the PRO
XX polypeptide or anti-PRO antibody, e.g. cancer.
XX
XX Claim 2; Fig 125; 308pp; English.
XX
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers, and in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes. The PRO polypeptides are useful as
XX molecular markers for protein electrophoresis, and in tissue typing. This
XX sequence represents a human PRO polynucleotide of the invention.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 1679; DB 1; Length 1679;
XX Best Local Similarity 100.0%; Pred. No. 6.7e-05;
XX Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 GTTCTGTCCTTCAGAAAAGAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
XX
XX 1 GTTGTGTCCTTCAGAAAAGAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
XX
XX 61 AATCTATCAGAAAAGAGAAAAGAAAACCGAACCTGACAAAAGAGAAAAGAAAG 120
XX
XX 61 AATCTATCAGAAAAGAGAAAAGAAAACCGAACCTGACAAAAGAGAAAAGAAAG 120
XX
XX 121 AAGAAAAAATCATGAACCATCCAGCCAAAATGCATAATCTATCTCTTGGGCAT 180
XX
XX 121 AAGAAAAAATCATGAACCATCCAGCCAAAATGCATAATCTATCTCTTGGGCAT 180
XX
XX 181 CTTACCGGGGTGGCTGCTGTGTCTCTTCCAGAGAGTGCCTGCGCAGCGGAGATGC 240
XX
XX 181 CTTACCGGGGTGGCTGCTGTGTCTCTTCCAGAGAGTGCCTGCGCAGCGGAGATGC 240
XX
XX 241 CACCTTCCCAAGCTATGACAAACGTCAGTCCGCGCAGGGGAGAGCCCAACCTCTAG 300
XX
XX 241 CACCTTCCCAAGCTATGACAAACGTCAGTCCGCGCAGGGGAGAGCCCAACCTCTAG 300
XX
XX 301 GTGCACATTTGACAAACCGGGTACCCGGGTGGCTGGCTAAACCGCAGCAACCTCTCTA 360
XX
XX 301 GTGCACATTTGACAAACCGGGTACCCGGGTGGCTGGCTAAACCGCAGCAACCTCTCTA 360
XX
XX 361 TGCTGGGAATGACAAAGTGGTGGATCTCTCGGTGGTCTTCTTGAGCAACCCCAAC 420
XX
XX 361 TGCTGGGAATGACAAAGTGGTGGATCTCTCGGTGGTCTTCTTGAGCAACCCCAAC 420

QY 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACCTGTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACCTGTC 480
QY 481 GGTGACAGACAGAACACCCCAAGAACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGAACACCCCAAGAACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGCTAGACACGAGCCTACGCTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGCTAGACACGAGCCTACGCTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTTCGGCTTTGTAGTGAAGACGAATACTCTGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTTCGGCTTTGTAGTGAAGACGAATACTCTGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCCGCCCGCTGTGTCACGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCCGCCCGCTGTGTCACGAGAGTAAA 780
QY 781 GGTCAACCGTGAACCTATCCACCATACATTTCAAGAGCCCAAGGTTACAGTGTCCCGTGG 840
DB 781 GGTCAACCGTGAACCTATCCACCATACATTTCAAGAGCCCAAGGTTACAGTGTCCCGTGG 840
QY 841 ACAAAGGGGACACTGACAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
DB 841 ACAAAGGGGACACTGACAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
QY 901 CAAGATCACAAAGACTGATTGAGGAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
DB 901 CAAGATCACAAAGACTGATTGAGGAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CCTCTCAAAATCTCATCTCTTCTTCAATGTCTCTGAACATGACTATGGGAACACTACCT 1020
DB 961 CCTCTCAAAATCTCATCTCTTCTTCAATGTCTCTGAACATGACTATGGGAACACTACCT 1020
QY 1021 GGCCTCCAAAGCTGGGCCCAACCAATGCCAGATCATGCTATTGTCAGAGGGCGT 1080
DB 1021 GGCCTCCAAAGCTGGGCCCAACCAATGCCAGATCATGCTATTGTCAGAGGGCGCT 1080
QY 1081 CAGCAGGTGAGCAACGGCAGCTCGAGGAGGCGAGGCTCTGCTGCTGCTCTCTTCT 1140
DB 1081 CAGCAGGTGAGCAACGGCAGCTCGAGGAGGCGAGGCTCTGCTGCTGCTCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAATTTTGTATGTGAGTGCACCTTCCCACCCGGGAAAGCT 1200
DB 1141 GGTCTTGACCTGCTTCTCAATTTTGTATGTGAGTGCACCTTCCCACCCGGGAAAGCT 1200
QY 1201 GCGGCCACCCACCAACCAACACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
DB 1201 GCGGCCACCAACCAACCAACACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAGAAATCTTTGGGGGAAAGAGTGTAAAGAAAGAAATTTGAAATTTGCAAGTATGCA 1380
DB 1321 AAGAAATCTTTGGGGGAAAGAGTGTAAAGAAAGAAATTTGAAATTTGCAAGTATGCA 1380
QY 1381 TTTAGGTCAATTTAGAGTGTCTTTTCCAAACGGGGAAGAACACAGCACACCCCGGTTGGA 1440
DB 1381 TTTAGGTCAATTTAGAGTGTCTTTTCCAAACGGGGAAGAACACAGCACACCCCGGTTGGA 1440
QY 1441 CCCACTGCAAGCTGATGTCGAACCTCTTTGGTCCAGTGTGGCAGAGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGATGTCGAACCTCTTTGGTCCAGTGTGGCAGAGGCTCAGCCTC 1500

QY 841 ACAAAAGGGGACATCGACGTGTGAAGCCTCAGACGTCCTCAGCAGAAATTCAGTGTA 900
Db 841 ACAAAAGGGGACATCGACGTGTGAAGCCTCAGACGTCCTCAGCAGAAATTCAGTGTA 900
QY 901 CAAGGATGACAAAGACTGATTGAGGAAAGAAAGGGGTGAAGTGGAAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGATTGAGGAAAGAAAGGGGTGAAGTGGAAAACAGACCTTT 960
QY 961 CTTCTCAAAACTCATCTTCTCAATGCTCTCTGAACATGACTATGGGAACACTACCTTGGT 1020
Db 961 CTTCTCAAAACTCATCTTCTCAATGCTCTCTGAACATGACTATGGGAACACTACCTTGGT 1020
QY 1021 GGCTTCAACAGCTGGGACACCAATGCGAGCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCTTCAACAGCTGGGACACCAATGCGAGCATGCTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGCAGGTGAGCAACGCGACGTCGAGGAGGCGAGGCTGCTGCTGCTCTCTCTTCT 1140
Db 1081 CAGCAGGTGAGCAACGCGACGTCGAGGAGGCGAGGCTGCTGCTGCTCTCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTCTCAATTTTGTGATGTCGACCTTCCACCCCGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGCTCTCAATTTTGTGATGTCGACCTTCCACCCCGGGAAGGCT 1200
QY 1201 GCCGCCACACCAACCAACACAGCAATGGCAACCGACCAACCAATCAGATA 1260
Db 1201 GCCGCCACACCAACCAACACAGCAATGGCAACCGACCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTAAGAAACACAGCCTCATGAGCAGAAATTTAGGAGGAGGGAAC 1320
Db 1261 TATACAAATGAATTAAGAAACACAGCCTCATGAGCAGAAATTTAGGAGGAGGGAAC 1320
QY 1321 AAGGATACCTTGGGGGAAAGAGTTTAAAGAAATTTGAATTTGCCCTTGACAGATA 1380
Db 1321 AAGGATACCTTGGGGGAAAGAGTTTAAAGAAATTTGAATTTGCCCTTGACAGATA 1380
QY 1381 TTTAGGTACAAATGAGGTTTCTTTTCCAAACCGGGAAGAACACAGACACCCCGGCTTGA 1440
Db 1381 TTTAGGTACAAATGAGGTTTCTTTTCCAAACCGGGAAGAACACAGACACCCCGGCTTGA 1440
QY 1441 CCACCTGACAGCTGATCGTGCACCTCTTTGTCGACGTCGTCGAGGAGGCTCAGCTTC 1500
Db 1441 CCACCTGACAGCTGATCGTGCACCTCTTTGTCGACGTCGTCGAGGAGGCTCAGCTTC 1500
QY 1501 TCTGCCCCACAGAGTGGCCCCCAGCTGGAACATTTGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCCCACAGAGTGGCCCCCAGCTGGAACATTTGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATGACGACGACGAAATGAGACCTTCCGCCCCAGCGTGGCGTGGGCACTTTG 1620
Db 1561 GTCCATGACGACGACGAAATGAGACCTTCCGCCCCAGCGTGGCGTGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCGCGGTGTGTGTAACGTCGAAATATAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGCGGTGTGTGTAACGTCGAAATATAAGAGCAAAAAA 1679

RESULT 132

ADE75776
ID ADE75776 standard; cDNA; 1679 BP.

XX AC ADE75776;

DT 29-JAN-2004 (first entry)

DE Human PRO polynucleotide #188.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;

endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

Homo sapiens.

OS US2003211571-A1.

XX 13-NOV-2003.

XX 20-MAY-2002; 2002US-00152405.

XX 03-MAR-2000; 2000US-0187202P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

PI Baker KP, Baresini M, Deforge L, Deanovers L, Filvaroff E, Gao W;
PI Gerritsen ME, Gaddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2004-051576/05.

DR P-PSDB; ADE75777.

XX New secreted and transmembrane PRO polypeptide and nucleic acid encoding
it, for use in gene therapy, as diagnostic markers for the presence of a
disease condition, or as therapeutic targets for treating tumors,
diabetes, or arthritis.

PS Claim 2; Fig 375; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems. PRO
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent is also available in electronic format
from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTTGCCACAAAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTTGCCACAAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAGAAATCAGTAAAGCAATCCAGCCAAATGCAAAATCTATCTCTTGGCAAT 180
DB 121 AAGAAAGAAATCAGTAAAGCAATCCAGCCAAATGCAAAATCTATCTCTTGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTGCTCTCTCTCTTCAAGGAGTGCCTGCGCAGCGAGATGC 240
DB 181 CTTTCAGGGGCTGGCTGCTCTCTCTCTTCAAGGAGTGCCTGCGCAGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGAACAAGTGCCTGCGCAGCGAGGAGGAGGAGGAGGAG 300
DB 241 CACCTTCCCAAGCTATGGAACAAGTGCCTGCGCAGCGAGGAGGAGGAGGAGGAG 300
QY 301 GTGCATATTGACAAACCGGCTCACCGGCTGCGCTGAGTAAACCGCAGCACCATCTCTA 360
DB 301 GTGCATATTGACAAACCGGCTCACCGGCTGCGCTGAGTAAACCGCAGCACCATCTCTA 360
QY 361 TGTGGGAATGACAGTGTGCTGATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 420
DB 361 TGTGGGAATGACAGTGTGCTGATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 420
QY 421 GCAGTACAGCTGAGATCCAGAACTGATGATGATGATGATGATGATGATGATGATG 480
DB 421 GCAGTACAGCTGAGATCCAGAACTGATGATGATGATGATGATGATGATGATGATG 480
QY 481 GGTGACAGACAAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540
DB 481 GGTGACAGACAAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540
QY 541 CAAATTTGAGAGATTTCTTCAATATCTTCAATATCTTCAATATCTTCAATATCTT 600
DB 541 CAAATTTGAGAGATTTCTTCAATATCTTCAATATCTTCAATATCTTCAATATCTT 600
QY 601 CTGCATAGCAACTGTGAGACAGAGCTACGTTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGTGAGACAGAGCTACGTTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGAATTCAGGGCATCACCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGAATTCAGGGCATCACCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCCCAATGACGTGGCGCGCGCGCGCGCGCGCG 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCCCAATGACGTGGCGCGCGCGCGCGCGCGCG 780
QY 781 GGTCAAGTGAATCTCAGCCTACATCTTCAAGCCAGGTTACAGGTGTCCTCCGCTGG 840
DB 781 GGTCAAGTGAATCTCAGCCTACATCTTCAAGCCAGGTTACAGGTGTCCTCCGCTGG 840
QY 841 ACAAAGGGGACACTGCACTGTGAGAGCTCAGCAGTCCCTCAGCAGAAATCCAGTGTA 900
DB 841 ACAAAGGGGACACTGCACTGTGAGAGCTCAGCAGTCCCTCAGCAGAAATCCAGTGTA 900
QY 901 CAAAGTGAACAAAGACTGATGAGAGAAAGAGGGTGAAGTGAAGTGAAGTGAAGT 960
DB 901 CAAAGTGAACAAAGACTGATGAGAGAAAGAGGGTGAAGTGAAGTGAAGTGAAGT 960
QY 961 CCTCTCAAACTCATCTTCTCAATGCTCTGAAATGATGATGGAACACTACATTCGGT 1020
DB 961 CCTCTCAAACTCATCTTCTCAATGCTCTGAAATGATGATGGAACACTACATTCGGT 1020
QY 1021 GGCCTCCAAAGCTGGGCAACCAATGCGAGCATCATGCTATTTGTTCCAGGCGCGT 1080
DB 1021 GGCCTCCAAAGCTGGGCAACCAATGCGAGCATCATGCTATTTGTTCCAGGCGCGT 1080
QY 1081 CAGCGAGGTGAGCAACCGCAGCTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1140

DB 1081 CAGCGAGGTGAGCAACCGCAGCTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1140
QY 1141 GGTCTTGCACTGCTCTCTCAAAATTTGATGAGTGCACTTCCCAACCGGGAAGGCT 1200
DB 1141 GGTCTTGCACTGCTCTCTCAAAATTTGATGAGTGCACTTCCCAACCGGGAAGGCT 1200
QY 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260
DB 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260
QY 1261 TATCAAAATGAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGAAC 1320
DB 1261 TATCAAAATGAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGAAC 1320
QY 1321 AAAGAATATCTTTGGGGGAAAGAGTTTTAAAAAGAAATTCAAAATTCCTTGCAGATA 1380
DB 1321 AAAGAATATCTTTGGGGGAAAGAGTTTTAAAAAGAAATTCAAAATTCCTTGCAGATA 1380
QY 1381 TTTAGTACAATGGAGTTCTTTTCCAAAACGGGAAGAACACAGCAACCCGGCTTGA 1440
DB 1381 TTTAGTACAATGGAGTTCTTTTCCAAAACGGGAAGAACACAGCAACCCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCCAACGTGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCCAACGTGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGACAGCAACAGATGAGACTTCCGCGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
DB 1561 GTCCATAGACAGCAACAGATGAGACTTCCGCGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAACCGGCTGTGTTGAAACGTGAAATAAAAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAACCGGCTGTGTTGAAACGTGAAATAAAAAGAGCAAAAAA 1679

RESULT 133

ADE48856
ID ADE48856 standard; cDNA; 1679 BP.

XX ADE48856;

XX 29-JAN-2004 (first entry)

DE Human cDNA encoding secreted/transmembrane protein, PRO337.

XX Human; ss; gene; secreted protein; transmembrane protein; PRO;
cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
vulnery; auditory; tumour growth; retinal disorder;
sports-related joint problem; articular cartilage defects;
osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

XX Homo sapiens.

XX US2003104536-A1.

XX 05-JUN-2003.

XX 19-OCT-2001; 2001US-00166709.

XX 07-OCT-1998; 98WO-US021141.

XX 20-NOV-1998; 98WO-US024855.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 14-MAY-1999; 99WO-US010733.

XX 30-JUN-1999; 99WO-US012252.

XX 30-NOV-1999; 99WO-US028313.

XX 02-DEC-1999; 99WO-US028551.

841 ACAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATCCAGTGGTA 900
 Db |||
 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATCCAGTGGTA 900
 Qy |||
 901 CAAGATGACAAAAGACTGATTAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACTTT 960
 Db |||
 901 CAAGATGACAAAAGACTGATTAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACTTT 960
 Qy |||
 961 CCTCTCAAACTCATCTCTCTCTCAATGCTCTGAACATGACTATGGGAATACACTTGGCT 1020
 Db |||
 961 CCTCTCAAACTCATCTCTCTCTCAATGCTCTGAACATGACTATGGGAATACACTTGGCT 1020
 Qy |||
 1021 GGCCTCCAAAGTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGCT 1080
 Db |||
 1021 GGCCTCCAAAGTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGCT 1080
 Qy |||
 1081 CAGCGAGTGAACACGACGCTGAGGAGGAGGCTGGCTGGCTGCTGCTCTTCT 1140
 Db |||
 1081 CAGCGAGTGAACACGACGCTGAGGAGGAGGCTGGCTGGCTGCTGCTCTTCT 1140
 Qy |||
 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCACCGCGGAAGGCT 1200
 Db |||
 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCACCGCGGAAGGCT 1200
 Qy |||
 1201 GCGGCACACACACCAACACACACAGCAATGCAACGACGACGACCAACCAATCAGATA 1260
 Db |||
 1201 GCGGCACACACACCAACACACACAGCAATGCAACGACGACGACCAACCAATCAGATA 1260
 Qy |||
 1261 TATACAAATGAAATAGAGAAACACACGCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
 Db |||
 1261 TATACAAATGAAATAGAGAAACACACGCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
 Qy |||
 1321 AAAGATACCTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCATGACATA 1380
 Db |||
 1321 AAAGATACCTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCATGACATA 1380
 Qy |||
 1381 TTTAGTCAATGAGATTTCTTTTCCAAACGGGAAAGAACACAGCACACCCCGCTTGGGA 1440
 Db |||
 1381 TTTAGTCAATGAGATTTCTTTTCCAAACGGGAAAGAACACAGCACACCCCGCTTGGGA 1440
 Qy |||
 1441 CCCACTGCAAGTGCATGTCGACCTCTTGGTGCAGTGTGGGCAAGGCTCAGGCTC 1500
 Db |||
 1441 CCCACTGCAAGTGCATGTCGACCTCTTGGTGCAGTGTGGGCAAGGCTCAGGCTC 1500
 Qy |||
 1501 TCTGCCACAGAGTGCCTCCACAGTGGAACTTCTGGAGCTGGCCATCCCAATTCATCA 1560
 Db |||
 1501 TCTGCCACAGAGTGCCTCCACAGTGGAACTTCTGGAGCTGGCCATCCCAATTCATCA 1560
 Qy |||
 1561 GTCCATAGAGACGAAACAGATGAGACCTTCCGCGCCAGCGTGGCGTGGCGGCACTTTG 1620
 Db |||
 1561 GTCCATAGAGACGAAACAGATGAGACCTTCCGCGCCAGCGTGGCGTGGCGGCACTTTG 1620
 Qy |||
 1621 GTAGACTGTGCCACACGCGGTGCTGTGAAACCTGAAATAAAGAGCAAAAAAAA 1679
 Db |||
 1621 GTAGACTGTGCCACACGCGGTGCTGTGAAACCTGAAATAAAGAGCAAAAAAAA 1679
 Qy |||

RESULT 134
 ADD78422
 ID ADD78422 standard; cDNA; 1679 bp.
 XX AC ADD78422;
 XX DT
 XX 29-JAN-2004 (first entry)
 DE Novel human secreted and transmembrane protein PRO337 cDNA.
 KW human; secreted and transmembrane protein; PRO; gene; ss; cytosstatic;
 KW vulnarary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;

KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 XX gene therapy.
 OS Homo sapiens.
 XX US2003100737-A1.
 XX 29-MAY-2003.
 XX 28-AUG-2002; 2002US-00230438.
 XX 15-SEP-2000; 2000US-0232887P.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2004-008987/01.
 DR P-PSDB; ADD78423.
 XX
 XX New PRO polypeptide and nucleic acid encoding the polypeptide, useful for
 PT gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.
 XX
 XX Claim 2; SEQ ID NO 125; 309pp; English.
 XX
 XX The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1308, PRO1273, PRO1279, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1517, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (i) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (ii) encoding (i) is
 CC useful for chromosome and gene mapping or gene therapy. (ii) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTTCAAGCAAAACAGTGGATTTAAATCTCTCTTGCACAGCTTGAAGCAACAC 60
DB 1 GTTGTGCTCTTCAAGCAAAACAGTGGATTTAAATCTCTCTTGCACAGCTTGAAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACCATCCAGCCAAATAATGCAATTTCTATCTCTTTGGCAAT 180
DB 121 AAGAAAAAATCATGAAACCATCCAGCCAAATAATGCAATTTCTATCTCTTTGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTCTGTCTCTCTTCCAGAGGTGCCCGTCCGAGCGGAGATGC 240
DB 181 CTTTCAGGGGCTGGCTCTGTCTCTCTTCCAGAGGTGCCCGTCCGAGCGGAGATGC 240
QY 241 CACCTTCCCCAAAGCTATGACCAACGTCAGCGTCCGCGAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCCAAAGCTATGACCAACGTCAGCGTCCGCGAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACATATTGACCAACCGGTCCCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
DB 301 GTGCACATATTGACCAACCGGTCCCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
QY 361 TGCTGGGAATGACAAGTGGTGCCTCGGATCCTCGCGTGGTCTCTTCTGAGCAACACCCAAAC 420
DB 361 TGCTGGGAATGACAAGTGGTGCCTCGGATCCTCGCGTGGTCTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCAGATCCAGAAACGTCGATGTGTATGACGAGGGGCTTACCTGGTCC 480
DB 421 GCAGTACAGCATCAGATCCAGAAACGTCGATGTGTATGACGAGGGGCTTACCTGGTCC 480
QY 481 GGTGCAGACAGACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCAGACAGACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAAATTAAGCCTCAC 600
DB 541 CAAATTTGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAAATTAAGCCTCAC 600
QY 601 CTGCATAGCACTGGTAGACAGAGCCTACGGTTACTTTGAGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCACTGGTAGACAGAGCCTACGGTTACTTTGAGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGACGAATCTTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGACGAATCTTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
QY 721 AGGGGACTACAGTGCAGTGCCTCCATGACGTGGCGCCCGCTGGTACGGAGATGAA 780
DB 721 AGGGGACTACAGTGCAGTGCCTCCATGACGTGGCGCCCGCTGGTACGGAGATGAA 780
QY 781 GGTCAACCGTGAATCATCCACCATACATTTTCAAGAGCCCAAGGGTACAGGTGTCCCGTGG 840
DB 781 GGTCAACCGTGAATCATCCACCATACATTTTCAAGAGCCCAAGGGTACAGGTGTCCCGTGG 840
QY 841 ACRAAGGGGACACTGAGTGTGAGCCTCAGCATCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACRAAGGGGACACTGAGTGTGAGCCTCAGCATCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGAAGAACAGACCTTT 960
DB 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGAAGAACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTTAATGTCTCTGAACATGACTATGGGAACTACACTTGGCT 1020
DB 961 CCTCTCAAACTCATCTTCTTAATGTCTCTGAACATGACTATGGGAACTACACTTGGCT 1020
QY 1021 GGCTTCCAAACGCTGGGCGACACCAATGCCAGCATCATGTATTTGGTCCAGCGCCGT 1080
DB 1021 GGCTTCCAAACGCTGGGCGACACCAATGCCAGCATCATGTATTTGGTCCAGCGCCGT 1080

QY 1081 CAGCGAGGTGAGCAACGGCACGCTCGAGAGGGCAGGCTCGTCTGGCTGGCTCTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACGGCACGCTCGAGAGGGCAGGCTCGTCTGGCTGGCTCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTAGTGCACCTTCCCAACCCGGGAAAGGCT 1200
DB 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTAGTGCACCTTCCCAACCCGGGAAAGGCT 1200
QY 1201 GCCGCCACCCACACCAACACAGCATGSCACACCGACAGCAACCAATCAGATA 1260
DB 1201 GCCGCCACCCACACCAACACAGCATGSCACACCGACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAAGAATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAAAATTTGCCCTTCAGATA 1380
DB 1321 AAAGAATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAAAATTTGCCCTTCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACGGGAAAGAACACAGCACACCCGGCTTGG 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACGGGAAAGAACACAGCACACCCGGCTTGG 1440
QY 1441 CCCACTGCAAGCTGATCGTGCAACCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGATCGTGCAACCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACGTCGGAGACATTTGGAGCTGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCACGTCGGAGACATTTGGAGCTGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCTGGCGGCACTTTG 1620
DB 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCTGGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACCGCGTGTGTGTGAACGTGAATTAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACACCGCGTGTGTGTGAACGTGAATTAAGAGCAAAAAA 1679

RESULT 135
ADE41305
ID ADE41305 standard; cDNA; 1679 BP.
XX ADE41305;
XX
XX
XX 29-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane PRO polypeptide cDNA #28.
DE
XX
XX ss; gene; human; secreted protein; transmembrane protein;
KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; angiogenesis;
KW endothelial cell apoptosis; smooth muscle cell growth;
KW endothelial cell tube formation.
OS
XX Homo sapiens.
XX
XX US2003100497-A1.
XX
XX 29-MAY-2003.
XX
XX 16-AUG-2002; 2002US-00223085.
XX
XX 20-JUN-2001; 2001WO-US019692.
PR 09-JUL-2001; 2001WO-US021735.
PR 20-FEB-2002; 2002US-00081056.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI

PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
PI Watanabe CK, Williams PM, Wood WI, Ye W;
DR WPI; 2004-008957/01.
DR P-PSDB; ADE41306.
XX
PI New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO205 or
PT PRO214, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and for treating disorders involving
PT angiogenesis.
XX
PS Claim 2; SEQ ID NO 55; 492bp; English.
XX
CC The invention relates to an isolated nucleic acid encoding a secreted and
CC transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
CC by the nucleic acid, or an agonist or antagonist, is used to treat a
CC cardiovascular, endothelial, or angiogenic disorder in a mammal,
CC preferably a human. The human may have suffered a myocardial infarction
CC or has cardiac hypertrophy, trauma, a cancer, or age-related macular
CC degeneration. The cardiac hypertrophy is characterized by the presence of
CC an elevated level of PGR-2 alpha. A PRO polypeptide, given in the
CC specification, or an agonist is used to inhibit or stimulate endothelial
CC cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
CC hypertrophy. PRO1376 or PRO149 is used to stimulate angiogenesis.
CC PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
CC polypeptide, given in the specification, or an agonist is used to
CC stimulate or inhibit smooth muscle cell growth, or to induce endothelial
CC cell tube formation. The present sequence represents a cDNA encoding a
CC PRO polypeptide of the invention.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTGTGTCCTTCAGCAAAACAGTGAATTAATCTCTTGCACAGCTTGAGCCACAC 60
DB 1 GTGTGTCCTTCAGCAAAACAGTGAATTAATCTCTTGCACAGCTTGAGCCACAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAGAAATCATGAAGAAACATCGAGCAAAATGACAAATTCCTTGGGCAAT 180
DB 121 AAGAAAGAAATCATGAAGAAACATCGAGCAAAATGACAAATTCCTTGGGCAAT 180
QY 181 CTTTCAGGGGCTGGTGTCTGTGTCTCTTCCAGGAGTGCCTGCGCAGCGAGATGC 240
DB 181 CTTTCAGGGGCTGGTGTCTGTGTCTCTTCCAGGAGTGCCTGCGCAGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGACAAAGTACGGTCCGGCAGGGGAGAGCGCCCTCAG 300
DB 241 CACCTTCCCAAGCTATGGACAAAGTACGGTCCGGCAGGGGAGAGCGCCCTCAG 300
QY 301 GTGCATATTGACAAACCGGCTCACCCTGGTGGCTTAAACCGCAGCACCCTCTTA 360
DB 301 GTGCATATTGACAAACCGGCTCACCCTGGTGGCTTAAACCGCAGCACCCTCTTA 360
QY 361 TGTGGGAATGACAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 420
DB 361 TGTGGGAATGACAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 420
QY 421 GCAGTACAGCTCGAGATCCAGAACTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 480
DB 421 GCAGTACAGCTCGAGATCCAGAACTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 480
QY 481 GTGTGACAGACAAACCAAGAACTCTTGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GTGTGACAGACAAACCAAGAACTCTTGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCCTCAC 600

DB 541 CAAAATTGTAGAGATTTCTTCAGATATCTTCATTAATGAAGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACACAGACCTACCGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCATAGCAACTGGTAGACACAGACCTACCGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGAATTTCAAGGACATCCCGGAGCAGTTC 720
DB 661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGAATTTCAAGGACATCCCGGAGCAGTTC 720
QY 721 AGGGGACTACGAGTGCCTCCAATGACGTGCGCGCGCGCGCGCGCGCGCGCGCGCG 780
DB 721 AGGGGACTACGAGTGCCTCCAATGACGTGCGCGCGCGCGCGCGCGCGCGCGCGCG 780
QY 781 GGTCAACCGTGAATCTCCACCATATCTTCAAGACCAAGGTGACAGTGTCCCGTGGG 840
DB 781 GGTCAACCGTGAATCTCCACCATATCTTCAAGACCAAGGTGACAGTGTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGCACTGCAAGCTCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
DB 841 ACAAAGGGGACACTGCACTGCAAGCTCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
QY 901 CAAGGATGACAAAGACTGATTTGAAGAAAGAAAGGGTGAAGTGAAGAAAGAAAGAAAG 960
DB 901 CAAGGATGACAAAGACTGATTTGAAGAAAGAAAGGGTGAAGTGAAGAAAGAAAGAAAG 960
QY 961 CCTCTCAAAACTCATCTTCTCAATGTCTCTGAAACATGACTATGGGAACTACACTTGGT 1020
DB 961 CCTCTCAAAACTCATCTTCTCAATGTCTCTGAAACATGACTATGGGAACTACACTTGGT 1020
QY 1021 GGCTCTCAACAGCTGGGCGCACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGCT 1080
DB 1021 GGCTCTCAACAGCTGGGCGCACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGCT 1080
QY 1081 CAGCGAGGTGAGCAACCGCACCGTTCGAGAGAGGCGAGGCTGCGTCTGCTCTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACCGCACCGTTCGAGAGAGGCGAGGCTGCGTCTGCTCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTCTCTCAAAATTTTGTGATGTGAGTGCCTTCCCGACCGGGAAGGCT 1200
DB 1141 GGTCTTGCACTGCTCTCTCAAAATTTTGTGATGTGAGTGCCTTCCCGACCGGGAAGGCT 1200
QY 1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260
DB 1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260
QY 1261 TATACAAATGAATTAAGAAAGAACACAGCCTCATGCGGACAGAAATTTGAGGGAGGGGAAC 1320
DB 1261 TATACAAATGAATTAAGAAAGAACACAGCCTCATGCGGACAGAAATTTGAGGGAGGGGAAC 1320
QY 1321 AAGAATATCTTTGGGGGAAAGAGATTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAGAATATCTTTGGGGGAAAGAGATTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACCGGGGAAGAACACAGCACACCGGCTTGA 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACCGGGGAAGAACACAGCACACCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGCATCTGTGCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCATCTGTGCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACACAGAGTGCCTCCACAGTGAACATTTGTGAGTGTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACACAGAGTGCCTCCACAGTGAACATTTGTGAGTGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGACCAACAGATGAGCTTCCCGGCCCAAGCTGGCGCTCGGGCCTTTTG 1620
DB 1561 GTCCATAGACCAACAGATGAGCTTCCCGGCCCAAGCTGGCGCTCGGGCCTTTTG 1620
QY 1621 GTAGCTGTGCCACCGCGCTGTGTGTGAAACGTGAAATAAAAAGAGCAAAAAA 1679

[illegible]

RESULT 137

ADE21245
 ID ADE21245 standard; cDNA; 1679 BP.

AC ADE21245:

29-JAN-2004 (first entry)

DE Novel human secreted and transmembrane protein PRO337 cDNA.

KW Human; secreted and transmembrane protein; PRO; gene; ss; cytotstatic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;

KW	dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW	colon tumour; breast tumour; prostate tumour; rectal tumour;
KW	liver tumour; tissue typing; chromosome mapping; gene mapping;
XX	gene therapy.
XX	
OS	Homo sapiens.
XX	
XX	US2003100736-A1.
PN	
XX	
PD	29-MAY-2003.
XX	
PP	28-AUG-2002; 2002US-00230435.
XX	
PR	01-JUN-2001; 2001WO-US017800.
PR	29-JUN-2001; 2001WO-US021066.
PR	09-APR-2002; 2002US-00119480.
XX	
PA	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Desnoyers L, Geritsen ME, Goddard A, Godowski PJ;
PI	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX	
XX	WFI; 2004-008986/01.
DR	P-PSDB; ADE21246.
DR	

New PRO polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy, chromosome identification, tissue typing, or as hybridization probes in chromosome and gene mapping.

PS Claim 2; Fig 125; 309pp; English.

The invention describes an isolated PRO (secreted and transmembrane) polypeptide (1). PRO392, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO329, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO331, PRO357, PRO735, PRO155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF)- α from human blood. PRO392, PRO357, PRO735, PRO1306, PRO1419, PRO141, PRO247, PRO337, PRO526, PRO363, PRO533, PRO1083, PRO840, PRO1080, PRO1478, PRO1134, PRO626, PRO1005, PRO809, PRO1071, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412, PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567, PRO1887, PRO1928, PRO434, PRO1801, PRO4333, PRO3543, PRO4322, PRO3940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells. PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, CC

PRO4423, PRO5723, PRO1938, or PRO7423 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

Sequence 1679 BP: 498 A: 432 C: 419 G: 330 T: 0 U: 0 Other:

Query Match	100.0%;	Score 1679;	DB 1;	Length 1679;
Best Local Similarity	100.0%;	Pred. No. 6.7e-05;		
Matches 1679;	Conservative	0;	Mismatches 0;	Indels 0;
Gaps	0;			

QY 1 GTTGTGCTCTCAGCAAAACAGTGGATTTAAATCTCCTTGACAAAGCTTGAGCAACAC 60
Db 1 GTTGTGCTCTCAGCAAAACAGTGGATTTAAATCTCCTTGACAAAGCTTGAGCAACAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACCAATCAGCAAAATGCAAAATGCAAAATGCAAAATGCAAA 180
Db 121 AAGAAAAAATCATGAAACCAATCAGCAAAATGCAAAATGCAAAATGCAAAATGCAAA 180
QY 181 CTTACGGGGCTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 240
Db 181 CTTACGGGGCTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 240
QY 241 CACCTTCCCAAGCTATGACAAAGCTGACGGTCCGGGAGGGGAGAGCGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGACAAAGCTGACGGTCCGGGAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACATTTGACAAACCGGCTCACCGGCTGGCTGCTGCTGCTGCTGCTGCTGCTGCT 360
Db 301 GTGCACATTTGACAAACCGGCTCACCGGCTGGCTGCTGCTGCTGCTGCTGCTGCTGCT 360
QY 361 TGTGGGAATGACAAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
Db 361 TGTGGGAATGACAAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
QY 421 GCAGTACAGCATCAGATCAGATCAGATCAGATCAGATCAGATCAGATCAGATCAGAT 480
Db 421 GCAGTACAGCATCAGATCAGATCAGATCAGATCAGATCAGATCAGATCAGATCAGAT 480
QY 481 GGTGACAGACGACAAACCAAGACCTTAGGGTCCACTCATTTGTCAGATATCTCC 540
Db 481 GGTGACAGACGACAAACCAAGACCTTAGGGTCCACTCATTTGTCAGATATCTCC 540
QY 541 CAAATTTGTAGATTTCTTCAAGATCTCAGATCTCAGATCTCAGATCTCAGATCTCAG 600
Db 541 CAAATTTGTAGATTTCTTCAAGATCTCAGATCTCAGATCTCAGATCTCAGATCTCAG 600
QY 601 CTGCATAGCACTGGTAGACAGACGCTACGGTACTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCACTGGTAGACAGACGCTACGGTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTAGTGAAGCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACAGTGCAGTGCCTCCAATGACGTGCGCGCGCGCGCGCGCGCGCGCGCG 780
Db 721 AGGGGACTACAGTGCAGTGCCTCCAATGACGTGCGCGCGCGCGCGCGCGCGCGCGCG 780
QY 781 GGTCAACCGTGAATATCCACCATATTCAGAAAGCAAGGTACAGGTGTCCCGTGGG 840
Db 781 GGTCAACCGTGAATATCCACCATATTCAGAAAGCAAGGTACAGGTGTCCCGTGGG 840
QY 841 ACAAAAGGGGACACTGCACTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAAGGGGACACTGCACTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAAGACTGATGAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAAGACTGATGAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAAACATGACTATGGAAGTACACTTGGCT 1020
Db 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAAACATGACTATGGAAGTACACTTGGCT 1020
QY 1021 GGCCTCCAAAGCTGGGCCACCAATGCCAGATCATGTATTTGGTCAGGCGCGCT 1080
Db 1021 GGCCTCCAAAGCTGGGCCACCAATGCCAGATCATGTATTTGGTCAGGCGCGCT 1080
QY 1081 CAGCAGGTGAGCAACGCGACGTCAGAGGGGCGGCTGCTGCTGCTGCTGCTGCTTCT 1140

Db 1081 CAGCAGGTGAGCAACGCGACGTCAGAGGGGCGGCTGCTGCTGCTGCTGCTGCTTCT 1140
QY 1141 GGTCTTCCACTGCTTCTCAAAATTTGATGTAGTCCACTTCCCAACCGGGAAGGCT 1200
Db 1141 GGTCTTCCACTGCTTCTCAAAATTTGATGTAGTCCACTTCCCAACCGGGAAGGCT 1200
QY 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
Db 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
QY 1261 TATCAAAATGAAATAGAAAGAACACAGCCTCATGGACAGAAATTTGAGGGGAGGGAAC 1320
Db 1261 TATCAAAATGAAATAGAAAGAACACAGCCTCATGGACAGAAATTTGAGGGGAGGGAAC 1320
QY 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTCAGATA 1380
Db 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTCAGATA 1380
QY 1381 TTTAGGTACAAATGAGATTTCTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA 1440
Db 1381 TTTAGGTACAAATGAGATTTCTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGCATGTCGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGCATGTCGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCCAACAGAGTCCCGCCACGTGGAAACATTTCTGGAGCTGSCCATCCCAATTCATCA 1560
Db 1501 TCTGCCCAACAGAGTCCCGCCACGTGGAAACATTTCTGGAGCTGSCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGACGACGACAGAAATGAGACCTTCCCGCCCAAGCGTGGCGTCCGGCACCTTGG 1620
Db 1561 GTCCATAGACGACGACAGAAATGAGACCTTCCCGCCCAAGCGTGGCGTCCGGCACCTTGG 1620
QY 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGAAACGTGAAATATAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGAAACGTGAAATATAAGAGCAAAAAA 1679

RESULT 138
ADD77360
ID ADD77360 standard; cDNA; 1679 BP.

XX AC ADD77360;

XX DT 29-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX KW human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
XX KW vulnery; antiarthritic; pericyte cell proliferation;
XX KW pericyte cell differentiation; chondrocyte cell proliferation;
XX KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
XX KW (TNF)-alpha release; dermal fibroblast cell proliferation;
XX KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
XX KW colon tumour; breast tumour; prostate tumour; rectal tumour;
XX KW liver tumour; tissue typing; chromosome mapping; gene mapping;

XX OS Homo sapiens.

XX PN US2003100732-A1.

XX PD 29-MAY-2003.

XX PF 28-AUG-2002; 2002US-00230306.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX Baker KP, Deenoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CX, Wood WI;
XX P-PSDB; ADD77361.
DR WPI; 2004-008982/01.
DR P-PSDB; ADD77361.
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX Claim 2; SEQ ID NO 125; 308pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1150, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
CC PRO1328, PRO1330, PRO1305, PRO1273, PRO1329, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO1341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTGTGTCCTTCAGCAAAAACAGTGATTTAAATCTCCCTTGACCAAGCTTGAGAGCAAC 60
DB 1 GTGTGTCCTTCAGCAAAAACAGTGATTTAAATCTCCCTTGACCAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAAATCATGAAAAACATCAGCAAAAATGCAAAATTCATCTCTTGGGCAAT 180
DB 121 AAGAAAAAAATCATGAAAAACATCAGCAAAAATGCAAAATTCATCTCTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTGCTCTGTGCTCTTTCAAGAGAGTGCCCGGACGGAGATGC 240
DB 181 CTTACGGGGCTGGCTGCTCTGTGCTCTTTCAAGAGAGTGCCCGGACGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGACAAAGTGACGGTCCGGCAGGGGGAGAGCGCCCTCAG 300
DB 241 CACCTTCCCAAGCTATGACAAAGTGACGGTCCGGCAGGGGGAGAGCGCCCTCAG 300

DB 241 CACCTTCCCAAGCTATGACAAAGTGACGGTCCGGCAGGGGGAGAGCGCCCTCAG 300
QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGACCATCTCTA 360
DB 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGACCATCTCTA 360
QY 361 TGTGGAATGACAAAGTGGTGGCTCGATCTCGCTGGTGGTCTTCTGAGCAACACCAAC 420
DB 361 TGTGGAATGACAAAGTGGTGGCTCGATCTCGCTGGTGGTCTTCTGAGCAACACCAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGTC 480
QY 481 GGTGACAGACAGACACCCCAAGACCTCTAGGTCACCTCATTTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGACACCCCAAGACCTCTAGGTCACCTCATTTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCCTAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCCTAC 600
QY 601 CTGCATAGCACTGGTAGACAGGCTACGCTTACTTTGGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCACTGGTAGACAGGCTACGCTTACTTTGGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGAATACCTTGGAAATTCAGGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGACGAATACCTTGGAAATTCAGGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTAGGAGTGGCTCCCAATGACGTGGCCGGCCGGTGGTACGAGAGTAA 780
DB 721 AGGGGACTAGGAGTGGCTCCCAATGACGTGGCCGGCCGGTGGTACGAGAGTAA 780
QY 781 GGTCAACGTGAATATCCACCATACATATTTCAAGAACCAAGGTGACAGTGTCCCGTG 840
DB 781 GGTCAACGTGAATATCCACCATACATATTTCAAGAACCAAGGTGACAGTGTCCCGTG 840
QY 841 ACAAAGGGGACACTCGAGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTCGAGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAGACTGATTTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAAACATGACTATGGGAATACACTTGC 1020
DB 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAAACATGACTATGGGAATACACTTGC 1020
QY 1021 GGCTCTCAACAGCTGGGCCACACCAATGCCAGCATCATGCTATTGTTCCAGGGCCGT 1080
DB 1021 GGCTCTCAACAGCTGGGCCACACCAATGCCAGCATCATGCTATTGTTCCAGGGCCGT 1080
QY 1081 CAGCAGGTTGAGCAACCGGCAACCGTTCGAGAGGGGAGGCTCGCTCGCTCTCTCTTCT 1140
DB 1081 CAGCAGGTTGAGCAACCGGCAACCGTTCGAGAGGGGAGGCTCGCTCGCTCTCTCTTCT 1140
QY 1141 GGTCTTGCACTCTCTCAAAATTTTGTGATGTCCTCCCTCCCAACCGGGAAGGCT 1200
DB 1141 GGTCTTGCACTCTCTCAAAATTTTGTGATGTCCTCCCTCCCAACCGGGAAGGCT 1200
QY 1201 GCCGCCACCAACCAACCAACCAAGCAATGGCAACCGCAGCAACCAATCAGATA 1260
DB 1201 GCCGCCACCAACCAACCAACCAAGCAATGGCAACCGCAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTAAGAAACACAGGCTCATTTGGACAGAAATTTGAGGGGGGGAAC 1320
DB 1261 TATACAAATGAATTAAGAAACACAGGCTCATTTGGACAGAAATTTGAGGGGGGGAAC 1320
QY 1321 AAGAAATATCTTTGGGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTCCTTTGAGATA 1380
DB 1321 AAGAAATATCTTTGGGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTCCTTTGAGATA 1380

```
QY 1381 TTTAGTACAATGGAGTTTCTTTTCCCAACCGGAAGAACACAGACACACCGGCTTGG 1440
DB 1381 TTTAGTACAATGGAGTTTCTTTTCCCAACCGGAAGAACACAGACACACCGGCTTGG 1440
QY 1441 CCCACTGCAAGTGCATCTGCAACTCTTTTGTGCGAGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGTGCATCTGCAACTCTTTTGTGCGAGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACAGTGAACATTTCTGGAGTGGCCATCCCAATTCAATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCACAGTGAACATTTCTGGAGTGGCCATCCCAATTCAATCA 1560
QY 1561 GTCCATAGAGACGACAGATGAGACTTCCGCGCCACAGCGTGGCGGCACTTTG 1620
DB 1561 GTCCATAGAGACGACAGATGAGACTTCCGCGCCACAGCGTGGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACCGCGGTGTGTGTAACCTGGAATATAAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACACCGCGGTGTGTGTAACCTGGAATATAAAGAGCAAAAAA 1679

RESULT 139
AD20507
ID ADE20507 standard; cDNA; 1679 BP.
AC ADE20507;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss; cytosstatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
SS US2003100733-A1.
PN
PD 29-MAY-2003.
XX
PF 28-AUG-2002; 2002US-00230426.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
DR WPI; 2004-008983/01.
DR P-PSDB; ADE20508.
XX
PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX
PS Claim 2; Fig 125; 308pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
```

```
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1358,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO3441, PRO1801, PRO1409, PRO13543, PRO3444, PRO4332,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO329, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
```

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

```
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTTCAGCAAAACAGTGGATTTAAATCTCTTCGACAAAGTTTGAGAGCAACAC 60
DB 1 GTTGTGCTTTCAGCAAAACAGTGGATTTAAATCTCTTCGACAAAGTTTGAGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACCTGACAAAAAGAGAAAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACCTGACAAAAAGAGAAAAAGAAAG 120
QY 121 AAGAAAAAATATGAAAAACCATTCAGCCAAATGCAAAATGCAATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATATGAAAAACCATTCAGCCAAATGCAAAATGCAATCTATCTCTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTGCTCTGTGTCTCTTCCAGGAGTCCCGTGGCGAGCGAGATGC 240
DB 181 CTTACGGGGCTGGCTGCTCTGTGTCTCTTCCAGGAGTCCCGTGGCGAGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTTCAG 300
DB 241 CACCTTCCCAAGCTATGGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTTCAG 300
QY 301 GTGCACCTATTGACAAACCGGGTCCACCGGGTGGCTGGCTAAACCGCAGCACCCTCTCTA 360
DB 301 GTGCACCTATTGACAAACCGGGTCCACCGGGTGGCTGGCTAAACCGCAGCACCCTCTCTA 360
QY 361 TGCTGGGAATGACAAAGTGGTGGCTCTCGCGTGGTCTCTCTGAGCAACACCCAAAC 420
DB 361 TGCTGGGAATGACAAAGTGGTGGCTCTCGCGTGGTCTCTCTGAGCAACACCCAAAC 420
QY 421 GCAGTAGAGATCGAGATCCAGAACGTGGATGTGTATGACAGGGGCTTACACCTGCTC 480
DB 421 GCAGTAGAGATCGAGATCCAGAACGTGGATGTGTATGACAGGGGCTTACACCTGCTC 480
QY 481 GGTGCAGACAGACAAACCAACCGGAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCAGACAGACAAACCAACCGGAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
```

541 CAAAATTGTAGAGATTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
541 CAAAATTGTAGAGATTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
601 CTGCATAGCAACTGCTGACAGAGCCTACGTTTACTTTGGAGACACATCTCTCCCAAAGC 660
601 CTGCATAGCAACTGCTGACAGAGCCTACGTTTACTTTGGAGACACATCTCTCCCAAAGC 660
661 GGTGGCTTTGTGAGTGAAGACGAATCTTTGGAATTCAGGGCATCACCCGGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGACGAATCTTTGGAATTCAGGGCATCACCCGGGAGCAGTC 720
721 AGGGGACTACGAGTGCAGTCCCAATGAGTGGCGCGCCGTTGATCGGAGAGTAAA 780
721 AGGGGACTACGAGTGCAGTCCCAATGAGTGGCGCGCCGTTGATCGGAGAGTAAA 780
781 GGTCAACCGTGAACCTATCCACCATATCTTTGAGAACCAAGGTCACAGGTCTCCCGTGGG 840
781 GGTCAACCGTGAACCTATCCACCATATCTTTGAGAACCAAGGTCACAGGTCTCCCGTGGG 840
841 ACMAAGGGGACATGCGAGTGTGAGCTCAGCTGAGCTGCCCTCAGCAGCAATTCAGTGGTA 900
841 ACMAAGGGGACATGCGAGTGTGAGCTCAGCTGAGCTGCCCTCAGCAGCAATTCAGTGGTA 900
901 CAAGGATCACAAAAGACTGATTGAGGAAAGAAAGGGGTGAAAGTGGAAACACAGACCTTT 960
901 CAAGGATCACAAAAGACTGATTGAGGAAAGAAAGGGGTGAAAGTGGAAACACAGACCTTT 960
961 CTTCTCAAACTCATCTTCTTCAATGCTCTGACATGACTATGCGGAACTACACTTTCCT 1020
961 CTTCTCAAACTCATCTTCTTCAATGCTCTGACATGACTATGCGGAACTACACTTTCCT 1020
1021 GGCCTCCAAAGCTGGGCCCAACCAATGCCAGCATCATGCTATTTGGTCCAGCGCCGT 1080
1021 GGCCTCCAAAGCTGGGCCCAACCAATGCCAGCATCATGCTATTTGGTCCAGCGCCGT 1080
1081 CAGCAGTGTGACACGCGAGCTGAGGAGGCGAGGCTGCTGCTGCTGCTGCTTCT 1140
1081 CAGCAGTGTGACACGCGAGCTGAGGAGGCGAGGCTGCTGCTGCTGCTGCTTCT 1140
1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCCAACCGGGAAGGCT 1200
1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCCAACCGGGAAGGCT 1200
1201 GCGGCCACACACCAACCAACACAGCAATGGCAACACGAGCAGCAACCAATCAGATA 1260
1201 GCGGCCACACACCAACCAACACAGCAATGGCAACACGAGCAGCAACCAATCAGATA 1260
1261 TATCAAAATGAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGAAC 1320
1261 TATCAAAATGAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGAAC 1320
1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1381 TTTAGGTACATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCAGCACCCCGCTTGA 1440
1381 TTTAGGTACATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCAGCACCCCGCTTGA 1440
1441 CCCACTGAAGTGCATCGTGCACCTCTTTGGTCCAGTGTGGGCAAGGCTCAGCCTC 1500
1441 CCCACTGAAGTGCATCGTGCACCTCTTTGGTCCAGTGTGGGCAAGGCTCAGCCTC 1500
1501 TCTGCCACAGAGTGCCTCCCGTGGACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
1501 TCTGCCACAGAGTGCCTCCCGTGGACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
1561 GTCCATAGAGACGAACAGAAAGACCTTCCGGCCCAAGCGTGGCGTGGCGGACCTTG 1620
1561 GTCCATAGAGACGAACAGAAAGACCTTCCGGCCCAAGCGTGGCGTGGCGGACCTTG 1620
1621 GTAGACTGTGCCACACGCGCTGTGTTGTAACGTGAAATATAAAGAGCAAAAAA 1679

Db 1621 GTAGACTGTGCCACACGCGCTGTGTTGTGAACGTGAAATATAAAGAGCAAAAAA 1679

RESULT 140

ADD75572

ID ADD75572 standard; cDNA; 1679 BP.

XX ADD75572;

XX 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #63.

XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.

XX Homo sapiens.

XX US2003100064-A1.

XX 29-MAY-2003.

XX 12-AUG-2002; 2002US-00219060.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021086.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2004-008955/01.

XX P-PSDB; ADD75573.

XX New nucleic acid, for the manufacture of a medicament for diagnosing or
treating tumor or for measuring or detecting expression of an associated
gene.

XX Claim 2; Fig 125; 308pp; English.

XX The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers and in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes, the PRO polypeptides are useful as
XX molecular markers for protein electrophoresis, and in tissue typing. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX at seqdata.uspto.gov/sequence.html.

XX

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTTTCAGCAAAACAGTGGATTTAAATCTCTCTGCAAAAGGAGTGGAGCAAC 60
Db 1 GTTGTGCTTTCAGCAAAACAGTGGATTTAAATCTCTCTGCAAAAGGAGTGGAGCAAC 60

Qy 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

Qy 121 AAGAAAAAATCATGAAACCAATCCAGCCAAATATGCAATTTCTCTTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAACCAATCCAGCCAAATATGCAATTTCTCTTTGGGCAAT 180

Qy 181 CTTCAAGGGGCTGCTCTCTGTCTCTCTTCCAAAGAGTSCCGTGGGAGCGGATGC 240
Db 181 CTTCAAGGGGCTGCTCTCTGTCTCTCTTCCAAAGAGTSCCGTGGGAGCGGATGC 240

Qy 241 CACCTTCCCAAGCTATGACACAGTGAAGTCCGCGAGGGGAGAGCGCCCTCAG 300
Db 241 CACCTTCCCAAGCTATGACACAGTGAAGTCCGCGAGGGGAGAGCGCCCTCAG 300

Qy 301 GTGCACTATTGCAAAACCGGGTACCCGGGTGGCTTAAACCGGACACCATCTCTA 360
Db 301 GTGCACTATTGCAAAACCGGGTACCCGGGTGGCTTAAACCGGACACCATCTCTA 360

Qy 361 TGCTGGGAATGACAAGTGGTGGTGGTCTCTGGTGGTCTCTGAGCAACCAAC 420
Db 361 TGCTGGGAATGACAAGTGGTGGTGGTCTCTGGTGGTCTCTGAGCAACCAAC 420

Qy 421 GCAGTACAGCATCGAGTACAGAAACGTTGGTGTATGACAGGGGCTTTACACCTGC 480
Db 421 GCAGTACAGCATCGAGTACAGAAACGTTGGTGTATGACAGGGGCTTTACACCTGC 480

Qy 481 GGTGCAAGCAGCAACCAACAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
Db 481 GGTGCAAGCAGCAACCAACAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540

Qy 541 CAAATTTGTAGATTTCTTCAGATATCTCATTTAATGAAGGAAACAAATATTAGCCTC 600
Db 541 CAAATTTGTAGATTTCTTCAGATATCTCATTTAATGAAGGAAACAAATATTAGCCTC 600

Qy 601 CTGATAGCACTGGTAGACAGAGCCTACGGTTACTTTGAGACACATCTCTCCCAAGC 660
Db 601 CTGATAGCACTGGTAGACAGAGCCTACGGTTACTTTGAGACACATCTCTCCCAAGC 660

Qy 661 GGTGGCTTTGTGAGTGAAGACGATATCTTGAATTTGAGGATCAGCGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGACGATATCTTGAATTTGAGGATCAGCGGAGCAGTC 720

Qy 721 AGGGGACTACAGTGCAGTGCCTCAATGAGTGGCGCGCGCGCGTGTACGGAGTAA 780
Db 721 AGGGGACTACAGTGCAGTGCCTCAATGAGTGGCGCGCGCGCGTGTACGGAGTAA 780

Qy 781 GGTCAAGCTGAACTATCCACATACATTTGAGAGCAAGGTTACAGTGTCTCCCGTGG 840
Db 781 GGTCAAGCTGAACTATCCACATACATTTGAGAGCAAGGTTACAGTGTCTCCCGTGG 840

Qy 841 ACAAAAGGGGACCTGAGTGTGAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAAGGGGACCTGAGTGTGAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900

Qy 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960

Qy 961 CCTCTCAAACTCATCTTTCAATGTCTCTGAACTGATGGGAACTACATTCGCT 1020
Db 961 CCTCTCAAACTCATCTTTCAATGTCTCTGAACTGATGGGAACTACATTCGCT 1020

RESULT 141

ADD74088
ID ADD74088 standard; cDNA; 1679 BP.

XX AC ADD74088;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #63.

XX KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide; tumour; cancer; lung; colon; breast; prostate; rectum; liver;
XX KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
XX KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder; arthritis; sports injury; cytostatic; antiarthritic.

XX OS Homo sapiens.

XX PN US2003100708-A1.

XX PD 29-MAY-2003.

XX PF 09-AUG-2002; 2002US-00216160.

XX PR 01-AUG-2000; 2000US-0222425P.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

09-APR-2002; 2002US-00119480.
(GETH) GENENTECH INC.
Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;
Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
P-PSDB; ADD74089.
WPI; 2004-008958/01.
New secreted and transmembrane PRO polypeptide useful for preparing a
medicament for treating a condition that is responsive to the PRO
polypeptide or anti-PRO antibody, e.g. cancer.
Claim 2; Fig 125; 308pp; English.
The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioreactors. They are particularly useful for
detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
prostate tumour, rectal tumour or liver tumour) in a mammal, for
stimulating the release of tumour necrosis factor (TNF)-alpha from human
blood, for stimulating the proliferation or differentiation of
chondrocyte cells, for stimulating the proliferation of or gene
expression in pericyte cells or for stimulating the proliferation of
normal human dermal fibroblasts. The PRO nucleic acids are useful as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA, in preparing PRO polypeptides by recombinant
technology, in generating transgenic animals or knock-out animals which
may be used in the development and screening of therapeutically useful
reagents, in gene therapy, in chromosome identification, as chromosome
markers and in generating probes. The PRO polypeptides, or anti-PRO
antibodies, are useful for preparing a medicament for treating a
condition which is responsive to the PRO polypeptides or anti-PRO
antibodies, such as pericyte-associated tumours and bone and/or cartilage
disorders (e.g. arthritis, sports injuries), involving inducing the re-
differentiation of chondrocytes. The PRO polypeptides are useful as
molecular markers for protein electrophoresis, and in tissue typing. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent is also available in electronic format
at seqdata.uspto.gov/sequence.html.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 GTTGTCTCTTTCAGCAAAACAGTGGATTAAATCTCTTGTGCAAGCTTGAGCAACAC 60
1 GTTGTCTCTTTCAGCAAAACAGTGGATTAAATCTCTTGTGCAAGCTTGAGCAACAC 60
61 AATCTATCAGGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 120
61 AATCTATCAGGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 120
121 AGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 180
121 AGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 180
181 CTTTCAGGGGTGGTCTGTCTGTCTTCTTCAAGAGTGCCCGTCCGAGCGGAGATGC 240
181 CTTTCAGGGGTGGTCTGTCTGTCTTCTTCAAGAGTGCCCGTCCGAGCGGAGATGC 240
241 CACCTTCCCAAGCTATGAGCAACATCGAGCGGTCCGAGCGGAGAGAGAGAGAGAG 300
241 CACCTTCCCAAGCTATGAGCAACATCGAGCGGTCCGAGCGGAGAGAGAGAGAGAG 300
301 GTGCACTATGAGCAACATCGAGCGGTCCGAGCGGAGAGAGAGAGAGAGAGAGAG 360
301 GTGCACTATGAGCAACATCGAGCGGTCCGAGCGGAGAGAGAGAGAGAGAGAGAG 360

361 TGCTGGGAATGACAAAGTGGTGCTCGATCTCGCTGGTGTCTTCTTGAGCAACACCCAAAC 420
361 TGCTGGGAATGACAAAGTGGTGCTCGATCTCGCTGGTGTCTTCTTGAGCAACACCCAAAC 420
421 GCAGTACACATCGAGATCCAGAACGTGTGATGATGACAGAGGCGCTTACACCTGTCTC 480
421 GCAGTACACATCGAGATCCAGAACGTGTGATGATGATGACAGAGGCGCTTACACCTGTCTC 480
481 GGTGACAGACAGAACCAACCCCAAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
481 GGTGACAGACAGAACCAACCCCAAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
601 CTGCATAGCAACTGCTAGACAGAGCCCTACCGTTACTTTGGAGACACATCTCTCCAAAGC 660
601 CTGCATAGCAACTGCTAGACAGAGCCCTACCGTTACTTTGGAGACACATCTCTCCAAAGC 660
661 GGTGCTTTGTTGAGTGAAGAGATCTTGAATTCAGGGCATCACCCGGGAGCAGTC 720
661 GGTGCTTTGTTGAGTGAAGAGATCTTGAATTCAGGGCATCACCCGGGAGCAGTC 720
721 AGGGGACTACGAGTGCAGTGCCTTCAATGACGTGGCGCGCGCTGGTACGGAGAGTAAA 780
721 AGGGGACTACGAGTGCAGTGCCTTCAATGACGTGGCGCGCGCTGGTACGGAGAGTAAA 780
781 GGTACCGTGAATCTACCACTACATTAATTCAGAGCCAGAGGTACAGGTGTCCTGGTGG 840
781 GGTACCGTGAATCTACCACTACATTAATTCAGAGCCAGAGGTACAGGTGTCCTGGTGG 840
841 ACAAAGGGGACACTGCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
841 ACAAAGGGGACACTGCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
901 CAAGGATGACAAAGACTGATTAAGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGCTT 960
901 CAAGGATGACAAAGACTGATTAAGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGCTT 960
961 CCTCTCAAAACTCATCTTCTTCAATGCTCTGAAACATGACTATGGGAACTACACTTGCCT 1020
961 CCTCTCAAAACTCATCTTCTTCAATGCTCTGAAACATGACTATGGGAACTACACTTGCCT 1020
1021 GGCTCTCAACAGCTGGGCGACACCAATGCGAGCATCTGCTATTTGGTCCAGGCGCGCT 1080
1021 GGCTCTCAACAGCTGGGCGACACCAATGCGAGCATCTGCTATTTGGTCCAGGCGCGCT 1080
1081 CAGCGAGTGCAGCAACGCGACGTCGAGGAGGCGAGCTGCTGCTGCTGCTGCTCTTCT 1140
1081 CAGCGAGTGCAGCAACGCGACGTCGAGGAGGCGAGCTGCTGCTGCTGCTGCTCTTCT 1140
1141 GGTCTTGCACTGCTTCTCAAAATTTTGTGATGTCGCTTCTCCCAACCCCGGAGAGGCT 1200
1141 GGTCTTGCACTGCTTCTCAAAATTTTGTGATGTCGCTTCTCCCAACCCCGGAGAGGCT 1200
1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1261 TATACAAATGAATTAAGAGAAACAAGCTCTATGGGACAGAAATTTGAGGGAGGGAAC 1320
1261 TATACAAATGAATTAAGAGAAACAAGCTCTATGGGACAGAAATTTGAGGGAGGGAAC 1320
1321 AAGAGATCTTTGCGGGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
1321 AAGAGATCTTTGCGGGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACCGGGAAGAACACAGCAGACCCCGCTTGA 1440
1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACCGGGAAGAACACAGCAGACCCCGCTTGA 1440
1441 CCCACTGCAAGTGCATCGTGCAACCTCTTTGGTGCAGTGTGGGAGAGGCTCAGCCTC 1500

1441	CCCAC	TGCAAGCTCAT	CGTGC	AACCTCTTT	GTGTC	CAGTGTG	GGCAAGGCTCAG	CCTC	1500
	DB								
1501	TCTGCC	CACAGAGTG	CCCCC	CACGTGG	AACATTT	TGGAGCTG	GCATCC	CAAAATCA	1560
	QY								
1501	TCTGCC	CACAGAGTG	CCCCC	CACGTGG	AACATTT	TGGAGCTG	GCATCC	CAAAATCA	1560
	DB								
1561	GTCCAT	ATAGACG	MAAGA	ATGAG	ACCTT	CCGGCC	CAAGCGT	GGCGTGGG	1620
	QY								
1561	GTCCAT	ATAGACG	MAAGA	ATGAG	ACCTT	CCGGCC	CAAGCGT	GGCGTGGG	1620
	DB								
1621	GTGAG	CTGTGCC	ACCAC	CGGCGT	GTGTT	GTGA	ACGTGA	ATAAAG	1679
	QY								
1621	GTGAG	CTGTGCC	ACCAC	CGGCGT	GTGTT	GTGA	ACGTGA	ATAAAG	1679
	DB								

RESULT 142
ADD74334
ID ADD74334 standard; cDNA; 1679 BP.

AC ADD74334;

29-JAN-2004 (first entry)

XX
DE Human PRO polynucleotide #63.

Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
 tumour; cancer; lung; colon; trnf-; prostate; rectum; liver;
 tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
 pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
 arthritis; sports injury; cyostatic; antiarthritic.

XX
OS
Homo sapiens.

PN US2003100709-A1.

PD 29-MAY-2003.

09-AUG-2002; 2002US-00216162.

25-JUL-2000: 2000US-0220585P.

PR 01-JUN-2001; 2001WC-US017800
PR 29-JUN-2001; 2001WC-US021066.

XX
FR 2002-APR-09; 2002-APR-09

PA (GETH) GENENTECH INC.
XX

PI Baker KP, Desnoyers L
PT Grimaldi JC, Gurnev A

XX WPI; 2004-008959/01.
DR P-PSDB: ADD74335.
XX

XX New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.

xx
PS Claim 2: Fig 125; 309pp; English.

The invention relates to human PRO polypeptides (secreted and transmembrane polypeptides) and the PRO polynucleotides encoding them. The PRO polypeptides and polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. They are particularly useful for detecting tumours (e.g. lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour) in a mammal, for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells or for stimulating the proliferation of normal human dermal fibroblasts. The PRO nucleic acids are useful as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant technology, in generating transgenic animals or knock-out animals which

Db 781 GGTACCGTGAATATCCACCATACATTTTCAGAACCCAGGTTACAGGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACATGCGAGTGTGAAGCTTCAGAGCTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACATGCGAGTGTGAAGCTTCAGAGCTCCCTCAGCAGAAATTCAGTGGTA 900
Qy 901 CAAGGATCAAAAAGACATGATTGAAGGAAAGAAAGGGGTGAAGTGAAGAACAGACCTTT 960
Db 901 CAAGGATCAAAAAGACATGATTGAAGGAAAGAAAGGGGTGAAGTGAAGAACAGACCTTT 960
Qy 961 CCTCTCAAAATCATCTTCTTCAATGTCTCTGAACATGACATATGGGAATACACTTCGGT 1020
Db 961 CCTCTCAAAATCATCTTCTTCAATGTCTCTGAACATGACATATGGGAATACACTTCGGT 1020
Qy 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGT 1080
Qy 1081 CAGCAGGTGAGCAACGCGCATGTCGAGGAGGCGAGGTCGCTGCTGCTGCTGCTCTTCT 1140
Db 1081 CAGCAGGTGAGCAACGCGCATGTCGAGGAGGCGAGGTCGCTGCTGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGACCTGCTTCTCAAAATTTTGAATGAGTGCACCTTCCCGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAAAATTTTGAATGAGTGCACCTTCCCGGGAAGGCT 1200
Qy 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Qy 1261 TATACAAATGAATTTAGAGAAACACACGCTTCAGGAGCAAAATTTGAGGAGGGAAC 1320
Db 1261 TATACAAATGAATTTAGAGAAACACACGCTTCAGGAGCAAAATTTGAGGAGGGAAC 1320
Qy 1321 AAAGAATACTTTGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCTTTCAGATA 1380
Db 1321 AAAGAATACTTTGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCTTTCAGATA 1380
Qy 1381 TTTAGTACATGAGTTTCTTTTCCAAACGGGAGAACACACAGCAGCAGCCGCTTGGGA 1440
Db 1381 TTTAGTACATGAGTTTCTTTTCCAAACGGGAGAACACACAGCAGCAGCCGCTTGGGA 1440
Qy 1441 CCCACTGCAAGCTGATCGTGAACCTCTTTGGTGCCAGTGTGGGCAAGGCTCAGGCTC 1500
Db 1441 CCCACTGCAAGCTGATCGTGAACCTCTTTGGTGCCAGTGTGGGCAAGGCTCAGGCTC 1500
Qy 1501 TGTGCCACAGAGTGCCTCCAGTGGACATCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TGTGCCACAGAGTGCCTCCAGTGGACATCTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGCAACAGAAATGAGACCTTCCGGGCCAAGCGTGGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGCAACAGAAATGAGACCTTCCGGGCCAAGCGTGGCGTGGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACAGCGCGTGTGTGAAACGTGAAATTAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACAGCGCGTGTGTGAAACGTGAAATTAAGAGCAAAAAAAA 1679

RESULT 143

ADD76064

ID ADD76064 standard; cDNA; 1679 BP.

AC ADD76064;

XX ADD76064;

DT 29-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO337 cDNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;

(TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
gene therapy.

XX Homo sapiens.

XX OS2003100718-AL.

XX 29-MAY-2003.

XX PF 13-AUG-2002; 2002US-00219467.

XX 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

Baker KF, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

WPI; 2004-008968/01.

P-PSDB; ADD76065.

New secreted and transmembrane PRO polypeptides and nucleic acids, useful
in gene therapy, or for preparing a medicament for treating a condition
that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
cancer.

Claim 2; SEQ ID NO 125; 308pp; English.

The invention describes an isolated PRO (secreted and transmembrane)
polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
useful for stimulating the proliferation of or gene expression in
pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
for stimulating the proliferation or differentiation of chondrocyte
cells. PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
are useful for stimulating the release of tumour necrosis factor (TNF)-
alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO1214,
PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO1080,
PRO1278, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
stimulating the proliferation of normal human dermal fibroblasts cells.

PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
inhibiting the proliferation of normal human dermal fibroblast cells. PRO
polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
are useful for detecting the presence of tumour in a mammal which
involves comparing the level of expression of the above PRO polypeptides
in a test sample of cells taken from the mammal, and a control sample of
normal cells of the same cell type, where a higher level of expression of
the PRO polypeptides in the test sample as compared to the control sample
is indicative of the presence of tumour in the mammal. The tumour is lung
tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
liver tumour. (I) is useful as molecular weight markers, for tissue
typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
useful for chromosome and gene mapping or gene therapy. (II) is useful
for generating transgenic animals or knock-out animals which are useful
for screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
is useful for treating bone and/or cartilage disorders (e.g., arthritis,
sport injuries). This sequence encodes a human secreted and transmembrane
PRO polypeptide.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query March 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTTCAGCAAAACAGTGAATTAATCTCTTCGACAAAGCTTGAGCAACAC 60
Db 1 GTTGTGCTTTCAGCAAAACAGTGAATTAATCTCTTCGACAAAGCTTGAGCAACAC 60

QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

QY 121 AAGAAAAAATCATGAAAAACATCAGCCAAAAATGCAAAATTCATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACATCAGCCAAAAATGCAAAATTCATCTCTTGGGCAAT 180

QY 181 CTTTCAGGGGCTGGCTCTGCTCTCTTCTCAAGAGTGCCCGTCCGACGAGATGC 240
Db 181 CTTTCAGGGGCTGGCTCTGCTCTCTTCTCAAGAGTGCCCGTCCGACGAGATGC 240

QY 241 CACCTTCCCAAGCTATGGAACAAAGTGCCTCGGCAAGGGGGAGAGCGCCCTCAG 300
Db 241 CACCTTCCCAAGCTATGGAACAAAGTGCCTCGGCAAGGGGGAGAGCGCCCTCAG 300

QY 301 GTGCACTATGACACCGGCTCACCGGCTGCTGCTTAACCGCAGCACCATCTCTA 360
Db 301 GTGCACTATGACACCGGCTCACCGGCTGCTGCTTAACCGCAGCACCATCTCTA 360

QY 361 TGTGGAATGACAAAGTGTGCTGCTCTCTCGCTGCTCTTCTGAGCAACACCCAAAC 420
Db 361 TGTGGAATGACAAAGTGTGCTGCTCTCTCGCTGCTCTTCTGAGCAACACCCAAAC 420

QY 421 GCAGTACAGATCAGATCAGAAAGTGTGATGACAGAGGCGCTTACACCTGCTC 480
Db 421 GCAGTACAGATCAGATCAGAAAGTGTGATGACAGAGGCGCTTACACCTGCTC 480

QY 481 GGTGCAAGACAAACCAAGACCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCAAGACAAACCAAGACCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540

QY 541 CAAAAATTGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAAATTAGCTCAC 600
Db 541 CAAAAATTGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAAATTAGCTCAC 600

QY 601 CTGCATAGCAACTGTGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGTGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660

QY 661 GGTGCTTTGTGAGTGAAGACAAATCTGGAATTCAGGGCATCACCCGGAGCAGTC 720
Db 661 GGTGCTTTGTGAGTGAAGACAAATCTGGAATTCAGGGCATCACCCGGAGCAGTC 720

QY 721 AGGGGACTAGTGCAGTGCCTCCCAATGACGTGGCGCGCTGTTACGAGAGTAA 780
Db 721 AGGGGACTAGTGCAGTGCCTCCCAATGACGTGGCGCGCTGTTACGAGAGTAA 780

QY 781 GGTACCGTGAATTCACCAATPACATTTTCAAGGCAAGGGTACAGGTGTCCCGTGG 840
Db 781 GGTACCGTGAATTCACCAATPACATTTTCAAGGCAAGGGTACAGGTGTCCCGTGG 840

QY 841 ACAAGGGGACACTGAGTGAAGCCTCAGCAGTCCCTCAGCAGATTTCCAGTGTGA 900
Db 841 ACAAGGGGACACTGAGTGAAGCCTCAGCAGTCCCTCAGCAGATTTCCAGTGTGA 900

QY 901 CAAGGATGACAAAGACTGTTGAAGGAAAGAAAGGGTGAAGTGGAAAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGTTGAAGGAAAGAAAGGGTGAAGTGGAAAAACAGACCTTT 960

QY 961 CCTCTCAAACTCATCTTCTCAATCTCTGACATGACTATGGAACTACACTTGGCT 1020
Db 961 CCTCTCAAACTCATCTTCTCAATCTCTGACATGACTATGGAACTACACTTGGCT 1020

QY 1021 GGCTTCAAAAGTGGGCGACACCAATGCGACATCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCTTCAAAAGTGGGCGACACCAATGCGACATCATGCTATTTGGTCCAGGCGCGT 1080

QY 1081 CAGCAGGTGAGCAACGCGACAGCTCGAGGAGGGCAGGCTCGCTGTGCTCTTCT 1140
Db 1081 CAGCAGGTGAGCAACGCGACAGCTCGAGGAGGGCAGGCTCGCTGTGCTCTTCT 1140

QY 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGTATGTAGTGCCACTTCCCCACCCGGGAAAGGT 1200
Db 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGTATGTAGTGCCACTTCCCCACCCGGGAAAGGT 1200

QY 1201 GCCGCCACACACACACCAACCAACAGCAATGGCAACACCCGACAGCAACCAATCAGATA 1260
Db 1201 GCCGCCACACACACACCAACCAACAGCAATGGCAACACCCGACAGCAACCAATCAGATA 1260

QY 1261 TATACAAATGAAATTAAGAGAAAACACAGCCTCATGCGACAGAAATTTGAGGGAGGGAAC 1320
Db 1261 TATACAAATGAAATTAAGAGAAAACACAGCCTCATGCGACAGAAATTTGAGGGAGGGAAC 1320

QY 1321 AAGAAATACCTTTGGGGGGAAGAGTTTTTAAAAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
Db 1321 AAGAAATACCTTTGGGGGGAAGAGTTTTTAAAAAAGAAATTTGAAATTTGCTTTGCAGATA 1380

QY 1381 TTTAGGTACAAATGGAGTTTTTCTTTTCCCAAACGGGGAAGAACACAGCACACCCGGCTTGA 1440
Db 1381 TTTAGGTACAAATGGAGTTTTTCTTTTCCCAAACGGGGAAGAACACAGCACACCCGGCTTGA 1440

QY 1441 CCCACTGCAAGCTGCATCGTGAACCTCTTTGGTGGCAGTGTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGCATCGTGAACCTCTTTGGTGGCAGTGTGGGCAAGGCTCAGCCTC 1500

QY 1501 TCTGCCACAGAGTGCCTCCCAACGTCGAAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCCAACGTCGAAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560

QY 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCGGGCCAAGCGTGGCGCTGGGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCGGGCCAAGCGTGGCGCTGGGGCACTTTG 1620

QY 1621 GTACACTGTGCCACACCGCGTGTGTTGTAAGCTGAAATTAAGAGCAAAAAAAA 1679
Db 1621 GTACACTGTGCCACACCGCGTGTGTTGTAAGCTGAAATTAAGAGCAAAAAAAA 1679

RESULT 144

ADD85556

ID ADD85556 standard; cDNA; 1679 BP.

XX AC ADD85556;

XX XX 29-JAN-2004 (first entry)

XX XX Novel human secreted and transmembrane protein PRO337 cDNA.

XX XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
XX KW vulnary; antiarthritic; pericyte cell proliferation;
XX KW pericyte cell differentiation; chondrocyte cell proliferation;
XX KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
XX KW (TNF)-alpha release; dermal fibroblast cell proliferation;
XX KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
XX KW colon tumour; breast tumour; prostate tumour; rectal tumour;
XX KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX KW gene therapy.

XX OS Homo sapiens.

XX XX US2003100721-A1.

XX XX 29-MAY-2003.

XX PD 13-AUG-2002; 2002US-00219473.

XX XX 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX	(GETH) GENENTECH INC.	
PA	Baker KP, Desnoyers L, Gerritsen MB, Goddard A, Godowski PJ;	
PI	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;	
PP	WPI; 2004-008971/01.	
XX	P-PSDB; ADD85557.	
DR		
XX	New secreted and transmembrane PRO polypeptides and nucleic acids, useful	
PT	in gene therapy, or for preparing a medicament for treating a condition	
PT	that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.	
PT	cancer.	
XX		
PS	Claim 2; SEQ ID NO 125; 308pp; English.	
XX		
CC	The invention describes an isolated PRO (secreted and transmembrane)	
CC	polypeptide (I). PRO982, PRO1160, PRO1197 or PRO1329 polypeptide are	
CC	useful for stimulating the proliferation of or gene expression in	
CC	pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful	
CC	for stimulating the proliferation or differentiation of chondrocyte	
CC	cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide	
CC	are useful for stimulating the release of tumour necrosis factor (TNF)-	
CC	alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,	
CC	PRO247, PRO337, PRO536, PRO363, PRO531, PRO1083, PRO840, PRO1080,	
CC	PRO1478, PRO1134, PRO825, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,	
CC	PRO1025, PRO1181, PRO1186, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,	
CC	PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,	
CC	PRO1343, PRO1370, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,	
CC	PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,	
CC	PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for	
CC	stimulating the proliferation of normal human dermal fibroblasts cells.	
CC	PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,	
CC	PRO5723, PRO5725, PRO7154 or PRO7425 polypeptide are useful for	
CC	inhibiting the proliferation of normal human dermal fibroblast cells. PRO	
CC	polypeptides such as PRO6004, PRO4981, PRO1714, PRO5778, PRO4332, etc.,	
CC	are useful for detecting the presence of tumour in a mammal which	
CC	involves comparing the level of expression of the above PRO polypeptides	
CC	in a test sample of cells taken from the mammal, and a control sample of	
CC	normal cells of the same cell type, where a higher level of expression of	
CC	the PRO polypeptides in the test sample as compared to the control sample	
CC	is indicative of the presence of tumour in the mammal. The tumour is lung	
CC	tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or	
CC	liver tumour. (I) is useful as molecular weight markers, for tissue	
CC	typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is	
CC	useful for chromosome and gene mapping or gene therapy. (II) is useful	
CC	for generating transgenic animals or knock-out animals which are useful	
CC	screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide	
CC	is useful for treating bone and/or cartilage disorders (e.g., arthritis,	
CC	sport injuries). This sequence encodes a human secreted and transmembrane	
CC	PRO polypeptide.	
XX		
SQ	Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;	
	Query Match 100.0%; Score 1679; DB 1; Length 1679;	
	Best Local Similarity 100.0%; Pred. No. 6.7e-05;	
	Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0	
QY	1 GTTGTGTCCTTCAGCAAAACAGTGGATTTAATCTCTTCGCAAGCTTGAGAGCAACAC 60	
DB		
DB	1 GTTGTGTCCTTCAGCAAAACAGTGGATTTAATCTCTTCGCAAGCTTGAGAGCAACAC 60	
QY	61 AATCTATCAGGAAGAAAGAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAG 120	
DB		
DB	61 AATCTATCAGGAAGAAAGAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAG 120	
QY	121 AAGAAAAAANAATCATGAAACCAATCCAGCCAAAAATGCAGATTCTATCTCTTGGGCAAT 180	
DB		
DB	121 AAGAAAAAANAATCATGAAACCAATCCAGCCAAAAATGCAGATTCTATCTCTTGGGCAAT 180	
QY	181 CTTACGGGGCTGGTCTGTGTGTCCTTCCAAAGAGTCCCGTCGACGAGGAGATGC 240	
DB		
DB	181 CTTACGGGGCTGGTCTGTGTGTCCTTCCAAAGAGTCCCGTCGACGAGGAGATGC 240	

QY 1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAATTCGAAATTCGCTTGCAGATA 1380
 Db 1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAATTCGAAATTCGCTTGCAGATA 1380
 QY 1381 TTATGATCAATGAGATTTCTTTCCCAACCGGGAAGAACACAGACACACCGGCTTGA 1440
 Db 1381 TTATGATCAATGAGATTTCTTTCCCAACCGGGAAGAACACAGACACACCGGCTTGA 1440
 QY 1441 CCACATGCAAGCTGCATCTGCAACCTCTTTGTGCGCAGTGTGGGCAAGGGCTCAGCCTC 1500
 Db 1441 CCACATGCAAGCTGCATCTGCAACCTCTTTGTGCGCAGTGTGGGCAAGGGCTCAGCCTC 1500
 QY 1501 TCTGCCACAGAGTGCCTCCCAACGTCGAAATCTTGGAGTGGCCATCCCAATCAATCA 1560
 Db 1501 TCTGCCACAGAGTGCCTCCCAACGTCGAAATCTTGGAGTGGCCATCCCAATCAATCA 1560
 QY 1561 GTCCATAGAGACCAACAGATGAGACTTCCCGCCCAAGCGTGGCGCTGGCGGCACTTGG 1620
 Db 1561 GTCCATAGAGACCAACAGATGAGACTTCCCGCCCAAGCGTGGCGCTGGCGGCACTTGG 1620
 QY 1621 GTAGACTGTGCCACCGGCGTGTGTGAAACGTGAATTAAGAGCAAAAAAAA 1679
 Db 1621 GTAGACTGTGCCACCGGCGTGTGTGAAACGTGAATTAAGAGCAAAAAAAA 1679

RESULT 145
 ADE23904
 ID ADE23904 standard; cDNA; 1679 BP.
 AC ADE23904;
 XX ADE23904;
 DT 29-JAN-2004 (first entry)
 XX cDNA encoding human PRO polypeptide #188.

Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 liver; microvascular endothelial cell; glucose; PFA;
 skeletal muscle cell; adipocyte cell; pericyte cell;
 inner ear utricular supporting cell; T-lymphocyte cell;
 endothelial cell tube formation; bone disorder; cartilage disorder;
 sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 immune system cell infiltration.

XX Homo sapiens.
 OS US2003092110-A1.
 XX 15-MAY-2003.
 XX 03-MAY-2002; 2002US-00137864.
 XX 03-MAR-2000; 2000US-0187202P.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 Pi Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Pi Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2004-020235/02.
 XX P-PSDB; ADE23905.
 XX New secreted and transmembrane nucleic acids and polypeptides, designated
 PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
 PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
 PT cancer.
 XX Claim 2; Fig 375; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems. PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPIO website at seqdata.uspto.gov.
 XX

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTCGCAAGCTTGAGACAACAC 60
 Db 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTCGCAAGCTTGAGACAACAC 60
 QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 Db 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 QY 121 AAGAAAAAATCATGAAAAATCATGAAAAATCATGAAAAATCATGAAAAATCATG 180
 Db 121 AAGAAAAAATCATGAAAAATCATGAAAAATCATGAAAAATCATGAAAAATCATG 180
 QY 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCCAAGGAGTCCCGTGGCAGCGAGATGC 240
 Db 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCCAAGGAGTCCCGTGGCAGCGAGATGC 240
 QY 241 CACCTTCCCAAGCTATGGAACAAGTGAACGGTCCGGCAGGGGAGAGCGCACCTCAG 300
 Db 241 CACCTTCCCAAGCTATGGAACAAGTGAACGGTCCGGCAGGGGAGAGCGCACCTCAG 300
 QY 301 GTGCACTATTGACACACCGGCTCACCCGGTGGCTGGCTTAACCGCAGCACCATCTCTTA 360
 Db 301 GTGCACTATTGACACACCGGCTCACCCGGTGGCTGGCTTAACCGCAGCACCATCTCTTA 360
 QY 361 TGCTGGGAATGACAAAGTGGTGGCTGGATCCTCGGTGGTCTCTTGAGCAACACCCAAAC 420
 Db 361 TGCTGGGAATGACAAAGTGGTGGCTGGATCCTCGGTGGTCTCTTGAGCAACACCCAAAC 420
 QY 421 GCAGTACAGCATCGAGATCCAGAACTGATGATGATGATGATGATGATGATGATGATG 480
 Db 421 GCAGTACAGCATCGAGATCCAGAACTGATGATGATGATGATGATGATGATGATGATG 480

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems.
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTGTCACAAAGCTTGAGAGCAAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTGTCACAAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACCAATCCAGCCAAAGAAATGCAATCTCTTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAACCAATCCAGCCAAAGAAATGCAATCTCTTTGGGCAAT 180
QY 181 CTTACGGGGTGCTGCTCTGTGTCTCTTCCAGAGAGTCCCGTGGCAGCGGAGATGC 240
DB 181 CTTACGGGGTGCTGCTCTGTGTCTCTTCCAGAGAGTCCCGTGGCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGACAACTGACGCTGACGCTGACGCTGACGCTGACGCTGAC 300
DB 241 CACCTTCCCAAGCTATGACAACTGACGCTGACGCTGACGCTGACGCTGACGCTGAC 300
QY 301 GTGCACATTTGACAAACCGGCTGACCGGGTGCTGCTGCTGCTGCTGCTGCTGCTGCT 360
DB 301 GTGCACATTTGACAAACCGGCTGACCGGGTGCTGCTGCTGCTGCTGCTGCTGCTGCT 360
QY 361 TGCTGGGAATGACAAAGTGGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
DB 361 TGCTGGGAATGACAAAGTGGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
QY 421 GCAGTACAGCATCAGAGATCCAGAAACGTTGATGATGAGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCAGAGATCCAGAAACGTTGATGATGAGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGACAGACAAACCAACCAAGAGCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
DB 481 GGTGACAGACAAACCAACCAAGAGCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
QY 541 CAAAATTGTAGAGATTTCTTCAGATATCTCATTAATGAAAGGGAAACAAATATTAGCTCAC 600
DB 541 CAAAATTGTAGAGATTTCTTCAGATATCTCATTAATGAAAGGGAAACAAATATTAGCTCAC 600
QY 601 CTGCATAGCACTGGTAGACAGAGCTTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCATAGCACTGGTAGACAGAGCTTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGACGAATATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGACGAATATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
QY 721 AGGGGACTACAGTGCAGTGCTCCCAATGACGTGGCGCGCGCGTGGTGCAGAGAGTAA 780

DB 721 AGGGGACTACAGTGCAGTGCTCCCAATGACGTGGCGCGCGCGTGGTGCAGAGAGTAA 780
QY 781 GGTCAACGCTGAACATATCCACATATTTTCAGAAAGCCAGGTTACAGGTGTCCCGTGGG 840
DB 781 GGTCAACGCTGAACATATCCACATATTTTCAGAAAGCCAGGTTACAGGTGTCCCGTGGG 840
QY 841 AAAAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 AAAAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGATGACAAAAGACTGATTGAAGAAAGAAAGGGTGAAGTGGAAACACAGACCTTT 960
DB 901 CAAGATGACAAAAGACTGATTGAAGAAAGAAAGGGTGAAGTGGAAACACAGACCTTT 960
QY 961 CCTCTCAAAACTCATCTCTTCAATGTCTTGAACATGACTATATGGAACATACACTTGGT 1020
DB 961 CCTCTCAAAACTCATCTCTTCAATGTCTTGAACATGACTATATGGAACATACACTTGGT 1020
QY 1021 GGCCTTCAAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
DB 1021 GGCCTTCAAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGCGAGTGAAGCAACGGCAGCTCGAGAGGGCAGGCTGCTGCTGCTGCTGCTGCTTCT 1140
DB 1081 CAGCGAGTGAAGCAACGGCAGCTCGAGAGGGCAGGCTGCTGCTGCTGCTGCTTCT 1140
QY 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTAGTGCCACTTCCCTCCACCGGGAAAGCT 1200
DB 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTAGTGCCACTTCCCTCCACCGGGAAAGCT 1200
QY 1201 GCCGCCACACACACCAACCAACAGCAATGGCAACAGCAAGCAACCAATCAGATA 1260
DB 1201 GCCGCCACACACACCAACCAACAGCAATGGCAACAGCAAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAA 1320
DB 1261 TATACAAATGAAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAA 1320
QY 1321 AAAGTAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGAAATTTGAAATTT 1380
DB 1321 AAAGTAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGAAATTTGAAATTT 1380
QY 1381 TTTAGGTCAATGGAGTTTCTTTTCCAAACGGGAAAGAAACACAGCACACCGCGGTTGGA 1440
DB 1381 TTTAGGTCAATGGAGTTTCTTTTCCAAACGGGAAAGAAACACAGCACACCGCGGTTGGA 1440
QY 1441 CCCACTGCAAGTGCATCGTGCAACCTTTTGGTCCAGTGTGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGTGCATCGTGCAACCTTTTGGTCCAGTGTGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCCAAGAGTGCCTCCCAACCTGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCCAAGAGTGCCTCCCAACCTGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGAGCAACAGATGAGACCTTCGGGCCAAGCGTGGCGCTGGCGGCACTTTG 1620
DB 1561 GTCCATAGAGAGCAACAGATGAGACCTTCGGGCCAAGCGTGGCGCTGGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAAGCGGCTGCTGCTGAAACCTGAAATATAAAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAAGCGGCTGCTGCTGAAACCTGAAATATAAAAGAGCAAAAAA 1679

RESULT 147
ADD87372
ID ADD87372 standard; cDNA; 1679 BP.
XX
AC ADD87372;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; liver; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassemia; immune system cell infiltration.

Homo sapiens.

US2003203439-A1.

30-OCT-2003.

17-MAY-2002; 2002US-00147499.

04-AUG-1998; 98US-0095301P.

02-JUN-1999; 99WO-US012252.

30-MAR-2000; 2000US-00380137.

30-MAR-2000; 2000WO-US008439.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Pilvaroff E, Gao W;

Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2004-021362/02.

P-PSDB; ADD87373.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or PRO4978, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 375; 648pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note:

CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTCTCTTCAGCAAAACAGTGGATTTAAATCTCTTGCACACAGCTTGAGAGACAC 60
Db 1 GTTGTCTCTTCAGCAAAACAGTGGATTTAAATCTCTTGCACACAGCTTGAGAGACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGCACAAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGCACAAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAATGCAAAATCTATCTCTTGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAATGCAAAATCTATCTCTTGGCAAT 180
QY 181 CTTACAGGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGCCTGCGCAGCGGAGATGC 240
Db 181 CTTACAGGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGCCTGCGCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGCAACAGTGAAGTCCGGAGGGGAGAGCGCACCTCTAG 300
Db 241 CACCTTCCCAAGCTATGCAACAGTGAAGTCCGGAGGGGAGAGCGCACCTCTAG 300
QY 301 GTCCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCATCTCTA 360
Db 301 GTCCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCATCTCTA 360
QY 361 TGTCTGGGAATGACAAAGTGTGCTGATCCTGCGTGGTCTCTTGTAGCAACACCCAAAC 420
Db 361 TGTCTGGGAATGACAAAGTGTGCTGATCCTGCGTGGTCTCTTGTAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCCAGATCCAGAACCTGATGTATGACAGGGGCCCTTACACCTGTCTC 480
Db 421 GCAGTACAGCATCCAGATCCAGAACCTGATGTATGACAGGGGCCCTTACACCTGTCTC 480
QY 481 GGTGCGAGACAGCAACACCCGCTTCAAGGTCCTCACTTGTGCAAGATATCTCTCC 540
Db 481 GGTGCGAGACAGCAACACCCGCTTCAAGGTCCTCACTTGTGCAAGATATCTCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCCTCAC 600
Db 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGCGCTTTGTAGTGAAGAGCAATACCTTGAATTTCAAGGTCATCCCGGGGAGCAGTC 720
Db 661 GGTGCGCTTTGTAGTGAAGAGCAATACCTTGAATTTCAAGGTCATCCCGGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTTCCAAATGACGTGGCGCGCCCGTGGTACGAGAGTAAA 780
Db 721 AGGGGACTACGAGTGCAGTGCCTTCCAAATGACGTGGCGCGCCCGTGGTACGAGAGTAAA 780
QY 781 GGTCCCGTGAATCTCCACCATACATTTTCAGAACCAAGGGTACAGGTGTCTCCCGTGG 840
Db 781 GGTCCCGTGAATCTCCACCATACATTTTCAGAACCAAGGGTACAGGTGTCTCCCGTGG 840
QY 841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCTCCCTCAGCAGAAATTCAGGTGTA 900
Db 841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCTCCCTCAGCAGAAATTCAGGTGTA 900
QY 901 CAAGGATGACAAAGACTGATGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGATGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960

QY 961 CCTCTCAAACTCATCTTCTCAATGCTCTGACATGACTATGGAACTACACTTGGCT 1020
DB 961 CCTCTCAAACTCATCTTCTCAATGCTCTGACATGACTATGGAACTACACTTGGCT 1020
QY 1021 GGCTCTCAACAAAGCTGGGCCACACCAATGCGCATCATCTATTTGGTCCAGGCGCGT 1080
DB 1021 GGCTCTCAACAAAGCTGGGCCACACCAATGCGCATCATCTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGGAGGTGAGCAAGCGGACGTCGAGGAGGAGGCTGGCTGCTGCTGCTTCT 1140
DB 1081 CAGGAGGTGAGCAAGCGGACGTCGAGGAGGAGGCTGGCTGCTGCTGCTTCT 1140
QY 1141 GGTCTTGCACTGCTTCTCAAAATTTTGTGATGCTGCTGCTGCTGCTGCTGCT 1200
DB 1141 GGTCTTGCACTGCTTCTCAAAATTTTGTGATGCTGCTGCTGCTGCTGCTGCT 1200
QY 1201 GCGGCMCAACACACACACACACACACACACACACACACACACACACACACAT 1260
DB 1201 GCGGCMCAACACACACACACACACACACACACACACACACACACACACAT 1260
QY 1261 TATACAAATGAATTAAGAAACACACACACACACACACACACACACACACAC 1320
DB 1261 TATACAAATGAATTAAGAAACACACACACACACACACACACACACACAC 1320
QY 1321 AAAGAATACCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAAGAATACCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACATGAGTTTCTTTTCCAAACCGGAGAACACACACACACACACAC 1440
DB 1381 TTTAGGTACATGAGTTTCTTTTCCAAACCGGAGAACACACACACACACACAC 1440
QY 1441 CCACCTGCAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1500
DB 1441 CCACCTGCAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1500
QY 1501 TCTGCCACACAGTGGCCCCACCTGAGAACATTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACACAGTGGCCCCACCTGAGAACATTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATGAGACGACGACGACGACGACGACGACGACGACGACGACGACGACGAC 1620
DB 1561 GTCCATGAGACGACGACGACGACGACGACGACGACGACGACGACGACGAC 1620
QY 1621 GTAGACTGTCACACCGGCTGTGTGTAACCTGTAACCTGTAACCTGTAACCT 1679
DB 1621 GTAGACTGTCACACCGGCTGTGTGTAACCTGTAACCTGTAACCTGTAACCT 1679

RESULT 148
ADE05105
ID ADE05105 standard; cDNA; 1679 BP.
AC ADE05105;
XX
DT 29-JAN-2004 (first entry)
XX Human PRO polynucleotide #63.
XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
FN US2003100726-A1.
XX
PD 29-MAY-2003.
XX
PF 26-AUG-2002; 2002US-00227878.
XX

05-JUN-2000; 2000US-0209832P.
15-SEP-2000; 2000US-0232887P.
01-JUN-2001; 2001WO-US017800.
29-JUN-2001; 2001WO-US021066.
09-APR-2002; 2002US-00119480.
(GETH) GENENTECH INC.
Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
P-PSDB; ADE05106.
WPI; 2004-008976/01.
New secreted and transmembrane PRO polypeptides and nucleic acids, useful
in gene therapy, or for preparing a medicament for treating a condition
that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
cancer.
Claim 2; Fig 125; 308bp; English.
The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioreactors. They are particularly useful for
detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
prostate tumour, rectal tumour or liver tumour) in a mammal, for
stimulating the release of tumour necrosis factor (TNF)-alpha from human
blood, for stimulating the proliferation or differentiation of
chondrocyte cells, for stimulating the proliferation of or gene
expression in pericyte cells or for stimulating the proliferation of
normal human dermal fibroblasts. The PRO nucleic acids are useful as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA, in preparing PRO polypeptides by recombinant
technology, in generating transgenic animals or knock-out animals which
may be used in the development and screening of therapeutically useful
reagents, in gene therapy, in chromosome identification, as chromosome
markers and in generating probes. The PRO polypeptides, or anti-PRO
antibodies, are useful for preparing a medicament for treating a
condition which is responsive to the PRO polypeptides or anti-PRO
antibodies, such as pericyte-associated tumours and bone and/or cartilage
disorders (e.g. arthritis, sports injuries), involving inducing the re-
differentiation of chondrocytes. The PRO polypeptides are useful as
molecular markers for protein electrophoresis, and in tissue typing. This
sequence represents a human PRO polynucleotide of the invention.
Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACATCCAGCCAAATGCAAAATCTATCTTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACATCCAGCCAAATGCAAAATCTATCTTCTTGGGCAAT 180
QY 181 CTTACGGGGTGGCTGCTGTCTCTTCAAGAGAGTCCCGTCCAGCGAGATGC 240
DB 181 CTTACGGGGTGGCTGCTGTCTCTTCAAGAGAGTCCCGTCCAGCGAGATGC 240
QY 241 CACTTTCCTCCAAAGCTATGGAACAACGTCGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
DB 241 CACTTTCCTCCAAAGCTATGGAACAACGTCGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACATATTGACACCGGGTCAACCGGGTGGCTAAACCGCAGCACCACCTCTCTA 360

301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGATTAACCGCAGCACCATTCTCTA 360
361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTTCGCTGGTCTCTCTGAGCAACACCCAAAC 420
361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTTCGCTGGTCTCTCTGAGCAACACCCAAAC 420
421 GCAGTACAGCATCGAGATCCAGAACCGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
421 GCAGTACAGCATCGAGATCCAGAACCGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
481 GGTGACAGACACCAACCAACAGACCTCTAGGCTCCACCTATTGTGCAAGTATCTCC 540
481 GGTGACAGACACCAACCAACAGACCTCTAGGCTCCACCTATTGTGCAAGTATCTCC 540
541 CAAATTTGTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
541 CAAATTTGTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
601 CTGCATACCAACTGTGACAGAGCCTTACGCTTACCTTTGAGACACATCTCTCCCAAGC 660
601 CTGCATACCAACTGTGACAGAGCCTTACGCTTACCTTTGAGACACATCTCTCCCAAGC 660
661 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
721 AGGGACTACGAGTGCAGTCTCCATGAGTGGCGCGCCGCTGTGAGGAGGATGATA 780
721 AGGGACTACGAGTGCAGTCTCCATGAGTGGCGCGCCGCTGTGAGGAGGATGATA 780
781 GGTCAACCGTGAACATATCCACCATATATTTCAAGAACCAAGGATACAGTGTCCCGTGGG 840
781 GGTCAACCGTGAACATATCCACCATATATTTCAAGAACCAAGGATACAGTGTCCCGTGGG 840
841 ACAGAGGGGACATGAGTGTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGT 900
841 ACAGAGGGGACATGAGTGTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGT 900
901 CAAAGATCAGAAAGACTGATTTGAAGGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
901 CAAAGATCAGAAAGACTGATTTGAAGGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
961 CTTCTCAAACTCATCTCTTCAATGCTCTGAACATGATGATGAGTATGAGTATGAGTATG 1020
961 CTTCTCAAACTCATCTCTTCAATGCTCTGAACATGATGATGAGTATGAGTATGAGTATG 1020
1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1081 CAGCAGGTGAGCAACCGGACAGTTCGAGGAGGCGAGGCTGCGTCTGGCTGCTGCTCTTCT 1140
1081 CAGCAGGTGAGCAACCGGACAGTTCGAGGAGGCGAGGCTGCGTCTGGCTGCTGCTCTTCT 1140
1141 GGTCTTGACCTGCTCTTCAATTTTGAATGAGTGGCCACTTCCCAACCGGGAAGGCT 1200
1141 GGTCTTGACCTGCTCTTCAATTTTGAATGAGTGGCCACTTCCCAACCGGGAAGGCT 1200
1201 GCGGCCACCAACCAACCAACAGCAATGGCAACAGCAGCAACCAACCAATCAGATA 1260
1201 GCGGCCACCAACCAACCAACAGCAATGGCAACAGCAGCAACCAACCAATCAGATA 1260
1261 TATACAAATGAATTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
1261 TATACAAATGAATTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
1321 AAAGAATACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGAAATTTGAAATTTGAA 1380
1321 AAAGAATACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGAAATTTGAAATTTGAA 1380
1381 TTTAGGTACATGGATTTCTTTTCCCAACCGGGAAGACACAGCAGCACCAGGCTTGA 1440

1381 TTTAGGTACATGGATTTCTTTTCCCAACCGGGAAGACACAGCAGCACCAGCTTGA 1440
1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTGGTGGCCAGTGTGGCAAGGCTCAGCCTC 1500
1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTGGTGGCCAGTGTGGCAAGGCTCAGCCTC 1500
1501 TCTGCCACAGAGTGGCCGCCACAGTGGAAATTCGTGAGCTGGCCATCCCAATTCATCA 1560
1501 TCTGCCACAGAGTGGCCGCCACAGTGGAAATTCGTGAGCTGGCCATCCCAATTCATCA 1560
1561 GTCCATAGAGACGAAACAGATGAGACCTTCGGGCCCAAGCGTGGCGCTGGCGGACCTTTG 1620
1561 GTCCATAGAGACGAAACAGATGAGACCTTCGGGCCCAAGCGTGGCGCTGGCGGACCTTTG 1620
1621 GTAGACTGTGCCACACCGGCTGTGTGTAACCTGTAATTAAGAGAGCAAAAAA 1679
1621 GTAGACTGTGCCACACCGGCTGTGTGTAACCTGTAATTAAGAGAGCAAAAAA 1679

RESULT 149
ADD75318
ID ADD75318 standard; cDNA; 1679 BP.
XX
AC ADD75318;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #63.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide; tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN US2003100714-A1.
XX
PD 29-MAY-2003.
XX
PF 13-AUG-2002; 2002US-00219071.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021086.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
DR MPI; 2004-008964/01.
DR P-PSDB; ADD75319.
XX
PT New secreted and transmembrane PRO polypeptide useful for preparing a medicament for treating a condition that is responsive to the PRO polypeptide or anti-PRO antibody, e.g. cancer.
XX
PS Claim 2; Fig 125; 308pp; English.
XX
CC The invention relates to human PRO polypeptides (secreted and transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioeffectors. They are particularly useful for detecting tumours (e.g. lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour) in a mammal, for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells or for stimulating the proliferation of normal human dermal fibroblasts. The PRO nucleic acids are useful as hybridisation probes, in chromosome and gene mapping, in generating

CC anti-trans RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent can also be obtained in electronic
CC format directly from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTTACGAAACAGTGGATTTAAATCTCTTGCACAGCTTGAGAGCAAC 60
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1 GTTGTGCTCTTACGAAACAGTGGATTTAAATCTCTTGCACAGCTTGAGAGCAAC 60
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 121 AAGAAAAAATCATGAAACCATCAGCCCAAAATGCACATTTCTCTTGGCCAT 180
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 121 AAGAAAAAATCATGAAACCATCAGCCCAAAATGCACATTTCTCTTGGCCAT 180
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 181 CTTTACGGGCTGGCTGCTGTGTCTCTTCCAGGAGTGCCTGCGCAGCGGAGATGC 240
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 181 CTTTACGGGCTGGCTGCTGTGTCTCTTCCAGGAGTGCCTGCGCAGCGGAGATGC 240
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 241 CACTTCCCAAGCTATGACAACTGACGCTGCGGAGGAGGAGCGCCACCTCTAG 300
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 241 CACTTCCCAAGCTATGACAACTGACGCTGCGGAGGAGGAGCGCCACCTCTAG 300
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 301 GTGCACATTTGACAAACCGGCTGCTGCTCTTCCAGGAGTGCCTGCTCTA 360
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 301 GTGCACATTTGACAAACCGGCTGCTGCTCTTCCAGGAGTGCCTGCTCTA 360
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 361 TGCTGGAAATGACAAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 361 TGCTGGAAATGACAAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 421 GCAGTACAGCATCGAGATCAGAACGCTGATGATGATGATGATGATGATGATGATG 480
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 421 GCAGTACAGCATCGAGATCAGAACGCTGATGATGATGATGATGATGATGATGATG 480
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 481 GGTGACAGACAGCAACCAACCAAGACCTTAGGGTCCACCTCATTTGCAAGTATCTCC 540
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 481 GGTGACAGACAGCAACCAACCAAGACCTTAGGGTCCACCTCATTTGCAAGTATCTCC 540
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 541 CAAATTTGTAGATTTCTTCCAGTATCTCCATTTAGAGGAGCAATATTAGCTCTAC 600
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 541 CAAATTTGTAGATTTCTTCCAGTATCTCCATTTAGAGGAGCAATATTAGCTCTAC 600
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGAGAGACATCTCTCCAAAGC 660
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGAGAGACATCTCTCCAAAGC 660
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 661 GGTGGCTTTGTAGTGAAGACGATATCTTGGAAATTCAGGGCATCACCCGGGAGATC 720
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 661 GGTGGCTTTGTAGTGAAGACGATATCTTGGAAATTCAGGGCATCACCCGGGAGATC 720
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 721 AGGGGACTACAGTGCAGTGCCTCCATGAGCTGGCGCGCCCGTGGTACGGAGATGAA 780
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 721 AGGGGACTACAGTGCAGTGCCTCCATGAGCTGGCGCGCCCGTGGTACGGAGATGAA 780
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||

QY 781 GGTACCGTGAACCTATCCACATACATTTTCCAGAGCCAGGGTACAGGTGTCCCGTGGG 840
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 781 GGTACCGTGAACCTATCCACATACATTTTCCAGAGCCAGGGTACAGGTGTCCCGTGGG 840
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATCCAGTGGTA 900
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATCCAGTGGTA 900
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 901 CAAGATGACAAAGACTGATTGAAGGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 901 CAAGATGACAAAGACTGATTGAAGGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGATATGGGAACATACCTTCGT 1020
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGATATGGGAACATACCTTCGT 1020
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1021 GGCTCTCAAGCTGGGCCACCAATGCCAGATCATGCTATTTTGGTCCAGCGCGCT 1080
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1021 GGCTCTCAAGCTGGGCCACCAATGCCAGATCATGCTATTTTGGTCCAGCGCGCT 1080
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1081 CAGCGAGTGAAGCAACCGCAGCTCGAGGAGGCGAGCTGCTGTGGTCTGCTCTTCT 1140
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1081 CAGCGAGTGAAGCAACCGCAGCTCGAGGAGGCGAGCTGCTGTGGTCTGCTCTTCT 1140
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1141 GGTCTTGACCTGCTCTCAAAATTTTGAATGAGTGCACCTTCCCGACCGGGAAGCT 1200
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1141 GGTCTTGACCTGCTCTCAAAATTTTGAATGAGTGCACCTTCCCGACCGGGAAGCT 1200
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1201 GCCGCCACACCAACCAACAGCAATGCAACAGCAAGCAACCAATCAGATA 1260
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1201 GCCGCCACACCAACCAACAGCAATGCAACAGCAAGCAACCAATCAGATA 1260
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1261 TATCAAAATGAATTTAGAGAAACAGCCTCATGGGACAGAAATTTGAGGAGGGAAC 1320
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1261 TATCAAAATGAATTTAGAGAAACAGCCTCATGGGACAGAAATTTGAGGAGGGAAC 1320
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1321 AAAGTAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1321 AAAGTAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1381 TTTAGGTAAATGAGATTTTCTTTCCAAACGGGAAAGAACACAGCACACCGGCTTGG 1440
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1381 TTTAGGTAAATGAGATTTTCTTTCCAAACGGGAAAGAACACAGCACACCGGCTTGG 1440
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1441 CCCACTGCAAGCTCATCGTCAACCTTTTGGTGGCAGTGTGGCAGGAGCTCAGCCTC 1500
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1441 CCCACTGCAAGCTCATCGTCAACCTTTTGGTGGCAGTGTGGCAGGAGCTCAGCCTC 1500
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1501 TCTGCCACAGAGTGCCTCCACCTGGAACATTTGGAGCTGGCCATCCCAATCAATCA 1560
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1501 TCTGCCACAGAGTGCCTCCACCTGGAACATTTGGAGCTGGCCATCCCAATCAATCA 1560
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1561 GTCCATAGAGAGACAGATGAGACCTTCCGGCCCAAGCTGGGCTGGCGGACCTTTG 1620
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1561 GTCCATAGAGAGACAGATGAGACCTTCCGGCCCAAGCTGGGCTGGCGGACCTTTG 1620
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1621 GTAGACTGTGCCACCGCTGCTGTGTAACCTGTAACCTGTAACCTGTAACCTGTAAC 1679
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
QY 1621 GTAGACTGTGCCACCGCTGCTGTGTAACCTGTAACCTGTAACCTGTAACCTGTAAC 1679
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 150
ADD76862
ID ADD76862: standard; cDNA; 1679 BP.
XX
AC ADD76862;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
vulnerary; anti-arthritis; pericyte cell proliferation;

pericyte cell differentiation; chondrocyte cell proliferation;
 chondrocyte cell differentiation; tumour necrosis factor alpha release;
 (TNF)-alpha release; dermal fibroblast cell proliferation;
 dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 colon tumour; breast tumour; prostate tumour; rectal tumour;
 liver tumour; tissue typing; chromosome mapping; gene mapping;
 gene therapy.
 XX Homo sapiens.
 OS
 XX US2003100715-A1.
 PN
 XX 29-MAY-2003.
 PD
 XX
 XX 13-AUG-2002; 2002US-00219074.
 XX
 XX 22-JUN-1999; 99US-0140650P.
 PR
 XX 20-MAY-2000; 2000WO-US014941.
 PR
 XX 01-JUN-2001; 2001WO-US017800.
 PR
 XX 29-JUN-2001; 2001WO-US021066.
 PR
 XX 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JP, Watanabe CK, Wood WI;
 XX P-P8DB; ADD76863.
 DR
 XX WPI; 2004-008965/01.
 DR
 XX P-P8DB; ADD76863.
 XX
 XX New secreted and transmembrane PRO polypeptide useful for preparing a
 PT medicament for treating a condition that is responsive to the PRO
 PT polypeptide or anti-PRO antibody, e.g. cancer.
 XX
 XX Claim 2; SEQ ID NO 125; 308pp; English.
 XX
 XX The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1567, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match	100.0%	Score 1679	DB 1	Length 1679
Best Local Similarity	100.0%	Pred. No. 6.7e-05		
Matches 1679	Conservative	0	Mismatches 0	Indels 0
Gaps	0			
QY 1	GTGTGTCCTTACGAAAACAGTGATTAATCTCTTGCACAAAGCTTGAGAGCAAC	60		
DB 1	GTGTGTCCTTACGAAAACAGTGATTAATCTCTTGCACAAAGCTTGAGAGCAAC	60		
QY 61	AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120		
DB 61	AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120		
QY 121	AGAAAAAATATCATGAAAACCATCCAGCCAAAATGCAATTTCTATCTTTGGCAAT	180		
DB 121	AGAAAAAATATCATGAAAACCATCCAGCCAAAATGCAATTTCTATCTTTGGCAAT	180		
QY 181	CTTCAGGGGCTGGCTGCTCTGTCTCTTCCAGAGAGTGCCGCGCAGCGGAGATGC	240		
DB 181	CTTCAGGGGCTGGCTGCTCTGTCTCTTCCAGAGAGTGCCGCGCAGCGGAGATGC	240		
QY 241	CACCTTCCCAAGAGCTATGGACAAAGCTGAGCGGCGGCGGCGGCGGCGGCGG	300		
DB 241	CACCTTCCCAAGAGCTATGGACAAAGCTGAGCGGCGGCGGCGGCGGCGGCGG	300		
QY 301	GTGCACCTATTGACAAACCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	360		
DB 301	GTGCACCTATTGACAAACCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	360		
QY 361	TGCTGGGAATGACAACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	420		
DB 361	TGCTGGGAATGACAACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	420		
QY 421	GCAGTACAGCTGAGATCCAGAACCTGATGATGATGATGATGATGATGATGATG	480		
DB 421	GCAGTACAGCTGAGATCCAGAACCTGATGATGATGATGATGATGATGATGATG	480		
QY 481	GGTGCAGACAGACACACCCCAAGACCTCTAGGTCCTCACTTGTGCAAGTATCTCC	540		
DB 481	GGTGCAGACAGACACACCCCAAGACCTCTAGGTCCTCACTTGTGCAAGTATCTCC	540		
QY 541	CAAAATGTAGATTTCTTCCAGATATCTTCCAGATATCTTCCAGATATCTTCC	600		
DB 541	CAAAATGTAGATTTCTTCCAGATATCTTCCAGATATCTTCCAGATATCTTCC	600		
QY 601	CTGCATAGCAATCTGTAGACAGAGCTACCGGTTACTTGGAGACACATCTCTCCAAAGC	660		
DB 601	CTGCATAGCAATCTGTAGACAGAGCTACCGGTTACTTGGAGACACATCTCTCCAAAGC	660		
QY 661	GGTTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGGATCACCCGGGAGCAGTC	720		
DB 661	GGTTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGGATCACCCGGGAGCAGTC	720		
QY 721	AGGGGACTACGAGTGCAGTGCCTTCCAAATGACGTCGGCGCGCGCGCGCGCGCG	780		
DB 721	AGGGGACTACGAGTGCAGTGCCTTCCAAATGACGTCGGCGCGCGCGCGCGCGCG	780		
QY 781	GGTACCGTGAATCTTCCACCATATCTTCCAGAGCAAGGGGTACAGGTGTCCTCCCTGGG	840		
DB 781	GGTACCGTGAATCTTCCACCATATCTTCCAGAGCAAGGGGTACAGGTGTCCTCCCTGGG	840		
QY 841	ACAAAAGGACACTGAGTGTGAGCGCTCCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900		
DB 841	ACAAAAGGACACTGAGTGTGAGCGCTCCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900		
QY 901	CAAGGATGACAAAGACTGATTAAGAGAAAGGGGTGAAGTGGGAAAGACAGACTTT	960		
DB 901	CAAGGATGACAAAGACTGATTAAGAGAAAGGGGTGAAGTGGGAAAGACAGACTTT	960		
QY 961	CTCTCTCAAACTCATCTTCTTCAATGCTCTGCTGCTGCTGCTGCTGCTGCTGCTG	1020		
DB 961	CTCTCTCAAACTCATCTTCTTCAATGCTCTGCTGCTGCTGCTGCTGCTGCTGCTG	1020		

QY 1021 GGCCTCCACAGCTGGGCGCACCAATGCGCAGCATCATGCTATTGTTGGTCCAGGGCGGT 1080
 DB 1021 GGCCTCCACAGCTGGGCGCACCAATGCGCAGCATCATGCTATTGTTGGTCCAGGGCGGT 1080
 QY 1081 CAGCGAGGTGAGCAACGCGACCTCGAGGAGGCGCTGCTGCTGGCTGCTCTTCT 1140
 DB 1081 CAGCGAGGTGAGCAACGCGACCTCGAGGAGGCGCTGCTGCTGGCTGCTCTTCT 1140
 QY 1141 GGTCTTGCACTGCTTCTCAATTTTGTGAGTGCCACTTCCACCCCGGGAAGGCT 1200
 DB 1141 GGTCTTGCACTGCTTCTCAATTTTGTGAGTGCCACTTCCACCCCGGGAAGGCT 1200
 QY 1201 GCGGCCACACACACACACCAACAGCAATGCGCAACCGACAGCAACCAATCAGATA 1260
 DB 1201 GCGGCCACACACACACCAACAGCAATGCGCAACCGACAGCAACCAATCAGATA 1260
 QY 1261 TATACAAATGAATTAAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAC 1320
 DB 1261 TATACAAATGAATTAAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAC 1320
 QY 1321 AAGAAATACCTTTGGGGGAAAGAGTTTAAAGAGAAATTTGAAATTTGCTTGCAGATA 1380
 DB 1321 AAGAAATACCTTTGGGGGAAAGAGTTTAAAGAGAAATTTGAAATTTGCTTGCAGATA 1380
 QY 1381 TTTAGTACAAATGAGGTTTCTTTTCCAAACCGGGAAGAACACAGCACACCCGGCTTGA 1440
 DB 1381 TTTAGTACAAATGAGGTTTCTTTTCCAAACCGGGAAGAACACAGCACACCCGGCTTGA 1440
 QY 1441 CCCACTGCAAGCTGCAATGCGCAACCTTTTGTGCGAGTGCGGCAAGGCTCAGCCCTC 1500
 DB 1441 CCCACTGCAAGCTGCAATGCGCAACCTTTTGTGCGAGTGCGGCAAGGCTCAGCCCTC 1500
 QY 1501 TCTGCCACAGAGTGCCCCCACTGGAAACATTTGAGAGTGCGCATCCCAATTTCAATCA 1560
 DB 1501 TCTGCCACAGAGTGCCCCCACTGGAAACATTTGAGAGTGCGCATCCCAATTTCAATCA 1560
 QY 1561 GTCCATGACAGCAAGCAATGAGACTTCCGCGCCAGCGTGCGTGCGGCACTTTG 1620
 DB 1561 GTCCATGACAGCAAGCAATGAGACTTCCGCGCCAGCGTGCGTGCGGCACTTTG 1620
 QY 1621 GTAGACTGTGCCACCCAGCGGTGTGTTGTGAACGTTGAATTAAGAGCAAAAAAAA 1679
 DB 1621 GTAGACTGTGCCACCCAGCGGTGTGTTGTGAACGTTGAATTAAGAGCAAAAAAAA 1679
 RESULT 151
 ADD86630
 ID ADD86630 standard; cDNA; 1679 BP.
 AC ADD86630;
 XX 29-JAN-2004 (first entry)
 DE Novel human secreted and transmembrane protein PRO337 cDNA.
 KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX Homo sapiens.
 OS Homo sapiens.
 XX US2003100719-A1.
 FN 29-MAY-2003.
 PD 14-AUG-2002; 2002US-00219469.
 XX

PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 FI WPI: 2004-0089969/01.
 DR P-PSDB; ADD86631.
 DR
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, or for preparing a medicament for treating a condition
 PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
 PT cancer.
 XX Claim 2; SEQ ID NO 125; 308pp; English.
 PS
 XX The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1026, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTGTGTCCTTCAGCAACACAGTGGATTAAATCTCTTGGCAGCAAGCTTGAGGCAACAC 60
 DB 1 GTGTGTCCTTCAGCAACACAGTGGATTAAATCTCTTGGCAGCAAGCTTGAGGCAACAC 60
 QY 61 AATCTATCAGGAAAGAAAGAAAGAAAAACCGAACCTTGACAAAAAGAGAAAAAGAG 120
 DB 61 AATCTATCAGGAAAGAAAGAAAGAAAAACCGAACCTTGACAAAAAGAGAAAAAGAG 120
 QY 121 AAGAAAAAAATCATGAAACCAATCCAGCCAAATGACCAATTTCTCTTGGGCAAT 180
 DB 121 AAGAAAAAAATCATGAAACCAATCCAGCCAAATGACCAATTTCTCTTGGGCAAT 180

181 CTTCAAGGGGTGGTGTCTGTGTCTCTTCAAGGAGTGCCTCGCGAGCGAGATGC 240
181 CTTCAAGGGGTGGTGTCTGTGTCTCTTCAAGGAGTGCCTCGCGAGCGAGATGC 240
241 CACCTTCCCAAGCTATGGACAACGTCAGCTCGGCGAGGGGAGAGCGCACCTCTCAG 300
241 CACCTTCCCAAGCTATGGACAACGTCAGCTCGGCGAGGGGAGAGCGCACCTCTCAG 300
301 GTGCACTATTGACAAACCGGGTCAACCCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
301 GTGCACTATTGACAAACCGGGTCAACCCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
361 TGCTGGGAATGCAAGTGGTCTGGATCCCTCGGTGTCTCTTGAGCAACACCCCAAC 420
361 TGCTGGGAATGCAAGTGGTCTGGATCCCTCGGTGTCTCTTGAGCAACACCCCAAC 420
421 GCAGTACAGATCGAGATCCAGAACGTCGATGTGTATGACAGGGCCCTTACACTGCTC 480
421 GCAGTACAGATCGAGATCCAGAACGTCGATGTGTATGACAGGGCCCTTACACTGCTC 480
481 GGTGAGACAGACACCAACCAAGACCTCTAGGTCACCTCATTTGGCAAGTATCTCC 540
481 GGTGAGACAGACACCAACCAAGACCTCTAGGTCACCTCATTTGGCAAGTATCTCC 540
541 CAAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAAACATATTAGCCTCAC 600
541 CAAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAAACATATTAGCCTCAC 600
601 CTGCATAGCAACTGTAGACAGAGCCCTACGGTACTTTGGAGACACATCTCTCCGAAGC 660
601 CTGCATAGCAACTGTAGACAGAGCCCTACGGTACTTTGGAGACACATCTCTCCGAAGC 660
661 GGTGGCTTTGTGAGTGAAGACGAATACCTTGAATAATTCAGGGCATACCCGGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGACGAATACCTTGAATAATTCAGGGCATACCCGGGAGCAGTC 720
721 AGGGGACTACGATGAGTGCCTCCATGAGCTGGCCCGGCCCGGTGGTACGGAGATGAA 780
721 AGGGGACTACGATGAGTGCCTCCATGAGCTGGCCCGGCCCGGTGGTACGGAGATGAA 780
781 GGTCAACGTTGAATATCCACCATATATTTCAGAACCAAGGATACAGGTGTCCTCGTGG 840
781 GGTCAACGTTGAATATCCACCATATATTTCAGAACCAAGGATACAGGTGTCCTCGTGG 840
841 ACAAAGGGGACACTGTCAGTGTGAAGCTTCAGACGTCCTCCCTCAGAGAAATTCAGTGTGA 900
841 ACAAAGGGGACACTGTCAGTGTGAAGCTTCAGACGTCCTCCCTCAGAGAAATTCAGTGTGA 900
901 CAAGGATGACAAAGACTGATTGAAGGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
901 CAAGGATGACAAAGACTGATTGAAGGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
961 CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGGCT 1020
961 CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGGCT 1020
1021 GGCCTTCAACAGCTGGGCGACCAATGCTGAGTATGCTTATTTGGTCCAGGCGCGT 1080
1021 GGCCTTCAACAGCTGGGCGACCAATGCTGAGTATGCTTATTTGGTCCAGGCGCGT 1080
1081 CAGCGAGGTGAGCAACGGCAGCTCGAGGAGGCGAGGCTGCGTGTGCTGCTCTTCT 1140
1081 CAGCGAGGTGAGCAACGGCAGCTCGAGGAGGCGAGGCTGCGTGTGCTGCTCTTCT 1140
1141 GGTCTTGCACCTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCCGCGGGAAGGCT 1200
1141 GGTCTTGCACCTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCCGCGGGAAGGCT 1200
1201 GCGGCCACCAACCAACCAACCAAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
1201 GCGGCCACCAACCAACCAACCAAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
1261 TATACAAATGAAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320

1261 TATACAAATGAAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320
1321 AAAGAAATACCTTTGGGGGAAAAGAGTTTTAAAAAAGAAATTTGAAAATTTGCTTGCAGATA 1380
1321 AAAGAAATACCTTTGGGGGAAAAGAGTTTTAAAAAAGAAATTTGAAAATTTGCTTGCAGATA 1380
1381 TTTAGGTACAATGGAGTTTCTTTTCCCAACCGGAAGAACACACACACCCCGGCTTGA 1440
1381 TTTAGGTACAATGGAGTTTCTTTTCCCAACCGGAAGAACACACACACCCCGGCTTGA 1440
1441 CCCACTGCAAGCTGCATCGTGCAACCTCTTTGTCGCAAGTGGGCAAGGGCTCAGCCTC 1500
1441 CCCACTGCAAGCTGCATCGTGCAACCTCTTTGTCGCAAGTGGGCAAGGGCTCAGCCTC 1500
1501 TGTGCCCAACAGAGTGCCTCCACAGTGGAAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
1501 TGTGCCCAACAGAGTGCCTCCACAGTGGAAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGCGCCCAAGCGTGGCGCTCGGCGCACTTTG 1620
1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGCGCCCAAGCGTGGCGCTCGGCGCACTTTG 1620
1621 GTAGACTGTGCCACCAACCGGCTGTGTGTGTAACGCTGAAATTAAGAGCAAAAAAAA 1679
1621 GTAGACTGTGCCACCAACCGGCTGTGTGTGTAACGCTGAAATTAAGAGCAAAAAAAA 1679

RESULT 152

ADE89238

ID ADE89238 standard; cdNA; 1679 BP.

XX AC ADE89238;

XX AC ADE89238;

XX 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #188.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX liver; microvascular endothelial cell; glucose; FFA;

XX skeletal muscle cell; adipocyte cell; pericyte cell;

XX inner ear utricular supporting cell; r-lymphocyte cell;

XX endothelial cell tube formation; bone disorder; cartilage disorder;

XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX immune system cell infiltration.

XX Homo sapiens.

XX OS

XX PN US2003199062-A1.

XX XX

XX PD 23-OCT-2003.

XX XX

XX PF 17-APR-2002; 2002US-00124823.

XX XX

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019093.

XX PR 14-SEP-1998; 98WO-US019094.

XX PR 14-SEP-1998; 98WO-US019177.

XX PR 16-SEP-1998; 98WO-US019330.

XX PR 17-SEP-1998; 98WO-US019437.

XX PR 07-OCT-1998; 98WO-US021141.

XX PR 29-OCT-1998; 98WO-US022991.

XX PR 20-NOV-1998; 98WO-US024855.

XX PR 01-DEC-1998; 98WO-US025108.

XX PR 03-JAN-1999; 99WO-US000106.

```
PR 08-MAR-1999; 99WO-US0005028.
PR 10-MAR-1999; 99WO-US0005190.
PR 10-MAR-1999; 2000WO-US0006319.
PR 20-APR-1999; 99WO-US0008615.
PR 02-MAY-1999; 99WO-US0107033.
PR 08-JUN-1999; 99WO-US0201111.
PR 01-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 03-OCT-1999; 99WO-US021547.
PR 29-NOV-1999; 99WO-US022089.
PR 30-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US0000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 20-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US0006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021666.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2004-041360/04.
DR P-PSDB; ADE89239.
XX
XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
PS Claim 2; SEQ ID NO 375; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
SQ
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGACCAAGCTTGAGACAC 60
DDB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGACCAAGCTTGAGACAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAAACCGAACTCTGACAAAAAGAGAAAAAGAG 120
DDB 61 AATCTATCAGGAAAGAAAGAAAGAAAAACCGAACTCTGACAAAAAGAGAAAAAGAG 120
```


Db 1141 GGTCTTGGACCTGCTTCTCAAAATTTTGAATGAGTGCCACTTCCACCACCGGGAAGGCT 1200
Qy 1201 GCGGCCACACACACACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
Db 1201 GCGGCCACACACACACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
Qy 1261 TATACAAATGAATTTAGAAAGCAACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Db 1261 TATACAAATGAATTTAGAAAGCAACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Qy 1321 AAAGAATATCTTTGGGGGGAAGAGATTTTAAAAAGAGAAATGAAATTTGCCCTTGCAGATA 1380
Db 1321 AAAGAATATCTTTGGGGGGAAGAGATTTTAAAAAGAGAAATGAAATTTGCCCTTGCAGATA 1380
Qy 1381 TTTAGTACATAGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCGCGGCTTGA 1440
Db 1381 TTTAGTACATAGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCGCGGCTTGA 1440
Qy 1441 CCACATGCAAGCTGCACTGTCGAACCTTTTGGTGCAGATGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCACATGCAAGCTGCACTGTCGAACCTTTTGGTGCAGATGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCGCCACAGTGGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCGCCACAGTGGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGAACAGAAATGAGACTTCCGGGCCCAAGCGTGGCGCTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAACAGAAATGAGACTTCCGGGCCCAAGCGTGGCGCTGGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAAACGTGAAATAAAAAGACAAAAAAA 1679
Db 1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAAACGTGAAATAAAAAGACAAAAAAA 1679

RESULT 154
ADD78098
ID ADD78098 standard; cdna; 1679 BP.
AC ADD78098;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN US2003100731-A1.
XX
PD 29-MAY-2003.
XX
PF 28-AUG-2002; 2002US-00230234.
XX
PR 01-JUN-2001; 2001WO-US017800.
XX
PR 29-JUN-2001; 2001WO-US021066.
XX
PR 03-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2004-008981/01.
DR

DR P-PSDB; ADD78099.
XX
PT New PRO polypeptide and nucleic acid useful for gene therapy, chromosome
identification, tissue typing, or as hybridization probes in chromosome
and gene mapping.
XX
PS Claim 2; SEQ ID NO 125; 308pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
useful for stimulating the proliferation of or gene expression in
pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
for stimulating the proliferation or differentiation of chondrocyte
cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
are useful for stimulating the release of tumour necrosis factor (TNF)-
alpha from human blood. PRO363, PRO357, PRO725, PRO1306, PRO1419, PRO214,
PRO247, PRO337, PRO526, PRO363, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,
PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
stimulating the proliferation of normal human dermal fibroblasts cells.
PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
inhibiting the proliferation of normal human dermal fibroblast cells. PRO
polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
are useful for detecting the presence of tumour in a mammal which
involves comparing the level of expression of the above PRO polypeptides
in a test sample of cells taken from the mammal, and a control sample of
normal cells of the same cell type, where a higher level of expression of
the PRO polypeptides in the test sample as compared to the control sample
is indicative of the presence of tumour in the mammal. The tumour is lung
tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
liver tumour. (I) is useful as molecular weight markers, for tissue
typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
useful for chromosome and gene mapping or gene therapy. (II) is useful
for generating transgenic animals or knock-out animals which are useful
screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
is useful for treating bone and/or cartilage disorders (e.g., arthritis,
sport injuries). This sequence encodes a human secreted and transmembrane
PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGCTTTCAGCAACACAGTGGATTTAAATCTCTTGCACAACTTGAGAGCAACAC 60
Db 1 GTTGTGCTTTCAGCAACACAGTGGATTTAAATCTCTTGCACAACTTGAGAGCAACAC 60
Qy 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 ARGAAAAAATCATGAAACCATCCAGCCCAAAATGCAAAATCTCTTCTTGGGCAAT 180
Db 121 ARGAAAAAATCATGAAACCATCCAGCCCAAAATGCAAAATCTCTTCTTGGGCAAT 180
Qy 181 CTTCAAGGGGCTGGCTCTGTGTCTCTTCCAAAGAGTGCCTGCGCAGCGGAGATGC 240
Db 181 CTTCAAGGGGCTGGCTCTGTGTCTCTTCCAAAGAGTGCCTGCGCAGCGGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGACACACGTGAGTCCCGGAGGGGAGAGGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGACACACGTGAGTCCCGGAGGGGAGAGGCCACCTCAG 300
Qy 301 GTGCACCTATTGACAAACCGGGTCCCGGGTGGCTGTGCTTAAACCGCAGCACCACCTCTA 360
Db 301 GTGCACCTATTGACAAACCGGGTCCCGGGTGGCTGTGCTTAAACCGCAGCACCACCTCTA 360

QY	361	TGCTGGAAATGACAAGTGGTCCCTGGATCCTCGCTGGTCCCTTCTGAGCAACACCCAAAC	420
DB	361		
QY	421	GCAGTACAGCATCGAGATCCAGAACGTGGAATGTGATGACGAGGGCCCTTACACCTGCTC	480
DB	421		
QY	481	GGTGCAGACAGACAACCCACCACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
DB	481		
QY	541	CAAAATTTGATAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC	600
DB	541	CAAAATTTGATAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC	
QY	601	CTGCATAGCAACTGTTAGACACAGGCTACGGTTACTTGGAGACACATCTCTCCCAAAGC	660
DB	601	CTGCATAGCAACTGTTAGACACAGGCTACGGTTACTTGGAGACACATCTCTCCCAAAGC	
QY	661	GGTTGGCTTTGTGAGTCAAGACCAATACTTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
DB	661	GGTTGGCTTTGTGAGTCAAGACCAATACTTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	
QY	721	AGGGGACTACGAGTGCAGTCCCAATGACGTGGCGCGCCCGTGGTACGAGAGATAA	780
DB	721	AGGGGACTACGAGTGCAGTCCCAATGACGTGGCGCGCCCGTGGTACGAGAGATAA	
QY	781	GGTCACCGTGAACCTATCCACATACATTTCAGAAGCCAAAGGTACAGGTGTCCCCGTGGG	840
DB	781	GGTCACCGTGAACCTATCCACATACATTTCAGAAGCCAAAGGTACAGGTGTCCCCGTGGG	
QY	841	ACAAAAGGGGACACTGCAAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
DB	841	ACAAAAGGGGACACTGCAAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	
QY	901	CAGGATGACAAAAGACTGATTTGAAGAAAGAAAGGGGTCAAAGTGGMAACAGACCTTT	960
DB	901	CAGGATGACAAAAGACTGATTTGAAGAAAGAAAGGGGTCAAAGTGGMAACAGACCTTT	
QY	961	CCTCTCAAACTCATCTTTCTCAATGTCTCTGAACATGACTATGGAACTPACACTTGCCT	1020
DB	961	CCTCTCAAACTCATCTTTCTCAATGTCTCTGAACATGACTATGGAACTPACACTTGCCT	
QY	1021	GGCCTCCACAGCTGGGCCACACCAATGCCAGCATCATCTATTTGTCACGGCCCGT	1080
DB	1021	GGCCTCCACAGCTGGGCCACACCAATGCCAGCATCATCTATTTGTCACGGCCCGT	
QY	1081	CAGCGAGTCAAGCAACGGCAGCTCGAGGAGGAGGCTGCGTCTGGGTGTGCTCTTCT	1140
DB	1081	CAGCGAGTCAAGCAACGGCAGCTCGAGGAGGAGGCTGCGTCTGGGTGTGCTCTTCT	
QY	1141	GGTCTTGCACTGCTTCTCAAAATTTGATGTAGTGCACATTCGCCACCCGGGAAGGCT	1200
DB	1141	GGTCTTGCACTGCTTCTCAAAATTTGATGTAGTGCACATTCGCCACCCGGGAAGGCT	
QY	1201	GGCGCCACCAACCAACACAGCAATGGCAACACCGACAGCAACCAATCAGATA	1260
DB	1201	GGCGCCACCAACCAACACAGCAATGGCAACACCGACAGCAACCAATCAGATA	
QY	1261	TATACAAATGAAATTTAGAAGAAAACACAGCTCATGGGACGAAATTTGAGGGAGGGGAAC	1320
DB	1261	TATACAAATGAAATTTAGAAGAAAACACAGCTCATGGGACGAAATTTGAGGGAGGGGAAC	
QY	1321	AAAGATACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTCTTCAGATA	1380
DB	1321	AAAGATACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTCTTCAGATA	
QY	1381	TTTAGGTACAATGGAGTTTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGG	1440
DB	1381	TTTAGGTACAATGGAGTTTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGG	

Qy	1441	CCCACTGCAAGCTGCAATCTGTCGCAACTCTTTGGTGCACATGTGGGCAAGGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGCTGCAATCTGTCGCAACTCTTTGGTGCACATGTGGGCAAGGGCTCAGCCTC	1500
Qy	1501	TCCTGCCCAACAGAGTGCCTCCCACTGTGGAACATTCCTGGAGCTGGCCATCCCAAAATTCAAATCA	1560
Db	1501	TCCTGCCCAACAGAGTGCCTCCCACTGTGGAACATTCCTGGAGCTGGCCATCCCAAAATTCAAATCA	1560
Qy	1561	GTCCATAGACACGAAACAGAAATGAGACCTTCGGCCCAAGCGTGGCGCTGCGGGCACTTTG	1620
Db	1561	GTCCATAGACACGAAACAGAAATGAGACCTTCGGCCCAAGCGTGGCGCTGCGGGCACTTTG	1620
Qy	1621	GTAGACTGTGCCACCGCGCGTGTGTGTGTAACGTTGAAATATAAAAGAGCAAAAAAAA	1679
Db	1621	GTAGACTGTGCCACCGCGCGTGTGTGTGTAACGTTGAAATATAAAAGAGCAAAAAAAA	1679
RESULT 155			
ADE18377			
ID	ADE18377 standard; cDNA; 1679 BP.		
XX			
XX	ADE18377;		
XX			
DT	29-JAN-2004 (first entry)		
XX			
DE	Human PRO polynucleotide #188.		
XX			
Kw	Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
Kw	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
Kw	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
Kw	liver; microvascular endothelial cell; glucose; FFA;		
Kw	skeletal muscle cell; adipocyte cell; pericyte cell;		
Kw	inner ear utricular supporting cell; T-lymphocyte cell;		
Kw	endothelial cell tube formation; bone disorder; cartilage disorder;		
Kw	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
Kw	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		
Kw	immune system cell infiltration.		
XX			
OS	Homo sapiens.		
XX			
PN	US2003194794-A1.		
XX			
PD	16-OCT-2003.		
XX			
PF	17-APR-2002; 2002US-00125805.		
XX			
PR	31-MAR-1997; 97WO-US005230.		
PR	12-JUN-1998; 98WO-US012456.		
PR	14-JUL-1998; 98WO-US014552.		
PR	28-AUG-1998; 98WO-US017888.		
PR	10-SEP-1998; 98WO-US018824.		
PR	14-SEP-1998; 98WO-US019093.		
PR	14-SEP-1998; 98WO-US019094.		
PR	14-SEP-1998; 98WO-US019177.		
PR	16-SEP-1998; 98WO-US019330.		
PR	17-SEP-1998; 98WO-US019437.		
PR	07-OCT-1998; 98WO-US021141.		
PR	29-OCT-1998; 98WO-US022991.		
PR	29-OCT-1998; 98WO-US022992.		
PR	20-NOV-1998; 98WO-US024855.		
PR	01-DEC-1998; 98WO-US025108.		
PR	05-JAN-1999; 99WO-US000106.		
PR	08-MAR-1999; 99WO-US005028.		
PR	10-MAR-1999; 99WO-US005190.		
PR	20-APR-1999; 2000WO-US006319.		
PR	14-MAY-1999; 99WO-US008615.		
PR	02-JUN-1999; 99WO-US010733.		
PR	01-SEP-1999; 99WO-US020111.		
PR	08-SEP-1999; 99WO-US020594.		
PR	13-SEP-1999; 99WO-US020944.		
PR	15-SEP-1999; 99WO-US021090.		
PR	15-SEP-1999; 99WO-US021547.		

PR	05-OCT-1999;	99WO-US023089.	PA	(GETH) GENENTECH INC.
PR	29-NOV-1999;	99WO-US028214.	XX	
PR	30-NOV-1999;	99WO-US028313.	PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PR	30-NOV-1999;	99WO-US028409.	PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PR	01-DEC-1999;	99WO-US028301.	PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
PR	01-DEC-1999;	99WO-US028634.	XX	
PR	02-DEC-1999;	99WO-US028551.	DR	WPI; 2004-021079/02.
PR	02-DEC-1999;	99WO-US028564.	DR	P-PSDB; ADE18378.
PR	02-DEC-1999;	99WO-US028565.	XX	
PR	16-DEC-1999;	99WO-US030095.	PT	New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PR	20-DEC-1999;	99WO-US030091.	PT	PRO4978, for use in molecular biology, chromosome and gene mapping, in
PR	20-DEC-1999;	99WO-US030999.	PT	generating antisense RNA and DNA, and in gene therapy.
PR	22-DEC-1999;	99WO-US030720.	XX	
PR	30-DEC-1999;	99WO-US031243.	PS	Claim 2; SEQ ID NO 375; 638pp; English.
PR	30-DEC-1999;	99WO-US031274.	XX	
PR	05-JAN-2000;	2000WO-US000219.	CC	The invention relates to isolated human PRO polypeptides (secreted and
PR	06-JAN-2000;	2000WO-US000277.	CC	transmembrane polypeptides) and the polynucleotides encoding them. The
PR	06-JAN-2000;	2000WO-US000376.	CC	invention also relates to an antibody which specifically binds to a PRO
PR	11-FEB-2000;	2000WO-US003565.	CC	polypeptide, a method for stimulating the release of tumour necrosis
PR	18-FEB-2000;	2000WO-US004341.	CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the
PR	18-FEB-2000;	2000WO-US004342.	CC	proliferation or differentiation of chondrocyte cells and a method for
PR	22-FEB-2000;	2000WO-US004414.	CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
PR	24-FEB-2000;	2000WO-US004914.	CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
PR	24-FEB-2000;	2000WO-US005004.	CC	polynucleotides are useful in molecular biology, including uses as
PR	01-MAR-2000;	2000WO-US005601.	CC	hybridisation probes, in chromosome and gene mapping, in generating
PR	02-MAR-2000;	2000WO-US005746.	CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also
PR	02-MAR-2000;	2000WO-US005841.	CC	be used in preparing PRO polypeptides by recombinant techniques and in
PR	15-MAR-2000;	2000WO-US006884.	CC	generating either transgenic animals or knock-out animals which are
PR	20-MAR-2000;	2000WO-US007377.	CC	useful in the development and screening of therapeutically useful
PR	21-MAR-2000;	2000WO-US007532.	CC	reagents. The PRO polypeptides or antibodies are used in preparing a
PR	21-MAR-2000;	2000WO-US008439.	CC	medicament for treating a condition responsive to the polypeptides or
PR	17-MAY-2000;	2000WO-US013705.	CC	antibodies, such as tumours, for stimulating and inhibiting proliferation
PR	22-MAY-2000;	2000WO-US014042.	CC	of human microvascular endothelial cells, for modulating the uptake of
PR	30-MAY-2000;	2000WO-US014941.	CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for
PR	02-JUN-2000;	2000WO-US015264.	CC	stimulating differentiation of adipocyte cells, for stimulating
PR	28-JUL-2000;	2000WO-US020710.	CC	proliferation of or gene expression in pericyte cells, for stimulating
PR	11-AUG-2000;	2000WO-US022031.	CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte
PR	23-AUG-2000;	2000WO-US023522.	CC	cells, for inducing endothelial cell tube formation and for treating
PR	24-AUG-2000;	2000WO-US023328.	CC	various bone and/or cartilage disorders such as sports injuries and
PR	08-NOV-2000;	2000WO-US030952.	CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans
PR	10-NOV-2000;	2000WO-US030873.	CC	from cartilage are useful for treating sports-related joint problems,
PR	01-DEC-2000;	2000WO-US032678.	CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
PR	20-DEC-2000;	2000US-00747259.	CC	polypeptides are also useful for treating various mammalian haemoglobin-
PR	20-DEC-2000;	2000WO-US034956.	CC	associated disorders such as various thalassaemias and conditions which
PR	28-FEB-2001;	2001US-00796498.	CC	may benefit from enhanced local immune system cell infiltration. This
PR	28-FEB-2001;	2001WO-US008520.	CC	sequence represents a human PRO polynucleotide of the invention. Note:
PR	01-MAR-2001;	2001WO-US008666.	CC	The sequence data for this patent is also available in electronic format
PR	09-MAR-2001;	2001US-00802706.	CC	from USPTO at seqdata.uspto.gov/sequence.html.
PR	14-MAR-2001;	2001US-00815744.	XX	
PR	22-MAR-2001;	2001US-00808689.	SQ	Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
PR	05-APR-2001;	2001US-00828366.		Query Match 100.0%; Score 1679; DB 1; Length 1679;
PR	10-MAY-2001;	2001US-00854208.		Best Local Similarity 100.0%; Pred. No. 6,7e-05;
PR	18-MAY-2001;	2001US-00860216.		Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
PR	25-MAY-2001;	2001US-00866028.		
PR	25-MAY-2001;	2001US-00866034.		
PR	01-JUN-2001;	2001WO-US017092.	QY	1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCAACAAGTTGAGAGCAAC 60
PR	01-JUN-2001;	2001US-00872035.	DB	1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCAACAAGTTGAGAGCAAC 60
PR	01-JUN-2001;	2001WO-US017800.	QY	61 AATCTATCAGGAAGAAGAAAGAAAACCCGACCTGACAAAAGAGAGAAAAGAAG 120
PR	05-JUN-2001;	2001US-00874503.	DB	61 AATCTATCAGGAAGAAGAAAGAAAACCCGACCTGACAAAAGAGAGAAAAGAAG 120
PR	14-JUN-2001;	2001US-00882636.	QY	121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAATTCATCTATCTCTTGGCAAT 180
PR	20-JUN-2001;	2001WO-US019692.	DB	121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAATTCATCTATCTCTTGGCAAT 180
PR	21-JUN-2001;	2001US-00887879.	QY	181 CTTTCACGGGCTGGCTCTGTGTCTCTTCCAGGAGTGCCGTCGCGAGGAGATGC 240
PR	22-JUN-2001;	2001WO-US021066.	DB	181 CTTTCACGGGCTGGCTCTGTGTCTCTTCCAGGAGTGCCGTCGCGAGGAGATGC 240
PR	29-JUN-2001;	2001WO-US021735.	QY	241 CACCTTCCCAAGCTATGGACAACTGACGTCGCGAGGGGAGAGGCCACCTCAG 300
PR	18-JUL-2001;	2001US-00908827.		
PR	08-AUG-2001;	2001US-00924419.		
PR	09-AUG-2001;	2001US-00927796.		
PR	16-AUG-2001;	2001US-00931836.		
PR	19-DEC-2001;	2001US-00028072.		
XX				

Db 241 CACCTTCCCAGCTATGGAACAACGTCAGCGTCCGGCAGGGGAGAGCGCCACCTCAG 300
Qy 301 GTGCACTATTGACAAACCGGCTACCCGGGTGGCTGGCTAAACCGGAGACCACTCTCTA 360
Db 301 GTGCACTATTGACAAACCGGCTACCCGGGTGGCTGGCTAAACCGGAGACCACTCTCTA 360
Qy 361 TGTGCGGAATGACAAGTGGTGGCTGGATCTCCGCTGGTCTCTCTGAGCAAACCCAAAC 420
Db 361 TGTGCGGAATGACAAGTGGTGGCTGGATCTCCGCTGGTCTCTCTGAGCAAACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGGCCCTTACCTGTCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGGCCCTTACCTGTCTC 480
Qy 481 GGTGCGAGACAAACACCCCAAGACCTCTAGGTCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCGAGACAAACACCCCAAGACCTCTAGGTCACCTCATTTGTGCAAGTATCTCC 540
Qy 541 CAAAAATTGTAGAGATTCTTTAGATATCTCCATTAATGAGGAAACAATATTAGCCTCAC 600
Db 541 CAAAAATTGTAGAGATTCTTTAGATATCTCCATTAATGAGGAAACAATATTAGCCTCAC 600
Qy 601 CTGCTAGCACTGTGTAGACAGAGCTAGGTTACTTTGGAGACATCTCTCCCAAGC 660
Db 601 CTGCTAGCACTGTGTAGACAGAGCTAGGTTACTTTGGAGACATCTCTCCCAAGC 660
Qy 661 GGTGGCTTTGTAGTCAAGACGAATACTTGGAAATTCAGGCAATCACCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTAGTCAAGACGAATACTTGGAAATTCAGGCAATCACCGGGAGCAGTC 720
Qy 721 AGGGGAATCAGTGCAGTGCCTCCAAATGACGTGGCGCGCCGCTGGTACGGAGATAA 780
Db 721 AGGGGAATCAGTGCAGTGCCTCCAAATGACGTGGCGCGCCGCTGGTACGGAGATAA 780
Qy 781 GGTCAACGTAATCATCCACATACATTTCCAGAGCCAGAGGTACAGGTGTCCCGTGGG 840
Db 781 GGTCAACGTAATCATCCACATACATTTCCAGAGCCAGAGGTACAGGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
Qy 901 CAAGGTGACAAAGACTGATTGAGGAAAGAAAGGGGTGAAAGTGAAGAAACAGACTTT 960
Db 901 CAAGGTGACAAAGACTGATTGAGGAAAGAAAGGGGTGAAAGTGAAGAAACAGACTTT 960
Qy 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACTGACTATGGGAATACACTTGGCT 1020
Db 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACTGACTATGGGAATACACTTGGCT 1020
Qy 1021 GGCTCCAAAGCTGGGCCACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCTCCAAAGCTGGGCCACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Qy 1081 CAGCGAGTGAACACGCGCAGTCCAGAGGGCAGGCTGGCTGGCTGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGAACACGCGCAGTCCAGAGGGCAGGCTGGCTGGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGACCTGTTCTCAAAATTTGATGTAGTGCACCTTCCCAACCGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGTTCTCAAAATTTGATGTAGTGCACCTTCCCAACCGGGAAGGCT 1200
Qy 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
Db 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
Qy 1261 TATCAAAATGAATTAAGAAACACAGCTTCATGGGACAGAAATTTAGGGGGGGAAC 1320
Db 1261 TATCAAAATGAATTAAGAAACACAGCTTCATGGGACAGAAATTTAGGGGGGGAAC 1320
Qy 1321 AAAGATACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGATACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380

Qy 1381 TTTAGGTACATGAGTGTCTTTTCCAAACCGGAAGAACACAGCACACCCGGCTTGA 1440
Db 1381 TTTAGGTACATGAGTGTCTTTTCCAAACCGGAAGAACACAGCACACCCGGCTTGA 1440
Qy 1441 CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTGGCAGTGTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTGGCAGTGTGGGCAAGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCACGCTGGAAACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACGCTGGAAACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGAAACAGATGACCTTCCGGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGATGACCTTCCGGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACAGCGCGTGTGTGTAACGTGAATATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACAGCGCGTGTGTGTAACGTGAATATAAAGAGCAAAAAA 1679

RESULT 156
ADE88686
ID ADE88686 standard; cDNA; 1679. BP.
XX
AC ADE88686;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199054-A1.
XX
PD 23-OCT-2003.
XX
PF 12-APR-2002; 2002US-00121054.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.

```
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US020731.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866024.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00892636.
PR 19-JUN-2001; 2001US-00896342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00897879.
PR 22-JUN-2001; 2001WO-US020116.
PR 23-JUN-2001; 2001US-00921066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.

PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen WE, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX
XX NPI; 2004-041356/04.
DR P-PSDB; ADE88687.
XX
XX Novel secreted and transmembrane polypeptides, PRO useful for treating
PT bone disorders, arthritis, heart attack, injuries, tumors, and
PT stimulating release of TNF-alpha from human blood.
XX
XX Claim 2; SEQ ID NO 375; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems, PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGTTTGAGGACAC 60
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGTTTGAGGACAC 60
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 61 AATCTATCAGGAAGAAAGAAAGAAAAAACCGAAGCTCGCAAAAAAGAGAAAAAGAG 120
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 121 AAGAAAAAATATGAAAAACCATCCAGCCAAAAATGCAAAATCTATCTCTTGGGCAAT 180
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 121 AAGAAAAAATATGAAAAACCATCCAGCCAAAAATGCAAAATCTATCTCTTGGGCAAT 180
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 181 CTTTCAGGGGCTGCTGCTCTGTGTCTCTTCCAAAGAGTGCCTCGCCAGCGAGATGC 240
```


PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081223P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082566P.
PR 21-APR-1998; 98US-0082568P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 27-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084602P.
PR 07-MAY-1998; 98US-0084620P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 13-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087108P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-JAN-1999; 99WO-US000528.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 28-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 08-JAN-2000; 2000WO-US000277.
PR 08-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US04341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUL-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
(ASHK/) ASHKENAZI A. J.
PA (BAKE/) BAKER K. P.
PA (BOTS/) BOTSTEIN D.
PA (DESN/) DESNOYERS L.
PA (EATO/) EATON D. L.
PA (FERR/) FERRARA N.
PA (FILV/) FILVAROFF E.
PA (FONG/) FONG S.
PA (GAOW/) GAO W.
PA (GERB/) GERBER H.
PA (GERE/) GERITSEN M. E.
PA (GODD/) GODDARD A.
PA (GODO/) GODOWSKI P. J.
PA (GIRM/) GIRMALDI J. C.
PA (GURN/) GURNEY A. L.
PA (HILL/) HILLAN K. J.
PA (KLJA/) KLJAVIN I. J.
PA (KUOS/) KUO S. S.

KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN US2003100729-A1.
 XX
 PD 29-MAY-2003.
 XX
 PF 28-AUG-2002; 2002US-00230113.
 XX
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WJ;
 XX WPI; 2004-008979/01.
 DR P-PSDB; ADD77607.
 XX
 PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, or for preparing a medicament for treating a condition
 PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
 PT cancer.
 XX
 PS Claim 2; SEQ ID NO 125; 308pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (i). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419,
 CC PRO247, PRO337, PRO536, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1186, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1340, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
 CC PRO1887, PRO1328, PRO4341, PRO1801, PRO4333, PRO3543, PRO4444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO3723, PRO5725, PRO7134, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (ii) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (ii) encoding (i) is
 CC useful for chromosome and gene mapping or gene therapy. (iii) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 GTTGTCTCCTCAGCAAAACAGTGGATTTAAATCTCCTTGCAAGCTTGAGAGCAACAC 60
 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 121 AAGAAAAAAATCATGAAACCATCCAGCAAAATGACAAATTTCTATCTTTGGGCAAT 180
 121 AAGAAAAAAATCATGAAACCATCCAGCAAAATGACAAATTTCTATCTTTGGGCAAT 180
 181 CTTTACGGGGCTGGCTGCTCTGTCTTTTCAAGAGTGGCCGTCGCGAGCGGAGATGC 240
 181 CTTTACGGGGCTGGCTGCTCTGTCTTTTCAAGAGTGGCCGTCGCGAGCGGAGATGC 240
 241 CACCTTCCCAAGCTATGACAAACCTGACGGTCCGGCAGGGGAGAGCCCAACCTCAG 300
 241 CACCTTCCCAAGCTATGACAAACCTGACGGTCCGGCAGGGGAGAGCCCAACCTCAG 300
 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGCTTAAACCGGAGCAACATCTCTA 360
 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGCTTAAACCGGAGCAACATCTCTA 360
 361 TGTCTGGAAATGACAAAGTGGTGGTCTGCTGATCCTCGGTGGTCTCTTGAGCAACACCCAAAC 420
 361 TGTCTGGAAATGACAAAGTGGTGGTCTGCTGATCCTCGGTGGTCTCTTGAGCAACACCCAAAC 420
 421 GCAGTACAGATCGAGATCCAGAAACCTGGATGTGTATGACAGGGGCCCTTACCTGTCTC 480
 421 GCAGTACAGATCGAGATCCAGAAACCTGGATGTGTATGACAGGGGCCCTTACCTGTCTC 480
 481 GGTGCAAGACAGCAACACCCCAAGACCTTAGGTCCACCTCATTTGTCAAGATTTCTCC 540
 481 GGTGCAAGACAGCAACACCCCAAGACCTTAGGTCCACCTCATTTGTCAAGATTTCTCC 540
 541 CAAAATTTAGAGATTTCTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
 541 CAAAATTTAGAGATTTCTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
 601 CTCATAGCAACTGTAGTACGAGACCTACGTTACTTGGAGACACATCTCTCCCAAGC 660
 601 CTCATAGCAACTGTAGTACGAGACCTACGTTACTTGGAGACACATCTCTCCCAAGC 660
 661 GGTGCTTTTGTGAGTGAAGACGAATATCTTGAATTTACGGGCAATCACCCTGGAGCAGTC 720
 661 GGTGCTTTTGTGAGTGAAGACGAATATCTTGAATTTACGGGCAATCACCCTGGAGCAGTC 720
 721 AGGGGACTACGAGTGCAGTGCCTCCATCACTGGCGCGCGCGCTGTGACGAGAGTAAA 780
 721 AGGGGACTACGAGTGCAGTGCCTCCATCACTGGCGCGCGCGCTGTGACGAGAGTAAA 780
 781 GGTCAACCGTGAATATCCACCATACATTTTCAAGAACCAAGGGTACAGGTGTCCCGTGG 840
 781 GGTCAACCGTGAATATCCACCATACATTTTCAAGAACCAAGGGTACAGGTGTCCCGTGG 840
 841 ACAAAGGGGACACTGCAGTGAAGCCTCAGAGTCCCTCAGCAGAAATTCAGTGTGA 900
 841 ACAAAGGGGACACTGCAGTGAAGCCTCAGAGTCCCTCAGCAGAAATTCAGTGTGA 900
 901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
 901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
 961 CCTCTCAAAACATCATTTCTTCAATGTCTCTGAACATGATGGAATACACTTGGCT 1020
 961 CCTCTCAAAACATCATTTCTTCAATGTCTCTGAACATGATGGAATACACTTGGCT 1020
 1021 GGCTCTCAACAGCTGGGCCACCAATGCCAGCATCATGCTATTGCTCCAGGCGCGCT 1080
 1021 GGCTCTCAACAGCTGGGCCACCAATGCCAGCATCATGCTATTGCTCCAGGCGCGCT 1080
 1081 CAGCGAGGTGAGCAACCGGCAACGTCGAGAGGGGAGGCTCGGCTCGCTCGCTCTTCT 1140
 1081 CAGCGAGGTGAGCAACCGGCAACGTCGAGAGGGGAGGCTCGGCTCGCTCGCTCTTCT 1140

QY 1141 GGTCTTGGACCTGCTTCTCAAAATTTTGTATGATGCGCACTTCCACCCCGGAAGGCT 1200
DB |||||
QY 1141 GGTCTTGGACCTGCTTCTCAAAATTTTGTATGATGCGCACTTCCACCCCGGAAGGCT 1200
DB |||||
QY 1201 GCGGCACACACACACACACACACACACACACACACACACACACACACACACACAC 1260
DB |||||
QY 1201 GCGGCACACACACACACACACACACACACACACACACACACACACACACACACAC 1260
DB |||||
QY 1261 TATACAAATGAATTAAGAAAGAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAC 1320
DB |||||
QY 1261 TATACAAATGAATTAAGAAAGAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAC 1320
DB |||||
QY 1321 AAAGATACCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTCAGAAATTCCTTTCAGAGATA 1380
DB |||||
QY 1321 AAAGATACCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTCAGAAATTCCTTTCAGAGATA 1380
DB |||||
QY 1381 TTTAGTACATGAGTCTTTCTTTTCCCAACCGGGAAGAACACAGACACACCCGGCTTGGATA 1440
DB |||||
QY 1381 TTTAGTACATGAGTCTTTCTTTTCCCAACCGGGAAGAACACAGACACACCCGGCTTGGATA 1440
DB |||||
QY 1441 CCACCTGCAAGCTGCACTGCAACCTCTTTGGTGCAGTGGGCAAGGGCTCAGCCTC 1500
DB |||||
QY 1441 CCACCTGCAAGCTGCACTGCAACCTCTTTGGTGCAGTGGGCAAGGGCTCAGCCTC 1500
DB |||||
QY 1501 TCTGCCACACAGAGTGCCTCCACAGTGAACATTTCTGGAGCTGCCATCCCAATTCATCA 1560
DB |||||
QY 1501 TCTGCCACACAGAGTGCCTCCACAGTGAACATTTCTGGAGCTGCCATCCCAATTCATCA 1560
DB |||||
QY 1561 GTCCATAGACGACGACGATGAGCTTCCGCGCCAGCGTGGCGCTCGCGGCTCTTGG 1620
DB |||||
QY 1561 GTCCATAGACGACGACGATGAGCTTCCGCGCCAGCGTGGCGCTCGCGGCTCTTGG 1620
DB |||||
QY 1621 GTAGACTGTGCCACACCGGCTGTGTGTGAACGTTGAATTAAGAAAGACCAAAAAA 1679
DB |||||
QY 1621 GTAGACTGTGCCACACCGGCTGTGTGTGAACGTTGAATTAAGAAAGACCAAAAAA 1679
DB |||||

RESULT 159
ADD77852
ID ADD77852 standard; cDNA; 1679 BP.
AC ADD77852;
XX
AC ADD77852;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
XX US2003100730-A1.
XX
XX 29-MAY-2003.
XX
XX 28-AUG-2002; 2002US-00230183.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX
XX 29-JUN-2001; 2001WO-US021066.
XX
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI

PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2004-008980/01.
DR P-PSDB; ADD77853.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
PT cancer.
XX
XX Claim 2; SEQ ID NO 125; 308pp; English.
PS
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO331, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO3441, PRO1801, PRO4333, PRO3543, PRO3444, PRO4332,
CC PRO5940, PRO5079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO1714, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
XX
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTTAAATCTCTTGCACAAAGCTTGAGCAACAC 60
DB 1 GTTGTGCTCTTCAGCAAAACAGTGGATTTAAATCTCTTGCACAAAGCTTGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACCATCCAGCCAAAAAATGCACAAATCTATCTTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAACCATCCAGCCAAAAAATGCACAAATCTATCTTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTGCTGTCTTCTTCCAAAGGAGTCCCGTCCGACGGAGATGC 240
DB 181 CTTACGGGGCTGGCTGCTGTCTTCTTCCAAAGGAGTCCCGTCCGACGGAGATGC 240
QY 241 CACCTTCCCAAGAGCTATGGCAACAGTGCAGCGTCCGGCAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGAGCTATGGCAACAGTGCAGCGTCCGGCAGGGGAGAGCGCCACCTCAG 300

QY	301	GTGCAC	TATTGGA	CAACCGGG	GTCA	CCCGGG	TGGCCTGG	CTAAACCGG	CAGACCAAT	CTCTTA	360
Db	301	GTGCAC	TATTGGA	CAACCGGG	GTCA	CCCGGG	TGGCCTGG	CTAAACCGG	CAGACCAAT	CTCTTA	360
QY	361	TGCTGG	GAATGAC	CAAGTGG	TGCTGG	ATCCTCG	GTGTCTTCT	GAGCAAC	ACC	CAAAAC	420
Db	361	TGCTGG	GAATGAC	CAAGTGG	TGCTGG	ATCCTCG	GTGTCTTCT	GAGCAAC	ACC	CAAAAC	420
QY	421	GCAGT	CAGCATCG	AGATCC	AGAACTG	ATGATG	ACGAGG	GGCCCTTA	CACCTG	CTC	480
Db	421	GCAGT	CAGCATCG	AGATCC	AGAACTG	ATGATG	ACGAGG	GGCCCTTA	CACCTG	CTC	480
QY	481	GGTGC	CAGACAG	CAAC	CCAAAG	ACCTCT	AGGTC	CACTCAT	TATGTG	CAAGTATCT	540
Db	481	GGTGC	CAGACAG	CAAC	CCAAAG	ACCTCT	AGGTC	CACTCAT	TATGTG	CAAGTATCT	540
QY	541	CAAAA	TTGTAG	AGATTTCT	TAC	ATATCT	CAATTA	TGAAG	GGAA	CAATAT	600
Db	541	CAAAA	TTGTAG	AGATTTCT	TAC	ATATCT	CAATTA	TGAAG	GGAA	CAATAT	600
QY	601	CTSCAT	AGCAACTG	GTAG	AC	CAGAG	CTAC	GGTTACT	TGTG	GAGAC	660
Db	601	CTSCAT	AGCAACTG	GTAG	AC	CAGAG	CTAC	GGTTACT	TGTG	GAGAC	660
QY	661	GGTTGG	CTTTGT	CA	GTAG	AC	CAAG	CAATACT	TGGAA	TT	720
Db	661	GGTTGG	CTTTGT	CA	GTAG	AC	CAAG	CAATACT	TGGAA	TT	720
QY	721	AGGG	ACTAC	AGTGC	AGTGC	CTCC	ATGAC	GTGG	CGCG	CGCG	780
Db	721	AGGG	ACTAC	AGTGC	AGTGC	CTCC	ATGAC	GTGG	CGCG	CGCG	780
QY	781	GGTCA	CGGTGA	ACTAT	CC	ACATAC	TTTC	CAGA	AGCC	AGGGT	840
Db	781	GGTCA	CGGTGA	ACTAT	CC	ACATAC	TTTC	CAGA	AGCC	AGGGT	840
QY	841	ACAAA	AGGG	CAC	CTG	AGTGC	TAAG	CTCC	CAG	AGTCC	900
Db	841	ACAAA	AGGG	CAC	CTG	AGTGC	TAAG	CTCC	CAG	AGTCC	900
QY	901	CAAG	GTATG	CA	AAAG	ACTG	ATTG	AG	AAAG	AAAG	960
Db	901	CAAG	GTATG	CA	AAAG	ACTG	ATTG	AG	AAAG	AAAG	960
QY	961	CTCT	CAAA	ACTCAT	CTTCT	CAATG	CTCT	GAC	ATG	ATG	1020
Db	961	CTCT	CAAA	ACTCAT	CTTCT	CAATG	CTCT	GAC	ATG	ATG	1020
QY	1021	GGCT	CTCAA	CAAG	CTGG	CCAC	CAATG	CC	AGCAT	CAT	1080
Db	1021	GGCT	CTCAA	CAAG	CTGG	CCAC	CAATG	CC	AGCAT	CAT	1080
QY	1081	CAGG	AGGTG	AG	CAAC	CGG	CTG	AGG	AGG	AGG	1140
Db	1081	CAGG	AGGTG	AG	CAAC	CGG	CTG	AGG	AGG	AGG	1140
QY	1141	GGTCT	TGC	ACTG	CTTCT	CAAA	TTTT	GATG	TG	AGTGC	1200
Db	1141	GGTCT	TGC	ACTG	CTTCT	CAAA	TTTT	GATG	TG	AGTGC	1200
QY	1201	GC	GC	CA	CC	CA	CA	CA	AG	CAAT	1260
Db	1201	GC	GC	CA	CC	CA	CA	CA	AG	CAAT	1260
QY	1261	TAT	CA	AA	TG	AA	TG	AA	TG	AA	1320
Db	1261	TAT	CA	AA	TG	AA	TG	AA	TG	AA	1320
QY	1321	AA	GA	AT	PA	CTTT	TGG	GG	GG	AA	1380
Db	1321	AA	GA	AT	PA	CTTT	TGG	GG	GG	AA	1380

1381	TTTAGGTCAATGGAGTCTTTCTTTTCCAAACGGGAGAAACACAGCACACCGCGCTTGA	1444
QY		
1381	TTTAGGTCAATGGAGTCTTTCTTTTCCAAACGGGAGAAACACAGCACACCGCGCTTGA	1440
DB		
1441	CCACTGCAAGTCGATCGTGCACACTCTTTGGTGCAGTGTGGCAGAGGCTCAGCCTC	1500
QY		
1441	CCACTGCAAGTCGATCGTGCACACTCTTTGGTGCAGTGTGGCAGAGGCTCAGCCTC	1500
DB		
1501	TCTGCCCAAGAGTGCGCCCAACGTGGAAACATTTCTGGAGTGGCCCATCCCAAAATTC	1560
QY		
1501	TCTGCCCAAGAGTGCGCCCAACGTGGAAACATTTCTGGAGTGGCCCATCCCAAAATTC	1560
DB		
1561	GTCCATAGACAGCAACAGAAATGAGACCTTCGGCCCAACGCGTGGCGCTCGCGGCACTTTG	1620
QY		
1561	GTCCATAGACAGCAACAGAAATGAGACCTTCGGCCCAACGCGTGGCGCTCGCGGCACTTTG	1620
DB		
1621	GTAGACTGTGCCACACACGCGCTGTGTCTGTGAACCTGAAATATAAAGAGCAAAAAAAA	1679
QY		
1621	GTAGACTGTGCCACACACGCGCTGTGTCTGTGAACCTGAAATATAAAGAGCAAAAAAAA	1679
DB		

RESULT 160

ADD85310
ID ADD85310 standard; cDNA: 1679 BP.

AC ADD85310;

DT 29-JAN-2004 (first entry)

Novel human secreted and transmembrane protein PRO337 cDNA.

human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
vulnery; antitritic; pericyte cell proliferation;
pericyte cell differentiation; chondrocyte cell proliferation;
chondrocyte cell differentiation; tumour necrosis factor alpha release;
(TNF)-alpha release; dermal fibroblast cell proliferation;
dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
colon tumour; breast tumour; prostate tumour; rectal tumour;
liver tumour; tissue typing; chromosome mapping; gene mapping;
gene therapy.

OS Homo sapiens.

PN US2003100725-A1.

29-MAY-2003

26-AUG-2002: 2002US-00227876-

15-SEP-2000 2000IS-0232887D

01-JUN-2001; 2001WO-US017800.
PR
38-JUN-2001; 2001WO-US031055
PP

PR 09-APR-2002; 2002US-00119480.

PA (GETH) GENENTECH INC.

PI Baker KP, Desnoyers L

XX WPI; 2004-008975/01.
DR DR P-PSDB; ADD85311.
DR DR

PT New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.

PS Claim 2: SEO ID NO 125: 308pp: English.

The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte

CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO1263, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO1096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 CC
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTCAGCAAAAAGTGGATTAAATCTCTTCGACAAAGCTTGAGAGCAAC 60
 DB 1 GTTGTGCTTCAGCAAAAAGTGGATTAAATCTCTTCGACAAAGCTTGAGAGCAAC 60
 QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 DB 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 QY 121 AAGAAAGAAATCATGAAAGCAATCCAGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
 DB 121 AAGAAAGAAATCATGAAAGCAATCCAGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
 QY 181 CTTCCAGGGGTGGCTGCTCTGTGCTCTTCCAGAGAGTGGCGTGGCAGCGGAGATGC 240
 DB 181 CTTCCAGGGGTGGCTGCTCTGTGCTCTTCCAGAGAGTGGCGTGGCAGCGGAGATGC 240
 QY 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGCAGGGGGAGAGCGCCACCCCTCAG 300
 DB 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGCAGGGGGAGAGCGCCACCCCTCAG 300
 QY 301 GTGCACATATTGACAAACCGGGTACCCGGGTGGCTGGCTAAACCGCAGCACCATCTCTTA 360
 DB 301 GTGCACATATTGACAAACCGGGTACCCGGGTGGCTGGCTAAACCGCAGCACCATCTCTTA 360
 QY 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCTCGGTGGTCTCTTGTGAGCAACCCCAAC 420
 DB 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCTCGGTGGTCTCTTGTGAGCAACCCCAAC 420
 QY 421 GCAGTACAGCATCGAGATCCAGACCGTGGATGTATGAGGGGCCCTTACACCTGCTC 480
 DB 421 GCAGTACAGCATCGAGATCCAGACCGTGGATGTATGAGGGGCCCTTACACCTGCTC 480
 QY 481 GGTGACAGACACCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 DB 481 GGTGACAGACACCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

QY 541 CAAAATGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
 DB 541 CAAAATGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
 QY 601 CTGCATAGCAAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
 DB 601 CTGCATAGCAAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
 QY 661 GGTGGCTTCTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
 DB 661 GGTGGCTTCTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
 QY 721 AGGGGACTACGAGTGCAGTGCTCCAAATAGCGTGGCGGCCCTGTGTGACGAGAGTAAA 780
 DB 721 AGGGGACTACGAGTGCAGTGCTCCAAATAGCGTGGCGGCCCTGTGTGACGAGAGTAAA 780
 QY 781 GGTACCGTGAACATATCACCATATCTTCAAGAGCCAGAGGTACAGGTGTCCTCGTGG 840
 DB 781 GGTACCGTGAACATATCACCATATCTTCAAGAGCCAGAGGTACAGGTGTCCTCGTGG 840
 QY 841 ACAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
 DB 841 ACAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
 QY 901 CAGGATCACAAGACACTGATTGAAGAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
 DB 901 CAGGATCACAAGACACTGATTGAAGAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
 QY 961 CTTCTCAAAATCATCTCTTCTTCAATGTCTCTGAACATGACTATGGGAATACACTTGGT 1020
 DB 961 CTTCTCAAAATCATCTCTTCTTCAATGTCTCTGAACATGACTATGGGAATACACTTGGT 1020
 QY 1021 GGCCTTCAAAAGCTGGGCCACCAATGCCAGCATCATGCTATTGTGTCAGGGCCGT 1080
 DB 1021 GGCCTTCAAAAGCTGGGCCACCAATGCCAGCATCATGCTATTGTGTCAGGGCCGT 1080
 QY 1081 CAGCGAGTGAAGCAACGCGCTCGAGGAGGCGAGCTCGCTGCTGCTGCTCTCTCTCT 1140
 DB 1081 CAGCGAGTGAAGCAACGCGCTCGAGGAGGCGAGCTCGCTGCTGCTGCTCTCTCTCT 1140
 QY 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGTATGTGAGTGCCTTTCCCAACCCGGGAAAGCT 1200
 DB 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGTATGTGAGTGCCTTTCCCAACCCGGGAAAGCT 1200
 QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
 DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
 QY 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAA 1320
 DB 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAA 1320
 QY 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGAAATTTGAAAT 1380
 DB 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGAAATTTGAAAT 1380
 QY 1381 TTTAGGTCAATGGAGTTTCTTTTCCCAAGGGGAAACACAGCACCACCCGGTTCGA 1440
 DB 1381 TTTAGGTCAATGGAGTTTCTTTTCCCAAGGGGAAACACAGCACCACCCGGTTCGA 1440
 QY 1441 CCCACTGCAAGCTGATGTGCAACCTCTTTGGTGGCAGTGTGGCAGAGGCTCAGCCTC 1500
 DB 1441 CCCACTGCAAGCTGATGTGCAACCTCTTTGGTGGCAGTGTGGCAGAGGCTCAGCCTC 1500
 QY 1501 TCTGCCCAAGAGTGCCTCCACCTGAGTGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
 DB 1501 TCTGCCCAAGAGTGCCTCCACCTGAGTGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
 QY 1561 GTCCATAGAGAGCAAGATGAGACCTTCGGGCCAAGCGTGGCGCTCGGGGCACTTTG 1620
 DB 1561 GTCCATAGAGAGCAAGATGAGACCTTCGGGCCAAGCGTGGCGCTCGGGGCACTTTG 1620
 QY 1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAAACCTGTGAAATATAAAGAGCAAAAAA 1679

DB 1621 GTAGACTGTGCCACCACCGCGTGTGTGTGAACGTGAATATAAAGAGACAAAAA 1679
|||||
RESULT 161
ADD73842
ID ADD73842 standard; cDNA; 1679 BP.
XX
AC ADD73842;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #63.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN US2003100710-A1.
XX
PD 29-MAY-2003.
XX
PF 09-AUG-2002; 2002US-00216164.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 15-SEP-2000; 2000US-0232887P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
DR WPI; 2004-008960/01.
XX
PT P-PSDB; ADD73843.
XX
PT New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.
XX
PS Claim 2; Fig 125; 309pp; English.
XX
CC The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format

CC at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatch 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGTGACAAAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGTGACAAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACATCCAGCAAAATGCAATTCCTCTCTTGGCAAT 180
DB 121 AAGAAAAAATCATGAAACATCCAGCAAAATGCAATTCCTCTCTTGGCAAT 180
QY 181 CTTACGGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGCCTGCGCAGCGGAGATGC 240
DB 181 CTTACGGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGCCTGCGCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGAACAACTGACGGTCCGGAGGGGAGAGCGCACCTCTAG 300
DB 241 CACCTTCCCAAGCTATGGAACAACTGACGGTCCGGAGGGGAGAGCGCACCTCTAG 300
QY 301 GTGCACCTATTGCAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
DB 301 GTGCACCTATTGCAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
QY 361 TGTGGGAATGACAAAGTGTGCTGATCTCTGCGTGGTCTCTTGTGAGCAACCCAAAC 420
DB 361 TGTGGGAATGACAAAGTGTGCTGATCTCTGCGTGGTCTCTTGTGAGCAACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACTGTGATGACAGGGGCGCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACTGTGATGACAGGGGCGCTTACACCTGCTC 480
QY 481 GGTGCGACAGACAAACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCGACAGACAAACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
DB 541 CAAATTTGTAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
QY 601 CTCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGGAAATTCAGGGCATCACCGGGGAGCTC 720
DB 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGGAAATTCAGGGCATCACCGGGGAGCTC 720
QY 721 AGGGGACTACAGTGCAGTGCCTCCAATGACGTGGCGCGCGCGCGCTGCTACGAGATAA 780
DB 721 AGGGGACTACAGTGCAGTGCCTCCAATGACGTGGCGCGCGCGCGCTGCTACGAGATAA 780
QY 781 GGTACCGTGAATATCCACCATACATTTTCAGNAGCCAGGGTACAGGTGTCCCGTGG 840
DB 781 GGTACCGTGAATATCCACCATACATTTTCAGNAGCCAGGGTACAGGTGTCCCGTGG 840
QY 841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGACAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGACAGAAATTCAGTGGTA 900
QY 901 CAGGATGACAAAGACTGATTAAGGAAAGAGGGGTGAAGTGAAGTGAAGTGAAGTGAAGT 960
DB 901 CAGGATGACAAAGACTGATTAAGGAAAGAGGGGTGAAGTGAAGTGAAGTGAAGTGAAGT 960
QY 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGGAATACACTTTCGT 1020

961	Db		CTCTCAAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGAACTTACACTTTGGCT	1020
1021	Qy		GGCTCCAAAGAGCTGGGCCACCAATGCGAGCATCATGCTATTTTGGTCCAGGCGCCCT	1080
1021	Db		GGCTCCAAAGAGCTGGGCCACCAATGCGAGCATCATGCTATTTTGGTCCAGGCGCCCT	1080
1081	Qy		CAGCGAGGTGAGCAACGGGCACTGAGAGGGCAGGCTGCGTCTGGCTGCTGCTCTTCT	1140
1081	Db		CAGCGAGGTGAGCAACGGGCACTGAGAGGGCAGGCTGCGTCTGGCTGCTGCTCTTCT	1140
1141	Qy		GGCTTTGCACCTGCTTCTCAAAATTTTGTGATGAGTGCCTCTCCCAACCGGGAAGGCT	1200
1141	Db		GGCTTTGCACCTGCTTCTCAAAATTTTGTGATGAGTGCCTCTCCCAACCGGGAAGGCT	1200
1201	Qy		GGCGCCACCAACCAACCAACCAACAGCAATGGCAACCCGACAGCAACCAATCAGATA	1260
1201	Db		GGCGCCACCAACCAACCAACCAACAGCAATGGCAACCCGACAGCAACCAATCAGATA	1260
1261	Qy		TATACAAATGAAATTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGGAGAAC	1320
1261	Db		TATACAAATGAAATTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGGAGAAC	1320
1321	Qy		AAAGAAATCTTTGGGGGAAAAAGAGTTTTAAAAAGAAATTTGAAATTTGCCTTGCAGATA	1380
1321	Db		AAAGAAATCTTTGGGGGAAAAAGAGTTTTAAAAAGAAATTTGAAATTTGCCTTGCAGATA	1380
1381	Qy		TTTAGGTACATGGAGTTTTCTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA	1440
1381	Db		TTTAGGTACATGGAGTTTTCTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA	1440
1441	Qy		CCCACTGCAAGCTGCACTGTCGCAACTCTTTGGTGCAGTGTGGCAAGGGCTCAGCCTC	1500
1441	Db		CCCACTGCAAGCTGCACTGTCGCAACTCTTTGGTGCAGTGTGGCAAGGGCTCAGCCTC	1500
1501	Qy		TTGCCCCACAGAGTGCCCCACGCTGGAACATCTGAGAGTGGCCATCCCAATCAATCA	1560
1501	Db		TTGCCCCACAGAGTGCCCCACGCTGGAACATCTGAGAGTGGCCATCCCAATCAATCA	1560
1561	Qy		GTCCATAGAGACGAACAGAAATGAGACTTCCGSCCAAGCTGGCGCTGGGCACTTTG	1620
1561	Db		GTCCATAGAGACGAACAGAAATGAGACTTCCGSCCAAGCTGGCGCTGGGCACTTTG	1620
1621	Qy		GTAGACTGTGCCACCAACGGCGTGTGTGTGAACGTGAAATAAAAAGAGCAAAAAAA	1679
1621	Db		GTAGACTGTGCCACCAACGGCGTGTGTGTGAACGTGAAATAAAAAGAGCAAAAAAA	1679
RESULT 162				
ADD74580				
IX	ADD74580	standard; cDNA; 1679 BP.		
AC	ADD74580;			
XX	29-JAN-2004	(first entry)		
DT	Human PRO	polynucleotide #63.		
DE	Human; PRO; Gene; ss; secreted polypeptide; transmembrane polypeptide;			
XX	tumour; cancer; lung; colon; breast; prostate; rectum; liver;			
KW	tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;			
KW	pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;			
XX	arthritis; sports injury; cytostatic; antiarthritic.			
OS	Homo sapiens.			
XX	US2003100713-A1.			
PN	29-MAY-2003.			
XX	13-AUG-2002; 2002US-00219065.			
XX	25-JUL-2000; 2000US-0220638P.			
XX				

	01-JUN-2001; 2001WO-US017800.
PR	29-JUN-2001; 2001WO-US021066.
PR	09-APR-2002; 2002US-00119480.
PA	(GETH) GENENTECH INC.
XX	Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI	WPI; 2004-008963/01.
XX	P-PSDB; ADD74581.
DR	
XX	New secreted and transmembrane PRO polypeptide useful for preparing a
PT	medicament for treating a condition that is responsive to the PRO
PT	polypeptide or anti-PRO antibody, e.g. cancer.
XX	
XX	Claim 2; Fig 125; 308pp; English.
CC	The invention relates to human PRO polypeptides (secreted and
CC	transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC	The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC	diagnostics, biosensors or bioreactors. They are particularly useful for
CC	detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC	prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC	stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC	blood, for stimulating the proliferation or differentiation of
CC	chondrocyte cells, for stimulating the proliferation of or gene
CC	expression in pericyte cells or for stimulating the proliferation of
CC	normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC	hybridisation probes, in chromosome and gene mapping, in generating
CC	antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC	technology, in generating transgenic animals or knock-out animals which
CC	may be used in the development and screening of therapeutically useful
CC	reagents, in gene therapy, in chromosome identification, as chromosome
CC	markers and in generating probes. The PRO polypeptides, or anti-PRO
CC	antibodies, are useful for preparing a medicament for treating a
CC	condition which is responsive to the PRO polypeptides or anti-PRO
CC	antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC	disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC	differentiation of chondrocytes. The PRO polypeptides are useful as
CC	molecular markers for protein electrophoresis, and in tissue typing. This
CC	sequence represents a human PRO polynucleotide of the invention. Note:
CC	The sequence data for this patent can also be obtained in electronic
CC	format directly from USPTO at seqdata.uspto.gov/sequence.html.
XX	
XX	Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
	Query Match 100.0%; Score 1679; DB 1; Length 1679;
	Best Local Similarity 100.0%; Pred.No. 6.7e-05;
	Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY	1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCCTTGACAAGCTTGAGACCAAC 60
Db	1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCCTTGACAAGCTTGAGACCAAC 60
QY	61 AATCTATCAGGAAGAAGAAAAGAAAAAACCAGACTGACAAAAGTGCACAAATTCCTTTGGCAAT 120
Db	61 AATCTATCAGGAAGAAGAAAAGAAAAAACCAGACTGACAAAAGTGCACAAATTCCTTTGGCAAT 120
QY	121 AAGAAAAAATAATCATGAAAACCATCCAGCGCAAAAATTCGACAAATTCCTTTGGCAAT 180
Db	121 AAGAAAAAATAATCATGAAAACCATCCAGCGCAAAAATTCGACAAATTCCTTTGGCAAT 180
QY	181 CTTCACGGGCTGGCTGCTCTGTGCTCTTTCCAAGGAGTCCCGTGCACGCGGAGATGC 240
Db	181 CTTCACGGGCTGGCTGCTCTGTGCTCTTTCCAAGGAGTCCCGTGCACGCGGAGATGC 240
QY	241 CACCTTCCCRAAGCTATGGACACGTTGACGTTCCGCGGGGGAGCGCCACCTCTCAG 300
Db	241 CACCTTCCCRAAGCTATGGACACGTTGACGTTCCGCGGGGGAGCGCCACCTCTCAG 300
QY	301 GTGCACTATTGCACAAACCGGGTTCACCCGGGTGGCTTAACCCGGAGACCACTCTCTA 360

Db 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGCACCATCTCTTA 360
QY 361 TGCTGGGAATGACAAAGTGGTGCCTGGATCTCTGGGTGGTCTTCTTGAGCAACACCCAAAC 420
Db 361 TGCTGGGAATGACAAAGTGGTGCCTGGATCTCTGGGTGGTCTTCTTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGACGCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGACGCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGACAGACAGCAACACCAACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGACAGACAGCAACACCAACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAGGGGAACAATATTAGCCTCAC 600
Db 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAGGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACAGAGCCCTACCGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCCCTACCGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGACGATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
QY 721 AGGGACTACGAGTGCAGTCTCCATGACGTGGCGCGCGCTGGTACGAGAGTAAA 780
Db 721 AGGGACTACGAGTGCAGTCTCCATGACGTGGCGCGCGCTGGTACGAGAGTAAA 780
QY 781 GGTCACTGAACTATCCACCATATTTTGAAGACCAAGGTTACAGGTGTCCCGTGGG 840
Db 781 GGTCACTGAACTATCCACCATATTTTGAAGACCAAGGTTACAGGTGTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGACGTGTGAGCTCAGCAGTCCCTCAGCAAGATTCAGATGGTA 900
Db 841 ACAAAGGGGACACTGACGTGTGAGCTCAGCAGTCCCTCAGCAAGATTCAGATGGTA 900
QY 901 CAAGGATCAAAAAGACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAACAGACCTTT 960
Db 901 CAAGGATCAAAAAGACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTCTTCTTCAATGCTCTGACATGACTATGGGAACCTACCTTCGT 1020
Db 961 CCTCTCAAACTCATCTCTTCTTCAATGCTCTGACATGACTATGGGAACCTACCTTCGT 1020
QY 1021 GGCCTTCAACAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCT 1080
Db 1021 GGCCTTCAACAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCT 1080
QY 1081 CAGCGAGTGAACACGACGCTCGAGGAGGCGAGGCTGCTGCTGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGAACACGACGCTCGAGGAGGCGAGGCTGCTGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGGCCACTTCCCAACCGGGGAAAGGCT 1200
Db 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGGCCACTTCCCAACCGGGGAAAGGCT 1200
QY 1201 GCCGCCACACACCAACCAACAGCAATGGCAATGGCAACCGACAGCAACCAATCAGATA 1260
Db 1201 GCCGCCACACACCAACCAACAGCAATGGCAATGGCAACCGACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Db 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTCAATGAGATTTCTTTTCCCAACCGGAGAGACACAGCAGCACCCCGCTTGA 1440
Db 1381 TTTAGGTCAATGAGATTTCTTTTCCCAACCGGAGAGACACAGCAGCACCCCGCTTGA 1440

RESULT 163

ADD77108

ID ADD77108 standard; cDNA; 1679 BP.

XX AC ADD77108;

XX XX

DT 29-JAN-2004 (first entry)

XX XX

DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnery; aniarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW Gene therapy.

XX Homo sapiens.
XX OS

XX US2003100716-A1.
XX PN

XX 29-MAY-2003.
XX PD

XX 13-AUG-2002; 2002US-00219077.
XX PF

XX 01-JUN-2001; 2001WO-US017800.
XX PR

XX 29-JUN-2001; 2001WO-US021056.
XX PR

XX 09-APR-2002; 2002US-00119480.
XX PR

XX (GETH) GENENTECH INC.
XX PA

XX Baker KD, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI: 2004-008966/01.
XX DR

XX P-PSDB; ADD77109.
XX DR

XX PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy, or for preparing a medicament for treating a condition
XX PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
XX cancer.

XX Claim 2; SEQ ID NO 125; 308pp; English.
XX PS

XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO329, PRO1372 or PRO4405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF).
XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,

CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1403, PRO1474, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO1341, PRO1801, PRO4333, PRO3543, PRO4444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO529, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO237, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTCTTCGACAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTCTTCGACAGCTTGAGAGCAAC 60

QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

QY 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
DB 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180

QY 181 CTTTCAGGGGCTGGCTGCTGTGTCTCTTCAGAGAGTGCCTGCGGAGCGGAGATGC 240
DB 181 CTTTCAGGGGCTGGCTGCTGTGTCTCTTCAGAGAGTGCCTGCGGAGCGGAGATGC 240

QY 241 CACCTTCCCAAGCTATGCAACAGTGCAGTCCGCGAGGGGAGAGCGGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGCAACAGTGCAGTCCGCGAGGGGAGAGCGGCCACCTCAG 300

QY 301 GTGCACTATTGCAACCGGCTCACCGGGTGGCTGCTTAACCGGAGCAACCTCTCTA 360
DB 301 GTGCACTATTGCAACCGGCTCACCGGGTGGCTGCTTAACCGGAGCAACCTCTCTA 360

QY 361 TGTCTGGGAATGCAAGTGGTGCCTGGATCTCTCGGTGGTCTCTTTCAGCAACCCAAAC 420
DB 361 TGTCTGGGAATGCAAGTGGTGCCTGGATCTCTCGGTGGTCTCTTTCAGCAACCCAAAC 420

QY 421 GCAGTACAGCATCGAGATCAGACAGTGGATGTGTATGAGCGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCAGACAGTGGATGTGTATGAGCGGGCCCTTACACCTGCTC 480

QY 481 GGTTCAGACAGCAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
DB 481 GGTTCAGACAGCAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540

QY 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACATATTAAGCTCAC 600
DB 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACATATTAAGCTCAC 600

QY 601 CTGCATAGCAACTGGTAGACCAGAGGCTAGGTTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTAGACCAGAGGCTAGGTTACTTGGAGACACATCTCTCCCAAGC 660

QY 661 GGTTCGCTTTGTGAGTGAAGACCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTTCGCTTTGTGAGTGAAGACCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720

QY 721 AGGGGACTACGAGTCAGTGCCTCCAAATGACGTGGCGGCGCCGCTGGTACGAGAGTAAA 780
DB 721 AGGGGACTACGAGTCAGTGCCTCCAAATGACGTGGCGGCGCCGCTGGTACGAGAGTAAA 780

QY 781 GGTTCACCGTCAACTATCCACATACATATTCAGAAAGCAAGGGTACAGGTGTCCCGTGGG 840
DB 781 GGTTCACCGTCAACTATCCACATACATATTCAGAAAGCAAGGGTACAGGTGTCCCGTGGG 840

QY 841 ACAAAGGGGACACTGCACTGAGTGTGAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGCACTGAGTGTGAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900

QY 901 CAAGGATGACAAAGACTGATTTGAGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTTGAGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960

QY 961 CCTCTCAAAACTCATCTCTTCTCAATGTCTGAAACATGACTATGGGAACTACACTTCGT 1020
DB 961 CCTCTCAAAACTCATCTCTTCTCAATGTCTGAAACATGACTATGGGAACTACACTTCGT 1020

QY 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGGT 1080
DB 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGGT 1080

QY 1081 CAGCGAGTGTAGCAACGGCAGCTCGAGAGGGGAGGCTGGTCTGTGGTCTGCTCTTCT 1140
DB 1081 CAGCGAGTGTAGCAACGGCAGCTCGAGAGGGGAGGCTGGTCTGTGGTCTGCTCTTCT 1140

QY 1141 GGTCTTGCACTGCTCTCTCAAAATTTGATGTAGTGCACCTTCCCGACCCGGGAGAGCT 1200
DB 1141 GGTCTTGCACTGCTCTCTCAAAATTTGATGTAGTGCACCTTCCCGACCCGGGAGAGCT 1200

QY 1201 GCCGCCACACACACCAACCAACAGCAATGCAACACCAAGCAAGCAACCAATCAGATA 1260
DB 1201 GCCGCCACACACACCAACCAACAGCAATGCAACACCAAGCAAGCAACCAATCAGATA 1260

QY 1261 TATACAAATGAAATTTAGAAAGAAACACAGCTTCATGGGACAGAAATTTGAGGGAGGGGAA 1320
DB 1261 TATACAAATGAAATTTAGAAAGAAACACAGCTTCATGGGACAGAAATTTGAGGGAGGGGAA 1320

QY 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGAAATTTGAAATTTGAAATTT 1380
DB 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGAAATTTGAAATTTGAAATTT 1380

QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACGGGAAAGAAACACAGCACACCCGGCTTGA 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACGGGAAAGAAACACAGCACACCCGGCTTGA 1440

QY 1441 CCCACTGCAAGCTGATCGTGCACCTTTTGGTGGCAGTGTGGCAGAGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGATCGTGCACCTTTTGGTGGCAGTGTGGCAGAGGCTCAGCCTC 1500

QY 1501 TCTGCCCCACAGAGTGCCTCCACAGTGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCCCACAGAGTGCCTCCACAGTGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560

QY 1561 GTCCATAGAGAGAAACAGATGAGACCTTCGGCCAGAGCTGGGCTGCGGCACTTTG 1620
DB 1561 GTCCATAGAGAGAAACAGATGAGACCTTCGGCCAGAGCTGGGCTGCGGCACTTTG 1620

QY 1621 GTAGACTGTGCCACACCGCGTGTGTGTGAAAACGTGAAAATGAAAAGAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACACCGCGTGTGTGTGAAAACGTGAAAATGAAAAGAGAGCAAAAAA 1679

RESULT 164

ADD85802
ID ADD85802 standard; cDNA; 1679 BP.

XX AC ADD85802;

XX DT 29-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.

XX OS Homo sapiens.

XX PN US2003100720-A1.

XX PD 29-MAY-2003.

XX PF 14-AUG-2002; 2002US-00219471.

XX PR 18-NOV-1998; 98US-0108843P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI: 2004-008970/01.
XX P-PSDB; ADD85803.

XX PT New secreted and transmembrane PRO polypeptide useful for preparing a

XX PT medicament for treating a condition that is responsive to the PRO

XX PS polypeptide or anti-PRO antibody, e.g. cancer.

XX PS Claim 2; SEQ ID NO 125; 308pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (1). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1317, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10095 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO1154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of

CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (III) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

SQ Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Fred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAAACAGTGGATTTAAATCTCTTGCAACAGCTTGAGAGCAACAC 60

DB 1 GTTGTGTCCTTCAGCAAAAACAGTGGATTTAAATCTCTTGCAACAGCTTGAGAGCAACAC 60

QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

QY 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAAATGCAAAATTCATCTCTTGGGCAAT 180

DB 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAAATGCAAAATTCATCTCTTGGGCAAT 180

QY 181 CTTTACGGGGCTGGTGTCTGTGTCTCTTCAAGAGTGGCCGCTGCGAGCGGAGATGC 240

DB 181 CTTTACGGGGCTGGTGTCTGTGTCTCTTCAAGAGTGGCCGCTGCGAGCGGAGATGC 240

QY 241 CACCTTCCCCCAAGCTATGGACAACTGACGGTCCGGCAGGGGAGAGGCCACCTCAG 300

DB 241 CACCTTCCCCCAAGCTATGGACAACTGACGGTCCGGCAGGGGAGAGGCCACCTCAG 300

QY 301 GTCACATATTGACAAACCGGGTCAACCGGTGCGCTGGCTTAAACCGGAGCACCATCTCTA 360

DB 301 GTCACATATTGACAAACCGGGTCAACCGGTGCGCTGGCTTAAACCGGAGCACCATCTCTA 360

QY 361 TGTGCGGAATGACAACTGGTGTGCTGATCCTCGGTGGTCTTCTTGAGCAACACCAAC 420

DB 361 TGTGCGGAATGACAACTGGTGTGCTGATCCTCGGTGGTCTTCTTGAGCAACACCAAC 420

QY 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACAGGGGCCCTTACCTGTCTC 480

DB 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACAGGGGCCCTTACCTGTCTC 480

QY 481 GGTGACAGACAGCAACCCCAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

DB 481 GGTGACAGACAGCAACCCCAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

QY 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTTAATGAAGGGAACAATATTAGCCTCAC 600

DB 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTTAATGAAGGGAACAATATTAGCCTCAC 600

QY 601 CTGCATAGCACTGGTAGCAGGCTTACGCTTACTTGGAGACACATCTCTCCCAAGC 660

DB 601 CTGCATAGCACTGGTAGCAGGCTTACGCTTACTTGGAGACACATCTCTCCCAAGC 660

QY 661 GGTGGCTTTGTGAGTGAAGACGAATACATCTGGAATTTAGGGGCATCACCCTGGGAGCAGTC 720

DB 661 GGTGGCTTTGTGAGTGAAGACGAATACATCTGGAATTTAGGGGCATCACCCTGGGAGCAGTC 720

QY 721 AGGGGACTAGCAGTGCAGTGCCTCCATGACGTGGCGCGCCGCTGGTACGAGAGTAAA 780

DB 721 AGGGGACTAGCAGTGCAGTGCCTCCATGACGTGGCGCGCCGCTGGTACGAGAGTAAA 780

QY 781 GGTACCGGTGAATCTATCCACCAATACATTTTCAAGAGCAAGGGGTACAGGTGTCCCGGTGG 840

DB 781 GGTACCGGTGAATCTATCCACCAATACATTTTCAAGAGCAAGGGGTACAGGTGTCCCGGTGG 840

QY 841 ACAAAGGGGACACTGAGTGTGAGGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGAGTGTGAGGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAGAGCTGATTGAAAGAAAGGGGTGAAAGTGCAGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGAGCTGATTGAAAGAAAGGGGTGAAAGTGCAGAAACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTCAATGTCTGTGAACATGACTATGGGAACTACACTTGGCT 1020
Db 961 CCTCTCAAACTCATCTTCTCAATGTCTGTGAACATGACTATGGGAACTACACTTGGCT 1020
QY 1021 GGCCTCCAAAGCTGGGCGACACCAATGCGCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCCTCCAAAGCTGGGCGACACCAATGCGCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGCGAGTGAGCAACGGCAGCTGCGAGGAGGCGAGCTGGCTGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGAGCAACGGCAGCTGCGAGGAGGCGAGCTGGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTCTCAATTTTGTATGTGAGTGCCTCCCTCCCGGGGAAAGGCT 1200
Db 1141 GGTCTTGACCTGCTCTCAATTTTGTATGTGAGTGCCTCCCTCCCGGGGAAAGGCT 1200
QY 1201 GCGGCCACCAACCAACACAGCAATGCGCAACCGCAGCAACCAATCAGATA 1260
Db 1201 GCGGCCACCAACCAACACAGCAATGCGCAACCGCAGCAACCAATCAGATA 1260
QY 1261 TATCAAAATGAATAGAAACACAGCTCTATGGGACAGAAATTTAGGGGGGAC 1320
Db 1261 TATCAAAATGAATAGAAACACAGCTCTATGGGACAGAAATTTAGGGGGGAC 1320
QY 1321 AAAGAATACCTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGAATACCTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTAGGTACATGAGTCTTTTCCCAAACGGGAAGAACACAGACACACCGGCTTGA 1440
Db 1381 TTAGGTACATGAGTCTTTTCCCAAACGGGAAGAACACAGACACACCGGCTTGA 1440
QY 1441 CCACCTCAAGCTGATCGTGCACCTTTTGTGTCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCACCTCAAGCTGATCGTGCACCTTTTGTGTCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACAGTGGAACTTTGAGAGCTGGGCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACAGTGGAACTTTGAGAGCTGGGCATCCCAATTCATCA 1560
QY 1561 GTCCATAGACGACAGATGAGACCTTCGGCCCAAGCGTGGCGTGGGGCACTTTG 1620
Db 1561 GTCCATAGACGACAGATGAGACCTTCGGCCCAAGCGTGGCGTGGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAACGGGCTGTGTTGTGAACGTGAAATATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCAACGGGCTGTGTTGTGAACGTGAAATATAAAGAGCAAAAAA 1679

RESULT 165
ADE05351
ID ADE05351 standard; cDNA; 1679 BP.

XX AC ADE05351;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #63.

XX KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
XX KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
XX KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
XX KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
XX KW arthritis; sports injury; cytostatic; antiarthritic.

XX Homo sapiens.
XX US2003100723-A1.
XX 29-MAY-2003.
XX 13-AUG-2002; 2002US-00219482.
XX 26-JUL-2000; 2000US-0220893P.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen MB, Goddard A, Godowski PJ,
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2004-008973/01.
XX P-PSDB; ADE05352.
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy, or for preparing a medicament for treating a condition
XX that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
XX cancer.
XX Claim 2; Fig 125; 308pp; English.
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers and in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes. The PRO polypeptides are useful as
XX molecular markers for protein electrophoresis, and in tissue typing. This
XX sequence represents a human PRO polynucleotide of the invention.

XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGACACAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGACACAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAACCGACCTGCACAAAAAGAAAAAGAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAACCGACCTGCACAAAAAGAAAAAGAG 120
QY 121 AAGAAAAAATCATGAAAAACATCCAGCCAAAAATGCACAAATTTATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACATCCAGCCAAAAATGCACAAATTTATCTCTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTGCTCTCTCTCTTCCAGGAGTGCCCGTGCAGCGGAGATGC 240

181 CTTTACGGGGTGGCTGCTGCTGCTCTTCTTCACAGAGTGGCCGTGGCAGCGGAGTGC 240
241 CACCTTCCCCAAGAGTATGGAACAACGTGAACGGTCCGGCAGGGGAGAGCGCCACCTTCAG 300
241 CACCTTCCCCAAGAGTATGGAACAACGTGAACGGTCCGGCAGGGGAGAGCGCCACCTTCAG 300
301 GTGCACATATTGACAAACCGGGTCCACCGGGTGGCTGGCTAAACCGGAGCACCATCTCTTA 360
301 GTGCACATATTGACAAACCGGGTCCACCGGGTGGCTGGCTAAACCGGAGCACCATCTCTTA 360
361 TGCTGGGAATGACAAAGTGGTGGCTGGATCTCTGGGTGGTCTCTGAGCAACACCCAAAC 420
361 TGCTGGGAATGACAAAGTGGTGGATCTCTGGGTGGTCTCTGAGCAACACCCAAAC 420
421 GCAGTACAGATCCAGATCCAGATCCAGATCCAGATCCAGATCCAGATCCAGATCCAGATCC 480
421 GCAGTACAGATCCAGATCCAGATCCAGATCCAGATCCAGATCCAGATCCAGATCCAGATCC 480
481 GGTGCAGACAGACAAACCCAAAGACCTCTAGGGTCCACCTATTGTGCAAGTATCTCC 540
481 GGTGCAGACAGACAAACCCAAAGACCTCTAGGGTCCACCTATTGTGCAAGTATCTCC 540
541 CAAATTTGTAGAGATTTCTTCTGAGATATCTCCATTAATGAGGGACCAATATTAGCCTCAC 600
541 CAAATTTGTAGAGATTTCTTCTGAGATATCTCCATTAATGAGGGACCAATATTAGCCTCAC 600
601 CTGCATAGCAACTGCTAGACAGAGCCTTACCTTCTTGGAGACACATCTCTCCCAAAGC 660
601 CTGCATAGCAACTGCTAGACAGAGCCTTACCTTCTTGGAGACACATCTCTCCCAAAGC 660
661 GGTGGCTTTGTGAGTGAAGACGATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGACGATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
721 AGGGACTACGAGTGCAGTGCCTTCCATGAGTGGCGCGCCGCTGGTACGAGAGTAAA 780
721 AGGGACTACGAGTGCAGTGCCTTCCATGAGTGGCGCGCCGCTGGTACGAGAGTAAA 780
781 GGTCAAGTGAACATTCACATATCATATTCAGAGCCAGAGGTACAGGTGTCCTCCGTTGG 840
781 GGTCAAGTGAACATTCACATATCATATTCAGAGCCAGAGGTACAGGTGTCCTCCGTTGG 840
841 ACAAAGGGGACATCGCAGTGTGAAGCTCAGAGCTCCCTCAGCAGATTCACAGTGGTA 900
841 ACAAAGGGGACATCGCAGTGTGAAGCTCAGAGCTCCCTCAGCAGATTCACAGTGGTA 900
901 CAAGATGACAAAAGACTGATTTGAAGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
901 CAAGATGACAAAAGACTGATTTGAAGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGAACTACACTTTCGT 1020
961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGAACTACACTTTCGT 1020
1021 GGCCTCCAAAGCTGGGCCCAACCAATGCGCAGATCATGCTATTTGGTCCAGCGCGGT 1080
1021 GGCCTCCAAAGCTGGGCCCAACCAATGCGCAGATCATGCTATTTGGTCCAGCGCGGT 1080
1081 CAGCGAGTGAACAGCAGCAGTCCAGAGGGGCGAGCTGCTGGCTGGCTGCTCTTCT 1140
1081 CAGCGAGTGAACAGCAGCAGTCCAGAGGGGCGAGCTGCTGGCTGGCTGCTCTTCT 1140
1141 GGTCTTGACCTGCTCTTCAATTTTGTATGTGAGTGCCATCTCCCAACCGGGAAAGGCT 1200
1141 GGTCTTGACCTGCTCTTCAATTTTGTATGTGAGTGCCATCTCCCAACCGGGAAAGGCT 1200
1201 GCGGCACACCAACCAACAGCAGATGGCAACCGCAGACGACCAATCAGATA 1260
1201 GCGGCACACCAACCAACAGCAGATGGCAACCGCAGACGACCAATCAGATA 1260
1261 TATACAAATGAAATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320

1261 TATACAAATGAAATAGAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGGAAC 1320
1321 AAAGAATACTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAAATTTGCCCTTCAGATA 1380
1321 AAAGAATACTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAAATTTGCCCTTCAGATA 1380
1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACGGGAGAAACACAGCAGACACCGGCTTGG 1440
1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACGGGAGAAACACAGCAGACACCGGCTTGG 1440
1441 CCCACTGCAAGTGCATGTCGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
1441 CCCACTGCAAGTGCATGTCGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
1501 TCTGCCACAGAGTGCCTCCACCTGGAACATTTCTGGAGCTGCCCATCCAAATTCAAATCA 1560
1501 TCTGCCACAGAGTGCCTCCACCTGGAACATTTCTGGAGCTGCCCATCCAAATTCAAATCA 1560
1561 GTCCATAGAGACGAACAGATAGACCTTCCGCCCCAAGCGTGGCGCTTCGGGCACTTTG 1620
1561 GTCCATAGAGACGAACAGATAGACCTTCCGCCCCAAGCGTGGCGCTTCGGGCACTTTG 1620
1621 GTAGACTGTGCCACCAACCGGCTGTGTGAAACCTGAAATTAATAAGAGCAAAAAAAA 1679
1621 GTAGACTGTGCCACCAACCGGCTGTGTGAAACCTGAAATTAATAAGAGCAAAAAAAA 1679

RESULT 166
ADD74826

ID ADD74826 standard; cDNA; 1679 BP.

XX ADD74826;

AC ADD74826;

XX 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #63.

Human; PRO; Gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.

XX Homo sapiens.

XX US2003100724-A1.

XX 29-MAY-2003.

XX 26-AUG-2002; 2002US-00227874.

XX 01-MAR-2001; 2001WO-US006666.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephen JF, Watanabe CK, Wood WI;

XX WPI: 2004-008974/01.

XX P-PSDB; ADD74827.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
in gene therapy, or for preparing a medicament for treating a condition
that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
cancer.

XX Claim 2; Fig 125; 309pp; English.

XX The invention relates to human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the PRO polynucleotides encoding them.

XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioreactors. They are particularly useful for

CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent can also be obtained in electronic
CC format directly from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6,7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTTGCAAAAGCTTGAGCAACAC 60
Db 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTTGCAAAAGCTTGAGCAACAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAACCGAAGCTGCAAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAACCGAAGCTGCAAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAATAATGCAATTCCTCTTTGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAATAATGCAATTCCTCTTTGGCAAT 180
Qy 181 CTTACGGGGCTGGCTCTGTGTCTTCTTCAAGAGTCCCGTCCGAGCGGAGATGC 240
Db 181 CTTACGGGGCTGGCTCTGTGTCTTCTTCAAGAGTCCCGTCCGAGCGGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGACAACTGACGGTCCGGCAGGGGGAGCGCCACCTCTAG 300
Db 241 CACCTTCCCAAGCTATGACAACTGACGGTCCGGCAGGGGGAGCGCCACCTCTAG 300
Qy 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGCAATCTCTTA 360
Db 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGCAATCTCTTA 360
Qy 361 TGCTGGGAATGACAAGTGGTCCCTGGATCCTCGGTGGTCTCTTCTGAGCAACCCAAAC 420
Db 361 TGCTGGGAATGACAAGTGGTCCCTGGATCCTCGGTGGTCTCTTCTGAGCAACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
Qy 481 GGTGAGACAGCAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGAGACAGCAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
Qy 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTAC 600
Db 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTAC 600
Qy 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGAGACACATCTCTCCCAAGC 660

Qy 661 GTTTGGCTTTGTGAGTGAGAACGAAATCTTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
Db 661 GTTTGGCTTTGTGAGTGAGAACGAAATCTTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTGACAGTGCCTCCATGACGTGGCGCGCCCGTGTACGGAGAGTAAA 780
Db 721 AGGGGACTACGAGTGACAGTGCCTCCATGACGTGGCGCGCCCGTGTACGGAGAGTAAA 780
Qy 781 GGTCAACCGTGAACATATCCACATATTTAGAAAGCCAAAGGTACAGGTGTCCCGTGGG 840
Db 781 GGTCAACCGTGAACATATCCACATATTTAGAAAGCCAAAGGTACAGGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGAGTGTA 900
Db 841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGAGTGTA 900
Qy 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGAAGAACACACCTTT 960
Db 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGAAGAACACACCTTT 960
Qy 961 CCTCTCAAACTCATCTTCTCAATGTCTCTGACATGATATGGAACATACACTTCGGT 1020
Db 961 CCTCTCAAACTCATCTTCTCAATGTCTCTGAAACATGACTATGGGAATACACTTCGGT 1020
Qy 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCT 1080
Db 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCT 1080
Qy 1081 CAGGAGGTGAGCAACCGCAGCTCGAGGAGGCGAGGTGGTCTGGCTGCTCTCTCTCT 1140
Db 1081 CAGGAGGTGAGCAACCGCAGCTCGAGGAGGCGAGGTGGTCTGGCTGCTCTCTCTCT 1140
Qy 1141 GGTCTTGACCTGTCTCTCAATTTTGTATGTAGTGGCCACTTCCCAACCGGGGAAAGCT 1200
Db 1141 GGTCTTGACCTGTCTCTCAATTTTGTATGTAGTGGCCACTTCCCAACCGGGGAAAGCT 1200
Qy 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
Db 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
Qy 1261 TATACAAATGAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAA 1320
Db 1261 TATACAAATGAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAA 1320
Qy 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCTTCAGATA 1380
Db 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCTTCAGATA 1380
Qy 1381 TTTAGGTACATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCACCACCGGCTTGA 1440
Db 1381 TTTAGGTACATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCACCACCGGCTTGA 1440
Qy 1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGGCCCCACGCTGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGGCCCCACGCTGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGAAACAGATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCCTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCCTTTG 1620
Qy 1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAAAGCTGGAATTAAGAGGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAAAGCTGGAATTAAGAGGCAAAAAAAA 1679

RESULT 167
AAZ47893 standard; cDNA; 1693 BP.
ID AAZ47893
XX

AAZ47893;
 10-MAR-2000 (first entry)
 Human protein encoding cDNA SEQ ID NO:3.
 Human; haematopoietic cell regulation; tissue generation; repair; reparation;
 activin; inhibin; taxis; chemotaxis; blood coagulation; thrombus;
 receptor; ligand; autoimmunity; infection-related immunodeficiency;
 inflammatory disorder; neurological disease; ss.
 Homo sapiens.
 Key Location/Qualifiers
 CDS 214..1164
 /*tag= a
 WO9958668-A1.
 18-NOV-1999.
 13-MAY-1999; 99WO-JP002485.
 14-MAY-1998; 98JP-00131815.
 (ONOI) ONO PHARM CO LTD.
 Fukushima D, Shibayama S, Tada H;
 WPI: 2000-062298/05.
 P-FSDB; AAY57601.
 New polypeptides of human origin having cell regulatory, tissue
 generation, coagulant and other activities.
 Claim 5; Page 42-45; 84pp; Japanese.
 The present sequence encodes a specifically claimed novel human protein.
 The novel human protein can be used in therapeutic drugs for the
 prevention and treatment of a broad range of disorders including
 autoimmune and infection-related immunodeficiency, inflammatory
 disorders, and neurological diseases. The novel protein is expected of
 having haematopoietic cell regulatory activity, tissue generation/
 reparation activity, activin/inhibin activity, taxis/chemotaxis activity,
 blood coagulation and thrombus activity, and receptor/ligand activity
 Query Match 99.0%; Score 1661.9; DB 1; Length 1693;
 Best Local Similarity 99.9%; Pred. No. 7.9e-05;
 Matches 1673; Conservative 0; Mismatches 1; Indels 1; Gaps 1;
 6 GTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAAATCT 65
 1 GTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAAATCT 60
 66 ATCAGGAAAGAAAGAAAG-AAAAAACCAGACCTGACAAAAAAGAAAGAAAGAAAGA 124
 61 ATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGA 120
 125 AAAAAAATCATGAAACCATCCAGCCAAATGCAAAATCTATCTCTTGGGCAATCTTC 184
 121 AAAAAAATCATGAAACCATCCAGCCAAATGCAAAATCTATCTCTTGGGCAATCTTC 180
 185 ACGGGGCTGGCTGCTGCTGCTCTTCCAGAGAGTGGCCGCGCAGCGAGATGCCACC 244
 181 ACGGGGCTGGCTGCTGCTGCTCTTCCAGAGAGTGGCCGCGCAGCGAGATGCCACC 240
 245 TTCCCAAGAGCTATGGAACAACTGACGTCGGCAGGGGAGAGCGCCACCTCAGGTGC 304
 241 TTCCCAAGAGCTATGGAACAACTGACGTCGGCAGGGGAGAGCGCCACCTCAGGTGC 300
 305 ACTATTGACACCGGGTGCACCCGGGTGGCTTAACCCGACGACCATCTCTATGCT 364

301 ACTATTGACAAACGGGTACCCGGGTGGCTGGCTAAACCCGAGCACCATCTCTATGCT 360
 365 GGAATGACAAAGTGGTGCCTGGATCTCGCGTGGTCTCTTCTGAGCAACACCAAGCGCAG 424
 361 GGAATGACAAAGTGGTGCCTGGATCTCGCGTGGTCTCTTCTGAGCAACACCAAGCGCAG 420
 425 TAGAGCATCGAGATCCAGAACGTCGATGTCATGAGAGGGCCCTTACACCTGCTCGGTG 484
 421 TAGAGCATCGAGATCCAGAACGTCGATGTCATGAGAGGGCCCTTACACCTGCTCGGTG 480
 485 CAGACAGACAAACCCCAAGAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCCAAA 544
 481 CAGACAGACAAACCCCAAGAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCCAAA 540
 545 ATTGTAGAGATTCTTTCAGATATCTCCATTAATGAAGGAAACAAATATTAGCTCAGCTGC 604
 541 ATTGTAGAGATTCTTTCAGATATCTCCATTAATGAAGGAAACAAATATTAGCTCAGCTGC 600
 605 ATAGCAACTGGTAGACAGAGCCTACGTTACTTGGAGACACATCTCTCCCAAGGGTT 664
 601 ATAGCAACTGGTAGACAGAGCCTACGTTACTTGGAGACACATCTCTCCCAAGGGTT 660
 665 GGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCGGGAGCAGTCAGGG 724
 661 GGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCGGGAGCAGTCAGGG 720
 725 GACTACGAGTGCAGTGCCTCCCAATGACGTGGCGCGCTGTGTACGAGAGTAAAGTGC 784
 721 GACTACGAGTGCAGTGCCTCCCAATGACGTGGCGCGCTGTGTACGAGAGTAAAGTGC 780
 785 ACCGTGAACATATCCACCATACATTTTCAAGAACCAAGGTACAGGTGTCCCGTGGACAA 844
 781 ACCGTGAACATATCCACCATACATTTTCAAGAACCAAGGTACAGGTGTCCCGTGGACAA 840
 845 AAGGGGACACTGCAGTGTGAGCCCTCAGCAGTCCCTCAGCAGCATTCAGAGTGGTACAG 904
 841 AAGGGGACACTGCAGTGTGAGCCCTCAGCAGTCCCTCAGCAGCATTCAGAGTGGTACAG 900
 905 GATGACAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTTCTCTC 964
 901 GATGACAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTTCTCTC 960
 965 TCAAACTCATCTCTTCAATGTCCTGAACTGACTATGGAACTACACTTGGTGGCC 1024
 961 TCAAACTCATCTCTTCAATGTCCTGAACTGACTATGGAACTACACTTGGTGGCC 1020
 1025 TCCAACAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGCTCAGC 1084
 1021 TCCAACAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGCTCAGC 1080
 1085 GAGTGAAGCAACGGCAGCTGAGAGGGCAGCGTGGTCTGCTGCTGCTCTCTGCTC 1144
 1081 GAGTGAAGCAACGGCAGCTGAGAGGGCAGCGTGGTCTGCTGCTGCTCTCTGCTC 1140
 1145 TTGCACCTGCTTCTCAAAATTTTGTGAGTGGTCCACTTCCCCACCGGAAAGGGTGGCG 1204
 1141 TTGCACCTGCTTCTCAAAATTTTGTGAGTGGTCCACTTCCCCACCGGAAAGGGTGGCG 1200
 1205 CACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1264
 1201 CACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
 1265 CAAATGAAATTAGAAGAAACACACACCTCATGGGACAGAAATTTGAGGGAGGGGAAACAA 1324
 1261 CAAATGAAATTAGAAGAAACACACACCTCATGGGACAGAAATTTGAGGGAGGGGAAACAA 1320
 1325 AATCTTTGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCTTTGCGAGATATTTA 1384
 1321 AATCTTTGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCTTTGCGAGATATTTA 1380
 1385 GGTACAACTGAGTTTTCTTTTCCCAACCGGGAAGAACACAGACACACCGCGCTTGACCCA 1444

Db 1381 GGTAACATGGAGTTTCTTTTCCAAACGGGAAGAAACACAGCACACCCGGCTTGGACCCA 1440
QY 1445 CTGCAAGTCATCGTGCACCTTTTGGTGCCAGTGTGGCAAGGCTCAGCCTCTCTG 1504
Db 1441 CTGCAAGTCATCGTGCACCTTTTGGTGCCAGTGTGGCAAGGCTCAGCCTCTCTG 1500
QY 1505 CCACAGAGTGCCTCCACAGTGGAAACATTTCTGGAGCTGGCCATCCCAAAATTCATCAGTCC 1564
Db 1501 CCACAGAGTGCCTCCACAGTGGAAACATTTCTGGAGCTGGCCATCCCAAAATTCATCAGTCC 1560
QY 1565 ATAGAGCAGCAAGATGAGACCTTCGGCCCAAGCGTGGCGTGGCGCACTTTGGTAG 1624
Db 1561 ATAGAGCAGCAAGATGAGACCTTCGGCCCAAGCGTGGCGTGGCGCACTTTGGTAG 1620
QY 1625 ACTGTGCCACACGGCGTGTGTGTGAACAGTGAATAAAGAGCAAAAAA 1679
Db 1621 ACTGTGCCACACGGCGTGTGTGTGAACAGTGAATAAAGAGCAAAAAA 1675

RESULT 168
AAA88791
ID AAA88791 standard; cDNA; 2012 BP.
XX
AC AAA88791;
XX
DT 19-FEB-2001 (first entry)
XX
DE Human SECC cDNA Clone 11753149.0.37.
XX
KW SECC; human; diagnosis; gene therapy; cell adhesion; ss.
XX
OS Homo sapiens.

XX FH Key Location/Qualifiers
XX CDS 501..1535
FT /*tag= a
FT sig_peptide 501..599
FT /*tag= b
FT mat_peptide 600..1532
FT /*tag= c
XX
XX WO200061754-A2.

XX
XX 19-OCT-2000.
XX
XX 07-APR-2000; 2000WO-US009392.
XX
XX 09-APR-1999; 99US-0128514P.
XX 03-MAR-2000; 2000US-0186592P.
XX 06-APR-2000; 2000US-00544511.

XX (CURA-) CURAGEN CORP.
XX
XX Fernandez E, Vernet C, Shinkets R;
XX
XX WPI; 2000-679487/66.
XX P-PSDB; AAB19722.

XX SECC polypeptides and the nucleic acids that encode them, useful for
XX diagnosing, preventing and treating e.g. cancers, inflammation, arthritis
XX and immunological disorders.

XX Claim 14; Fig 3; 143pp; English.

XX The present sequence is that of SECC Clone 11753149.0.37, which resembles
XX rat neural cell adhesion molecule neurotrimin and human opioid binding
XX protein/cell adhesion molecule OBCAM. The clone was initially identified
XX in human foetal brain tissue. The invention provides novel SECC
XX polynucleotides (see AAB8789-804) and the secreted or membrane-
XX associated proteins encoded by them (see AAB19720-34). SECC
XX polynucleotides, polypeptides and antibodies can be used in the
XX detection, diagnosis and treatment (including gene therapy) of a broad
XX range of pathological states

XX
SQ Sequence 2012 BP; 567 A; 503 C; 512 G; 430 T; 0 U; 0 Other;
Query Match 97.9%; Score 1643.4; DB 1; Length 2012;
Best Local Similarity 99.9%; Pred. No. 7.9e-05;
Matches 1644; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 GTTGTGTCCTTTCAGCAAAACAGTGGATTAAATCTCTCTTGCAAGCTTGGAGCAACAC 60
Db GTTGTGTCCTTTCAGCAAAACAGTGGATTAAATCTCTCTTGCAAGCTTGGAGCAACAC 427
QY 61 AATCTATCAGAAAGAAAGAAAGAAACCGAACTCTGACAAAGAAAGAAAGAAAG 120
Db AATCTATCAGAAAGAAAGAAAGAAACCGAACTCTGACAAAGAAAGAAAGAAAG 487
QY 121 AAGAAAAAATCATGAAACCATCCAGCCAAAAATGCACAAATCTATCTCTTGGCAAT 180
Db AAGAAAAAATCATGAAACCATCCAGCCAAAAATGCACAAATCTATCTCTTGGCAAT 547
QY 181 CTTACGGGGTGGCTGCTGTCTCTTCCAAAGAGTGCCCTGCGCAGCGAGATGC 240
Db CTTACGGGGTGGCTGCTGTCTCTTCCAAAGAGTGCCCTGCGCAGCGAGATGC 607
QY 241 CACCTTCCCAAGCTATGGACAGCTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
Db CACCTTCCCAAGCTATGGACAGCTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 667
QY 301 GTGCACATTGACAAACCGGGTCAACCCGGGTGGCTTAAACCGCAGCACCATCTCTA 360
Db GTGCACATTGACAAACCGGGTCAACCCGGGTGGCTTAAACCGCAGCACCATCTCTA 727
QY 361 TGCTGGGATGACAAAGTGGTGGCTGGATCTCTGGCTGGTCTCTTGAGCAACACCCAAAC 420
Db TGCTGGGATGACAAAGTGGTGGCTGGATCTCTGGCTGGTCTCTTGAGCAACACCCAAAC 787
QY 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACGTCTC 480
Db GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACGTCTC 847
QY 481 GGTGCAGACAGCAACCAACCCAAAGACCTCTAGGGTCCACTATTTGTGCAAGTATCTCC 540
Db GGTGCAGACAGCAACCAACCCAAAGACCTCTAGGGTCCACTATTTGTGCAAGTATCTCC 907
QY 541 CAAAATTGTAGAGATTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Db CAAAATTGTAGAGATTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 967
QY 601 CTGCATAGCAACTGGTAGACACAGAGCCTTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db CTGCATAGCAACTGGTAGACACAGAGCCTTACGGTTACTTTGGAGACACATCTCTCCAAAGC 1027
QY 661 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
Db GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATACCCGGGAGCAGTC 1087
QY 721 AGGGGACTACAGTGCAAGTGCTCCCAATGACGTGGCCGCCCGCTGGTACGGAGAGTAAA 780
Db AGGGGACTACAGTGCAAGTGCTCCCAATGACGTGGCCGCCCGCTGGTACGGAGAGTAAA 1147
QY 781 GGTACCGTGAAGTATCCACCATATCTCAGAGCCAAAGGTAAGGTACAGGTGTCCCGTGG 840
Db GGTACCGTGAAGTATCCACCATATCTCAGAGCCAAAGGTAAGGTACAGGTGTCCCGTGG 1207
QY 841 AAAAAAGGGGACACTGCAAGTGTGAAGCTCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGTA 900
Db AAAAAAGGGGACACTGCAAGTGTGAAGCTCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGTA 1267
QY 901 CAAGATGACAAAAGACTGATTGAAGAAAGAAAGGGGTGAAAGTGGAAACACACCTTT 960
Db CAAGATGACAAAAGACTGATTGAAGAAAGAAAGGGGTGAAAGTGGAAACACACCTTT 1327
QY 961 CCTCTCAAAATCTATCTTCTCAATGTCTCTGAACATGACTATGGGAACATACCTTGGT 1020

Db 1328 CCTCTCAAACTCATCTCTTCAATGTCCTGAACATGACTATATGGAACTACACTTGGCT 1387
Qy 1021 GGCCTCCAAAGCTGGGCCACACCAATCCAGCATCATGCTATTTGGTCCAGCGCCGT 1080
Db 1398 GGCCTCCAAAGCTGGGCCACACCAATCCAGCATCATGCTATTTGGTCCAGCGCCGT 1447
Qy 1081 CAGGAGGTGAGCAACGCGCAGTCGAGAGGGCAGGCTGCTGCTGCTGCTGCTTCT 1140
Db 1448 CAGGAGGTGAGCAACGCGCAGTCGAGAGGGCAGGCTGCTGCTGCTGCTGCTTCT 1507
Qy 1141 GGTCTTGACCTGCTTCTCAATTTTGTAGTGGCCTTCCACCCCGGGAAGGCT 1200
Db 1508 GGTCTTGACCTGCTTCTCAATTTTGTAGTGGCCTTCCACCCCGGGAAGGCT 1567
Qy 1201 GCGGCCACCAACACCAACCAACAGCAATGCAACAGCAGCAACCAATCAGATA 1260
Db 1568 GCGGCCACCAACCAACCAACAGCAATGCAACAGCAGCAACCAATCAGATA 1627
Qy 1261 TATACAAATGAATATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGGGAAC 1320
Db 1628 TATACAAATGAATATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGGGAAC 1687
Qy 1321 AAAGAATATCTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTTCAGATA 1380
Db 1688 AAAGAATATCTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTTCAGATA 1747
Qy 1381 TTAGGTACATGAGTTTCTTTTCCAAACGGGAGACACAGCACACCCGCTTGA 1440
Db 1748 TTAGGTACATGAGTTTCTTTTCCAAACGGGAGAAACACAGCACACCCGCTTGA 1807
Qy 1441 CCCACTGCAAGTGCATCGTCAACCTCTTTGGTGCCAGTGTGGGCAAGGCTCAGCCTC 1500
Db 1808 CCCACTGCAAGTGCATCGTCAACCTCTTTGGTGCCAGTGTGGGCAAGGCTCAGCCTC 1867
Qy 1501 TCTGCCACAGAGTCCCGCCACGTGGAAATCTTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1868 TCTGCCACAGAGTCCCGCCACGTGGAAATCTTGGAGCTGGCCATCCCAATTCATCA 1927
Qy 1561 GTCCATAGACGAAACAGAAATGAGACCTTCCGCGCCAGCGTGGCGTGGGCACTTTG 1620
Db 1928 GTCCATAGACGAAACAGAAATGAGACCTTCCGCGCCAGCGTGGCGTGGGCACTTTG 1987
Qy 1621 GTAGACTGTGCCACACCGCGCTGTG 1645
Db 1988 GTAGACTGTGCCACACCGCGCTGTG 2012

RESULT 169
ADD18290
ID ADD18290 standard; DNA; 2012 BP.
XX
AC ADD18290;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human molecule (MOL) protein MOL11 DNA sequence.
XX
KW molecule protein; MOL protein; MOLX; MOLX agonist; MOLX antagonist;
KW cardiant; antidiabetic; antiatherosclerotic; gene therapy;
KW MOLX-associated disorder; cardiomyopathy; diabetes; atherosclerosis; ds;
KW human; MOL11.
XX
OS Homo sapiens.
XX
PN WO2003003984-A2.
XX
PD 16-JAN-2003.
XX
PF 03-JUL-2002; 2002WO-US021268.
XX
PR 05-JUL-2001; 2001US-0303169P.
PR 05-JUL-2001; 2001US-0303241P.
PR 26-SEP-2001; 2001US-00965212.

PR 26-SEP-2001; 2001US-00966545.
PR 26-SEP-2001; 2001US-00966546.
PR 01-APR-2002; 2002US-0368996P.
PR 01-APR-2002; 2002US-0369065P.
PR 08-MAY-2002; 2002US-0378730P.
PR 30-MAY-2002; 2002US-0384327P.
PR 07-JUN-2002; 2002US-0386816P.
PR 17-JUN-2002; 2002US-00174372.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Fernandes ER, Vernet CAM, Shimkets RA, Anderson DM, Padigaru M;
PI Boldog FL, Li L, Shenoy SG, Casman SJ, Rastelli L, Alsobrook JP;
PI Burgess CE, Grosse WM, Gusev VI, Ji W, Lepley DM, Liu X, Mezick AJ;
PI Patturajan M, Shen L, Spaderna SK, Spytek KA, Szekeres ES;
PI Taupier RJ, Tchervet V, Zerhusen BD, Voss EZ;
XX
DR WPI; 2003-210304/20.
DR P-PSDB; ADD18291.
XX
XT New MOLX polypeptide, nucleic acid or MOLX-specific antibody, useful for
PT preparing a composition for treating or preventing a MOLX-associated
PT disorder, e.g., cardiomyopathy, diabetes or atherosclerosis.
XX
PS Claim 8; SEQ ID NO 139; 371pp; English.
XX
CC This invention relates to novel human nucleic acid sequences which encode
CC novel molecule (MOL) proteins numbered MOL1-23, referred to generally in
CC the specification as MOLX. Compounds which modulate the function of the
CC MOLX proteins of the invention, MOLX agonists or antagonists, may have
CC cardiant, antidiabetic or antiatherosclerotic activities. In addition,
CC the DNA and protein sequences disclosed may prove useful for gene
CC therapy. The protein, nucleic acid or antibody is useful for preparing a
CC composition for treating or preventing a MOLX-associated disorder, for
CC example cardiomyopathy, diabetes or atherosclerosis. The present sequence
CC is the DNA sequence encoding a MOL protein of the invention.
XX
SQ Sequence 2012 BP; 567 A; 503 C; 512 G; 430 T; 0 U; 0 Other;

Query Match 97.9%; Score 1643.4; DB 1; Length 2012;
Best Local Similarity 99.9%; Pred No. 7.9e-05;
Matches 1644; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 GTGTGTCTCTCAGCAAAACAGTGGATTTAAATCTCTTGACAAAGTTGAGAGCAAC 60
Db 368 GTTGTGCTCTCAGCAAAACAGTGGATTTAAATCTCTTGACAAAGTTGAGAGCAAC 427
Qy 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 428 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 487
Qy 121 AAGAAAAAATCATGAAACCATCCAGCCAAAAATGCACAAATTCATCTCTTGGCAAT 180
Db 488 AAGAAAAAATCATGAAACCATCCAGCCAAAAATGCACAAATTCATCTCTTGGCAAT 547
Qy 181 CTTTCAGGGGCTGGTCTCTGTCTCTTCCAGGAGTCCCGTCCGAGGAGATGC 240
Db 548 CTTTCAGGGGCTGGTCTCTGTCTCTTCCAGGAGTCCCGTCCGAGGAGATGC 607
Qy 241 CACCTTCCCCAAAGCTATGACAAAGTGCAGCGTCCGCGAGGGGAGAGCGCCACCTCAG 300
Db 608 CACCTTCCCCAAAGCTATGACAAAGTGCAGCGTCCGCGAGGGGAGAGCGCCACCTCAG 667
Qy 301 GTGCACTATTGACACCGGCTCACCCGGTGGCTTAAACCCGACGACCATCTCTA 360
Db 668 GTGCACTATTGACACCGGCTCACCCGGTGGCTTAAACCCGACGACCATCTCTA 727
Qy 361 TGTGGGAATGACAAAGTGGTGGTCTCGATCTCTCGCTGGTCTCTTCTGAGCAACACCAAC 420
Db 728 TGTGGGAATGACAAAGTGGTGGTCTCGATCTCTCGCTGGTCTCTTCTGAGCAACACCAAC 787
Qy 421 GCAGTACAGCATCGAGATCCCAAGCGTGGATGTGTATGAGGGGCTTACACCTGCTC 480

```
Db 788 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 847
Qy 481 GGTGCAGACAGACAACCCACCAAGACCTCTTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540
Db 848 GGTGCAGACAGACAACCCACCAAGACCTCTTAGGCTCCACCTCATTTGTGCAAGTATCTCC 907
Qy 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAGAAATATTAGCCTCAC 600
Db 908 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAGAAATATTAGCCTCAC 967
Qy 601 CTGCATAGCAACTGTGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
Db 968 CTGCATAGCAACTGTGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAAGC 1027
Qy 661 GGTGTGCTTTGTAGTGAAGAGAGAAATACCTTGAAATTCAGGCGATCACCCGGAGAGTC 720
Db 1028 GGTGTGCTTTGTAGTGAAGAGAGAAATACCTTGAAATTCAGGCGATCACCCGGAGAGTC 1087
Qy 721 AGGGGACTACGAGTGCAGTCCCTCCAAATGACGTGGCGCGCGGTGTACGGAGAGTAA 780
Db 1088 AGGGGACTACGAGTGCAGTCCCTCCAAATGACGTGGCGCGCGGTGTACGGAGAGTAA 1147
Qy 781 GGTACCGTGAATATCCACATACATATTCAGAAAGCCAAAGGTACAGGTGTCCCGTGGG 840
Db 1148 GGTACCGTGAATATCCACATACATATTCAGAAAGCCAAAGGTACAGGTGTCCCGTGGG 1207
Qy 841 ACAAAGGGGACACTGCAGTGTGAGCGCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
Db 1208 ACAAAGGGGACACTGCAGTGTGAGCGCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 1267
Qy 901 CAAAGGATGACAAAGACTGATTGAAAGGAAAGAGGGTGAAGTGGAAAGACAGACCTTT 960
Db 1268 CAAAGGATGACAAAGACTGATTGAAAGGAAAGAGGGTGAAGTGGAAAGACAGACCTTT 1327
Qy 961 CCTCTCAAACTCATCTTCTCAATGTCTGACATGATATGGGAATACATCTGCT 1020
Db 1328 CCTCTCAAACTCATCTTCTCAATGTCTGACATGATATGGGAATACATCTGCT 1387
Qy 1021 GGCTTCCAAAGCTGGGCGACACCAATGCGACATCATCTATTGGTCCAGGCGCGCT 1080
Db 1388 GGCTTCCAAAGCTGGGCGACACCAATGCGACATCATCTATTGGTCCAGGCGCGCT 1447
Qy 1081 CAGCAGGTGAGCAACGGCAAGTGCAGAGGGGAGGCTGCTGCTGCTGCTGCTTCTTCT 1140
Db 1448 CAGCAGGTGAGCAACGGCAAGTGCAGAGGGGAGGCTGCTGCTGCTGCTGCTTCTTCT 1507
Qy 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTAGTGCACCTTCCCGACCGGGAAGGCT 1200
Db 1508 GGTCTTGCACTGCTTCTCAAAATTTGATGTAGTGCACCTTCCCGACCGGGAAGGCT 1567
Qy 1201 GCGGCCACCAACCAACCAACAGCAATGGCAACCGGACAGCAACCAATCAGATA 1260
Db 1568 GCGGCCACCAACCAACCAACAGCAATGGCAACCGGACAGCAACCAATCAGATA 1627
Qy 1261 TATCAAAATGAATTAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Db 1628 TATCAAAATGAATTAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1687
Qy 1321 AAGAATACCTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1688 AAGAATACCTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1747
Qy 1381 TTTAGTACATGAGATTTCTTTTCCAAACGGGAGAGACAGACACACCGGCTTGA 1440
Db 1748 TTTAGTACATGAGATTTCTTTTCCAAACGGGAGAGACAGACACACCGGCTTGA 1807
Qy 1441 CCCACTGCAAGCTGCACTGTCGCAACCTTCTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1808 CCCACTGCAAGCTGCACTGTCGCAACCTTCTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC 1867
Qy 1501 TCTGCCACAGAGTGGCCCCCAGTGGGAACATTTCTGGAGCTGGGCATCCCAATTCATCA 1560
Db 1868 TCTGCCACAGAGTGGCCCCCAGTGGGAACATTTCTGGAGCTGGGCATCCCAATTCATCA 1927
```

```
Qy 1561 GTCATAGACGACGAAACAGAAATGAGACCTTCGCGCCCAAGCGTGGCGTGGCGCACTTTG 1620
Db 1928 GTCATAGACGACGAAACAGAAATGAGACCTTCGCGCCCAAGCGTGGCGTGGCGCACTTTG 1987
Qy 1621 GTACACTGTGCCACCAACGCGGTGTG 1645
Db 1988 GTACACTGTGCCACCAACGCGGTGTG 2012

RESULT 170
AAA88790
ID AAA88790 standard; cDNA; 1603 BP.
XX
AC AAA88790;
XX
DT 19-FEB-2001 (first entry)
XX
DE Human SECX cDNA Clone 11753149.0.6.
XX
KW SECX; human; diagnosis; gene therapy; cell adhesion; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
CDS 92..1126
FT sig_peptide 92..190 b
FT mat_peptide 191..1123
FT /*tag= c
XX
FN WO200061754-A2.
XX
PD 19-OCT-2000.
XX
PF 07-APR-2000; 2000WO-US009392.
XX
PR 09-APR-1999; 99US-0128514P.
PR 03-MAR-2000; 2000US-0186592P.
PR 06-APR-2000; 2000US-00544511.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Fernandez E, Vernet C, Shinkets R;
XX
WPI; 2000-679487/66.
P-PSDB; AAB19721.
XX
PT SECX polypeptides and the nucleic acids that encode them, useful for
diagnosing, preventing and treating e.g. cancers, inflammation, arthritis
and immunological disorders.
XX
PS Claim 14; Fig 2; 143pp; English.
XX
CC The present sequence is that of SECX Clone 11753149.0.6, which resembles
rat neural cell adhesion molecule neurotin and human opioid binding
protein/cell adhesion molecule OBCAM. The clone was initially identified
in human foetal brain tissue. The invention provides novel SECX
polynucleotides (see AAB8789-804) and the secreted or membrane-
associated proteins encoded by them (see AAB19720-34). SECX
polynucleotides, polypeptides and antibodies can be used in the
detection, diagnosis and treatment (including gene therapy) of a broad
range of pathological states
XX
SQ Sequence 1603 BP; 466 A; 422 C; 405 G; 310 T; 0 U; 0 Other;

Query Match 95.4%; Score 1601.4; DB 1; Length 1603;
Best Local Similarity 99.9%; Pred. No. 0.00015;
Matches 1602; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 43 CAGCTTGAGACACACAAATCTATCAGAAAGAAAGAAAGAAACCGACCTGACA 102
```


XX Human Kruppel associated DNA binding protein 42 cDNA.
DE
XX
KW Human; Kruppel associated DNA binding protein 42; gene; ss; cytostatic;
KW virucide; immunomodulator; antiinflammatory; haemostatic; tumour; cancer;
KW haemopathy; HIV infection; nervous system disease; developmental disease;
KW hereditary disease; endocrine system disease; immune system disease;
KW immunological disease; inflammation; human immunodeficiency virus.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 330..1475
FT /tag= a
FT /product= "Human Kruppel associated DNA binding protein
FT 42"
XX
XX WO200183541-A1.
XX
XX 08-NOV-2001.
XX
XX 28-APR-2001; 2001WO-CN000661.
XX
XX 29-APR-2000; 2000CN-00115515.
XX
XX (SHAN-) SHANGHAI BIOWINDOW GENE DEV INC.
XX
XX Mao Y, Xie Y;
XX
XX WPI: 2002-062108/08.
XX P-PSDB; AAU79205.
XX
XX Human Kruppel-associated DNA-binding protein 42 and encoded
XX polynucleotide, applicable in diagnosis and treatment of developmental
XX disorders, cancer, hemopathy, HIV infection, immunological diseases and
XX various inflammations.
XX
XX Claim 6; Page 30-31; 38pp; Chinese.
XX
XX The invention relates to the human Kruppel associated DNA binding protein
XX 42 and the polynucleotide encoding it. The sequences of the invention are
XX applicable in diagnosis and treatment of different kinds of tumour,
XX haemopathy, HIV infection, nervous system disease, developmental disease,
XX hereditary disease, endocrine system disease, immune system disease,
XX immunological disease and various inflammations. This sequence represents
XX cDNA encoding the human Kruppel associated DNA binding protein 42
XX
XX Sequence 1873 BP; 563 A; 468 C; 471 G; 371 T; 0 U; 0 Other;
XX
XX Query Match 93.6%; Score 1571.3; DB 1; Length 1873;
XX Best Local Similarity 93.1%; Pred. No. 0.00017;
XX Matches 1674; Conservative 0; Mismatches 2; Indels 123; Gaps 4;
XX
XX 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGGCAAGCTTGAGAGCAAC 60
XX 50 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGGCAAGCTTGAGAGCAAC 109
XX 61 AATCTATCAGGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 120
XX 110 AATCTATCAGGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 169
XX 121 AAGAAAAAATCATGAAACCATCAGCCCAAAATGCAATTCATCTCTTGGGCAAT 180
XX 170 AAGAAAAAATCATGAAACCATCAGCCCAAAATGCAATTCATCTCTTGGGCAAT 229
XX 181 CTTTCAGGGGCTGGTGTCTGTGTCTCTTCCA----- 213
XX 230 CTTTCAGGGGCTGGTGTCTGTGTCTCTTCCAAGTAAAGTACATTCCTGCTCAT 289
XX 214 ----- 213
XX 290 CCCCAGGCAAGTTGGATGTTTTTAAAGTGGAAAAAATAATCAACGGAAAAAGAACGG 349

QY 214 -----AGGAGTCCCGTGGCCAGCGAGATGC 240
Db 350 GGAAGGTGGGAAGAGGTGGAATGGAAGGGCACAGAGTGCCTGGTGCAGCGGAGATGC 409
QY 241 CACCTTCCCAAGAGTATGGAACAGTCAAGTCCGGTCCGGAGGGGAGAGCGCCACCTTCAG 300
Db 410 CACCTTCCCAAGAGTATGGAACAGTCAAGTCCGGTCCGGAGGGGAGAGCGCCACCTTCAG 469
QY 301 GTGCTACTATTGACAAACCGGCTCACCCGGGTGGCTTAAACCGCAGCAGCATCCTCTA 360
Db 470 GTGCTACTATTGACAAACCGGCTCACCCGGGTGGCTTAAACCGCAGCAGCATCCTCTA 529
QY 361 TGTGTGGAATGACAAAGTGTGCTCGATCTCGTGTGCTCTTCTGTGAGACACACCAAC 420
Db 530 TGTGTGGAATGACAAAGTGTGCTCGATCTCGTGTGCTCTTCTGTGAGACACACCAAC 589
QY 421 GCAGTACAGCATCGAGATCCAGAACGTGTGATGACAGAGGGCCCTTACACCTGTCTC 480
Db 590 GCAGTACAGCATCGAGATCCAGAACGTGTGATGATGACAGAGGGCCCTTACACCTGTCTC 649
QY 481 GGTGACAGACAGAACCCCAAGACCTCTAGGTGCCACCTCATTTGTGAAAGTATCTCC 540
Db 650 GGTGACAGACAGAACCCCAAGACCTCTAGGTGCCACCTCATTTGTGAAAGTATCTCC 709
QY 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
Db 710 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 769
QY 601 CTGCATAGCAACTGTGTAGACAGAGCTTACGTGTACTTGGAGACACATCTCTCCAAAGC 660
Db 770 CTGCATAGCAACTGTGTAGACAGAGCTTACGTGTACTTGGAGACACATCTCTCCAAAGC 829
QY 661 GGTGTGCTTTGTGAGTGAAGACGAATACCTTGAATAATCAGGGCATCACCCTGGAGCAGTC 720
Db 830 GGTGTGCTTTGTGAGTGAAGACGAATACCTTGAATAATCAGGGCATCACCCTGGAGCAGTC 889
QY 721 AGGGGACTACGAGTGCAGTGCCTTCCAATGACGTGGCCGCCCTGGTACGAGAGTAAA 780
Db 890 AGGGGACTACGAGTGCAGTGCCTTCCAATGACGTGGCCGCCCTGGTACGAGAGTAAA 949
QY 781 GGTACCGTGAATATCCACCATACATTTTCAGAACGAGGTACAGGTGTCCCGTGGG 840
Db 950 GGTACCGTGAATATCCACCATACATTTTCAGAACGAGGTACAGGTGTCCCGTGGG 1009
QY 841 ACAAAGGGGACACTGCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 1010 ACAAAGGGGACACTGCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 1069
QY 901 CAAGATGACAAAGACTGATTTGAAGAGAAAGAGGTGAAGTGAAGTGAAGTGAAGTCTTT 960
Db 1070 CAAGATGACAAAGACTGATTTGAAGAGAAAGAGGTGAAGTGAAGTGAAGTGAAGTCTTT 1129
QY 961 CCTCTCAAAACTCATCTTCTCAATCTCTGAAACATGACTATGGGAACTACACTTTGCGT 1020
Db 1130 CCTCTCAAAACTCATCTTCTCAATCTCTGAAACATGACTATGGGAACTACACTTTGCGT 1189
QY 1021 GGCCTCCAAAGCTGGGCCACACCAATGTCAGCAGCATCTGTTATTTGGTCCAGGCCCGT 1080
Db 1190 GGCCTCCAAAGCTGGGCCACACCAATGTCAGCAGCATCTGTTATTTGGTCCAGGCCCGT 1249
QY 1081 CAGCGGTGAGCAACGGCACGTCGAGGAGGGGAGGCTGGCTCTGGCTGTGCTCTTCT 1140
Db 1250 CAGCGGTGAGCAACGGCACGTCGAGGAGGGGAGGCTGGCTCTGGCTGTGCTCTTCT 1309
QY 1141 GGTCTTGCACTGCTCTCAAAATTTTGTAGTGTGCTCTTCCCAACCGGGAAGGCT 1200
Db 1310 GGTCTTGCACTGCTCTCAAAATTTTGTAGTGTGCTCTTCCCAACCGGGAAGGCT 1368
QY 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db 1369 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1427
QY 1261 TATACAAATGAAATTAGAAGAAAACAGCCTCATTTGGGACAGAAATTTGAGGGAGGGAAC 1320

Db 1428 TATACAAATGAAATAGAGAAACACAGCCTCATGG-CAGAAATTTGAGGAGGGAAAC 1486
QY 1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAATGAAATTTGCTTGCAGATA 1380
Db 1487 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAATGAAATTTGCTTGCAGATA 1546
QY 1381 TTATGATACATGGAGTTTCTTTTCCCAACGGGAAGAACACAGACACCCGGTTGGA 1440
Db 1547 TTATGATACATGGAGTTTCTTTTCCCAACGGGAAGAACACAGACACCCGGTTGGA 1606
QY 1441 CCCACTGACGCTGATCTGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1607 CCCACTGCAAGCTGATCTGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1666
QY 1501 TCTGCCACAGAGTGCCTCCACAGTGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
Db 1667 TCTGCCACAGAGTGCCTCCACAGTGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1726
QY 1561 GTCCATAGAGACGAACAGATGAGACTTCCGGCCCAAGCTGGCGCTGGGGCACTTTG 1620
Db 1727 GTCCATAGAGACGAACAGATGAGACTTCCGGCCCAAGCTGGCGCTGGGGCACTTTG 1786
QY 1621 GTAGACTGTGCCACCGGGCTGTGTGTGAACGTGAATTAAGAGCAAAAAA 1679
Db 1787 GTAGACTGTGCCACCGGGCTGTGTGTGAACGTGAATTAAGAGCAAAAAA 1845

RESULT 173
AA157869
ID AA157869 standard; cdna; 1678 BP.
AC AA157869;
XX
XX 22-OCT-2001 (first entry)
DE Human polynucleotide SEQ ID NO 72.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia; ss.
XX
OS Homo sapiens.
XX
XX W0200153312-AL.
XX
XX 26-JUL-2001.
XX
XX 26-DEC-2000; 2000WO-US034263.
XX
XX 23-DEC-1999; 99US-00471275.
XX
XX 21-JAN-2000; 2000US-00488725.
XX
XX 25-APR-2000; 2000US-00552317.
XX
XX 20-JUN-2000; 2000US-00598042.
XX
XX 19-JUL-2000; 2000US-00620312.
XX
XX 03-AUG-2000; 2000US-00653450.
XX
XX 14-SEP-2000; 2000US-00662191.
XX
XX 19-OCT-2000; 2000US-00693036.
XX
XX 29-NOV-2000; 2000US-00727344.
XX
XX (HYSE-) HYSEQ INC.
XX
XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
XX Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J, Zhao QA;
XX Zhou P, Goodrich R, Drmanac RT;
XX
XX WPI; 2001-442253/47.
XX
XX P-PSDB; AAM38713.
XX
XX Novel nucleic acids and polypeptides, useful for treating disorders such

as central nervous system injuries.
XX
XX Claim 1; SEQ ID NO 72; 10078pp; English.
XX
XX The invention relates to human nucleic acids (AA157798-AA161369) and the
XX encoded polypeptides (AAM38642-AAM42213) with nootropic,
XX immunosuppressant and cytostatic activity. The polynucleotides are useful
XX in gene therapy. A composition containing a polypeptide or polynucleotide
XX of the invention may be used to treat diseases of the peripheral nervous
XX system, such as peripheral nervous injuries, peripheral neuropathy and
XX localised neuropathies and central nervous system diseases, such as
XX Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
XX lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
XX utilisation of the activities such as: Immune system suppression,
XX Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
XX and thrombolytic activity, cancer diagnosis and therapy, drug screening,
XX assays for receptor activity, arthritis and inflammation, leukaemias and
XX C.N.S disorders. Note: The sequence data for this patent did not form
XX part of the printed specification
XX
XX Sequence 1678 BP; 420 A; 468 C; 451 G; 339 T; 0 U; 0 Other;
XX
XX Query Match 86.8%; Score 1457; DB 1; Length 1678;
XX Best Local Similarity 100.0%; Pred. No. 0.00054;
XX Matches 1457; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 214 AGGAGTGCCTGCGCGAGGAGATGCCACCTTCCCAAGCTATGACACGTCGACCGT 273
Db 222 AGGAGTGCCTGCGCGAGGAGATGCCACCTTCCCAAGCTATGACACGTCGACCGT 281
QY 274 CCGGAGGGGAGAGCGCCACCTCAGTGCACTATTGACAAACCGGTCACCCGGTGGC 333
Db 282 CCGGAGGGGAGAGCGCCACCTCAGTGCACTATTGACAAACCGGTCACCCGGTGGC 341
QY 334 CTGGCTAAACCGCAGCACCATCTCTATGCTGGGAATGACAAGTGTGCTTGGATCTCTCG 393
Db 342 CTGGCTAAACCGCAGCACCATCTCTATGCTGGGAATGACAAGTGTGCTTGGATCTCTCG 401
QY 394 CTGTGCTCTTCTGAGCAACACCCAAACGCTACAGCATCGAGATCCAGAACGTCGATGT 453
Db 402 CTGTGCTCTTCTGAGCAACACCCAAACGCTACAGCATCGAGATCCAGAACGTCGATGT 461
QY 454 GTATGACAGGGCCCTTACACTGCTCGGTGACAGACAGAACCCACCCAAAGACTCTAG 513
Db 462 GTATGACAGGGCCCTTACACTGCTCGGTGACAGACAGAACCCACCCAAAGACTCTAG 521
QY 514 GGTCCACCTCATTTGTGCAAGTATCTCCCAAAATTTGAGAGATTTCTTTCAGATATCTCCAT 573
Db 522 GGTCCACCTCATTTGTGCAAGTATCTCCCAAAATTTGAGAGATTTCTTTCAGATATCTCCAT 581
QY 574 TAATGAGGGAACAATATTAGCCTCACTGATAGCAACTGCTAGACAGAGCCTACCGT 633
Db 582 TAATGAGGGAACAATATTAGCCTCACTGATAGCAACTGCTAGACAGAGCCTACCGT 641
QY 634 TACTTGGAGACACATCTCTCCAAAGCGTTGGCTTTGTGAGTGAAGACGAATACTTGGGA 693
Db 642 TACTTGGAGACACATCTCTCTCCAAAGCGTTGGCTTTGTGAGTGAAGACGAATACTTGGGA 701
QY 694 AATTGAGGCACTACCCCGGAGCAGTACGGGACTACAGTGTGCTGCTCAATGAGCT 753
Db 702 AATTGAGGCACTACCCCGGAGCAGTACGGGACTACAGTGTGCTGCTCAATGAGCT 761
QY 754 GGCCTGGCGCTGTGCTACGGAGTAAAGTCCCGTGAACCTATCCACCATACATTTTCAGA 813
Db 762 GGCCTGGCGCTGTGCTACGGAGTAAAGTCCCGTGAACCTATCCACCATACATTTTCAGA 821
QY 814 AGCCAAAGGTCAGGTGCTCCCGTGGGACAAAGGGGACACTGCAAGTGTGAAGCTCAGC 873
Db 822 AGCCAAAGGTCAGGTGCTCCCGTGGGACAAAGGGGACACTGCAAGTGTGAAGCTCAGC 881
QY 874 AGTCCCTCAGCAGAAATTTCCAGTGTGTACAGGATGACAAAGACTGATTGAGGAAAGAA 933
Db 882 AGTCCCTCAGCAGAAATTTCCAGTGTGTGTACAGGATGACAAAGACTGATTGAGGAAAGAA 941

Db 765 TACTTGGAGACACATCTCTCCAAAGCGGTGGCTTTGTGAGTGAAGACGAATACTTGA 824
Qy 694 AATTTCAGGGATACACCGGAGCAGTCAAGGGACTAGAGTGCAGTGCCTCCATGACGT 753
Db 825 AATTTCAGGGATACACCGGAGCAGTCAAGGGACTAGAGTGCAGTGCCTCCATGACGT 884
Qy 754 GGCGCGCCCGTGTGATCGGAGTAAGAGTCAACCGTCAATTCACCATACATTTTCA 813
Db 885 GGCGCGCCCGTGTGATCGGAGTAAGAGTCAACCGTCAATTCACCATACATTTTCA 944
Qy 814 AGCCAAAGGTACAGGTGTCCCGTGGGACAAAGAGGGACACTGACAGTGTGAAGCCTCAGC 873
Db 945 AGCCAAAGGTACAGGTGTCCCGTGGGACAAAGAGGGACACTGACAGTGTGAAGCCTCAGC 1004
Qy 874 AGTCCCTCTCAGCAGAAATTCAGTGGTACAAAGGTGACAAAGAGTGAATTCGAAGCAAGAA 933
Db 1005 AGTCCCTCTCAGCAGAAATTCAGTGGTACAAAGGTGACAAAGAGTGAATTCGAAGCAAGAA 1064
Qy 934 AGGGGTGAAGTGAAGAAACAGACCTTTCTCTCAAACTCATCTTTCTCAATGCTCTGA 993
Db 1065 AGGGGTGAAGTGAAGAAACAGACCTTTCTCTCAAACTCATCTTTCTCAATGCTCTGA 1124
Qy 994 ACATGACTATGGGAATACACTTTCGTTGGCTCTCAACAGCTGGGCCACACCAATCCGAG 1053
Db 1125 ACATGACTATGGGAATACACTTTCGTTGGCTCTCAACAGCTGGGCCACACCAATCCGAG 1184
Qy 1054 CATCATGCTATTTGGTCCAGCGCGCTGACGAGGTGAGCAACCGCACGTCGAGGAGGCG 1113
Db 1185 CATCATGCTATTTGGTCCAGCGCGCTGACGAGGTGAGCAACCGCACGTCGAGGAGGCG 1244
Qy 1114 AGGTGCGTCTGGCTGCTCTCTCTGCTCTTGCACCTCTCTCAATTTTGTATGA 1173
Db 1245 AGGTGCGTCTGGCTGCTCTCTCTGCTCTTGCACCTCTCTCAATTTTGTATGA 1304
Qy 1174 GTGCACCTTCCCAACCGGGAAGGCTGCGGCCACCAACCAACCAACCAACCAACCAATG 1233
Db 1305 GTGCACCTTCCCAACCGGGAAGGCTGCGGCCACCAACCAACCAACCAACCAACCAATG 1364
Qy 1234 GCACACCGACAGCAACCAATCAGATATACAAATGAATTAAGAGAAACACAGCCTCA 1293
Db 1365 GCACACCGACAGCAACCAATCAGATATACAAATGAATTAAGAGAAACACAGCCTCA 1424
Qy 1294 TGGGACAGAAATTTGAGGAGGGGAAACAAAGATACTTTGGGGGAAAGAGTTTAAAA 1353
Db 1425 TGGGACAGAAATTTGAGGAGGGGAAACAAAGATACTTTGGGGGAAAGAGTTTAAAA 1484
Qy 1354 AAGAAATGAATTTGCTTGCAGATATTTAGGTACAAATGAGATTTCTTTTCCCAAACG 1413
Db 1485 AAGAAATGAATTTGCTTGCAGATATTTAGGTACAAATGAGATTTCTTTTCCCAAACG 1544
Qy 1414 GGAAGAACACAGCACACCGGCTTGAACCCACCTGCAAGCTGCATCGTCAACCTCTTGG 1473
Db 1545 GGAAGAACACAGCACACCGGCTTGAACCCACCTGCAAGCTGCATCGTCAACCTCTTGG 1604
Qy 1474 TGCAGTGTGGCAAGGGCTCAGCCTCTCTGCCCACAGAGTGTCCCAACGTGGAACATTC 1533
Db 1605 TGCAGTGTGGCAAGGGCTCAGCCTCTCTGCCCACAGAGTGTCCCAACGTGGAACATTC 1664
Qy 1534 TGGAGCTGGCCATCCCAATTCATCAGTCCATAGAGCAAGCAAGATGAGC----- 1586
Db 1665 TGGAGCTGGCCATCCCAATTCATCAGTCCATAGAGCAAGCAAGATGAGC----- 1724
Qy 1587 -----CTTCCGCGCCCAAGCGTGGCGCTCGCGGCACCTTTGGTAGCTGTGCCA 1633
Db 1725 CCCAAGCGTGGCGCTTCCGCGCCCAAGCGTGGCGCTCGCGGCACCTTTGGTAGCTGTGCCA 1784
Qy 1634 CCAGCGGTGTGTGTGAACGTGAATATAAAGAGCAAAAAA 1679
Db 1785 CCAGCGGTGTGTGTGAACGTGAATATAAAGAGCAAAAAA 1830

RESULT 175
ABX76448

ID XX ABX76448 standard; DNA; 1839 BP.
AC XX ABX76448;
DT XX 02-APR-2003 (first entry)
DE XX Lung cancer-associated polynucleotide #312.
KW Lung cancer-associated polynucleotide; gene; ds; cytostatic; emphysema;
antiflammatory; antiasthmatic; non-small cell lung cancer; atelectasis;
small cell lung cancer; benign lesion; precancerous lesion; bronchitis;
chronic obstructive pulmonary disease; hypersensitivity pneumonitis;
interstitial pulmonary fibrosis; fibrosis; asthma; bronchiectasis.
OS Unidentified.
XX XX WO200286443-A2.
PN XX 31-OCT-2002.
PD XX 18-APR-2002; 2002WO-US012476.
PF XX 18-APR-2001; 2001US-0284770P.
PR 10-MAY-2001; 2001US-0290492P.
PR 09-NOV-2001; 2001US-0339245P.
PR 13-NOV-2001; 2001US-0350666P.
PR 29-NOV-2001; 2001US-0334370P.
PR 12-APR-2002; 2002US-0372246P.
XX (EOSB-) EOS BIOTECHNOLOGY INC.
PA Aziz N, Murray R;
XX WPI; 2003-093161/08.
DR P-PSDB; ABUS6719.
XX Detecting a lung cancer-associated transcript in a cell from a patient
for treating lung cancer, by contacting a biological sample from the
patient with a polynucleotide that exhibits increased or decreased
expression in lung cancer.
XX Claim 22; Page 430-431; 453pp; English.
XX The invention relates to a method for detecting a lung cancer-associated
transcript in a cell from a patient, comprising contacting a biological
sample from the patient with a polynucleotide that selectively hybridizes
to a sequence that is at least 80 % identical to a gene that exhibits
increased or decreased expression in lung cancer samples. Lung cancer-
associated polynucleotides and polypeptides are used for identifying a
compound that modulates a lung cancer-associated polypeptide, for
inhibiting proliferation of a lung cancer-associated cell to treat lung
cancer in a patient and for treating a mammal having lung cancer by
administering a modulatory compound identified. The methods are useful
for treating lung cancer, such as small cell lung cancer, non-small cell
lung cancer or other benign or precancerous lesions, e.g. atelectasis,
emphysema, bronchitis, chronic obstructive pulmonary disease, fibrosis,
hypersensitivity pneumonitis, interstitial pulmonary fibrosis, asthma and
bronchiectasis. The genes, polynucleotides and polypeptides are useful
for diagnostic purposes and as targets for screening for therapeutic
compounds that modulate lung cancer, such as antibodies. Sequences
ABX76124-ABX76474 represent lung cancer-associated polynucleotides of the
invention
SQ Sequence 1839 BP; 464 A; 506 C; 503 G; 366 T; 0 U; 0 Other;

Query Match 85.9%; Score 1442.8; DB 1; Length 1839;
Best Local Similarity 98.5%; Pred. No. 0.00056;
Matches 1464; Conservative 0; Mismatches 2; Indels 20; Gaps 1;
Qy 214 AGGAGTGCCTGGCGCAGCGAGATGCCACCTTCCCAAGCTATGGACACGTCGCGT 273
Db 345 AGGAGTGCCTGGCGCAGCGAGATGCCACCTTCCCAAGCTATGGACACGTCGCGT 404

CC The invention relates to human nucleic acids (AA157798-AA161369) and the
 CC encoded polypeptides (AM38442-AM42213) with neurotropic,
 CC immunosuppressant and cytoskeletal activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral neuropathies, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: Immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukaemias and
 CC C.N.S disorders. Note: The sequence data for this patent did not form
 CC part of the printed specification
 CC XX

SQ Sequence 1690 BP; 482 A; 416 C; 425 G; 367 T; 0 U; 0 Other;

Query Match 78.4%; Score 1316.5; DB 1; Length 1690;
 Best Local Similarity 99.8%; Pred. No. 0.002;
 Matches 1348; Conservative 0; Mismatches 3; Gaps 3;

QY 1 GTTGTGCTCTCAGCAAAACAGTGAATTAATCTCCTTGCAAGCTTGAGAGCAAC 60
 Db |||||
 QY 341 GTTGTGCTCTCAGCAAAACAGTGAATTAATCTCCTTGCAAGCTTGAGAGCAAC 400
 Db |||||
 QY 61 AATCTATCAGGAAAGAAAGAAAGAAACCGAACCTGACAAAAGAAAGAAAG 120
 Db |||||
 QY 401 AATCTATCAGGAAAGAAAGAAAGAAACCGAACCTGACAAAAGAAAGAAAG 460
 Db |||||
 QY 121 AAGAAAAAATCATGAACCATCCAGCCAAAATGCAATTCATCTCTTGGGCAAT 180
 Db |||||
 QY 461 AAGAAAAAATCATGAACCATCCAGCCAAAATGCAATTCATCTCTTGGGCAAT 520
 Db |||||
 QY 181 CTTACGGGGCTGGTCTGTGCTCTTCCAGAGAGTGCCGTCGCGAGGAGATGC 240
 Db |||||
 QY 521 CTTACGGGGCTGGTCTGTGCTCTTCCAGAGAGTGCCGTCGCGAGGAGATGC 580
 Db |||||
 QY 241 CACCTTCCCAAGATATGGAACAAGTCCGTCGCGAGGAGATGCACCTCCAG 300
 Db |||||
 QY 581 CACCTTCCCAAGATATGGAACAAGTCCGTCGCGAGGAGATGCACCTCCAG 640
 Db |||||
 QY 301 GTGCACTATTGACACCGGGTCACCGGGTGGCTTAAACCGACCATCTCTTA 360
 Db |||||
 QY 641 GTGCACTATTGACACCGGGTCACCGGGTGGCTTAAACCGACCATCTCTTA 700
 Db |||||
 QY 361 TGCTGGGAATGACAGTGGTGCCTGGATCCTCGGTGGTCTCTTGAGCAACACCCAAAC 420
 Db |||||
 QY 701 TGCTGGGAATGACAGTGGTGCCTGGATCCTCGGTGGTCTCTTGAGCAACACCCAAAC 760
 Db |||||
 QY 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACCTGCTC 480
 Db |||||
 QY 761 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACCTGCTC 820
 Db |||||
 QY 481 GGTGAGACAGCAACACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 Db |||||
 QY 821 GGTGAGACAGCAACACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 880
 Db |||||
 QY 541 CAATAATTGATAGATTTCTCAGATATCTCAATTAAGAGGAAACAATATTAGCTTCAC 600
 Db |||||
 QY 881 CAATAATTGATAGATTTCTCAGATATCTCAATTAAGAGGAAACAATATTAGCTTCAC 940
 Db |||||
 QY 601 CTGCATAGCACTGGTAGACACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
 Db |||||
 QY 941 CTGCATAGCACTGGTAGACACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 1000
 Db |||||
 QY 661 GGTGGCTTTGTAGTGAAGAGAAATATTGGAAATTCAGGGCATACCCGGAGAGATC 720
 Db |||||
 QY 1001 GGTGGCTTTGTAGTGAAGAGAAATATTGGAAATTCAGGGCATACCCGGAGAGATC 778
 Db |||||
 QY 721 AGGGGACTACGAGTGCAGTGCCTCCAATGAGT-GGCCGCGCCGCT-GGTACGGAGATA 778
 Db |||||
 QY 1061 AGGGGACTACGAGTGCAGTGCCTCCAATGAGTGGGGCCGCCCGTGGTACGGAGATA 1120
 Db |||||

QY 779 AAGTCAACCGTGAACATATCCACATATCATTTCAAGAGCCAAAGGTACAGGTGTCCTCGTG 838
 Db |||||
 QY 1121 AAGTCAACCGTGAACATATCCACATATCATTTCAAGAGCCAAAGGTACAGGTGTCCTCGTG 1180
 Db |||||
 QY 839 GGACAAAAGGGGACATCGAGTGTGAAGCCTCAGAGTCCCTCAGCAGAAATTCAGTGG 898
 Db |||||
 QY 1181 GGACAAAAGGGGACATCGAGTGTGAAGCCTCAGAGTCCCTCAGCAGAAATTCAGTGG 1240
 Db |||||
 QY 899 TACAAGATACAAAAGACATGATTGAAGGAAAGAAAGGGGTGAAGTGGAAACAGACCT 958
 Db |||||
 QY 1241 TACAAGATACAAAAGACATGATT-AAGGAAAGAAAGGGGTGAAGTGGAAACAGACCT 1299
 Db |||||
 QY 959 TTCTCTCRAAACTCATCTTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGC 1018
 Db |||||
 QY 1300 TTCTCTCRAAACTCATCTTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGC 1359
 Db |||||
 QY 1019 GTGSCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTGTCAGGCGCC 1078
 Db |||||
 QY 1360 GTGSCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTGTCAGGCGCC 1419
 Db |||||
 QY 1079 GTCAGGAGGTGAGCAACCGCACGTGAGGAGGGCAGGCTGCTGCTGCTGCTGCTCTT 1138
 Db |||||
 QY 1420 GTCAGGAGGTGAGCAACCGCACGTGAGGAGGGCAGGCTGCTGCTGCTGCTGCTCTT 1479
 Db |||||
 QY 1139 CTGCTCTTGACCTGCTCTTCAAAATTTGATGTGAGTGCACCTTCCACCCCGGAAAGG 1198
 Db |||||
 QY 1480 CTGCTCTTGACCTGCTCTTCAAAATTTGATGTGAGTGCACCTTCCACCCCGGAAAGG 1539
 Db |||||
 QY 1199 CTGCGCCACCCACCCACCAACCAACAGCAATGGCAACCCAGCAGCAACCAATCAGA 1258
 Db |||||
 QY 1540 CTGCGCCACCCACCCACCAACCAACAGCAATGGCAACCCAGCAGCAACCAATCAGA 1599
 Db |||||
 QY 1259 TATATCAATTAAGAAATAGAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGA 1318
 Db |||||
 QY 1600 TATATCAATTAAGAAATAGAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGA 1659
 Db |||||
 QY 1319 ACAAGAATACTTTGGGGGGAAAGAGTTT 1349
 Db |||||
 QY 1660 ACAAGAATACTTTGGGGGGAAAGAGTTT 1690
 Db |||||

RESULT 177

AAZ47892
 ID AAZ47892 standard; cDNA; 1032 BP.

XX AAZ47892;

XX AC AC

XX DT 10-MAR-2000 (first entry)

XX Human protein encoding cDNA SEQ ID NO:2.

XX Human; haematopoietic cell regulation; tissue generation; reparation;
 KW activin; inhibin; taxis; chemotaxis; blood coagulation; thrombus;
 KW receptor; ligand; autoimmune; infection-related immunodeficiency;
 KW inflammatory disorder; neurological disease; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

XX CDS 1..1032
 FT /tag= a
 FT /note= "no stop codon given"

XX WO9958668-A1.

XX 18-NOV-1999.

XX 13-MAY-1999; 99WO-JP002485.

XX 14-MAY-1998; 96JP-00131815.

XX (ONCY) ONO PHARM CO LTD.

XX Fukushima D, Shibayama S, Tada H;
XX WPI; 2000-062298/05.
DR P-PSDB; AAY57601.
XX New polypeptides of human origin having cell regulatory, tissue
PT generation, coagulant and other activities.
XX Claim 4; Page 41; 84pp; Japanese.
XX The present sequence encodes a specifically claimed novel human protein.
CC The novel human protein can be used in therapeutic drugs for the
CC prevention and treatment of a broad range of disorders including
CC autoimmune and infection-related immunodeficiency, inflammatory
CC disorders, and neurological diseases. The novel protein is expected of
CC having haematopoietic cell regulatory activity, tissue generation/
CC reparation activity, activin/inhibin activity, taxis/chemotaxis activity,
CC blood coagulation and thrombus activity, and receptor/ligand activity
XX Sequence 1032 BP; 267 A; 281 C; 270 G; 214 T; 0 U; 0 Other;
SQ

Query Match 61.5%; Score 1032; DB 1; Length 1032;
Best Local Similarity 100.0%; Pred. No. 0.047;
Matches 1032; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 134 ATGAAACCATCCAGCAAAATGCAATTTCTATCTTTGGCAATCTTCAAGGGGCTG 193
Db 1 ATGAAACCATCCAGCAAAATGCAATTTCTATCTTTGGCAATCTTCAAGGGGCTG 60

QY 194 GTGTCTCTGTCTCTTCCAGAGAGTGCCCGTGGCAGCGGAGATGCCACCTTCCCCAAA 253
Db 61 GCTGTCTCTGTCTCTTCCAGAGAGTGCCCGTGGCAGCGGAGATGCCACCTTCCCCAAA 120

QY 254 GCTATGGCAACGTGACGCTCCGGCAGGGGAGAGCGCCACCTCAGGTGCACATTGAC 313
Db 121 GCTATGGCAACGTGACGCTCCGGCAGGGGAGAGCGCCACCTCAGGTGCACATTGAC 180

QY 314 AACCGGGTCACCGGGTGCCCTGGCTAAACCCAGCAGCACCCTCTATCTGGGAATGAC 373
Db 181 AACCGGGTCACCGGGTGCCCTGGCTAAACCCAGCAGCACCCTCTATCTGGGAATGAC 240

QY 374 AGTGGTGCTGGATCCTCGCTGGCTCTTCTGAGCAGCAGCAGCAGCAGCAGCAGCAGC 433
Db 241 AGTGGTGCTGGATCCTCGCTGGCTCTTCTGAGCAGCAGCAGCAGCAGCAGCAGCAGC 300

QY 434 GAGATCCAGAACGTGGATGTATGACAGAGGCGCCCTTACACCTGTCTGGTGACAGAC 493
Db 301 GAGATCCAGAACGTGGATGTATGACAGAGGCGCCCTTACACCTGTCTGGTGACAGAC 360

QY 494 AACCCCAAGACCTTAGGTCCACCTCATTTGCAAGTATCTCCCAAAATTTAGAG 553
Db 361 AACCCCAAGACCTTAGGTCCACCTCATTTGCAAGTATCTCCCAAAATTTAGAG 420

QY 554 ATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCTCACCTGCATAGCAACT 613
Db 421 ATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCTCACCTGCATAGCAACT 480

QY 614 GGTAGACAGAGCTACGGTTACTTTGGAGACACATCTCTCCAAAGCGGTTGGCTTTGTG 673
Db 481 GGTAGACAGAGCTACGGTTACTTTGGAGACACATCTCTCCAAAGCGGTTGGCTTTGTG 540

QY 674 AGTGAAGACGAATACCTTGAATTTCAAGGATCAGCGGAGCAGTACAGGAGCTACGAG 733
Db 541 AGTGAAGACGAATACCTTGAATTTCAAGGATCAGCGGAGCAGTACAGGAGCTACGAG 600

QY 734 TGCAGTGCCTCAATGAATGCGCGGCGCCGTGGTACGAGAGTAAAGGTCAACCGTGAAC 793
Db 601 TGCAGTGCCTCAATGAATGCGCGGCGCCGTGGTACGAGAGTAAAGGTCAACCGTGAAC 660

QY 794 TATCCACCATACATTTCAAGCAAGCCAGGTACAGGTGTCCTGGGACAAAGGGGACA 853
Db 661 TATCCACCATACATTTCAAGCAAGCCAGGTACAGGTGTCCTGGGACAAAGGGGACA 720

QY 854 CTGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATCCAGTGGTACAAGGATGACAAA 913
Db 721 CTGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATCCAGTGGTACAAGGATGACAAA 780

QY 914 AGACTGATTGAAGGAAGAAAGGGGTGAAGTGGAAACAGACCTTTCTCTCAAACTC 973
Db 781 AGACTGATTGAAGGAAGAAAGGGGTGAAGTGGAAACAGACCTTTCTCTCAAACTC 840

QY 974 ATCTTTCTCAATGTCTCTGAACATGACTATGGGAACATACACTTGGCCTCCAAACAAG 1033
Db 841 ATCTTTCTCAATGTCTCTGAACATGACTATGGGAACATACACTTGGCCTCCAAACAAG 900

QY 1034 CTGGGCCACACCAATGCCAGCATCATCTATTGGTCCAGGCGCCCTCAGCGAGGTGAGC 1093
Db 901 CTGGGCCACACCAATGCCAGCATCATCTATTGGTCCAGGCGCCCTCAGCGAGGTGAGC 960

QY 1094 AACGGCACGTCGAGGAGGGCAGGCTCGCTGTGGCTCTGCTCTCTTGTGTTTGCACCTG 1153
Db 961 AACGGCACGTCGAGGAGGGCAGGCTCGCTGTGGCTCTGCTCTCTTGTGTTTGCACCTG 1020

QY 1154 CTCTCTCAATTT 1165
Db 1021 CTCTCTCAATTT 1032

Search completed: June 4, 2004, 16:54:05
Job time : 290 secs